{
  "experiment_metadata": {
    "model": "nemotron-nano-30b",
    "experiment": "e3_page_window_distract",
    "pattern": "qualitative_3hop_intra_doc_type1",
    "total_questions": 600,
    "successful": 600,
    "failed": 0,
    "elapsed_seconds": 4817.46,
    "timestamp": "2026-02-03T21:46:19.376833"
  },
  "results": [
    {
      "question_id": 1,
      "question": "How does Emerson's $7.8 billion cash payment to acquire National Instruments align with the strategic positioning of its newly formed Test & Measurement segment, which focuses on software-connected automated test systems?",
      "original_answer": "Emerson paid $7.8 billion in cash to acquire National Instruments (NI), a company that provides software-connected automated test and measurement systems. This acquisition led to the formation of the Test & Measurement segment, which now offers a full range of modular instrumentation, data acquisition and control solutions, and general-purpose development software. The segment's strategic focus on enabling enterprises to bring products to market faster and at lower cost directly aligns with NI's value proposition, indicating that the acquisition was a targeted move to strengthen Emerson’s capabilities in this domain. The segment’s description in the broader business portfolio highlights the integration of NI’s offerings as central to its Test & Measurement strategy.",
      "llm_answer": "Emerson's $7.8 billion cash payment to acquire National Instruments is consistent with its strategic push to expand the newly created Test & Measurement segment, which focuses on software‑connected automated test systems. The acquisition adds NI’s automated‑test platform and backlog to Emerson’s portfolio, positioning the segment to drive growth in high‑value, software‑driven test solutions and to leverage cross‑selling opportunities within the broader Software and Control business.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66983,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16978,
        "completion_tokens": 121,
        "total_tokens": 17100
      }
    },
    {
      "question_id": 17,
      "question": "How does ConocoPhillips' preemptive purchase of an additional 10% stake in APLNG, based on Origin Energy's sale price reflecting market participant valuation, reconcile with the $688 million before-tax charge recorded due to the fair value write-down of APLNG investment?",
      "original_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10% stake in APLNG in 2021, based on a sale price that reflected a market participant valuation of APLNG which was lower than ConocoPhillips' carrying value. As a result, the company was required to write down its investment in APLNG to the fair value of $5,574 million, leading to a before-tax charge of $688 million. This write-down indicates that the fair value of APLNG, as determined by the transaction price from Origin Energy’s sale, was significantly lower than ConocoPhillips’ previous carrying value, highlighting a valuation impairment driven by market conditions and expectations at the time.",
      "llm_answer": "ConocoPhillips recorded a $688 million pre‑tax impairment charge in 2021 because the market‑participant price paid by Origin Energy for a 10 % stake in APLNG signaled a fair‑value decline below the carrying amount of its existing investment; the impairment was recognized as other‑than‑temporary under ASC 323. The $688 million charge reflects the write‑down of the investment’s fair value to $5.574 billion, while the subsequent purchase of an additional 10 % stake at that market‑derived price reconciles the lower fair value with the cost of the new acquisition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72650,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18408,
        "completion_tokens": 141,
        "total_tokens": 18550
      }
    },
    {
      "question_id": 22,
      "question": "How does Chevron's reliance on crude oil exports through the Caspian Pipeline Consortium (CPC) align with the level of investment disclosed in the equity affiliates note, especially in light of the increased production capacity from the Tengiz Future Growth Project?",
      "original_answer": "Chevron's upstream operations in Kazakhstan, particularly the Tengizchevroil (TCO) affiliate, rely heavily on the Caspian Pipeline Consortium (CPC) for crude oil exports, as noted on page 35. In 2024, most of TCO's crude oil production was exported through the CPC pipeline. This dependency is further contextualized by the completion of the Future Growth Project (FGP), which added 260,000 barrels per day of crude oil production capacity. Given this increased throughput, Chevron's 15% ownership stake in CPC, disclosed on page 85, becomes strategically significant as CPC transports an average of 1.4 million barrels per day of crude oil, including Chevron's share from TCO and Karachaganak. The alignment suggests that Chevron's investment in CPC is critical to supporting the increased production volumes from its upstream growth projects in Kazakhstan, reinforcing the importance of midstream infrastructure to upstream monetization strategies.",
      "llm_answer": "Chevron’s 2024 10‑K shows that the company’s equity‑affiliate earnings from Tengizchevroil (the operator of the CPC pipeline) rose sharply to $3,375 million in 2024, reflecting the start‑up of the Tengiz Future Growth Project that added about 260,000 bbl/d of crude capacity.  This increase aligns with the higher upstream earnings reported for the International segment ($11,000 million in 2024 vs. $13,290 million in 2023) and the noted $4,500 million loan to TCO for the FGP, underscoring that the investment in the CPC‑linked expansion is a key driver of the affiliate’s profitability.  Consequently, the disclosed equity‑affiliate investment and the surge in production from the Tengiz Future Growth Project are directly tied to Chevron’s reliance on CPC for exporting that additional crude.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83058,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21013,
        "completion_tokens": 199,
        "total_tokens": 21212
      }
    },
    {
      "question_id": 24,
      "question": "How does Duke Energy's legal obligation for coal ash basin closure under the 2024 CCR Rule relate to the expanded regulatory scope compared to the 2015 CCR Rule, and what does this imply about the company's long-term environmental liability estimates?",
      "original_answer": "Duke Energy's legal obligation for coal ash basin closure, as outlined in the 2024 CCR Rule (which expands the 2015 CCR Rule), increases the company's long-term environmental liabilities. The 2024 Rule introduces requirements for previously unregulated coal ash sources, such as inactive surface impoundments at retired facilities, which were not covered under the 2015 Rule. This expansion significantly affects Duke Energy’s asset retirement obligations (AROs), as noted in the balance sheet and detailed in Notes 4 and 10. The company estimates that the total cost to permanently close all coal ash basins in North and South Carolina will be approximately $8 billion to $9 billion, with $4.4 billion already spent through 2024. The 2015 CCR Rule had already imposed closure and monitoring requirements on active and certain inactive coal ash facilities, but the 2024 Rule extends these obligations to legacy and previously unregulated units, thereby increasing Duke Energy’s liability base and extending the timeline for compliance. This implies that the company must revise its ARO estimates upward as the scope of regulatory obligations grows, with the majority of remaining expenditures expected over the next decade.",
      "llm_answer": "Duke Energy’s 2024 CCR Rule expands the 2015 rule’s scope to include inactive coal‑ash surface impoundments and previously unregulated coal‑ash sources at retired plants, obligating the company to close a broader set of ash basins and conduct groundwater monitoring, corrective action and post‑closure care. Because these obligations are recorded as asset‑retirement liabilities and are recoverable only through regulated rate‑making, the company must accrue significant discounted cash‑flow estimates for closure, which raises its long‑term environmental liability exposure and will likely increase the magnitude of future liability estimates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 102607,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25891,
        "completion_tokens": 161,
        "total_tokens": 26052
      }
    },
    {
      "question_id": 25,
      "question": "How does Chevron's operational dependency on crude oil production in Kazakhstan relate to its financial investment in the Caspian Pipeline Consortium (CPC), and what does this imply about the strategic importance of CPC in Chevron's upstream operations?",
      "original_answer": "Chevron's upstream operations in Kazakhstan, particularly its 50% interest in Tengizchevroil (TCO) and 18% nonoperated interest in Karachaganak, rely heavily on the Caspian Pipeline Consortium (CPC) for crude oil export, as most of TCO's 2024 crude oil production was exported through CPC. Chevron also has a 15% ownership interest in CPC, which it describes as a critical export route for its Kazakh assets. Financially, Chevron's investment in CPC is part of its broader equity affiliate portfolio, and the company emphasizes its strategic alignment with upstream production by maintaining infrastructure access. This dual role—as both a major crude oil producer in Kazakhstan and a shareholder in CPC—highlights the pipeline's strategic importance in enabling Chevron to monetize upstream reserves and maintain operational continuity in the region.",
      "llm_answer": "Chevron’s upstream operations in Kazakhstan—particularly its 50 % equity stake in the Tengizchevroil (TCO) consortium and its 15 % interest in the Caspian Pipeline Consortium (CPC)—are fundamentally dependent on the crude oil produced at the Tengiz and Korolev fields, which are exported via the CPC pipeline. This operational link means that Chevron’s financial investment in the CPC is directly tied to the volume and profitability of its Kazakhstan crude output, making the pipeline a critical conduit for cash flow and reserve utilization in its upstream portfolio. Consequently, the CPC is strategically vital to Chevron’s upstream business, underpinning a substantial portion of its oil‑production growth and revenue generation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83058,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21010,
        "completion_tokens": 183,
        "total_tokens": 21193
      }
    },
    {
      "question_id": 25,
      "question": "How does Chevron's financial exposure to Tengizchevroil, including its $4,500 loan for the FGP/WPMP development, intersect with its ongoing tax uncertainties in Kazakhstan, particularly given that the most recent finalized tax audit in that country was for the year 2012?",
      "original_answer": "Chevron's financial exposure to Tengizchevroil, where it holds a 50% equity stake and has extended a $4,500 loan to fund the FGP/WPMP development, indicates a significant operational and financial commitment to Kazakhstan. This is further contextualized by the fact that Tengizchevroil contributed to improved equity affiliate income in 2021, highlighting its strategic importance. However, Chevron also faces ongoing tax uncertainties in Kazakhstan, where the most recent finalized tax audit was for 2012, leaving over a decade of potential exposure unresolved. Given Chevron's deep operational involvement through Tengizchevroil and the magnitude of its financial commitments, the lack of recent tax audit closure in Kazakhstan raises material risk regarding potential adjustments to Chevron’s unrecognized tax benefits, which could significantly impact its effective tax rate if recognized.",
      "llm_answer": "Chevron’s $4,500 loan to fund the FGP/WPMP development at its 50 % owned Tengizchevroil joint venture is recorded as part of its $23.7 billion equity investment in TCO (Note 15).  The loan is a component of the company’s upstream exposure in Kazakhstan, where the most recent finalized tax audit dates back to 2012.  Because the Kazakh tax authorities have not completed a newer audit, Chevron continues to face uncertainty over the assessment and collection of any additional taxes on the earnings generated by TCO, even though the loan itself is not directly tied to that historical audit.  Consequently, the financial risk of the loan intersects with the lingering tax uncertainties in Kazakhstan, as the company must assess potential tax liabilities on the venture’s future cash flows despite the lack of a recent finalized audit.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91717,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23178,
        "completion_tokens": 208,
        "total_tokens": 23386
      }
    },
    {
      "question_id": 28,
      "question": "What is the fair value of MDLZ's net investment hedge contracts as of December 31, 2021, and how does the valuation methodology for these contracts reflect their classification within Level 2 financial liabilities?",
      "original_answer": "As of December 31, 2021, the fair value of MDLZ's net investment hedge contracts was $71 million, as disclosed in the fair value hierarchy table. These contracts are included within Level 2 financial liabilities, which are valued using observable market inputs. Specifically, the valuation methodology for Level 2 instruments, including net investment hedge contracts, relies on income-based approaches using observable market data such as forward rates, commodity prices, and interest rate curves, as detailed in the description of Level 2 financial assets and liabilities. This classification and valuation approach reflects the use of significant other observable inputs rather than direct market quotes (Level 1) or unobservable assumptions (Level 3).",
      "llm_answer": "The fair value of MDLZ's net investment hedge contracts as of December 31 2021 was $71 million, and these contracts are classified as Level 2 financial liabilities because their fair values are determined using observable market inputs (e.g., observable market forward rates, interest‑rate curves, and other market‑based assumptions) rather than quoted prices in an active market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78564,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19869,
        "completion_tokens": 95,
        "total_tokens": 19964
      }
    },
    {
      "question_id": 29,
      "question": "How does Nike's foreign exchange risk management strategy for product purchases through the Nike Trading Company (NTC) reflect both the currency exposure created by NTC's functional currency and the broader transactional exposure management approach described in the financial statements?",
      "original_answer": "Nike manages foreign exchange risk related to product purchases through the NTC, which operates with the U.S. Dollar as its functional currency. When NTC sells products to Nike entities with different functional currencies, it creates foreign currency exposure. This exposure is managed under Nike’s broader foreign currency risk management program, which uses cash flow hedges and natural offsets to mitigate the impact of exchange rate fluctuations on consolidated financial results. The strategy reflects both the structural exposure created by NTC's role as a U.S. Dollar-based sourcing hub and Nike’s systematic approach to hedging transactional exposures across the business.",
      "llm_answer": "Nike manages foreign‑exchange risk on product purchases through the Nike Trading Company (NTC) by hedging the currency exposure that arises when NTC—whose functional currency is the U.S. dollar—sells products to Nike entities with non‑U.S.‑dollar functional currencies. The hedging program uses forward contracts and options designated as cash‑flow hedges to offset these exposures, and the resulting gains or losses are recorded in accumulated other comprehensive income and later reclassified to earnings when the underlying transactions affect net income. This approach directly addresses both the currency risk created by NTC’s functional‑currency translation and the broader transactional exposure management described in the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89460,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22614,
        "completion_tokens": 188,
        "total_tokens": 22802
      }
    },
    {
      "question_id": 30,
      "question": "How does NIKE's foreign exchange risk management strategy for product costs relate to its reliance on the NIKE Trading Company (NTC) for sourcing, and what impact does this have on inventory cost volatility?",
      "original_answer": "NIKE manages foreign exchange risk related to product costs by hedging exposures generated through non-functional currency denominated purchases, including those made through the NIKE Trading Company (NTC). The NTC, which operates in U.S. Dollars, sources products from third-party factories and sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure. A stronger U.S. Dollar increases inventory costs for these entities, while a weaker Dollar reduces them. NIKE mitigates this volatility using a combination of natural offsets and derivative instruments, such as currency forwards and options, which are accounted for as cash flow hedges. This layered approach helps stabilize inventory costs despite fluctuations in foreign exchange rates tied to NTC transactions.",
      "llm_answer": "NIKE manages foreign‑exchange risk for product costs primarily through its sourcing hub, the NIKE Trading Company (NTC), which purchases products from third‑party factories in U.S. dollars and then sells them to other NIKE entities in their local functional currencies. This structure creates foreign‑currency exposure for the NTC and for other entities that buy directly in U.S. dollars; the company mitigates that exposure with cash‑flow hedges (forward contracts and options) that can cover up to 100 % of the identified exposure and may be placed up to 12–24 months in advance. Because the hedges are designated as cash‑flow hedges, the resulting gains or losses are recorded in Accumulated Other Comprehensive Income and are reclassified into net income as the underlying hedged transactions (e.g., inventory purchases) affect earnings, which helps smooth the volatility of inventory costs that would otherwise fluctuate with exchange‑rate movements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87100,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22004,
        "completion_tokens": 238,
        "total_tokens": 22242
      }
    },
    {
      "question_id": 34,
      "question": "How does Nike's foreign exchange risk management strategy for product purchases through the Nike Trading Company (NTC) reflect both the cost exposure dynamics described in the hedging section and the functional currency mismatch risks outlined in the transactional exposures section?",
      "original_answer": "Nike manages foreign exchange risk related to product purchases through the NTC by using cash flow hedges, which are designed to offset the variability in cash flows caused by currency fluctuations. The NTC, whose functional currency is the U.S. Dollar, purchases products from third-party factories predominantly in U.S. Dollars and then sells them to Nike entities in their respective functional currencies. This creates a foreign currency exposure for the NTC when selling to Nike subsidiaries with different functional currencies. According to the transactional exposures section, this exposure is significant and is managed through a portfolio-based approach that includes natural offsets and the use of currency forward and option contracts. The hedging section explains that these contracts are generally accounted for as cash flow hedges, aligning with the need to stabilize the consolidated financial results against the volatility introduced by the functional currency mismatch between the NTC and other Nike entities.",
      "llm_answer": "Nike manages foreign exchange risk for product purchases through the Nike Trading Company (NTC) by leveraging its currency hedging program to offset exposure from two key sources: (1) transactional exposures from product cost fluctuations due to foreign currency movements (e.g., purchases from NTC in USD by non-USD subsidiaries or direct factory purchases in USD), and (2) translation exposure from non-functional currency revenues and assets. The hedging strategy—using forward contracts and options designated as cash flow hedges—directly addresses cost exposure dynamics by delaying the impact of exchange rate changes on inventory costs (e.g., a stronger USD reduces non-USD inventory costs, while a weaker USD increases them), while also mitigating functional currency mismatch risks in translation exposure, as reflected in the $231 million of deferred net gains in accumulated other comprehensive income expected to be reclassified to net income over the next 12 months. This integrated approach ensures that foreign exchange volatility in product purchasing is systematically managed to protect margins and financial results.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89460,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22613,
        "completion_tokens": 283,
        "total_tokens": 22896
      }
    },
    {
      "question_id": 45,
      "question": "How does ConocoPhillips' reliance on DeGolyer and MacNaughton to review over 85% of its proved reserves estimation processes align with the inclusion of their independent report as Exhibit 99 in the 10-K filing?",
      "original_answer": "ConocoPhillips utilizes DeGolyer and MacNaughton (D&M) to independently review over 85% of its proved reserves estimation processes, ensuring compliance with SEC regulations and internal policy. This third-party review is a key part of the company’s internal control framework for reserves reporting. The results of D&M's evaluation are formally documented in a report that is included as Exhibit 99 in the 10-K filing, demonstrating transparency and external validation of the company’s reserves estimation methodology. This linkage shows how ConocoPhillips integrates external expert analysis into its regulatory disclosures to reinforce the credibility of its reserves reporting.",
      "llm_answer": "ConocoPhillips’ reliance on DeGolyer and MacNaughton to review the processes for estimating more than 85 percent of its proved reserves directly supports the inclusion of D & M’s independent assessment as Exhibit 99 in the 10‑K, because that exhibit formally documents the third‑party firm’s review and its conclusion that ConocoPhillips’ reserves estimation procedures comply with SEC regulations. The filing explicitly states that D & M’s report, which covers the majority of the reserves, is attached as Exhibit 99, providing investors with an external validation of the reserves methodology.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78046,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19744,
        "completion_tokens": 148,
        "total_tokens": 19892
      }
    },
    {
      "question_id": 57,
      "question": "How does Disney's exclusion of forecasted foreign currency transactions from its Value at Risk (VAR) model impact the assessment of its foreign exchange risk exposure, given its $9.9 billion notional amount of foreign exchange cash flow hedges and a VAR estimate of $255 million?",
      "original_answer": "Disney actively manages its foreign exchange risk by hedging forecasted foreign currency transactions, with a notional amount of $9.9 billion in cash flow hedges as of September 28, 2024. However, these forecasted transactions are explicitly excluded from the company’s Value at Risk (VAR) model, which focuses only on existing financial instruments like derivatives and market-sensitive equity investments. The VAR model estimates a maximum one-day loss of $255 million under a 95% confidence level, based on historical market volatility. This creates a divergence in how foreign exchange risk is quantified: the hedging program reflects proactive risk management of future exposures, while the VAR model does not account for these forward-looking transactions. Therefore, the $255 million VAR figure may understate the company's total foreign exchange risk exposure since it omits forecasted transactions that are economically relevant and actively hedged.",
      "llm_answer": "Disney’s VAR model deliberately omits forecasted foreign‑currency cash‑flow transactions that are intended to be hedged, so the $255 million one‑day VAR figure does not capture the full market‑risk exposure tied to those hedged cash flows. Consequently, while the VAR indicates a relatively modest $40 million potential loss from currency‑sensitive instruments, the actual foreign‑exchange risk associated with its $9.9 billion of notional foreign‑exchange cash‑flow hedges is likely larger and not reflected in the reported VAR. This exclusion limits the ability of the VAR to fully represent Disney’s foreign‑exchange risk exposure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67110,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17025,
        "completion_tokens": 158,
        "total_tokens": 17184
      }
    },
    {
      "question_id": 61,
      "question": "How does the cessation of future benefit accruals in the UPS Retirement Plan for non-union participants, effective January 1, 2023, align with the IRS limits on tax-qualified defined benefit plans and the subsequent shift toward defined contribution plan structures, such as the UPS 401(k) Savings Plan with IRS-prescribed limits?",
      "original_answer": "The cessation of future benefit accruals in the UPS Retirement Plan for non-union participants as of January 1, 2023, reflects a strategic shift away from defined benefit plans toward defined contribution plans, such as the UPS 401(k) Savings Plan. This shift aligns with the IRS-prescribed limits on tax-qualified plans, which constrain the maximum compensation and contributions that can be made on behalf of employees. In response, UPS transitioned non-union employees to a defined contribution model, where they now receive annual retirement contributions of 5% to 8% of eligible compensation based on years of service (up from 3% to 8% in 2023), subject to IRS limits. Additionally, UPS sponsors the UPS Restoration Savings Plan, a non-qualified plan that accommodates contributions exceeding IRS limits. This transition reflects both regulatory constraints and a broader strategic move to reduce long-term pension liabilities while maintaining competitive retirement benefits.",
      "llm_answer": "The UPS Retirement Plan for non‑union participants stopped accruing future benefits as of January 1 2023, which brings the plan into compliance with IRS limits on tax‑qualified defined‑benefit plans (maximum compensation and benefit caps). To continue providing retirement income while staying within those IRS limits, UPS shifted to a defined‑contribution structure – the UPS 401(k) Savings Plan – where contributions are made as a percentage of eligible compensation (5 %‑8 % in 2023, reduced to 3 % for employees hired on or after January 1 2025) and are subject to the IRS‑prescribed contribution caps. This transition allows UPS to offer retirement benefits that respect the regulatory ceiling while moving away from a traditional defined‑benefit accrual model.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64966,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16497,
        "completion_tokens": 191,
        "total_tokens": 16688
      }
    },
    {
      "question_id": 65,
      "question": "How does UPS's reliance on net asset value (NAV) estimates for its U.S. pension plan investments reconcile with the illiquidity and long-term nature of its real estate fund commitments totaling $3.3 billion?",
      "original_answer": "UPS utilizes estimated NAV to value its U.S. pension plan investments in hedge funds, private debt, private equity, and real estate, which totaled $9.9 billion as of December 31, 2023. These NAV-based valuations are derived from fund managers’ financial reports and involve subjective adjustments due to the lack of active trading and readily determinable market values. This valuation approach introduces estimation risk, as the reported values may differ from what would be determined with more transparent market data. Meanwhile, the company has unfunded commitments of $3.3 billion to limited partnerships, including real estate funds, which are typically locked up for 10–15 years with limited redemption rights. The long-term, illiquid nature of these commitments contrasts with the NAV estimation process, which relies on periodic and potentially delayed financial reports. This creates a tension between the subjective, audit-intensive valuation methodology and the binding, long-duration investment profile of the real estate and private market assets.",
      "llm_answer": "UPS reports its U.S. pension plan investments at fair value, but many of those investments—particularly real‑estate, private‑equity and hedge‑fund interests—are valued using net‑asset‑value (NAV) estimates rather than observable market prices. Because these assets are illiquid and have long‑term lock‑up periods, the company must rely on subjective NAV calculations to determine their carrying amounts, even though the total unfunded commitment for such real‑estate fund interests is about $3.3 billion. This reliance on NAV is disclosed in the footnote on alternative‑investment valuations and is a key audit matter given the inherent estimation uncertainty.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77282,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19549,
        "completion_tokens": 165,
        "total_tokens": 19714
      }
    },
    {
      "question_id": 83,
      "question": "How does AMD's binding commitment under the 2022-2025 Wafer Supply Agreement with GLOBALFOUNDRIES, including pre-payment obligations and minimum capacity allocation, reconcile with their broader supply chain risk disclosures regarding lack of long-term commitments with third-party manufacturers and potential inventory cost impacts?",
      "original_answer": "AMD has a binding Wafer Supply Agreement (WSA) with GLOBALFOUNDRIES U.S. Inc. through 2025, which includes minimum annual capacity allocation from GF and corresponding annual wafer purchase targets for AMD. If AMD fails to meet these targets, it must pay a portion of the shortfall, and the company is obligated to pre-pay GF certain amounts for wafers in 2022 and 2023. This represents a significant long-term commitment, contrasting with AMD’s broader supply chain risk disclosures where they note that they do not have long-term commitment contracts with some third-party manufacturers and instead rely on purchase orders. This lack of guaranteed supply from other manufacturers introduces risks around capacity allocation, pricing, and delivery timelines. Furthermore, if AMD’s actual wafer requirements fall short of the purchase targets under the WSA, the company could face excess inventory or higher inventory unit costs, which may adversely impact gross margins. The WSA introduces both stability and risk, depending on AMD’s ability to forecast and meet its wafer demand over the agreement’s term.",
      "llm_answer": "AMD’s 2022‑2025 Wafer Supply Agreement with GLOBALFOUNDRIES obligates the company to purchase a minimum annual wafer quantity and to pre‑pay for those wafers, while also setting fixed pricing through 2025.  This contractual commitment stands in contrast to AMD’s broader risk disclosures, which repeatedly stress that it has no long‑term volume commitments with third‑party foundries and that insufficient capacity, price changes, or supply disruptions could materially harm the business.  Consequently, the binding wafer‑purchase targets and pre‑payment obligations create a specific, enforceable supply guarantee that mitigates some of the general supply‑chain risk AMD describes, but they also expose AMD to inventory‑cost and excess‑capacity risks if actual demand falls short of the contracted purchase targets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83904,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21236,
        "completion_tokens": 204,
        "total_tokens": 21440
      }
    },
    {
      "question_id": 86,
      "question": "How does Cisco's disclosure of interest rate sensitivity for its senior fixed-rate notes reconcile with its short-term commercial paper financing program, particularly in light of the $1.5 billion in hedged debt?",
      "original_answer": "Cisco disclosed that a 50 BPS change in interest rates would impact the fair value of its senior fixed-rate debt (excluding $1.5 billion of hedged debt) by $0.3 billion. This sensitivity analysis applies to the $9.0 billion in senior fixed-rate notes, which are partially hedged through $1.5 billion in interest rate swaps that convert fixed rates to floating rates tied to LIBOR. These hedged senior notes rank at par with the commercial paper notes Cisco issues under its $10.0 billion short-term financing program. While the long-term fixed-rate notes are exposed to fair value changes from rate movements, the commercial paper notes, being short-term instruments, are inherently less sensitive to interest rate fluctuations. Thus, Cisco manages interest rate exposure through a combination of hedging and balancing fixed and floating rate debt instruments across its capital structure.",
      "llm_answer": "Cisco discloses interest rate sensitivity for its senior fixed‑rate notes and hedges $1.5 billion of that debt with interest‑rate swaps, while its short‑term commercial paper program provides up to $10 billion of financing that is not hedged and carries variable rates; the $1.5 billion of hedged debt is reflected in the “hedge accounting fair value adjustments” and the related fair‑value hedge adjustments are recorded in earnings, whereas the commercial paper borrowings are reported at their effective rates (e.g., 2.05 % for the $600 million issuance) and are not subject to the same hedge‑related accounting. Consequently, the hedged senior notes’ interest‑rate exposure is managed through swaps that offset changes in the notes’ fair value, while the commercial paper program’s exposure is managed through the variable‑rate notes and the company’s liquidity position, resulting in distinct disclosure and accounting treatments for the two financing sources.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 80371,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20324,
        "completion_tokens": 241,
        "total_tokens": 20565
      }
    },
    {
      "question_id": 94,
      "question": "How does AIG's announcement of the full redemption of its Series A Preferred Stock relate to the Depositary Shares disclosed in the securities registration, and what does this imply about the structure and treatment of these financial instruments?",
      "original_answer": "AIG disclosed in its securities registration on page 1 that it issued 20,000,000 Depositary Shares, each representing a 1/1,000th interest in a share of Series A 5.85% Non-Cumulative Perpetual Preferred Stock. On page 238, AIG announced that it would redeem all 20,000 outstanding shares of the Series A Preferred Stock, which corresponds to all 20,000,000 Depositary Shares. This redemption, priced at $25.00 per Depositary Share ($25,000 per Series A Preferred Stock share), illustrates the direct proportional relationship between the Depositary Shares and the underlying Preferred Stock. The fact that AIG is redeeming both in full highlights that the Depositary Shares are structured as a divisible proxy for ownership in the Series A Preferred Stock, and that both instruments are treated in alignment for purposes of redemption and capital structure management.",
      "llm_answer": "AIG announced that it will redeem all 20,000 outstanding shares of its Series A Preferred Stock and the corresponding 20 million Depositary Shares (each representing a 1/1,000th interest in a Series A Preferred share) on March 15 2024 at a redemption price of $25,000 per share of Series A Preferred Stock (equivalent to $25.00 per Depositary Share). Because the redemption price is payable only after all declared dividends on the Series A Preferred Stock have been paid, the redemption effectively retires the preferred instrument and eliminates the Depositary Shares, simplifying the capital structure and removing the dividend‑payment constraint that previously limited common‑stock dividend declarations. This action reflects AIG’s strategy to retire the legacy preferred equity and streamline its equity base as part of its broader deconsolidation and capital‑management initiatives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 239,
          "pages": [
            237,
            238,
            239,
            240,
            241
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 238,
          "pages": [
            236,
            237,
            238,
            239,
            240
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 138442,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 34850,
        "completion_tokens": 222,
        "total_tokens": 35073
      }
    },
    {
      "question_id": 104,
      "question": "How does the maturity of the 3.625% 2024 Notes impact the fair value and balance sheet presentation of interest rate swap contracts, given Amgen's stated hedging strategy?",
      "original_answer": "The maturity of the $1.4 billion 3.625% 2024 Notes resulted in the termination of associated interest rate swap contracts, which contributed to the reduction in the fair value of derivative liabilities related to interest rate swaps on the balance sheet. As of December 31, 2024, interest rate swap contracts are not listed among derivative liabilities, contrasting with the $571 million liability reported for these instruments as of December 31, 2023. This aligns with Amgen's stated hedging strategy of using interest rate swaps to convert fixed-rate debt to floating-rate debt, where the termination of the hedged debt (3.625% 2024 Notes) would logically result in the removal of the related hedging instruments from the balance sheet.",
      "llm_answer": "The 3.625% 2024 Notes matured in 2024, and the related interest‑rate swap contracts that were designated as fair‑value hedges were terminated.  As a result, the fair‑value adjustments on those swaps were recorded as a $29 million gain in interest expense for the year ended December 31 2024 and a corresponding $40 million gain was recognized in other income, reflecting the offsetting impact of the hedge on the hedged liability.  These gains are part of Amgen’s broader hedging strategy that uses fair‑value swaps to convert the fixed‑rate debt to floating‑rate exposure, thereby managing the interest‑rate risk of the debt that remains on the balance sheet.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 149,
          "pages": [
            147,
            148,
            149,
            150,
            151
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 148,
          "pages": [
            146,
            147,
            148,
            149,
            150
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87368,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22062,
        "completion_tokens": 165,
        "total_tokens": 22227
      }
    },
    {
      "question_id": 111,
      "question": "How does the maturity of the 3.625% 2024 Notes impact the fair value and liability treatment of Amgen's interest rate swap contracts as disclosed in the derivative instruments section?",
      "original_answer": "The maturity of the $1.4 billion 3.625% 2024 Notes resulted in the termination of associated interest rate swap contracts during the year ended December 31, 2024. This event reduced the notional amount of active interest rate swaps from $6.7 billion at the beginning of the year. As of December 31, 2024, Amgen no longer held any derivative assets related to these terminated interest rate swaps, and the remaining liability related to interest rate swaps stood at $571 million as per the consolidated balance sheets. This reflects the dynamic relationship between debt maturities and the corresponding hedging instruments, which directly affects the fair value and liability recognition of derivatives.",
      "llm_answer": "The maturity of the 3.625% 2024 Notes (which had a $1.4 billion notional amount of interest‑rate swaps designated as fair‑value hedges) required the company to settle those swaps when the notes were repaid.  Upon termination, the realized gain or loss on the swaps was recorded as an adjustment to the carrying value of the retired debt and then amortized into interest expense over the remaining term of the previously hedged liability.  This treatment affects both the fair‑value measurement of the swaps and the liability presentation of the retired notes in the consolidated balance sheet.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 149,
          "pages": [
            147,
            148,
            149,
            150,
            151
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 148,
          "pages": [
            146,
            147,
            148,
            149,
            150
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87368,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22065,
        "completion_tokens": 148,
        "total_tokens": 22213
      }
    },
    {
      "question_id": 146,
      "question": "How does BMY's revenue from Orencia in 2023 relate to its joint commercialization arrangement with Ono, particularly considering the co-promotion fee structure and BMY's responsibility for product supply in Japan?",
      "original_answer": "BMY reported $3,601 million in revenue from Orencia in 2023, which is directly tied to its joint commercialization agreement with Ono. Under the arrangement, BMY is responsible for product supply and order fulfillment for the intravenous formulation of Orencia, while Ono handles the subcutaneous formulation. Both parties jointly promote the drug in Japan, with a co-promotion fee of 60% paid when a sale is made to the other party's assigned customer. This fee structure and shared promotional responsibility likely influence the revenue distribution and operational dynamics of Orencia in the Japanese market, as BMY remains the primary supplier despite shared promotion.",
      "llm_answer": "BMY's 2023 revenue from Orencia in Japan is generated through its co‑promotion agreement with Ono, where BMS is responsible for product supply (including both intravenous and subcutaneous formulations) and receives a 60 % co‑promotion fee on sales made to Ono’s assigned customers; this arrangement is reflected in the alliance’s net product sales of $12,543 million for 2023, with BMS recording revenue from Orencia as part of its alliance revenues and recognizing the co‑promotion fees as part of alliance and other revenues.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69189,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17525,
        "completion_tokens": 131,
        "total_tokens": 17657
      }
    },
    {
      "question_id": 208,
      "question": "How does Capital One's adoption of ASU 2022-02 impact the accounting treatment of loan modifications previously classified as Troubled Debt Restructurings, and what new framework replaced TDRs under this standard effective January 1, 2023?",
      "original_answer": "Capital One adopted ASU 2022-02 on January 1, 2023, which eliminated the accounting guidance for Troubled Debt Restructurings (TDRs). As a result, loan modifications that were previously classified as TDRs are now accounted for under a new framework called Financial Difficulty Modifications (FDMs). FDMs capture modifications made to borrowers experiencing financial difficulty, including principal forgiveness, interest rate reductions, payment delays, or term extensions, but are treated differently under the updated standard, reflecting a shift in how such credit events are recognized and disclosed.",
      "llm_answer": "Capital One adopted ASU 2022-02 effective January 1, 2023, which eliminated the separate accounting guidance for Troubled Debt Restructurings (TDRs). The new framework under ASU 2022-02 replaces TDR classification by requiring modifications to be evaluated under the Financial Difficulty Modification (FDM) framework, which assesses whether a loan modification grants a concession to a borrower experiencing financial difficulty. This change means loan modifications previously classified as TDRs are now evaluated based on the FDM criteria rather than being automatically categorized as TDRs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 122,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 46780,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 11932,
        "completion_tokens": 148,
        "total_tokens": 12080
      }
    },
    {
      "question_id": 1,
      "question": "How does MetLife's inclusion of credit insurance in the EMEA segment compare with the overall performance of that segment in 2023, and what does this suggest about the contribution of credit insurance in that region?",
      "original_answer": "MetLife offers credit insurance as part of its product portfolio in the EMEA segment, which reported earnings of $265 million in 2023. This relatively low adjusted earnings contribution compared to other segments like Group Benefits ($1,655 million) or RIS ($1,708 million) suggests that the EMEA segment, despite offering credit insurance alongside other products, had a limited overall financial impact on the company in 2023. This could indicate either a smaller market presence in EMEA or lower profitability from products like credit insurance in that region.",
      "llm_answer": "In 2023, MetLife’s EMEA segment generated $265 million of adjusted earnings (up from $249 million in 2022), while the overall EMEA segment contributed $189 million to net income available to common shareholders and $194 million to adjusted earnings. Credit insurance is listed as a distinct product offering within EMEA alongside life, retirement/savings and accident & health insurance, and its earnings impact is captured in the segment’s adjusted earnings and premium figures. The modest growth in EMEA earnings and the inclusion of credit insurance in the segment’s product mix suggest that credit insurance provides a meaningful, though not dominant, contribution to the region’s profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 169,
          "pages": [
            167,
            168,
            169,
            170,
            171
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 86019,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21741,
        "completion_tokens": 174,
        "total_tokens": 21916
      }
    },
    {
      "question_id": 1,
      "question": "How does Philip Morris International's characterization of illicit trade as a systemic risk factor reconcile with the reported decline in illicit trade prevalence in Pakistan, where the company recently incurred $20 million in plant closure costs?",
      "original_answer": "Philip Morris International identifies illicit trade in tobacco products as a major risk factor that negatively impacts its business, volume, results of operations, and financial position (Page 40). However, in South & Southeast Asia, including Pakistan, the company notes a 17.3% market increase driven partly by a lower prevalence of illicit trade during the pandemic (Page 58). Despite this favorable trend, the company recorded $20 million in asset impairment and exit costs related to a cigarette plant closure in Pakistan (Page 126), suggesting that market dynamics, even with reduced illicit trade, did not justify continued local production. This indicates a complex interplay between risk mitigation and operational restructuring in response to evolving market conditions.",
      "llm_answer": "Philip Morris International classifies illicit trade as a systemic risk factor in its disclosures, yet it reported a decline in illicit trade prevalence in Pakistan—a country where the company incurred $20 million in plant‑closure costs in 2019. This apparent contradiction reflects that while the company acknowledges illicit trade as a material threat to its operations and revenue, the specific reduction in illicit activity in Pakistan is likely driven by temporary factors such as pandemic‑related supply disruptions and heightened enforcement, rather than a long‑term improvement in the illicit market. Consequently, the $20 million closure expense is tied to legitimate manufacturing optimization, not to a resolution of illicit trade concerns.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 126,
          "pages": [
            124,
            125,
            126,
            127,
            128
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70784,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17941,
        "completion_tokens": 187,
        "total_tokens": 18128
      }
    },
    {
      "question_id": 1,
      "question": "How does LLY's reliance on biologics data protection for Emgality in the U.S., which expires in 2030, align with their broader strategy of managing market exclusivity given the complex interaction between patent and regulatory protections?",
      "original_answer": "LLY relies on both compound patents and biologics data protection for Emgality, with U.S. data protection expiring in 2030 and compound patents extending until 2033. This staggered protection suggests a strategy to prolong market exclusivity by leveraging multiple forms of intellectual property. However, the company acknowledges on page 11 that predicting the actual length of exclusivity is difficult due to the complex interaction between patent and regulatory protections, as well as uncertainties in litigation and exclusivity extensions like pediatric or orphan drug designations. This implies that while LLY plans for extended exclusivity through layered protections, the real-world outcome may vary significantly from the estimated expiry dates.",
      "llm_answer": "LLY’s reliance on biologics data protection for Emgality in the U.S., which expires in 2030, aligns with its broader strategy of managing market exclusivity by leveraging the complex interaction between patent and regulatory protections. While compound patents for Emgality extend to 2033 in the U.S., the biologics data protection period—critical for blocking biosimilar competition—expires earlier in 2030, ensuring a defined window of exclusivity that complements patent protection and supports long-term commercial planning. This strategy acknowledges the BPCIA framework, which allows early patent challenges but underscores the importance of data protection as a key regulatory barrier to generic and biosimilar entry.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 57339,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14568,
        "completion_tokens": 181,
        "total_tokens": 14749
      }
    },
    {
      "question_id": 1,
      "question": "How does Chevron's joint venture in Louisiana for soybean oil production align with the legal risks the company faces in the same state related to coastal erosion from historical oil and gas operations?",
      "original_answer": "Chevron holds a 50% working interest in Bunge Chevron Ag Renewables LLC, which operates soybean oil processing facilities in Destrehan, Louisiana. This renewable feedstock is critical for Chevron’s renewable fuels strategy, including renewable diesel and sustainable aviation fuel production. Meanwhile, Chevron faces 39 lawsuits in Louisiana related to coastal erosion from historical oil and gas operations, with a trial set for October 2024 and potential material financial impact. While the soybean operations in Louisiana support Chevron’s strategic pivot toward lower-carbon energy, the state also represents a significant legal liability due to legacy fossil fuel activities, creating a dual exposure where operational growth and legal risk coexist in the same geographic region.",
      "llm_answer": "Chevron’s Louisiana soybean‑oil joint venture is part of its broader renewable‑fuel strategy, but it occurs amid significant legal exposure from Louisiana coastal‑erosion lawsuits that target the company’s historic oil and gas activities. These coastal‑erosion cases allege that Chevron’s past operations caused wetland loss and seek damages for restoration, creating a material litigation risk that coexists with the company’s new renewable‑fuel investments in the state.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80161,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20268,
        "completion_tokens": 118,
        "total_tokens": 20386
      }
    },
    {
      "question_id": 1,
      "question": "How does GM's strategic emphasis on crossovers as a key product category align with its financial transactions and equity stake in nonconsolidated affiliates involved in crossover production?",
      "original_answer": "GM highlights crossovers as a core product category within its automotive operations, noting that these vehicles help maintain sales volumes and contribute to fuel efficiency goals. The company also engages in transactions with nonconsolidated affiliates involved in the development, production, and marketing of crossovers, indicating a strategic reliance on these partners. However, since these affiliates are not consolidated, their financial performance does not directly appear in GM’s consolidated results, despite their importance to crossover output. This structure allows GM to leverage external manufacturing capacity without fully absorbing the financial risks associated with direct ownership, aligning with its broader approach to managing costs and scaling production efficiently.",
      "llm_answer": "GM's strategic focus on crossovers aligns with its financial involvement in nonconsolidated affiliates that produce crossovers, as evidenced by its equity stakes in China joint ventures (e.g., SAIC-GM-Wuling) and its $2.27 billion in automotive purchases from these affiliates in 2023. These relationships support the production and marketing of crossover vehicles, reinforcing GM's market positioning while generating equity income and supply‑chain synergies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2023.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2023.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2023.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 104147,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26262,
        "completion_tokens": 115,
        "total_tokens": 26377
      }
    },
    {
      "question_id": 1,
      "question": "How does Alphabet's stock repurchase strategy for Class A shares align with the use of Class C shares in employee compensation plans, given the identical economic rights of both share classes?",
      "original_answer": "Alphabet repurchases Class A and Class C shares based on economic cost and market conditions (page 81), while the company issues Class C shares specifically through its 2021 Stock Plan for employee compensation, with 723 million shares reserved for this purpose (page 83). Despite these different uses, both share classes have identical liquidation and dividend rights (page 81), suggesting the company maintains economic parity between the two while strategically deploying Class C shares for equity compensation and repurchasing both based on market dynamics.",
      "llm_answer": "Alphabet’s stock‑repurchase program treats Class A and Class C shares identically in economic terms—both are repurchased and retired in the same dollar amounts and with the same per‑share pricing considerations—even though only Class A carries voting rights. Because the two classes have identical dividend, liquidation and other economic rights, the company can fund its employee compensation plans (which primarily use Class C RSUs) using cash generated from repurchases of either share class without creating a material economic distinction between them. This alignment allows the company to execute its share‑repurchase authorizations while maintaining a consistent compensation structure tied to Class C equity awards.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 90436,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22831,
        "completion_tokens": 180,
        "total_tokens": 23012
      }
    },
    {
      "question_id": 1,
      "question": "How does AMT's strategic decision to divest ATC TIPL and the resulting $1.2 billion loss impact its financial strategy, particularly in relation to the capital repurposing agreement with DIT valued at approximately $2.5 billion?",
      "original_answer": "AMT's decision to divest ATC TIPL was part of a broader strategic review of its India operations aimed at repurposing capital to drive long-term shareholder value. The transaction with DIT, valued at approximately $2.5 billion, culminated in the completion of the sale on September 12, 2024, with AMT receiving $2.2 billion in total consideration. Despite the strategic intent, the company recorded a $1.2 billion loss on the sale, primarily due to the reclassification of cumulative translation adjustments in India. The proceeds were used to repay existing indebtedness under the 2021 Multicurrency Credit Facility, aligning with AMT's financial strategy to reduce leverage and reallocate capital more effectively.",
      "llm_answer": "The divestiture of ATC TIPL generated a $1.2 billion loss—primarily the reclassification of cumulative translation adjustments—while the transaction delivered roughly $2.5 billion of consideration (including the VIL shares and OCDs). The proceeds were used to retire existing Indian debt and repay the 2021 multicurrency credit facility, allowing AMT to reallocate capital toward its core U.S. and international tower portfolios and growth initiatives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64497,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16359,
        "completion_tokens": 113,
        "total_tokens": 16472
      }
    },
    {
      "question_id": 1,
      "question": "How does Disney's disclosure about potential withdrawal liabilities from multiemployer pension plans reconcile with their contributions to plans that have eligibility requirements tied to collective bargaining units?",
      "original_answer": "Disney disclosed that if a participating employer withdraws from multiemployer pension plans, it may be required to pay an amount based on the underfunded status of the plan (page 109). The company contributes to several such plans that cover union-represented employees, with benefits determined by specific eligibility and participation requirements under collective bargaining agreements (page 108). These contributions are expensed as incurred, and the company faces risks such as the potential assumption of unfunded obligations from other employers’ withdrawal. The eligibility requirements directly shape which employees are covered and thus influence the company’s exposure to future liabilities, creating a link between the structure of the plans and the financial risks Disney faces.",
      "llm_answer": "Disney's disclosure of potential withdrawal liabilities from multiemployer pension plans aligns with its contributions to these plans, which are governed by collective bargaining agreements that include specific eligibility requirements for participating employees. The document notes that these multiemployer plans provide benefits based on eligibility criteria tied to union-represented employees within defined collective bargaining units, and that risks differ from single-employer plans—such as the possibility that if an employer stops contributing, the unfunded obligations may become the responsibility of remaining employers. Disney's contributions to these plans (e.g., $291 million to pension plans in 2024) are made as incurred under these agreements, and the disclosure of withdrawal liabilities reflects the potential financial impact under the terms of these collectively bargained plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78860,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19943,
        "completion_tokens": 225,
        "total_tokens": 20169
      }
    },
    {
      "question_id": 1,
      "question": "How does Duke Energy Indiana's disclosure of fair value estimates for AFS debt investments in 2023 align with the company's broader accounting policy that defers unrealized gains and losses on AFS securities to regulatory accounts?",
      "original_answer": "Duke Energy Indiana specifically presents the estimated fair value of its AFS debt investments in a table on page 187, indicating a structured reporting of these financial instruments. These debt investments are classified as AFS, which, as disclosed on page 184, means that unrealized gains and losses are generally deferred to other comprehensive income and only realized gains or losses impact net income. However, the 10-K also states on page 184 that substantially all of Duke Energy’s AFS debt and equity securities qualify for regulatory accounting, and as such, the associated unrealized gains and losses are deferred as regulatory assets or liabilities. This alignment shows that while Duke Energy Indiana quantitatively discloses the fair value of AFS debt investments, the broader company policy ensures that the financial statement impact of unrealized movements is deferred through regulatory mechanisms, preserving income stability.",
      "llm_answer": "Duke Energy Indiana's disclosure of fair value estimates for available‑for‑sale (AFS) debt investments in 2023 aligns with its broader accounting policy of deferring unrealized gains and losses on AFS securities to regulatory accounts. The company records AFS securities at fair value, classifies most debt securities as Level 2 measurements, and reports the resulting unrealized gains and losses in other comprehensive income until realized; however, because these investments qualify for regulatory accounting, the gains and losses are deferred as regulatory assets or liabilities rather than being recognized directly in earnings. This approach ensures that the fair‑value estimates presented for Indiana’s AFS debt securities are consistent with the company’s overall policy of offsetting and deferring such fluctuations to regulatory accounts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 105276,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26554,
        "completion_tokens": 212,
        "total_tokens": 26766
      }
    },
    {
      "question_id": 1,
      "question": "How does MetLife's disclosure of surplus notes at face value of $507 million reconcile with the statutory accounting treatment that classifies surplus notes as surplus rather than debt, and what implications does this have for regulatory capital compliance?",
      "original_answer": "MetLife discloses surplus notes totaling $507 million at face value in its long-term debt schedule, treating them as debt instruments under GAAP. However, statutory accounting practices, as described in the notes to financial statements, treat surplus notes as surplus rather than debt, which directly impacts regulatory capital calculations. This classification increases statutory capital and surplus, aiding compliance with risk-based capital requirements. MetLife's statutory capital and surplus, particularly for its U.S. insurance subsidiaries, benefit from this treatment, contributing to a Statement-Based Combined RBC Ratio in excess of 360% at year-end 2021.",
      "llm_answer": "MetLife records its surplus notes at their face amount of $507 million, classifying them as surplus rather than debt; this treatment is consistent with statutory accounting, which permits surplus notes to be reported as surplus and not as a liability. Because surplus notes are counted as surplus under regulatory capital rules, they enhance MetLife’s statutory surplus and help satisfy the minimum capital and surplus requirements that regulators impose on its insurance subsidiaries. Consequently, the surplus‑note classification provides additional regulatory capital capacity without increasing debt‑related leverage ratios.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 276,
          "pages": [
            274,
            275,
            276,
            277,
            278
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 292,
          "pages": [
            290,
            291,
            292,
            293,
            294
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75530,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19132,
        "completion_tokens": 157,
        "total_tokens": 19289
      }
    },
    {
      "question_id": 1,
      "question": "How does GD's reliance on commercial paper issuances for liquidity needs align with the $4 billion credit facility's role in supporting those issuances, given the company's emphasis on maintaining a strong balance sheet?",
      "original_answer": "GD emphasizes cash flow generation and prudent capital deployment to maintain a strong balance sheet. It views commercial paper issuances as a supplement to operating cash flow for meeting liquidity needs. However, the company also maintains a $4 billion committed credit facility that explicitly supports these commercial paper issuances, acting as a backup liquidity source. This dual approach reflects a strategy that balances operational flexibility with financial stability, especially as the credit facility is set to expire in March 2027, prompting potential renewal or replacement planning.",
      "llm_answer": "General Dynamics relies on commercial paper for short‑term liquidity but maintains a $4 billion committed credit facility to back those issuances and preserve a strong balance sheet, using the facility as a backup source of working‑capital support.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 44379,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 11326,
        "completion_tokens": 62,
        "total_tokens": 11388
      }
    },
    {
      "question_id": 1,
      "question": "How does ExxonMobil's current production growth of 111 thousand oil-equivalent barrels per day reconcile with its planned acquisition of Pioneer Natural Resources, which adds over 700 thousand oil-equivalent barrels per day in production capacity?",
      "original_answer": "ExxonMobil reported a net production growth of 111 thousand oil-equivalent barrels per day in 2023, excluding divestments and entitlements. The acquisition of Pioneer Natural Resources, expected to close in Q2 2024, adds over 700 thousand oil-equivalent barrels per day of production capacity as of Q3 2023. This suggests that the Pioneer acquisition significantly accelerates ExxonMobil's production scale, potentially increasing its daily output by more than sixfold compared to its organic growth in 2023.",
      "llm_answer": "ExxonMobil's current production growth of 111 thousand oil‑equivalent barrels per day reflects net organic growth after accounting for entitlements, divestments, government‑mandated curtailments and other factors; this growth is separate from the additional capacity it will gain from the pending Pioneer Natural Resources acquisition, which is projected to add more than 700 thousand oil‑equivalent barrels per day of production. The 111 k bbl/d increase is expected to be more than offset by the ~700 k bbl/d of new capacity from Pioneer, so the combined effect will be a substantial boost to overall production.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 61576,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15634,
        "completion_tokens": 153,
        "total_tokens": 15787
      }
    },
    {
      "question_id": 2,
      "question": "How does Target's profit-sharing arrangement with TD on Target Credit Card receivables align with the observed decline in RedCard penetration between fiscal years 2022 and 2023?",
      "original_answer": "Target receives a percentage of profits from the Target Credit Card and Target MasterCard receivables under a program agreement with TD, as disclosed in the accrued liabilities section (page 48). This financial arrangement incentivizes Target to promote RedCard usage. However, the RedCard Penetration metric, which includes the Target Credit Card, declined from 19.8% in fiscal 2022 to 18.6% in fiscal 2023 (page 27), suggesting reduced guest adoption or usage of these payment instruments. This decline may impact future profit-sharing revenue from TD unless offset by higher per-customer spending among existing RedCard users.",
      "llm_answer": "Target's profit-sharing arrangement with TD Bank on Target Credit Card receivables generates $667 million of credit‑card profit‑sharing income in 2023 (down from $734 million in 2022). This decline coincides with a drop in RedCard penetration—from 20.5 % in fiscal 2022 to 18.6 % in fiscal 2023—reflecting fewer RedCard‑linked transactions and thus lower profit‑sharing revenue. Consequently, the reduced RedCard penetration aligns with the observed decrease in credit‑card profit‑sharing income.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_3_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 49165,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12512,
        "completion_tokens": 124,
        "total_tokens": 12636
      }
    },
    {
      "question_id": 2,
      "question": "How does BMY's shared liability with AstraZeneca for Onglyza-related litigation risk, as disclosed in the legal proceedings section, reconcile with its continued financial stake in the product as indicated in the trademark disclosure?",
      "original_answer": "BMY shares potential liability with AstraZeneca for Onglyza-related litigation, as noted in the legal proceedings section where both companies are co-defendants in ongoing cardiovascular injury claims from the product's use. Despite divesting Onglyza to AstraZeneca in 2014, BMY still retains a financial stake in the product, as evidenced by the trademark disclosure in the document. This dual exposure—both legal and financial—suggests that while BMY no longer directly markets or profits from Onglyza, it remains vulnerable to legacy liabilities and maintains a residual economic interest in the product through its trademark rights.",
      "llm_answer": "Based on the document, BMY's shared liability for Onglyza-related litigation is explicitly stated in the \"Onglyza*\" section (page 118) where it notes that “any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca” following the 2014 sale of the product to AstraZeneca. This arrangement reconciles with BMY’s continued financial stake in the product, as reflected in the trademark disclosure on page 132, which identifies the “Onglyza*” trademark as owned by BMY (and co‑owned with AstraZeneca), indicating that BMY retains an ownership interest while also sharing legal responsibility for related claims.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 118,
          "pages": [
            116,
            117,
            118,
            119,
            120
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 106683,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26909,
        "completion_tokens": 159,
        "total_tokens": 27068
      }
    },
    {
      "question_id": 2,
      "question": "How does ExxonMobil's 2023 production performance of 3.7 million oil-equivalent barrels per day align with its planned $65 billion merger with Pioneer Natural Resources, which holds over 2.3 billion barrels of proved reserves?",
      "original_answer": "ExxonMobil's 2023 production remained flat at 3.7 million oil-equivalent barrels per day, with growth in Permian and Guyana offsetting divestments and curtailments. The company plans to enhance future production through its $65 billion merger with Pioneer Natural Resources, which brings over 2.3 billion barrels of proved reserves and over 700 thousand oil-equivalent barrels per day of production capacity. This strategic move is expected to offset current production stagnation and expand ExxonMobil's resource base in the Midland Basin, aligning with its long-term upstream growth objectives.",
      "llm_answer": "ExxonMobil’s 2023 upstream production of 3.7 million oil‑equivalent barrels per day aligns with the company’s strategic push toward the $65 billion merger with Pioneer Natural Resources, which holds over 2.3 billion barrels of proved reserves. The merger, valued at roughly $65 billion and structured as a stock‑for‑stock transaction (≈546 million ExxonMobil shares), is expected to close in Q2 2024 pending regulatory approval. By adding Pioneer’s extensive Midland Basin acreage and production, the deal would augment ExxonMobil’s reserve base and production capacity, supporting its long‑term growth objectives while integrating Pioneer’s 700 k bbl/d of output that complements ExxonMobil’s existing 3.7 M bbl/d production level.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 61576,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15629,
        "completion_tokens": 183,
        "total_tokens": 15812
      }
    },
    {
      "question_id": 2,
      "question": "How does Microsoft's redemption of $986 million in Nuance convertible senior notes relate to the strategic integration of Nuance's AI solutions within Microsoft's enterprise services portfolio?",
      "original_answer": "Microsoft's redemption of $986 million in Nuance convertible senior notes indicates a financial restructuring milestone following the acquisition, aligning with the strategic integration of Nuance's conversational AI and ambient intelligence solutions into Microsoft's Enterprise and Partner Services. This integration supports Microsoft's broader cloud and AI strategy, as Nuance's offerings now contribute to Microsoft's competitive positioning in enterprise AI and developer tools.",
      "llm_answer": "Microsoft's redemption of Nuance's $986 million convertible senior notes was a routine financing activity that cleared legacy debt on Nuance’s balance sheet after the 2022 acquisition. This cleanup allowed Microsoft to fully integrate Nuance’s AI‑driven healthcare and enterprise solutions into its Intelligent Cloud segment without any outstanding convertible obligations, thereby streamlining the technology stack and supporting the broader strategic goal of embedding Nuance’s conversational AI capabilities across Microsoft’s enterprise services portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50798,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12925,
        "completion_tokens": 140,
        "total_tokens": 13065
      }
    },
    {
      "question_id": 2,
      "question": "How does Disney's reported subscriber base for Lifetime compare with its equity stake in A+E Networks, particularly considering the financial implications of A+E's international distribution and Disney's investment valuation on its balance sheet?",
      "original_answer": "Disney reports that Lifetime, which is part of the A+E Networks portfolio, reaches 69 million domestic subscribers, similar to A&E's reach. A+E Networks is a 50%-owned equity investee of Disney, and its international distribution through multi-year licensing agreements likely contributes to the $0.8 billion excess of Disney’s book value over A+E’s underlying net assets, as noted in the equity investments section. This valuation premium, combined with A+E’s global presence and subscriber base, reflects strategic financial and operational alignment in Disney’s media portfolio.",
      "llm_answer": "Disney reports a subscriber base of 69 million for Lifetime within A+E Networks, while its equity stake in A+E is 50 % (shared with Hearst). The international distribution of A+E channels generates revenue that is recorded under Disney’s “TV/SVOD distribution licensing” and “Content License Early Termination” line items, contributing to the overall revenue pool that supports Disney’s balance‑sheet valuation of the investment; however, the subscriber figures for Lifetime are distinct from Disney’s equity ownership and do not directly affect the carrying amount of its A+E investment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 51817,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13193,
        "completion_tokens": 147,
        "total_tokens": 13340
      }
    },
    {
      "question_id": 2,
      "question": "Given Simon Property Group's disclosure of $5.2 billion in mortgage indebtedness tied to non-recourse mortgage notes with cross-default provisions on certain property pools, how does the company's compliance with covenants at year-end 2023 reconcile with the material adverse effect risk posed by potential defaults under these cross-default provisions?",
      "original_answer": "Simon Property Group disclosed $5.2 billion in mortgage indebtedness at December 31, 2023, secured by 38 properties under 35 non-recourse mortgage notes, including two pools of cross-defaulted and cross-collateralized mortgages covering five properties. While the company confirmed compliance with all covenants related to these notes at year-end, the cross-default provisions mean that a default on any mortgage in a pool could trigger acceleration of all indebtedness in that pool. This creates a material adverse effect risk on the company's financial condition and liquidity if any single default were to occur. The disclosure on page 70 reinforces that covenant compliance assessments specifically considered these cross-default provisions, indicating proactive risk mitigation in a potentially volatile real estate environment.",
      "llm_answer": "Simon Property Group maintains compliance with covenants on its unsecured debt and secured mortgage notes as of December 31 2023, with all financial and non‑financial covenants satisfied and no material adverse effect noted from cross‑default provisions. However, the company acknowledges that a severe and prolonged disruption in the global financial markets could trigger defaults under the cross‑default clauses of certain non‑recourse mortgage pools, potentially accelerating indebtedness and materially affecting its financial condition and liquidity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74267,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18834,
        "completion_tokens": 139,
        "total_tokens": 18973
      }
    },
    {
      "question_id": 2,
      "question": "How does AMT's strategic handling of the VIL Optionally Convertible Debentures (VIL OCDs) in 2024, including their conversion and subsequent sale, reconcile with the earlier goodwill impairment charge related to its India business in 2023?",
      "original_answer": "AMT initially faced financial uncertainty with VIL in India, leading to a $322.0 million goodwill impairment charge in 2023 due to the Indian Supreme Court's rulings and VIL's partial payments. In response, AMT accepted VIL OCDs in February 2023 as a payment mechanism, which were later converted into VIL equity in March 2024 and fully sold off by June 2024, yielding a $46.4 million gain. This strategic financial maneuver allowed AMT to recover from earlier impairments and manage exposure to a volatile Indian market, reflecting a shift from operational risk mitigation to a capital realization strategy.",
      "llm_answer": "The $322 million goodwill impairment recorded in 2023 for the India reporting unit reflected the decline in the unit’s fair value, which was identified during the strategic review of the India business.  In 2024, AMT monetized the VIL Optionally Convertible Debentures by converting a portion into VIL equity and selling the shares and the remaining debentures, generating a $46 million gain that was reported in discontinued‑operations.  This disposal of the VIL OCDs and the associated revenue recognition reconciles with the earlier impairment by effectively exiting the India business, removing the exposure that gave rise to the goodwill write‑down.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89396,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22588,
        "completion_tokens": 163,
        "total_tokens": 22751
      }
    },
    {
      "question_id": 2,
      "question": "How does CVS's acquisition of Oak Street Health, which contributed to a goodwill increase in 2023, align with the regulatory risks associated with participation in CMS Innovation Center models like ACO REACH, particularly given the uncertainty around ongoing participation and potential payment reductions in those models?",
      "original_answer": "CVS acquired Oak Street Health in 2023, which contributed to an increase in the company’s goodwill (from $6.6 billion in cumulative impairments as of 2024). Oak Street Health participates in CMS Innovation Center models such as ACO REACH, which are described as subject to annual changes that typically reduce available payments and lack a defined path for ongoing participation beyond their end date. These regulatory and financial risks, outlined in the risk factors section, could threaten the long-term value and performance of the acquired business, thereby placing downward pressure on the goodwill associated with the acquisition. This creates a tension between the strategic investment made in 2023 and the potential for future impairment due to external regulatory instability.",
      "llm_answer": "CVS's acquisition of Oak Street Health contributed to a goodwill increase in 2023, but this expansion heightens regulatory risks tied to participation in CMS Innovation Center models like ACO REACH. These models involve annual changes that can reduce participant payments—including post-performance-year benchmark adjustments and fixed end dates without guaranteed renewal—creating uncertainty about continued involvement and potential payment reductions, which directly impacts Oak Street Health's Medicare-dependent revenue and its exposure to regulatory shifts in government health programs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 150,
          "pages": [
            148,
            149,
            150,
            151,
            152
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72460,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18374,
        "completion_tokens": 148,
        "total_tokens": 18522
      }
    },
    {
      "question_id": 2,
      "question": "How does Emerson's acquisition investment of $7,833 million in National Instruments align with the strategic positioning of Automated Test Systems within the newly formed Test & Measurement segment?",
      "original_answer": "Emerson's acquisition of National Instruments (NI) for $7,833 million in cash paid to acquire the remaining shares reflects a strategic move to expand its capabilities in software-connected automated test systems. NI's core offering—automated test and measurement systems—now forms the foundation of Emerson’s newly created Test & Measurement segment, which is positioned to enable enterprises to bring products to market faster and at lower cost. This strategic alignment is reinforced by the segment’s description in the Control Systems & Software section, where it emphasizes the full range of customer needs addressed by modular instrumentation, data acquisition, and general-purpose development software. Thus, the acquisition investment directly supports the positioning and scope of the Automated Test Systems within Emerson’s broader software and control business strategy.",
      "llm_answer": "Emerson's $7,833 million acquisition investment in National Instruments was strategically positioned to expand the newly created Test & Measurement segment, which is reported within the Software and Control business group. The acquisition added NI's automated test and measurement systems—providing software‑connected solutions that help enterprises bring products to market faster and at lower cost—directly into Emerson's portfolio, thereby strengthening the segment's growth prospects and contributing to the overall revenue and earnings performance reflected in the segment reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66983,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16972,
        "completion_tokens": 147,
        "total_tokens": 17119
      }
    },
    {
      "question_id": 2,
      "question": "Why is Mississippi Power Company able to file its 2022 Form 10-K using the reduced disclosure format, and how does this streamlined reporting approach align with its status as a subsidiary that does not issue separate annual reports to its parent company, The Southern Company?",
      "original_answer": "Mississippi Power Company files its 2022 Form 10-K using the reduced disclosure format because it meets the conditions outlined in General Instructions I(1)(a) and (b) of Form 10-K, which apply to certain subsidiaries of a registrant. This reduced format aligns with its operational structure as a subsidiary that does not issue separate annual reports to its sole shareholder, The Southern Company, as disclosed in the supplemental information. This streamlined reporting approach reflects a regulatory accommodation for entities like Mississippi Power that are fully owned and whose financial information is consolidated within the parent company's disclosures, thereby reducing redundant reporting obligations.",
      "llm_answer": "Mississippi Power Company can file its 2022 Form 10-K using the reduced disclosure format because, as stated in the filing, \"Each of Georgia Power Company, Mississippi Power Company, Southern Power Company, and Southern Company Gas meets the conditions set forth in General Instructions I(1)(a) and (b) of Form 10-K and is therefore filing this Form 10-K with the reduced disclosure format specified in General Instructions I(2)(b), (c), and (d) of Form 10-K.\" This streamlined reporting approach aligns with its status as a subsidiary that does not issue separate annual reports to its parent company, The Southern Company, since all such subsidiaries (including Mississippi Power) are filing their reports under the same reduced disclosure framework as permitted by the SEC for entities meeting those specific conditions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 372,
          "pages": [
            344,
            345,
            346,
            347,
            348
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 67121,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17026,
        "completion_tokens": 205,
        "total_tokens": 17232
      }
    },
    {
      "question_id": 3,
      "question": "How does MS's Enterprise Risk Management (ERM) framework, which includes oversight of operational risk, address the potential impact of physical climate risks on its facilities and people, as highlighted in the Climate Risk section?",
      "original_answer": "Morgan Stanley’s ERM framework, described on page 55, is designed to identify, monitor, and mitigate principal risks—including operational risk—across all business segments. On page 75, the firm acknowledges that physical climate risks, such as floods, hurricanes, and rising sea levels, could pose increased operational risk to its facilities and personnel. The Climate Risk section further explains that these risks are integrated into the firm’s broader risk management processes through oversight by the Board’s Risk Committee (BRC) and the Climate Risk Committee, co-chaired by the Chief Risk Officer and Chief Sustainability Officer. This demonstrates that while operational risk is a core component of the ERM framework, the firm has specifically adapted its governance to incorporate physical climate risk as a subset of operational risk, ensuring it is managed within the same structured oversight mechanisms.",
      "llm_answer": "Morgan Stanley’s Enterprise Risk Management (ERM) framework embeds climate‑risk oversight within its Board‑level Risk Committee (BRC) and the dedicated Climate Risk Committee, which is co‑chaired by the Chief Risk Officer and Chief Sustainability Officer. This structure ensures that physical climate risks—such as acute events (e.g., floods, hurricanes, wildfires) and chronic shifts (e.g., sea‑level rise, droughts)—are evaluated for their potential to increase credit and operational risk to the Firm’s facilities and people, and that transition risks are integrated into scenario analysis and risk‑management processes across the organization.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 73784,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18681,
        "completion_tokens": 161,
        "total_tokens": 18842
      }
    },
    {
      "question_id": 3,
      "question": "How does MDLZ's classification of Net Investment Hedge Contracts within Level 2 financial assets align with the specific fair value disclosure of $71 million for these contracts as of December 31, 2021?",
      "original_answer": "MDLZ classifies Net Investment Hedge Contracts as part of Level 2 financial assets because their fair value is determined using observable market inputs, such as forward rates and commodity prices, rather than relying on unobservable assumptions. This classification is consistent with the $71 million fair value of these contracts disclosed in the derivatives table, which falls entirely under the Level 2 category, indicating that no Level 1 or Level 3 inputs were used for their valuation. The alignment between the valuation methodology and the disclosed amount underscores the company's consistent application of fair value accounting principles for these instruments.",
      "llm_answer": "MDLZ classifies its Net Investment Hedge Contracts as Level 2 financial assets, and the disclosed fair‑value of those contracts was $71 million as of December 31, 2021, which reflects the Level 2 valuation methodology described in the footnote tables.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78564,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19866,
        "completion_tokens": 62,
        "total_tokens": 19929
      }
    },
    {
      "question_id": 3,
      "question": "How does COP's investment in PALNG, which involved interest rate swaps under ASC Topic 815, impact its revenue recognition policy for derivative contracts governed by the same accounting standard?",
      "original_answer": "COP's investment in PALNG, which included interest rate swaps under ASC Topic 815, demonstrates its use of derivative instruments to manage financial risk. In 2024, COP recognized $35 million in 'Equity in earnings of affiliates' related to de-designated swaps on PALNG’s term loans. Separately, ASC Topic 815 also governs COP’s revenue recognition policy for physical gas contracts that qualify as derivatives, though these contracts are not accounted for under ASC Topic 606. This reveals a dual application of ASC Topic 815: once in managing financing risk through affiliate investments and again in revenue recognition for commodity derivatives, suggesting a coordinated approach to financial and operational risk management under the same accounting framework.",
      "llm_answer": "The interest rate swaps executed by PALNG under ASC Topic 815 are treated as cash‑flow hedges, so changes in their fair value are recorded in other comprehensive income and re‑classified into earnings when the hedged forecasted transactions affect earnings. Because the swaps are designated hedges of the variable‑rate financing for the PALNG project, they do not alter ConocoPhillips’ revenue‑recognition policy for its derivative contracts; revenue from derivatives continues to be recognized on a net basis (or gross when not designated as hedges) in accordance with ASC 815, with the swaps simply adding a hedging layer that moves fair‑value gains/losses out of earnings until the related cash‑flow event occurs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69915,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17712,
        "completion_tokens": 179,
        "total_tokens": 17891
      }
    },
    {
      "question_id": 3,
      "question": "How does AMT's strategic decision to convert and sell VIL OCDs and shares relate to the prior revenue deferrals and impairment charges associated with VIL in India?",
      "original_answer": "AMT initially faced uncertainty with VIL's partial payments in 2022, leading to $27.3 million in deferred revenue and asset impairments totaling $508.6 million in 2022 and 2023. In response, AMT accepted VIL OCDs in 2023 as part of a payment arrangement. By 2024, AMT converted and sold these VIL OCDs and shares, generating $238 million in net proceeds and recognizing a $46.4 million gain. This sequence reflects a strategic pivot from a distressed receivables position to a monetization strategy that ultimately offset prior losses and supported capital recovery.",
      "llm_answer": "The strategic conversion and sale of VIL’s optionally convertible debentures (VIL OCDs) and the subsequent sale of the resulting VIL Shares generated $46.4 million of gains that were recorded in discontinued‑operations income, while the earlier deferral of $27.3 million of revenue related to VIL’s unpaid amounts in India was fully recognized in 2024. This revenue recognition offset prior impairments and the $322 million goodwill charge recorded in 2023, illustrating how the divestiture and associated cash proceeds resolved the earlier revenue deferrals and valuation concerns tied to VIL in India.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89396,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22569,
        "completion_tokens": 150,
        "total_tokens": 22720
      }
    },
    {
      "question_id": 3,
      "question": "How does Mississippi Power Company's status as a separate registrant in the combined 10-K filing reflect the application of the reduced disclosure format, and what does this imply about its reporting obligations compared to The Southern Company's consolidated disclosures?",
      "original_answer": "Mississippi Power Company, as a separate registrant in the combined 10-K filing, is subject to the reduced disclosure format under General Instructions I(2)(b), (c), and (d) of Form 10-K because it meets the conditions outlined in General Instructions I(1)(a) and (b). This format limits the extent of disclosures it must provide, particularly in Part III, where it incorporates by reference specified portions of The Southern Company's and Alabama Power Company's proxy statements. Unlike The Southern Company, which provides consolidated disclosures and full proxy materials, Mississippi Power Company is not required to prepare or file an annual report or proxy statement with the SEC, underscoring a distinction in reporting obligations based on registrant classification and regulatory relief afforded under the reduced disclosure framework.",
      "llm_answer": "Mississippi Power Company's separate registration as a registrant in the combined 10-K filing demonstrates its use of the reduced disclosure format permitted under General Instruction I(2)(b), (c), and (d) for smaller reporting companies. This format allows Mississippi Power to file a standalone 10-K with significantly less detailed information compared to The Southern Company's consolidated disclosures, which include comprehensive financial statements, extensive footnotes, and full Item 10-14 disclosures. Consequently, Mississippi Power's reporting obligations are substantially simplified, requiring only the minimal disclosures mandated for smaller registrants, while The Southern Company, as a larger entity, must provide extensive, integrated financial and governance information across all its subsidiaries. This distinction reflects Mississippi Power's status as a smaller reporting company under the SEC's rules, exempting it from the full suite of disclosure requirements applicable to the parent company and other larger subsidiaries.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 372,
          "pages": [
            344,
            345,
            346,
            347,
            348
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 67121,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17025,
        "completion_tokens": 262,
        "total_tokens": 17287
      }
    },
    {
      "question_id": 3,
      "question": "How does the restricted voting structure of Class C Common Stock, which limits voting rights to only specific corporate events, influence its treatment in the diluted earnings per share calculation that assumes conversion into Class A Common Stock?",
      "original_answer": "The restricted voting structure of Class C Common Stock, which only allows voting in specific circumstances such as mergers or amendments to the certificate of incorporation, reflects its subordinate governance position relative to Class A Common Stock. Despite this limited voting power, the diluted earnings per share calculation assumes the conversion of Class C Common Stock into Class A Common Stock on an as-converted basis, effectively granting it equal economic treatment in financial reporting. This creates a contrast between the governance rights (limited voting) and economic treatment (full conversion for EPS), suggesting a separation between shareholder influence and financial equity in the company’s reporting framework.",
      "llm_answer": "The restricted voting structure of Class C Common Stock—limited to a narrow set of corporate actions and requiring approval by the holders of each series of preferred stock—means that, for purposes of diluted earnings‑per‑share, the conversion of Class C into Class A shares is treated as if those shares had full voting rights. Consequently, the as‑converted share count used in the diluted‑EPS calculation assumes that Class C shares can be converted into Class A shares on a one‑for‑one basis, and the earnings allocation and weighted‑average share denominator reflect this conversion regardless of the limited voting rights that remain in place. This treatment ensures that the potential dilution from converting Class C is fully captured in the diluted EPS denominator.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 107580,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 27129,
        "completion_tokens": 193,
        "total_tokens": 27323
      }
    },
    {
      "question_id": 3,
      "question": "How does UPS's use of net asset value (NAV) to measure certain investments relate to its $2.7 billion in unfunded commitments to private equity funds, and what implications does this have for liquidity risk management?",
      "original_answer": "UPS utilizes NAV as a practical expedient to value certain alternative investments, including private equity funds, due to the lack of readily determinable fair values. These NAV-based investments include UPS’s $2.7 billion in unfunded commitments to private equity and other limited partnerships, which are expected to be funded over the next three to six years. Given that redemptions in these funds are generally restricted until the end of the partnership term (10–15 years), this creates a liquidity risk, as UPS must manage its cash flow commitments without the ability to easily liquidate these positions. The use of NAV introduces valuation uncertainty, which compounds the challenge of managing liquidity against these long-term, illiquid commitments.",
      "llm_answer": "UPS uses NAV to value its private‑equity, private‑debt and other alternative investments, which are recorded as Level 3 assets in its pension‑plan disclosures. As of 2024 the company reports $2.7 billion of unfunded commitments to these private‑equity and private‑debt funds, meaning it must supply additional capital to meet the funds’ investment calls. Because these commitments are not liquid and can require cash on short notice, they increase the plan’s exposure to funding shortfalls and create a liquidity‑risk factor that UPS must monitor and fund through discretionary contributions or other assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70907,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17954,
        "completion_tokens": 152,
        "total_tokens": 18106
      }
    },
    {
      "question_id": 4,
      "question": "How does Mastercard's concern about technology companies developing competitive products relate to its reliance on those same companies to enhance payment safety and deliver services, and what operational or strategic risks does this dual relationship introduce?",
      "original_answer": "Mastercard identifies that technology companies may develop products that compete with or replace its own payment offerings, potentially forcing changes in its pricing or practices (page 31). At the same time, Mastercard collaborates with these same technology firms to enhance payment safety and deliver services efficiently (page 32). This dual relationship introduces strategic risks, such as giving partners access to Mastercard data, which could provide them with a competitive advantage if not properly managed. Additionally, if Mastercard cannot keep pace technologically, these partners may opt to use their own platforms, reducing their reliance on Mastercard’s network and increasing competitive pressure.",
      "llm_answer": "Mastercard simultaneously worries that tech giants could create rival payment products that bypass its network, yet it relies on those same companies—fintechs, digital‑payment platforms and mobile‑payment providers—to boost the security and functionality of its services. This dual relationship exposes the company to several risks: it must continually invest in advanced security and innovation to stay ahead of the tech firms’ capabilities, and any disruption, data‑breach, or competitive move by those partners could impair its network, erode brand trust, invite tighter regulation, and force costly remediation or pricing concessions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 88271,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22306,
        "completion_tokens": 159,
        "total_tokens": 22465
      }
    },
    {
      "question_id": 4,
      "question": "How does MDLZ's use of Level 1 commodity futures for hedging specific raw material costs, such as cocoa and sugar, reflect in their fair value measurement methodology and exposure management strategy?",
      "original_answer": "MDLZ utilizes Level 1 commodity futures, which are exchange-traded instruments valued based on quoted market prices on commodity exchanges, to hedge price risks related to forecasted purchases of raw materials like cocoa, sugar, and sweeteners. These futures are part of a broader risk management strategy that also includes Level 2 instruments and are managed through counterparties with investment-grade ratings to mitigate credit risk. The fair value methodology for Level 1 instruments ensures transparency and reduces pricing model risk, aligning with MDLZ's approach to managing market and credit risks across its derivative portfolio.",
      "llm_answer": "MDLZ’s use of Level 1 commodity futures to hedge specific raw‑material costs such as cocoa and sugar is reflected in its fair‑value measurement methodology as a Level 1 input—quoted market prices on commodity exchanges—resulting in a fair‑value gain of $161 million (recorded in other current assets) and a corresponding Level 2 offset of $90 million for OTC commodity forwards and options. This approach allows the company to lock in purchase prices, thereby managing exposure to commodity price volatility while maintaining a clear, auditable valuation path that feeds into its overall hedging strategy and risk‑management framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 69495,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17602,
        "completion_tokens": 158,
        "total_tokens": 17761
      }
    },
    {
      "question_id": 4,
      "question": "How does SPG's redemption of 75,000 preferred units in 2024 relate to Simon's ability to redeem Series J 8 3/8% Preferred Stock starting in 2027, and what does this imply about the structure of noncontrolling interests in the Operating Partnership?",
      "original_answer": "SPG's Operating Partnership redeemed 75,000 preferred units in 2024, reducing the carrying value of these units to $15.5 million by year-end. These preferred units are linked to Simon, which issues Series J 8 3/8% Preferred Stock that it can redeem starting in 2027 at $50 per share plus unpaid dividends. The redemption of preferred units by the Operating Partnership reflects Simon's broader control over capital structure decisions, as Simon, acting as the general partner, governs all operational and distribution decisions. This structure implies that noncontrolling interests in the Operating Partnership, including preferred units, are ultimately subject to Simon’s discretion, as highlighted in the governance section on page 108, where Simon may choose to settle exchange rights in common stock rather than cash, reinforcing its control and influence over equity classification.",
      "llm_answer": "The redemption of 75,000 of SPG’s 7.50% cumulative redeemable preferred units in 2024 reflects the cash‑redemption provision of that preferred‑unit series, which is accounted for as temporary equity because the Operating Partnership could be required to settle the redemption in cash.  This redemption activity reduces the carrying amount of the preferred‑unit liability and, together with the related noncontrolling redeemable interests, is presented outside of permanent equity; consequently, the structure of the noncontrolling interests in the Operating Partnership consists of both permanent‑equity limited‑partner units and temporary‑equity preferred units that may be redeemed (e.g., the Series J 8 3⁄8% preferred units that become redeemable in 2027).",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74118,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18771,
        "completion_tokens": 189,
        "total_tokens": 18961
      }
    },
    {
      "question_id": 4,
      "question": "How does Disney's equity stake in A+E, which operates Lifetime and A&E channels with 69 million domestic subscribers each, relate to the $0.8 billion excess book value attributed to amortizable intangible assets and goodwill in their equity investments?",
      "original_answer": "Disney's equity stake in A+E, a joint venture with Hearst that operates channels including A&E and Lifetime—both with 69 million domestic subscribers—forms a key part of their media investment portfolio. As a 50% owner, Disney reports its share of A+E's financial results under 'Equity in the income (loss) of investees, net.' On the other hand, Disney's broader equity investments, including A+E, show a $0.8 billion excess of book value over the underlying net assets, attributed to intangible assets and goodwill from acquisitions. This suggests that despite A&E and Lifetime having similar subscriber bases, the valuation premium in intangible assets reflects strategic value from brand equity, programming rights, or distribution agreements embedded in A+E's operations, which Disney indirectly owns part of through its stake.",
      "llm_answer": "Disney's 50% equity stake in A+E Networks (which operates Lifetime and A&E with 69 million domestic subscribers each) is accounted for as an equity investment. The $0.8 billion excess book value attributed to amortizable intangible assets and goodwill in Disney's equity investments (specifically noted for A+E in the \"Investments, Equity Basis\" section) reflects the premium paid for this stake, which is tied to A+E's extensive distribution reach (69 million subscribers) and content assets. This excess value is amortized over time, aligning with the valuation of A+E's intangible assets derived from its subscriber base and programming.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 51817,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13194,
        "completion_tokens": 160,
        "total_tokens": 13354
      }
    },
    {
      "question_id": 4,
      "question": "How does AMT's decision to terminate the $10.5 billion JPM Bridge Loan Commitment without drawing on it relate to their broader financing strategy for the CoreSite Acquisition, especially in light of the $4.5 billion in USD Delayed Draw Term Loans they ultimately utilized?",
      "original_answer": "AMT entered into the $10.5 billion JPM Bridge Loan Commitment as a contingency to finance the CoreSite Acquisition, but terminated it after securing $4.5 billion in USD Delayed Draw Term Loans through a combination of a $3.0 billion 364-day loan and a $1.5 billion two-year loan. This indicates that AMT's financing strategy prioritized long-term committed credit facilities over bridge financing, allowing them to proceed with the acquisition without incurring immediate bridge loan obligations. The termination of the JPM Bridge Loan Commitment reflects AMT's confidence in its alternative financing arrangements.",
      "llm_answer": "AMT terminated the $10.5 billion JPM Bridge Loan Commitment because it had already secured sufficient financing for the CoreSite acquisition through its existing credit facilities—specifically the $4.5 billion USD Delayed Draw Term Loans and the broader $10.5 billion of committed capacity under the 2021 Multicurrency Credit Facility, 2021 Credit Facility, 2021 Term Loan and the USD Delayed Draw facilities—so the bridge loan was no longer needed. Consequently, the company relied on the $4.5 billion USD Delayed Draw Term Loans (plus the rest of its credit facilities) to fund the CoreSite purchase rather than drawing on the terminated bridge commitment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 65784,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16697,
        "completion_tokens": 164,
        "total_tokens": 16862
      }
    },
    {
      "question_id": 4,
      "question": "How does Duke Energy's use of storm recovery property to secure $1,007 million in storm recovery bonds relate to the restricted cash balances reported in their consolidated balance sheets?",
      "original_answer": "Duke Energy Carolinas and Duke Energy Progress transferred storm recovery property worth $237 million and $770 million respectively to special purpose subsidiaries to secure storm recovery bonds issued in November 2021. These bonds, which are secured solely by the storm recovery property and customer charges, created restricted cash balances that appear in the consolidated balance sheets under 'Other' within current and noncurrent assets. The restricted cash balances directly reflect the financial structure established through the storm recovery bond issuance.",
      "llm_answer": "Duke Energy’s storm‑recovery property was used as collateral to issue $1,007 million of storm‑recovery bonds, and the related financing is reflected on the consolidated balance sheets as a long‑term debt obligation.  Consequently, the $1,007 million of storm‑recovery bonds appears as a component of “Long‑Term Debt” (and the associated restricted cash balances are recorded in “Other Assets” under restricted cash) in the consolidated balance sheets of Duke Energy Carolinas and Duke Energy Progress, matching the amounts shown in the VIE summary tables for DECNCSF and DEPNCSF.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 94140,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23761,
        "completion_tokens": 144,
        "total_tokens": 23906
      }
    },
    {
      "question_id": 5,
      "question": "How does Mastercard's concern about technology companies developing competitive platforms relate to its reliance on those same companies to enhance payment safety and security, and what specific risks does this dual relationship pose to its ability to maintain transaction volumes?",
      "original_answer": "Mastercard identifies that technology companies could develop platforms that disintermediate it from digital payments, threatening its transaction volumes and competitive position. However, the company also partners with these same technology firms to enhance payment safety and security and deliver payment-related services. This dual relationship creates a strategic tension: while collaboration is necessary to remain technologically competitive and maintain customer trust, it also risks giving these partners access to Mastercard data, which could be used to build competing offerings. Additionally, if Mastercard cannot keep pace with technological innovation, customers may opt to use alternative technologies developed by these companies, further reducing transaction volumes and negatively impacting revenue.",
      "llm_answer": "Mastercard worries that tech firms are building rival payment platforms that could bypass its network, yet it still depends on those same firms to power its security tools and protect transactions. This creates a dual risk: the partners could erode Mastercard’s transaction volume by diverting traffic, while any security breach or service outage in their systems could expose Mastercard to fraud, reputational damage, costly penalties and loss of confidence in its payment ecosystem.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 88271,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22311,
        "completion_tokens": 121,
        "total_tokens": 22432
      }
    },
    {
      "question_id": 5,
      "question": "How does the valuation methodology for MDLZ's net investment hedge contracts, which are categorized under Level 2 financial assets, reconcile with the $71 million fair value disclosed for these contracts as of December 31, 2021?",
      "original_answer": "MDLZ categorizes its net investment hedge contracts under Level 2 financial assets, which are valued using observable market inputs such as forward rates and commodity index prices. As of December 31, 2021, the fair value of these contracts was reported at $71 million. This valuation aligns with the Level 2 methodology, which relies on income-based approaches using observable inputs rather than direct market prices or unobservable assumptions. The $71 million figure reflects the application of these valuation techniques, specifically tailored for over-the-counter derivatives without active quoted market prices, thus ensuring consistency between the disclosed fair value and the valuation methodology described for Level 2 financial assets.",
      "llm_answer": "The $71 million fair‑value amount reported for MDLZ’s Level 2 net‑investment‑hedge contracts represents the cumulative fair‑value of those hedge instruments (cross‑currency swaps and forwards) as of 31 December 2021. This valuation is derived using observable market inputs (e.g., forward rates, interest‑rate curves) and is reflected in the Level 2 column of the fair‑value hierarchy, which also includes the $71 million net‑investment‑hedge derivative contracts disclosed in the footnote on derivative accounting. Consequently, the $71 million figure aligns with the disclosed fair‑value of the Level 2 net‑investment‑hedge contracts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78564,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19873,
        "completion_tokens": 159,
        "total_tokens": 20032
      }
    },
    {
      "question_id": 5,
      "question": "How does the spin-off of Greenstone and its combination with Mylan impact Pfizer's segment reporting structure and revenue classification post-2020, particularly in relation to contract manufacturing and transitional supply agreements?",
      "original_answer": "Pfizer spun off its Upjohn Business, including Greenstone, on November 16, 2020, and combined it with Mylan to form Viatris. Following this transaction, Pfizer reorganized its commercial operations and began managing its business through two operating segments: Biopharma and PC1. PC1 includes revenues from contract manufacturing, such as Comirnaty-related manufacturing activities for BioNTech ($320 million in 2021), as well as revenues from manufacturing and supply agreements with former legacy Pfizer businesses, including transitional agreements with Viatris. This reorganization and the spin-off directly influenced how Pfizer classified its revenues post-2020, separating innovative biopharma operations from contract and transitional manufacturing activities.",
      "llm_answer": "The spin‑off of Greenstone and its merger with Mylan to form Viatris was accounted for as a discontinued operation, and beginning in Q4 2020 the former Upjohn Business (including Greenstone) and the Mylan‑Japan collaboration were removed from Pfizer’s segment reporting.  As part of the 2021 commercial re‑organization Pfizer created a new operating segment, PC1, which now includes revenues from contract manufacturing (e.g., certain Comirnaty manufacturing for BioNTech and transitional supply agreements with Viatris) that were previously reported within the Hospital therapeutic area.  This restructuring revised prior‑period segment information so that contract‑manufacturing and transitional supply‑agreement revenues are now captured under the PC1 segment rather than the legacy Hospital segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2022.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 117613,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 29639,
        "completion_tokens": 200,
        "total_tokens": 29840
      }
    },
    {
      "question_id": 5,
      "question": "How does Microsoft's redemption of $986 million in Nuance convertible senior notes relate to the strategic integration of Nuance's AI solutions within Microsoft's Intelligent Cloud segment and its broader competitive positioning in enterprise AI?",
      "original_answer": "Microsoft's redemption of $986 million in Nuance convertible senior notes indicates a significant financial step in the post-acquisition restructuring of Nuance, aligning its financial obligations with Microsoft's balance sheet. This financial integration supports the strategic assignment of Nuance-related goodwill to the Intelligent Cloud segment, attributed to anticipated synergies from integrating Nuance’s conversational AI and ambient intelligence solutions. The inclusion of Nuance professional services within Microsoft’s Enterprise and Partner Services highlights the operational integration of Nuance’s offerings, enhancing Microsoft’s competitive positioning in enterprise AI against rivals like Amazon and Google. Together, these elements show a coordinated effort to embed Nuance’s AI capabilities into Microsoft’s broader cloud and enterprise service portfolio to drive competitive differentiation and customer value.",
      "llm_answer": "Microsoft's redemption of $986 million of Nuance’s convertible senior notes—recorded as a liability reduction in the Intelligent Cloud segment—reflects the successful integration of Nuance’s AI capabilities into Azure and other cloud services, reinforcing Microsoft’s competitive edge in enterprise AI. This financial maneuver underscores how the acquisition enhances Microsoft’s AI portfolio, driving synergies that strengthen its position against rivals such as Amazon, Google, and specialized AI providers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50798,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12938,
        "completion_tokens": 127,
        "total_tokens": 13065
      }
    },
    {
      "question_id": 5,
      "question": "How does the termination of the $10.5 billion JPM Bridge Loan Commitment relate to AMT's broader financing strategy as evidenced by the 2-year term loan agreement with JPMorgan Chase Bank, N.A.?",
      "original_answer": "AMT initially secured a $10.5 billion JPM Bridge Loan Commitment to finance the CoreSite Acquisition, but terminated it upon securing sufficient committed amounts under other facilities, including the 2021 Multicurrency Credit Facility and the 2021 Term Loan. Despite the termination, AMT maintained a strategic relationship with JPMorgan Chase Bank, N.A., as evidenced by the subsequent 2-Year Term Loan Agreement entered into on December 8, 2021. This indicates that while AMT did not need to draw on the bridge loan, it continued to rely on JPMorgan as a key financing partner, aligning with its broader strategy of diversifying and optimizing capital structure.",
      "llm_answer": "The termination of the $10.5 billion JPM Bridge Loan Commitment was directly tied to the broader financing strategy that relied on the newly‑structured 2‑year term loan and the other 2021 credit facilities.  As disclosed on page 52, the bridge commitment was fully terminated on December 8 2021 because the $10.5 billion of committed bridge financing was no longer needed once the $4.388 billion 2021 Multicurrency Credit Facility, the $1.41 billion 2021 Credit Facility, the $1.0 billion 2021 Term Loan and the delayed‑draw term loans (including the 2‑year USD facility) were in place.  This allowed AMT to retire the bridge loan and instead fund the CoreSite acquisition and repay existing indebtedness through the longer‑dated term loan and revolving facilities, reflecting a shift toward a more stable, multi‑year capital structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2022.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 74410,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18833,
        "completion_tokens": 209,
        "total_tokens": 19042
      }
    },
    {
      "question_id": 5,
      "question": "How does AMT's decision to report ATC TIPL as discontinued operations relate to the specific financial terms of the DIT acquisition agreement, and what does the resulting $1.2 billion loss indicate about the strategic repurposing of capital from the India market?",
      "original_answer": "AMT initially reported ATC TIPL as discontinued operations (page 40), signaling a strategic shift away from its India operations. This decision culminated in the ATC TIPL Transaction with DIT, an infrastructure investment trust sponsored by Brookfield, where DIT acquired 100% of ATC TIPL for up to 210 billion INR (~$2.5 billion), with final proceeds at closing amounting to 182 billion INR (~$2.2 billion). The $1.2 billion loss recorded on the sale primarily stemmed from the reclassification of cumulative translation adjustments in India upon exiting the market. This loss indicates that while the transaction provided liquidity to repay $2.2 billion of debt under the 2021 Multicurrency Credit Facility, the long-term currency translation exposure and operational costs in India outweighed the benefits of continued ownership, supporting the strategic rationale for divestiture.",
      "llm_answer": "The $1.2 billion loss reflects the reclassification of India’s cumulative translation adjustment and other transaction costs incurred when exiting the market, which the company decided to report as a discontinued operation under the ATC TIPL sale agreement. This strategic repurposing of capital from the India market enabled the company to focus on higher‑return opportunities elsewhere.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64497,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16368,
        "completion_tokens": 97,
        "total_tokens": 16465
      }
    },
    {
      "question_id": 5,
      "question": "How does Merck's revenue growth from Verquvo in its own marketing territories compare with the potential future milestone payments to Bayer AG, and what does this imply about the financial dynamics of their collaboration?",
      "original_answer": "Merck reported that sales of Verquvo (alongside Adempas) in its marketing territories grew 14% in 2021, primarily driven by higher demand in Europe. In the same collaboration framework, Merck made a $375 million sales-based milestone payment to Bayer in 2020 and anticipated a further $400 million in potential milestone payments triggered by future sales performance. This indicates that while Merck is experiencing growth in its own commercial regions, the collaboration includes significant contingent liabilities tied to Bayer's development contributions, which could impact Merck's future profitability if Verquvo continues to scale globally.",
      "llm_answer": "Merck's revenue growth from Verquvo in its own marketing territories is modest—Verquvo generated only $7 million of net sales for Merck in 2021, while the collaboration with Bayer is expected to deliver up to $400 million in additional sales‑based milestone payments to Bayer. This contrast highlights that the financial upside from Verquvo sales is limited compared with the potentially large milestone payments, underscoring a dynamic where Bayer stands to earn substantially more through future milestone triggers than Merck does from Verquvo sales alone.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 62,
          "pages": [
            60,
            61,
            62,
            63,
            64
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71997,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18233,
        "completion_tokens": 139,
        "total_tokens": 18372
      }
    },
    {
      "question_id": 5,
      "question": "How does Southern Company's use of intra-contract netting in derivative agreements affect its exposure to events of default, particularly in light of the $106 million in cash collateral posted by Southern Power and the potential for collateral requirements triggered by credit downgrades?",
      "original_answer": "Southern Company utilizes intra-contract netting in derivative agreements to offset receivables and payables, including those arising from events of default, which helps mitigate counterparty credit risk. This netting is reflected in the fair value presentation of derivative assets and liabilities on the balance sheet. However, the company remains exposed to events of default as certain agreements may require collateral posting, particularly if a subsidiary's credit rating drops below investment grade. Southern Power had $106 million in cash collateral posted under PPAs that could require additional collateral upon a credit downgrade, even though accelerated payment is not mandated. This highlights how intra-contract netting reduces exposure in derivative settlements but does not eliminate the liquidity risk associated with collateral calls triggered by credit events.",
      "llm_answer": "Southern Company's use of intra-contract netting in derivative agreements allows it to offset receivables and payables across contracts and against cash collateral, reducing net exposure to credit defaults. While $106 million of cash collateral was posted by Southern Power related to PPA credit assurances, the company's maximum potential collateral requirements under downgrade-triggered contracts total $33 million at BBB/Baa2 and $407 million at BBB‑/Baa3; however, these thresholds are well below the $106 million collateral already posted, indicating that the posted cash provides a buffer against additional collateral calls if credit ratings were to fall further.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 115,
          "pages": [
            113,
            114,
            115,
            116,
            117
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79366,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20093,
        "completion_tokens": 167,
        "total_tokens": 20260
      }
    },
    {
      "question_id": 6,
      "question": "What was the contribution of Cheese & Grocery in the AMEA region as a percentage of MDLZ's total net revenues in 2021, and how does this compare to its absolute revenue contribution in 2022?",
      "original_answer": "In 2021, Cheese & Grocery in the AMEA region contributed 1.7% of MDLZ's total net revenues, which equates to $450 million. In 2022, the absolute revenue contribution from Cheese & Grocery in the AMEA region was $437 million. This shows a slight decline in absolute terms despite the percentage contribution remaining relatively aligned year-over-year.",
      "llm_answer": "The contribution of Cheese & Grocery in the AMEA region was 7.1% of MDLZ’s total net revenues in 2021. In 2022, this category generated $1,054 million of segment operating income, representing a 22.0% share of AMEA’s segment operating income.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 137,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82868,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20942,
        "completion_tokens": 60,
        "total_tokens": 21003
      }
    },
    {
      "question_id": 6,
      "question": "How does the growth in EVENITY's contribution to Amgen's 2024 product sales align with the financial impact of Amgen's profit-sharing arrangement with UCB, given the $547 million global profit and loss share expense recorded in 2024?",
      "original_answer": "Amgen reported that EVENITY was among the brands contributing to a 26% U.S. volume growth and 17% ROW volume growth in 2024, indicating strong performance of the product. However, under Amgen's collaboration with UCB for EVENITY, Amgen shares global development costs and commercialization profits and losses equally with UCB. In 2024, this profit-sharing arrangement resulted in a $547 million expense recorded under Cost of Sales. Therefore, while EVENITY contributed positively to product sales volume, the financial benefit was partially offset by the shared profit obligations with UCB, reducing the net margin impact of EVENITY's growth.",
      "llm_answer": "The growth in EVENITY’s contribution to Amgen’s 2024 product sales is consistent with the $547 million profit‑and‑loss share expense recorded for 2024, reflecting the equal sharing of global development costs and commercialization profits and losses with UCB under their collaboration. This expense underscores the financial impact of the partnership while EVENITY’s sales continue to expand.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63992,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16240,
        "completion_tokens": 98,
        "total_tokens": 16338
      }
    },
    {
      "question_id": 6,
      "question": "How does Chevron's financial exposure to Tengizchevroil, including its loan of $4.5 billion for the FGP/WPMP development, intersect with its ongoing tax uncertainties in Kazakhstan, where audits remain unresolved since 2012?",
      "original_answer": "Chevron has a 50% equity stake in Tengizchevroil (TCO), which operates major oil fields in Kazakhstan, and has extended a $4.5 billion loan to TCO to fund the Future Growth Project and Wellhead Pressure Management Project (FGP/WPMP). This indicates a significant financial and operational commitment to Kazakhstan. However, Chevron also faces unresolved tax matters in Kazakhstan, where tax audits have not been finalized since 2012, contributing to $5,288 million in total unrecognized tax benefits at the end of 2021. The combination of Chevron's large-scale investment and ongoing tax exposure in Kazakhstan suggests that regulatory or financial risks in the region could materially impact both its operational projects and tax liabilities.",
      "llm_answer": "Chevron’s $4.5 billion loan to fund the FGP/WPMP development at Tengizchevroil is recorded as part of its $23.7 billion equity investment in TCO (Note 15).  This investment sits alongside the unresolved Kazakh tax audits that have persisted since 2012, creating a financial exposure that is amplified by the loan’s size and the uncertain tax environment.  Consequently, the loan heightens Chevron’s exposure to potential tax adjustments or liabilities arising from the lingering Kazakhstan audits.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91717,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23166,
        "completion_tokens": 124,
        "total_tokens": 23290
      }
    },
    {
      "question_id": 6,
      "question": "How does Apple's characterization of Taiwan as a geopolitical and supply chain risk factor align with the financial performance of the Greater China segment, which includes Taiwan, given the segment's $74.2 billion in net sales and $31.153 billion in operating income in 2022?",
      "original_answer": "Apple identifies Taiwan as a critical part of its supply chain and highlights it as a geopolitical risk due to its location within a region prone to trade disputes, public health crises, and other disruptions. Despite these concerns, the Greater China segment—which includes Taiwan—delivered strong financial results in 2022 with $74.2 billion in net sales and $31.153 billion in operating income, reflecting the region's importance to Apple's revenue and profitability. This juxtaposition suggests that while Apple is exposed to operational and political risks in Taiwan, the region remains a key contributor to the company's financial success, highlighting a tension between risk exposure and economic benefit.",
      "llm_answer": "Apple's 2022 10‑K identifies Taiwan as a geopolitical and supply‑chain risk factor, but the Greater China segment—including Taiwan—generated $74.2 billion in net sales and $31.153 billion in operating income that year, underscoring its strong financial contribution despite the identified risks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62270,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15818,
        "completion_tokens": 73,
        "total_tokens": 15892
      }
    },
    {
      "question_id": 6,
      "question": "How does the expansion of Booking.com's flight offering into 34 markets align with the increase in merchant transaction costs tied to Booking.com's accommodation services, given BKNG's strategic focus on the Connected Trip?",
      "original_answer": "BKNG's strategic focus on the Connected Trip emphasizes offering a seamless travel experience, which includes expanding flight offerings as a core component. In 2021, Booking.com expanded its flight offering into 34 markets, aligning with the company's vision to integrate travel elements such as flights, accommodations, and ground transportation. This expansion is directly tied to the increase in merchant transaction costs of $215 million, primarily driven by the growth in merchant accommodation reservation services at Booking.com. The increase in costs reflects the rising transaction volume and operational scale associated with BKNG's strategic push to enhance its service offerings and provide a more comprehensive travel experience. The alignment between the flight expansion and the rise in transaction costs highlights how BKNG's investment in diversified and integrated travel services supports its broader goal of driving consumer loyalty and frequency through the Connected Trip.",
      "llm_answer": "The expansion of Booking.com’s flight offering into 34 markets directly supports its Connected Trip strategy, which aims to create a seamless, integrated travel experience that includes flights alongside accommodations and other services. This expansion is tied to the growth in merchant transaction costs associated with accommodation services, as the increased merchant revenue from expanded flight bookings reflects higher transaction volumes and the associated operational costs (e.g., payment processing, customer service, and compliance). The Connected Trip vision relies on integrating flight offerings into its broader ecosystem to enhance customer loyalty and frequency, which in turn drives higher merchant revenues and necessitates investments in infrastructure, technology, and compliance—factors that contribute to rising merchant transaction costs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 63892,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16205,
        "completion_tokens": 215,
        "total_tokens": 16421
      }
    },
    {
      "question_id": 6,
      "question": "How does the voting power structure of CMCSA's Class A and Class B common stock, where Class B shares carry 15 votes each and are fully owned by Brian L. Roberts, relate to the company's stock repurchase activity and equity changes reported in 2024?",
      "original_answer": "CMCSA's Class A common stockholders hold 66 2/3% of the combined voting power, while Class B common stock, which carries 15 votes per share and is fully owned by Brian L. Roberts, accounts for the remaining 33 1/3%. Despite this concentrated voting structure, the company repurchased $7.25 billion worth of common stock in 2024, primarily from Class A shares, reducing retained earnings and impacting equity balances. Notably, Class B common stock had no change in balance during the year, indicating that repurchases did not affect the concentrated voting power held by Roberts.",
      "llm_answer": "The Class B shares, which carry 15 votes per share and are wholly owned by Brian L. Roberts, represent roughly one‑third of the combined voting power of Comcast’s common stock. This concentrated voting control does not directly affect the company’s share‑repurchase activity, but the 2024 repurchase disclosures show that the Board terminated the prior $20 billion authorization and adopted a new $15 billion program, under which the company repurchased about 212 million Class A shares for roughly $8.6 billion during the year. The equity section of the balance sheet reflects the resulting reductions in treasury stock and retained earnings, illustrating how the voting‑power structure coexists with the reported equity changes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70318,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17820,
        "completion_tokens": 182,
        "total_tokens": 18003
      }
    },
    {
      "question_id": 6,
      "question": "How does the fair value of the VIL OCDs issued by VIL in 2023 relate to the impairment charges recorded by AMT on tenant-related intangible assets tied to VIL during the same period?",
      "original_answer": "The fair value of the VIL OCDs at issuance was approximately $116.5 million, significantly lower than their face value of $193.2 million, reflecting the financial instability of VIL. This instability was a contributing factor to AMT recording impairment charges on tenant-related intangible assets tied to VIL, including $411.6 million in 2022 and continued exposure in 2023, as AMT updated its fair value estimates and carried $344.8 million in tenant-related intangible assets for VIL as of December 31, 2023.",
      "llm_answer": "The fair value of the VIL OCDs issued in 2023 was approximately $116.5 million, which was recorded as a reduction of tenant‑related intangible assets tied to VIL.  During the same period AMT recorded impairment charges of $411.6 million on those tenant‑related intangible assets, reflecting the decline in their recoverable value relative to the OCDs’ fair value.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20563,
        "completion_tokens": 90,
        "total_tokens": 20654
      }
    },
    {
      "question_id": 6,
      "question": "How does SPG's redemption of Series J 8 3/8% Cumulative Redeemable Preferred Stock in 2024 relate to Simon's ability to issue common stock as a redemption option, and what does this imply about SPG's capital structure flexibility as analyzed in the consolidated financial statements?",
      "original_answer": "SPG redeemed 75,000 preferred units for $7.5 million in 2024, which included the liquidation value and accrued distributions. These preferred units are linked to Simon, which issued the Series J 8 3/8% Cumulative Redeemable Preferred Stock and retains the right to redeem it in cash or common stock. The Operating Partnership’s ability to redeem units held by limited partners is tied to Simon’s discretion to issue shares of common stock, which is highlighted in the consolidated financial statements as a key factor in classifying these units as permanent equity. This structure provides SPG with flexibility to manage its capital structure without necessarily using cash, aligning with Simon’s governance and control over the Operating Partnership.",
      "llm_answer": "SPG's redemption of its Series J 8 3⁄8% Cumulative Redeemable Preferred Stock in 2024—allowing redemption on or after October 15, 2027 at $50 per share plus accrued dividends—demonstrates that the company can use the preferred‑stock redemption feature as a lever to raise cash and thereby create an additional source of equity capital for issuing common stock. This flexibility is reflected in the consolidated financial statements, where the preferred‑stock redemption price and accumulated premium are disclosed as part of temporary equity, and the related cash outflows (e.g., the $7.5 million redemption of 75,000 units in 2024) are recorded against the equity of the Operating Partnership. Consequently, the ability to redeem preferred securities provides SPG with a strategic capital‑structure lever that enhances its capacity to issue or repurchase common stock while maintaining a relatively agile balance‑sheet profile.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74118,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18780,
        "completion_tokens": 232,
        "total_tokens": 19012
      }
    },
    {
      "question_id": 6,
      "question": "How does BMY's increased royalty revenue from Keytruda in 2023 relate to Merck's obligation to pay declining royalties on global Keytruda sales through 2026, and how does this reflect on BMY's intellectual property licensing strategy?",
      "original_answer": "BMY reported increased royalty revenue in 2023 due to higher Keytruda royalties, which aligns with Merck's obligation to pay a 6.5% royalty on global Keytruda sales through 2023, decreasing to 2.5% from 2024 to 2026 under the global patent license agreement with BMS and Ono. BMY’s trademark ownership of Keytruda, as noted in the exhibit list, supports its ongoing entitlement to a share of these royalties. This declining royalty structure reflects a strategic licensing framework that secures near-term revenue while allowing for long-term market expansion by reducing Merck’s cost burden post-2023.",
      "llm_answer": "BMY's increased royalty revenue from Keytruda in 2023 reflects Merck's obligation to pay declining royalties on global Keytruda sales through 2026, as outlined in the patent license agreement where Merck pays 6.5% royalties through 2023 and 2.5% from 2024-2026, with payments shared 75/25 between BMS and Ono after fee adjustments. This structure demonstrates BMY's strategic IP licensing approach of securing long-term royalty streams from blockbuster drugs like Keytruda while acquiring rights to high-potential assets through upfront payments and milestones, as evidenced by its licensing deals with Immatics, Agenus, and Dragonfly, though it terminated the Dragonfly IL-12 license in 2023 after a $175M milestone payment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84981,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21487,
        "completion_tokens": 181,
        "total_tokens": 21668
      }
    },
    {
      "question_id": 6,
      "question": "How does MetLife's treatment of surplus notes under statutory accounting practices affect its regulatory capital position compared to GAAP reporting, given the carrying value of surplus notes at year-end 2021?",
      "original_answer": "MetLife's statutory accounting practices treat surplus notes as surplus rather than debt, which enhances the statutory capital position of its insurance subsidiaries. This contrasts with GAAP reporting, where surplus notes would typically be classified as liabilities. At December 31, 2021, the carrying value of surplus notes was $505 million, which contributed to the statutory capital and surplus of MetLife's U.S. insurance subsidiaries. This favorable treatment under statutory accounting supports a stronger regulatory capital position, as it increases the reported surplus without increasing liabilities, thereby improving key solvency ratios like the Statement-Based Combined RBC Ratio, which was in excess of 360% at year-end 2021.",
      "llm_answer": "MetLife reports surplus notes at a carrying value of $505 million (face $507 million less $2 million of unamortized discount and issuance costs) on its December 31 2021 balance sheet. Because surplus notes are treated as surplus rather than debt under statutory accounting, they are counted as surplus for regulatory capital purposes but are excluded from GAAP‑reported long‑term debt; this results in a lower GAAP debt balance ($13.9 billion vs. $14.6 billion on a statutory basis) while preserving a stronger surplus position for regulatory capital.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 292,
          "pages": [
            290,
            291,
            292,
            293,
            294
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 276,
          "pages": [
            274,
            275,
            276,
            277,
            278
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75530,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19120,
        "completion_tokens": 137,
        "total_tokens": 19258
      }
    },
    {
      "question_id": 6,
      "question": "How does Target's profit-sharing arrangement with TD on the Target Credit Card receivables align with the observed decline in RedCard penetration from 2022 to 2023, and what might this imply about the financial performance of the credit card program?",
      "original_answer": "Target receives a percentage of the profits generated by the Target Credit Card and Target MasterCard receivables through a program agreement with TD, which underwrites, funds, and owns the receivables. Meanwhile, RedCard penetration, which includes the Target Credit Card, declined from 19.8% in 2022 to 18.6% in 2023. This drop suggests a reduction in the proportion of sales made using RedCards, which could negatively impact the volume of credit card receivables and, consequently, the profit-sharing revenue from TD. Therefore, despite TD managing the credit risk and receivables, the decline in RedCard usage may signal a potential headwind for Target’s ancillary income from the credit card program.",
      "llm_answer": "Target's credit card profit-sharing arrangement with TD Bank generates revenue from a percentage of profits on Target Credit Card receivables, but this revenue declined from $734 million in 2022 to $667 million in 2023, mirroring the observed drop in RedCard penetration (from 20.5% to 18.6%). This decline in credit card profit-sharing income, combined with the broader revenue contraction (total revenue fell 1.6% to $107.4 billion), suggests the Target Credit Card program's financial performance weakened in 2023, likely due to reduced consumer usage of RedCards despite the ongoing 5% discount incentive.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_3_rel": {
          "source_file": "TGT_10k_2023.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 49165,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12531,
        "completion_tokens": 152,
        "total_tokens": 12683
      }
    },
    {
      "question_id": 6,
      "question": "How does the divestiture of KO Transmission's pipeline facilities in February 2023 impact Duke Energy's exposure to FERC cybersecurity compliance risks outlined in the risk factors section, given KO Transmission's prior role as an interstate pipeline operator subject to FERC regulations?",
      "original_answer": "The divestiture of KO Transmission's pipeline facilities in February 2023 likely reduces Duke Energy's direct exposure to FERC cybersecurity compliance risks associated with operating interstate natural gas infrastructure, as KO Transmission is no longer an active subsidiary. However, since Duke Energy remains subject to FERC regulations through other entities like Piedmont and Duke Energy Ohio's remaining operations, the company still faces cybersecurity compliance obligations under FERC-enforced standards such as those from the North American Electric Reliability Corporation (NERC). The risk factors section highlights that cybersecurity breaches could lead to operational disruption, financial loss, and regulatory penalties, which remain relevant even after the divestiture due to Duke Energy’s continued regulated operations under FERC oversight.",
      "llm_answer": "The divestiture of KO Transmission’s pipeline facilities in February 2023 removes an interstate natural‑gas pipeline that was subject to FERC regulation from Duke Energy’s operations. Because the pipeline was a regulated asset, its removal eliminates the associated FERC cybersecurity compliance obligations that applied to that regulated entity. Consequently, Duke Energy’s exposure to FERC‑related cybersecurity risk is reduced, as the remaining regulated assets now fall under the other subsidiaries and the former KO Transmission unit no longer incurs FERC‑mandated cybersecurity standards or related compliance costs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 101983,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25750,
        "completion_tokens": 155,
        "total_tokens": 25905
      }
    },
    {
      "question_id": 7,
      "question": "How does ConocoPhillips' $688 million before-tax charge related to its APLNG investment reconcile with the ongoing production of CBM in the Bowen and Surat basins, given APLNG's $4.7 billion outstanding project finance balance as of December 31, 2023?",
      "original_answer": "ConocoPhillips recorded a $688 million before-tax charge in 2021 when exercising its preemption right to purchase an additional 10% stake in APLNG, reflecting a market participant view of APLNG's fair value that was below the carrying value of COP's existing investment. Despite this write-down, APLNG continues to produce coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, which is processed into LNG and sold under long-term agreements. As of December 31, 2023, APLNG still carried $4.7 billion in outstanding project finance debt, indicating continued capital intensity and operational commitment to the CBM production and LNG export infrastructure. This suggests that while COP recognized a significant impairment in value earlier, the asset remains strategically important and operationally active, supported by long-term financing and sales agreements.",
      "llm_answer": "The $688 million pre‑tax impairment charge recorded in 2021 reflects a decline in the fair value of ConocoPhillips’ 47.5 % equity method investment in APLNG, which is focused on producing coal‑bed methane (CBM) from the Bowen and Surat basins.  Although APLNG’s project‑finance facilities still have a $4.7 billion outstanding balance as of Dec 31 2023, the impairment was triggered by a market‑based valuation that fell below the investment’s carrying amount, not by any change in the ongoing CBM production from those basins.  The charge therefore represents a one‑time write‑down of the investment’s fair value, while APLNG continues to operate its CBM assets and service its project‑finance debt.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72650,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18403,
        "completion_tokens": 175,
        "total_tokens": 18578
      }
    },
    {
      "question_id": 7,
      "question": "How does Qualcomm's exposure to revenue volatility from licensee disputes over royalty payments reconcile with their accounting policy that recognizes royalty revenue based on preliminary licensee estimates before final reporting is completed?",
      "original_answer": "Qualcomm faces material exposure from licensees who may delay, underreport, or refuse to pay royalties owed under license agreements (page 27), which directly conflicts with their accounting policy that recognizes royalty revenues based on preliminary estimates provided by these same licensees before final royalty reports are submitted (page 69). This creates a risk of significant revenue reversals if the preliminary estimates materially differ from actual reported sales, especially in cases where licensees are already disputing or non-compliant with contractual obligations. Although the company applies judgment to constrain revenue recognition when significant reversal risks exist, the binding arbitration provisions in license agreements do not prevent revenue recognition delays, further amplifying the volatility and uncertainty in reported licensing revenues.",
      "llm_answer": "Qualcomm recognizes royalty revenue based on preliminary, licensee‑provided estimates of unit sales before the licensee finalizes its reports, and it records adjustments to revenue when actual royalty amounts reported by licensees differ from those initial estimates. This approach allows the company to recognize revenue in the period the underlying sales occur, while acknowledging that the final royalty amounts may vary and are settled in subsequent periods.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 100080,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25258,
        "completion_tokens": 115,
        "total_tokens": 25373
      }
    },
    {
      "question_id": 7,
      "question": "How does Intel's strategic decision to divest its NAND memory business to SK hynix, including the Fab Assets in Dalian, relate to its continued manufacturing and sale of NAND wafers using those same assets, and what does this imply about Intel's ongoing involvement in NAND production post-divestiture?",
      "original_answer": "Intel signed an agreement with SK hynix in October 2020 to divest its NAND memory business, including the Fab Assets in Dalian, China. The first closing of the transaction, completed on December 29, 2021, included the sale of the Fab Assets and the NAND SSD Business to SK hynix. Despite this divestiture, Intel entered into a NAND wafer manufacturing and sale agreement, under which it continues to manufacture NAND memory wafers using the Dalian Fab Assets for SK hynix until the second closing. This implies that although Intel is exiting direct ownership of NAND manufacturing infrastructure, it maintains a transitional operational role in NAND production, supporting SK hynix’s ramp-up while gradually reducing its own exposure to NAND manufacturing.",
      "llm_answer": "Intel’s 2020 agreement to sell its NAND memory business—including the Dalian fab assets—to SK hynix stipulated that Intel would continue to **manufacture and sell NAND wafers to SK hynix using those same Dalian facilities under a separate wafer‑supply agreement** until the second closing of the transaction. This arrangement means Intel retained **limited, contractual involvement in NAND production after the divestiture**, primarily as a wafer supplier rather than an independent producer; consequently, Intel’s ongoing NAND wafer sales are **directly tied to the SK hynix deal and do not represent a broader, standalone NAND manufacturing strategy**.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31066,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 8015,
        "completion_tokens": 163,
        "total_tokens": 8179
      }
    },
    {
      "question_id": 7,
      "question": "How does Southern Company's increasing investment in SNG, which stood at $1,245 million as of December 31, 2024, align with the financial and regulatory risks associated with SNG's $3 billion pipeline project that is still pending FERC approval and not expected to be completed until 2029?",
      "original_answer": "Southern Company's investment in SNG has grown to $1,245 million as of December 31, 2024, reflecting a continued strategic commitment to the entity. SNG is currently developing a $3 billion pipeline project aimed at increasing its pipeline capacity by 1.3 billion cubic feet per day, with Southern Company Gas holding a 50% share of the project costs. However, the project remains subject to regulatory approvals, including from FERC, and is not expected to be completed until 2029. Given this timeline and the uncertainty of approval, the investment exposes Southern Company to regulatory and financial risk, especially since the outcome of the project cannot be determined at this time. This raises questions about the risk-adjusted rationale behind increasing capital allocation to SNG despite the unresolved status of a major capital project.",
      "llm_answer": "Southern Company’s $1,245 million investment in SNG reflects its 50 % ownership share in the joint venture that is building a $3 billion pipeline, a project that remains subject to FERC approval and is not slated for completion until 2029. While the investment aligns with Southern Company’s broader expansion strategy, the prolonged regulatory uncertainty and the long‑term timeline expose the company to financial and regulatory risks, including potential cost overruns and the need to fund a sizable portion of the project before any revenue can be realized.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 217,
          "pages": [
            215,
            216,
            217,
            218,
            219
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 86858,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21965,
        "completion_tokens": 140,
        "total_tokens": 22105
      }
    },
    {
      "question_id": 7,
      "question": "How does the valuation methodology for MDLZ's Level 2 financial assets, including net investment hedge contracts valued at $71 million, reflect the company's reliance on observable market inputs rather than unobservable assumptions?",
      "original_answer": "MDLZ reports that its Level 2 financial assets, which include $71 million in net investment hedge contracts, are primarily valued using observable market inputs such as forward exchange rates, commodity index prices, and interest rate curves. These inputs are applied through income-based approaches, such as discounted cash flow analyses or models that use market-observable parameters like volatility and dividend yields. This indicates that the valuation methodology emphasizes transparency and market-based data rather than internally derived or speculative assumptions, aligning with the fair value hierarchy's requirement for Level 2 classification based on significant observable inputs.",
      "llm_answer": "MDLZ’s Level 2 valuation of its net investment hedge contracts—reported at a fair value of $71 million and disclosed as using “Significant Other Observable Inputs” (Level 2) rather than Level 3 unobservable assumptions—demonstrates that the company bases the hedge’s value on quoted market rates, observable forward curves and other market‑derived inputs, reinforcing its reliance on observable rather than internally generated assumptions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78564,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19874,
        "completion_tokens": 110,
        "total_tokens": 19984
      }
    },
    {
      "question_id": 8,
      "question": "How does American Express's discussion of regulatory pressure on interest rate caps in its Supervision and Regulation section reconcile with its sensitivity analysis showing that higher interest rates would have a detrimental impact on net interest income, given the assumptions around repricing risk and deposit behavior?",
      "original_answer": "American Express highlights in its Supervision and Regulation section that there are regulatory proposals to cap credit card interest rates, which could materially impact revenue growth and profitability by restricting its ability to appropriately price products. This regulatory risk directly ties to the repricing risk discussed in the interest rate sensitivity analysis, where the company assumes that interest-rate sensitive assets and liabilities reprice in line with benchmark rates, subject to applicable interest rate caps or floors. The sensitivity analysis shows that higher interest rates would have a detrimental impact on net interest income, suggesting that American Express's earnings are vulnerable to both regulatory intervention limiting rate increases and broader market rate fluctuations. The connection between these sections indicates that while the company is exposed to regulatory constraints on upward repricing, it also faces financial risk if rates rise and its cost of funds increases faster than it can adjust pricing or asset yields, especially given that certain deposits may reprice at lower magnitudes than market rates.",
      "llm_answer": "American Express acknowledges that regulatory caps on interest rates could constrain its ability to reprice assets and liabilities, but its sensitivity analysis (Table 23) assumes that deposit repricing is slower than benchmark‑rate movements and that caps limit the full benefit of higher rates. Consequently, while higher market rates would increase the economic value of equity, the company projects a net‑interest‑income drag because the capped repricing of deposits prevents it from fully passing on rate hikes, leading to a modeled reduction in net interest income under higher‑rate shocks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77354,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19596,
        "completion_tokens": 149,
        "total_tokens": 19745
      }
    },
    {
      "question_id": 8,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, as outlined in the separation agreements, impact the financial presentation of discontinued operations in Merck's consolidated income statement through June 2, 2021?",
      "original_answer": "Merck's ongoing manufacturing relationship with Organon for finished pharmaceutical products, as detailed in the manufacturing and supply agreements (MSAs), generated $219 million in sales and $195 million in cost of sales in 2021. Despite Organon being classified as a discontinued operation through June 2, 2021, the continuation of these supply agreements created a dual financial relationship—where Merck both operated Organon’s legacy businesses and provided critical manufacturing services post-spin-off. This duality complicates the clean separation of Organon’s financial results from Merck’s ongoing operations, suggesting that the discontinued operations presentation may not fully capture the interdependent financial impact of the spin-off and the continuing supply chain relationship.",
      "llm_answer": "The separation agreements require Merck to continue manufacturing finished pharmaceutical products for Organon under manufacturing and supply agreements (MSAs) and to provide transition services. These ongoing relationships generate sales and cost of sales that are included in Merck’s consolidated income statement through the spin‑off date (June 2 2021). Because the results of the spun‑off businesses—including the manufacturing revenue and associated costs—are reported as discontinued operations, the income (and related tax effects) from these MSAs is presented within “Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests” in the consolidated statement of income up to June 2 2021. Consequently, the manufacturing relationship is reflected in the financial presentation of discontinued operations, with the related revenue and expenses recorded through the spin‑off date.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 146,
          "pages": [
            144,
            145,
            146,
            147,
            148
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68538,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17380,
        "completion_tokens": 232,
        "total_tokens": 17612
      }
    },
    {
      "question_id": 8,
      "question": "How does ConocoPhillips' preemptive purchase of an additional 10% stake in APLNG, following Origin Energy's partial divestiture, reconcile with the $688 million before-tax charge recorded against the carrying value of APLNG, given that APLNG remains a key part of COP's LNG strategy?",
      "original_answer": "ConocoPhillips exercised its preemption right in December 2021 to purchase an additional 10% stake in APLNG when Origin Energy sought to sell part of its interest. However, the sales price reflected a market participant view of APLNG's fair value that was below COP's carrying value, leading to a $688 million before-tax charge. Despite this impairment, APLNG remains strategically important to COP, as it provides access to coal bed methane resources in Australia and enhances COP's LNG position through long-term sales agreements and operations in the Asia-Pacific region. The charge indicates a near-term financial impact, but the continued investment suggests long-term strategic confidence in APLNG's role within COP's portfolio.",
      "llm_answer": "The $688 million pre‑tax impairment recorded in 2021 reflects that the fair value of APLNG—determined by the observable market price implied by Origin Energy’s $1.645 billion sale of a 10 % stake—was below the carrying amount of ConocoPhillips’ existing 47.5 % interest. After the impairment, ConocoPhillips retained a $5.4 billion carrying value in APLNG, which represents the historical cost basis of its investment adjusted for basis‑difference amortization; the subsequent 2023 purchase of an additional 10 % stake simply increased its ownership share but did not alter the previously written‑down carrying amount. Thus, the pre‑tax charge is reconciled with the ongoing LNG strategy by recognizing that the impairment captured the decline in fair value at the time of the preemption exercise, and the later stake acquisition is accounted for under the equity‑method investment without revisiting that prior impairment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72650,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18411,
        "completion_tokens": 230,
        "total_tokens": 18642
      }
    },
    {
      "question_id": 8,
      "question": "How does the difference in transfer restrictions between the Cruise Class G Preferred Shares issued in 2021 and the Cruise Class F Preferred Shares issued in 2019 reflect on GM's strategic control and investment timeline for Cruise Holdings?",
      "original_answer": "The Cruise Class G Preferred Shares, issued in 2021, carry a four-year transfer restriction without written consent from both GM and Cruise Holdings' Board of Directors, while the Cruise Class F Preferred Shares, issued in 2019, had a transfer restriction until May 7, 2023—approximately four years after their issuance. This indicates that GM has maintained a consistent strategy of limiting investor liquidity and preserving control over the timeline of Cruise Holdings' development and potential IPO. The alignment in restriction periods across both share classes suggests GM's intent to manage investor expectations and maintain strategic control over Cruise's commercialization path, particularly as both share classes convert into IPO shares at specified ratios. This reinforces GM’s long-term approach to Cruise’s monetization and strategic alignment with key investors.",
      "llm_answer": "The transfer restrictions on the Cruise Class G Preferred Shares—specifically a four‑year lock‑up that requires written consent from both GM and Cruise Holdings before they can be sold—underscore GM’s desire to retain strategic control over Cruise while still allowing the shares to be converted into public equity at an IPO. This contrasts with the earlier Cruise Class F Preferred Shares, which were subject to a shorter transfer restriction (until May 7 2023) and carried voting rights tied to a single director election. By imposing a longer lock‑up on the newer Class G shares, GM signals a more deliberate, staged investment timeline: it seeks to protect its stake and governance influence in Cruise until a public listing can be achieved, ensuring that any transfer of control is tightly managed and aligned with GM’s long‑term autonomous‑vehicle strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84134,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21266,
        "completion_tokens": 215,
        "total_tokens": 21482
      }
    },
    {
      "question_id": 8,
      "question": "How does BKNG's investment in KAYAK, which contributes to its intangible assets, relate to the company's decision to exclude KAYAK's search queries from gross bookings metrics, and what does this imply about the strategic alignment between asset valuation and operational performance measurement?",
      "original_answer": "BKNG reports that a 'substantial portion' of its intangible assets and goodwill relates to the acquisition of KAYAK, indicating a significant valuation placed on the brand. However, the company explicitly states that KAYAK's search queries do not contribute to gross bookings, which is the primary metric used to assess the volume of travel services booked through OTC brands. This suggests a misalignment between the asset valuation, which emphasizes KAYAK's strategic importance, and the operational performance measurement, which does not factor in KAYAK's user engagement through search queries. This distinction implies that while KAYAK is considered valuable enough to justify intangible asset recognition, its direct financial contribution to core revenue-driving activities (as measured by gross bookings) may be limited or indirect.",
      "llm_answer": "BKNG's investment in KAYAK—recorded as part of its intangible assets—is reflected in the company's decision to exclude KAYAK's search queries from its gross bookings metric, which focuses only on bookings from its OTC (online travel agency) brands. This exclusion underscores a strategic alignment where asset valuation (recognizing KAYAK's intangible value) is decoupled from operational performance measurement (gross bookings), allowing BKNG to track revenue-generating activity separately from assets that may not directly contribute to short-term booking volume. Consequently, while KAYAK's search activity drives user engagement and potentially long-term brand value, it is not factored into the core operational metric used to gauge growth, highlighting a disconnect between how the company values its intangible assets and how it measures operational success.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 118,
          "pages": [
            116,
            117,
            118,
            119,
            120
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 47021,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12008,
        "completion_tokens": 216,
        "total_tokens": 12224
      }
    },
    {
      "question_id": 8,
      "question": "How does Disney's use of foreign exchange forward and option contracts to hedge $9.9 billion in firm commitments as of September 28, 2024, relate to the exclusion of these commitments from the Value at Risk (VAR) model that estimated a maximum one-day loss of $255 million?",
      "original_answer": "Disney uses foreign exchange forward and option contracts to hedge $9.9 billion in firm commitments and forecasted transactions as of September 28, 2024, with gains and losses deferred in AOCI until the transactions occur. However, in the VAR model disclosed on page 60, the company explicitly excludes firm commitments, accounts receivable, and payable denominated in foreign currencies from the risk analysis. Despite this exclusion, the VAR model still estimates a maximum one-day loss of $255 million as of the same fiscal year-end, reflecting the company's broader exposure to interest rate, foreign exchange, commodities, and equity market fluctuations. This suggests that while Disney actively hedges its firm commitments, the VAR model focuses on the residual risk in financial instruments rather than the underlying commercial exposures.",
      "llm_answer": "Disney's foreign exchange forward and option contracts hedge $9.9 billion of firm commitments, but these commitments are excluded from the VAR model because the model only incorporates debt, derivatives and market‑sensitive investments, and it expressly omits forecasted transactions, firm commitments and foreign‑currency receivables/payables that are intended to be hedged. Consequently, the VAR‑based maximum one‑day loss of $255 million does not capture the risk associated with those hedged firm commitments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68308,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17323,
        "completion_tokens": 128,
        "total_tokens": 17452
      }
    },
    {
      "question_id": 8,
      "question": "How does the significant disparity in voting power between Class A and Class B common stockholders, with only 3 record holders of Class B stock controlling 33 1/3% of voting power, relate to the $4.0 billion in Class A stock repurchases during 2021?",
      "original_answer": "The 3 record holders of Class B common stock control 33 1/3% of the combined voting power due to the 15-vote per share structure, giving them disproportionate influence despite representing a small number of holders. Meanwhile, the company repurchased $4.0 billion of Class A common stock in 2021, which is the class with significantly less voting power but a much larger number of holders (352,581 as of December 31, 2021). This suggests that while Class A shareholders are numerous and see tangible capital return through share repurchases, the voting control remains concentrated in a small group of Class B shareholders, creating a governance structure where economic returns and voting influence are decoupled.",
      "llm_answer": "The $4.0 billion of Class A stock repurchases in 2021 was executed under the newly expanded $10 billion share‑repurchase authorization that was approved in May 2021, and the purchases occurred while the company’s voting power was heavily concentrated—only three record holders of Class B stock controlled one‑third of the total voting power, giving them outsized influence over corporate decisions such as authorizing large buybacks. This disparity in voting power thus underlies the board’s ability to green‑light and implement a substantial repurchase program despite the relatively small number of Class B shareholders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 49842,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12700,
        "completion_tokens": 155,
        "total_tokens": 12856
      }
    },
    {
      "question_id": 8,
      "question": "How does Emerson's equity compensation disclosure regarding unvested Performance Stock Units (PSUs) tied to AspenTech's performance goals reconcile with the increased stock compensation expense attributed to AspenTech equity plans in the consolidated income statement?",
      "original_answer": "Emerson's 2024 10-K reveals that at September 30, 2024, 4 million shares were reserved for future issuance under AspenTech's equity compensation plans, including performance stock units (PSUs) that vest based on predefined goals such as annual contract value and free cash flows. These PSUs, which can vest up to 175% of target upon exceeding performance goals or not vest at all if minimum thresholds are not met, directly contribute to the stock compensation expense recognized in the consolidated financial statements. This aligns with the reported increase in stock compensation expense of $50 million in 2023 attributed to AspenTech stock plans, which was included in SG&A expenses, showing how the performance-based equity incentives for AspenTech employees translate into measurable financial impacts on Emerson's consolidated results post-acquisition.",
      "llm_answer": "Emerson’s equity‑compensation disclosure shows that the unvested Performance Stock Units (PSUs) tied to AspenTech’s performance goals are evaluated each quarter for the likelihood of achieving the predefined targets, and any compensation expense is recorded based on the anticipated level of attainment. This quarterly assessment of performance‑goal probability directly drives the stock‑compensation expense recognized in the consolidated income statement, which explains why the expense line for AspenTech equity plans increased in 2024 despite the PSUs remaining unvested. Consequently, the higher expense reflects the updated fair‑value estimates and the probability‑based accrual of compensation cost for those PSUs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69984,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17742,
        "completion_tokens": 180,
        "total_tokens": 17922
      }
    },
    {
      "question_id": 8,
      "question": "How does the change in UPS Retirement Plan contribution structure for non-union employees hired on or after January 1, 2025, relate to the IRS limits on tax-qualified defined contribution plans, and how does this reflect a broader shift in UPS's retirement benefits strategy as evidenced by the cessation of future benefit accruals in the UPS Retirement Plan for non-union participants effective January 1, 2023?",
      "original_answer": "The UPS Retirement Plan for non-union employees hired on or after January 1, 2025, will receive a flat 3% annual contribution, down from a range of 3% to 8% based on years of vesting service prior to this change. This adjustment aligns with IRS limits on tax-qualified defined contribution plans, which cap contributions and compensation levels for such plans. UPS also ceased future benefit accruals for non-union participants in the UPS Retirement Plan effective January 1, 2023, signaling a strategic shift toward defined contribution plans like the UPS 401(k) Savings Plan. This reflects a broader trend of reducing long-term pension liabilities and transferring retirement risk to employees, while still offering competitive retirement benefits within regulatory constraints.",
      "llm_answer": "The shift to a flat 3% employer contribution to the UPS 401(k) Savings Plan for non‑union hires beginning January 1 2025—subject to the IRS limits on tax‑qualified defined‑contribution plans—replaces the prior accrual of benefits under the UPS Retirement Plan, which was halted for non‑union participants as of January 1 2023. This change reflects UPS’s broader strategy of moving away from traditional defined‑benefit accruals and toward a capped, contribution‑based retirement benefit that aligns with IRS‑imposed contribution limits.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64966,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16517,
        "completion_tokens": 134,
        "total_tokens": 16651
      }
    },
    {
      "question_id": 9,
      "question": "How does MDLZ's use of commodity futures to hedge input cost volatility relate to their classification and valuation methodology for Level 1 financial assets, and what does this reveal about their risk management approach for exchange-traded derivatives?",
      "original_answer": "MDLZ utilizes commodity futures to hedge against price risks associated with forecasted purchases of raw materials such as cocoa, sugar, and wheat (page 94). These commodity futures are classified as Level 1 financial assets (page 112), indicating they are exchange-traded instruments valued using quoted market prices on commodity exchanges. The valuation methodology for Level 1 assets reflects transparency and liquidity, aligning with MDLZ's strategy of using non-speculative, risk-mitigating instruments. This classification and valuation approach reveals that MDLZ prioritizes instruments with observable market pricing to manage commodity exposure in a manner consistent with their stated risk management policies.",
      "llm_answer": "MDLZ classifies commodity derivatives as Level 1 financial assets when they are exchange-traded futures with quoted prices in active markets, which are recorded at fair value on the balance sheet. This classification aligns with their broader Level 1 valuation methodology for exchange-traded derivatives, where fair value is determined using quoted market prices. Their use of commodity futures to hedge input cost volatility reflects a systematic risk management approach that integrates these instruments into their formal hedging program, with gains/losses on designated cash flow hedges recorded in accumulated other comprehensive earnings before reclassification to earnings. This structured use of exchange-traded derivatives demonstrates a disciplined, accounting-compliant strategy to manage commodity price risk while maintaining clear separation between designated hedges (accounted for under hedge accounting) and economic hedges (recorded at fair value with changes in earnings).",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 69495,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17616,
        "completion_tokens": 248,
        "total_tokens": 17864
      }
    },
    {
      "question_id": 9,
      "question": "How does AbbVie's fair value accounting treatment for the Cerevel Therapeutics funding agreements, which include milestone-based repayment terms for tavapadon, relate to the deferred tax liabilities recognized as a result of the acquisition?",
      "original_answer": "AbbVie accounts for the Cerevel Therapeutics funding agreements under the fair value option, with a $246 million financing liability recognized at acquisition based on a probability-weighted model and Monte Carlo simulations for milestone and royalty payments. These agreements, which are contingent on FDA approval of tavapadon, represent a long-term financial obligation tied to the success of a specific drug candidate. Concurrently, AbbVie recognized deferred tax liabilities due to the acquisition, primarily stemming from the excess book basis over tax basis of intangible assets. This indicates that while AbbVie has assumed contingent financial obligations (like the funding agreements), it has also taken on long-term tax implications from the acquisition, suggesting a complex interplay between contingent liabilities and tax planning considerations. The fair value treatment of the funding agreements and the deferred tax liabilities both reflect the broader financial impact of the Cerevel acquisition on AbbVie’s balance sheet.",
      "llm_answer": "The fair value accounting for the Cerevel Therapeutics funding agreements—characterized by milestone‑based repayment terms for tavapadon—required the company to estimate future regulatory, sales‑milestone and royalty payments using probability‑weighted models and Monte Carlo simulations, then discount those cash‑flow estimates to present value. This valuation produced a contingent consideration liability (recorded as a financing liability) that is re‑measured each reporting period; changes in its fair value flow through earnings (recorded in “other expense, net”) and also affect the deferred tax balance because the liability’s tax basis differs from its book basis. Consequently, the deferred tax liabilities recognized after the acquisition reflect the tax impact of the remeasured contingent consideration and the related intangible‑asset fair‑value adjustments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91919,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23222,
        "completion_tokens": 218,
        "total_tokens": 23440
      }
    },
    {
      "question_id": 9,
      "question": "How does ConocoPhillips' financial exposure to Alba Plant LLC, as detailed in its contingent obligations, relate to its production and monetization of condensate from the Alba Unit and other upstream assets?",
      "original_answer": "ConocoPhillips has a $116 million maximum potential future payment exposure through its guarantee of Alba Plant LLC, a joint venture where it holds a 52.2% interest. This financial risk is tied to Alba Plant LLC’s role in processing natural gas from the Alba Unit, which includes extracting and selling condensate at market prices—revenue from which is reflected in COP’s 'Equity in earnings of affiliates'. Meanwhile, in another section, COP describes its broader condensate production activities, such as at the Aasta Hansteen Field in the Norwegian Sea, where condensate is produced and transported to market. The financial guarantees tied to Alba Plant LLC directly support the infrastructure that enables COP to monetize condensate and LPG from the Alba Unit, linking its upstream production to downstream processing and revenue generation, while also exposing the company to contingent liabilities that could impact its financial position if triggered.",
      "llm_answer": "ConocoPhillips’ 64.2 % stake in the Alba Unit gives it operational control and a significant equity interest in the Alba Plant LLC, which processes the unit’s natural gas under a fixed‑rate, long‑term contract. The plant extracts condensate and LPG from the gas stream and sells them at market prices, while the processed gas is sent to EG LNG for liquefaction and export. Thus, the company’s financial exposure to Alba Plant LLC is directly tied to the volume of condensate and LPG it can monetize from the Alba Unit and other upstream assets, feeding into its “Equity in earnings of affiliates” line on the income statement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56148,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14268,
        "completion_tokens": 156,
        "total_tokens": 14425
      }
    },
    {
      "question_id": 9,
      "question": "How does Intel's divestiture of its NAND memory business to SK hynix, including the Dalian fabrication facility, align with its continued manufacturing and sale of NAND wafers using those same assets until the second closing?",
      "original_answer": "Intel signed an agreement with SK hynix in October 2020 to divest its NAND memory business, including the Dalian fabrication facility and related tangible assets (Fab Assets), as well as the NAND SSD Business, with the first closing completed on December 29, 2021. Despite selling the Fab Assets, Intel entered into a NAND wafer manufacturing and sale agreement with SK hynix, under which Intel continued to manufacture and sell NAND memory wafers using those very assets until the second closing. This indicates a transitional manufacturing arrangement that allows Intel to maintain short-term production continuity while gradually exiting the NAND memory manufacturing space.",
      "llm_answer": "Intel’s divestiture of its NAND memory business to SK hynix includes the Dalian fabrication facility, but under a “NAND wafer manufacturing and sale agreement” the company will continue to produce and sell NAND memory wafers using those same assets until the second closing of the transaction. This arrangement allows Intel to retain limited manufacturing and sales of NAND wafers while fully deconsolidating the NAND OpCo Business in early 2022.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31066,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 7996,
        "completion_tokens": 111,
        "total_tokens": 8107
      }
    },
    {
      "question_id": 9,
      "question": "How does Microsoft's investment in Azure, as noted in the operating expenses section, align with the growth trajectory of the Server products and cloud services segment, which includes Azure, given the 22% year-over-year revenue increase in that segment?",
      "original_answer": "Microsoft's Server products and cloud services segment, which includes Azure, saw a revenue increase from $79,970 million in 2023 to $97,726 million in 2024, representing a 22% year-over-year growth. This growth is attributed in part to Azure's expansion, driven by consumption-based services and AI infrastructure scaling. In response to this growth, Microsoft increased its investments in Azure, as noted in the operating expenses section, where expenses were driven by 'investments in Azure' despite a slight overall decrease in operating expenses. This indicates a strategic reallocation of resources to capitalize on Azure's growth potential and strengthen its market position in cloud and AI services.",
      "llm_answer": "Microsoft's investment in Azure aligns directly with the strong growth trajectory of the Server products and cloud services segment, which includes Azure. This segment demonstrated a 22% year-over-year revenue increase to $97,726 million in fiscal year 2024, driven by Azure's expansion and scaling of AI infrastructure, as noted in the operating expenses and revenue breakdowns across the Intelligent Cloud segment. The company explicitly states that Azure revenue grew 30% year-over-year, contributing to the segment's 20% overall revenue growth and 31% operating income growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 55295,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14069,
        "completion_tokens": 145,
        "total_tokens": 14214
      }
    },
    {
      "question_id": 9,
      "question": "How does Disney's use of Level 3 valuation techniques for non-recurring fair value measures in fiscal 2024 relate to the triggering events that led to impairment charges, and how does this align with their stated impairment testing methodology for long-lived assets?",
      "original_answer": "Disney evaluates certain assets for non-recurring fair value measurement when triggering events occur, such as a decrease in estimated future cash flows, which led to impairment charges in the second and fourth quarters of fiscal 2024. These fair value measurements use Level 3 valuation techniques, primarily discounted cash flow analysis. On another section of the filing, Disney states that when triggering events occur, they test long-lived assets for impairment by comparing estimated undiscounted future cash flows to the asset's carrying value, depending on whether the asset is held for use or sale. This indicates that the Level 3 fair value assessments are directly tied to the triggering events that initiate impairment testing, aligning the valuation methodology with the broader asset recovery evaluation framework.",
      "llm_answer": "Disney's use of Level 3 valuation techniques for non-recurring fair value measures in fiscal 2024—specifically for impairment charges tied to long-lived assets and content libraries—directly relates to triggering events such as significant declines in estimated future cash flows, which necessitate testing for recoverability under its impairment methodology. This aligns with the company's stated approach of testing long-lived assets for impairment when events or changes in circumstances indicate that the carrying amount may not be recoverable, requiring a comparison of undiscounted cash flows to the asset group's carrying amount, with Level 3 inputs (e.g., discounted cash flow models) critical to estimating fair value when market inputs are unavailable. The document confirms that such impairment assessments, including those for content assets and long-lived assets, rely on Level 3 valuation techniques involving discounted cash flows and significant management assumptions about future revenues, margins, and discount rates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83634,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21153,
        "completion_tokens": 259,
        "total_tokens": 21412
      }
    },
    {
      "question_id": 9,
      "question": "How does Simon Property Group's financial benefit from its investment in J.C. Penney, including the equity transaction with SPARC Group, contrast with the impact of ownership dilution in SPARC Group earlier in the year?",
      "original_answer": "Simon Property Group derived a $100.5 million non-cash pre-tax gain from J.C. Penney's acquisition of SPARC Group, which was renamed Catalyst. This transaction solidified SPG's 31.3% noncontrolling interest in the newly combined entity. However, earlier in the year, SPG experienced ownership dilution in SPARC Group when the latter issued equity to a third party, reducing SPG’s stake to 33.3% and resulting in a $145.8 million non-cash pre-tax gain due to deemed disposal. While both events contributed positively to SPG's financials, the J.C. Penney transaction reflects a strategic consolidation benefit, whereas the SPARC dilution reflects a partial exit with a tax-deferred gain, highlighting different strategic and financial outcomes from similar equity-level activities.",
      "llm_answer": "Simon Property Group's financial benefit from its investment in J.C. Penney through the SPARC Group equity transaction is reflected in a non‑cash pre‑tax gain of $100.5 million recognized in 2024, which is recorded in “gain due to disposal, exchange, or revaluation of equity interests, net” and results in a $25.1 million deferred tax expense. This gain contrasts with earlier dilution events in SPARC Group, where each dilution (e.g., the 2023 equity issuance that reduced the Company’s stake to 33.3 %) triggered a non‑cash pre‑tax gain—$145.8 million in 2023—also recorded in the same line item, but without the same immediate cash proceeds or tax expense associated with the later SPARC‑J.C. Penney transaction.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 115,
          "pages": [
            113,
            114,
            115,
            116,
            117
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75295,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19063,
        "completion_tokens": 179,
        "total_tokens": 19242
      }
    },
    {
      "question_id": 9,
      "question": "How does the allocation of $21.7 billion in Alphabet's 2023 stock-based compensation expense tied to Class C stock issuance reconcile with the treatment of Class B stock in diluted net income per share calculations, given the structural relationship between these share classes?",
      "original_answer": "Alphabet's 2023 stock-based compensation expense of $21.7 billion is largely tied to awards expected to settle in Class C stock, indicating a direct financial impact from issuing this share class. Meanwhile, the diluted net income per share calculation for Class A stock assumes the conversion of Class B stock, which is not treated as dilutive when calculating diluted earnings for Class B itself. Despite these differences in treatment across compensation and earnings per share disclosures, both Class C and Class B shares participate equally in undistributed earnings due to identical dividend and liquidation rights. This structural alignment ensures that while Class C stock is operationally central to compensation programs, Class B stock retains a distinct role in EPS calculations, reflecting the company's capital structure design.",
      "llm_answer": "The $21.7 billion stock‑based compensation expense tied to Class C stock issuance is recorded as part of Alphabet’s overall SBC expense and is recognized over the vesting period of the underlying RSUs. Because Class B shares automatically convert to Class A shares (and ultimately to Class C) when calculating diluted earnings per share, the conversion of Class B to Class A is reflected in the diluted‑share denominator, but it does not change the per‑share allocation of undistributed earnings—Class A, B and C continue to receive the same per‑share amount of net income. Consequently, the SBC expense tied to Class C issuance is accounted for in the diluted‑share calculations only through the increased share count from RSU conversions, not through any special treatment of Class B shares.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 90436,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22853,
        "completion_tokens": 198,
        "total_tokens": 23051
      }
    },
    {
      "question_id": 9,
      "question": "How does the $1.2 billion loss on the sale of ATC TIPL reflect in the consolidated financial statements, given that the transaction proceeds were primarily used to repay the 2021 Multicurrency Credit Facility and the sale is referenced in the context of asset retirement obligations?",
      "original_answer": "The $1.2 billion loss on the sale of ATC TIPL, which includes a $1.1 billion reclassification of cumulative translation adjustments, is recorded in 'Loss from discontinued operations, net of taxes' in the consolidated statements of operations for the year ended December 31, 2024. The proceeds from the $2.2 billion transaction were used to repay existing indebtedness under the 2021 Multicurrency Credit Facility, directly impacting the company’s liabilities and cash flow statement. Additionally, the sale of ATC TIPL is referenced in the context of asset retirement obligations as part of broader asset disposals affecting the company’s real estate and infrastructure portfolio, indicating a strategic realignment of capital and asset base.",
      "llm_answer": "The $1.2 billion loss on the sale of ATC TIPL appears in the consolidated statements of operations as a “Loss on sale of ATCTIPL” within the “Loss from discontinued operations, net of taxes” line item.  The loss of $1,245.5 million (primarily the $1.1 billion reclassification of cumulative translation adjustment) is reflected in the 2024 loss from discontinued operations of $978.3 million, and the corresponding contingent tax‑indemnification liability of $53.9 million is recorded in other non‑current liabilities.  The proceeds from the sale were used to repay the 2021 Multicurrency Credit Facility, and the transaction also triggered the settlement of the India Term Loan and related interest expense within discontinued operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2024.pdf",
          "target_page": 148,
          "pages": [
            142,
            143,
            144,
            145,
            146
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62433,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15857,
        "completion_tokens": 184,
        "total_tokens": 16042
      }
    },
    {
      "question_id": 9,
      "question": "How does Boeing's continued partnership with Citibank, N.A. as administrative agent under both the 2019 Five-Year Credit Agreement and the newly executed 2023 Five-Year Credit Agreement reflect on the company's strategic approach to credit facility management and lender relationships?",
      "original_answer": "Boeing's continued engagement with Citibank, N.A. as administrative agent across both the 2019 and 2023 Five-Year Credit Agreements indicates a strategic preference for maintaining continuity and established trust with key financial partners. This consistency in lender relationships suggests that Boeing values Citibank’s role in facilitating stable access to capital, particularly during periods of financial stress or restructuring. The presence of Citibank in both agreements, despite the multi-year gap and potential market changes, underscores Boeing's reliance on proven financial partnerships to manage liquidity and credit risk.",
      "llm_answer": "Boeing's continued use of Citibank, N.A. as administrative agent across both its 2019 Five-Year Credit Agreement and the newly executed 2023 Five-Year Credit Agreement demonstrates a deliberate strategy of maintaining a stable, long-term relationship with a key financial partner to manage its revolving credit facilities. This consistency underscores Boeing's preference for institutional continuity in its credit governance, leveraging established banking relationships to support its capital structure while facilitating new financing arrangements through the 2023 agreement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64957,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16483,
        "completion_tokens": 144,
        "total_tokens": 16628
      }
    },
    {
      "question_id": 9,
      "question": "How does MET's valuation methodology for Structured Securities, including RMBS, reflect in their Level 3 fair value disclosures, and what does this imply about the sensitivity of their RMBS portfolio to market pricing assumptions?",
      "original_answer": "MET reports a total fair value of $4,551 million for Structured Securities as of December 31, 2023, within Level 3 of the fair value hierarchy, indicating significant unobservable inputs. These Structured Securities include RMBS, which MET values using market pricing techniques and quoted prices. On page 272, MET discloses that an increase in market pricing inputs would raise the estimated fair value of RMBS, showing that the RMBS portfolio is particularly sensitive to changes in market pricing assumptions. This sensitivity, combined with the Level 3 classification, implies that the valuation of RMBS within Structured Securities involves considerable judgment and model dependence, which could lead to material changes in fair value with shifts in market conditions.",
      "llm_answer": "MET’s valuation methodology for Structured Securities, including RMBS, relies on Level 3 inputs such as market‑pricing quotes, matrix pricing and discounted cash‑flow models that incorporate significant unobservable assumptions (e.g., default probabilities, loss‑severity, prepayment rates). These inputs are explicitly disclosed in the fair‑value hierarchy tables (pages 94, 272‑274) and show that the estimated fair value of RMBS and related structured securities is highly sensitive to changes in those assumptions—particularly default and loss‑severity rates—so that shifts in market pricing assumptions can materially affect the reported fair‑value of the RMBS portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 274,
          "pages": [
            272,
            273,
            274,
            275,
            276
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 272,
          "pages": [
            270,
            271,
            272,
            273,
            274
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 151043,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 37999,
        "completion_tokens": 169,
        "total_tokens": 38168
      }
    },
    {
      "question_id": 9,
      "question": "Given that UPS contributed $139 million to the New York State Teamsters Conference Pension and Retirement Fund in 2023, which is subject to a Rehabilitation Plan (RP) requirement, how does this contribution align with UPS's statement that collectively bargained contributions satisfy all implemented RP requirements without requiring surcharges?",
      "original_answer": "UPS contributed $139 million to the New York State Teamsters Conference Pension and Retirement Fund in 2023, which is in the red zone and subject to an implemented RP requirement. According to UPS, their collectively bargained contributions satisfy all RP requirements, and no surcharges are imposed. This indicates that UPS's $139 million contribution meets the financial obligations under the Rehabilitation Plan without requiring additional payments beyond the agreed-upon contractual rates.",
      "llm_answer": "UPS's $139 million contribution to the New York State Teamsters Conference Pension and Retirement Fund is made under a collectively‑bargained agreement that already satisfies the fund’s rehabilitation‑plan (RP) requirements. Because the agreement’s negotiated contribution rates meet the RP funding schedule, no additional surcharges are required.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22213,
        "completion_tokens": 86,
        "total_tokens": 22300
      }
    },
    {
      "question_id": 9,
      "question": "How does COP's investment in PALNG, which involved interest rate swaps under ASC Topic 815, impact its revenue recognition policy for derivative contracts governed by the same accounting standard?",
      "original_answer": "COP's investment in PALNG, which included interest rate swaps designated under ASC Topic 815, reflects its involvement in complex derivative instruments for risk management. However, when PALNG de-designated part of these swaps in 2024, the associated $35 million in unrealized changes flowed through 'Equity in earnings of affiliates,' indicating a shift in how those derivatives are accounted for. Meanwhile, COP applies ASC Topic 815 to certain physical gas contracts that fall outside ASC Topic 606, treating them as derivatives for revenue recognition. This suggests that while COP uses ASC Topic 815 both for hedging investments (like in PALNG) and for revenue from commodity contracts, the financial impact is recognized differently—either through equity earnings or directly as revenue—depending on the nature and context of the derivative.",
      "llm_answer": "ConocoPhillips’ investment in PALNG, which involved interest rate swaps designated under ASC Topic 815 as cash‑flow hedges, does not alter the company’s revenue‑recognition policy for derivative contracts governed by the same standard. The swaps are accounted for as hedges of forecasted cash flows, with changes in fair value recorded in other comprehensive income and re‑classified into earnings when the hedged transactions occur; revenue from derivative contracts continues to be recognized on a net basis when the underlying physical contracts settle, consistent with the company’s existing ASC 815 accounting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69915,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17712,
        "completion_tokens": 153,
        "total_tokens": 17866
      }
    },
    {
      "question_id": 9,
      "question": "How does Southern Company's financial dependency on SCS for power pool services relate to its equity earnings from SNG, given SCS's role in arranging natural gas transportation through SNG?",
      "original_answer": "Southern Company (SO) relies on SCS to arrange natural gas transportation services from SNG, which is a key input for power generation. In 2024, SO incurred significant costs through SCS for these services, which are included in operations and maintenance expenses or capitalized. SCS, acting as an agent for SO's subsidiaries, manages long-term agreements with SNG for gas transportation, which are essential for fulfilling energy production needs. Meanwhile, Southern Company Gas, a subsidiary of SO, earns equity method income from its investment in SNG, totaling $146 million in 2024. This creates a dual relationship where SO indirectly supports SNG through contracted transportation fees (via SCS), while also benefiting financially from SNG’s performance through equity earnings. The interplay highlights a strategic alignment in SO’s upstream and downstream operations, balancing cost obligations with investment returns within the same value chain.",
      "llm_answer": "Southern Company's power pool services from SCS are recorded as purchased power costs in its subsidiaries' income, while its equity earnings from Southern Power reflect the profit share from the power pool arrangements, including the natural gas transportation costs arranged through SNG that support SCS's operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 217,
          "pages": [
            215,
            216,
            217,
            218,
            219
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 67624,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17132,
        "completion_tokens": 79,
        "total_tokens": 17212
      }
    },
    {
      "question_id": 10,
      "question": "How does MetLife's treatment of surplus notes under statutory accounting principles affect its ability to pay dividends, given the differences in how surplus notes are reported in the long-term debt disclosures?",
      "original_answer": "MetLife's statutory accounting practices treat surplus notes as surplus rather than debt, which increases statutory capital and surplus and thereby influences the calculation of allowable dividends. This treatment contrasts with the GAAP-based long-term debt disclosures on page 276, where surplus notes are reported with a face value of $507 million and a weighted average interest rate of 7.79%, reflecting their debt-like characteristics. The statutory treatment enhances MetLife's capacity to pay dividends by inflating surplus, while the GAAP presentation highlights the financial liability associated with surplus notes, indicating a more conservative view of the company's financial position.",
      "llm_answer": "MetLife’s statutory accounting treats surplus notes as equity rather than debt, which limits the amount of surplus that can be distributed as dividends from its insurance subsidiaries. Because dividend capacity is tied to statutory surplus (including surplus notes), the company must maintain sufficient surplus to meet regulatory requirements before paying dividends to its parent. This constraint, combined with the need to preserve surplus for solvency and capital adequacy, restricts MetLife’s ability to pay dividends from its subsidiaries.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 292,
          "pages": [
            290,
            291,
            292,
            293,
            294
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 276,
          "pages": [
            274,
            275,
            276,
            277,
            278
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75530,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19121,
        "completion_tokens": 136,
        "total_tokens": 19257
      }
    },
    {
      "question_id": 10,
      "question": "How does ConocoPhillips' $688 million before-tax charge related to the fair value write-down of APLNG reconcile with their operational exposure in Queensland, Australia, particularly given the long-term sales agreements and financing structure of the APLNG joint venture?",
      "original_answer": "ConocoPhillips took a $688 million before-tax charge in 2021 to write down its investment in APLNG to its fair value of $5,574 million, reflecting a market participant view that the carrying value was too high. This write-down occurred despite APLNG's long-term sales agreements and a structured $4.7 billion project finance facility that extends through 2030, both of which are key components of its operational stability in Queensland, Australia. The contrast between the impairment charge and the long-term contractual and financial framework of APLNG suggests that short-term market or risk assessments may have outweighed the long-term strategic positioning of the asset at the time of the valuation.",
      "llm_answer": "ConocoPhillips recorded a $688 million pre‑tax impairment charge in 2021 after determining that the fair value of its 47.5 % stake in APLNG—driven by a market‑based valuation that fell below the carrying amount of its investment—was impaired; this write‑down reflects the joint venture’s long‑term LNG sales agreements and its financing structure, which ties cash flows to the project’s economics in Queensland, Australia. The impairment was recognized despite the existence of long‑term sales contracts because the valuation relied on observable market participant inputs that indicated a decline in fair value, prompting the company to adjust the carrying amount of its equity method investment in APLNG accordingly.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72650,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18408,
        "completion_tokens": 179,
        "total_tokens": 18588
      }
    },
    {
      "question_id": 10,
      "question": "How does the difference in transfer restrictions between Cruise Class G and Class F Preferred Shares impact GM's liquidity planning and strategic control over Cruise Holdings?",
      "original_answer": "The Cruise Class G Preferred Shares issued in 2021 carry a four-year transfer restriction, expiring in 2025, while the earlier issued Cruise Class F Preferred Shares had a transfer restriction that expired in May 2023. This staggered restriction timeline allows GM to maintain strategic influence over Cruise Holdings for a longer period through the Class G shares, particularly during critical phases of development and potential IPO planning. Additionally, the Class G shares grant voting rights on all matters submitted for vote, whereas Class F shares are limited to voting on the election of one director. These differences suggest GM may be calibrating its control and exit strategy in stages, aligning with its broader liquidity planning and long-term strategic goals for Cruise as outlined in the consolidated financial statements.",
      "llm_answer": "The transfer restrictions on Cruise Class G Preferred Shares—specifically a four‑year lock‑up that requires written consent from both GM and Cruise’s board before they can be sold—limit the ability of Cruise Holdings to raise additional capital or liquidate its stake quickly. This restriction forces GM to plan its liquidity around a longer‑term horizon for Cruise, ensuring that any financing needs of Cruise are met through internal sources or delayed dispositions, while also preserving GM’s strategic control over Cruise’s governance and future IPO timing. Consequently, GM must factor the lock‑up period into its cash‑flow forecasts and capital‑allocation decisions, maintaining tighter control over Cruise’s equity structure and preventing premature exits that could disrupt GM’s long‑term autonomous‑vehicle strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84134,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21250,
        "completion_tokens": 206,
        "total_tokens": 21456
      }
    },
    {
      "question_id": 10,
      "question": "Given Apple's significant net sales of $74.2 billion from the Greater China region in 2022, how does the company's reliance on China Mainland within this region for manufacturing and supply chain operations expose it to risk, particularly in light of the geopolitical and public health challenges described in the risk factors section?",
      "original_answer": "Apple reported $74.2 billion in net sales from the Greater China region in 2022, which includes China Mainland, Hong Kong, and Taiwan. This region is not only a major revenue contributor but also a critical part of Apple's global supply chain. However, the company's operations are exposed to significant risks due to its reliance on China Mainland for manufacturing and logistics. As noted in the risk factors section, geopolitical tensions between the U.S. and China have led to tariffs that increase the cost of Apple's products and components, potentially reducing gross margins and consumer demand. Additionally, public health issues like the ongoing impact of the COVID-19 pandemic can disrupt supply chains, delay product delivery, and affect consumer confidence and spending. These combined factors illustrate how Apple's strategic and operational exposure to the Greater China region, particularly China Mainland, presents both opportunity and risk.",
      "llm_answer": "Apple's reliance on China Mainland for manufacturing and supply‑chain operations creates significant exposure to geopolitical tensions, trade disputes, and pandemic‑related disruptions; tariffs or export controls can raise component costs and make its products less competitive, while any interruption at single‑source suppliers in China can halt production, limit the ability to meet demand, and materially impair the company's financial results.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62270,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15833,
        "completion_tokens": 111,
        "total_tokens": 15944
      }
    },
    {
      "question_id": 10,
      "question": "Given Disney's exposure to floating-rate borrowings as of September 28, 2024, how does the lack of designated pay-fixed interest rate swaps impact their interest rate risk management strategy, especially in light of their broader use of cash flow hedges for foreign exchange risk?",
      "original_answer": "Disney reported floating-rate borrowings as of September 28, 2024, with interest rates in effect on that date, which may not reflect future costs. Although the company utilizes pay-fixed interest rate swaps to convert floating-rate debt to fixed-rate debt, it did not have any such swaps designated as cash flow hedges at the end of fiscal 2024. This contrasts with their active use of foreign exchange cash flow hedges, where $9.9 billion in notional amounts were designated to manage currency risk. The absence of designated pay-fixed swaps suggests Disney is not actively hedging interest rate risk on floating-rate borrowings through cash flow hedges, potentially leaving them exposed to rate increases, even as they proactively manage foreign exchange volatility.",
      "llm_answer": "Disney’s floating‑rate borrowings are managed primarily through pay‑floating interest‑rate swaps that convert fixed‑rate debt to variable‑rate exposure, while foreign‑exchange risk is mitigated by cash‑flow hedges of forecasted foreign‑currency transactions. Because the Company does not use pay‑fixed swaps designated as cash‑flow hedges for its floating‑rate borrowings, it relies on the fair‑value swaps and foreign‑exchange contracts to limit interest‑rate and currency volatility, rather than on designated pay‑fixed hedges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80409,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20351,
        "completion_tokens": 132,
        "total_tokens": 20483
      }
    },
    {
      "question_id": 10,
      "question": "How does the significant disparity in voting power between Class A and Class B common stockholders, with only 3 record holders of Class B stock controlling 33⅓% of voting power, relate to the $4.0 billion in Class A stock repurchases during 2021?",
      "original_answer": "The 3 record holders of Class B common stock control 33⅓% of the combined voting power, with each share carrying 15 votes, and Mr. Brian L. Roberts owning all outstanding shares. This concentrated voting power ensures continued influence over corporate decisions. Meanwhile, in 2021, the company repurchased $4.0 billion worth of Class A common stock, which is subject to broader public ownership (352,581 holders) and carries fewer voting rights. The repurchase of Class A shares may serve to return capital to the broader shareholder base while maintaining strategic control with the Class B holders. This reflects a capital allocation strategy that balances shareholder returns with governance stability.",
      "llm_answer": "The $4 billion of Class A share repurchases in 2021 was funded with cash generated from operations and available liquidity, not with debt proceeds; the repurchases occurred while the company’s debt‑to‑EBITDA covenant remained comfortably satisfied, underscoring that the buy‑back was financed by the firm’s strong cash flow rather than by borrowing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 49842,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12699,
        "completion_tokens": 87,
        "total_tokens": 12787
      }
    },
    {
      "question_id": 10,
      "question": "How does Boeing's 2023 Five-Year Credit Agreement, which Citibank, N.A. administers, relate to the company's broader credit arrangements with Citibank as disclosed in the exhibits filed with the 2023 10-K?",
      "original_answer": "Boeing's 2023 Five-Year Credit Agreement, administered by Citibank, N.A., is part of a broader set of credit arrangements with Citibank as disclosed in the exhibits to the 2023 10-K, which also includes a 364-Day Credit Agreement and a Three-Year Credit Agreement, both dated August 24, 2023 and August 25, 2022 respectively. These agreements highlight Citibank's role as a key financial partner for Boeing, providing flexible financing solutions during a period of ongoing financial challenges.",
      "llm_answer": "The Boeing Company's 2023 Five-Year Credit Agreement, administered by Citibank, N.A., is explicitly disclosed as part of the company's broader credit arrangements in the exhibits filed with its 2023 10-K, specifically referenced in Item 10.4 and Item 10.5 of the filing, which detail the original agreement dated October 30, 2019, and its August 25, 2022 amendment, both of which involve Citibank, N.A. as administrative agent alongside JPMorgan Chase Bank, N.A.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64957,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16463,
        "completion_tokens": 115,
        "total_tokens": 16579
      }
    },
    {
      "question_id": 10,
      "question": "How does The Goldman Sachs Group, Inc.'s guarantee of Goldman Sachs Bank USA's obligations relate to the stricter 'Category I' capital and liquidity standards it is subject to under U.S. federal bank regulations?",
      "original_answer": "The Goldman Sachs Group, Inc. provides guarantees for certain obligations of Goldman Sachs Bank USA, as evidenced by the Amended and Restated General Guarantee Agreement dated September 28, 2018. This financial backing implies a direct corporate responsibility for the Bank USA's liabilities. Goldman Sachs Bank USA, in turn, is subject to 'Category I' standards under the Federal Reserve Board's Capital Framework because of the firm's designation as a global systemically important bank (G-SIB). These standards impose advanced risk-based capital and leverage requirements, which are quantitatively measured and also subject to qualitative regulatory judgment. The combination of direct liability guarantees and elevated regulatory scrutiny highlights the strategic and regulatory interdependence between the parent company and its banking subsidiary in maintaining financial stability.",
      "llm_answer": "The Goldman Sachs Group’s guarantee of Goldman Sachs Bank USA’s obligations means that the parent company is legally liable for any shortfalls of the bank, which is especially important because both the Group and GS Bank USA must meet the stricter “Category I” capital and liquidity standards imposed by U.S. federal bank regulators on globally systemically important banks. These Category I requirements—higher risk‑based capital ratios, additional buffers (including the G‑SIB surcharge and counter‑cyclical buffer) and a 100 % LCR/NSFR floor—apply to the bank’s activities and are enforced through the Group’s guarantee, ensuring that any capital or liquidity deficiencies of the bank would be absorbed by the parent.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 248,
          "pages": [
            243,
            244,
            245,
            246,
            247
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81079,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20501,
        "completion_tokens": 180,
        "total_tokens": 20681
      }
    },
    {
      "question_id": 10,
      "question": "How does ConocoPhillips' impairment of its APLNG investment in 2021 relate to its operational exposure in Queensland, Australia, particularly considering the structure of APLNG's long-term gas sales agreements in the region?",
      "original_answer": "ConocoPhillips impaired its APLNG investment by $688 million in 2021 due to a decline in fair value, as noted on page 119. APLNG operates in Queensland, Australia, where it produces coal bed methane (CBM) from the Bowen and Surat basins and exports LNG, primarily under long-term sales agreements, as detailed on page 100. Page 99 confirms ConocoPhillips' 37.5% ownership in APLNG, underscoring its significant operational exposure in Queensland. The impairment suggests that despite long-term contracts, market conditions or operational risks in Queensland may have negatively impacted the investment's valuation, highlighting a contrast between contractual stability and asset valuation risk.",
      "llm_answer": "ConocoPhillips recorded a $688 million non‑cash impairment of its APLNG investment in the fourth quarter of 2021 because the pre‑emptive purchase price paid to Origin Energy was below the carrying value of the existing stake.  This impairment reflects the company’s exposure to Queensland’s long‑term gas sales agreements—under those contracts APLNG sells the bulk of its LNG under fixed, long‑term sales and purchase agreements to Asia‑Pacific markets—so the write‑down signals that the value of its Queensland‑based LNG operations, which are dependent on those long‑term contracts, had fallen below the book value of the equity investment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65860,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16701,
        "completion_tokens": 160,
        "total_tokens": 16861
      }
    },
    {
      "question_id": 11,
      "question": "How does MET's disclosure of $72 million in collateral pledged to the FHLB of Des Moines in one section relate to the $2 million in liabilities reported to the same institution in another section, and what does this imply about MET's financial relationship with this counterparty?",
      "original_answer": "MET reports $72 million in collateral pledged to the FHLB of Des Moines in the collateral table on page 199, while on page 198, it shows only $2 million in liabilities to the same institution. This suggests that MET's exposure to the FHLB of Des Moines is primarily secured through collateral rather than direct liabilities, indicating a limited but collateral-backed financial relationship with this counterparty.",
      "llm_answer": "MET reports $72 million of collateral pledged to the FHLB of Des Moines in the “Collateral” column of the table showing FHLB of Des Moines liabilities (page 199), while the same table lists only $2 million of liabilities to that FHLB. This $72 million figure represents the estimated fair‑value of the collateral (mortgage‑backed securities) that backs the funding agreements with the Des Moines FHLB, whereas the $2 million liability reflects the outstanding balance of those funding agreements. Consequently, the collateral amount is far larger than the recorded liability, indicating that MET maintains a substantial pledged‑asset buffer to secure its obligations to the FHLB, underscoring a strong collateral‑backed financing relationship with that counterparty.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 199,
          "pages": [
            197,
            198,
            199,
            200,
            201
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 199,
          "pages": [
            197,
            198,
            199,
            200,
            201
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 198,
          "pages": [
            196,
            197,
            198,
            199,
            200
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 234004,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 58745,
        "completion_tokens": 191,
        "total_tokens": 58937
      }
    },
    {
      "question_id": 11,
      "question": "How does MDLZ's inclusion of net investment hedge contracts within Level 2 financial liabilities reflect both the valuation methodology and the fair value disclosure practices for derivative instruments?",
      "original_answer": "MDLZ categorizes net investment hedge contracts as part of Level 2 financial liabilities, indicating that their fair value is determined using observable market inputs rather than quoted prices or unobservable data. Specifically, the fair value of these contracts is derived from an income approach based on observable market factors, aligning with the broader Level 2 valuation methodology. On page 111, the company discloses that the fair value of net investment hedge contracts was $71 million as of December 31, 2021, and this entire amount falls under Level 2 inputs, confirming that no Level 1 or Level 3 valuations are involved. This synthesis reveals that MDLZ relies on market-observable models for these contracts and transparently reports their fair value within the appropriate hierarchy level.",
      "llm_answer": "MDLZ reports net investment hedge contracts (cross‑currency interest‑rate swaps and forwards) at a fair value of $71 million and discloses them as Level 2 instruments measured using observable market inputs (e.g., forward rates, observable market rates) rather than quoted prices, reflecting a valuation methodology that relies on significant other observable inputs. This inclusion in Level 2 financial liabilities underscores the company’s fair‑value disclosure practice of presenting derivative instruments at their current market‑based fair values, with the hedge’s gains/losses recorded in accumulated other comprehensive earnings and subsequently reclassified into earnings as the hedge matures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78564,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19866,
        "completion_tokens": 175,
        "total_tokens": 20042
      }
    },
    {
      "question_id": 11,
      "question": "How does Chevron's acquisition of Hess Corporation, valued at $53 billion, reflect compliance with the Hart-Scott-Rodino Act, and what implications does this have given the ongoing arbitration related to the Stabroek Block operating agreement?",
      "original_answer": "Chevron's acquisition of Hess Corporation, valued at $53 billion, required compliance with the Hart-Scott-Rodino Act, as evidenced by the FTC's review and the consent agreement entered into by Chevron, Hess, and the FTC to address antitrust concerns. Despite this regulatory clearance, the transaction remains subject to the outcome of an arbitration related to the Stabroek Block operating agreement, where a decision against Hess Guyana could prevent the deal from closing. This highlights a dual dependency: regulatory compliance under the Hart-Scott-Rodino Act was satisfied, but external legal uncertainties tied to Hess’s Guyana assets still pose a material risk to the completion of the acquisition.",
      "llm_answer": "Chevron's $53 billion acquisition of Hess complies with the Hart‑Scott‑Rodino Act, which requires filing of pre‑merger notification and allows the FTC to review the deal; the company has filed the necessary HSR notice and secured FTC clearance, but the transaction remains subject to an ongoing arbitration over the Stabroek Block operating‑agreement right‑of‑first‑refusal, a risk that could prevent the merger from closing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 93873,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23707,
        "completion_tokens": 106,
        "total_tokens": 23813
      }
    },
    {
      "question_id": 11,
      "question": "How does Nike's foreign exchange hedging strategy for product cost exposures through the Nike Trading Company (NTC) align with the financial impact of U.S. Dollar fluctuations on inventory costs described in the transactional exposures section?",
      "original_answer": "Nike manages foreign exchange risk related to product cost exposures by using derivatives designated as cash flow hedge instruments, particularly for purchases made through the Nike Trading Company (NTC), which operates in U.S. Dollars and sells to Nike entities in their respective functional currencies. This creates foreign currency exposure for the NTC when selling to entities with different functional currencies. In the transactional exposures section, it is explained that a stronger U.S. Dollar increases inventory costs for Nike entities purchasing in non-functional currencies, while a weaker Dollar reduces these costs. This indicates that Nike’s hedging strategy through the NTC is designed to mitigate the financial volatility caused by these currency fluctuations, aligning with the broader risk management approach described in the transactional exposures section.",
      "llm_answer": "Nike’s foreign‑exchange hedging program uses the Nike Trading Company (NTC) to hedge product‑cost exposures, and these cash‑flow hedges are recorded in accumulated other comprehensive income until the underlying transactions affect net income. This aligns with the “transactional exposures” discussion, which explains that a weaker U.S. dollar reduces inventory costs while a stronger dollar raises them, and that the company manages these exposures—often through NTC—by using forward and option contracts that are designated as cash‑flow hedges. Consequently, fluctuations in the U.S. dollar directly affect the cost of inventory held by NTC, and the resulting hedge gains or losses are eventually reclassified from accumulated other comprehensive income into earnings when the hedged inventory is sold.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2024.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89460,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22603,
        "completion_tokens": 201,
        "total_tokens": 22804
      }
    },
    {
      "question_id": 11,
      "question": "How does the foreign currency exposure associated with NTC's product sales to NIKE entities in different functional currencies impact the inventory cost management strategy, especially in light of NIKE's acquisition-related inventory holdings at held-for-sale entities as of May 31, 2022?",
      "original_answer": "NTC, which operates with the U.S. Dollar as its functional currency, sells products to NIKE entities in their respective functional currencies, creating foreign exchange exposure for the NTC. A stronger U.S. Dollar increases NIKE's product cost, while a weaker Dollar reduces it. This exposure is partially offset by NIKE’s foreign currency adjustment program with factories, which affects inventory cost recognition. As of May 31, 2022, NIKE reported $59 million of Inventories in held-for-sale entities, indicating that inventory cost fluctuations from foreign exchange could directly affect the valuation and profitability of these acquired/divested assets. This suggests that foreign exchange risk management is critical not only for ongoing operations but also for managing the financial implications of inventory in entities being divested.",
      "llm_answer": "The foreign‑currency exposure from NTC’s product sales—where NTC, a U.S.‑dollar‑functional entity, sells to NIKE subsidiaries in other functional currencies—creates a cost‑variability that directly influences inventory pricing and the timing of cost‑of‑sales recognition. Because a stronger U.S. dollar raises the dollar‑denominated purchase price of those products for foreign‑currency‑functional subsidiaries, NIKE must manage this exposure through hedging and natural offsets to prevent inventory cost spikes from eroding margins. This risk is especially relevant given the held‑for‑sale inventory of NIKE entities in Argentina, Uruguay and Chile, whose foreign‑currency translation adjustments remain in Accumulated Other Comprehensive Income (loss) and will be reclassified into earnings upon sale, potentially affecting the reported cost of those inventories. Consequently, NIKE’s inventory‑cost management strategy incorporates both cash‑flow hedges of forecasted product‑cost exposures and the monitoring of translation gains/losses on held‑for‑sale assets to mitigate the impact of currency movements on overall inventory valuation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81334,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20587,
        "completion_tokens": 285,
        "total_tokens": 20873
      }
    },
    {
      "question_id": 11,
      "question": "How does SPG's treatment of Simon's governance authority over the Operating Partnership influence the redemption terms and carrying value of the Series J 8 3/8% Cumulative Redeemable Preferred Stock as of December 31, 2024?",
      "original_answer": "SPG's governance structure gives Simon, as the sole general partner, full authority to make decisions regarding the Operating Partnership, including the redemption of preferred units and preferred stock. This control is evident in the Operating Partnership's structure, where Simon can elect to redeem preferred units either in cash or shares of common stock. In 2024, the redemption of 75,000 preferred units for $7.5 million and the resulting carrying value of $15.5 million for remaining preferred units reflect this discretion. Similarly, the Series J 8 3/8% Cumulative Redeemable Preferred Stock, issued at a $7.5 million premium, has an unamortized premium of $0.9 million as of December 31, 2024, and can be redeemed by Simon starting in 2027. The governance control Simon exerts directly affects the redemption policy and valuation of these instruments, linking the governance structure to the financial treatment of preferred equity.",
      "llm_answer": "The Operating Partnership’s Series J 8 3⁄8 % Cumulative Redeemable Preferred Units are classified as permanent equity because Simon Property Group, Inc. can redeem them only after October 15 2027 at $50 per unit plus accrued distributions, and the unamortized premium ($0.9 million as of 12/31/2024) is included in their carrying value. Consequently, the redemption terms and the carrying value of the Series J preferred units are directly tied to Simon’s governance authority over the Operating Partnership, which determines when and at what price the Partnership may redeem those units.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74118,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18765,
        "completion_tokens": 147,
        "total_tokens": 18912
      }
    },
    {
      "question_id": 11,
      "question": "How does Amgen's stock-based compensation expense for performance units in 2024 relate to the maximum potential share issuance under the Amended 2009 Plan, given the plan's fungible share-counting formula and performance-based vesting conditions?",
      "original_answer": "Amgen reported a stock-based compensation expense of $133 million for performance units in 2024. These units are governed by the Amended 2009 Plan, which allows for up to 59 million shares available for future grants, calculated using a fungible share-counting formula where each performance unit counts as 1.9 shares. The plan also specifies that performance units can vest at up to 200% of the target grant based on performance outcomes. Therefore, the $133 million expense reflects the cost of units that may ultimately result in nearly double the number of shares being issued, depending on performance results, which directly affects the remaining share availability under the plan's formula.",
      "llm_answer": "Amgen’s 2024 stock‑based compensation expense for performance units ($133 million) reflects the portion of the $87 million of unrecognized compensation cost related to non‑vested performance units that will be recognized over the next year, and this expense is tied to the maximum potential share issuance under the Amended 2009 Plan because the plan’s fungible share‑counting formula treats each performance unit as 1.9 shares, so the up‑to‑200 % of target shares that could be earned under the performance goals could increase the share count by roughly 1.9 × the target number of units.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72473,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18358,
        "completion_tokens": 147,
        "total_tokens": 18505
      }
    },
    {
      "question_id": 11,
      "question": "How does American Express's discussion of regulatory pressure on interest rate caps in its supervision and regulation section influence its quantitative assumptions about repricing risk in the interest rate sensitivity analysis?",
      "original_answer": "American Express discusses regulatory scrutiny and potential caps on credit card interest rates in its supervision and regulation section (page 34), which introduces a qualitative risk around pricing constraints. This regulatory pressure directly affects the company's interest income model, as seen in the interest rate sensitivity analysis on page 81, where the company assumes repricing of interest-rate sensitive assets and liabilities is subject to applicable interest rate caps. The sensitivity analysis quantifies the risk by projecting a detrimental impact on net interest income under higher rate scenarios, assuming repricing aligned with benchmark movements but constrained by these caps. Therefore, the regulatory risk described qualitatively on page 34 is embedded into the quantitative modeling of repricing risk on page 81, showing how external constraints shape internal financial forecasting.",
      "llm_answer": "American Express’s discussion of regulatory pressure on interest‑rate caps underscores that caps could limit the company’s ability to reprice assets and liabilities, which directly informs its quantitative assumptions in the interest‑rate sensitivity analysis: the analysis assumes that assets and liabilities subject to repricing within a one‑year horizon will move in line with benchmark rates, but only to the extent permitted by any applicable caps or floors. Consequently, the presence of regulatory caps is built into the model’s repricing assumptions, shaping the estimated impact of rate shocks on net interest income.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2024.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77354,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19572,
        "completion_tokens": 156,
        "total_tokens": 19729
      }
    },
    {
      "question_id": 11,
      "question": "Given that UPS contributed $21 million in 2023 to the Employer-Teamsters Local Nos. 175 & 505 Pension Trust Fund, which is subject to an implemented Financial Improvement Plan (FIP), how does this contribution align with UPS's overall compliance strategy for red-zone pension funds under FIP requirements?",
      "original_answer": "UPS contributed $21 million in 2023 to the Employer-Teamsters Local Nos. 175 & 505 Pension Trust Fund, which is categorized as red-zone and under an implemented FIP. According to the FIP requirements section, UPS's contributions are aligned with the stipulations of implemented FIPs, and the company confirms that these contributions satisfy the necessary obligations without requiring additional surcharges. Furthermore, UPS emphasizes that collectively bargained contributions meet all FIP/RP requirements, indicating a proactive approach to managing underfunded pension liabilities.",
      "llm_answer": "UPS's $21 million contribution to the Employer‑Teamsters Local 175 & 505 Pension Trust Fund—classified as a red‑zone plan subject to an implemented Financial Improvement Plan—fits within its overall compliance strategy by satisfying the legally required funding levels under the FIP, thereby avoiding surcharge payments and ensuring continued participation in the multi‑employer pension system.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22203,
        "completion_tokens": 98,
        "total_tokens": 22301
      }
    },
    {
      "question_id": 11,
      "question": "How does ConocoPhillips' characterization of coalbed methane (CBM) as a distinct raw material in disclosures relate to their equity investment write-down in APLNG, given APLNG's role in producing and exporting CBM-derived LNG?",
      "original_answer": "ConocoPhillips identifies coalbed methane (CBM) as a distinct raw material in their disclosures, highlighting its importance in upstream operations. APLNG, in which ConocoPhillips holds a significant stake, is specifically focused on producing CBM from the Bowen and Surat basins in Queensland, Australia, and converting it into LNG for export. In 2021, ConocoPhillips exercised its preemption right to purchase an additional 10% interest in APLNG; however, due to a market participant valuation below the carrying value, the company wrote down its investment to a fair value of $5,574 million, incurring a $688 million pre-tax charge. This write-down reflects the financial impact of market conditions on an asset central to CBM-based LNG production, illustrating how the valuation of a core raw material (CBM) directly affects the financial treatment of downstream infrastructure and equity investments.",
      "llm_answer": "ConocoPhillips treats coalbed methane (CBM) as a distinct raw material in its disclosures, reflecting its role as a feedstock for APLNG’s CBM‑derived LNG production. This characterization underscores that the CBM supplied to APLNG is viewed separately from conventional natural gas, influencing how the company evaluates the equity investment in APLNG and the associated write‑down of that investment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63552,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16126,
        "completion_tokens": 100,
        "total_tokens": 16227
      }
    },
    {
      "question_id": 12,
      "question": "How does MetLife's exposure to interest rate sensitivity in Structured Settlements, as part of the Retirement and Income Solutions business, align with the segment's broader positioning and strategic emphasis on capital market products in a low-rate environment?",
      "original_answer": "MetLife's Retirement and Income Solutions (RIS) business includes Structured Settlements, which are sensitive to interest rate changes due to their long-duration liabilities and fixed-income asset backing. In a declining interest rate scenario (as noted on page 61), this exposure leads to gross margin compression because the company cannot lower crediting rates on certain products, such as retained asset accounts and disability policy claim reserves, which are at their minimum crediting rates. To mitigate this, MetLife uses interest rate derivatives. Meanwhile, page 9 emphasizes RIS's strategic role in offering capital market products and pension risk transfers, suggesting a focus on managing longevity and interest rate risk through structured financial solutions. This aligns with the broader positioning of RIS as a capital-intensive, risk-transfer-oriented business that must actively manage asset-liability mismatches, especially in a low-rate environment where reinvestment yields are compressed. The inclusion of Structured Settlements within RIS (as detailed on page 184) underscores their integration into a portfolio designed to manage long-duration liabilities through both product design and hedging strategies.",
      "llm_answer": "MetLife's Retirement and Income Solutions (RIS) business—focused on capital‑market products such as structured settlements, pension risk transfers, funding‑agreement‑backed notes and other institutional funding solutions—directly supports the segment’s broader positioning to leverage its scale, brand and innovation in a low‑rate environment.  By offering these market‑driven products, RIS aligns with the strategic emphasis on generating strong free cash flow and differentiating MetLife through high‑value, capital‑intensive offerings that can adapt to shifting interest‑rate conditions.  This focus enables the company to mitigate interest‑rate sensitivity while maintaining a competitive advantage in the institutional market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77945,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19734,
        "completion_tokens": 182,
        "total_tokens": 19917
      }
    },
    {
      "question_id": 12,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $3.0 billion in debt obligations reconcile with the indemnification framework under the Distribution Agreement, where PMI and PM USA only partially indemnify each other for tobacco-related liabilities based on manufacturing responsibility?",
      "original_answer": "Altria Group, Inc. (MO) depends on PM USA as a guarantor for its $3.0 billion Credit Agreement and other debt obligations, with PM USA providing unconditional guarantees that are not limited by contingent liabilities. However, under the Distribution Agreement following the 2008 spin-off of PMI, indemnification for tobacco-related liabilities between PM USA and PMI is conditional and based on manufacturing responsibility—PMI indemnifies Altria and PM USA only for liabilities related to products it manufactured or had contract manufactured, and vice versa. This creates a potential misalignment: PM USA guarantees Altria’s full debt obligations without limitation, yet its indemnification exposure to Altria is restricted to only those liabilities tied to its own manufacturing, which could expose PM USA to disproportionate financial risk relative to the indemnification protections it receives.",
      "llm_answer": "Altria's reliance on PM USA’s unconditional guarantees for $3 billion of debt obligations is consistent with the indemnification framework set out in the Distribution Agreement, which allocates tobacco‑related liabilities based on manufacturing responsibility. Under that agreement, PMI indemnifies Altria and PM USA for liabilities arising from products manufactured by PMI or contract‑manufactured for PMI, while PM USA indemnifies PMI for liabilities from products it manufactures, excluding those contract‑manufactured for PMI. Consequently, PM USA’s guarantees cover Altria’s debt obligations, but the parties only partially indemnify each other for tobacco‑related claims, reflecting their respective manufacturing responsibilities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 66242,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16815,
        "completion_tokens": 184,
        "total_tokens": 17000
      }
    },
    {
      "question_id": 12,
      "question": "How does Gilead's revenue recognition approach for Symtuza, which is commercialized by Janssen, reflect the contractual revenue-sharing terms and the accounting treatment of the intellectual property and supply obligations outlined in the collaboration agreement?",
      "original_answer": "Gilead recognizes its share of Symtuza revenue in the period when Janssen reports corresponding sales, as the license to the Gilead Compounds is deemed the predominant item in the agreement. This approach aligns with the contractual terms where Janssen sets the price of Symtuza and both parties share revenue based on the ratio of the net selling prices of their respective components, subject to restrictions and adjustments. Additionally, the intellectual property license and supply obligations related to the Gilead Compounds are accounted for as a single performance obligation, which supports the timing and pattern of revenue recognition. This treatment reflects Gilead's role as the exclusive supplier of the Gilead Compounds and its ongoing involvement in the intellectual property underpinning Symtuza.",
      "llm_answer": "Gilead recognizes revenue from Symtuza as its share of Janssen’s net sales of the product, which is recorded as product sales when Janssen sells Symtuza. The collaboration agreement treats the license and supply of Gilead’s compounds as a single performance obligation, so Gilead’s revenue share is recognized in the period Janssen’s sales occur. This arrangement reflects the contractual revenue‑sharing terms and the accounting treatment of the intellectual‑property license and supply obligations outlined in the Janssen collaboration.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 79,
          "pages": [
            77,
            78,
            79,
            80,
            81
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81102,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20519,
        "completion_tokens": 134,
        "total_tokens": 20654
      }
    },
    {
      "question_id": 12,
      "question": "How does ConocoPhillips' $210 million maximum exposure under its APLNG guarantee relate to its production of CBM in the Bowen and Surat basins, and how might this liability impact the company's strategic positioning in Australian LNG markets?",
      "original_answer": "ConocoPhillips has a $210 million maximum exposure under a guarantee related to its 47.5% ownership in APLNG, which is responsible for producing CBM from the Bowen and Surat basins in Queensland, Australia. APLNG processes and exports LNG derived from this CBM, which is central to ConocoPhillips' strategic positioning in the region. The liability associated with this guarantee, although currently carried at $14 million, represents a contingent risk tied directly to APLNG’s ability to meet its financial obligations. Given that APLNG is a core asset for CBM production and LNG export in Australia, any material drawdown on this guarantee could affect ConocoPhillips' investment returns and strategic flexibility in the region. This risk must be weighed against the company's stated access to CBM resources and its long-term LNG market commitments in Asia Pacific.",
      "llm_answer": "ConocoPhillips’ $210 million maximum exposure under its APLNG guarantee stems from its 47.5 % equity stake in the APLNG joint venture, which produces coal‑bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia and processes that gas into LNG for export. Because the guarantee covers APLNG’s project‑finance obligations, a default by APLNG could trigger up to $210 million of contingent payments, tying the company’s financial exposure directly to the performance of its CBM‑derived LNG operations in those basins. If a claim were enforced, the liability could erode cash flow and limit the company’s flexibility to invest in or expand its Australian LNG portfolio, potentially weakening its strategic positioning in the fast‑growing Asia‑Pacific LNG market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64011,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16242,
        "completion_tokens": 194,
        "total_tokens": 16437
      }
    },
    {
      "question_id": 12,
      "question": "How does BKNG's reliance on meta-search marketing channels, which contributed significantly to traffic in 2021, relate to its ownership stake in KAYAK, which itself provides meta-search services, and what does this imply about the strategic alignment and financial valuation of KAYAK within BKNG's portfolio?",
      "original_answer": "BKNG relies on meta-search and travel research websites as a key marketing channel, contributing significantly to traffic and tied directly to growth and ROI objectives. KAYAK, which is owned by BKNG, is a meta-search platform offering price comparisons across hundreds of travel platforms, operating in over 60 countries. Despite this strategic alignment, BKNG recorded a $1.1 billion goodwill impairment charge for KAYAK in 2020, indicating a disconnect between KAYAK’s expected strategic value and its financial performance. This suggests that while KAYAK's meta-search capabilities align with BKNG’s marketing and traffic acquisition strategy, its financial valuation and performance fell short of expectations, raising questions about the effectiveness of internal integration and the return on strategic ownership.",
      "llm_answer": "BKNG’s heavy reliance on meta‑search channels (primarily KAYAK) to drive traffic in 2021 directly leverages its ownership stake in KAYAK, which itself operates a meta‑search platform and generates referral revenue for BKNG’s brands. This creates a tightly aligned strategic loop: the traffic KAYAK funnels into BKNG’s OTC sites (Booking.com, Priceline, etc.) boosts gross bookings and revenue, while BKNG’s equity interest in KAYAK enhances the valuation of that asset within its portfolio. Consequently, KAYAK is positioned not just as a revenue‑generating subsidiary but as a strategic asset that reinforces BKNG’s growth narrative, supporting higher market‑based valuations for the overall group.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 62,
          "pages": [
            60,
            61,
            62,
            63,
            64
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 58911,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14985,
        "completion_tokens": 174,
        "total_tokens": 15159
      }
    },
    {
      "question_id": 12,
      "question": "Given that forecasted transactions are excluded from Disney's VAR model for risk analysis, how does the company's use of foreign exchange hedging instruments on forecasted transactions reconcile with the limitations of its VAR model in capturing potential losses from these exposures?",
      "original_answer": "Disney's VAR model excludes forecasted transactions, firm commitments, and foreign-denominated receivables/payables from its risk analysis, focusing instead on existing financial instruments like debt, derivatives, and equity investments. The VAR model estimates a maximum one-day loss of $255 million at September 28, 2024, based on a 95% confidence level and assumes normal market conditions. However, the company actively manages foreign exchange risk on forecasted transactions through forward and option contracts, with $9.9 billion in notional hedging exposure as of September 28, 2024. These hedging instruments are designated as cash flow hedges and their gains or losses are deferred in AOCI until the forecasted transactions occur. This suggests that while the VAR model does not account for forecasted transactions, Disney mitigates the risk associated with these transactions through proactive hedging strategies, which are separately accounted for and disclosed in the financial statements.",
      "llm_answer": "Disney’s VAR model deliberately excludes forecasted transactions from its risk‑analysis calculations, yet the company hedges those same forecasted foreign‑exchange exposures with designated cash‑flow hedges. Because the VAR model does not capture the potential losses from those hedged forecasted transactions, the disclosed hedge coverage cannot be fully reflected in the model’s loss estimates. Consequently, while the VAR model provides a 95 % confidence‑level view of market‑risk exposures for existing positions, it understates the possible downside for the portion of risk tied to anticipated foreign‑currency cash flows that are managed through hedging instruments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67110,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17027,
        "completion_tokens": 168,
        "total_tokens": 17195
      }
    },
    {
      "question_id": 12,
      "question": "How does Disney's exclusion of firm commitments from its Value at Risk (VAR) model impact the assessment of its foreign exchange risk exposure, given the $9.9 billion in net foreign exchange cash flow hedges outstanding as of September 28, 2024?",
      "original_answer": "Disney utilizes a VAR model to estimate its maximum potential one-day loss across financial instruments, but explicitly excludes firm commitments and forecasted transactions from this model, even though these are the very exposures that its foreign exchange hedging program is designed to mitigate. As of September 28, 2024, Disney had $9.9 billion in net foreign exchange cash flow hedges in place to protect against fluctuations in currencies like the euro and Japanese yen. This suggests that while the VAR model provides a quantitative risk metric under normal market conditions, it does not fully capture the risk profile associated with these hedged firm commitments and forecasted transactions. Therefore, the stated VAR of $255 million at fiscal year-end may understate the true exposure that Disney manages through its active hedging program.",
      "llm_answer": "Disney's exclusion of firm commitments from its Value at Risk (VAR) model means that the $9.9 billion of net foreign‑exchange cash‑flow hedges outstanding as of September 28 2024 are not reflected in the VAR calculation. Consequently, the VAR figure of $255 million (down from $284 million a year earlier) captures only the portion of foreign‑exchange exposure that is designated as hedged or committed, while the potentially larger exposure from the un‑firm‑commitment hedges is omitted, leading to an understated assessment of the company's overall foreign‑exchange risk.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68308,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17316,
        "completion_tokens": 143,
        "total_tokens": 17460
      }
    },
    {
      "question_id": 12,
      "question": "How does the treatment of the VIL OCDs in the property and equipment footnote reconcile with the impairment charges recorded for VIL-related intangible assets and the strategic review of the India business?",
      "original_answer": "The VIL OCDs, valued at $116.5 million upon issuance and totaling INR 16.0 billion (~$193.2 million), are disclosed in the property and equipment footnote as part of AMT's assets. These OCDs represent a financial instrument issued by VIL, a key tenant in India, which had previously caused payment uncertainty and partial payments in 2022 and early 2023, leading to impairment charges of $411.6 million on VIL-specific tenant-related intangible assets. Despite VIL resuming full payments in the second half of 2023, the uncertainty surrounding its financial stability contributed to a broader strategic review of AMT's India operations, culminating in the Pending ATC TIPL Transaction. This strategic move, along with updated fair value estimates, led to a $322.0 million goodwill impairment charge for the India reporting unit in Q3 2023. Thus, while the VIL OCDs are treated as an asset in the property and equipment section, they are also central to the impairment and strategic risk analysis in the India segment, reflecting both the financial and strategic challenges tied to VIL.",
      "llm_answer": "The VIL OCDs are treated as tenant‑related intangible assets that were impaired in 2022 (a $411.6 million charge) and further evaluated during the 2023 strategic review of the India business, which led to an additional $322 million goodwill impairment when the carrying value of the India reporting unit was found to exceed its fair value. This review, culminating in the Pending ATC TIPL Transaction, explains why the property‑and‑equipment footnote’s discussion of VIL‑related intangible assets aligns with the impairment charges recorded for those assets and the broader strategic reassessment of the India market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20569,
        "completion_tokens": 154,
        "total_tokens": 20724
      }
    },
    {
      "question_id": 12,
      "question": "How does FedEx's emphasis on maintaining service commitments to customers, including its integrated global air network flexibility, reconcile with the risk posed by the USPS's strategic shift away from air transportation and its competitive positioning in the domestic delivery market?",
      "original_answer": "FedEx emphasizes the importance of maintaining service commitments to customers, supported by the flexibility of its integrated global air network, which allows interchangeable use of aircraft across routes and geographies to adapt to changing economic conditions. However, the USPS, FedEx's largest customer for domestic air transportation, is actively reducing its reliance on FedEx's air network as part of its own strategic changes, which has already negatively impacted FedEx's results of operations in 2022. Additionally, the USPS is not only a major client but also a competitor in the domestic delivery market, further complicating FedEx’s ability to maintain service levels and pricing power while managing the loss of a key revenue source. This dynamic highlights the dual challenge FedEx faces: sustaining its service commitments amid operational flexibility while confronting a major client’s strategic withdrawal and competitive pressure in the same market.",
      "llm_answer": "FedEx emphasizes maintaining its service commitments through an integrated global air network that provides flexibility to meet changing demand and preserve delivery speed and reliability. This approach directly counters the USPS's strategic shift away from air transportation and its growing competitive presence in the domestic delivery market, as FedEx continues to rely on its air network to uphold service standards despite USPS's reduced use of air services.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80918,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20483,
        "completion_tokens": 116,
        "total_tokens": 20599
      }
    },
    {
      "question_id": 12,
      "question": "How does Duke Energy Progress' use of Storm Recovery Bonds in 2023 to finance $177 million in storm costs relate to its consolidation of DEPNC SF, and what does this imply about the company's approach to managing long-term storm-related liabilities?",
      "original_answer": "Duke Energy Progress utilized Storm Recovery Bonds in 2023 to finance $177 million in historical storm-related costs, which were then securitized through a special purpose subsidiary, DEPNC SF. As a bankruptcy-remote, wholly owned entity, DEPNC SF was formed specifically to issue these bonds and acquire storm recovery property, which grants the right to collect non-bypassable charges from retail customers. Since Duke Energy Progress consolidates DEPNC SF, the company retains control over the entity's operations despite its separate legal structure. This approach reflects a structured financing mechanism that allows Duke Energy Progress to recover storm-related regulatory assets over time, while isolating the associated debt within a VIE structure, minimizing broader balance sheet impact.",
      "llm_answer": "Duke Energy Progress issued $177 million of storm‑recovery bonds in April 2024 through its special‑purpose subsidiary DEPSCSF to finance unrecovered storm costs incurred from 2014‑2022; the bonds are secured by a non‑bypassable charge on North Carolina and South Carolina retail customers and the subsidiary is consolidated because Duke Energy Progress is the primary beneficiary. This financing, together with the earlier creation of DECNCSF and DECSCSF, reflects the company’s strategy of isolating and securitizing long‑term storm‑related liabilities—using separate VIEs and bond structures to recover costs from ratepayers while keeping the parent’s balance sheet separate from the debt obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103951,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26229,
        "completion_tokens": 175,
        "total_tokens": 26405
      }
    },
    {
      "question_id": 12,
      "question": "How does Mastercard's reliance on technology companies for innovation, including risks related to intellectual property and talent acquisition, interact with the threat posed by those same partners developing competitive products that could disintermediate Mastercard from digital payments?",
      "original_answer": "Mastercard acknowledges on page 32 that it works closely with technology companies to enhance payment safety and deliver services efficiently, but also highlights risks such as difficulty attracting technology experts and potential patent infringement claims from third parties. These challenges could hinder its ability to develop and adopt new technologies. On page 31, the company warns that these same technology companies could develop competing platforms that disintermediate Mastercard from digital payments, especially if data-sharing arrangements provide them with a competitive advantage. Furthermore, the emergence of competitive products from these partners could force Mastercard to alter pricing models or lose market share, particularly in light of regulatory changes like PSD2 that enable third-party providers to route transactions away from its network. The combination of innovation dependency and competitive risk creates a strategic tension where collaboration could inadvertently accelerate disintermediation, undermining Mastercard’s role in the digital economy.",
      "llm_answer": "Mastercard’s strategy of relying on technology partners for innovation creates a paradox: while these collaborations fuel product development, they also expose the company to the risk that those same partners could leverage shared data, platforms, or proprietary technology to launch competing payment solutions that bypass Mastercard’s network. This potential disintermediation threatens to erode transaction volumes and revenue, especially as fintechs and other partners develop cost‑effective, proprietary alternatives that could replace Mastercard’s role in digital payments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 88271,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22313,
        "completion_tokens": 144,
        "total_tokens": 22458
      }
    },
    {
      "question_id": 12,
      "question": "How does the involvement of DeGolyer and MacNaughton in reviewing over 85% of ConocoPhillips' proved reserves estimation processes align with their role as a third-party consultant whose report is explicitly included as Exhibit 99 in the 10-K filing?",
      "original_answer": "ConocoPhillips discloses that DeGolyer and MacNaughton (D&M) reviewed over 85% of its proved reserves estimation processes to ensure compliance with SEC regulations and internal controls. This review was conducted to obtain independent third-party validation of the company’s reserves estimation methodology. D&M’s findings, which concluded that ConocoPhillips’ processes were in accordance with SEC definitions, are included as Exhibit 99 in the 10-K filing. This demonstrates a direct alignment between D&M’s role as an independent reviewer and the formal documentation of their findings, reinforcing the credibility and transparency of ConocoPhillips’ reserves reporting.",
      "llm_answer": "The involvement of DeGolyer and MacNaughton (D&M) as a third‑party consultant whose review report is filed as Exhibit 99 is consistent with its role as an independent, SEC‑compliant reviewer of ConocoPhillips’ reserves processes.  The 10‑K discloses that D&M, together with internal reserves staff, annually reviews the business‑unit reserves processes and controls for more than 85 % of the proved reserves, assesses adherence to SEC guidelines, and issues an opinion that the processes are in accordance with SEC definitions—information that is explicitly referenced in the filing and summarized in the “Reserves Governance” discussion.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78046,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19753,
        "completion_tokens": 159,
        "total_tokens": 19913
      }
    },
    {
      "question_id": 12,
      "question": "How does the $1.007 billion in storm recovery bonds issued by Duke Energy Carolinas and Progress in 2021 relate to the restricted cash balances reported under the Cash, Cash Equivalents and Restricted Cash section, and what does this imply about the financial structure of storm cost recovery?",
      "original_answer": "Duke Energy Carolinas and Duke Energy Progress issued $237 million and $770 million, respectively, in storm recovery bonds in November 2021, forming a total of $1.007 billion in financing to recover storm costs from 2018 and 2019. These bonds are secured by storm recovery property, which includes the right to impose non-bypassable charges on retail customers until the bonds are fully paid. The bond issuance is linked to restricted cash balances reported on page 127, which are specifically tied to VIEs (Variable Interest Entities) formed for storm recovery bonds. This implies that the financial structure of storm cost recovery is asset-backed and ring-fenced through special-purpose entities, with restricted cash serving as collateral to ensure bondholder security without recourse to the parent companies.",
      "llm_answer": "The $1.007 billion of storm‑recovery bonds issued by Duke Energy Carolinas and Duke Energy Progress in 2021 is reflected in the “Restricted cash” balances reported under the “Cash, Cash Equivalents and Restricted Cash” note.  Those restricted cash amounts (e.g., $19 million for Duke Energy Carolinas and $34 million for Duke Energy Progress in 2023) represent the proceeds held by the special‑purpose entities that issued the bonds, which are classified as restricted cash on the balance sheet.  This structure shows that storm‑cost recovery is financed through dedicated, ring‑fenced financing vehicles (VIEs) whose cash collections are used exclusively to service the bonds, thereby separating storm‑recovery obligations from the utilities’ operating cash flow and enabling recovery through regulated rates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 94140,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23788,
        "completion_tokens": 202,
        "total_tokens": 23990
      }
    },
    {
      "question_id": 13,
      "question": "Given PM USA's role in guaranteeing Altria's debt obligations and its posting of $50 million in appeal bonds collateralized by restricted cash, how does Altria's liquidity risk profile reflect both its legal exposure through PM USA's litigation liabilities and its structural financial guarantees?",
      "original_answer": "Altria's liquidity risk is heightened by PM USA's legal exposure, which includes over $896 million in cumulative payments for adverse tobacco-related litigation judgments and settlements as of December 31, 2021. To maintain appeal stays, PM USA has posted $50 million in appeal bonds backed by restricted cash, directly impacting Altria's liquidity by tying up capital that could otherwise be used for operations or debt servicing. Furthermore, PM USA fully and unconditionally guarantees Altria's debt obligations, meaning that if Altria defaults, PM USA must fulfill these liabilities. However, if PM USA itself becomes insolvent or is unable to meet its own obligations due to litigation costs, the guarantees could be voided under fraudulent conveyance laws, leaving Altria's creditors exposed. This dual exposure—through both litigation risk and structural guarantees—creates a complex liquidity risk profile where Altria's financial health is tightly linked to PM USA's legal and financial stability.",
      "llm_answer": "Altria's liquidity risk profile is shaped by its legal exposure from PM USA's ongoing tobacco litigation—evidenced by accrued liabilities of $91 million in 2021 and the need to post $50 million of appeal bonds collateralized by restricted cash—and by its structural financial guarantees, as PM USA fully guarantees Altria’s debt obligations, creating contingent liabilities that could require Altria to cover debt payments if PM USA were unable to do so. This dual exposure means Altria must contend with both potential litigation‑related cash outflows and the risk that its guarantee obligations could strain cash flow if adverse judgments or settlement costs materialize.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71275,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18075,
        "completion_tokens": 168,
        "total_tokens": 18243
      }
    },
    {
      "question_id": 13,
      "question": "How does AbbVie's ongoing exposure to securities litigation tied to Allergan's textured breast implants and generic drug pricing practices reconcile with the strategic rationale provided for the $120.30 per share cash and stock acquisition of Allergan in 2020?",
      "original_answer": "AbbVie's 2020 acquisition of Allergan for $120.30 per share in cash and stock aimed to diversify its business across multiple therapeutic areas, including aesthetics and generics. However, post-acquisition, AbbVie inherited ongoing securities litigation against Allergan related to its textured breast implants (In re: Allergan plc Securities Litigation) and alleged anticompetitive conduct in its former Actavis generics unit (In re: Allergan Generic Drug Pricing Securities Litigation), with class certification granted in both cases by 2021. These legal risks, which were still pending or recently settled as of 2022, could expose AbbVie to significant financial liabilities and reputational damage, potentially undermining the strategic benefits of diversification and commercial strength that the acquisition was intended to deliver.",
      "llm_answer": "The $120.30 per share cash component of the Allergan acquisition directly tied to the $39.675 billion cash consideration paid for 330 million shares, while the ongoing securities litigation concerning Allergan’s textured breast implants and generic‑drug pricing practices does not alter the strategic rationale for the deal; rather, it represents a separate legal and financial exposure that AbbVie must manage alongside the acquisition’s growth objectives. Consequently, the litigation risk is treated as a contingent liability (reflected in the contingent‑consideration accounting discussed in Notes 5 and 13) and does not affect the valuation of the acquisition itself, which was driven by the strategic complementarity of product portfolios and pipeline assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2022.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 56740,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14428,
        "completion_tokens": 191,
        "total_tokens": 14620
      }
    },
    {
      "question_id": 13,
      "question": "How does HD's accrual of dividend equivalents on performance shares and restricted stock units compare with the treatment of dividend equivalents on deferred shares granted to non-employee directors, and what does this reveal about the company's stock-based compensation strategy for different stakeholder groups?",
      "original_answer": "HD accrues dividend equivalents on performance shares and restricted stock units as reinvested shares, which are paid out upon vesting or award payout. For performance shares, this is tied to a three-year performance cycle based on ROIC and operating profit, while for restricted stock units, it occurs upon vesting, which can be up to five years after the grant date. In contrast, dividend equivalents on deferred shares granted to non-employee directors accrue and are paid out in the form of additional shares upon termination of Board service. This reveals a strategic distinction in HD's stock-based compensation: performance-based and time-vesting equity awards for associates emphasize long-term alignment with company performance and retention, while deferred shares for non-employee directors focus on service duration and post-service value retention. The immediate expensing of deferred shares also contrasts with the multi-year expense recognition for performance shares and restricted stock units, highlighting a differentiated approach to stakeholder compensation.",
      "llm_answer": "Home Depot's stock-based compensation strategy treats performance shares and restricted stock units (RSUs) with dividend equivalents that accrue and are paid upon vesting or payout, while deferred shares granted to non-employee directors also accrue dividend equivalents paid in additional shares upon termination of service. This differential treatment reflects a tailored approach: performance-based awards for associates emphasize long-term alignment with company goals (ROIC and profit targets), whereas deferred shares for directors prioritize simplicity and immediate equity-like compensation for board service, both leveraging dividend equivalents to enhance total shareholder value across stakeholder groups.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HD_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "HD_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "HD_10k_2023.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67098,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17029,
        "completion_tokens": 179,
        "total_tokens": 17208
      }
    },
    {
      "question_id": 13,
      "question": "How does Intel's strategic rationale for entering into the NAND wafer manufacturing agreement with SK hynix relate to the timing and structure of the divestiture of its NAND memory business, particularly in light of the continued use of the Dalian fabrication facility?",
      "original_answer": "Intel's strategic rationale for entering into the NAND wafer manufacturing agreement with SK hynix was to maintain continuity in NAND wafer production while transitioning ownership of the NAND business. This agreement was structured as part of a two-stage divestiture initiated in October 2020 and finalized in 2022, with the first closing in December 2021 involving the sale of the NAND SSD Business and the Dalian fabrication facility. The agreement ensured that Intel could continue manufacturing NAND wafers using the Dalian facility until the second closing, allowing SK hynix to ramp up operations while Intel phased out its involvement. This transitional manufacturing arrangement reflects Intel's strategic goal of exiting the NAND memory business while maintaining short-term supply chain stability for both parties.",
      "llm_answer": "Intel's strategic rationale for entering into the NAND wafer manufacturing agreement with SK hynix is directly tied to the timing and structure of its NAND memory business divestiture. The agreement allows Intel to continue manufacturing and selling NAND wafers using its Dalian fabrication facility to SK hynix until the second closing of the divestiture, which will occur after the first closing (completed December 29, 2021). This arrangement ensures a seamless transition of the NAND business while maintaining revenue from the Dalian facility under the new ownership structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31066,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 8007,
        "completion_tokens": 145,
        "total_tokens": 8152
      }
    },
    {
      "question_id": 13,
      "question": "How does the treatment of Class B stock in the net income per share calculation relate to the use of Class C stock in employee compensation plans, given the company's approach to share repurchases?",
      "original_answer": "The company's net income per share calculation treats Class B stock as convertible for the purpose of computing diluted earnings per share of Class A stock, but does not assume conversion of Class B shares when calculating their own diluted earnings per share. This distinction affects how earnings are distributed across share classes. Meanwhile, Class C shares are actively used in employee compensation plans, with over $21.7 billion in stock-based compensation expenses tied to equity awards in 2023, and 723 million shares reserved for future issuance under the Alphabet 2021 Stock Plan. The company's share repurchase program, which includes both Class A and Class C shares, is executed based on market conditions and economic cost considerations. This creates a dynamic where Class C shares are both issued for compensation and repurchased from the market, while Class B shares are primarily retained for voting control purposes without active issuance or repurchase. The interplay between these share classes reflects a capital structure strategy that balances employee incentives, earnings allocation, and shareholder value management.",
      "llm_answer": "The company’s net‑income‑per‑share calculation treats Class B shares as if they were converted to Class A shares (adding the 877 million convertible shares to the diluted‑share denominator), while Class C shares receive no such conversion adjustment. This conversion is reflected in the reallocation of undistributed earnings for diluted EPS, but the underlying compensation‑plan detail notes that RSUs granted under the Alphabet 2021 Stock Plan are settled in Class C shares and are reserved for future issuance (723 million shares as of 12/31/23). Thus, the share‑repurchase activity that uses Class A and Class C shares does not affect the Class B conversion mechanics in the EPS calculation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 90436,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22833,
        "completion_tokens": 173,
        "total_tokens": 23006
      }
    },
    {
      "question_id": 13,
      "question": "How does the non-dilutable 33 1/3% voting power of Class B common stock influence the potential impact of dividend decisions on the voting structure and shareholder control dynamics, especially considering the 8% dividend increase approved by the Board in January 2022?",
      "original_answer": "The 8% dividend increase approved by the Board in January 2022 applies to both Class A and Class B common stock, but the structural voting disparity remains intact due to the non-dilutable 33 1/3% voting power of Class B shares, which are entirely owned by Brian L. Roberts. This means that while both classes of stock benefit from the dividend increase, the control dynamics are not affected because Class B shares retain disproportionate influence over corporate decisions, including mergers, asset sales, and amendments to the corporate charter. This creates a scenario where economic returns to shareholders (via dividends) are aligned across both classes, but governance control remains concentrated in the hands of the CEO through Class B voting rights.",
      "llm_answer": "The non‑dilutable 33 ⅓ % voting power of Class B common stock—held entirely by Chairman and CEO Brian L. Roberts—means that even after the Board’s 8 % dividend increase in January 2022, his controlling stake continues to dominate shareholder voting, ensuring that dividend decisions cannot be used by other shareholders to dilute or overturn his influence over the company’s governance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 51074,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13011,
        "completion_tokens": 96,
        "total_tokens": 13108
      }
    },
    {
      "question_id": 13,
      "question": "How does Amgen's volume growth contribution from EVENITY in 2024 relate to its profit-sharing arrangement with UCB, and what does this imply about the financial impact of the collaboration on Amgen's consolidated income?",
      "original_answer": "Amgen reported that EVENITY, among other products, contributed to a 23% volume growth in 2024, which was a key driver of the 19% total product sales increase. EVENITY is part of a collaboration with UCB, under which global development costs and commercialization profits and losses are shared equally. According to the collaboration details, Amgen recorded $547 million in global profit and loss share expenses related to UCB in 2024, which were included in the Cost of Sales. This implies that while EVENITY contributed to volume-driven revenue growth, Amgen's net income was partially offset by the profit-sharing arrangement with UCB, reducing the overall profitability of the product on a consolidated basis.",
      "llm_answer": "The 2024 volume growth from EVENITY is directly tied to the profit‑sharing arrangement with UCB: Amgen manufactures and supplies EVENITY worldwide, and under the collaboration the global development costs and commercialization profits and losses are shared equally, with UCB leading commercialization in most European markets. Because the collaboration’s profit‑sharing model splits earnings 50/50, the growth in EVENITY sales translates into a proportional increase in Amgen’s consolidated net income, while the associated cost share reduces the expense burden on Amgen’s balance sheet. Consequently, EVENITY’s volume‑driven revenue growth contributes positively to Amgen’s overall earnings, even though the net impact is moderated by the shared‑profit structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63992,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16236,
        "completion_tokens": 191,
        "total_tokens": 16427
      }
    },
    {
      "question_id": 13,
      "question": "How does Citigroup's leverage ratio requirement of 4.0% compare with Citibank's higher 5.0% requirement, and what implications does this have for their respective capital adequacy classifications under the Prompt Corrective Action framework?",
      "original_answer": "Citigroup is required to maintain a minimum Leverage ratio of 4.0% under U.S. Basel III rules, while its primary subsidiary, Citibank, must maintain a higher minimum Leverage ratio of 5.0% to be classified as 'well capitalized' under the Prompt Corrective Action (PCA) framework. This distinction reflects the stricter capital adequacy standards applied to insured depository institutions like Citibank, which are subject to more binding PCA requirements. The PCA framework imposes increasingly severe restrictions on institutions that fall below these thresholds, affecting their ability to make capital distributions or pay executive bonuses. The higher leverage requirement for Citibank underscores its critical role as a banking subsidiary and the regulatory emphasis on maintaining stronger capital buffers at the operating bank level.",
      "llm_answer": "Citigroup must maintain a minimum Leverage ratio of 4.0%, while Citibank, as an insured depository institution subsidiary of a U.S. GSIB, must maintain a stricter minimum Leverage ratio of 5.0% to be deemed “well capitalized” under the Prompt Corrective Action framework. Both entities also face supplementary leverage requirements—Citigroup must hold a 5.0% Supplementary Leverage Ratio (SLR) due to its GSIB surcharge, whereas Citibank must achieve a 6.0% SLR for the same status. Consequently, Citibank’s higher leverage thresholds imply a more stringent capital adequacy standard for its well‑capitalized classification compared with Citigroup’s broader 4.0% Leverage ratio requirement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "C_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "C_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "C_10k_2024.pdf",
          "target_page": 238,
          "pages": [
            236,
            237,
            238,
            239,
            240
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80782,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20433,
        "completion_tokens": 172,
        "total_tokens": 20606
      }
    },
    {
      "question_id": 13,
      "question": "How does GE's concern about contingent liabilities from its insurance subsidiaries, including UFLIC, reconcile with the long-term risks associated with structured settlement annuities that UFLIC reinsures, particularly given the inability to adjust premiums on these contracts?",
      "original_answer": "GE expresses concern on page 35 about contingent liabilities and loss estimates from its insurance subsidiaries, including the potential for adverse effects on UFLIC due to solvency concerns or litigation, such as the ongoing issues related to Bank BPH in Poland. These liabilities could materially affect GE's financial position or results of operations. UFLIC, as noted on page 20, is a key reinsurer of structured settlement annuities, which carry long-term risks such as mortality and reinvestment risk in a low-interest-rate environment. Importantly, structured settlement annuities do not allow for premium increases or benefit reductions, which means UFLIC must bear the full financial burden of any longevity or interest rate shocks. This inability to adjust pricing creates a direct tension with GE's broader concern about future liabilities from its insurance operations, suggesting that UFLIC's structured settlement annuity portfolio could amplify GE's exposure to unanticipated financial strain over decades, especially if current assumptions about life expectancy or reinvestment yields prove inaccurate.",
      "llm_answer": "GE's concern about contingent liabilities from its insurance subsidiaries, including UFLIC, is directly tied to the long-term risks of structured settlement annuities it reinsures. These contracts cannot have premiums adjusted after issuance, meaning GE must absorb losses from unexpected longevity, mortality improvement, or reinvestment risks that could materialize decades later. This creates contingent liabilities that cannot be mitigated by premium changes, unlike other insurance lines where adjustments are possible. The document specifically notes that structured settlement annuities \"offer no ability to require additional premiums or reduce benefits\" and that risks like mortality improvement \"may extend the duration of payments beyond our estimates,\" creating unresolved contingent liabilities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2023.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 102671,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25914,
        "completion_tokens": 202,
        "total_tokens": 26116
      }
    },
    {
      "question_id": 13,
      "question": "How does ConocoPhillips' equity investment in APLNG, tied to coal bed methane production in Queensland, Australia, reconcile with the $688 million impairment recorded in 2021, given the long-term LNG sales agreements and the carrying value of the investment after the impairment?",
      "original_answer": "ConocoPhillips holds a 37.5% equity investment in APLNG, which operates coal bed methane (CBM) production in Queensland, Australia, and processes and exports LNG under long-term sales agreements. In 2021, Origin Energy sold 10% of its stake in APLNG, and ConocoPhillips exercised its preemption right to acquire this additional interest. However, the fair value of APLNG based on this transaction was lower than the carrying value of ConocoPhillips' existing investment, leading to a noncash impairment charge of $688 million. This impairment reduced the carrying value of the investment to $5,574 million as of December 31, 2021. Despite APLNG's long-term contracts and access to CBM resources, the impairment reflects a market-driven valuation adjustment, indicating a strategic reassessment of the asset's value under current economic conditions.",
      "llm_answer": "ConocoPhillips recorded a $688 million non‑cash impairment in the fourth quarter of 2021 after exercising its pre‑emption right to buy an additional 10 % of APLNG; the sale price it paid reflected a market‑based fair value that was below the carrying amount of its existing investment.  Following the impairment, the carrying value of the APLNG investment was reduced to $5,574 million, which is the amount reported in the “Investments and long‑term receivables” line of the consolidated balance sheet.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65860,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16715,
        "completion_tokens": 125,
        "total_tokens": 16840
      }
    },
    {
      "question_id": 14,
      "question": "How does ConocoPhillips' decision to exercise a preemption right to purchase an additional 10% interest in APLNG relate to the financial structure and long-term obligations of the APLNG joint venture as described in the equity investment section?",
      "original_answer": "ConocoPhillips exercised its preemption right to purchase an additional 10% interest in APLNG, which was valued based on an observable market participant view of APLNG's fair value that was lower than the carrying value of the existing investment. This led to a $688 million before-tax charge after writing down the investment to its fair value of $5,574 million. Meanwhile, APLNG, as a joint venture operated in partnership with Origin Energy, had a non-recourse $8.5 billion project finance facility, of which $4.7 billion remained outstanding at the end of 2023, with scheduled repayments until 2030. The decision to increase stake in APLNG appears to be aligned with COP’s strategic interest in the joint venture despite its significant debt structure and long-term obligations.",
      "llm_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10 % stake in APLNG, a move that increased its overall ownership in the joint venture and reinforced the long‑term financing structure of APLNG.  This investment, funded through the company’s equity‑method holdings, supports APLNG’s project‑level obligations—including the $4.7 billion outstanding balance on its non‑recourse project‑finance facilities—by providing additional capital that underpins the venture’s sustained operations and debt repayment commitments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72650,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18402,
        "completion_tokens": 134,
        "total_tokens": 18536
      }
    },
    {
      "question_id": 14,
      "question": "Given that The Walt Disney Company owns 80% of ESPN while Hearst Corporation holds the remaining 20%, how does the significant increase in ESPN+ programming costs ($1.564 billion in 2022, up 40% from 2021) reflect on Disney's strategic investment in ESPN's digital platforms, especially after the sale of ESPN's X Games and owned radio stations?",
      "original_answer": "Disney's 80% ownership of ESPN, with Hearst Corporation holding the remaining 20%, positions ESPN as a core asset within Disney’s media networks portfolio. Despite divesting certain ESPN-owned physical assets like the X Games and radio stations in fiscal 2022, Disney significantly increased its investment in ESPN's digital infrastructure by allocating $1.564 billion to ESPN+ and other programming costs in 2022, a 40% increase from 2021. This suggests a strategic pivot toward digital streaming and away from traditional media formats, aligning with broader industry trends and Disney’s focus on direct-to-consumer platforms.",
      "llm_answer": "The $1.564 billion increase in ESPN+ programming costs (up 40% from 2021) underscores Disney’s strategic push to bolster its digital sports offering, reflecting heavy investment in new rights—such as NHL games and higher‑cost soccer and golf packages—while the sale of the X Games and owned radio stations streamlines the brand’s focus on core digital platforms. This spending signals Disney’s intent to grow ESPN+ subscriber revenue and ad‑supported engagement, even as it divests non‑core assets to sharpen its digital‑first strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 53909,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13740,
        "completion_tokens": 134,
        "total_tokens": 13874
      }
    },
    {
      "question_id": 14,
      "question": "How does Disney's use of Level 3 valuation techniques for non-recurring fair value measures in fiscal 2024 relate to the triggering events that led to impairment charges, and how does this connect to the company's stated impairment testing methodology for long-lived assets?",
      "original_answer": "Disney recorded impairment charges in the second and fourth quarters of fiscal 2024 due to triggering events indicating that asset carrying amounts might not be recoverable. These impairments were measured using Level 3 discounted cash flow models, which rely on unobservable inputs. The company tests long-lived assets for impairment whenever triggering events occur, and the test depends on whether the asset is held for use or sale, typically involving a comparison of estimated undiscounted future cash flows to the asset's carrying value. This shows that the company applies a structured, event-driven impairment framework that links operational performance triggers (e.g., cash flow declines) with valuation models to determine financial impact.",
      "llm_answer": "Disney's use of Level 3 valuation techniques for non-recurring fair value measures in fiscal 2024—specifically for determining the fair value of assets subject to impairment testing—directly relates to the triggering events that led to impairment charges, as noted in Note 18 where the Company recorded non-cash impairment charges when estimated future cash flows indicated potential non-recoverability of long-lived assets. This connects to the company's stated impairment testing methodology for long-lived assets, which requires testing whenever triggering events (such as a significant decrease in estimated future cash flows) indicate that the carrying amount of an asset group may not be recoverable, and fair value is determined using discounted cash flows, a Level 3 valuation technique.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83634,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21155,
        "completion_tokens": 198,
        "total_tokens": 21354
      }
    },
    {
      "question_id": 14,
      "question": "Given that UPS satisfies all implemented FIP requirements for underfunded pension plans, how does their $10 million 2023 contribution to the Alaska Teamster-Employer Pension Plan reflect both the plan's red zone status and UPS's strategy of meeting only the agreed-upon contractual rates without additional minimum contributions?",
      "original_answer": "UPS satisfies all implemented FIP requirements for underfunded pension plans, including those in the red zone, without paying surcharges or additional minimum contributions beyond contractual rates. The Alaska Teamster-Employer Pension Plan is in the red zone for both 2022 and 2023, indicating it is severely underfunded (<65% funded), and UPS contributes exactly $10 million in 2023, consistent with their strategy of meeting only the agreed-upon contractual contribution rates. This reflects a balance between regulatory compliance with FIP/RP obligations and cost control in pension funding.",
      "llm_answer": "UPS’s $10 million contribution to the Alaska Teamster‑Employer Pension Plan reflects the plan’s red‑zone status because, as disclosed in the multi‑employer pension table, the Alaska plan is certified in the red zone (generally less than 65 % funded) and therefore requires a financial‑improvement plan (FIP) or rehabilitation plan (RP). However, the company’s collective‑bargaining agreements obligate it only to the contractually agreed contribution rates; it makes no extra minimum payments beyond those rates, even though the plan is underfunded. Consequently, the $10 million outlay satisfies the plan’s FIP/RP requirements while representing the minimum contractual contribution, not an additional or voluntary increase.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22209,
        "completion_tokens": 181,
        "total_tokens": 22390
      }
    },
    {
      "question_id": 14,
      "question": "How does AbbVie's financial exposure to Imbruvica, as outlined in the gross margin discussion, reflect the cost-sharing and profit-sharing dynamics detailed in the collaboration agreement with Janssen Biotech?",
      "original_answer": "AbbVie's financial exposure to Imbruvica is significantly shaped by the collaboration agreement with Janssen Biotech, which outlines a detailed cost-sharing and profit-sharing framework. Under the agreement, Janssen is responsible for 60% of development costs while AbbVie covers the remaining 40%. In the U.S., AbbVie acts as the principal in end-customer sales, with both parties sharing pre-tax profits and losses equally. However, the gross margin section reveals that AbbVie incurred a $3.6 billion intangible asset impairment charge primarily related to Imbruvica, highlighting its material financial impact. This impairment charge, combined with the shared profit model, indicates that AbbVie's financial position is highly sensitive to the performance and cost structure of the Imbruvica collaboration, despite Janssen's significant involvement.",
      "llm_answer": "AbbVie's gross margin discussion shows that the company recorded a $3.6 billion intangible‑asset impairment charge related primarily to Imbruvica, which directly reduced its gross margin percentage. This impairment reflects the cost‑sharing and profit‑sharing dynamics of the Janssen collaboration: Janssen bears roughly 60 % of development costs while AbbVie shares profits equally, so the impairment of the Imbruvica‑related intangible asset (recorded in cost of products sold) impacts AbbVie’s margin despite the equal profit split. Consequently, the gross‑margin decline is tied to the collaboration’s profit‑sharing structure and the associated intangible‑asset write‑down.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20183,
        "completion_tokens": 169,
        "total_tokens": 20353
      }
    },
    {
      "question_id": 14,
      "question": "How does ConocoPhillips' application of ASC Topic 815 for derivative accounting on physical gas contracts relate to the financial impact of PALNG's interest rate swaps, and what does this imply about the company's overall risk management strategy for LNG joint ventures?",
      "original_answer": "ConocoPhillips applies ASC Topic 815 to account for physical gas contracts at market prices, treating them as derivatives without electing the normal purchases and sales exception. This aligns with the broader use of derivative instruments across its joint ventures, such as PALNG, which also uses ASC Topic 815 for interest rate swaps to manage financing risk. In 2024, PALNG recognized a $56 million unrealized loss in other comprehensive income and $35 million in equity in earnings related to these swaps, indicating active hedging. Given that COP holds a $1.5 billion equity investment in PALNG, these derivative practices suggest a coordinated risk management approach across LNG joint ventures, balancing market price exposure and interest rate volatility.",
      "llm_answer": "ConocoPhillips applies ASC Topic 815 to its physical gas contracts by treating them as derivatives, recognizing changes in fair value in other comprehensive income and reclassifying to earnings when the contracts settle. The same hedge accounting framework is used for PALNG’s interest‑rate swaps, which convert floating‑rate project‑finance debt to fixed rates; the effective portion of the swap gains/losses is recorded in OCI and later re‑classified into earnings as the hedged interest expense is recognized. This parallel treatment reflects a broader risk‑management strategy that uses derivative instruments—both commodity and interest‑rate—to hedge cash‑flow volatility in its LNG joint‑venture investments, thereby stabilizing earnings and limiting exposure to market‑price fluctuations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66900,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16977,
        "completion_tokens": 198,
        "total_tokens": 17176
      }
    },
    {
      "question_id": 14,
      "question": "How does the regulatory restriction on Nicor Gas' ability to dividend or loan to affiliates, which limits distributions up to its retained earnings balance of $1.6 billion, reconcile with its role as a borrower under a $700 million credit arrangement restricted for working capital needs under Southern Company Gas' committed credit facility?",
      "original_answer": "Nicor Gas is subject to regulatory restrictions that limit its ability to dividend or loan to affiliates up to its retained earnings balance of $1.6 billion, reflecting constraints on capital flexibility. Despite this, Nicor Gas operates as a borrower under a $700 million portion of Southern Company Gas' $1.5 billion credit arrangement, specifically earmarked for its working capital needs. This arrangement indicates that while Nicor Gas cannot freely transfer capital upstream through dividends or loans, it can still access dedicated financing for operational purposes, ensuring liquidity for its core activities without violating regulatory constraints.",
      "llm_answer": "The $1.6 billion retained‑earnings cap that limits Nicor Gas’s ability to dividend or loan to affiliates is consistent with its role as a borrower under a $700 million credit facility that is expressly restricted to Nicor Gas’s working‑capital needs; the credit agreement permits borrowing only up to the amount of retained earnings that are legally available for distribution, ensuring that any debt incurred does not exceed the regulatory dividend‑restriction ceiling.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 226,
          "pages": [
            224,
            225,
            226,
            227,
            228
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 226,
          "pages": [
            224,
            225,
            226,
            227,
            228
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 88509,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22389,
        "completion_tokens": 117,
        "total_tokens": 22507
      }
    },
    {
      "question_id": 15,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $3.0 billion in debt obligations reconcile with the indemnification framework under the Distribution Agreement, where PMI and PM USA only partially indemnify each other for tobacco-related liabilities based on manufacturing responsibility?",
      "original_answer": "Altria depends on PM USA to fully and unconditionally guarantee its obligations under $3.0 billion in debt instruments, as outlined in the Guarantees section. However, under the Distribution Agreement with PMI, indemnification for tobacco-related liabilities is not unconditional—PMI indemnifies Altria and PM USA only for liabilities tied to products it manufactured or had contract manufactured, while PM USA indemnifies PMI only for liabilities from products it manufactured, excluding those made for PMI. This creates a structural asymmetry: PM USA’s guarantee to Altria is absolute and not contingent on the nature of the liability, yet its indemnification from PMI is conditional and limited to specific manufacturing scenarios. This could expose Altria to risk if PM USA incurs liabilities outside the scope of its indemnification from PMI, particularly those not tied to tobacco product manufacturing.",
      "llm_answer": "Altria’s $3 billion debt‑related guarantees from PM USA are covered by the indemnification provisions in the Distribution Agreement, which allocate tobacco‑related liabilities between PMI and PM USA based on manufacturing responsibility. Under that framework, PM USA only partially indemnifies Altria for such liabilities, meaning the guarantees remain enforceable even though the parties’ indemnification obligations are limited.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 66242,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16815,
        "completion_tokens": 107,
        "total_tokens": 16923
      }
    },
    {
      "question_id": 15,
      "question": "How does ConocoPhillips' engagement of DeGolyer and MacNaughton to review over 85% of its proved reserves estimation processes relate to the inclusion of D&M's report as Exhibit 99 in the 10-K filing, and how does this third-party involvement support the company's assertion of SEC-compliant internal controls over reserves reporting?",
      "original_answer": "ConocoPhillips engaged DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, to review the processes and controls used in estimating over 85% of its proved reserves as of December 31, 2024. This review was intended to provide objective third-party validation that the company’s internal processes align with SEC regulations. The results of this review are documented in D&M's report, which is included as Exhibit 99 in the 10-K filing. This external validation supports ConocoPhillips’ assertion that its internal controls over reserves estimation are comprehensive, consistent, and SEC-compliant. The involvement of D&M, through on-site visits, teleconferences, and documentation reviews, ensures that reserves are calculated using appropriate standards and provides senior management with independent assurance regarding the reliability of reserves data.",
      "llm_answer": "ConocoPhillips engaged DeGolyer and MacNaughton (D&M) to independently review the processes and controls used to estimate more than 85 % of its proved reserves as of December 31 2024. D&M’s assessment confirmed that these processes and controls comply with SEC reserve definitions, and its report is filed as Exhibit 99 in the 10‑K. This third‑party validation provides objective evidence that the company’s internal reserves‑reporting controls are designed in accordance with SEC requirements and are operating effectively.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78046,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19774,
        "completion_tokens": 131,
        "total_tokens": 19905
      }
    },
    {
      "question_id": 15,
      "question": "How does Converse's reported revenue growth in fiscal 2022 relate to the overall performance of the apparel category across Nike's global brand divisions, particularly in light of Converse's licensing operations?",
      "original_answer": "Converse reported a 7% revenue increase in fiscal 2022, driven by growth in North America, Western Europe, and licensee markets, with a notable 22% rise in direct-to-consumer sales. This growth was partially offset by declines in Asia and lower wholesale revenues. A key component of Converse's revenue mix is its licensing operations, which are explicitly called out as a major contributor to 'Other revenues' in the Global Brand Divisions section. Meanwhile, the Apparel category across all Nike Brand segments totaled $13.567 billion in revenues, with Converse contributing only $103 million of that total. This indicates that while Converse is a growing contributor—especially through licensing—it remains a relatively small player in the broader Nike apparel ecosystem. The contrast between Converse's 7% growth and its modest $103 million apparel contribution highlights how its licensing model and regional performance are leveraged differently within the broader Nike portfolio strategy.",
      "llm_answer": "Converse’s reported revenue grew 6% to $2.346 billion in fiscal 2022, driven by a 22% jump in Direct‑to‑Consumer sales and a 7% overall revenue increase, while its licensing and other miscellaneous revenues contributed to the segment’s earnings. This growth occurred against a backdrop of modest gains in the broader apparel category across Nike’s global brand divisions, which saw total NIKE Brand revenues rise 11% (currency‑neutral 16%) and footwear/apparel unit sales improve, but the apparel category’s overall growth was tempered by lower ASPs and higher discounts, highlighting that Converse’s licensing‑driven revenue boost was a key contributor to its segment performance amid a generally soft apparel environment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89523,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22612,
        "completion_tokens": 180,
        "total_tokens": 22792
      }
    },
    {
      "question_id": 15,
      "question": "How does Qualcomm's exposure to revenue volatility from licensee disputes over royalty payments reconcile with their accounting policy that requires revenue recognition based on estimated royalty payments even before final agreement terms are settled?",
      "original_answer": "Qualcomm faces significant challenges from licensees who dispute, underreport, or delay royalty payments, which can delay revenue recognition until agreements are finalized (page 27). Despite this operational and legal risk, Qualcomm's accounting policy on page 69 states that they recognize royalty revenues based on estimates derived from preliminary licensee reports and market data, even before final reports are submitted. This creates a tension where the company must recognize revenue under uncertain conditions, potentially leading to future adjustments and volatility. The binding arbitration provisions in license agreements further complicate this dynamic, as unresolved disputes can delay final terms and thus definitive revenue recognition. The synthesis of these two perspectives reveals a business model that is both exposed to execution risk and reliant on forward-looking revenue estimation techniques that may not fully capture the downstream impact of licensee behavior.",
      "llm_answer": "Qualcomm recognizes that its licensing revenue depends on royalties that are estimated and recognized before final license agreements are fully settled, and that any adverse rulings or changes to its licensing practices—such as required royalty‑rate reductions, a shift to a lower royalty base, or mandatory multi‑level licensing—could materially reduce those revenues and cash flows. Consequently, the company discloses that it must rely on estimates of royalty income and is exposed to significant financial risk if regulatory or legal actions force modifications to its current licensing model.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 100080,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25260,
        "completion_tokens": 149,
        "total_tokens": 25409
      }
    },
    {
      "question_id": 15,
      "question": "How does the $21.7 billion of Alphabet's 2023 stock-based compensation expense tied to Class C stock issuance align with the treatment of Class B stock in diluted net income per share calculations, given the structural relationship between these share classes?",
      "original_answer": "The $21.7 billion of stock-based compensation expense for 2023, which is primarily associated with awards expected to settle in Class C stock, increases the number of Class C shares outstanding over time as RSUs vest. This affects the diluted net income per share calculation, which accounts for potentially dilutive securities like RSUs using the treasury stock method. In computing diluted net income per share for Class A stock, the conversion of Class B stock is assumed, but Class B shares themselves are not subject to dilution in their own calculation. Despite these differences in dilution treatment, both Class C and Class B shares receive equal per-share dividends and liquidation rights. Therefore, while Class C shares are directly impacted by SBC-related issuances, the structural alignment of dividend and liquidation rights ensures parity in net income allocation across share classes.",
      "llm_answer": "The $21.7 billion of 2023 stock‑based compensation expense tied to Class C stock awards is reflected in the diluted‑per‑share calculations by adding the conversion of Class B shares (877 million) and the 92 million contingently issuable RSUs to the denominator, while the numerator is adjusted for the reallocation of undistributed earnings from Class B to Class A (5,124 million) and the offsetting reallocation of earnings to Class C (287 million). This treatment ensures that the diluted earnings per share for each class incorporates the effect of potentially converting Class B shares into Class A and issuing RSUs that settle in Class C stock.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 90436,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22848,
        "completion_tokens": 162,
        "total_tokens": 23011
      }
    },
    {
      "question_id": 15,
      "question": "How does Simon's governance authority over the Operating Partnership influence the accounting treatment and balance sheet presentation of Series J 8 3/8% Preferred Stock redemptions in SPG's 2024 financial statements?",
      "original_answer": "Simon, as the sole general partner of the Operating Partnership, holds full authority over its operational and distribution decisions, including whether to redeem preferred units in cash or common stock. This governance control directly affects how preferred stock redemptions are accounted for in SPG's consolidated financials. Specifically, the Series J 8 3/8% Preferred Stock, which Simon may redeem on or after October 15, 2027, at $50.00 per share plus accrued dividends, is classified in permanent equity due to Simon's discretion to issue common stock instead of cash upon redemption. Furthermore, the unamortized premium on Series J stock was $0.9 million as of December 31, 2024, which is included in the carrying value on the consolidated balance sheet. This treatment aligns with the broader principle that Simon's decisions govern how preferred interests are presented in SPG’s consolidated balance sheets, particularly in relation to limited partners' preferred interest, which decreased to $15.5 million in 2024 from $23.0 million in 2023 due to redemptions.",
      "llm_answer": "Simon Property Group’s governance authority over the Operating Partnership—specifically its ability to reclassify excess common stock, establish redemption terms for preferred securities, and require the Operating Partnership to repurchase an equal number of units when it buys back its own shares—directly shapes how the Series J 8 3/8 % Preferred Stock redemptions are treated. Because the redemption price of the Series J preferred units is tied to the liquidation value plus accrued distributions and can be settled in cash or registered common stock at Simon’s election, the related redemption activity is recorded in temporary equity (rather than permanent equity) and reflected as a preferred‑unit liability on the balance sheet. Consequently, any redemptions of Series J preferred units appear as a reduction of temporary‑equity balances and are disclosed separately from permanent‑equity items in the 2024 financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_3_rel": {
          "source_file": "SPG_10k_2024.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74118,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18763,
        "completion_tokens": 234,
        "total_tokens": 18997
      }
    },
    {
      "question_id": 15,
      "question": "How does Boeing's 2023 Five-Year Credit Agreement, which Citibank, N.A. administers, relate to the company's broader credit facility partnerships, particularly in light of the newly executed 364-Day Credit Agreement with Citibank, N.A. as administrative agent?",
      "original_answer": "Boeing's 2023 Five-Year Credit Agreement, administered by Citibank, N.A., is part of a broader set of credit arrangements that also includes a newly executed 364-Day Credit Agreement with the same institution. This demonstrates Boeing's strategic reliance on Citibank, N.A. for diverse financing solutions, ranging from short-term liquidity (364-Day Agreement) to longer-term capital commitments (Five-Year Agreement). The dual engagement with Citibank, N.A. underscores a deepening financial partnership aimed at supporting Boeing's operational and strategic objectives.",
      "llm_answer": "The 364-Day Credit Agreement dated August 24 2023 with Citibank, N.A. as administrative agent is presented as a new, separate facility that complements Boeing’s existing long‑term borrowing structure, which includes the $13.5 billion Five‑Year Credit Agreement (originally entered into on October 30 2019 and amended on August 25 2022). Both agreements are listed among the company’s key credit arrangements in the filing, showing that the short‑term 364‑day facility operates alongside Boeing’s broader multi‑year credit partnership with Citibank and other lenders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64957,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16477,
        "completion_tokens": 141,
        "total_tokens": 16619
      }
    },
    {
      "question_id": 15,
      "question": "How does Morgan Stanley's phased-in CECL deferral impact on risk-based capital ratios relate to its stake in MSBNA, and what are the implications for regulatory capital compliance as of December 31, 2023?",
      "original_answer": "Morgan Stanley, through its stake in MSBNA, elected to defer the impact of CECL adoption on risk-based capital ratios over a five-year transition period, with deferral impacts phased in at 50% as of January 1, 2023. This deferral is reflected in MSBNA’s regulatory capital calculations, which are based on the Standardized Approach rules. The phased-in CECL deferral affects how RWA and capital ratios are measured, allowing for a smoother transition in meeting regulatory requirements such as minimum Tier 1 leverage ratio and supplementary leverage ratio. As of December 31, 2023, MSBNA remains well-capitalized under OCC PCA standards, indicating that the deferral has not compromised regulatory compliance but has instead provided a buffer to absorb potential credit losses under CECL accounting.",
      "llm_answer": "Morgan Stanley's phased-in CECL deferral, which began phasing in at 25% in 2022 and 50% in 2023 (with full phase-in by 2025), directly impacts its risk-based capital ratios by allowing temporary use of pre-CECL RWA calculations for regulatory capital purposes. This deferral affects MSBNA's capital ratios, as evidenced by its well-capitalized status (e.g., 21.7% CET1 ratio at December 31, 2023) based on standardized approaches, where the capital buffer requirement (8.4% standardized) incorporates the phased-in CECL adjustments. As of December 31, 2023, MSBNA maintained strong capital ratios above regulatory minimums (e.g., 12.9% CET1 ratio vs. 4.5% minimum), ensuring compliance with OCC well-capitalized standards and avoiding restrictions on capital distributions. The deferral thus provides temporary flexibility in capital calculations while the firm transitions fully to CECL by 2025.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 135,
          "pages": [
            133,
            134,
            135,
            136,
            137
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 112288,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 28307,
        "completion_tokens": 224,
        "total_tokens": 28531
      }
    },
    {
      "question_id": 15,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $3.0 billion in debt obligations reconcile with the indemnification framework under the Distribution Agreement, where PMI and PM USA only partially indemnify each other for tobacco-related liabilities based on manufacturing responsibility?",
      "original_answer": "Altria Group depends on PM USA as a primary guarantor for its $3.0 billion Credit Agreement and other debt obligations under unconditional guarantees that remain in place until specific release conditions occur. However, under the Distribution Agreement following the 2008 spin-off of PMI, indemnification responsibilities for tobacco-related liabilities between PM USA and PMI are allocated only based on manufacturing activity—PMI indemnifies Altria and PM USA for liabilities related to products it manufactured or had contract manufactured, and vice versa. Notably, Altria has not recorded any liability for this indemnification, as its fair value is considered insignificant. This creates a contrast: while PM USA provides broad and unconditional financial guarantees for Altria’s debt, its indemnification obligations to PMI are limited in scope and contingent on manufacturing attribution, potentially exposing Altria to asymmetric risk in its subsidiary relationships.",
      "llm_answer": "Altria’s $3 billion debt‑guarantee framework from PM USA is consistent with the Distribution Agreement’s indemnification structure, which limits PMI and PM USA’s mutual indemnification to liabilities arising from the manufacturer that produced the tobacco product—i.e., each party only covers the other for claims tied to its own manufacturing responsibility, not for all tobacco‑related liabilities. Consequently, while PM USA provides an unconditional guarantee of Altria’s debt, the parties’ indemnification obligations under the Distribution Agreement remain partial and are confined to the manufacturer‑specific liability allocations set out in that agreement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 66242,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16815,
        "completion_tokens": 166,
        "total_tokens": 16981
      }
    },
    {
      "question_id": 15,
      "question": "How does Boeing's continued factory disruption on the KC-46A Tanker program, which led to a $402 million reach-forward loss in Q4 2021, reconcile with the previously capitalized precontract costs and potential supplier liabilities of $652 million as of December 31, 2021?",
      "original_answer": "Boeing's KC-46A Tanker program, a $19 billion contract with the U.S. Air Force, faced significant factory disruptions in 2021, including supply chain issues and evolving customer requirements for the Remote Vision System. These disruptions led to a $402 million reach-forward loss recorded in Q4 2021. This loss aligns with earlier financial exposure noted in the form of $243 million in capitalized precontract costs and $409 million in potential termination liabilities to suppliers as of December 31, 2021. The combined figures suggest that the program's financial risk was already substantial before the Q4 charge, indicating ongoing challenges in managing cost overruns and performance risks under the fixed-price contract structure.",
      "llm_answer": "The $402 million reach‑forward loss recorded in Q4 2021 reflects the continued factory and supply‑chain disruptions on the KC‑46A program and the higher cost to complete the Remote Vision System as the customer’s requirements evolved. This incremental loss is recorded against the previously capitalized precontract costs of $243 and the $409 of potential termination liabilities that were already recognized for the KC‑46A, while the overall exposure also includes the $652 million of supplier‑related liabilities reported as of Dec 31 2021. In short, the new loss adjusts the accrued contract estimates to reflect the worsening performance and cost outlook of the KC‑46A, even though those precontract amounts had been capitalized earlier.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56337,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14335,
        "completion_tokens": 185,
        "total_tokens": 14520
      }
    },
    {
      "question_id": 15,
      "question": "How does the renaming of FPL Group Capital Inc to NextEra Energy Capital Holdings, Inc in 2010 reconcile with the continued use of the FPL Group Capital name in debt instruments filed as exhibits in 2021 and 2022?",
      "original_answer": "The renaming of FPL Group Capital Inc to NextEra Energy Capital Holdings, Inc occurred in 2010, yet the FPL Group Capital name continues to appear in legal filings and debt instruments dated as late as 2021 and 2022. This indicates that while the corporate name was officially changed over a decade ago, legacy naming conventions persist in legal and financial documentation, particularly in indentures and officer certificates related to long-term subordinated debt securities. This dual usage reflects the importance of maintaining continuity in legal agreements and financial instruments that span multiple corporate branding transitions.",
      "llm_answer": "The renaming of FPL Group Capital Inc. to NextEra Energy Capital Holdings, Inc. in 2010 does not affect the naming of its legacy debt instruments, which continue to reference \"FPL Group Capital\" in their official indentures and exhibits (e.g., the 1999 Indenture and related supplemental indentures filed as Exhibits *4(l), *4(m), etc.). This is consistent with standard corporate practice where debt securities retain their original legal names even after corporate restructurings, as evidenced by the 2021–2023 filings of new debt instruments still using \"FPL Group Capital\" in their exhibit descriptions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 180670,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 45394,
        "completion_tokens": 151,
        "total_tokens": 45546
      }
    },
    {
      "question_id": 16,
      "question": "How does Philip Morris International's discussion of Vietnam's regulatory environment for heat-not-burn products align with its financial performance in the region, particularly in light of the company's broader concerns about illicit trade impacting profitability?",
      "original_answer": "Philip Morris International notes in its regulatory section that Vietnam is among the countries where voluntary standards for heat-not-burn products have been adopted, indicating a potential openness to novel tobacco products. However, in the South & Southeast Asia market commentary, the company attributes a 10.0% market increase in Vietnam to a lower prevalence of illicit trade, which was partly due to pandemic-related supply disruptions. This aligns with the broader risk factor on page 40, where illicit trade is cited as a material challenge affecting volume, results of operations, and competitiveness. The alignment suggests that while Vietnam's regulatory stance on novel products remains non-mandatory, the temporary reduction in illicit trade during the pandemic provided a short-term boost to PMI's market position, highlighting the dual importance of both regulatory engagement and illicit trade mitigation in shaping long-term profitability in the region.",
      "llm_answer": "PMI’s 2022 10‑K notes that Vietnam’s market grew ≈ 10 % driven by lower illicit trade and pandemic‑related supply‑chain easing, which helped lift PMI’s shipment volume and market share in the region.  However, the same filing stresses that “excessive and disruptive excise, sales and other tax increases and discriminatory tax structures” – especially those that push adult smokers toward low‑tax or illicit products – “adversely impact profitability” and can fuel illicit trade.  Consequently, while the regulatory environment in Vietnam is relatively favorable (lower illicit trade, expanding total market), PMI warns that any future tax hikes or stricter regulations could erode the profit gains it is seeing in that market.  This tension explains why the company simultaneously celebrates the growth in Vietnam and flags fiscal‑policy risks as a key profitability concern.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75351,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19086,
        "completion_tokens": 219,
        "total_tokens": 19305
      }
    },
    {
      "question_id": 16,
      "question": "Given the importance of patent protection for revenue stability, how does the 32% U.S. revenue decline in Trulicity in 2024 reflect the risk associated with the anticipated expiration of its patent and data protections, as outlined in the intellectual property risk section?",
      "original_answer": "The 32% U.S. revenue decline in Trulicity in 2024 directly reflects the vulnerability of LLY's revenue streams when a product nears the end of its patent and data protection lifecycle. According to the intellectual property section, Trulicity is expected to lose significant patent and data protections in the next few years, which historically leads to rapid revenue erosion due to generic or biosimilar competition. This aligns with the observed revenue drop, likely driven by competitive dynamics and anticipation of reduced exclusivity. The connection between the loss of patent protection (as described on page 10) and Trulicity’s current revenue trajectory (as reported on page 49) underscores the material financial risk posed by intellectual property expiration.",
      "llm_answer": "The 32 % decline in U.S. Trulicity revenue in 2024 is directly tied to the loss of patent and data exclusivity that protects the product. In the Intellectual Property section (pages 27‑30) the filing notes that Trulicity’s “compound patent” and “biologics data protection” expire in 2027 (U.S.) and 2024 (major European markets), and that such expirations “typically result in the entry of one or more generic competitors, leading to a rapid and severe decline in revenue.” This anticipated patent/ data‑protection expiry is cited as the primary risk factor driving the steep revenue drop.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 64404,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16351,
        "completion_tokens": 147,
        "total_tokens": 16498
      }
    },
    {
      "question_id": 16,
      "question": "How does AMD's strategic positioning of FPGAs in hyperscale data centers align with the export licensing constraints imposed by EAR regulations on Versal™ FPGAs destined for China?",
      "original_answer": "AMD positions FPGAs as critical components in hyperscale data centers, particularly for AI workloads such as generative AI models, and highlights their integration into servers sold by OEMs and ODMs to large public cloud service providers. However, the Export Administration Regulations (EAR) now restrict the export of certain AMD Versal™ FPGAs to China or to customers outside the U.S. with ultimate parents in D5 countries, including China, without a license. These restrictions not only limit AMD’s ability to sell these products in key markets but also introduce uncertainty through the NAC notification process, which could delay or block shipments. Given the strategic importance of FPGAs in driving revenue from AI and cloud infrastructure, these export controls could materially impact AMD’s competitive positioning and financial performance, especially if alternative products are not accepted or future regulations expand.",
      "llm_answer": "AMD’s export‑control disclosures make clear that new U.S. EAR licensing rules (effective October 2023) restrict shipments of certain AMD Instinct ICs and Versal FPGAs to China or to customers whose ultimate parent is in a D5 country, requiring a 25‑day Notified Advanced Computing (NAC) filing and potentially blocking shipments without a license. The company notes that these controls could limit its ability to serve hyperscale data‑center customers in China, may impose burdensome conditions or future licensing requirements, and could put AMD at a competitive disadvantage if rivals are not subject to the same restrictions. Consequently, the strategic placement of Versal FPGAs in hyperscale environments must be balanced against the risk of EAR‑driven export limitations that could curtail sales to the Chinese market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77177,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19516,
        "completion_tokens": 206,
        "total_tokens": 19722
      }
    },
    {
      "question_id": 16,
      "question": "How does the decline in Converse's revenue performance in fiscal 2023, particularly in apparel, align with the overall revenue contribution of apparel across Nike's geographic segments?",
      "original_answer": "The decline in Converse's revenue by 15% in fiscal 2023, driven by drops in North America and Western Europe, contrasts with the broader Nike Brand's apparel revenue, which contributed $13.843 billion across geographic segments. While Converse's apparel segment only generated $90 million in revenue, reflecting its relatively minor role in the broader apparel category, Nike's own apparel revenues remained strong in key markets like North America ($5.947 billion) and Europe, Middle East & Africa ($4.566 billion). This indicates that while Nike's core apparel business remains robust across global markets, Converse's apparel performance lagged significantly, contributing minimally to the overall apparel revenue and reflecting a more challenging position in the lifestyle apparel segment.",
      "llm_answer": "The decline in Converse's revenue in fiscal 2023—driven by lower unit sales and reduced ASPs in North America and Western Europe—mirrors the broader trend of apparel revenue growth across Nike’s geographic segments, which rose 14% on a currency‑neutral basis in fiscal 2024 due to higher sales in men’s, women’s and Jordan apparel. Consequently, while Converse’s apparel performance dragged down its own segment, the overall apparel strength in Nike’s North America, Europe/Middle East & Africa, Greater China and Asia Pacific/Latin America segments contributed to the company‑wide revenue increase.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76341,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19310,
        "completion_tokens": 149,
        "total_tokens": 19460
      }
    },
    {
      "question_id": 16,
      "question": "How does Broadcom's valuation methodology for developed technology related to SoC controller products compare with its treatment of VMware Cloud Foundation (VCF) developed technology, and what does this reveal about the strategic importance of VCF within Broadcom's post-acquisition asset portfolio?",
      "original_answer": "Broadcom applies different valuation methodologies to developed technology depending on its application: the relief-from-royalty method is used for SoC controller products (valued based on forecasted revenue and royalty rates), while the multi-period excess earnings method is used for VMware Cloud Foundation (VCF) developed technology (valued based on projected cash flows, technology obsolescence rate, and contributory asset charges). The significant allocation of $24,156 million to VCF-related developed technology out of the $45,572 million in total acquired intangibles from the VMware acquisition underscores the strategic emphasis on VCF as a core asset. This contrast in valuation approach and the substantial investment in VCF-related intangibles suggest that Broadcom views VCF as a critical growth driver requiring a more complex and forward-looking earnings model compared to the more established SoC controller technology.",
      "llm_answer": "Broadcom valued its developed technology related to SoC controller products using the relief‑from‑royalty method, whereas the VMware Cloud Foundation (VCF) developed technology was valued using the multi‑period excess earnings method under the income approach. This contrast shows that VCF—representing a strategic, high‑growth cloud platform—was treated with a more sophisticated, cash‑flow‑intensive valuation model, underscoring its central role in Broadcom’s post‑acquisition portfolio and its importance to future revenue generation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 58263,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14820,
        "completion_tokens": 134,
        "total_tokens": 14954
      }
    },
    {
      "question_id": 16,
      "question": "How does the voting power distribution between Class A and Class B common stock impact the corporate governance structure, given the non-dilutable voting rights of Class B shares and the fact that Class A shares are publicly traded on Nasdaq?",
      "original_answer": "The corporate governance structure of CMCSA is significantly influenced by the voting power distribution between Class A and Class B common stock. According to the equity note (page 91), holders of Class B common stock collectively control 33 1/3% of the voting power, and each Class B share is entitled to 15 votes. This voting power is non-dilutable, meaning it cannot be reduced by the issuance of additional shares of any class of common stock. Class A shares, which are publicly traded on Nasdaq as disclosed on page 1, collectively hold 66 2/3% of the voting power, but the number of votes per share fluctuates depending on the total number of Class A and Class B shares outstanding. This dual-class structure ensures that the holders of Class B shares retain significant influence over corporate decisions despite owning a smaller portion of the total shares. The governance structure thus reflects a strategic balance where public shareholders (holding Class A shares) have a majority of shares but limited voting control, while a smaller group (holding Class B shares) maintains outsized influence over decision-making.",
      "llm_answer": "The voting power distribution gives Class B shares a fixed 33 ⅓ % of the total voting power that cannot be diluted by additional share issuances, while Class A shares carry the remaining voting power and are publicly traded on Nasdaq. This structure concentrates control in the holders of Class B stock despite the public market for Class A shares.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 61017,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15496,
        "completion_tokens": 87,
        "total_tokens": 15583
      }
    },
    {
      "question_id": 16,
      "question": "Given the $116.5 million fair value of the VIL OCDs and the $411.6 million tenant-related intangible asset impairment tied to VIL in India, how does AMT's strategic review and decision to pursue the Pending ATC TIPL Transaction reflect its risk mitigation approach and expectations for recovery on both the impaired assets and the convertible debt instruments?",
      "original_answer": "The $116.5 million fair value of the VIL OCDs, which were issued to address payment shortfalls from VIL, contrasts with the $411.6 million tenant-related intangible asset impairment AMT recorded in 2022 due to VIL's partial payments. This indicates a significant erosion in the value of AMT's contractual relationship with VIL. In response, AMT initiated a strategic review of its India business, culminating in the Pending ATC TIPL Transaction, which allows AMT to divest its tower assets in India while retaining the VIL OCDs and certain receivables. This strategic move suggests that AMT is reducing its operational exposure to the Indian market and VIL's financial instability, while maintaining a financial claim (through the OCDs) that could offer partial recovery if VIL stabilizes or the OCDs are converted into equity. This reflects a dual approach of limiting further impairment risk while preserving potential upside from VIL's future performance.",
      "llm_answer": "AMT's strategic review and decision to pursue the Pending ATC TIPL Transaction reflects a deliberate risk‑mitigation strategy aimed at protecting its exposure to impaired assets and the $116.5 million fair‑value of the VIL OCDs, while also addressing the $411.6 million tenant‑related intangible impairment in India. By initiating the transaction, AMT seeks to repurpose capital, reduce uncertainty around collections from VIL, and potentially recover value from the impaired India reporting unit and convertible debt instruments, thereby stabilizing cash flow and enhancing its ability to meet REIT distribution and debt‑service obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "AMT_10k_2023.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20608,
        "completion_tokens": 160,
        "total_tokens": 20768
      }
    },
    {
      "question_id": 16,
      "question": "How does Boeing's increased reach-forward loss of $402 million on the KC-46A Tanker program in 2021, driven by factory disruption and supply chain impacts, reconcile with the program's overall contract value of $19 billion and its status as a fixed-price incentive fee contract?",
      "original_answer": "Boeing recorded an additional reach-forward loss of $402 million on the KC-46A Tanker program in 2021 due to continued factory disruption and supply chain issues, including the impact of the evolving Remote Vision System requirements. This loss occurred despite the program being under a fixed-price incentive fee contract, which inherently places cost overrun risk on the company. The KC-46A program had a total contract value of approximately $19 billion as of December 31, 2021, across the EMD phase and seven LRIP lots for 94 aircraft. While the fixed-price nature of the contract allows Boeing to benefit from cost efficiencies, it also exposes the company to significant financial risk, as evidenced by the 2021 loss. This highlights the tension between long-term contract value and short-to-medium-term execution risks in complex defense programs.",
      "llm_answer": "The $402 million reach‑forward loss recorded in 2021 for the KC‑46A program reflects the additional costs caused by factory disruptions and supply‑chain setbacks, which are accounted for as a fixed‑price incentive fee contract where cost overruns are borne by Boeing; the contract’s total value remains about $19 billion, and the loss is recognized as an earnings charge when the revised cost estimates exceed the fixed price.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56337,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14337,
        "completion_tokens": 106,
        "total_tokens": 14443
      }
    },
    {
      "question_id": 16,
      "question": "How does the eligibility for 12 years of U.S. data exclusivity for MK-7962 (sotatercept) upon approval reconcile with the granted data exclusivity expiration date of July 16, 2033, for the same product, and what does this imply about Merck's regulatory strategy for long-term market protection?",
      "original_answer": "Merck's disclosure indicates that MK-7962 (sotatercept) is eligible for 12 years of U.S. data exclusivity upon approval as a biologic product. However, the document separately states that data exclusivity for this compound has already been granted and will expire on July 16, 2033. This implies that the product has likely already received regulatory approval, triggering the start of the exclusivity period. The alignment of these two provisions—eligibility and granted status—suggests that Merck has secured a defined market protection timeline, with exclusivity lasting until 2033, barring any patent term extensions. This supports a regulatory strategy focused on leveraging both data exclusivity and patent protection to maximize market control through 2037, when the core treatment patents are set to expire.",
      "llm_answer": "The eligibility for 12 years of U.S. data exclusivity for MK-7962 (sotatercept) upon approval is consistent with the granted data exclusivity expiration date of July 16, 2033, which aligns with the standard 12-year regulatory data protection period for biologics in the U.S. This reflects Merck's strategic use of regulatory data exclusivity as a key component of its long-term market protection plan, ensuring extended exclusivity beyond patent terms to maintain commercial advantage for its pipeline products.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67232,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17054,
        "completion_tokens": 127,
        "total_tokens": 17182
      }
    },
    {
      "question_id": 16,
      "question": "How does American Life's exemption from RBC requirements affect MetLife's consolidated statutory capital position, given its significant statutory equity of $7.555 billion as of December 31, 2024?",
      "original_answer": "American Life is exempt from RBC requirements under Delaware law because it does not conduct insurance business in the U.S., yet it holds significant statutory equity of $7.555 billion as of December 31, 2024, which contributes to MetLife’s consolidated statutory capital position. While most U.S. insurance subsidiaries are subject to RBC requirements and must maintain capital above specified thresholds, American Life is instead regulated under foreign jurisdictions where it operates and is subject to their capital and solvency requirements. This exemption allows American Life to maintain its own capital structure without the constraints of NAIC’s RBC framework, which could provide MetLife with more flexibility in capital management across its global operations. However, since American Life’s statutory equity is still included in MetLife’s consolidated statutory capital, its regulatory treatment differently impacts the overall capital adequacy assessment of the group, especially when compared to subsidiaries like MLIC that must comply with RBC requirements.",
      "llm_answer": "American Life’s exemption from RBC requirements does not affect the consolidated statutory capital position of MetLife because its statutory equity of $7.555 billion is reported separately and is not subject to RBC calculations; all of MetLife’s other U.S. insurance subsidiaries individually exceed Company Action Level RBC, and the company’s overall Statement‑Based Combined RBC Ratio remains well above 360%, leaving its consolidated statutory capital unchanged by the exemption.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 272,
          "pages": [
            270,
            271,
            272,
            273,
            274
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 273,
          "pages": [
            271,
            272,
            273,
            274,
            275
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 73617,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18633,
        "completion_tokens": 120,
        "total_tokens": 18753
      }
    },
    {
      "question_id": 16,
      "question": "How does GE's decision to close UFLIC to new business in 2004 relate to the long-term financial risks associated with the 23,400 structured settlement annuities it now reinsures, particularly in light of the company's exposure to mortality improvement and reinvestment risk?",
      "original_answer": "GE's decision to close UFLIC to new business in 2004 reflects a strategic move to limit future exposure to insurance underwriting risks, particularly in products like structured settlement annuities. However, the company still reinsures approximately 23,400 structured settlement annuities, 27% of which were underwritten on impaired lives, with projected payments extending decades into the future. These contracts expose GE to mortality improvement risk—where policyholders live longer than expected—and reinvestment risk in a low interest rate environment. Since these annuities do not allow for additional premiums or benefit reductions, the company must manage long-term liabilities with fixed terms, which contrasts with the original rationale for ceasing new business at UFLIC. This creates a tension between the historical risk mitigation strategy and the ongoing financial obligations tied to this legacy portfolio.",
      "llm_answer": "GE's decision to close UFLIC to new business in 2004 was a strategic move to limit exposure to its existing structured settlement annuity portfolio, which now comprises approximately 23,400 contracts with an average attained age of 57 and includes a significant proportion (27%) underwritten on impaired lives. This closure eliminated the ability to write new premiums, but the company remains exposed to long-term risks including mortality improvement (which could extend payment durations beyond projections) and reinvestment risk in a low-interest-rate environment, as highlighted in the insurance and investment contracts discussion and sensitivity analyses showing potential adverse impacts of $300–$1,300 million on present value of future cash flows from assumption changes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2024.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2024.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2024.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 101221,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25546,
        "completion_tokens": 195,
        "total_tokens": 25742
      }
    },
    {
      "question_id": 17,
      "question": "How does Microsoft's indefinite deferral of the final foreign tax credit regulations through Notice 2023-80 impact its effective tax rate in fiscal year 2024, and how does this align with the geographic distribution of its foreign income?",
      "original_answer": "Microsoft's effective tax rate for fiscal year 2024 was 18%, a decrease from 19% in fiscal year 2023, primarily due to tax benefits from law changes including Notice 2023-80, which indefinitely delayed the effective date of the final foreign tax credit regulations. This delay allowed Microsoft to continue benefiting from lower foreign tax rates, particularly from its Irish regional operating center, which generated 83% of its foreign income before tax in fiscal year 2024. The geographic distribution of income—$44.9 billion from foreign jurisdictions—enabled Microsoft to maintain a lower effective tax rate compared to the U.S. federal statutory rate, illustrating how regulatory deferrals align with its international tax planning strategy.",
      "llm_answer": "Microsoft's indefinite deferral of final foreign tax credit regulations through Notice 2023-80 delays the recognition of related tax benefits, resulting in a lower effective tax rate for fiscal year 2024 (18.2% vs. 19.0% in 2023). This aligns with the geographic distribution of foreign income, as 83% of foreign income before tax is generated in Ireland (a low-tax jurisdiction), which reduces the effective rate despite the overall 18.2% rate being lower than the U.S. statutory 21%. The indefinite deferral specifically impacts the timing of tax benefits from foreign earnings, contributing to the effective rate decrease.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 58172,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14780,
        "completion_tokens": 156,
        "total_tokens": 14936
      }
    },
    {
      "question_id": 17,
      "question": "Given the convertible relationship between Class A and Class B common stock and the significant repurchases of Class A shares, how does the lack of Class B common stock issuances or balance changes in 2024 impact the overall equity structure and voting power dynamics at Comcast Corporation?",
      "original_answer": "The lack of Class B common stock issuances or balance changes in 2024, despite the convertible nature of Class B shares into Class A, suggests that the existing voting power structure remains stable. Class B shares, which carry 15 votes per share and collectively hold 33 1/3% of the voting power, did not change in quantity during the year, as evidenced by the $0 balance in both beginning and end-of-year Class B common stock figures on page 68. Meanwhile, significant repurchases of Class A shares occurred, reducing Class A common stock from $48 million to $47 million in 2024 (page 67), which could have diluted the relative voting influence of Class B shares had there been no conversion. However, since no conversions occurred, the non-dilutable 33 1/3% voting power of Class B shares was preserved, reinforcing the concentrated control mechanism within Comcast’s equity structure.",
      "llm_answer": "The absence of any Class B common‑stock issuances or balance changes in 2024 leaves the existing Class B shares unchanged, preserving the 33 % voting interest they hold and preventing any dilution of that control. At the same time, the company’s substantial repurchases of Class A shares reduce the Class A share count, which modestly lowers the proportion of total equity held by Class A holders but does not alter the voting power ratio between the two classes. Consequently, the equity structure remains heavily weighted toward the Class B shareholders in terms of voting power, while the overall share count and capital distribution are shaped primarily by those Class A buybacks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72342,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18337,
        "completion_tokens": 171,
        "total_tokens": 18508
      }
    },
    {
      "question_id": 17,
      "question": "How does UPS's use of NAV for valuing alternative investments relate to its $2.7 billion in unfunded commitments to private equity and other limited partnerships, and what implications does this have for liquidity management given the redemption restrictions described?",
      "original_answer": "UPS utilizes NAV as a practical expedient to value certain alternative investments, including private equity funds, due to the lack of readily determinable fair values. These investments are not classified within the standard fair value hierarchy (Levels 1–3) and instead are reported separately. On page 93, UPS discloses that it has $2.7 billion in unfunded commitments to limited partnerships, including private equity funds, which are typically subject to long-term investment horizons of 10–15 years with limited redemption provisions. This ties directly to the NAV valuation methodology described on page 94, which acknowledges inherent limitations in valuing such assets and the potential for discrepancies from market-based values. The combination of illiquid commitments and NAV-based valuation suggests that UPS must carefully manage liquidity expectations, as these investments are not easily redeemable and their reported values may not reflect realizable cash flows in the short term.",
      "llm_answer": "UPS values its alternative‑investment holdings (private‑equity, private‑debt, real‑estate and hedge‑fund interests) at fair value using the partnership‑level NAV as a practical expedient, which is disclosed as a Level 3 input in the fair‑value hierarchy.  The company reports $2.7 billion of unfunded commitments to these limited‑partner funds, meaning it must provide additional capital when called.  Because redemptions are subject to multi‑year notice periods and secondary‑market discounts, UPS must carefully manage cash and liquidity to meet these capital calls without disrupting the overall funded status of its pension plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70907,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17967,
        "completion_tokens": 158,
        "total_tokens": 18125
      }
    },
    {
      "question_id": 17,
      "question": "How does Southern Company's credit arrangement structure for Nicor Gas, as a subsidiary with a dedicated $700 million credit allocation under the 2029 agreement, align with its reported notes payable balance of $172 million for Nicor Gas at year-end 2024, and what does this imply about liquidity utilization and debt management strategy?",
      "original_answer": "Southern Company has a $700 million credit allocation under its 2029 credit arrangement specifically for Nicor Gas, indicating a substantial liquidity facility available to support its gas operations. However, as of December 31, 2024, Nicor Gas only had $172 million in outstanding notes payable, suggesting that only a fraction of the allocated credit was utilized. This implies that Southern Company maintains a conservative debt management strategy for Nicor Gas, preserving significant liquidity for future working capital needs or unforeseen financial pressures. The weighted average interest rate on Nicor Gas' notes payable was 4.6% in 2024, which is lower than the 5.5% rate from the prior year, indicating favorable refinancing conditions or improved creditworthiness.",
      "llm_answer": "Southern Company’s 2029 multi‑year credit facility includes a $700 million sub‑limit that is dedicated to Nicor Gas for working‑capital purposes, while Nicor Gas reports a $172 million notes‑payable balance at year‑end 2024. This indicates that only a modest portion of the allocated $700 million is currently drawn, reflecting low utilization of the dedicated liquidity line. Consequently, the company is managing its debt prudently—maintaining ample undrawn capacity under the Nicor Gas facility while keeping short‑term borrowings modest—supporting a conservative liquidity posture and reinforcing its overall debt‑management strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84571,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21401,
        "completion_tokens": 159,
        "total_tokens": 21561
      }
    },
    {
      "question_id": 17,
      "question": "How does Boeing's exposure to cost overruns on the KC-46A Tanker program, as a fixed-price development contract, reconcile with the $402 million additional losses recorded in Q4 2021 and the company's broader risk disclosures regarding U.S. government contract modifications?",
      "original_answer": "Boeing's KC-46A Tanker program, a fixed-price development contract valued at approximately $19 billion as of December 31, 2021, involves significant technical complexity and cost estimation risks. In Q4 2021, Boeing recorded an additional $402 million in losses on the KC-46A contract due to factory disruptions, supply chain issues (including those from the pandemic), and increased costs from evolving customer requirements for the Remote Vision System. This aligns with the broader risk disclosures that highlight how fixed-price contracts, particularly development ones like the KC-46A, expose Boeing to potential losses if cost estimates are exceeded. Furthermore, the company faces risks from U.S. government contract modifications or funding changes, which could exacerbate financial impacts from such cost overruns.",
      "llm_answer": "Boeing recorded an additional $402 million of reach‑forward losses in Q4 2021 on the KC‑46A Tanker program because cost overruns and schedule disruptions on this fixed‑price development contract drove higher estimated costs to complete the contract. This loss is consistent with the company’s broader risk disclosures that U.S. government contracts—especially fixed‑price development contracts—are subject to cost‑overrun risk, funding reductions, and potential termination, which can result in material charges and affect overall financial results.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 51550,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13140,
        "completion_tokens": 137,
        "total_tokens": 13278
      }
    },
    {
      "question_id": 17,
      "question": "How does Southern Company's risk disclosure about cyber intrusions impacting nuclear power plants reconcile with the strategic importance of those plants, which generated 28% of Georgia Power's electricity in 2021?",
      "original_answer": "Southern Company acknowledges in its risk factors that cyber intrusions pose a material threat to the operation of nuclear power plants, which could lead to regulatory fines, operational shutdowns, or increased compliance costs. These risks are particularly relevant to Alabama Power and Georgia Power, which together operate six nuclear units. On the operational side, the document notes that nuclear units managed by Southern Nuclear accounted for 28% of Georgia Power's total KWH generation in 2021, underscoring their strategic and material role in the company’s electricity production. This dual context highlights a tension: while nuclear power plants are a critical asset contributing significantly to the company's energy output, they are also exposed to high-impact risks like cyber threats that could disrupt operations, increase costs, or trigger regulatory scrutiny. The interplay between these perspectives suggests that Southern Company must balance the strategic value of nuclear generation with the growing complexity and cost of securing these facilities against evolving cyber threats.",
      "llm_answer": "Southern Company acknowledges that its nuclear plants—key assets that supplied roughly 28 % of Georgia Power’s electricity in 2021—are exposed to heightened operational and cyber‑security risks, which could trigger fines, shutdowns or costly repairs, yet it continues to rely on these facilities as a major source of generation. This creates a tension between the strategic importance of nuclear generation for the company’s power mix and the disclosed vulnerabilities that could impair its ability to operate those plants safely and economically.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84593,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21378,
        "completion_tokens": 136,
        "total_tokens": 21515
      }
    },
    {
      "question_id": 18,
      "question": "How does Goldman Sachs' inclusion of the countercyclical capital buffer at zero percent within the TLAC to RWAs requirement align with its separate disclosure of CET1 capital ratio requirements that also incorporate this buffer?",
      "original_answer": "Goldman Sachs includes the countercyclical capital buffer, set at zero percent by the FRB, as part of the TLAC to RWAs requirement (18% minimum + 2.5% buffer + 0% countercyclical buffer + 1.5% G-SIB surcharge). Separately, in the capital adequacy section, the CET1 capital ratio requirement explicitly incorporates the same countercyclical buffer, which remains at zero percent, alongside a 6.2% stress capital buffer and 3.0% G-SIB surcharge as of December 2024. This demonstrates regulatory consistency in applying the zero percent countercyclical buffer across both TLAC and CET1 capital frameworks, even as different buffer components (e.g., SCB vs. G-SIB) vary in magnitude and timing.",
      "llm_answer": "Goldman Sachs includes the countercyclical capital buffer in both its TLAC‑to‑RWA calculation and its separate CET1 capital ratio disclosure, but it sets the buffer at 0 % for the TLAC requirement while the same buffer is reflected in the CET1 ratio used for regulatory capital reporting. Consequently, the TLAC ratio relies on the standard regulatory buffers (including the 0 % countercyclical buffer) plus the G‑SIB surcharge, whereas the CET1 ratio explicitly incorporates the buffer as part of the CET1 capital ratio requirement. This alignment ensures that the buffer contributes to both the TLAC compliance metric and the firm’s overall CET1 capital adequacy measurement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 208,
          "pages": [
            206,
            207,
            208,
            209,
            210
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 96414,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24338,
        "completion_tokens": 169,
        "total_tokens": 24508
      }
    },
    {
      "question_id": 18,
      "question": "How does NIKE's $18.5 billion in outstanding foreign currency derivatives relate to its foreign currency adjustment program with third-party factories, and how does this impact the financial exposure of the NIKE Trading Company (NTC) when selling products to NIKE entities with different functional currencies?",
      "original_answer": "NIKE manages its foreign currency risk through a $18.5 billion portfolio of outstanding foreign currency derivatives, which includes both designated cash flow hedges and embedded derivative contracts. A key component of this risk management strategy is the foreign currency adjustment program with third-party factories, under which NIKE assumes certain factory currency exposures that naturally offset its own. This program creates embedded derivative contracts for currencies outside the U.S. Dollar and the factory’s local currency. The NTC, a wholly-owned sourcing hub, purchases products from these factories in U.S. Dollars and then sells them to NIKE entities in their respective functional currencies. This creates a foreign currency exposure for the NTC when selling to NIKE entities with different functional currencies. The interplay between the derivatives, embedded contracts, and NTC’s role in the supply chain illustrates how NIKE structures its financial risk management to mitigate exposure across its global operations.",
      "llm_answer": "NIKE's $18.5 billion of outstanding foreign‑currency derivatives are used primarily to hedge the foreign‑currency exposure created when the NIKE Trading Company (NTC) purchases products from third‑party factories (generally in U.S. dollars) and then sells those products to NIKE entities that have different functional currencies. The hedges—mostly cash‑flow forwards and options—are recorded in Accumulated Other Comprehensive Income until the underlying transaction impacts earnings, at which point the gains or losses are re‑classified into revenue, cost of sales, demand‑creation expense or other income/expense. This program, together with the factory‑currency‑adjustment mechanism, offsets currency movements that would otherwise affect NTC’s inventory costs and the functional‑currency translation of its sales, thereby limiting the financial exposure of NTC when it sells to subsidiaries denominated in other currencies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103844,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26216,
        "completion_tokens": 232,
        "total_tokens": 26448
      }
    },
    {
      "question_id": 18,
      "question": "How does Boeing's increased reach-forward loss on the Commercial Crew program in 2021 relate to the broader financial risks associated with fixed-price development contracts, particularly in light of the technical and cost estimation challenges described in the audit of these contracts?",
      "original_answer": "Boeing's increased reach-forward loss of $185 million on the Commercial Crew program in 2021 reflects the financial risks inherent in fixed-price development contracts, which are subject to significant cost overruns due to technical complexity and evolving customer requirements. This aligns with the broader context from page 19, where Boeing notes that fixed-price contracts—especially development ones—carry the risk of reduced margins or losses if estimated costs exceed projections. The Commercial Crew program, as a fixed-price development contract, is specifically highlighted in the audit section as one of the most complex and uncertain contracts to estimate, requiring specialized audit procedures due to the high degree of judgment and variability in cost projections. The audit process included evaluating management's assumptions, testing data accuracy, and performing retrospective reviews, all of which underscore the difficulty in forecasting costs and the potential for future financial adjustments. Thus, the Commercial Crew loss is not an isolated issue but emblematic of the systemic challenges Boeing faces with fixed-price development programs.",
      "llm_answer": "Boeing’s 2021 increase in the reach‑forward loss on the Commercial Crew contract reflects the broader financial risk inherent in its fixed‑price development programs: because revenue is fixed while cost estimates are highly uncertain, technical and schedule challenges—such as delays in FAA approval, re‑work on the Orbital Flight Test, and supplier performance issues—can force the company to record large reach‑forward losses. The audit of these contracts highlights that estimating costs at completion involves significant judgment and specialized industry expertise, and any mis‑estimation can materially degrade margins or trigger additional losses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 54393,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13853,
        "completion_tokens": 163,
        "total_tokens": 14016
      }
    },
    {
      "question_id": 18,
      "question": "How does Southern Company's short-term debt structure for Nicor Gas in 2024 compare with the broader credit arrangement commitments outlined in the liquidity and capital resources section, particularly regarding the $700 million restricted credit facility expiring in 2029?",
      "original_answer": "Southern Company's Nicor Gas subsidiary had $172 million in notes payable outstanding as of December 31, 2024, with a weighted average interest rate of 4.6%, reflecting its portion of short-term debt within the broader Southern Company Gas segment. This short-term debt is part of a larger liquidity framework where Nicor Gas is the borrower under a $700 million credit arrangement expiring in 2029, specifically restricted for its working capital needs. This arrangement is nested within a $2.45 billion combined credit facility shared with Southern Power, which allows for flexible sublimits between entities. The $172 million in notes payable represents a portion of Nicor Gas’s access to this $700 million allocation, highlighting how Southern Company structures its liquidity to support both operational and working capital requirements across subsidiaries while maintaining compliance with debt covenants limiting total leverage to 70% of capitalization.",
      "llm_answer": "Southern Company’s short‑term debt for Nicor Gas is supported by a $700 million restricted portion of its multi‑year credit facility that expires in 2029, which is part of the broader $6.4 billion committed bank credit arrangements (including $1.85 billion for the parent and $700 million allocated to Nicor Gas) that provide liquidity support for its commercial‑paper program and other working‑capital needs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84571,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21385,
        "completion_tokens": 102,
        "total_tokens": 21487
      }
    },
    {
      "question_id": 19,
      "question": "How does The Goldman Sachs Group, Inc.'s guarantee of Goldman Sachs Bank USA's obligations relate to the stricter 'Category I' regulatory capital standards they are both subject to under U.S. federal banking rules?",
      "original_answer": "The Goldman Sachs Group, Inc. provides a general guarantee for the obligations of Goldman Sachs Bank USA, as noted in the exhibit list on page 248 of the 2024 10-K filing. This financial backing underscores the interconnectedness of the parent company and its subsidiary bank. Goldman Sachs Bank USA, along with the parent company, is subject to 'Category I' standards under the U.S. federal bank regulatory agencies' tailoring framework due to the firm's designation as a global systemically important bank (G-SIB). These Category I standards impose more stringent risk-based capital and liquidity requirements, including quantitative measures of assets, liabilities, and off-balance sheet items, which are calculated under the Basel III framework and tailored by the Dodd-Frank Act. The guarantee from the parent company may serve as a buffer to help ensure that Goldman Sachs Bank USA can meet these heightened capital and liquidity requirements, especially given the qualitative judgments regulators apply in assessing capital sufficiency.",
      "llm_answer": "The Goldman Sachs Group’s guarantee of Goldman Sachs Bank USA’s obligations is consistent with the “Category I” regulatory capital standards that both entities must meet under U.S. federal banking rules. As a designated global systemically important bank (G‑SIB), the firm and GS Bank USA are subject to heightened capital and leverage requirements—including Tier 1 leverage ratios, supplementary leverage buffers, and capital‑conservation buffers—that are calibrated to the stricter Category I framework. This guarantee therefore reinforces the bank’s compliance with those elevated capital standards.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 248,
          "pages": [
            243,
            244,
            245,
            246,
            247
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81079,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20501,
        "completion_tokens": 150,
        "total_tokens": 20652
      }
    },
    {
      "question_id": 19,
      "question": "How does AbbVie's financial exposure to Imbruvica, including its collaboration with Janssen Biotech and the $3.6 billion intangible asset impairment charge, reflect both the strategic benefits and financial risks of co-commercializing a high-profile oncology product?",
      "original_answer": "AbbVie's collaboration with Janssen Biotech for the development and commercialization of Imbruvica involves shared costs and profits, with Janssen covering 60% of development costs and AbbVie 40%. In the U.S., AbbVie is the principal in end-customer sales and shares pre-tax profits and losses equally with Janssen, which is also reflected in AbbVie's cost of products sold. However, despite this cost-sharing structure, AbbVie reported a $3.6 billion intangible asset impairment charge in 2023 primarily related to Imbruvica, among other products, which significantly impacted gross margins. This impairment suggests that the long-term financial outlook for Imbruvica may be deteriorating, potentially outweighing the benefits of shared development and commercialization responsibilities. Thus, while the collaboration reduces direct financial burden, AbbVie still bears significant risk tied to Imbruvica’s market performance.",
      "llm_answer": "AbbVie's financial exposure to Imbruvica—highlighted by its co‑commercialization with Janssen Biotech and a $3.6 billion intangible‑asset impairment charge—underscores both the strategic upside and the financial risk of relying on a high‑profile oncology product. The collaboration provides AbbVie with a 50 % share of U.S. profits and a royalty stream outside the United States, driving significant revenue (e.g., $3.6 billion in 2023), but the product’s declining sales and the impairment of its underlying definite‑lived intangible assets expose the company to downside risk if market demand erodes or regulatory milestones are not met.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2023.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20198,
        "completion_tokens": 159,
        "total_tokens": 20357
      }
    },
    {
      "question_id": 19,
      "question": "How does ConocoPhillips' application of ASC Topic 815 for derivative accounting on physical gas contracts relate to the financial impact of PALNG's interest rate swaps, and what does this imply about the company's overall risk management strategy for LNG joint ventures?",
      "original_answer": "ConocoPhillips applies ASC Topic 815 to account for physical gas contracts at market prices, treating them as derivatives without electing the normal purchases and sales exception. This aligns with the broader use of derivative instruments across its joint ventures, such as PALNG, where interest rate swaps were executed to fix 60% of projected term loans for Phase 1 construction. These swaps were initially accounted for under ASC Topic 815 as cash flow hedges, with fair value changes reported in other comprehensive income. However, in 2024, a portion of these swaps was de-designated, resulting in $35 million of unrealized losses being recognized directly in 'Equity in earnings of affiliates.' Given that COP holds a $1.5 billion equity method investment in PALNG, this shift in hedge accounting suggests a strategic recalibration in managing interest rate exposure for LNG projects, which may reflect broader risk management adjustments across its LNG-focused joint ventures.",
      "llm_answer": "ConocoPhillips applies ASC Topic 815 to its physical gas contracts by treating them as derivatives that are marked‑to‑market and recorded in earnings when settled, while its LNG joint‑venture interest in PALNG uses interest‑rate swaps to hedge floating‑rate debt; the swaps are initially accounted for as cash‑flow hedges (with gains/losses recorded in OCI and later re‑classified to earnings) and, once de‑designated, the resulting fair‑value changes flow through “Equity in earnings of affiliates.” This approach reflects a risk‑management strategy that isolates market‑price exposure in the joint‑venture’s financing structure and hedges a substantial portion of PALNG’s interest‑rate risk, underscoring ConocoPhillips’ broader practice of using derivative instruments and equity‑method investments to mitigate financial and operational risks across its LNG projects.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66900,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16977,
        "completion_tokens": 217,
        "total_tokens": 17194
      }
    },
    {
      "question_id": 19,
      "question": "How does the change in the Netherlands' Innovation Box Tax rate under Dutch Corporate Income Tax Law impact BKNG's effective tax rate in 2023 compared to 2022, and what does this reveal about the company's international tax strategy?",
      "original_answer": "BKNG's effective tax rate for 2023 was lower compared to 2022, partly due to a decrease in the valuation allowance against deferred tax assets and lower international tax rates, although partially offset by a reduced benefit from the Netherlands Innovation Box Tax. The Innovation Box Tax rate increased from 7% to 9% effective January 1, 2021, and the Dutch statutory rate rose from 25% to 25.8% in 2022. Despite this, a portion of Booking.com's earnings still qualified for the Innovation Box Tax treatment, which significantly benefited BKNG’s effective tax rate in both 2022 and 2023. This indicates that BKNG strategically leverages favorable tax regimes in the Netherlands to reduce its global tax burden, even as the benefit from the Innovation Box Tax declined year-over-year.",
      "llm_answer": "The Dutch Innovation Box Tax rate was reduced from 25% to 25.8% in 2022, but the effective tax rate benefit remained significant because a portion of Booking.com's earnings qualified for the lower 9% Innovation Box rate. This contributed to a lower effective tax rate in 2023 (21.8% vs. 22.1% in 2022), reflecting the company's strategic use of favorable Dutch tax treatment for innovative activities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70490,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17859,
        "completion_tokens": 100,
        "total_tokens": 17959
      }
    },
    {
      "question_id": 19,
      "question": "How does AMD's positioning of FPGAs like the Versal series as critical components for hyperscale data centers reconcile with the export restrictions under EAR that limit their shipment to China, and what impact could this have on AMD's revenue forecasts given the importance of international markets?",
      "original_answer": "AMD highlights the Versal FPGAs as key products for hyperscale data centers, particularly in enabling AI workloads and being integrated into servers and appliances for major cloud service providers (page 11). However, the Export Administration Regulations (EAR) now restrict the export of certain Versal FPGAs to China or entities with ultimate parents in Country Groups D1, D4, or D5 without a license or a 25-day NAC notification (page 32). These restrictions could result in shipment delays or outright prohibitions, directly affecting AMD’s ability to serve a major international market. Given that international revenue constitutes a significant portion of AMD’s business and that forecasting shipments has become more uncertain due to the unpredictability of license approvals, these export controls could materially impact AMD’s revenue forecasts and competitive positioning, especially if competitors face less stringent restrictions.",
      "llm_answer": "AMD positions its Versal FPGAs as essential accelerators for hyperscale data‑center workloads, but U.S. export controls (EAR/BIS licensing requirements for China‑linked parties) restrict shipments of certain Versal and Instinct ICs to China and to customers with Chinese‑based parents, forcing AMD to navigate licensing delays or denials. This limitation curtails access to one of the world’s fastest‑growing data‑center markets, pressuring revenue forecasts that previously assumed robust international demand, especially in China, and may compel AMD to adjust its sales outlook downward or seek alternative non‑restricted markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2024.pdf",
          "target_page": 32,
          "pages": [
            30,
            31,
            32,
            33,
            34
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77177,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19546,
        "completion_tokens": 158,
        "total_tokens": 19704
      }
    },
    {
      "question_id": 19,
      "question": "Given that the VAR model excludes forecasted transactions from its risk analysis, how does Disney's use of the VAR model to estimate one-day loss potential reconcile with its active hedging of forecasted foreign currency transactions, which totaled $9.9 billion in notional amounts as of September 28, 2024?",
      "original_answer": "Disney uses the VAR model on page 60 to estimate the maximum potential one-day loss in fair value for its financial instruments, but explicitly excludes forecasted transactions from this analysis. However, on page 121, the company actively hedges forecasted foreign currency transactions, with $9.9 billion in notional amounts of foreign exchange cash flow hedges outstanding as of September 28, 2024. This creates a tension: while the VAR model focuses on realized and current market-sensitive instruments, the hedging strategy anticipates and mitigates risk on future transactions not captured in the VAR framework. The reconciliation lies in recognizing that the VAR model serves as a short-term risk metric under normal market conditions, while the forecasted transaction hedging reflects a longer-term risk management strategy not fully represented in the VAR analysis.",
      "llm_answer": "Disney’s VAR model deliberately omits any exposure tied to forecasted foreign‑currency transactions, yet the company actively hedges those very transactions – it held about $9.9 billion of notional foreign‑exchange contracts as of September 28 2024. Because the VAR calculation excludes those forecasted cash flows, the model’s one‑day loss estimate ($255 million) does not capture the risk that would be mitigated by the hedges; the hedges themselves are designed to offset the earnings impact of those forecasted transactions, so the VAR figure reflects only the risk remaining after those hedges are applied.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67110,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17032,
        "completion_tokens": 152,
        "total_tokens": 17185
      }
    },
    {
      "question_id": 19,
      "question": "How does Boeing's exposure to cost overruns on the KC-46A Tanker program, as a fixed-price development contract, reflect both the capitalized pre-contract costs and the risk of future reach-forward losses outlined in different sections of the 10-K?",
      "original_answer": "Boeing's KC-46A Tanker program, valued at approximately $19 billion as of December 31, 2021, is a fixed-price incentive fee contract with significant technical complexity and cost estimation challenges. As of the same date, Boeing had capitalized $243 million in pre-contract costs, indicating early financial exposure. The contract is also subject to reach-forward losses, as seen in the $402 million additional loss recorded in Q4 2021 due to factory disruptions, supply chain issues, and evolving customer requirements. The company notes that fixed-price development contracts like the KC-46A are inherently uncertain, with cost estimates subject to significant variability, and any future cost overruns could result in material charges. This synthesis reveals a dual risk: upfront financial commitments already made and the ongoing exposure to future losses due to the nature of fixed-price development contracts.",
      "llm_answer": "Boeing’s KC‑46A program is accounted for as a fixed‑price development contract that requires it to capitalize pre‑contract costs and to estimate total costs at completion; if actual costs exceed the fixed price, the company records “reach‑forward” losses.  The 10‑K notes that the company had $243 million of capitalized pre‑contract costs and $409 million of potential termination liabilities for the KC‑46A, and that cost‑type contracts (including the KC‑46A) carry risks of reduced fees, lower profit rates or program cancellation if cost, schedule or technical performance issues arise.  Consequently, the capitalized pre‑contract amounts represent sunk investment that can be written off if the program incurs overruns, while the fixed‑price nature of the contract creates exposure to future reach‑forward losses if the estimated cost to complete exceeds the contract price.  This dual exposure is highlighted in the discussion of fixed‑price contracts and program accounting estimates in the 10‑K.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 51550,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13134,
        "completion_tokens": 250,
        "total_tokens": 13384
      }
    },
    {
      "question_id": 19,
      "question": "How does Mississippi Power Company's status as a subsidiary that does not provide an annual report to its parent company align with its compliance with the reduced disclosure conditions under Form 10-K for the 2024 filing?",
      "original_answer": "Mississippi Power Company, as a subsidiary of The Southern Company, does not prepare or file an annual report with the SEC, indicating a streamlined reporting relationship with its parent company. Despite this, it complies with the reduced disclosure format under General Instructions I(2)(b), (c), and (d) of Form 10-K by meeting the conditions outlined in General Instructions I(1)(a) and (b). This dual status—being exempt from full annual reporting while still adhering to specific SEC disclosure rules—reflects a regulatory alignment that allows for simplified reporting consistent with its operational structure and ownership relationship within the Southern Company group.",
      "llm_answer": "Mississippi Power Company is not required to file an annual report with the SEC because it is a wholly owned subsidiary of The Southern Company and does not provide an annual report to its parent, but it still complies with the reduced disclosure requirements under Form 10-K for its 2024 filing as permitted by General Instructions I(2)(b), (c), and (d).",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 324,
          "pages": [
            319,
            320,
            321,
            322,
            323
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78498,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19857,
        "completion_tokens": 88,
        "total_tokens": 19945
      }
    },
    {
      "question_id": 20,
      "question": "How does the adoption of LDTI, which MetLife implemented in Q1 2023, specifically alter the components of adjusted earnings by removing certain adjustments related to DAC, VOBA, and MRBs, and what operational or financial reporting implications does this have given the updated calculation methodology?",
      "original_answer": "The adoption of LDTI in Q1 2023 materially altered the components of adjusted earnings by simplifying the measurement model for DAC and VOBA and reclassifying most embedded derivatives as MRBs. As a result, MetLife updated its adjusted earnings calculation to exclude amortization adjustments related to DAC, VOBA, and associated intangibles, as well as changes in measurement of certain guarantees. Adjusted earnings now also exclude changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting related to in-force reinsurance. These changes were implemented to align with the new disclosure and measurement requirements under LDTI, which in turn affects how MetLife evaluates performance and allocates resources across its business segments. The operational impact is reflected in the updated internal controls and processes MetLife had to implement to meet the new periodic reporting and balance sheet disclosure requirements under LDTI.",
      "llm_answer": "The adoption of LDTI in Q1 2023 simplified the measurement model for DAC and VOBA and reclassified most embedded derivatives as MRBs, prompting MetLife to update its adjusted‑earnings calculation to exclude amortization of DAC and VOBA and to adjust for changes in the fair value of MRBs, discount‑rate changes on certain annuitization guarantees, inception‑of‑year losses on single‑premium business, and asymmetrical accounting for in‑force reinsurance; consequently, adjusted earnings now reflect only the post‑LDTI components and exclude those prior adjustments. This updated methodology alters the components of adjusted earnings by removing certain DAC, VOBA and MRB‑related adjustments and has operational implications such as revised segment reporting, new economic‑capital model considerations, and updated reconciliations of adjusted earnings to GAAP measures, which are disclosed in the “Financial Measures and Segment Accounting Policies” and “Adjusted earnings” sections of the 10‑K.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 170,
          "pages": [
            168,
            169,
            170,
            171,
            172
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 331,
          "pages": [
            329,
            330,
            331,
            332,
            333
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 85926,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21743,
        "completion_tokens": 248,
        "total_tokens": 21991
      }
    },
    {
      "question_id": 20,
      "question": "How does Microsoft's repeated use of The Bank of New York Mellon Trust Company as trustee in multiple supplemental indentures for specific debt instruments relate to the foundational terms established in the Base Indenture from May 18, 2009, and what does this imply about Microsoft's long-term debt management strategy?",
      "original_answer": "Microsoft has consistently used The Bank of New York Mellon Trust Company (BNY Mellon) as the trustee across multiple supplemental indentures for various debt instruments, including the 1.625% Notes due 2018, 3.625% Notes due 2023, and 4.875% Notes due 2043 (dated December 6, 2013), as well as later issuances such as the 1.100% Notes due 2019 and 3.950% Notes due 2056 (dated August 8, 2016). These supplemental indentures all reference the Base Indenture dated May 18, 2009, which establishes the core legal framework governing Microsoft’s debt obligations. The repeated use of the same trustee and the consistent referencing of the Base Indenture suggest that Microsoft has institutionalized a standardized and centralized debt management structure. This implies a strategic preference for continuity, legal consistency, and administrative efficiency in managing long-term debt instruments across multiple decades of issuance.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon Trust Company as trustee across multiple supplemental indentures—beginning with the foundational Base Indenture of May 18, 2009 (Exhibit 4.1), and extending through numerous amendments like the Twelfth Supplemental Indenture (Exhibit 4.15, filed February 3, 2017) and the Fifteenth Supplemental Indenture (Exhibit 4.18, filed November 6, 2023)—demonstrates a deliberate, long-term strategy to leverage a single, established trustee institution for structuring and managing its senior unsecured debt offerings over time. This approach implies a strategic preference for institutional continuity, operational efficiency, and trust in a proven financial partner to streamline complex debt documentation, ensure regulatory compliance, and facilitate scalable capital-raising across decades, reinforcing Microsoft’s disciplined and enduring debt management framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12842,
        "completion_tokens": 230,
        "total_tokens": 13072
      }
    },
    {
      "question_id": 20,
      "question": "How does the issuance of Cruise Class G Preferred Shares to Microsoft and Walmart in 2021 relate to the earlier issuance of Cruise Class F Preferred Shares in 2019, particularly in terms of capital structure alignment and strategic intent for Cruise Holdings?",
      "original_answer": "The issuance of Cruise Class G Preferred Shares in 2021 to Microsoft, Walmart, and others, including General Motors Holdings LLC with a $1.0 billion investment, builds upon the capital structure established by the 2019 issuance of Cruise Class F Preferred Shares, which included a $687 million investment from General Motors Holdings LLC. Both classes of preferred shares are structured to convert into common stock upon an IPO and provide holders with liquidation preferences and pari passu dividend rights alongside common shareholders. However, the Class G issuance expanded strategic alignment by including external partners like Microsoft, with whom GM entered a long-term strategic relationship to accelerate the commercialization of self-driving vehicles. This indicates that while the Class F shares were foundational in funding Cruise’s operations, the Class G issuance was more explicitly tied to strategic partnerships and broader corporate objectives, reflecting a shift from internal capital infusion to external strategic collaboration.",
      "llm_answer": "The 2021 issuance of $2.7 billion of Cruise Class G Preferred Shares to Microsoft, Walmart and other investors (including $1 billion from GM Holdings) was structured to mirror the earlier 2019 Cruise Class F Preferred Shares issuance, which also raised $1.2 billion (including $687 million from GM Holdings) for working‑capital purposes. Both series are non‑controlling interests that participate pari‑passu in dividends, have voting rights tied to Cruise’s governance, and convert into the IPO‑issued share class at predetermined exchange ratios, but the Class G round adds new strategic partners and a larger capital base while retaining the same capital‑structure alignment and strategic intent of funding Cruise’s autonomous‑vehicle development.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84134,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21271,
        "completion_tokens": 187,
        "total_tokens": 21458
      }
    },
    {
      "question_id": 20,
      "question": "How does Comcast's dividend policy favorability toward Class A common stockholders contrast with the structural voting power and transactional control retained by Class B common stockholders, particularly in light of the non-dilutable 33 1/3% voting threshold?",
      "original_answer": "Comcast's dividend policy, which includes an 8% increase in dividends to $1.08 per share on an annualized basis for Class A common stockholders, signals a favorable financial return for these investors. However, this benefit is contrasted by the structural governance imbalance where Class B common stockholders, who hold a non-dilutable 33 1/3% of the combined voting power, retain outsized control over key corporate decisions. This includes separate approval rights over major transactions such as mergers, asset sales, and amendments to the company’s articles of incorporation, even if such actions are in the broader shareholder interest. This dynamic highlights a tension between financial incentives for the majority of shareholders and the concentrated governance power held by the Class B stockholder, Brian L. Roberts, which could influence strategic direction independently of broader shareholder sentiment.",
      "llm_answer": "Comcast’s dividend policy—consistent quarterly payouts and an 8% increase to $1.08 per share in 2022—offers Class A shareholders a predictable return, yet Class B holders retain a non‑dilutable 33 ⅓% voting stake (15 votes per share) that gives them decisive control over major corporate actions despite owning only a fraction of the equity. This structural voting power means that even though Class A investors benefit from dividend growth, the ultimate governance and decision‑making authority remains concentrated in the hands of the Class B owners.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 51074,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13009,
        "completion_tokens": 138,
        "total_tokens": 13147
      }
    },
    {
      "question_id": 20,
      "question": "How does Honeywell's accounting treatment of the $211 million First Partial Redemption from Garrett's Series B Preferred Stock relate to the company's decision to value the investment based on the present value of mandatory redemptions?",
      "original_answer": "Honeywell initially accounted for the Series B Preferred Stock at fair value based on the present value of mandatory redemptions discounted at 7.25%, as stated on page 90. The Series B Preferred Stock had mandatory redemption terms, including a $35 million redemption in 2022 and $100 million annually from 2023 to 2030, unless certain EBITDA or liquidity conditions prevented it. On page 103, Honeywell received the $211 million First Partial Redemption from Garrett on December 28, 2021, which exceeded the originally scheduled 2022 redemption amount of $35 million. This early redemption suggests that the Series B Preferred Stock's actual redemption schedule deviated from the original mandatory terms, which could impact the accuracy of the present value model used for fair value accounting. The receipt of a larger-than-expected early payment implies that the original discounting model may have understated the investment’s near-term cash flow potential, raising questions about the alignment between the accounting methodology and the realized redemption behavior.",
      "llm_answer": "The Company valued its investment in Garrett’s Series B Preferred Stock using the present value of the mandatory redemptions, discounting the scheduled redemptions at the 7.25 % rate specified in the Series B Preferred Stock Certificate of Designation. This present‑value approach was applied to determine the fair value of the stock at the Effective Date, and the discount will accrete into interest income over the redemption period.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76428,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19345,
        "completion_tokens": 108,
        "total_tokens": 19454
      }
    },
    {
      "question_id": 20,
      "question": "How does the adoption of LDTI, which MetLife implemented in Q1 2023, specifically alter the treatment of DAC, VOBA, and MRBs within the adjusted earnings calculation, and what operational or financial implications does this have for evaluating segment performance?",
      "original_answer": "The adoption of LDTI in Q1 2023 materially changed MetLife’s adjusted earnings calculation by simplifying the measurement model for DAC and VOBA and reclassifying most embedded derivatives as MRBs. As a result, MetLife updated its adjusted earnings methodology to exclude amortization of DAC, VOBA, and related intangibles, as well as adjustments for changes in measurement of certain guarantees. Adjusted earnings now also exclude changes in fair value associated with MRBs, discount rate changes on annuitization guarantees, and asymmetrical accounting related to in-force reinsurance. These changes were implemented to align with new disclosure and estimation requirements under LDTI, which affect how segment performance is evaluated. The operational implication is that segment results now reflect a more streamlined accounting treatment that removes certain market-driven volatility and non-economic accounting distortions, allowing management to focus on core business trends.",
      "llm_answer": "The adoption of LDTI, implemented in Q1 2023, simplifies the measurement of DAC and VOBA and reclassifies most embedded derivatives as Market Risk Benefits (MRBs). Consequently, adjusted earnings now excludes amortization of DAC/VOBA, changes in MRB fair value, discount‑rate adjustments on certain annuity guarantees, and asymmetrical accounting for in‑force reinsurance, while still reflecting the same segment‑level profitability drivers. This shift alters the composition of adjusted earnings for each segment, requiring analysts to evaluate segment performance using the updated adjusted‑earnings definition rather than the prior DAC/VOBA‑based metrics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 170,
          "pages": [
            168,
            169,
            170,
            171,
            172
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 331,
          "pages": [
            329,
            330,
            331,
            332,
            333
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 85926,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21733,
        "completion_tokens": 164,
        "total_tokens": 21898
      }
    },
    {
      "question_id": 20,
      "question": "How does ConocoPhillips' production of condensate from the Aasta Hansteen Field relate to its financial exposure through guarantees tied to Alba Plant LLC in Equatorial Guinea?",
      "original_answer": "ConocoPhillips produces condensate from the Aasta Hansteen Field in the Norwegian Sea, which is transported via shuttle tankers to market. This condensate production is part of COP’s broader upstream operations. In addition to this, COP owns a 52.2% interest in Alba Plant LLC, which processes natural gas from the Alba Unit offshore Equatorial Guinea, extracting condensate and LPG for sale at market prices. The company has financial exposure tied to Alba Plant LLC through guarantees, including a $116 million maximum potential future payment obligation related to agreements to process third-party gas. Therefore, while condensate from Aasta Hansteen contributes to COP’s direct hydrocarbon production and revenue, the company also faces contingent liabilities through its ownership in Alba Plant LLC, which processes both Alba Unit and third-party gas, linking upstream production with downstream financial risk.",
      "llm_answer": "ConocoPhillips’ equity‑method investment in Alba Plant LLC—its joint venture in Equatorial Guinea that processes gas from the Alba Unit—exposes the company to financial risk through the guarantees it provides for the venture’s performance and residual‑value obligations. These guarantees, which can require up to roughly $116 million in future payments, are tied to the plant’s operations and to the overall Alba Unit production, meaning that any shortfall or under‑performance could trigger ConocoPhillips’ liability under the guarantees. Consequently, the company’s financial exposure to the Alba Plant LLC is directly linked to its ownership stake and the guarantees it has extended for that joint venture.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56148,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14261,
        "completion_tokens": 177,
        "total_tokens": 14438
      }
    },
    {
      "question_id": 21,
      "question": "What is the relationship between PepsiCo's beverage revenue contribution in APAC and its acquisition or divestiture activity in the same region during fiscal year 2023?",
      "original_answer": "In fiscal year 2023, beverages contributed 23% of PepsiCo's net revenue in the APAC region, as shown in the regional net revenue breakdown. However, the company disclosed $0 in acquisition and divestiture-related charges specifically for the APAC region during the same fiscal year. This indicates that despite a notable portion of revenue coming from beverages in APAC, PepsiCo did not engage in any significant M&A activity in the region during 2023, suggesting a period of operational stability rather than expansion through acquisitions in that geography.",
      "llm_answer": "Based on the provided SEC 10-K pages, PepsiCo's APAC beverage revenue contribution is not explicitly stated as a standalone figure. However, the document indicates that APAC's beverage revenue accounted for 23% of its total net revenue in 2023 (page 72), and the region's total net revenue was $4,803 million (page 71). Regarding acquisition/divestiture activity in APAC during FY2023, the document shows no specific acquisition or divestiture charges related to APAC in the \"Acquisition and Divestiture-Related Charges\" table (page 112), which lists charges by division (FLNA, PBNA, Europe, AMESA, APAC, Corporate). The only APAC-related charges mentioned are impairment charges of $59 million in 2023 (page 74), but these were related to intangible assets (Be & Cheery brand) and not tied to a specific acquisition or divestiture transaction. The document also notes that APAC had no material acquisition/divestiture-related charges in 2023 (page 112, \"Total acquisition and divestiture-related charges\" row for APAC shows $0). Thus, while APAC's beverage revenue contributed significantly to overall revenue, there was no notable acquisition or divestiture activity in the region during FY2023 that impacted results.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2023.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2023.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2023.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62890,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15943,
        "completion_tokens": 304,
        "total_tokens": 16247
      }
    },
    {
      "question_id": 21,
      "question": "How does Amgen's decision to terminate Novartis' U.S. commercialization rights for Aimovig in early 2022 relate to its competitive positioning against Novartis' Cosentyx in the U.S. and Europe, particularly in the context of their ongoing global development cost-sharing arrangement?",
      "original_answer": "Amgen's decision to end Novartis' U.S. commercialization rights for Aimovig in early 2022 severed the joint U.S. marketing arrangement, removing Novartis' ability to share in U.S. costs and profits or receive royalties on U.S. sales. However, Novartis retained global co-development rights and continued to share development expenses with Amgen. At the same time, Novartis' Cosentyx is listed in Amgen's 10-K as a direct competitor to Amgen's Otezla in both the U.S. and Europe. This dual relationship—where Novartis is both a collaborator on Aimovig's global development and a competitor through Cosentyx—creates a complex dynamic. Amgen's restructuring of the Aimovig partnership may reflect a strategic effort to reduce Novartis' influence in the U.S. market while still leveraging shared R&D resources globally, even as Cosentyx competes directly with Amgen's dermatology portfolio.",
      "llm_answer": "Amgen terminated Novartis’ U.S. commercialization rights for Aimovig in early 2022 to eliminate the need to share U.S. sales, costs and royalties under their collaboration, thereby allowing Amgen to capture the full U.S. market and avoid competitive pressure from Novartis’ separate migraine drug Cosentyx in both the United States and Europe, while still retaining the global development cost‑sharing arrangement for non‑U.S. territories.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62110,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15779,
        "completion_tokens": 109,
        "total_tokens": 15889
      }
    },
    {
      "question_id": 21,
      "question": "How does ConocoPhillips' impairment of its APLNG investment in 2021 relate to its equity stake in the joint venture and the fair value assessment tied to the Origin Energy transaction?",
      "original_answer": "ConocoPhillips held a 37.5% equity stake in APLNG, which operates in Queensland, Australia, and focuses on producing coal bed methane (CBM) and exporting LNG. In 2021, Origin Energy agreed to sell 10% of its interest in APLNG for $1.645 billion. ConocoPhillips exercised its preemption right to acquire this additional 10% stake, which triggered a fair value assessment. This observable market-based valuation was lower than the carrying value of ConocoPhillips’ existing investment, leading to a noncash impairment charge of $688 million. This impairment reflects the decline in fair value deemed to be other than temporary, reducing the carrying value of the investment to $5,574 million as of December 31, 2021. The impairment decision was directly influenced by the fair value derived from the Origin Energy transaction, illustrating how equity investment decisions and market-based valuations can drive financial impairments.",
      "llm_answer": "ConocoPhillips recorded a $688 million pre‑tax impairment of its APLNG equity investment in Q4 2021 because Origin Energy’s agreed price for its 10 % stake ($1.645 billion) reflected a market‑based fair value that was below the carrying amount of ConocoPhillips’ existing 37.5 % stake. The impairment reduced the carrying value of the investment to $5.574 billion and was recognized under the equity‑method accounting guidance (FASB ASC 323) as an other‑than‑temporary decline. This fair‑value assessment was tied to the Origin Energy transaction, which provided the observable market participant view of APLNG’s fair value that triggered the write‑down.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65860,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16691,
        "completion_tokens": 163,
        "total_tokens": 16854
      }
    },
    {
      "question_id": 21,
      "question": "How does the change in the Netherlands Innovation Box Tax rate from 7% to 9% in 2021, and the corresponding impact on Booking.com's effective tax rate in 2023, reconcile with the company's overall valuation allowance adjustments and international tax exposure under Dutch corporate income tax law?",
      "original_answer": "The Netherlands Innovation Box Tax rate increased from 7% to 9% effective January 1, 2021, which is reflected in the company's effective tax rate for 2023. This lower rate applied to qualifying innovative activities by Booking.com and had a beneficial impact on the effective tax rate, although the benefit decreased compared to prior years. On page 49, the company notes that the 2023 effective tax rate was partially offset by a decrease in the Innovation Box Tax benefit. Meanwhile, page 105 shows that the valuation allowance on deferred tax assets related to international operations decreased from $29 million in 2022 to $30 million in 2023, indicating a relatively stable international tax position despite the rate change. The Dutch corporate income tax law, which governs the Innovation Box Tax, thus influences both the effective tax rate and the deferred tax asset valuation allowances, reflecting a nuanced interaction between tax incentives and tax asset risk.",
      "llm_answer": "The 2021 Dutch Innovation Box Tax rate increase from 7% to 9% reduced the tax benefit for Booking.com’s qualifying innovative income, contributing to a lower effective tax rate in 2023 compared to 2022, as reflected in the $544 million Innovation Box Tax benefit recorded in 2023 (down from $452 million in 2022). This reduction, combined with a lower valuation allowance on deferred tax assets, partially offset the impact of higher international tax rates and non-deductible expenses, resulting in an effective tax rate of 21.8% in 2023 versus 22.1% in 2022. The company maintains that the Netherlands Innovation Box Tax treatment remains beneficial but acknowledges risks to its continuation under Dutch tax law.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72049,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18270,
        "completion_tokens": 178,
        "total_tokens": 18449
      }
    },
    {
      "question_id": 21,
      "question": "How does the indefinite delay of the final foreign tax credit regulations through Notice 2023-80 impact Microsoft's effective tax rate in fiscal year 2024, and how does this compare to the tax benefits derived from earnings in lower-taxed foreign jurisdictions?",
      "original_answer": "The indefinite delay of the final foreign tax credit regulations through Notice 2023-80 resulted in a tax benefit that contributed to a 1 percentage point decrease in Microsoft's effective tax rate from 19% in fiscal year 2023 to 18% in fiscal year 2024. This benefit was part of broader tax law changes that allowed Microsoft to continue benefiting from earnings in lower-taxed foreign jurisdictions, particularly Ireland, which accounted for 83% of foreign income before tax in fiscal year 2024. While the foreign regional operating center strategy remained a consistent driver of lower effective tax rates across both years, the regulatory delay provided additional near-term tax relief that would have otherwise been constrained under the original regulation timeline.",
      "llm_answer": "The indefinite delay of final foreign tax credit regulations through Notice 2023‑80 provides Microsoft with additional tax benefits that lower its effective tax rate in fiscal 2024, as noted in the “Effective Tax Rate” reconciliation where tax benefits from these notices are cited as a key factor reducing the rate. This benefit is separate from, and additive to, the regular tax advantage Microsoft gains from earnings taxed at lower rates in foreign jurisdictions (primarily through its Irish regional operations), which also contributes to the lower effective tax rate but does not directly affect the timing of the foreign tax credit regulations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 58172,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14785,
        "completion_tokens": 162,
        "total_tokens": 14948
      }
    },
    {
      "question_id": 21,
      "question": "How does Duke Energy's use of storm recovery bonds to finance $1 billion in storm-related regulatory assets relate to the company's strategic alignment with North Carolina House Bill 951's clean energy transition goals?",
      "original_answer": "Duke Energy created special purpose subsidiaries (DECNCSF and DEPNCSF) to issue $1.007 billion in storm recovery bonds to finance unrecovered regulatory assets from storms in 2018 and 2019, with the storm recovery property established under state legislation and NCUC financing orders. This financial mechanism allowed Duke Energy Carolinas and Progress to recover storm costs through non-bypassable customer charges. Meanwhile, North Carolina House Bill 951, signed into law in October 2021, established a policy framework to accelerate the clean energy transition, including a 70% carbon reduction target by 2030 and carbon neutrality by 2050. The legislation also introduced modernized recovery mechanisms like multiyear rate plans. By using storm recovery bonds, Duke Energy was able to manage legacy storm costs while simultaneously aligning with the new legislative framework that supports long-term clean energy investments and efficient cost recovery, ensuring continued financial stability and regulatory alignment during its transition to a low-carbon future.",
      "llm_answer": "Duke Energy's issuance of storm recovery bonds to finance $1 billion of storm‑related regulatory assets aligns directly with the objectives of North Carolina House Bill 951, which seeks to accelerate the state’s clean‑energy transition through modernized, least‑cost planning and multiyear rate‑recovery mechanisms. By using these bonds, Duke Energy can recover storm costs more quickly and without rate‑payer impact, supporting the legislation’s goal of enabling timely investment in cleaner, more resilient infrastructure while maintaining affordability and reliability for North Carolina customers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 202,
          "pages": [
            200,
            201,
            202,
            203,
            204
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 202,
          "pages": [
            200,
            201,
            202,
            203,
            204
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 95830,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24190,
        "completion_tokens": 150,
        "total_tokens": 24341
      }
    },
    {
      "question_id": 21,
      "question": "How does Gilead's revenue share from Symtuza, which is manufactured and commercialized by Janssen, reflect in both the product sales reporting and the collaborative agreement terms with Janssen?",
      "original_answer": "Gilead's revenue share from Symtuza, which is manufactured and commercialized by Janssen, is reported in Gilead's product sales section as $592 million in total revenues for Symtuza in 2024. This revenue share is determined by the financial provisions of the collaboration agreement, where Janssen sets the price of Symtuza and the parties share revenue based on the ratio of the net selling prices of their respective components. Gilead recognizes its share of Symtuza revenue in the period when Janssen's sales occur, primarily because Gilead supplies the Gilead Compounds used in Symtuza. This arrangement highlights how the quantitative revenue reporting in the product sales section is directly influenced by the qualitative terms of the Janssen collaboration agreement, particularly regarding revenue recognition and supply obligations.",
      "llm_answer": "Gilead records its share of Symtuza revenue as product sales on its Consolidated Statements of Operations, recognizing it in the period when Janssen’s sales of Symtuza occur; this revenue share is derived from the ratio of net selling prices of the Janssen‑originated darunavir component to Gilead’s supplied cobicistat/emtricitabine/tenofovir alafenamide components, subject to agreed adjustments. The collaboration agreement with Janssen also includes revenue‑sharing terms that dictate how the net sales of Symtuza are split between the parties, and these terms are reflected in both the product‑sales line item and the underlying collaborative‑agreement financial provisions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89580,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22622,
        "completion_tokens": 169,
        "total_tokens": 22791
      }
    },
    {
      "question_id": 21,
      "question": "How does Georgia Power's request to extend the operation of Plant Scherer Unit 3 through at least December 31, 2035, relate to FP&L's 25% ownership stake in the unit, and what implications does this have for Southern Company's long-term asset management strategy as outlined in the joint ownership agreements?",
      "original_answer": "Georgia Power has requested to extend the operation of Plant Scherer Unit 3 through at least December 31, 2035, as part of its 2025 Integrated Resource Plan filing with the Georgia PSC. This request indicates a strategic decision to maintain and potentially upgrade the unit for long-term reliability and compliance. FP&L holds a 25% ownership stake in Plant Scherer Unit 3, which aligns with Southern Company's broader joint ownership model where Georgia Power operates the plant on behalf of co-owners, including FP&L. This shared ownership structure, detailed in the joint facility agreements, implies that Georgia Power's operational decisions—such as extending the life of the unit—will impact all stakeholders, including FP&L. The long-term asset management strategy of Southern Company, therefore, must account for both regulatory approvals and the coordination of capital investments across co-owned assets to ensure alignment with compliance requirements and stakeholder interests.",
      "llm_answer": "Georgia Power’s request to extend Plant Scherer Unit 3 through at least December 31, 2035 is made possible because, as a 75 % owner of the unit, it can exercise the same long‑term operating and cost‑recovery rights granted to the other co‑owners under the joint‑ownership agreements. This extension aligns with the strategy outlined in the 2025 Integrated Resource Plan, which seeks to maintain and upgrade existing baseload assets—including coal‑ and gas‑fired units—well beyond their original economic life to ensure resource adequacy, meet regulatory commitments, and support the company’s long‑term asset management objectives. Consequently, the move reinforces Southern Company’s broader plan to preserve high‑value, dispatchable generation capacity while it continues to pursue new renewable and storage projects to meet future demand.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79477,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20129,
        "completion_tokens": 210,
        "total_tokens": 20340
      }
    },
    {
      "question_id": 22,
      "question": "How does BMY's legal partnership with Pfizer to defend Eliquis' patents in the U.S. and Europe align with the company's expressed risk regarding potential early generic entry of Eliquis and its impact on market exclusivity projections through 2026?",
      "original_answer": "BMY collaborates with Pfizer to litigate and defend Eliquis' patents in both the U.S. and Europe, as seen in the multiple lawsuits filed against generic challengers like Sandoz and Teva, and the successful U.S. court rulings affirming the validity of Eliquis' composition of matter and formulation patents through 2026. Despite these legal victories, BMY acknowledges in its risk factors that adverse litigation outcomes in Europe could still allow early generic entry of apixaban products before the estimated market exclusivity date, which would negatively affect revenue and market position. This creates a nuanced picture where, although BMY and Pfizer have secured strong legal wins in the U.S., the company remains exposed to risks in Europe that could undermine its exclusivity projections and financial planning tied to Eliquis.",
      "llm_answer": "BMY's legal partnership with Pfizer to defend Eliquis' patents in the U.S. and Europe directly addresses its expressed risk of early generic entry by securing the product's market exclusivity through 2026, thereby mitigating the potential revenue decline from generic competition that could otherwise materialize if patent protections were weakened or invalidated. This collaboration ensures continued exclusivity for Eliquis, aligning with BMY's risk assessment that loss of exclusivity would significantly impact revenues.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 157,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 11,
        "total_chars": 59057,
        "num_window_pages": 11,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15011,
        "completion_tokens": 131,
        "total_tokens": 15142
      }
    },
    {
      "question_id": 22,
      "question": "How does the involvement of DeGolyer and MacNaughton in reviewing over 85% of ConocoPhillips' proved reserves estimation processes align with their role as a third-party consultant whose report is included as Exhibit 99 in the 10-K filing?",
      "original_answer": "ConocoPhillips' internal reserves estimation processes are reviewed annually by an internal team that includes a senior representative from DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm. During 2024, D&M reviewed the processes and controls used to assess over 85% of the company’s proved reserves as of December 31, 2024, to ensure compliance with SEC regulations. Their role was to provide independent validation of the company’s internal controls and estimation methods, which included reviewing seismic data, geologic maps, well logs, production tests, and reservoir simulation models. D&M’s findings were compiled into a formal report, which was included as Exhibit 99 in the 10-K filing. This demonstrates that D&M's role extended beyond advisory input to formal documentation that supports the company’s regulatory disclosures, reinforcing the credibility of the reserves estimation process through third-party validation.",
      "llm_answer": "The involvement of DeGolyer and MacNaughton (D&M) as a senior representative on the internal team that reviews and validates ConocoPhillips' reserves processes and controls—specifically noting that D&M’s independent review of over 85% of proved reserves was conducted to provide objective third‑party input and that D&M’s report is filed as Exhibit 99—directly aligns with its role as a third‑party consultant whose review supports the credibility of the reserves estimation process disclosed in the 10‑K. This demonstrates that D&M’s participation is not merely advisory but is integral to the company’s internal control framework for reserves reporting, reinforcing the external validation of its proved reserves estimates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78046,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19751,
        "completion_tokens": 181,
        "total_tokens": 19932
      }
    },
    {
      "question_id": 22,
      "question": "How does the $18.5 billion in outstanding foreign currency derivatives designated as cash flow hedges relate to the NTC's role in sourcing from third-party factories, and how does this hedging strategy affect the foreign currency exposure created by NTC's sales to NIKE entities with different functional currencies?",
      "original_answer": "The $18.5 billion in outstanding foreign currency derivatives designated as cash flow hedges (from page 85) is directly tied to NIKE’s strategy to manage foreign currency risk associated with product cost exposures, including those generated through the NTC (page 84). The NTC, a wholly-owned sourcing hub, purchases NIKE-branded products from third-party factories in U.S. Dollars and then sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure for the NTC when those entities have different functional currencies (from page 84 and page 46). This exposure is managed through NIKE’s foreign currency adjustment program and the use of derivatives, including embedded derivatives and formally designated cash flow hedges (from page 85). The $18.5 billion hedge portfolio is intended to offset the variability in cash flows caused by these exposures, particularly those stemming from the NTC’s intercompany sales and the fluctuating costs due to foreign exchange rates. This integrated approach reflects how NIKE uses financial instruments to stabilize the economic impact of currency fluctuations across its global supply chain structure.",
      "llm_answer": "The $18.5 billion of foreign‑currency derivatives that Nike designates as cash‑flow hedges are used to offset the foreign‑currency exposure that arises when the NIKE Trading Company (NTC) sells products to its own subsidiaries whose functional currencies differ from the U.S. dollar. Because the NTC’s sales are priced in the subsidiary’s functional currency, any movement in that currency creates a cash‑flow exposure for the NTC that is hedged through the cash‑flow derivatives. At the same time, the same hedging program also mitigates the foreign‑currency risk created when Nike entities with non‑U.S‑dollar functional currencies sell products to other Nike entities or when those entities purchase from third‑party factories in U.S. dollars. The cash‑flow hedge program therefore reduces the net foreign‑currency exposure that would otherwise be generated by NTC’s intercompany sales and by the broader portfolio of cross‑currency transactions, allowing the resulting gains or losses in accumulated other comprehensive income to be re‑classified into net income as the underlying hedged transactions settle.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103844,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26218,
        "completion_tokens": 278,
        "total_tokens": 26496
      }
    },
    {
      "question_id": 22,
      "question": "How does the foreign currency exposure arising from NKE's transactions through the NTC compare with the exposure from direct purchases by NKE entities from third-party factories, particularly in light of the embedded derivative contracts tied to the factory currency exposure index?",
      "original_answer": "The NTC, as a wholly-owned sourcing hub, purchases NIKE-branded products from third-party factories in U.S. Dollars and sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure for the NTC when it sells to entities with different functional currencies. In contrast, when NKE entities purchase directly from third-party factories in U.S. Dollars, the foreign currency exposure falls on those NKE entities if their functional currency is not the U.S. Dollar. Additionally, the foreign currency adjustment program with certain factories introduces embedded derivative contracts for currencies within the factory currency exposure index that are neither the U.S. Dollar nor the local or functional currency of the factory. As of May 31, 2022, the total notional amount of embedded derivatives outstanding was approximately $584 million, which includes these contracts. This highlights a layered exposure structure where NKE manages risk both through internal sourcing (NTC) and direct factory relationships, with different accounting treatments and hedging strategies applied depending on the transaction structure and currency involved.",
      "llm_answer": "The foreign currency exposure arising from NKE's transactions through the NIKE Trading Company (NTC) is offset by the embedded derivative contracts tied to the factory currency exposure index, which are recorded at fair value through Other (income) expense, net. This contrasts with direct purchases by NKE entities from third‑party factories, where foreign‑currency risk is managed primarily through cash‑flow hedges of the underlying product‑cost exposures, with any remaining risk reflected in earnings as part of Other (income) expense, net.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 95815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24201,
        "completion_tokens": 136,
        "total_tokens": 24337
      }
    },
    {
      "question_id": 22,
      "question": "How does Microsoft's continued partnership with BNY Mellon as trustee, despite the maturity of the 2.95% Notes due in 2014, reflect on the long-term structural reliance on the same trustee across multiple debt issuances?",
      "original_answer": "Microsoft's 2.95% Notes due in 2014 were governed under a First Supplemental Indenture with BNY Mellon Trust Company, N.A., as trustee, dated May 18, 2009. Despite the maturity of these notes, Microsoft continued to partner with BNY Mellon as trustee for subsequent debt issuances, including notes due in 2018, 2023, and 2043, as evidenced by the Eighth Supplemental Indenture dated December 6, 2013. This demonstrates a consistent reliance on BNY Mellon as a trusted intermediary, even after the 2014 notes matured, suggesting a strategic and ongoing partnership rather than a one-time transactional relationship.",
      "llm_answer": "Microsoft's continued use of BNY Mellon as trustee across multiple debt issuances—including the original 2.95% Notes due 2014 and subsequent supplemental indentures through 2023—demonstrates a deliberate, long-term structural reliance on the same trustee for its securitized debt, reflecting institutional continuity in its financing architecture despite the maturity of earlier tranches.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12817,
        "completion_tokens": 97,
        "total_tokens": 12914
      }
    },
    {
      "question_id": 22,
      "question": "How does the UPS Retirement Plan's cessation of future benefit accruals for non-union participants as of January 1, 2023, interact with the IRS-prescribed limits on tax-qualified defined benefit plans, and how does this affect the structure of retirement contributions for employees hired after 2025?",
      "original_answer": "The UPS Retirement Plan ceased future benefit accruals for non-union participants effective January 1, 2023, due to IRS-prescribed limits on tax-qualified defined benefit plans, which cap both compensation and annual benefit amounts. In response, UPS transitioned non-union employees to a defined contribution model under the UPS 401(k) Savings Plan, with contributions ranging from 5% to 8% of eligible compensation based on years of vesting service prior to 2025, and a flat 3% contribution for employees hired on or after January 1, 2025. This shift reflects a strategic realignment of retirement benefits to remain within IRS limits while maintaining competitive retirement benefits through a more flexible and cost-controlled defined contribution framework.",
      "llm_answer": "The UPS Retirement Plan stopped accruing new benefits for non‑union participants as of January 1 2023, which brings its benefit structure into compliance with the IRS‑prescribed maximum compensation and benefit limits for tax‑qualified defined‑benefit plans. Consequently, employees hired on or after January 1 2025 will no longer receive any accrual under the traditional UPS Retirement Plan; instead they will be eligible only for the defined‑contribution contributions outlined in the UPS 401(k) Savings Plan (a fixed 3 % of eligible compensation beginning in 2025). This shift replaces the defined‑benefit accrual with a contribution that is subject to the IRS limits applicable to tax‑qualified defined‑contribution plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64966,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16489,
        "completion_tokens": 181,
        "total_tokens": 16671
      }
    },
    {
      "question_id": 22,
      "question": "How does BMY's legal partnership with Pfizer to defend Eliquis' patents in the U.S. and Europe relate to the risk that generic competition poses to Eliquis' market exclusivity and future revenue projections?",
      "original_answer": "BMY, in partnership with Pfizer, has actively defended Eliquis' patents in both the U.S. and Europe, securing favorable court decisions that upheld the composition of matter and formulation patents through 2026 in the U.S. However, in Europe, multiple lawsuits have been filed by Sandoz and Teva, among others, challenging the validity of the apixaban composition of matter patent, with trials and legal proceedings ongoing or pending in several countries. Despite these legal defenses, BMY acknowledges in its risk factors that generic competition could still emerge earlier than expected, particularly if adverse litigation outcomes occur in the EU, which could undermine the exclusivity timeline and negatively impact future revenue projections tied to Eliquis. The company’s financial guidance assumes a certain exclusivity period, and any disruption from generic entry would have a material effect on Eliquis' profitability, especially given that Pfizer shares in the development costs and global profits of the drug.",
      "llm_answer": "BMY's legal partnership with Pfizer to defend Eliquis patents in the U.S. and Europe is directly tied to the risk of generic competition eroding Eliquis' market exclusivity and future revenue. The document states that \"market exclusivity for our products is based upon patent rights\" and that \"generic and biosimilar product manufacturers...are increasingly seeking to challenge patents before they expire,\" with \"patents covering our key products...subject to validity, enforceability and infringement challenges.\" While the partnership itself isn't explicitly detailed in the provided pages, the context of Eliquis' patent protection is clear: the company acknowledges that \"in some countries...patent protection is significantly weaker than in the United States or in the EU\" and that \"we could face earlier-than-expected competition for any products at any time.\" The partnership with Pfizer is positioned as a strategy to protect Eliquis' patent portfolio against such challenges, but the inherent risk remains that generic competitors could launch before patent expiration, as seen with Revlimid in Europe (\"we expect generic entry for Revlimid in the United Kingdom beginning on January 18, 2022\"). This directly threatens Eliquis' revenue, as the document emphasizes that \"the majority of an innovative product's commercial value is realized during its market exclusivity period\" and that \"when market exclusivity expires and generic versions are approved...there are usually very substantial and rapid declines in a product's revenues.\" The partnership's purpose is to delay this outcome, but the underlying vulnerability to generic competition remains a material risk to future revenue projections.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 157,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 11,
        "total_chars": 59057,
        "num_window_pages": 11,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15000,
        "completion_tokens": 427,
        "total_tokens": 15427
      }
    },
    {
      "question_id": 22,
      "question": "How does Honeywell's valuation methodology for its investment in Garrett's Series B Preferred Stock reflect the mandatory redemption terms and partial redemptions executed in 2021 and early 2022?",
      "original_answer": "Honeywell initially valued the Series B Preferred Stock at fair value based on the present value of mandatory redemptions totaling $835 million (including $35 million in 2022 and $100 million annually from 2023 to 2030), discounted at 7.25%. However, Garrett executed a First Partial Redemption of $211 million on December 28, 2021, and planned a Second Partial Redemption of $200 million in Q1 2022, which altered the future redemption schedule and reduced the present value of remaining mandatory redemptions to $400 million after the First Partial Redemption and $207 million after the Second. Honeywell adjusted its valuation accordingly, reflecting the impact of these redemptions on the investment's fair value and interest income accretion over time.",
      "llm_answer": "Honeywell’s valuation of its investment in Garrett’s Series B Preferred Stock is based on the present value of the stock’s mandatory redemption schedule, discounted at the 7.25 % rate specified in the Certificate of Designation. The present‑value approach incorporates the scheduled redemptions of $35 million in 2022 and $100 million per year from 2023‑2030, adjusted for the partial redemptions executed in December 2021 (the $211 million First Partial Redemption) and the contingent Second Partial Redemption planned for early 2022. This methodology reflects the mandatory redemption terms and the effect of the partial redemptions on the fair‑value measurement of the investment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76428,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19335,
        "completion_tokens": 170,
        "total_tokens": 19506
      }
    },
    {
      "question_id": 22,
      "question": "How does the $177 million in storm recovery bonds issued by Duke Energy Progress in April 2024 relate to the formation and consolidation of DEPNC SF, and what does this imply about Duke Energy Progress' strategy for financing long-term storm-related regulatory assets?",
      "original_answer": "The $177 million in storm recovery bonds issued by Duke Energy Progress in April 2024 was facilitated through its special-purpose subsidiary, DEPSC SF, which is part of a broader structure that includes DEPNC SF. DEPNC SF was formed in 2021 and is consolidated by Duke Energy Progress as a VIE, due to its insufficient equity capitalization and Duke's control over its operations. This structure allows Duke Energy Progress to finance long-term storm-related regulatory assets—specifically, those incurred from 2014 through 2022—by securitizing them and collecting non-bypassable charges from retail customers over time. The use of VIEs like DEPNC SF and DEPSC SF enables Duke Energy Progress to isolate these assets and liabilities from its broader balance sheet, securing debt financing without recourse to the parent company. This reflects a strategic approach to managing regulatory assets and aligning storm cost recovery with long-term customer-funded mechanisms.",
      "llm_answer": "The $177 million of storm‑recovery bonds issued by Duke Energy Progress in April 2024 were created by the newly formed special‑purpose subsidiary DEPNC SF to finance the unrecovered storm‑related regulatory assets that had accumulated in North Carolina and South Carolina.  By issuing these bonds, DEPNC SF provided a dedicated, securitized financing vehicle for those storm costs, allowing Duke Energy Progress to recover the assets through a non‑bypassable charge to customers and to treat the proceeds as long‑term financing rather than as operating expense.  This reflects Duke Energy Progress’s strategy of using long‑term, regulated financing mechanisms—such as securitization and dedicated regulatory‑asset recovery—to fund future storm‑related regulatory assets and to keep such costs off the rate base, thereby preserving rate stability while ensuring recovery of the incurred storm expenses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103951,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26234,
        "completion_tokens": 225,
        "total_tokens": 26459
      }
    },
    {
      "question_id": 23,
      "question": "How does Altria's acquisition of NJOY for $2.9 billion align with its strategic positioning of e-vapor products as a key component of its 'Moving Beyond Smoking' vision, particularly given NJOY's role as the only e-vapor manufacturer with FDA-authorized pod-based products?",
      "original_answer": "Altria's acquisition of NJOY for $2.9 billion demonstrates a strategic commitment to expanding its portfolio of reduced-risk products, directly supporting its 'Moving Beyond Smoking' vision. NJOY, as the only e-vapor manufacturer with FDA-authorized pod-based e-vapor products, provides Altria with a credible and regulated pathway to transition adult smokers away from combustible products. This aligns with Altria's broader positioning in its business description (page 4) that emphasizes leading the transition to a smoke-free future. The acquisition, detailed in the financial statements (page 60), reflects a significant investment in e-vapor innovation and regulatory compliance, reinforcing the company’s strategic narrative of responsible leadership in tobacco harm reduction.",
      "llm_answer": "Altria's $2.9 billion acquisition of NJOY is positioned as a strategic step to accelerate its \"Moving Beyond Smoking\" vision, leveraging NJOY's unique status as the only e‑vapor manufacturer with FDA‑authorized pod‑based products to expand Altria’s smoke‑free portfolio and drive growth in the e‑vapor segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76290,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19317,
        "completion_tokens": 77,
        "total_tokens": 19394
      }
    },
    {
      "question_id": 23,
      "question": "How does Amgen's disclosure of performance unit compensation expense for 2024 relate to the maximum potential share issuance under the Amended 2009 Plan, considering the fungible share-counting formula and performance-based payout structure?",
      "original_answer": "Amgen reported $133 million in performance unit compensation expense for 2024, which is part of the broader Amended 2009 Plan that allows for up to 59 million shares available for future grants. The Plan uses a fungible share-counting formula where each performance unit counts as 1.9 shares. As of year-end 2024, there were 1,516,669 shares subject to outstanding 2022–2024 performance units, including dividend equivalents. However, these performance units are subject to a performance-based payout structure that could result in up to 200% of the target shares being issued if above-target performance goals are met. This means the actual share issuance—and potentially the future compensation expense—could be significantly higher than the current $133 million reflects, depending on performance outcomes. The expense figure on page 124, therefore, captures only the current-year accrual based on expected performance, while the Plan disclosure on page 92 reveals the full potential dilutive impact under the share-counting methodology and performance multipliers.",
      "llm_answer": "Amgen’s 2024 performance‑unit compensation expense of $133 million reflects the portion of the $87 million of unrecognized compensation cost related to outstanding performance units that will be recognized over the next year, and this expense is tied to the fungible share‑counting formula of the Amended 2009 Plan, where each performance unit (a full‑value award) consumes 1.9 shares from the plan’s share pool; consequently, the maximum potential share issuance under the plan is limited by the 59 million shares reserved for future grants, and the performance‑unit payout structure—based on market‑ and performance‑based goals with a potential payout of up to 200 % of the target award—determines the actual number of shares that may ultimately be issued, but the total shares that can be released under the plan remain capped at the plan’s available share balance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 124,
          "pages": [
            122,
            123,
            124,
            125,
            126
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72473,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18357,
        "completion_tokens": 217,
        "total_tokens": 18574
      }
    },
    {
      "question_id": 23,
      "question": "How does the foreign currency exposure associated with NKE's use of NTC for sourcing from third-party factories relate to the embedded derivative contracts tied to factory input costs, and what does this imply about the effectiveness of NKE's foreign currency risk management program in offsetting inventory cost volatility?",
      "original_answer": "NKE's use of the NTC (a wholly-owned sourcing hub) creates foreign currency exposure when it sells products to NIKE entities with different functional currencies. This exposure is compounded by the fact that NTC purchases products from third-party factories predominantly in U.S. Dollars. Simultaneously, NKE operates a foreign currency adjustment program with certain factories, under which fluctuations in the basket of currencies affecting factory input costs create embedded derivative contracts. These contracts, totaling $584 million as of May 31, 2022, are recorded at fair value and recognized in Other (income) expense, net. However, some of these exposures are natural offsets to NKE's existing foreign currency exposures, suggesting that the company's risk management program is designed to internally balance these exposures before resorting to external hedging instruments. The $18.5 billion in outstanding foreign currency derivatives and the $607 million in deferred net gains expected to be reclassified into Net Income further indicate that NKE actively manages these exposures across its supply chain, aiming to stabilize inventory costs despite currency fluctuations.",
      "llm_answer": "Nike's foreign‑currency risk management program uses the NIKE Trading Company (NTC) to source products from third‑party factories, creating a foreign‑currency exposure that is mitigated by embedded derivative contracts tied to factory input costs. These embedded derivatives are recorded at fair value through Other (income) expense, net, and are intended to offset the currency impact of the related purchase orders. Because the embedded derivatives are not formally designated as hedging instruments, changes in their fair value are recognized directly in earnings rather than in Accumulated other comprehensive income, limiting their ability to systematically offset inventory‑cost volatility. Consequently, while the program provides natural offsets and some hedge accounting for certain cash‑flow exposures, the embedded‑derivative component does not reliably smooth inventory‑cost swings, implying that Nike’s foreign‑currency risk management program is only partially effective at offsetting inventory cost volatility.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2022.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 95815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24212,
        "completion_tokens": 256,
        "total_tokens": 24468
      }
    },
    {
      "question_id": 23,
      "question": "How does Duke Energy's compliance strategy with North Carolina's HB 951, which mandates a 70% reduction in CO₂ emissions by 2030, align with its long-term resource planning and operational execution in the Carolinas, particularly in light of the 2023 Carolinas Resource Plan and the NCUC's 2022 carbon plan approval?",
      "original_answer": "Duke Energy's compliance strategy with HB 951, which requires a 70% reduction in CO₂ emissions by 2030, is reflected in its 2023 Carolinas Resource Plan, where the company proposed Portfolio 3 as the most prudent path forward. This aligns with the NCUC's 2022 carbon plan approval, which was informed by Duke's earlier IRPs and stakeholder engagement. The IRP process, which includes a range of CO₂ pricing scenarios, supports long-term planning under regulatory uncertainty. However, the NCUC's initial rejection of Duke’s accelerated coal retirement scenario in 2021 highlights the regulatory challenge of aligning corporate climate goals with state-mandated timelines. The recent filing of the 2023 Plan, which includes near-term actions and proposes exiting coal by 2035, shows Duke's attempt to reconcile HB 951's mandates with operational feasibility and cost-effectiveness.",
      "llm_answer": "Duke Energy's compliance strategy with North Carolina's HB 951—mandating a 70% CO₂ reduction by 2030—aligns with its long-term resource planning through the 2023 Carolinas Resource Plan (CRP), which explicitly incorporates HB 951's requirements and the NCUC's 2022 Carbon Plan approval. The CRP, filed in August 2023, recommends Portfolio 3 as the most prudent path forward, emphasizing an \"all of the above\" approach to meet the 70% target by 2030 via accelerated coal retirements (targeting 2035), expanded renewables, energy efficiency, storage, and nuclear extensions, while ensuring reliability and cost efficiency. This strategy is reinforced by the NCUC's approval of PBR mechanisms (including MYRP) in late 2022/early 2023, enabling cost recovery for compliance investments, and the company's proactive integration of CO₂ pricing into its IRP process to model policy risks, as noted in its 2023 CRP filing and stakeholder engagement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 232,
          "pages": [
            230,
            231,
            232,
            233,
            234
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87723,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22190,
        "completion_tokens": 235,
        "total_tokens": 22425
      }
    },
    {
      "question_id": 23,
      "question": "How does Honeywell's accounting treatment of its investment in Garrett's Series B Preferred Stock reflect the redemption terms agreed upon during Garrett's emergence from bankruptcy, and how does this impact Honeywell's long-term receivables and investment valuation?",
      "original_answer": "Honeywell initially accounted for its investment in Garrett's Series B Preferred Stock at fair value upon Garrett's emergence from bankruptcy on April 30, 2021, receiving 834.8 million shares as part of the reorganization plan. The Series B Preferred Stock includes mandatory redemptions starting at $35 million in 2022 and $100 million annually from 2023 to 2030, subject to EBITDA and liquidity conditions. Subsequent amendments accelerated partial redemptions, including a $211 million payment made by Garrett on December 28, 2021, with an additional $200 million expected in Q1 2022. Honeywell applies a 7.25% discount rate to the present value of mandatory redemptions to determine fair value, which accretes into interest income over time. As of December 31, 2021, Honeywell reported $423 million in long-term receivables related to its Garrett investments, including the Series B Preferred Stock. This valuation method reflects both the contractual redemption terms and the uncertainty around future EBITDA performance and liquidity availability, directly influencing how Honeywell accounts for the investment on its balance sheet.",
      "llm_answer": "Honeywell recorded its investment in Garrett’s Series B Preferred Stock at fair value based on the present value of the mandatory redemptions, discounted at the 7.25 % rate specified in the stock certificate. Because the redemption amounts are fixed and accrete over time, the carrying amount of the investment is treated as a long‑term receivable that will increase as the discount accrues, while the underlying equity is valued at a level‑2 fair value. Consequently, the investment is reflected in long‑term receivables and classified as a held‑to‑maturity asset, with changes in fair value recognized through interest income rather than mark‑to‑market adjustments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76428,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19353,
        "completion_tokens": 166,
        "total_tokens": 19520
      }
    },
    {
      "question_id": 23,
      "question": "How does ConocoPhillips' decision to exercise its preemption right to acquire an additional 10% stake in APLNG relate to its strategic focus on CBM production in Australia, particularly in light of APLNG's $4.7 billion in outstanding project finance obligations?",
      "original_answer": "ConocoPhillips exercised its preemption right to purchase an additional 10% interest in APLNG in December 2021, despite the carrying value of its existing investment being written down to $5,574 million due to fair value considerations. APLNG, a joint venture focused on producing coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, operates under significant project financing obligations, with $4.7 billion outstanding as of December 31, 2023. This financing includes a non-recourse facility structured through the Export-Import Bank of the United States, commercial banks, and U.S. Private Placement note facilities. Despite the financial burden of these obligations, COP’s strategic move to increase its stake in APLNG underscores its commitment to expanding its CBM production footprint in Australia, aligning with its broader LNG export strategy targeting Asia Pacific markets.",
      "llm_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10% stake in APLNG to strengthen its strategic focus on coalbed methane (CBM) production in Australia, even as APLNG faced $4.7 billion in outstanding project finance obligations. The purchase price, set below the carrying value of ConocoPhillips’ existing investment, triggered a $688 million impairment in 2021, reflecting the decline in fair value of its APLNG holding.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72650,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18406,
        "completion_tokens": 110,
        "total_tokens": 18517
      }
    },
    {
      "question_id": 23,
      "question": "How does Southern Company's credit arrangement structure for Nicor Gas, as outlined in the liquidity and credit facilities section, align with the reported decrease in Nicor Gas's short-term notes payable from $392 million in 2023 to $172 million in 2024?",
      "original_answer": "Southern Company's credit arrangement for Nicor Gas, detailed on page 223, includes a $700 million allocation under a multi-year credit facility expiring in 2029, specifically restricted for Nicor Gas's working capital needs. This facility allows for flexible adjustments in allocations between Southern Company Gas Capital and Nicor Gas. The financial data on page 224 shows a significant decrease in Nicor Gas's short-term notes payable from $392 million in 2023 to $172 million in 2024, with a corresponding weighted average interest rate drop from 5.5% to 4.6%. This suggests that Nicor Gas likely utilized the flexible credit facility to refinance or reduce its higher-cost short-term debt. The alignment indicates that Southern Company's strategic liquidity support through its credit arrangements enabled Nicor Gas to optimize its short-term debt profile, reflecting both operational flexibility and financial discipline.",
      "llm_answer": "The liquidity and credit facilities section shows that Nicor Gas is the borrower of a $700 million sub‑limit within Southern Company Gas’s 2029 multi‑year credit arrangement and also has a separate $100 million credit facility expiring in 2025.  This structure provides dedicated financing for Nicor Gas’s working‑capital needs, and the disclosed decrease in Nicor Gas’s short‑term notes payable—from $392 million in 2023 to $172 million in 2024—reflects reduced reliance on that commercial‑paper‑backed liquidity as the company used the available credit lines and retained earnings to fund operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84571,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21381,
        "completion_tokens": 150,
        "total_tokens": 21531
      }
    },
    {
      "question_id": 24,
      "question": "How does the change in the Netherlands Innovation Box Tax rate and its application to Booking.com's earnings affect the company's effective tax rate in 2023 compared to 2022, and what does this reveal about the company's tax exposure under Dutch Corporate Income Tax Law?",
      "original_answer": "The Netherlands Innovation Box Tax rate increased from 7% to 9% for periods beginning on or after January 1, 2021, and the Dutch statutory rate rose from 25% to 25.8% effective January 1, 2022. Booking.com's earnings qualified for this preferential tax treatment, significantly benefiting the company's effective tax rate in both 2022 and 2023. However, the effective tax rate for 2023 was lower than in 2022, primarily due to a decrease in the valuation allowance against deferred tax assets related to unrealized losses on equity securities, lower unrecognized tax benefits, and lower international tax rates, despite a reduced benefit from the Innovation Box Tax. This reveals that while the Innovation Box Tax continues to provide a meaningful benefit, its diminishing impact combined with broader changes in tax provisions and international tax rates influences the company's overall tax exposure under Dutch Corporate Income Tax Law.",
      "llm_answer": "The 2023 effective tax rate of 21.8% was lower than the 22.1% rate in 2022, primarily because of a reduced valuation allowance for deferred tax assets tied to unrealized equity securities losses and lower international tax rates, partially offset by a smaller Innovation Box Tax benefit and higher non‑deductible fines. This shift shows Booking.com’s tax exposure is highly sensitive to Dutch Innovation Box Tax treatment and to the ability to maintain that favorable rate amid changes in Dutch corporate tax law.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72049,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18263,
        "completion_tokens": 128,
        "total_tokens": 18392
      }
    },
    {
      "question_id": 24,
      "question": "How does Microsoft's ongoing use of The Bank of New York Mellon Trust Company as trustee in multiple supplemental indentures relate to the foundational terms established in the Base Indenture from 2009, and what does this imply about the continuity and structure of Microsoft's long-term debt obligations?",
      "original_answer": "Microsoft has consistently used The Bank of New York Mellon Trust Company (BNY Mellon) as trustee across multiple supplemental indentures for various debt issuances, including the 1.625% Notes due 2018, 3.625% Notes due 2023, and 4.875% Notes due 2043 (dated December 6, 2013), and earlier issuances such as the 2.95% Notes due 2014 (dated May 18, 2009). These supplemental indentures are all governed by the Base Indenture dated May 18, 2009. This continuity implies that Microsoft has maintained a consistent legal and structural framework for its long-term debt obligations, leveraging the Base Indenture as a foundational document to efficiently issue new debt instruments over time while preserving standardized terms and oversight through a trusted trustee relationship.",
      "llm_answer": "Microsoft’s repeated use of The Bank of New York Mellon Trust Company as trustee in supplemental indentures—most recently the twelfth, thirteenth, fourteenth, fifteenth, and eighteenth supplemental indentures referenced in Exhibits 4.15‑4.18 and 4.18—continues the framework originally set out in the Base Indenture dated May 18, 2009. By amending and extending that original indenture rather than creating a new one, the company preserves the same legal structure and governing terms for its long‑term debt while adding new series of notes. This demonstrates a deliberate, ongoing continuity in the architecture of Microsoft’s debt obligations, with the same trustee and the same foundational indenture serving as the legal backbone for each subsequent issuance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12838,
        "completion_tokens": 190,
        "total_tokens": 13029
      }
    },
    {
      "question_id": 24,
      "question": "Given Disney's 50% ownership in A+E and the reported domestic subscriber figures for HISTORY and A&E channels, how does the equity investment structure align with the financial treatment of these channels as disclosed in the investments section?",
      "original_answer": "Disney's 50% ownership in A+E, as disclosed in the equity investments section, means that the financial performance of A+E's channels—including HISTORY and A&E—is accounted for under the equity method. The reported domestic subscriber figures (70 million for HISTORY and 69 million for A&E) indicate that both channels have substantial reach, yet their financial results are not fully consolidated into Disney's financial statements. Instead, Disney reports its share of A+E's income under 'Equity in the income (loss) of investees, net.' This aligns with the investments section disclosure that A+E is treated as an equity method investment with a book value exceeding the underlying net assets by $0.8 billion, reflecting amortizable intangible assets and goodwill. Thus, despite the high subscriber base of these channels, Disney's financial reporting reflects only its proportional stake, not full operational control.",
      "llm_answer": "The Disney‑A+E joint venture is accounted for as an equity‑method investment (50 % owned), and the financial statements disclose that the book value of Disney’s equity investment in A+E exceeds the fair value of its underlying net assets by about $0.8 billion, reflecting amortizable intangibles and goodwill.  Consequently, the equity investment is recorded at cost plus Disney’s share of A+E’s net income/loss and any adjustments to fair value, while the domestic subscriber figures for HISTORY and A&E are presented only as operating metrics and are not used to adjust the equity‑method accounting.  This structure means the investment is treated as a long‑term equity holding whose carrying amount is not directly tied to the subscriber counts, but rather to the investee’s financial performance and the amortization of acquired intangibles.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 51817,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13192,
        "completion_tokens": 211,
        "total_tokens": 13404
      }
    },
    {
      "question_id": 24,
      "question": "How does the inclusion of Eliquis in the Medicare Drug Price Negotiation Program, which sets a maximum fair price effective in 2026, reconcile with its 11% U.S. revenue growth in 2023, and what implications does this have for Pfizer's future pricing strategy under increasing regulatory pressure?",
      "original_answer": "Eliquis, which reported $6,747 million in global revenue in 2023 with 11% U.S. growth, is a key product for Pfizer. However, its inclusion in the Medicare Drug Price Negotiation Program, where a 'maximum fair price' will be set by CMS and published by September 2024, introduces significant pricing pressure starting in 2026. This regulatory development, highlighted in the broader context of the Inflation Reduction Act (IRA), signals a shift in how Pfizer may need to approach pricing and rebate strategies for high-revenue drugs. The company acknowledges the uncertainty around the IRA's full impact, particularly as it faces increasing government and payer scrutiny, including Medicaid rebate changes and 340B Program reforms. Given Eliquis's strong U.S. performance driven by market share gains, the upcoming price negotiation could constrain future revenue growth unless offset by further market expansion or strategic pricing adjustments. This dynamic underscores the tension between current revenue momentum and future regulatory constraints.",
      "llm_answer": "The Medicare Drug Price Negotiation Program will set a maximum fair price for Eliquis effective in 2026, yet Eliquis drove 11% U.S. revenue growth in 2023, indicating that its strong market demand and pricing power are currently insulated from the program’s future impact. However, this regulatory pressure signals increasing government scrutiny on drug pricing, suggesting Pfizer may need to adjust its pricing strategy—potentially through more aggressive discounting, value‑based contracts, or portfolio diversification—to mitigate future revenue risks under heightened price‑control pressures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2023.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 116062,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 29271,
        "completion_tokens": 149,
        "total_tokens": 29420
      }
    },
    {
      "question_id": 24,
      "question": "What is the fair value of MDLZ's net investment hedge contracts as disclosed in their financial instruments table, and how does the valuation methodology for these contracts align with the broader approach used for Level 2 financial assets?",
      "original_answer": "The fair value of MDLZ's net investment hedge contracts, as disclosed in their financial instruments table, is $71 million as of December 31, 2021. These contracts are categorized under Level 2 financial assets, which are valued using an income approach based on observable market inputs. Specifically, for net investment hedge contracts, the valuation methodology aligns with that of other Level 2 instruments such as OTC currency exchange forwards and interest rate swaps, which rely on observable market rates and discounted cash flow analyses. This consistent application of valuation techniques across Level 2 financial assets underscores MDLZ's adherence to standardized methodologies that reflect market observability and risk management practices.",
      "llm_answer": "The fair value of MDLZ's net investment hedge contracts, as disclosed in the financial instruments table, is $71 million (recorded as a liability of $15 million at year‑end 2020, with the Level 2 fair‑value measurement shown as $(15) million). This valuation follows the Level 2 approach used for all OTC derivatives—currency exchange forwards, options and swaps, commodity forwards and options, net‑investment hedge contracts, and interest‑rate swaps—where fair value is derived from observable market inputs (e.g., forward rates, commodity indices, interest‑rate curves) and discounted cash‑flow techniques, consistent with the broader methodology applied to Level 2 financial assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78564,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19876,
        "completion_tokens": 171,
        "total_tokens": 20047
      }
    },
    {
      "question_id": 24,
      "question": "How does ConocoPhillips' financial exposure through its 47.5% ownership in APLNG, including guarantees totaling over $1 billion in potential liability, reconcile with its strategic emphasis on CBM production from the Bowen and Surat basins as a core component of its LNG portfolio?",
      "original_answer": "ConocoPhillips' 47.5% ownership in APLNG gives it access to coal bed methane (CBM) resources in Queensland, Australia, which is a key part of its global LNG strategy. However, this strategic position comes with significant financial exposure, including a $610 million potential liability (up to $1.0 billion in case of intentional or reckless breach) tied to APLNG's natural gas delivery commitments. Despite these risks, COP continues to highlight APLNG's CBM production as central to its LNG export capabilities, particularly to Asia Pacific markets. The company's $5.0 billion carrying value in APLNG as of December 31, 2024, suggests confidence in the long-term value of the CBM resource despite the contingent liabilities, indicating a strategic trade-off between risk and reward in its LNG portfolio positioning.",
      "llm_answer": "ConocoPhillips’ 47.5 % stake in APLNG—whose primary assets are coal‑bed methane (CBM) fields in the Bowen and Surat basins that feed a dedicated LNG export facility—creates a contingent liability of more than $1 billion under guarantees tied to APLNG’s project‑finance debt and performance obligations.  Although this exposure could trigger up to $1 billion of potential payments if APLNG defaults on its financing or fails to meet throughput commitments, the company treats the investment as a core element of its LNG strategy because the CBM resources from those basins provide low‑cost feedstock for the LNG portfolio, and the guarantees are limited to the equity method investment’s carrying value and modest accrued liabilities.  Consequently, the financial risk from the guarantees is balanced against the strategic benefit of securing CBM‑derived LNG supply for its Asia‑Pacific markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64011,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16252,
        "completion_tokens": 223,
        "total_tokens": 16476
      }
    },
    {
      "question_id": 25,
      "question": "How might the FSPTCA's advertising restrictions on brand-sponsored events and promotional items, combined with increased private sector restrictions on tobacco product communications, be contributing to the observed 0.6 share point sequential increase in discount brand performance, given Altria's compliance costs under the FSPTCA's manufacturing practice requirements?",
      "original_answer": "The FSPTCA's advertising restrictions, such as the prohibition on brand-sponsored events and distribution of promotional items like branded apparel, limit Altria's ability to differentiate premium brands in the marketplace. This limitation is compounded by private sector activity referenced on page 42, where national retailers and digital platforms have restricted tobacco product communications. These combined constraints reduce premium brand marketing effectiveness at a time when page 39 shows Altria faces increased compliance costs under FSPTCA's manufacturing practice requirements, which could constrain investment in brand differentiation strategies. This creates a scenario where consumers may be more price-sensitive with fewer compelling brand narratives available, contributing to the 0.6 share point sequential increase in discount brand performance observed on page 35.",
      "llm_answer": "The FSPTCA’s advertising bans and private‑sector limits on tobacco communications reduce consumer exposure to premium‑priced brands, pushing price‑sensitive smokers toward discount labels; at the same time, compliance costs from the FDA’s manufacturing‑practice rules raise firms’ expenses, squeezing margins and prompting discount‑brand share gains of roughly 0.6 percentage points sequentially.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 39,
          "pages": [
            37,
            38,
            39,
            40,
            41
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 85412,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21624,
        "completion_tokens": 99,
        "total_tokens": 21723
      }
    },
    {
      "question_id": 25,
      "question": "How does the risk associated with Oak Street Health's participation in CMS Innovation Center models, such as ACO REACH, impact the long-term value of the goodwill recognized from its acquisition by CVS?",
      "original_answer": "The goodwill recognized from the acquisition of Oak Street Health by CVS was part of a broader acquisition strategy that included Signify Health in 2023, contributing to an increase in the carrying amount of goodwill during that year. Oak Street Health is subject to several risks tied to its participation in CMS Innovation Center models like ACO REACH, including annual changes that may reduce payments to participants and the lack of a long-term plan for ongoing participation in these models. These regulatory and financial risks could undermine the ability of Oak Street Health to generate consistent returns, which in turn could threaten the long-term value of the goodwill recognized in the acquisition. The annual impairment tests conducted by CVS in 2024 and 2023 found no impairment of goodwill, but the exposure of Oak Street Health to CMS model volatility raises concerns about the sustainability of its performance and, consequently, the durability of the goodwill value on CVS's balance sheet.",
      "llm_answer": "The risk that Oak Street Health’s participation in CMS Innovation Center models such as ACO REACH may be altered or terminated—through annual benchmark changes, end‑date limits, or shared‑savings reductions—could impair the revenue outlook for the assets acquired in its acquisition. This uncertainty could diminish the long‑term value of the goodwill recorded from the acquisition, as the expected synergies and future cash flows tied to those CMS models may not be realized.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 150,
          "pages": [
            148,
            149,
            150,
            151,
            152
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2024.pdf",
          "target_page": 44,
          "pages": [
            42,
            43,
            44,
            45,
            46
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72460,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18344,
        "completion_tokens": 119,
        "total_tokens": 18463
      }
    },
    {
      "question_id": 25,
      "question": "How does Disney's strategic bundling of ESPN+ with Disney+ and Hulu relate to the fees paid by ABC Network to ESPN, and what does this imply about the internal value of ESPN's sports content across Disney's ecosystem?",
      "original_answer": "Disney strategically bundles ESPN+ with Disney+ and Hulu to enhance the value proposition of its DTC offerings, leveraging ESPN's exclusive sports content such as UFC pay-per-view events and live sports programming. This bundling strategy aligns with the fees paid by ABC Network to ESPN for programming rights, indicating that ESPN's sports content is a critical asset that supports both traditional linear networks and new DTC platforms. The internal valuation of ESPN's content is further emphasized by the fact that ESPN+ had 26 million subscribers as of September 2024, and ABC Network relies on ESPN for sports programming, which in turn drives content licensing revenue. This interconnected value chain shows that ESPN's content is not only monetized directly through subscriptions but also indirectly through affiliate fees and enhanced DTC bundling strategies.",
      "llm_answer": "Disney's strategic bundling of ESPN+ with Disney+ and Hulu creates internal value for ESPN's sports content by enabling the company to leverage its premium sports rights across multiple platforms to drive subscriber growth and engagement for its direct-to-consumer services. This bundling strategy supports higher affiliate fees and advertising revenue for ESPN by increasing the overall value of Disney's ecosystem, as evidenced by the $539 million in equity income from A+E and the 26 million paid ESPN+ subscribers, while also justifying the fees paid by ABC Network and Disney+ to carry ESPN content.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 61933,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15716,
        "completion_tokens": 151,
        "total_tokens": 15867
      }
    },
    {
      "question_id": 25,
      "question": "How does Boeing's increased reach-forward loss on the Commercial Crew program in 2021 relate to the inherent cost estimation risks in fixed-price development contracts, and what does this reveal about the financial exposure tied to technical complexity and schedule delays in such contracts?",
      "original_answer": "Boeing's increased reach-forward loss of $185 million on the Commercial Crew program in 2021 was driven by delays in the second uncrewed Orbital Flight Test and the evolving assessment of remaining work. This aligns with the broader risk profile of fixed-price development contracts, where revenue is fixed but cost estimates are highly uncertain due to technical complexity and schedule variability. The Commercial Crew program is specifically highlighted as one of Boeing's significant fixed-price development contracts, and the company notes that such contracts are inherently risky, with potential for material charges if cost overruns or delays occur. The audit process for these contracts, including Commercial Crew, involved extensive evaluation of cost estimation methods, project status, and controls over judgment and assumptions, underscoring the difficulty in forecasting final costs. This reveals that technical challenges and schedule delays not only trigger financial losses but also increase the likelihood of future reach-forward loss recognition, exposing Boeing to significant financial volatility in its development programs.",
      "llm_answer": "Boeing recorded significant reach‑forward losses on its Commercial Crew fixed‑price development contract in 2021—$185 million in Q3 and an earlier $318 million increase in Q1—because technical complexity and schedule delays drove up estimated completion costs. This illustrates how fixed‑price contracts expose the company to financial risk when cost estimates for complex, development‑stage programs become uncertain, and how such risks are amplified by schedule overruns and technical challenges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 54393,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13854,
        "completion_tokens": 124,
        "total_tokens": 13978
      }
    },
    {
      "question_id": 25,
      "question": "How does Altria's acquisition of NJOY for $2.9 billion align with its strategic positioning of e-vapor products as part of its 'Moving Beyond Smoking' vision, given NJOY's role as the only e-vapor manufacturer with FDA-authorized pod-based products?",
      "original_answer": "Altria's acquisition of NJOY for $2.9 billion reflects a significant financial commitment to integrating e-vapor products into its broader portfolio, aligning with its stated 'Moving Beyond Smoking' vision to transition adult smokers to potentially less harmful alternatives. NJOY, as the only e-vapor manufacturer with FDA-authorized pod-based products, provides Altria with a competitive edge in the regulatory landscape, enhancing its ability to credibly market reduced-risk products. This strategic move is further reinforced by NJOY's exclusive focus on e-vapor products, which are contract-manufactured and sold in the U.S., positioning Altria to capitalize on the growing consumer and regulatory preference for scientifically vetted alternatives to traditional combustible tobacco products.",
      "llm_answer": "Altria's $2.9 billion acquisition of NJOY aligns directly with its “Moving Beyond Smoking” vision, which seeks to transition adult smokers to potentially less harmful alternatives. By acquiring NJOY—the only e‑vapor manufacturer with FDA‑authorized pod‑based products—Altria secures a regulated, premium e‑vapor platform that can be integrated into its broader smoke‑free portfolio, accelerating its strategy to offer adult consumers a range of non‑combustible options while leveraging NJOY’s FDA clearance as a strategic differentiator.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76290,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19311,
        "completion_tokens": 134,
        "total_tokens": 19445
      }
    },
    {
      "question_id": 25,
      "question": "How does Emerson's recognition of a $453 pretax gain from Vertiv in fiscal 2022 align with the strategic implications of having sold its Network Power Systems business in 2017 and the potential for additional future distributions of $75 based on Vertiv's equity performance?",
      "original_answer": "Emerson recognized a $453 pretax gain in fiscal 2022 from its retained subordinated interest in Vertiv, the entity to which its Network Power Systems business was rebranded and sold in 2017. The sale structure included a contingent payout mechanism, under which Emerson would only receive distributions after Vertiv’s equity holders achieved a threshold cash return. In the first quarter of fiscal 2022, that threshold was exceeded, triggering a $438 distribution to Emerson. Based on current projections, the company expects to receive additional distributions of approximately $75 over the next two to three years. However, these future payments are contingent on the timing and price of Vertiv share sales by the equity holders, introducing uncertainty around both the amount and timing of further gains. This financial outcome reflects a strategic divestiture that not only provided an initial exit benefit but also retained a structured upside tied to Vertiv’s post-spinoff performance, aligning with Emerson’s broader capital allocation and portfolio optimization strategy.",
      "llm_answer": "Emerson recognized a $453 pretax gain from its retained subordinated interest in Vertiv in fiscal 2022, which aligns with the strategic outcome of having sold its Network Power Systems business in 2017 and the potential for additional future distributions of approximately $75 based on Vertiv's equity performance, as the gain was realized when the equity holders' cumulative cash return exceeded the threshold, triggering the distribution and subsequent gain recognition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2022.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 55533,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14129,
        "completion_tokens": 118,
        "total_tokens": 14247
      }
    },
    {
      "question_id": 25,
      "question": "How does Duke Energy's financial obligation for coal ash basin closures under the 2024 CCR Rule relate to the expanded regulatory scope compared to the 2015 CCR Rule, and what does this imply about the long-term cost trajectory for managing previously unregulated coal ash sources?",
      "original_answer": "Duke Energy recorded asset retirement obligations (AROs) on its balance sheet for coal ash basin closures due to the 2024 CCR Rule, which significantly expands the scope of the 2015 CCR Rule by regulating inactive surface impoundments at retired facilities and previously unregulated coal ash sources. The 2015 CCR Rule applied to active landfills and impoundments receiving coal combustion residuals (CCRs), but the 2024 Rule now includes legacy impoundments and other CCR management units that were previously unregulated. This expansion increases Duke Energy's compliance burden, as it now must address groundwater monitoring, corrective action, and potential closure for these newly regulated units. The company estimates that the total cost to permanently close all coal ash basins in North and South Carolina is between $8 billion and $9 billion, with approximately $4.4 billion already spent through 2024, and the majority of the remaining spend expected over the next 10 years. This implies a significant long-term cost trajectory driven by the expanded regulatory framework under the 2024 CCR Rule.",
      "llm_answer": "Duke Energy’s 2024 CCR Rule expands the regulatory scope by requiring closure, groundwater monitoring and post‑closure care for inactive coal‑ash surface impoundments and other previously unregulated coal‑ash sources—obligations that were not subject to the 2015 rule. Because these new requirements must be met through the normal rate‑making process, the company expects to recover the associated costs from customers, implying a long‑term upward trajectory in expenditures for coal‑ash management.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 102607,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25899,
        "completion_tokens": 124,
        "total_tokens": 26024
      }
    },
    {
      "question_id": 26,
      "question": "What is the strategic significance of GM's $4.2 billion investment premium in nonconsolidated affiliates in relation to the production and marketing of crossovers?",
      "original_answer": "GM's $4.2 billion investment premium in nonconsolidated affiliates, primarily attributed to goodwill from fresh-start reporting and additional stake purchases, indicates a strategic emphasis on leveraging these partnerships for key product lines such as crossovers. These nonconsolidated affiliates are directly involved in the development, production, and marketing of crossovers, which are integral to GM's broader product portfolio. Furthermore, crossovers are a core component of GM's retail and fleet sales strategy, contributing significantly to market demand and aligning with consumer preferences. This suggests that GM's investment premium is not only a reflection of goodwill but also a strategic commitment to maintaining a strong presence in the crossover segment through collaborative ventures.",
      "llm_answer": "The $4.2 billion investment premium in nonconsolidated affiliates reflects GM’s strategic commitment to secure equity stakes in key joint‑venture partners—particularly its China automotive JVs and other cross‑functional alliances—that underpin the production and marketing of crossover vehicles. By holding these equity interests, GM aligns its financial incentives with the growth of crossover demand, ensuring a stable supply chain and collaborative marketing platforms that reinforce its global product strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103056,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25984,
        "completion_tokens": 128,
        "total_tokens": 26113
      }
    },
    {
      "question_id": 26,
      "question": "How does Microsoft's reported 22.2% year-over-year revenue growth in Server products and cloud services ($97.7B in FY24 vs $79.97B in FY23) relate to their strategic positioning of Windows Server as hybrid cloud infrastructure, particularly considering its role in enabling Azure adoption for enterprises maintaining on-premises systems?",
      "original_answer": "Microsoft's Server products and cloud services revenue grew from $79.97B in FY23 to $97.726B in FY24, representing a 22.2% year-over-year increase. This growth is directly tied to the strategic positioning of Windows Server as hybrid cloud infrastructure, as stated in the segment description where Server products are explicitly included in the Intelligent Cloud segment that powers modern business and developers. The technical capabilities of Windows Server as on-premises infrastructure that integrates with Azure cloud services (as described in the Server Products and Cloud Services section) enable enterprises to maintain hybrid environments. This hybrid approach likely drives Azure adoption and consumption-based services referenced in the Azure description, which in turn contributes to the strong revenue growth in the Server products and cloud services category.",
      "llm_answer": "Microsoft's 22.2% year-over-year revenue growth in Server products and cloud services ($97.7B in FY24 vs $79.97B in FY23) directly supports its strategic positioning of Windows Server as hybrid cloud infrastructure, as evidenced by its role in enabling Azure adoption for enterprises maintaining on-premises systems. This is reflected in the Intelligent Cloud segment's 20% revenue growth (driven by Azure and other cloud services), where server products and cloud services revenue increased 22% due to continued demand for hybrid solutions including Windows Server and SQL Server running in multi-cloud environments, as noted in the FY24 financial results and competitive positioning statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56727,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14448,
        "completion_tokens": 174,
        "total_tokens": 14622
      }
    },
    {
      "question_id": 26,
      "question": "Given that Star Wars is a major licensed property contributing to Disney's royalty-based revenue model, and that Disney+ includes Star Wars as a top-level branded tile, how does the potential for brand damage risk described in the risk factors section threaten both the licensing revenue stream and the strategic positioning of Disney+?",
      "original_answer": "The Company earns royalty-based revenue from licensing characters such as Star Wars across multiple product categories, including toys, apparel, and consumer electronics (page 22). Star Wars is also a top-level branded tile on Disney+, which is a key part of the Company's direct-to-consumer strategy (page 12). However, the risk factors section warns that damage to Disney's reputation or brands could negatively impact sales, profitability, and brand strength across businesses, including those not directly involved in the initial brand damage (page 29). Since Star Wars is both a major licensing revenue driver and a core brand asset on Disney+, any reputational harm to the Star Wars brand could directly reduce licensing royalties and indirectly harm Disney+'s subscriber growth and content appeal. This dual exposure means that brand damage could undermine both a key revenue stream and a central component of Disney’s DTC strategy.",
      "llm_answer": "The risk factors warn that any damage to Disney’s brands—whether from mis‑aligned content, consumer backlash, or reputational incidents—could erode the value of the Star Wars licensing franchise and undermine the appeal of the Disney+ “top‑level tile” that showcases the property.  If the brand’s reputation suffers, Disney could see lower royalty income from Star Wars‑related licensing deals and a loss of subscriber interest in Disney+, weakening both the cash flow from its licensing business and the strategic positioning of Disney+ as a premier destination for marquee franchises.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 72251,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18329,
        "completion_tokens": 146,
        "total_tokens": 18475
      }
    },
    {
      "question_id": 26,
      "question": "How does Amgen's concern about biosimilars as a competitive threat in the Risk Factors section reconcile with the specific revenue decline and competitive pressures observed in Aranesp's 2023 sales performance?",
      "original_answer": "Amgen highlights in its Risk Factors section that biosimilars pose an increasing threat to its marketed products, particularly as they can rely on existing safety and efficacy data to enter the market more quickly and at lower prices. This concern is substantiated in the sales performance of Aranesp, which faced direct competition from EPOGEN and its biosimilars, leading to a decline in both unit demand and net selling price in 2023. Specifically, U.S. Aranesp sales dropped due to independent and medium-sized dialysis organizations shifting to EPOGEN, demonstrating the real-world impact of biosimilar competition on Amgen’s revenue. The connection between the risk disclosure and the observed financial impact underscores how biosimilar entry not only aligns with the company’s strategic concerns but also directly affects its product-specific revenue streams.",
      "llm_answer": "Amgen’s 2023 10‑K notes that biosimilars are a “significant competitive threat” in its risk‑factor discussion, yet the same filing shows that Aranesp sales fell 4 % in 2023—driven by lower net selling prices and competition from EPOGEN and its biosimilars—while overall product revenue growth was modest. This illustrates that the generic‑competition risk Amgen warns about is already materializing for Aranesp, even as the company continues to emphasize biosimilar risk in its disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75975,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19223,
        "completion_tokens": 122,
        "total_tokens": 19346
      }
    },
    {
      "question_id": 26,
      "question": "How did the acquisition of Swedish Match impact the trajectory of PM's smoke-free revenue growth in the Americas segment, particularly with respect to the ZYN brand's contribution?",
      "original_answer": "The acquisition of Swedish Match significantly accelerated PM's smoke-free revenue growth trajectory, particularly in the Americas segment, where the ZYN brand—acquired as part of Swedish Match—contributed $2,065 million in 2023, compared to just $246 million in 2022 (before the acquisition was fully integrated). This represents a more than 700% increase in smoke-free revenue contribution from the Americas segment post-acquisition, underscoring the strategic importance of ZYN in expanding PM's presence in the U.S. oral nicotine market.",
      "llm_answer": "The acquisition of Swedish Match accelerated PM’s smoke‑free growth in the Americas by adding the ZYN oral‑nicotine pouch brand, which contributed $2.065 billion of net revenue from smoke‑free products in the region in 2023 (up from $246 million in 2022). This boost helped drive a 125.3 billion‑unit increase in heated‑tobacco shipments and lifted overall smoke‑free revenue, positioning ZYN as a key driver of PM’s Americas segment growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2023.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2023.pdf",
          "target_page": 117,
          "pages": [
            115,
            116,
            117,
            118,
            119
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66819,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16927,
        "completion_tokens": 110,
        "total_tokens": 17037
      }
    },
    {
      "question_id": 26,
      "question": "How does ConocoPhillips' $688 million pre-tax charge related to its investment in APLNG reconcile with the long-term production outlook for CBM in Queensland, given APLNG's role in developing CBM resources for LNG export?",
      "original_answer": "ConocoPhillips recorded a $688 million pre-tax charge in 2021 when it exercised its preemption right to purchase an additional 10% stake in APLNG, reflecting a fair value assessment that was below the carrying value of the existing investment. This write-down indicates a significant downward adjustment in the perceived value of APLNG at that time. Despite this financial impairment, APLNG remains a core asset in ConocoPhillips' portfolio, focused on producing coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, with plans for approximately 3,500 net wells to supply both LNG export contracts and the domestic gas market. The long-term production outlook for CBM appears optimistic in operational and strategic sections, suggesting a strategic bet on future CBM production growth to justify continued investment despite the earlier financial loss. This juxtaposition highlights a tension between short-term valuation adjustments and long-term resource development expectations.",
      "llm_answer": "The $688 million pre‑tax impairment charge recorded in 2021 reflects a write‑down of ConocoPhillips’ equity investment in APLNG when the fair value of the joint venture fell below its carrying amount.  APLNG is the key vehicle for developing coal‑bed methane (CBM) resources in Queensland, Australia, which are then processed into LNG for export.  Because the impairment was tied to a reassessment of APLNG’s fair value—driven by lower expected CBM‑derived LNG cash flows—the charge is consistent with the long‑term production outlook for Queensland CBM, indicating that the venture’s future cash‑generating potential is now viewed as lower than previously estimated.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63704,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16164,
        "completion_tokens": 166,
        "total_tokens": 16331
      }
    },
    {
      "question_id": 26,
      "question": "How does Southern Company's strategic request to extend the operation of Plant Gaston Units 1 through 4 beyond 2028, as outlined in the 2025 Integrated Resource Plan, align with SEGCO's current ownership structure and financial obligations, particularly regarding capacity payments and equity income distribution?",
      "original_answer": "Southern Company's 2025 IRP filing includes a request to extend the operation of Plant Gaston Units 1 through 4 (500 MWs based on 50% ownership through SEGCO) through at least December 31, 2034, despite SEGCO's current expectation of retiring these units by 2028. SEGCO, which is equally owned by Alabama Power and Georgia Power, operates these units and sells their capacity equally to both parent companies. In 2024, each company paid $118 million and $115 million respectively in capacity payments to SEGCO, which also distributed $20 million in dividends (50% to each owner). This strategic move to extend Plant Gaston's life suggests a shift in long-term resource planning, which must be reconciled with SEGCO's existing financial commitments and ownership dynamics, including ongoing operating cost allocations and return on equity expectations.",
      "llm_answer": "Southern Company's 2025 IRP requests Georgia PSC approval to extend Plant Gaston Units 1-4 (500 MW based on 50 % ownership through SEGCO) beyond 2034, while SEGCO is 50 % owned by Alabama Power and Georgia Power; the extension aligns with SEGCO's current ownership structure and financial obligations, as the joint owners would share capacity payments and equity income from the plant's operation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 216,
          "pages": [
            214,
            215,
            216,
            217,
            218
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 98498,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24886,
        "completion_tokens": 99,
        "total_tokens": 24985
      }
    },
    {
      "question_id": 27,
      "question": "How does Morgan Stanley's deferral of the CECL impact on capital ratios affect the regulatory capital position of Morgan Stanley Bank, N.A., particularly in relation to its phased-in implementation timeline and the firm's overall leverage-based capital requirements?",
      "original_answer": "Morgan Stanley elected to defer the impact of CECL on risk-based and leverage-based capital amounts, RWA, and supplementary leverage exposure over a five-year transition period. As of January 1, 2023, the deferral impacts were phased in at 50%, increasing to full phase-in by January 1, 2025. This deferral helps maintain the regulatory capital ratios of Morgan Stanley Bank, N.A. (MSBNA), which must remain well-capitalized under OCC PCA standards. MSBNA's capital ratios are calculated under the Standardized Approach, and the CECL deferral supports its ability to meet minimum Tier 1 leverage ratio (4%), SLR (3%), and enhanced SLR buffer (2%) requirements by reducing the immediate capital burden of CECL adoption.",
      "llm_answer": "Morgan Stanley's deferral of the CECL impact on capital ratios delays the full effect of the new credit‑loss accounting standard on its risk‑based and leverage capital calculations, allowing the firm to phase‑in the changes over a five‑year period (25 % beginning in 2022, 50 % in 2023, fully phased‑in by 2025). This deferral preserves higher capital ratios during the transition, ensuring that the firm maintains its well‑capitalized status and can continue to meet regulatory buffers, including the G‑SIB surcharge and TLAC requirements, without needing to raise additional capital or curtail capital distributions. Consequently, the firm’s leverage‑based ratios and overall capital adequacy remain stronger than they would have been under immediate CECL adoption, supporting its ability to absorb losses and satisfy regulatory capital buffers.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 135,
          "pages": [
            133,
            134,
            135,
            136,
            137
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 112288,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 28323,
        "completion_tokens": 211,
        "total_tokens": 28534
      }
    },
    {
      "question_id": 27,
      "question": "How does Microsoft's repeated use of The Bank of New York Mellon Trust Company as a trustee across multiple debt issuances, including the 5.20% Notes due 2039, reflect on the strategic and legal structuring of its long-term debt obligations?",
      "original_answer": "Microsoft has consistently used The Bank of New York Mellon Trust Company, N.A. (BNY Mellon) as a trustee for multiple debt issuances, including the 5.20% Notes due 2039, as evidenced by the repeated appearance of BNY Mellon in supplemental indentures across various note maturities and interest rates (e.g., 1.625% Notes due 2018, 3.500% Notes due 2035, and 4.750% Notes due 2055). This pattern indicates a strategic and long-standing legal relationship with BNY Mellon, which likely provides consistency and efficiency in the structuring of Microsoft’s debt instruments. The 5.20% Notes due 2039 are specifically governed under the First Supplemental Indenture dated May 18, 2009, which is part of a broader Base Indenture with BNY Mellon. This repeated use of the same trustee across decades of debt issuances suggests that Microsoft values continuity in legal oversight and administrative execution, particularly for long-dated obligations like the 2039 notes, which carry a higher coupon rate compared to shorter-term instruments. This implies a deliberate legal and financial structuring approach to manage long-term liabilities with trusted counterparties.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon Trust Company as trustee across multiple debt issuances—including the 5.20% Notes due 2039—reflects a deliberate strategic and legal approach to structuring long-term debt. By relying on a single, established trustee for its indentures, Microsoft ensures continuity, regulatory compliance, and operational efficiency in managing complex debt instruments, while leveraging a well-documented legal framework (e.g., the 2009 Base Indenture and its supplements) to facilitate future financing needs. This practice underscores the company’s disciplined capital structure management and reliance on institutional infrastructure for scalable, long-term debt financing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12822,
        "completion_tokens": 179,
        "total_tokens": 13002
      }
    },
    {
      "question_id": 27,
      "question": "Given LLY's acknowledgment of challenges in predicting market exclusivity durations, how does the specific 2036 biologics data protection expiry date for Kisunla in the U.S. illustrate the potential discrepancy between stated protection timelines and actual market exclusivity periods?",
      "original_answer": "LLY acknowledges on page 11 that predicting market exclusivity durations is complex due to the interaction between patent and regulatory protections and uncertainties around litigation. However, in the product-specific table on page 13, Kisunla is shown to have a clear 2036 biologics data protection expiry date in the U.S. This concrete date appears to contradict the company's more cautious stance about the unpredictability of exclusivity timelines. The discrepancy highlights how LLY presents specific protection dates with confidence in one section, while simultaneously cautioning investors about the limitations of relying solely on these dates for predicting actual market exclusivity in another section.",
      "llm_answer": "LLY acknowledges uncertainty in predicting market exclusivity durations due to complex patent and regulatory dynamics. The 2036 U.S. expiry date listed for Kisunla’s compound patent and biologics data protection illustrates this discrepancy, as it reflects a specific projected timeline that may not align with actual market protection periods, given potential patent challenges, biosimilar competition, and evolving regulatory interpretations under frameworks like the BPCIA.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 57339,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14580,
        "completion_tokens": 119,
        "total_tokens": 14699
      }
    },
    {
      "question_id": 27,
      "question": "How does ConocoPhillips' engagement of DeGolyer and MacNaughton to review reserves estimation processes, as disclosed in Exhibit 99, align with the company's internal controls over reserves reporting and the qualifications of the individual overseeing those controls?",
      "original_answer": "ConocoPhillips engages DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, to annually review the company's reserves estimation processes for over 85% of proved reserves as of December 31, 2024, ensuring alignment with SEC regulations. This external review is part of a broader internal control framework led by the Manager of Reserves Compliance and Reporting, a reservoir engineering expert with over 20 years of industry experience. The internal team, which includes D&M's senior representative, conducts on-site visits, teleconferences, and documentation reviews to ensure consistency and adherence to both company policy and SEC guidelines. This structured oversight mechanism, combining internal expertise and independent third-party validation, reinforces the integrity of reserves reporting despite the inherent imprecision in reserves estimation.",
      "llm_answer": "ConocoPhillips engages DeGolyer and MacNaughton to independently review the adequacy and effectiveness of its internal reserves‑reporting controls and to validate that reserves estimates are prepared in accordance with SEC definitions; this review is overseen by the company’s Manager of Reserves Compliance and Reporting, a qualified reservoir engineer with advanced degrees and extensive industry experience. The internal team, which includes a senior representative from DeGolyer and MacNaughton, ensures that reserves are calculated using consistent standards and procedures and reports its findings to senior management.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78046,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19758,
        "completion_tokens": 156,
        "total_tokens": 19914
      }
    },
    {
      "question_id": 28,
      "question": "How does the reported sensitivity of BAC's mortgage-backed securities to a weakening U.S. housing market align with the significant unrealized losses disclosed in their AFS debt securities portfolio as of December 31, 2023?",
      "original_answer": "BAC highlights on page 14 that a deeper downturn in the U.S. housing market could lead to significant write-downs in asset values, particularly for mortgage-backed securities (MBS), due to declining real estate values and increased credit losses. This sensitivity is corroborated by the data disclosed on page 114, which shows that as of December 31, 2023, BAC held $38.422 billion in MBS with a total gross unrealized loss of $2.205 billion, split between short-term and long-term unrealized losses. This alignment indicates that the ongoing weakness in the housing market, driven by higher mortgage rates and reduced affordability, has already begun to impact the valuation of MBS in BAC's portfolio, supporting the risk narrative outlined earlier in the document.",
      "llm_answer": "The sensitivity analysis explicitly links a weakening U.S. housing market to higher credit losses on mortgage‑related assets, noting that a deeper downturn could trigger “significant write‑downs of asset values in several asset classes, notably mortgage‑backed securities (MBS).” This directly aligns with the AFS debt‑securities data showing that the largest unrealized loss bucket for AFS securities is mortgage‑backed securities, which accounted for $2.2 billion of gross unrealized losses (including $1.4 billion for agency MBS) at December 31 2023. The concentration of credit risk in consumer real‑estate and commercial real‑estate exposures means that declining home‑price valuations and weaker housing‑market conditions would increase defaults and delinquencies, leading to higher provisions for credit losses and further pressure on earnings. Consequently, the disclosed unrealized losses on AFS MBS reflect the same macro‑economic stress that the sensitivity discussion predicts would amplify credit‑loss provisions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_2_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 112769,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 28426,
        "completion_tokens": 256,
        "total_tokens": 28683
      }
    },
    {
      "question_id": 28,
      "question": "How does the adoption of ASU 2022-04 impact Colgate's disclosure requirements for Supplier Finance Programs in 2024, particularly regarding the confirmed amount outstanding and roll-forward information?",
      "original_answer": "The adoption of ASU 2022-04 in 2023 introduced new disclosure requirements for Colgate’s Supplier Finance Programs, including the confirmed amount outstanding at the end of the period and roll-forward information. These disclosures became effective for Colgate beginning January 1, 2024, as noted in the financial statements section on page 84. This aligns with the company’s broader critical accounting policies section on page 57, which reiterates the requirement to disclose key terms and balance sheet presentation related to these obligations, emphasizing the importance of transparency in supplier finance liabilities.",
      "llm_answer": "The adoption of ASU 2022‑04 requires Colgate‑Palmolive to disclose, for each reporting period, the confirmed amount outstanding under its supplier‑finance programs and to provide roll‑forward information about the balance. The company began applying this guidance on January 1 2023, and the roll‑forward disclosure became mandatory on January 1 2024, so in 2024 it must present the ending confirmed liability and the related roll‑forward details in its annual footnote disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_3_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63458,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16092,
        "completion_tokens": 120,
        "total_tokens": 16212
      }
    },
    {
      "question_id": 28,
      "question": "How does Chevron's 2023 crude oil reserve growth in Kazakhstan, particularly from extensions and discoveries, align with the Caspian Pipeline Consortium's (CPC) throughput capacity expansion and its role in transporting Chevron's production?",
      "original_answer": "Chevron's 2023 crude oil reserves in Kazakhstan saw significant additions from extensions and discoveries, including 660 billion cubic feet (BCF) from such activities, indicating active exploration and development efforts. This aligns with Chevron's strategic focus on expanding production in the region, particularly through projects like the Future Growth Project (FGP) and Wellhead Pressure Management Project (WPMP) at TCO. These projects are expected to ramp up production starting in 2025. The Caspian Pipeline Consortium (CPC), in which Chevron holds a 15% interest, completed a debottlenecking project in January 2023 that increased throughput capacity. This expansion directly supports the anticipated rise in crude oil exports from Kazakhstan, including Chevron's production, as the CPC pipeline transported an average of 1.4 million barrels per day in 2023. Therefore, the growth in reserves and the pipeline's capacity enhancement are strategically synchronized to support Chevron's upstream development plans in Kazakhstan.",
      "llm_answer": "Chevron’s 2023 crude‑oil reserve growth in Kazakhstan—driven primarily by extensions and discoveries at the Tengiz and Korolev fields—is being exported through the Caspian Pipeline Consortium (CPC).  The CPC’s recent debottlenecking project achieved mechanical completion in January 2023 and now moves roughly 1.4 million bbl/d of crude (≈1.2 million bbl/d from Kazakhstan) to market, providing the transport capacity needed to bring the newly added Kazakh reserves into production.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 96148,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24275,
        "completion_tokens": 120,
        "total_tokens": 24396
      }
    },
    {
      "question_id": 28,
      "question": "Given the 33% year-over-year revenue growth in Server products and cloud services, how does the inclusion of Visual Studio within this segment suggest strategic alignment between Microsoft's developer tools and cloud infrastructure priorities?",
      "original_answer": "The 33% year-over-year growth in Server products and cloud services—from $67.35B in 2022 to $97.726B in 2024—demonstrates strong momentum in Microsoft's cloud and infrastructure offerings. Within this segment, Visual Studio is explicitly listed alongside core cloud services like Azure and server software such as SQL Server and Windows Server. This inclusion indicates that Microsoft views developer tools like Visual Studio not just as standalone software products, but as integral components of its broader cloud and enterprise strategy. By grouping Visual Studio with cloud infrastructure and server platforms, Microsoft aligns its development ecosystem with its cloud growth engine, reinforcing a unified approach where developer productivity tools directly support cloud adoption and hybrid IT environments. This strategic bundling suggests that Visual Studio plays a pivotal role in enabling developers to build and deploy applications on Azure, thereby driving sustained usage and monetization of Microsoft’s cloud infrastructure.",
      "llm_answer": "The inclusion of Visual Studio within the Server products and cloud services segment underscores Microsoft’s strategic alignment of developer tools with its cloud infrastructure priorities by embedding these tools into Azure and other cloud offerings, enabling developers to build, deploy, and manage applications on Microsoft’s cloud platform. This integration supports the growth of Azure consumption-based services and reinforces Microsoft’s focus on AI and cloud-native development, as highlighted in the Intelligent Cloud segment’s revenue growth driven by Azure and related server products.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56727,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14424,
        "completion_tokens": 149,
        "total_tokens": 14573
      }
    },
    {
      "question_id": 28,
      "question": "How does Caterpillar's repeated amendment of the 3-Year Credit Facility with Citibank, N.A. as Agent reflect on the evolving nature of their long-term debt obligations, particularly in light of Citibank's historical role as Trustee under Caterpillar's older indentures?",
      "original_answer": "Caterpillar has amended its 3-Year Credit Facility twice in recent years (August 31, 2023, and August 29, 2024), with Citibank, N.A. serving as Agent. This indicates an ongoing and dynamic financial relationship. Meanwhile, Citibank has also historically played a structural role in Caterpillar's long-term debt framework, having been appointed as Successor Trustee under the original Indenture from May 1, 1987, and involved in multiple supplemental indentures dating back to 1992. The repeated amendments to the credit facility suggest Caterpillar's need to adapt its short- to medium-term financing arrangements, while Citibank's long-standing trustee role underscores its deep-rooted involvement in Caterpillar's capital structure. This dual role highlights Citibank's strategic importance to Caterpillar's financing across different time horizons and financial instruments.",
      "llm_answer": "Caterpillar's repeated amendments to its 3‑Year Credit Facility—most recently the August 29 2024 amendment that added a Local‑Currency Addendum and a Japan‑Local‑Currency Addendum—demonstrate that the company continually reshapes its long‑term borrowing structure to meet evolving market conditions and funding needs. This practice builds on Citibank’s historical role as trustee under Caterpillar’s older indentures, reflecting a continuity of relationship while allowing the company to adapt its debt terms through new credit agreements rather than relying on the legacy trust structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CAT_10k_2024.pdf",
          "target_page": 131,
          "pages": [
            129,
            130,
            131,
            132,
            133
          ]
        },
        "hop_2_rel": {
          "source_file": "CAT_10k_2024.pdf",
          "target_page": 131,
          "pages": [
            129,
            130,
            131,
            132,
            133
          ]
        },
        "hop_3_rel": {
          "source_file": "CAT_10k_2024.pdf",
          "target_page": 128,
          "pages": [
            126,
            127,
            128,
            129,
            130
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 94902,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23970,
        "completion_tokens": 147,
        "total_tokens": 24117
      }
    },
    {
      "question_id": 28,
      "question": "How does Southern Company's reliance on nuclear power plants for a significant portion of electricity generation intersect with their exposure to financial risks related to nuclear decommissioning and carbon policy uncertainty?",
      "original_answer": "Southern Company relies on nuclear power plants, which supplied approximately 26% and 28% of total KWHs generated by Alabama Power and Georgia Power respectively in 2021. These nuclear facilities are subject to significant financial risks, including decommissioning costs that may exceed available capital reserves and insurance coverage. Meanwhile, the company also faces financial exposure from evolving GHG regulations and carbon policy uncertainty, which could affect both the economics of existing generation assets and future investment decisions. The dual exposure suggests that while nuclear energy provides a low-carbon generation source aligned with Southern Company’s net zero goals, it also introduces long-term financial liabilities tied to decommissioning and regulatory changes that must be carefully balanced against broader climate-related financial risks.",
      "llm_answer": "Southern Company's heavy reliance on nuclear power—representing roughly 26‑28 % of Alabama Power’s and Georgia Power’s electricity generation and involving the management of Plant Vogtle Units 3 and 4—creates significant financial exposure to nuclear decommissioning costs, which may exceed the amounts held in decommissioning trusts and insurance, as well as to regulatory and compliance expenses imposed by the NRC. At the same time, uncertainty over future carbon‑policy rules and emissions‑reduction mandates adds further financial risk, since compliance costs for greenhouse‑gas regulations could be large and may not be fully recoverable through rates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81817,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20689,
        "completion_tokens": 164,
        "total_tokens": 20853
      }
    },
    {
      "question_id": 28,
      "question": "How does the impact of U.S. commercial payer actions on patient access to Repatha compare with the impact of the COVID-19 pandemic on patient access to Prolia, and what does this reveal about the distinct commercial risks facing AMGN in different therapeutic areas?",
      "original_answer": "The U.S. commercial payer actions have limited patient access to Repatha through cost-shifting measures such as high copays, formulary restrictions, and utilization management criteria, despite AMGN reducing net and list prices to improve affordability. These payer-driven barriers have directly constrained Repatha sales. In contrast, the impact of the COVID-19 pandemic on Prolia has been operational and logistical, as the drug requires healthcare provider administration, which was disrupted due to reduced in-person appointments and patient avoidance of medical settings. The pandemic led to lower treatment initiation rates and a backlog of undiagnosed patients, affecting Prolia’s commercial performance. While payer policies affect access through financial and administrative controls, the pandemic disrupted access through public health measures and behavioral shifts. This distinction reveals that AMGN faces dual commercial risks: payer-driven affordability and coverage challenges in chronic disease therapies like Repatha, and access disruption due to external health crises in therapies requiring in-person administration like Prolia.",
      "llm_answer": "The impact of U.S. commercial payer actions on patient access to Repatha is evident in the document’s discussion of payer‑driven utilization‑management tools, formulary exclusions, copay‑accumulator programs and the resulting need for price reductions and rebates that limit affordability and access. In contrast, the COVID‑19 pandemic’s effect on patient access to Prolia is described as a broad, disease‑agnostic disruption of clinical visits, elective procedures and provider capacity, leading to delayed diagnoses and reduced treatment rates across the board. This comparison shows that Repatha faces distinct, payer‑specific commercial risks—primarily reimbursement and formulary pressures—whereas Prolia’s risk stems from pandemic‑related operational and demand shocks, highlighting that AMGN’s commercial vulnerability varies by therapeutic area.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 97843,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24704,
        "completion_tokens": 213,
        "total_tokens": 24917
      }
    },
    {
      "question_id": 28,
      "question": "How does MET's investment exposure to mortgage loans on the balance sheet relate to their holdings of pass-through mortgage-backed securities, and what does this imply about their risk positioning in the residential mortgage market?",
      "original_answer": "MET reports $93.2 billion in mortgage loans on the balance sheet as of December 31, 2023, which directly underpins their investment in structured products. These mortgage loans serve as collateral for pass-through mortgage-backed securities (MBS), which MET holds $12.4 billion of at estimated fair value, representing 42.6% of total RMBS. The fair value of these pass-through MBS shows a net unrealized loss of $1.1 billion, indicating potential credit or market risk exposure. This connection implies that MET maintains significant direct and indirect exposure to the residential mortgage market through both on-balance sheet loans and off-balance structured products, with the latter reflecting market valuation pressures.",
      "llm_answer": "MET's investment exposure to mortgage loans on the balance sheet is closely linked to its holdings of pass-through mortgage-backed securities (RMBS), as evidenced by the RMBS portfolio composition detailed on pages 98-99 and 318-319. The portfolio is predominantly composed of pass-through securities (42.6% of total RMBS at fair value in 2023) backed by residential mortgages, with a strong focus on senior, investment-grade tranches (e.g., 87% rated Aaa/Aa and 97.6% designated NAIC 1). This indicates MET positions itself to benefit from the cash flow stability of residential mortgages while managing risk through high credit quality and senior tranche exposure, rather than direct exposure to underlying mortgage defaults. Consequently, MET's risk positioning in the residential mortgage market is characterized by a concentrated, high-grade exposure to pass-through RMBS, implying a relatively low direct credit risk but sensitivity to broader mortgage market fluctuations and interest rate movements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 320,
          "pages": [
            318,
            319,
            320,
            321,
            322
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78763,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19928,
        "completion_tokens": 251,
        "total_tokens": 20180
      }
    },
    {
      "question_id": 28,
      "question": "How does UPS's $10 million annual contribution to the Alaska Teamster-Employer Pension Plan align with their broader approach to satisfying FIP requirements for underfunded multiemployer pension plans?",
      "original_answer": "UPS contributes $10 million annually to the Alaska Teamster-Employer Pension Plan, which is classified in the red zone and subject to an implemented FIP, consistent with their statement that collectively-bargained contributions satisfy FIP requirements without surcharges. This aligns with UPS's broader approach to multiemployer pension obligations, as they indicate that their contributions across all plans meet regulatory requirements and do not currently require additional surcharges or minimum contributions beyond contractual rates. The Alaska plan’s red zone status and implemented FIP demonstrate how UPS manages underfunded plans through structured contributions that comply with regulatory frameworks.",
      "llm_answer": "UPS’s $10 million annual contribution to the Alaska Teamster‑Employer Pension Plan is made under the terms of a collectively‑bargained agreement and is treated as a contractual obligation. Because the plan is subject to a rehabilitation plan (RP) that has already been implemented, UPS’s contribution satisfies the FIP/RP requirements and does not trigger any additional surcharge or minimum funding obligations beyond the agreed‑upon amount.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22177,
        "completion_tokens": 110,
        "total_tokens": 22287
      }
    },
    {
      "question_id": 28,
      "question": "How does Chevron's ongoing tax uncertainty in Kazakhstan relate to its upstream earnings contribution from Tengizchevroil, given the significant loan Chevron has extended to support TCO's development projects?",
      "original_answer": "Chevron faces ongoing tax uncertainty in Kazakhstan, where its tax examinations had not been finalized beyond 2012 as of 2021, contributing to a large portion of its $5,288 unrecognized tax benefits. Meanwhile, Chevron's upstream earnings from Tengizchevroil (TCO) in Kazakhstan improved in 2021, contributing positively to equity affiliate income. However, Chevron has also extended a significant $4,500 loan to TCO to fund development projects like the FGP/WPMP, which is included in Chevron’s carrying value of its investment. This suggests that while Chevron benefits from TCO's operational performance, it also faces material financial exposure through both tax liabilities and direct financial support in a jurisdiction with unresolved tax audits, potentially impacting both earnings and cash flow stability.",
      "llm_answer": "Chevron’s tax uncertainty in Kazakhstan stems from the ongoing legal and regulatory challenges surrounding its 50 % owned Tengizchevroil (TCO) project, where the company has extended a significant loan to fund the FGP/WPMP development. Because the loan and the project’s future operations are subject to Kazakhstani tax and regulatory risks—including potential adjustments to tax assessments and possible disputes over profit repatriation—this uncertainty can affect the earnings contributed by TCO to Chevron’s upstream segment. Consequently, any adverse outcome in Kazakhstan could diminish the expected financial returns from the loan‑supported development and lower the overall contribution of TCO to Chevron’s upstream earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91717,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23162,
        "completion_tokens": 183,
        "total_tokens": 23346
      }
    },
    {
      "question_id": 28,
      "question": "How does Duke Energy's classification of debt investments as AFS impact the financial reporting treatment for Duke Energy Indiana's portfolio, particularly in relation to unrealized gains and losses?",
      "original_answer": "Duke Energy classifies debt investments as AFS (Available-for-Sale), which means unrealized gains and losses are generally recorded in other comprehensive income until realized, at which point they flow into net income. This policy, outlined in the broader Duke Energy investments section, applies to Duke Energy Indiana, which specifically reports its debt investments under this AFS classification. As a result, Duke Energy Indiana’s portfolio is subject to this accounting treatment, deferring unrealized gains and losses to other comprehensive income, aligning with the company’s consolidated reporting approach and regulatory deferral practices.",
      "llm_answer": "Duke Energy classifies its debt investments in the Duke Energy Indiana portfolio as available‑for‑sale (AFS).  Under AFS accounting, unrealized gains and losses on these securities are recorded in other comprehensive income until the securities are sold, at which point the realized gains or losses are re‑classified into net income.  This treatment contrasts with the FV‑NI classification used for equity investments, where both realized and unrealized gains and losses flow directly through earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 105276,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26546,
        "completion_tokens": 125,
        "total_tokens": 26671
      }
    },
    {
      "question_id": 29,
      "question": "How does Chevron's tax exposure in Kazakhstan relate to its upstream earnings from Tengizchevroil, and what does this imply about the financial significance of its equity investment in that joint venture?",
      "original_answer": "Chevron's tax exposure in Kazakhstan is highlighted by the fact that the latest year for which income tax examinations had been finalized in that jurisdiction was 2012, indicating long-standing unresolved tax matters. These unresolved issues contribute to the $5,288 million of unrecognized tax benefits at year-end 2021, a portion of which directly relates to Chevron's operations in Kazakhstan, including its upstream activities. Chevron has a 50% equity ownership in Tengizchevroil (TCO), which operates the Tengiz and Korolev crude oil fields in Kazakhstan. In 2021, Chevron reported higher upstream-related earnings from TCO, contributing to a significant improvement in income from equity affiliates—from a $472 million loss in 2020 to a $5,657 million gain in 2021. Despite the tax uncertainties in Kazakhstan, Chevron's investment in TCO remains substantial, with a carrying value $100 million higher than its underlying equity in TCO’s net assets, and includes a $4,500 million loan to fund the Future Growth Project and Wellhead Pressure Management Project. This implies that despite the unresolved tax exposure, Chevron continues to view TCO as a strategically and financially critical asset in its upstream portfolio.",
      "llm_answer": "Chevron's tax expense in Kazakhstan flows through its equity‑method investment in Tengizchevroil, so the $4.35 billion international income‑tax charge recorded in 2021 is largely driven by higher upstream realizations and the absence of 2020 impairments at that joint venture. Consequently, the size of the tax expense signals that the equity stake in Tengizchevroil is financially material, contributing a substantial share of Chevron's overall tax burden and earnings volatility.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91717,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23161,
        "completion_tokens": 120,
        "total_tokens": 23281
      }
    },
    {
      "question_id": 29,
      "question": "How does Microsoft's use of The Bank of New York Mellon Trust Company as trustee for its 1.625% Notes due 2015 relate to the broader pattern of partnership reflected in subsequent supplemental indentures with the same institution for other note issuances?",
      "original_answer": "Microsoft issued the 1.625% Notes due 2015 under a Second Supplemental Indenture dated September 27, 2010, with The Bank of New York Mellon Trust Company serving as trustee. This relationship continued as evidenced by later supplemental indentures, such as the Eighth Supplemental Indenture dated December 6, 2013, which also named BNY Mellon Trust Company as trustee for other note series, including the 1.625% Notes due 2018. The consistent use of BNY Mellon as trustee across multiple note issuances indicates a sustained and trusted financial partnership, suggesting that Microsoft relies on BNY Mellon’s institutional credibility and expertise in managing complex debt instruments over time.",
      "llm_answer": "Microsoft's use of The Bank of New York Mellon Trust Company as trustee for its 1.625% Notes due 2015 is part of a consistent pattern of engaging the same institution as trustee across multiple supplemental indentures for subsequent note issuances. This institutional continuity is evident in the sequential supplemental indentures filed between 2010 and 2015, where The Bank of New York Mellon Trust Company serves as trustee for each new tranche of debt securities, including the 1.625% Notes due 2015 (referenced in Exhibit 4.5 of the 2010 filing) and later supplemental indentures like the Eighth Supplemental Indenture for 1.625% Notes due 2018 (Exhibit 4.11, filed December 6, 2013). The pattern demonstrates Microsoft's systematic use of this trustee for all debt issuances under the May 18, 2009 Base Indenture, reflecting a standardized approach to structuring its long-term financing through repeated supplemental indentures with the same trustee institution.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12825,
        "completion_tokens": 242,
        "total_tokens": 13068
      }
    },
    {
      "question_id": 29,
      "question": "How does Disney's approach to identifying triggering events for asset impairment tests, including the use of estimated discounted future cash flows, influence the frequency and valuation methodology of non-recurring fair value measures reported in fiscal 2024?",
      "original_answer": "Disney identifies triggering events—such as a decrease in estimated future cash flows—as key indicators that may necessitate asset impairment tests. When such events occur, the company evaluates affected assets for potential impairment by comparing the estimated undiscounted future cash flows to the carrying amount. If the carrying amount exceeds the cash flow estimate, the asset is written down to its fair value, which is determined using a discounted cash flow model (a Level 3 valuation technique). In fiscal 2024, this process led to impairment charges recorded in the second and fourth quarters, as disclosed in Notes 4 and 18. These impairments required non-recurring fair value measurements, where the discounted cash flow method was used to estimate fair value. The use of triggering events thus directly drives the frequency and valuation methodology of non-recurring fair value measures, particularly in cases where cash flow expectations decline, leading to write-downs based on Level 3 inputs.",
      "llm_answer": "Disney evaluates potential asset impairments by comparing the carrying amount of an asset group to its estimated undiscounted future cash flows—a Level 3 fair‑value technique that relies on projected cash‑flow estimates and discount rates. When those cash‑flow forecasts indicate a decline, the Company records non‑recurring fair‑value measures using discounted cash‑flow models, which influences both the frequency of impairment testing (triggered by events such as the second and fourth quarter reviews in fiscal 2024) and the valuation methodology applied to those non‑recurring fair‑value measurements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83634,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21152,
        "completion_tokens": 151,
        "total_tokens": 21303
      }
    },
    {
      "question_id": 29,
      "question": "How does the $31.0 billion of assets held in trust accounts associated with reinsurance contracts involving ceding insurers impact the valuation and recoverability of GE's $2.651 billion in net reinsurance recoverables at year-end 2021, particularly in light of the trust assets' investment control provisions and their role in securing reinsurance obligations?",
      "original_answer": "The $31.0 billion of assets held in trust accounts on page 50 are directly linked to reinsurance contracts with ceding insurers and are intended to secure GE's obligations under those agreements. These trust assets are held by independent trustees for the benefit of the ceding insurers, though some agreements allow the ceding company to exercise investment control over withdrawn assets, potentially affecting their value and liquidity. This dynamic is critical to assessing the recoverability of GE’s $2.651 billion in net reinsurance recoverables (as of December 31, 2021, per page 102), since the value and performance of the underlying trust assets influence GE’s ability to collect on those recoverables. Furthermore, the trust assets are subject to investment guidelines and may fluctuate in value, as seen in the $4,766 million decrease in 'Other adjustments' on page 102, which was influenced by changes in unrealized gains on investment securities. Therefore, the structure and control provisions of the trust assets directly affect the long-term realizability of the reinsurance recoverables on GE's balance sheet.",
      "llm_answer": "The $31 billion of trust assets held for ceding insurers provides collateral that backs the $2.651 billion of net reinsurance recoverables on GE’s run‑off policies; because those trust assets are subject to investment‑control provisions and can be withdrawn by the ceding companies, they serve as the primary source of security for the recoverables, ensuring that any shortfall in the reinsurers’ ability to pay is covered by the trust‑account assets. Consequently, the size and quality of the trust assets directly affect the valuation and recoverability of the $2.651 billion of reinsurance receivables recorded at year‑end 2021.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 74287,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18839,
        "completion_tokens": 157,
        "total_tokens": 18996
      }
    },
    {
      "question_id": 29,
      "question": "Given Southern Company's dividend policy history and Nicor Gas's $15 million increase in revenue tax expenses passed through to customers, how does the $1.3 billion in Nicor Gas's restricted retained earnings impact Southern Company's ability to maintain its dividend growth trajectory?",
      "original_answer": "Southern Company has maintained a consistent dividend policy, increasing payouts annually since 1948, with $2.62 per share paid in 2021. However, its ability to sustain this growth depends on dividends from subsidiaries like Nicor Gas. Nicor Gas is subject to regulatory restrictions that limit its ability to dividend or loan money to affiliates, with $1.3 billion in retained earnings restricted at year-end 2021. This significantly constrains Southern Company's access to Nicor Gas's earnings, even as revenue tax expenses at Nicor Gas increased by $15 million in 2021. Since Southern Company relies on subsidiary distributions to fund dividends, the restricted retained earnings at Nicor Gas create a structural limitation on how much can be upstreamed, directly affecting the parent company's capacity to continue increasing dividends at the same historical rate.",
      "llm_answer": "The $1.3 billion of restricted retained earnings at Nicor Gas limits the cash that can be distributed to its parent, reducing the amount of earnings available to fund Southern Company’s dividend growth, although the company can still meet its dividend target by drawing on other cash sources and retained earnings elsewhere in the system.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 261,
          "pages": [
            259,
            260,
            261,
            262,
            263
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56903,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14480,
        "completion_tokens": 84,
        "total_tokens": 14565
      }
    },
    {
      "question_id": 29,
      "question": "How does the decline in Bridion sales following EU market exclusivity loss in 2023 impact MRK's overall revenue concentration risk, particularly given the company's reliance on a small group of key products like Keytruda and Gardasil that accounted for 56% of total sales in 2023?",
      "original_answer": "The decline in Bridion sales following the loss of EU market exclusivity in 2023 exacerbates MRK's revenue concentration risk, as the company is heavily dependent on a small set of key products—primarily Keytruda and Gardasil/Gardasil 9—which together accounted for 56% of total sales in 2023. Bridion, once a significant contributor, has seen a substantial decline in sales due to generic competition, and with further losses expected in Japan and the U.S. in the coming years, MRK faces increased pressure to maintain profitability through its remaining key products. This underscores the risk associated with the company's reliance on a narrow product portfolio, especially as these products are also approaching patent expirations, which could further destabilize revenue streams.",
      "llm_answer": "The loss of EU market exclusivity for Bridion in 2023 has already caused a substantial decline in Bridion sales, highlighting the material adverse impact that loss of patent protection can have on a product that contributes significantly to Merck’s revenue. This reinforces the company’s overall revenue concentration risk, especially given that Keytruda and Gardasil/Gardasil 9 alone accounted for 56 % of total sales in 2023, meaning any future exclusivity losses—such as the anticipated 2028 U.S. loss of exclusivity for Keytruda—could sharply reduce sales of these key products and materially affect Merck’s results of operations and financial condition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77059,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19512,
        "completion_tokens": 164,
        "total_tokens": 19677
      }
    },
    {
      "question_id": 29,
      "question": "How does GE's continued exposure to structured settlement annuities, assumed through Union Fidelity Life Insurance Company, align with the disclosed risks around longevity and reinvestment in the insurance segment analysis?",
      "original_answer": "GE's exposure to structured settlement annuities through Union Fidelity Life Insurance Company (UFLIC) involves long-duration liabilities totaling $10.3 billion as of December 31, 2021. These annuities, primarily underwritten on impaired lives, carry significant longevity risk, as improvements in mortality could extend payment durations beyond projections. This aligns with the broader insurance segment's disclosure on page 48 that structured settlement annuities offer no ability to increase premiums or reduce benefits, making them particularly sensitive to life expectancy trends. Additionally, GE faces reinvestment risk due to a low-interest-rate environment, which could reduce investment margins needed to support these liabilities. Despite UFLIC being closed to new business since 2004, the long-duration nature of these contracts means GE must manage these risks over decades, relying on a $41.6 billion investment portfolio and future asset purchases to match liabilities. The structured settlement annuity risk profile contrasts with more flexible long-term care insurance contracts, where premium adjustments are possible, highlighting a key distinction in how GE manages different insurance liabilities.",
      "llm_answer": "GE’s exposure to structured‑settlement annuities through Union Fidelity Life Insurance Company is explicitly identified as a key risk in the insurance segment analysis. The filing notes that these contracts carry “mortality (i.e., life expectancy or longevity), mortality improvement … and reinvestment risk,” and that unlike long‑term care policies they provide no ability to adjust premiums or benefits. This aligns with the disclosed risk of longevity uncertainty and the need to reinvest assets in a low‑interest‑rate environment, both of which are central to the premium‑deficiency testing and reserve calculations described for the run‑off insurance portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 63929,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16211,
        "completion_tokens": 166,
        "total_tokens": 16377
      }
    },
    {
      "question_id": 29,
      "question": "How does ConocoPhillips' capital allocation strategy, as outlined in its disciplined investment framework, reconcile with its decision to exercise a preemptive right to acquire an additional 10% stake in APLNG at a valuation below carrying value, especially in light of the subsequent impairment charge recorded on its existing investment?",
      "original_answer": "ConocoPhillips emphasizes a disciplined investment framework focused on capital efficiency, cost control, and value maximization over production growth, particularly in commodity-driven cycles (page 40). Despite this, the company exercised its preemptive right to acquire an additional 10% in APLNG at a market-determined fair value below its carrying value, which led to a $688 million noncash impairment charge (page 119). This decision appears to be based on long-term strategic value expectations from APLNG’s LNG position and CBM resources in Australia, even though the investment was impaired due to a decline in fair value. The contrast between the capital discipline framework and the APLNG acquisition suggests a strategic bet on LNG growth potential in Asia Pacific markets, despite short-term valuation concerns.",
      "llm_answer": "ConocoPhillips exercised its preemption right to acquire an additional 10% stake in APLNG at a price below the carrying value of its existing investment, which triggered an impairment charge of $688 million (before‑tax) in the fourth quarter of 2021 to write down the investment to fair value. This impairment was recorded despite the company’s broader disciplined capital‑allocation framework that emphasizes sustaining production and returning cash to shareholders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 59219,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15073,
        "completion_tokens": 116,
        "total_tokens": 15190
      }
    },
    {
      "question_id": 30,
      "question": "How does MetLife's issuance of $2.5 billion in surplus notes by MetLife Reinsurance Company of Charleston relate to the prioritization of surplus notes in MetLife's broader debt structure, particularly in light of the contingent regulatory approval required for interest and principal payments?",
      "original_answer": "MetLife Reinsurance Company of Charleston (MRC), a wholly-owned subsidiary of MetLife, issued $2.5 billion in 35-year surplus notes in 2007 to provide statutory reserve support for closed block liabilities reinsured from MLIC. These surplus notes accrue interest based on SOFR (or previously LIBOR) and are contingent on South Carolina regulatory approval for any interest or principal payments. Meanwhile, in the broader debt structure disclosed on page 280, surplus notes are explicitly described as subordinate to all other obligations of the issuing operating company but senior to obligations of MetLife, Inc. itself. Additionally, the notes have a defined payment priority under the collateral financing arrangement. This dual perspective reveals that while the surplus notes are a significant long-term liability with unique regulatory constraints, they also hold a distinct structural position in the capital hierarchy, balancing subordination to senior debt with seniority over parent-level obligations.",
      "llm_answer": "MetLife’s $2.5 billion surplus‑note issuance by its Charleston‑based reinsurance subsidiary is positioned as a senior‑ranked, collateral‑backed financing that enjoys priority over other unsecured debt, but payments of interest and principal on those notes are expressly contingent on South Carolina regulatory approval. Consequently, while the surplus notes sit near the top of the capital structure—ranked above unsecured senior notes and other subordinated debt—they remain subject to a regulatory “gate” that can delay or block cash‑flow to noteholders until the required approval is obtained. This regulatory constraint is a key factor in how the company prioritizes and manages its broader debt hierarchy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 282,
          "pages": [
            280,
            281,
            282,
            283,
            284
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 282,
          "pages": [
            280,
            281,
            282,
            283,
            284
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 280,
          "pages": [
            278,
            279,
            280,
            281,
            282
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77216,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19553,
        "completion_tokens": 177,
        "total_tokens": 19731
      }
    },
    {
      "question_id": 30,
      "question": "How does Chevron's strategic investment in the Caspian Pipeline Consortium (CPC) align with its crude oil reserve growth and production ramp-up plans in Kazakhstan, particularly considering the expected start-up of the Future Growth Project (FGP) in 2025?",
      "original_answer": "Chevron's 15% interest in the Caspian Pipeline Consortium (CPC) is a critical enabler of its crude oil export strategy from Kazakhstan, where Chevron operates major assets like Tengiz and Karachaganak. The CPC pipeline transported an average of 1.2 million barrels per day of Kazakh crude oil in 2023, and the completion of the CPC debottlenecking project in January 2023 has increased throughput capacity, directly supporting the upcoming start-up of the Future Growth Project (FGP) in early 2025. This infrastructure enhancement aligns with Chevron's reserve additions in Kazakhstan, as evidenced by the 2023 reserves of 1,295 million barrels in affiliated companies, including TCO. The FGP is expected to ramp up to full production within three months of start-up, which will be critical in offsetting production declines observed in other regions and sustaining Chevron’s upstream crude oil reserves and production volumes.",
      "llm_answer": "Chevron’s strategic investment in the Caspian Pipeline Consortium (CPC) directly supports its reserve growth and production ramp‑up in Kazakhstan by providing the transportation corridor needed to move crude from the Tengiz and Korolev fields to market. The company’s 50 % stake in TCO, operator of the Future Growth Project (FGP), is on track for start‑up in the first half of 2025, and the CPC debottlenecking project—completed in January 2023—has increased throughput capacity to about 1.4 million bbl/d, enabling the FGP to reach full production within three months of its 2025 start‑up. This integrated approach aligns with Chevron’s broader reserve‑growth strategy and its goal to boost Kazakhstan crude output.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 96148,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24279,
        "completion_tokens": 179,
        "total_tokens": 24458
      }
    },
    {
      "question_id": 30,
      "question": "Given Visual Studio's inclusion in Server products and cloud services, how does its strategic positioning as a developer tool align with the 44% revenue growth ($67.35B to $97.73B) in Server products and cloud services from 2022 to 2024?",
      "original_answer": "Microsoft positions Visual Studio as a key component of its Intelligent Cloud segment, specifically within Server products and cloud services, which reported a 44% revenue increase from $67.35 billion in 2022 to $97.73 billion in 2024. This growth aligns with Microsoft’s strategic emphasis on empowering developers and IT professionals through integrated tools that support cloud application development and deployment on Azure. As a software development lifecycle tool included in the Server products category, Visual Studio contributes to this growth by enabling developers to build applications optimized for Microsoft’s cloud infrastructure, reinforcing the company’s competitive advantage in cloud services.",
      "llm_answer": "Microsoft's strategic positioning of Visual Studio within the Intelligent Cloud segment—highlighted by its inclusion alongside Azure, SQL Server, and GitHub—directly aligns with the 44% revenue growth in Server products and cloud services ($67.35B to $97.73B) from 2022 to 2024. This growth, driven by Azure's 30% expansion and increased consumption-based services, reflects Microsoft's focus on developer tools and cloud infrastructure, where Visual Studio serves as a critical enabler for building and deploying applications on its cloud platform. The 20% overall revenue growth in the Intelligent Cloud segment ($105.36B in 2024 vs. $87.91B in 2023) further underscores how Visual Studio's integration strengthens Microsoft's cloud ecosystem, fueling demand for server and cloud services.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56727,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14423,
        "completion_tokens": 197,
        "total_tokens": 14620
      }
    },
    {
      "question_id": 30,
      "question": "How does the non-dilutable 33 1/3% voting power of Class B common stock, which requires separate approval for major corporate transactions, reconcile with the dividend policy that applies equally to both Class A and Class B shares, given that holders of Class A shares collectively control 66 2/3% of the combined voting power?",
      "original_answer": "The 10-K filing reveals that while both Class A and Class B shares are subject to the same dividend policy—including the $1.08 annualized dividend per share approved in January 2022—the governance structure is asymmetric. Class B common stock, which is entirely beneficially owned by Brian L. Roberts, holds 33 1/3% of the combined voting power, a percentage that is generally non-dilutable. This class also has separate approval rights over several material corporate transactions, regardless of board or shareholder approval. Meanwhile, Class A shareholders collectively control 66 2/3% of the voting power, with votes per share determined by the relative number of Class A and Class B shares outstanding. This creates a governance dynamic where dividend treatment is equal, but control and strategic decision-making power are disproportionately concentrated in the Class B shares, raising implications for shareholder alignment and corporate strategy execution.",
      "llm_answer": "The non‑dilutable 33 ⅓ % voting power of Class B common stock (held entirely by Brian L. Roberts) is subject to separate shareholder‑approval requirements for certain material transactions, yet dividends on Class A and Class B shares are declared and paid equally on a per‑share basis, with each dividend contingent on Board approval. This arrangement means that, despite the Class B holders’ super‑majority voting rights, dividend distributions are treated uniformly for both classes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 51074,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13026,
        "completion_tokens": 121,
        "total_tokens": 13147
      }
    },
    {
      "question_id": 30,
      "question": "How does GE's disclosure of mortality and longevity risks in structured settlement annuities reconcile with the decision to maintain a significant stake in Union Fidelity Life Insurance Company (UFLIC), which produces these annuities and has been closed to new business since 2004?",
      "original_answer": "GE acknowledges significant mortality and longevity risks in its structured settlement annuities, noting that these contracts—primarily underwritten on impaired lives—carry the risk that beneficiaries may live longer than expected, extending payment durations and increasing liabilities. These risks are highlighted on page 48, where GE reports reinsuring approximately 27,400 structured settlement annuities with an average attained age of 54 and outlines the lack of ability to adjust premiums or reduce benefits. Despite these risks, GE maintains a substantial stake in UFLIC, which has been closed to new business since 2004 and is a key producer of these annuities. On page 47, UFLIC is described as reinsuring structured settlement annuities with and without life contingencies from Genworth Financial, and GE continues to manage these long-duration liabilities as part of its run-off insurance operations. The persistence of these liabilities, combined with the lack of new business inflows into UFLIC, suggests that GE must carefully manage its existing exposure through investment strategies and reinsurance, even as it faces the inherent unpredictability of mortality trends and reinvestment risk in a low-interest-rate environment.",
      "llm_answer": "GE maintains a significant stake in Union Fidelity Life Insurance Company (UFLIC) despite its closure to new business since 2004 because UFLIC remains a core component of GE’s run-off insurance portfolio, specifically for structured settlement annuities and long-term care insurance exposures. The disclosure of mortality and longevity risks in structured settlements directly informs the accounting for these legacy liabilities, which are supported by UFLIC’s existing reserves and reinsurance arrangements. This stake allows GE to manage the long-term obligations tied to these closed blocks, where mortality assumptions and reserve calculations continue to impact financial reporting, even as no new business is written.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 63929,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16225,
        "completion_tokens": 180,
        "total_tokens": 16406
      }
    },
    {
      "question_id": 30,
      "question": "How do the varying data protection expiry dates for Emgality across regions impact LLY's ability to predict the duration of market exclusivity for this product?",
      "original_answer": "LLY acknowledges on page 11 that predicting the duration of market exclusivity for its products is challenging due to the complex interaction between patent and regulatory protections, as well as uncertainties in patent litigation. For Emgality specifically, page 13 shows that data protection expires in different regions at different times—2030 in the U.S., 2028 in major European countries, and 2029 in Japan. These varying expiry dates compound the difficulty of predicting when true market exclusivity will end, as LLY must account for both the staggered regulatory protection timelines and the potential for legal challenges or extensions. This uncertainty affects how LLY strategizes lifecycle management and revenue forecasting for Emgality.",
      "llm_answer": "The varying data protection expiry dates for Emgality across regions (U.S. 2030, major European countries 2028, Japan 2029) directly impact LLY's ability to predict market exclusivity duration because these dates are tied to data protection periods under regulatory frameworks (e.g., U.S. data protection under BPCIA, EU/Japan periods), which can be subject to change based on regulatory decisions, legal challenges, or policy shifts. This variability introduces uncertainty in the effective exclusivity timeline, as data protection may expire before or alongside patent protections, potentially shortening the window of market exclusivity beyond the estimated dates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 57339,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14548,
        "completion_tokens": 166,
        "total_tokens": 14715
      }
    },
    {
      "question_id": 30,
      "question": "How does Emerson's strategic acquisition of NI for $8.653 billion, including the $7.833 billion cash payment to acquire the remaining shares, reflect the strategic importance of automated test systems in driving faster time-to-market and cost efficiency as described in the Test & Measurement segment's value proposition?",
      "original_answer": "Emerson's acquisition of NI for a total purchase consideration of $8.653 billion, including $7.833 billion in cash paid to acquire the remaining NI shares, underscores the strategic importance Emerson places on NI’s software-connected automated test systems. This aligns with the Test & Measurement segment’s stated value proposition of enabling enterprises to bring products to market faster and at a lower cost. The acquisition integrates NI’s capabilities into Emerson’s portfolio, reinforcing the company’s focus on delivering advanced test and measurement solutions that enhance speed and efficiency in product development cycles.",
      "llm_answer": "Emerson's $8.653 billion acquisition of National Instruments—including a $7.833 billion cash payment for the remaining shares—underscores the strategic role of automated test systems within the Test & Measurement segment, which the company highlights as a key driver for accelerating time‑to‑market and delivering cost efficiency. This is reflected in the segment’s value proposition of enabling enterprises to bring products to market faster and at lower cost, and is evident in the $1.464 billion of sales and the resulting net loss of $537 million attributed to the NI acquisition, which included inventory step‑up amortization, intangible amortization, retention bonuses, stock compensation and restructuring costs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66983,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17003,
        "completion_tokens": 179,
        "total_tokens": 17183
      }
    },
    {
      "question_id": 31,
      "question": "How does ConocoPhillips' financial exposure through its 47.5% stake in APLNG, including its guarantees and equity investment, relate to its production of coal bed methane (CBM) in Australia and the long-term financing obligations tied to the APLNG project?",
      "original_answer": "ConocoPhillips holds a 47.5% stake in APLNG, which is focused on producing coal bed methane (CBM) from the Bowen and Surat basins in Queensland, Australia, and exporting LNG to Asia Pacific markets. As of December 31, 2024, the carrying value of this equity investment was approximately $5.0 billion. APLNG has a long-term $8.5 billion project finance facility, with $4.0 billion still outstanding as of year-end 2024, requiring bi-annual principal and interest payments until September 2030. In addition, ConocoPhillips has issued multiple guarantees related to APLNG, including a $210 million guarantee tied to a project finance reserve account, a $610 million (up to $1.0 billion in case of intentional breach) guarantee related to natural gas delivery commitments, and $480 million in performance guarantees, with carrying values totaling $52 million as of December 31, 2024. These financial exposures illustrate the company’s significant long-term commitment to the APLNG project, which is directly tied to the production of CBM in Australia, highlighting the interplay between operational strategy and financial risk management.",
      "llm_answer": "ConocoPhillips holds a 47.5 % equity stake in APLNG, which produces coal‑bed methane (CBM) in Australia and exports LNG to the Asia‑Pacific region.  To support the APLNG project it has issued multiple guarantees—covering a $210 million project‑finance reserve withdrawal, a $610 million potential liability for natural‑gas delivery obligations, and a $480 million performance guarantee—reflecting its long‑term financing commitments tied to the joint‑venture’s $4 billion outstanding project‑finance facility that matures through 2030.  These guarantees, together with its equity investment, expose ConocoPhillips to the financial performance and debt service obligations of APLNG.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64011,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16246,
        "completion_tokens": 170,
        "total_tokens": 16416
      }
    },
    {
      "question_id": 31,
      "question": "How does Tesla's disclosure of warrant-related share dilution in the financial statements reconcile with the specific share issuances to 2019 Warrantholders in October 2024, and what impact did this have on Tesla's equity structure?",
      "original_answer": "Tesla's financial statements on page 64 show that warrants contributed 8 million shares to the diluted share count in 2024, down from 11 million in 2023. This reduction aligns with the October 2024 issuance of 2,894,424 shares to the 2019 Warrantholders, as disclosed in the Unregistered Sales of Equity Securities section on page 34. The exercise of these warrants under Rule 3(a)(9) of the Securities Act resulted in a net issuance of shares without cash proceeds, directly affecting Tesla’s equity structure by increasing the number of outstanding shares and reducing future dilution potential from these instruments.",
      "llm_answer": "Tesla disclosed that warrants issued in 2019 were exercised between October 1 and October 15 2024, resulting in the issuance of 2,894,424 shares to the 2019 warrantholders. This issuance was reflected in the diluted‑share calculations (warrants contributed 8 million diluted shares in 2024) and was accounted for as an equity transaction, so it did not affect net income but increased the total shares outstanding and thus diluted earnings per share. Consequently, Tesla’s equity structure was expanded by roughly 2.9 million shares, modestly diluting existing shareholders while leaving reported net income unchanged.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TSLA_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "TSLA_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "TSLA_10k_2024.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 49449,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12597,
        "completion_tokens": 154,
        "total_tokens": 12752
      }
    },
    {
      "question_id": 31,
      "question": "How does AT&T's continued depreciation of wireless tower assets originally sold to Crown Castle reconcile with the fixed-price purchase options Crown Castle holds at the end of the lease terms?",
      "original_answer": "AT&T continues to depreciate the wireless tower assets on its balance sheet because it did not transfer control of these assets in the transaction with Crown Castle, which prevented sale-leaseback accounting treatment. As of December 31, 2021, these tower assets had a net book value of $725 and were depreciated at a rate of $39 annually. Meanwhile, Crown Castle holds fixed-price purchase options for these towers at the end of their respective lease terms, totaling approximately $4,200 based on estimated fair market values at that time. This creates a contrast between AT&T's ongoing depreciation of the assets and the potential future transfer of ownership at predetermined prices that may not reflect actual market values at expiration.",
      "llm_answer": "AT&T continues to depreciate the wireless tower assets it originally sold to Crown Castle because it retained control of those assets under the lease‑back arrangement; consequently, the assets remain on its balance sheet and are depreciated over their useful lives. At the end of each lease term, Crown Castle holds a fixed‑price purchase option to buy the towers for an amount estimated at roughly $4.2 billion, which reflects their then‑fair market value. This depreciation and the existence of the fixed‑price purchase options are disclosed in Note 19 (Tower Transaction) of the 10‑K filing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 133,
          "pages": [
            131,
            132,
            133,
            134,
            135
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66030,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16730,
        "completion_tokens": 148,
        "total_tokens": 16878
      }
    },
    {
      "question_id": 31,
      "question": "What is the relationship between AspenTech's inclusion in Emerson's business segments and the increase in performance share expenses from $89 million in 2022 to $165 million in 2023?",
      "original_answer": "The increase in performance share expenses from $89 million in 2022 to $165 million in 2023 correlates with the inclusion of AspenTech in Emerson's business segments starting in 2023. AspenTech has its own stock-based compensation plans involving performance shares, which are now consolidated under Emerson's financial reporting. This consolidation likely contributed to the significant year-over-year increase in performance share expenses, reflecting the integration of AspenTech's compensation obligations into Emerson's financials.",
      "llm_answer": "The increase in performance share expenses from $89 million in 2022 to $165 million in 2023 reflects Emerson’s higher payout of performance‑share awards—driven by achieving a 118 % performance level for the 2021‑2023 performance period—while AspenTech’s stock‑based compensation (including performance shares) is accounted for within Emerson’s overall incentive‑share expense, contributing to the larger total expense reported for 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 59579,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15117,
        "completion_tokens": 109,
        "total_tokens": 15226
      }
    },
    {
      "question_id": 31,
      "question": "How does BMY's exposure to the Inflation Reduction Act's price negotiation provisions, as applied to Pomalyst, interact with the company's strategy to maintain market exclusivity for the drug through patent protections and regulatory exclusivity periods?",
      "original_answer": "BMY faces direct exposure under the Inflation Reduction Act (IRA), as Pomalyst was selected in January 2025 for government 'negotiation' of prices, with pricing decisions taking effect in 2027. This regulatory risk could lead to reduced revenue and accelerate erosion of market exclusivity prior to the expiration of relevant patents. At the same time, Pomalyst is among BMY’s key chemical products listed as benefiting from U.S. regulatory exclusivity protections, which typically last five years. However, the document notes that Paragraph IV certifications—generic challenges to patent validity—can be filed after four years, allowing generic manufacturers to seek FDA approval before exclusivity periods end. The combination of IRA-driven pricing constraints and the risk of early generic entry through ANDA filings creates a dual threat to Pomalyst's revenue stream, particularly since the drug is already under regulatory scrutiny both in terms of pricing and patent defensibility.",
      "llm_answer": "BMY's exposure to the Inflation Reduction Act's price negotiation provisions—particularly as they apply to Pomalyst—interacts with its broader strategy of relying on patent protections and regulatory exclusivity to maintain market exclusivity for its high‑value oncology drugs. The IRA’s mechanism for government price negotiation (e.g., the 2027 negotiation of Pomalyst) can accelerate revenue erosion before the product’s patent or regulatory exclusivity fully expires, forcing BMS to lean more heavily on extending patent life, pursuing supplemental protection certificates, and leveraging additional data exclusivity periods to preserve its pricing power. Consequently, while patent and regulatory exclusivity provide the primary shield for market exclusivity, the IRA’s price‑setting rules introduce a strategic risk that may shorten the effective exclusivity window for drugs like Pomalyst, prompting the company to pursue aggressive patent extensions and regulatory maneuvers to mitigate that risk.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 90605,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22897,
        "completion_tokens": 251,
        "total_tokens": 23148
      }
    },
    {
      "question_id": 31,
      "question": "How does Chevron's 2023 crude oil reserve growth in Kazakhstan, particularly from the Tengiz and Korolev fields, align with the Caspian Pipeline Consortium's (CPC) capacity expansion and its role in transporting Chevron's production?",
      "original_answer": "Chevron's crude oil reserve growth in Kazakhstan, particularly from the Tengiz and Korolev fields, is expected to be supported by the Caspian Pipeline Consortium's (CPC) increased throughput capacity following the completion of its debottlenecking project in January 2023. The Tengiz and Korolev fields, operated under TCO, saw mechanical completion of the Future Growth Project (FGP) in 2023, with full production expected to ramp up in early 2025. This expansion aligns with CPC's role in transporting an average of 1.4 million barrels of crude oil per day, including Chevron’s production, and its capacity increase to accommodate FGP's start-up. Chevron holds a 15% interest in CPC, reinforcing its strategic dependency on the pipeline for export logistics.",
      "llm_answer": "Chevron’s 2023 crude oil reserve growth in Kazakhstan—primarily from the Tengiz and Korolev fields operated by Tengizchevroil (TCO)—is directly linked to the Caspian Pipeline Consortium (CPC) pipeline, which transports the majority of this production to market. The CPC pipeline’s 2023 debottlenecking project increased throughput capacity, enabling higher export volumes from Kazakhstan to support TCO’s expanded output, including from the Future Growth Project (FGP) and related developments. This infrastructure expansion aligns with Chevron’s strategy to monetize its Kazakh reserves through reliable, high-capacity transport to global markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 96148,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24273,
        "completion_tokens": 162,
        "total_tokens": 24435
      }
    },
    {
      "question_id": 32,
      "question": "How does American Express's reliance on AENB for deposit funding interact with the leverage ratio requirements that constrain AENB's dividend payments, especially given AXP's overall regulatory capital position as of December 31, 2021?",
      "original_answer": "American Express relies on AENB as its primary deposit channel, with $84.4 billion in deposits as of December 31, 2021, which is critical for funding operations. However, AENB is subject to regulatory constraints that limit its ability to pay dividends to its parent, including the requirement to maintain minimum leverage ratios and capital adequacy standards. AENB had $3.6 billion in retained earnings available for dividends as of that date, but any distribution must also consider the impact on regulatory capital ratios. AXP itself is subject to Federal Reserve capital adequacy requirements and must maintain sufficient CET1, Tier 1, and Total capital ratios. Therefore, while AENB is a key source of funding for AXP, its ability to return capital to the parent is restricted by leverage and risk-based capital requirements, which in turn affects AXP’s broader capital management strategy and dividend policy.",
      "llm_answer": "American Express’s AENB subsidiary relies on deposits (AENB) to fund its operations, but its ability to pay dividends to its parent is constrained by regulatory capital and leverage requirements. As of December 31 2021, AENB had $3.6 billion of retained earnings available for dividends, yet its risk‑based capital ratios and the Federal Reserve’s dividend‑restriction policies limit any payout that would jeopardize compliance with the minimum CET1 (4.5 % + buffers) and leverage (4 %) capital standards. Consequently, while AENB generated $8.1 billion of dividends to its parent in 2021, future dividend levels must align with its capital plan and the effective minimum ratios (CET1 ≥ 7 %, leverage ≥ 4 %), ensuring that dividend payments do not erode the capital buffers needed to remain well‑capitalized.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71665,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18154,
        "completion_tokens": 202,
        "total_tokens": 18356
      }
    },
    {
      "question_id": 32,
      "question": "How does ConocoPhillips' production of condensate from the Aasta Hansteen Field relate to its financial exposure through guarantees tied to Alba Plant LLC, particularly in light of its equity earnings from LPG processing?",
      "original_answer": "ConocoPhillips produces condensate from the Aasta Hansteen Field in the Norwegian Sea, which is transported via shuttle tankers to market. Separately, the company owns a 52.2% interest in Alba Plant LLC, which processes natural gas from the Alba Unit offshore Equatorial Guinea, extracting condensate and LPG for sale at market prices. These revenues contribute to COP’s 'Equity in earnings of affiliates' line. Additionally, COP has guaranteed payment obligations tied to Alba Plant LLC with a maximum potential future payment of $116 million. This indicates that while COP benefits from condensate monetization through Alba Plant LLC’s processing, it also carries financial risk exposure through contractual guarantees, linking upstream condensate production to downstream processing and financial commitments.",
      "llm_answer": "ConocoPhillips’ equity earnings from the Alba Plant LLC in Equatorial Guinea arise from its 52.2 % ownership of the joint venture that processes natural‑gas condensate and LPG from the Alba Unit. The plant’s condensate is sold at market prices, and the resulting equity earnings are reported in “Equity in earnings of affiliates” on the consolidated income statement. Because the company guarantees certain performance and payment obligations of Alba Plant LLC (and related entities), any default or shortfall could trigger contingent liabilities under those guarantees, linking the financial exposure from the guarantees to the earnings generated by the condensate processing operation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56148,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14272,
        "completion_tokens": 171,
        "total_tokens": 14444
      }
    },
    {
      "question_id": 32,
      "question": "Given that NIKE emphasized strategic investment in accessories as part of its corporate-wide growth plan on page 33, and Converse is explicitly identified as a reportable segment responsible for accessories, how does Converse's 15% currency-neutral revenue decline in fiscal 2024 reflect on the effectiveness of NIKE's strategy as it pertains to the accessories category?",
      "original_answer": "NIKE's corporate strategy on page 33 highlights a focus on growing its portfolio of branded products, including accessories, through innovation and consumer connection. Accessories are positioned as part of the broader growth strategy, with investment prioritization intended to fuel future growth. However, Converse, which is the reportable segment responsible for athletic lifestyle sneakers, apparel, and accessories, reported a 15% currency-neutral revenue decline in fiscal 2024, driven by drops in both wholesale and direct-to-consumer channels across key markets. This decline suggests that despite NIKE's strategic emphasis on accessories, Converse—its primary vehicle for executing this strategy—faced executional and market challenges, including reduced traffic and increased promotional activity, which undermined revenue growth. Thus, the performance of Converse raises questions about the alignment or execution of the corporate strategy as it applies to the accessories segment.",
      "llm_answer": "Converse's 15% currency-neutral revenue decline in fiscal 2024 reflects a weakening in the accessories category's performance, despite NIKE's strategic emphasis on accessories investment. This decline—driven by reduced wholesale and direct-to-consumer sales across North America and Western Europe, with lower ASPs and promotional activity—indicates that the accessories segment (reportable as Converse) is not yet delivering on the growth expectations set by NIKE's corporate-wide strategy, even as the company prioritizes reinvestment in digital infrastructure and demand-sensing capabilities to fuel future growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 66336,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16859,
        "completion_tokens": 154,
        "total_tokens": 17013
      }
    },
    {
      "question_id": 32,
      "question": "How does the voting power disparity between Class A and Class B common stock, as outlined in the equity structure, influence the governance control dynamics despite the significant share repurchases of Class A common stock?",
      "original_answer": "The equity structure reveals that Class B common stock, which represents only 9,444,375 issued and outstanding shares, holds 33 1/3% of the combined voting power due to each share carrying 15 votes. This contrasts with Class A common stock, which has 4,842,108,959 shares issued and 3,969,317,931 outstanding, yet holds 66 2/3% of the voting power. Despite the company repurchasing 872,791,028 Class A shares, which have reduced the issued shares from 5,083,466,045 to 4,842,108,959, the governance control remains significantly influenced by the Class B shares, as they are non-dilutable and held entirely by Mr. Brian L. Roberts. This dynamic ensures continued concentrated control over major corporate decisions.",
      "llm_answer": "The voting power disparity—Class B shares carry 15 votes per share while Class A shares carry one vote—means that, despite substantial repurchases that reduce the number of Class A shares outstanding, the Roberts family (which owns all Class B shares) continues to control roughly one‑third of the total voting power. Consequently, even as the company buys back and retires large blocks of Class A stock, governance decisions remain heavily influenced by the Class B holders, limiting the impact of shareholder‑level pressure from the broader Class A investor base.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 58158,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14776,
        "completion_tokens": 141,
        "total_tokens": 14918
      }
    },
    {
      "question_id": 32,
      "question": "How does the significant increase in GD's plan assets measured using NAV for real estate funds from $8 million in other post-retirement benefit plans to $733 million in pension plan assets reflect different risk exposures or valuation methodologies across the two benefit plans?",
      "original_answer": "GD reports $733 million in NAV-measured real estate fund assets within its pension plan assets on page 96, while the same category shows only $8 million in the other post-retirement benefit plan on page 97. This stark difference suggests that real estate funds are a much larger component of the pension plan, which likely exposes the pension plan to greater valuation uncertainty due to the use of NAV as a practical expedient rather than observable market inputs. The lack of Level 1 or Level 2 pricing for NAV-measured real estate funds indicates a reliance on unobservable inputs, creating divergent risk profiles between the two benefit plans despite holding similar asset categories.",
      "llm_answer": "The increase in real estate fund assets from $8 million in other post‑retirement benefit plans to $733 million in pension plan assets reflects a shift in both risk exposure and valuation methodology. Pension‑plan real‑estate holdings are classified as Level 3 (unobservable inputs) and are valued using internally derived fair‑value estimates, whereas the smaller post‑retirement fund assets are measured at NAV as a practical expedient (effectively Level 1). Consequently, the pension plan’s larger, less liquid real‑estate exposure carries higher valuation uncertainty and different risk characteristics compared with the more readily observable, lower‑risk NAV‑valued holdings in the post‑retirement plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63071,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16010,
        "completion_tokens": 177,
        "total_tokens": 16187
      }
    },
    {
      "question_id": 32,
      "question": "Given Southern Company's stated useful life for wind assets and the capacity and contract period of the Skookumchuck wind project, how does the company's long-term asset planning align with its contractual revenue commitments for this specific wind facility?",
      "original_answer": "Southern Company reports a maximum useful life of 30 years for wind assets, yet the Skookumchuck wind project, with 136 MW of capacity, has a PPA contract period of 20 years. This suggests that while the asset may be capable of generating value for a longer period, the company's contractual revenue commitment for Skookumchuck is structured over a shorter timeframe, potentially reflecting market or regulatory constraints in long-term power purchase agreements for wind facilities.",
      "llm_answer": "Southern Company's 2021 10-K indicates that the Skookumchuck wind project (136 MW) has a contracted PPA period of 20 years, and the company assigns a 30‑year useful life to its wind assets. Because the PPA extends for two decades, the project's revenue stream is aligned with the longer end of the 30‑year depreciation schedule, ensuring that the asset's long‑term planning and depreciation assumptions support the contractual revenue commitments for the life of the agreement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71748,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18181,
        "completion_tokens": 119,
        "total_tokens": 18300
      }
    },
    {
      "question_id": 32,
      "question": "How does Schwab's ownership stake in TDAC, combined with TDAC's self-clearing operations through clearing houses like NSCC, create specific liquidity risk exposure given the recent margin requirement increases mentioned in the 10-K?",
      "original_answer": "Schwab owns TDAC, which operates as a self-clearing broker-dealer subject to SEC net capital rules (page 120). As part of its clearing operations, TDAC must maintain cash deposits and collateral with clearing houses like NSCC to meet fluctuating margin requirements tied to client trading activity and market volatility (page 14). The 10-K specifically notes that recent market volatility caused NSCC to increase margin requirements, forcing Schwab to deposit additional funds with clearing houses (page 22). This creates a direct liquidity risk chain: Schwab's ownership of TDAC means it must support TDAC's capital needs, while TDAC's clearing house obligations amplify liquidity pressures during volatile periods when margin calls spike.",
      "llm_answer": "Schwab’s 25% ownership stake in TDAC, combined with TDAC’s self‑clearing model that routes trades through clearing houses such as NSCC, creates liquidity risk because the firm must meet margin calls and fund settlement obligations even during periods of heightened market volatility. The recent margin‑requirement increases at the clearing houses can force Schwab to post additional cash or collateral, straining its liquidity and potentially triggering broader funding constraints if market stress coincides with its large retail‑client balances and margin‑lending exposure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74486,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18863,
        "completion_tokens": 143,
        "total_tokens": 19007
      }
    },
    {
      "question_id": 32,
      "question": "How does UPS's $139 million 2023 contribution to the New York State Teamsters Conference Pension and Retirement Fund demonstrate compliance with FIP requirements for red-zone pension plans?",
      "original_answer": "UPS satisfies all implemented FIP requirements through collectively-bargained contributions, as stated in the general pension plan overview on page 94. The New York State Teamsters Conference Pension and Retirement Fund is specifically identified on page 95 as a red-zone plan subject to an implemented FIP. UPS contributed $139 million to this fund in 2023, demonstrating that their contributions align with the financial improvement obligations tied to this red-zone plan. The data confirms that UPS's contributions meet the required levels without surcharges, consistent with their overall pension funding strategy.",
      "llm_answer": "UPS’s $139 million contribution to the New York State Teamsters Conference Pension and Retirement Fund is listed among the multi‑employer pension plans that are classified as “red‑zone” (i.e., less than 65 % funded). The table shows this plan’s 2023 zone status as **Red** and its **FIP/RP Status** as **Implemented**, confirming that a rehabilitation plan has been put in place. Because the plan’s contributions satisfy the requirements of the implemented rehabilitation plan, UPS’s payment meets the FIP/RP obligations required for red‑zone pension plans under the Pension Protection Act.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22174,
        "completion_tokens": 147,
        "total_tokens": 22321
      }
    },
    {
      "question_id": 33,
      "question": "How does the $122 million pre-tax gain from the remeasurement of PEP's equity stake in Sabra relate to the acquisition of Sabra Dipping Company as a wholly-owned subsidiary, and what strategic implications does this have for Frito-Lay North America's product portfolio?",
      "original_answer": "PEP recognized a $122 million pre-tax gain from remeasuring its previously held 50% equity stake in Sabra to fair value upon acquiring the remaining 50% ownership interest in Sabra Dipping Company, making it a wholly-owned subsidiary. This acquisition aligns with Frito-Lay North America's (FLNA) strategic focus on branded dips, as Sabra Dipping Company now contributes its refrigerated dips and spreads directly to FLNA’s broader portfolio of convenient foods. The financial gain reflects the increased control and integration of Sabra into FLNA’s operations, supporting PEP’s strategy to strengthen its position in the dips category through full ownership and operational consolidation.",
      "llm_answer": "The $122 million pre‑tax gain from remeasuring PepsiCo’s former 50 % equity stake in Sabra is recorded in the FLNA division’s selling, general and administrative expenses. This gain stems from the acquisition of Sabra’s remaining ownership that made it a wholly‑owned subsidiary, signaling that Sabra’s dip‑based product line is now fully integrated into PepsiCo’s portfolio and will contribute to FLNA’s snack‑food growth. Consequently, the transaction strengthens Frito‑Lay North America’s product offering and expands its revenue base through Sabra’s established refrigerated dip brands.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68657,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17407,
        "completion_tokens": 147,
        "total_tokens": 17555
      }
    },
    {
      "question_id": 33,
      "question": "How does Chevron's supply chain dependency on crude oil align with its financial stake in Chevron U.S.A. Inc., a subsidiary that directly manages crude oil exploration and production assets in the U.S.?",
      "original_answer": "Chevron Corporation depends on crude oil as a core raw material for its upstream and downstream operations (page 35). Chevron U.S.A. Inc. (CUSA), a major subsidiary in which Chevron holds a full ownership stake, manages most of Chevron's U.S. businesses, including those related to crude oil exploration, production, and refining (page 77). CUSA also oversees Chevron’s investment in Chevron Phillips Chemical Company LLC. This alignment indicates that Chevron’s supply chain reliance on crude oil is operationally and financially integrated through CUSA, which controls the upstream assets critical to Chevron’s business model. The structure allows Chevron to directly manage its crude oil supply base while consolidating financial performance through its majority-owned subsidiary.",
      "llm_answer": "Chevron's supply chain dependency on crude oil directly aligns with its financial stake in Chevron U.S.A. Inc. (CUSA), as CUSA manages the company's U.S. exploration and production assets, including crude oil operations. This is evidenced by CUSA's role in managing upstream activities and its significant financial contributions, such as $7,602 million in U.S. upstream net income in 2024 (per Note 6 and the Financial Table of Contents), which reflects its direct involvement in crude oil production that underpins Chevron's broader supply chain.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84673,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21396,
        "completion_tokens": 137,
        "total_tokens": 21533
      }
    },
    {
      "question_id": 33,
      "question": "How does Microsoft's treatment of Software Assurance (SA) in multi-year Enterprise Agreements affect the timing of revenue recognition for on-premises licenses compared to the invoicing terms outlined in the contracts?",
      "original_answer": "Microsoft includes Software Assurance (SA) in Enterprise Agreements, which are multi-year licensing programs designed for medium or large organizations. These agreements allow customers to purchase perpetual or subscription-based licenses over a three-year period. SA, which provides benefits like future software upgrades, is bundled with perpetual licenses in Enterprise Agreements. According to the accounting policy on page 64, revenue for multi-year on-premises licenses is recognized upfront even though invoicing occurs annually at the beginning of each coverage period. This creates a timing difference between when revenue is recognized and when cash is collected, resulting in recorded receivables. The upfront recognition reflects Microsoft's assessment of the standalone selling price (SSP) and the pattern of delivery of SA benefits across the customer portfolio. Thus, while invoicing is annual, revenue recognition is immediate, and SA plays a key role in structuring the customer relationship and determining the allocation of variable consideration.",
      "llm_answer": "Microsoft recognizes on‑premises perpetual licenses as distinct performance obligations that are transferred at a point in time, so revenue from those licenses is recognized upfront. When such licenses are sold together with Software Assurance (SA) under volume‑licensing agreements like Enterprise Agreements, the license and the SA are treated as separate obligations; revenue allocated to SA is recognized ratably over the contract period as the assurance services are delivered, even though the invoice for the multi‑year agreement may be issued annually at the start of each coverage year. Consequently, the timing of revenue recognition for the on‑premises license is independent of the invoicing schedule, whereas the portion tied to SA is spread over time in line with the multi‑year billing terms.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 54822,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13937,
        "completion_tokens": 201,
        "total_tokens": 14139
      }
    },
    {
      "question_id": 33,
      "question": "How does the absence of issued Class B Common Stock in 2024 impact the voting power structure and equity composition compared to the previous year, given its convertibility into Class A Common Stock?",
      "original_answer": "The absence of issued Class B Common Stock in 2024 removes the dual-class voting power dynamic, as Class B shares historically held 33⅓% of the voting power and were convertible into Class A shares. In 2023, Class A Common Stock had 4,842,108,959 issued shares with $48 billion in equity value, while Class B Common Stock had 9,444,375 issued and outstanding shares, contributing to a differentiated equity structure. By 2024, only Class A Common Stock remains issued (4,651,093,045 shares), with equity value declining slightly to $47 billion, suggesting a shift in governance and equity control. This structural change affects shareholder influence and aligns voting power exclusively with Class A shareholders.",
      "llm_answer": "The 2024 Consolidated Balance Sheet shows no Class B Common Stock issued or outstanding, whereas the 2023 balance sheet listed 9 million Class B shares. Because Class B shares carry 15 votes per share and collectively provide roughly one‑third of the total voting power, their absence eliminates that voting block. Consequently, voting power is now held solely by the remaining Class A shares, which represent about two‑thirds of the total vote, and any convertible Class B shares (which can be exchanged one‑for‑one into Class A) are no longer present to affect equity composition. This shift reduces the overall voting influence of the historically lower‑vote Class B stock and concentrates voting control in the Class A shareholders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72342,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18314,
        "completion_tokens": 184,
        "total_tokens": 18498
      }
    },
    {
      "question_id": 33,
      "question": "Given the conversion rights of Class B Common Stock into Class A Common Stock and the voting power distribution, how does the disclosed non-dilutable 33 1/3% voting control by Class B shares reconcile with the fact that Class A shares significantly outnumber Class B shares and are listed on Nasdaq?",
      "original_answer": "The disclosed capital structure on page 69 shows that Class B Common Stock consists of only 9,444,375 issued and outstanding shares compared to over 4.8 billion Class A shares. Despite this disparity, Note 12 on page 91 clarifies that Class B shares maintain a non-dilutable 33 1/3% of total voting power through their 15-vote entitlement per share, which compensates for their smaller quantity. This voting control mechanism is preserved even though Class B shares can convert to Class A shares, and Class A shares are publicly traded on Nasdaq as disclosed on page 1. The dual-class structure thus enables concentrated voting control while allowing for broader equity ownership through the Class A shares.",
      "llm_answer": "The disclosed non‑dilutable 33 ⅓ % voting control of Class B shares is reconciled by the fact that each Class B share carries 15 votes, while Class A shares have a variable vote that depends on the outstanding numbers of both classes, so the aggregate 33 ⅓ % voting power of Class B cannot be diluted by any future issuances of other stock. Although Class A shares vastly outnumber Class B shares, the voting‑power formula and the non‑dilution provision ensure that Class B’s 33 ⅓ % share of total voting power remains fixed, even though the company’s Class A common stock is listed on Nasdaq.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 61017,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15510,
        "completion_tokens": 148,
        "total_tokens": 15658
      }
    },
    {
      "question_id": 33,
      "question": "How does the strategic emphasis on the John Lewis-class Fleet Replenishment Oiler in the Marine Systems segment align with the $735 million contract awarded for its construction, and what does this indicate about GD's long-term naval shipbuilding priorities?",
      "original_answer": "The strategic emphasis on the John Lewis-class Fleet Replenishment Oiler, noted in the narrative section of GD's 10-K, highlights its importance in the company's naval shipbuilding portfolio, with deliveries planned into 2028. This aligns with the $735 million contract awarded in 2023 for the construction of an additional ship in this class, as disclosed in the Marine Systems segment's contract awards. The combination of long-term delivery planning and the significant contract value indicates that GD is prioritizing sustained investment in auxiliary naval vessels as part of its broader long-term shipbuilding strategy, balancing submarine and surface ship production.",
      "llm_answer": "The $735 million Navy contract for an additional John Lewis‑class (T‑AO‑205) fleet replenishment oiler is a direct component of the Marine Systems segment’s backlog, which totaled $73.2 billion at the end of 2023 and includes a steady pipeline of long‑term shipbuilding programs. This award underscores GD’s strategic focus on expanding its surface‑ship and auxiliary‑ship construction capabilities—particularly under the John Lewis class—to meet the Navy’s growing replenishment and logistics demands, reinforcing the company’s long‑term priority of sustaining and growing its naval shipbuilding portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31298,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 8065,
        "completion_tokens": 151,
        "total_tokens": 8216
      }
    },
    {
      "question_id": 33,
      "question": "How does BMY's regulatory exclusivity advantage for biologics like Opdualag intersect with its strategic positioning in the melanoma treatment market, particularly given the specific indication for unresectable or metastatic melanoma in patients 12 years and older?",
      "original_answer": "BMY benefits from a 12-year regulatory exclusivity period for biologics such as Opdualag, which is indicated for treating unresectable or metastatic melanoma in patients aged 12 and older. This exclusivity period provides a significant market protection window, allowing BMY to establish a strong foothold in the melanoma treatment market without biosimilar competition. The specific indication for Opdualag, targeting both adult and pediatric patients, enhances its market potential by broadening the patient population. This strategic positioning is reinforced by the regulatory framework, which delays biosimilar approval, thereby safeguarding BMY's market share during the exclusivity period.",
      "llm_answer": "BMY's regulatory exclusivity advantage for Opdualag—specifically its 12‑year U.S. biosimilar exclusivity for the Opdivo‑based combination therapy—creates a durable market‑protection window for the melanoma indication in patients aged 12 years and older. This regulatory moat reinforces BMY’s strategic positioning as a leading provider of innovative, checkpoint‑inhibitor‑based regimens in the high‑growth, unresectable/metastatic melanoma space, helping to sustain pricing power and long‑term revenue growth despite looming patent cliffs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 93225,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23545,
        "completion_tokens": 134,
        "total_tokens": 23680
      }
    },
    {
      "question_id": 33,
      "question": "How does Boeing's exposure to cost overruns on fixed-price development contracts, specifically the $402 million loss recorded on the KC-46A Tanker in 2021, reconcile with the continued production authorization of 94 aircraft across seven LRIP lots valued at $19 billion as of December 31, 2021?",
      "original_answer": "Boeing faces significant financial exposure on fixed-price development contracts like the KC-46A Tanker, as evidenced by the $402 million loss recorded in Q4 2021 due to supply chain disruptions and evolving customer requirements. Despite these challenges, the U.S. Air Force has authorized seven LRIP lots for 94 aircraft under the same program, with a total contract value of $19 billion as of year-end 2021. This continuation suggests that while Boeing bears the risk of cost overruns inherent in fixed-price development contracts, the strategic importance of the KC-46A program and its long-term revenue potential justify ongoing production, even in the face of near-term financial losses.",
      "llm_answer": "Boeing recorded a $402 million reach‑forward loss on the KC‑46A tanker in 2021, reflecting cost overruns on the fixed‑price development contract.  Nevertheless, the company continued to receive funding and authorized production of 94 KC‑46A aircraft across seven LRIP lots, a program valued at about $19 billion as of Dec 31 2021.  The contract’s fixed‑price nature means revenue is fixed while cost estimates remain uncertain, so the loss is offset by the ongoing authorization of additional lots and the associated $19 billion contract value.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 51550,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13145,
        "completion_tokens": 136,
        "total_tokens": 13281
      }
    },
    {
      "question_id": 33,
      "question": "Given ExxonMobil's long-standing operational presence in Nigeria since at least 2006, how does the company's exposure to production-sharing contracts (PSCs) in Nigeria—where the exploration period is typically 10 years and production period is 20 years—impact the classification and economic interest in proved reserves under SEC reporting requirements?",
      "original_answer": "ExxonMobil has operated in Nigeria since at least 2006, where its activities are governed by production-sharing contracts (PSCs) that typically include a 10-year exploration period and a 20-year production period, which may be extended. Under SEC reporting rules, proved reserves must be estimated with reasonable certainty to be economically producible prior to the expiration of contracts unless renewal is reasonably certain. Since Nigeria’s PSCs include defined expiration dates and partial relinquishment provisions under the Petroleum Industry Act, ExxonMobil must assess the likelihood of contract extensions when reporting proved reserves. As of year-end 2021, 12% of ExxonMobil’s total proved reserves on an oil-equivalent basis were associated with PSC arrangements, and reserves under these contracts vary inversely with price changes. Therefore, the finite duration and fiscal terms of Nigeria’s PSCs directly influence the economic interest and classification of reserves under SEC rules, particularly for deepwater offshore assets.",
      "llm_answer": "ExxonMobil’s Nigeria operations are conducted under production‑sharing contracts (PSCs) that typically grant a 10‑year exploration period followed by a 20‑year production period. Under U.S. SEC rules, proved reserves are classified only for the portion of those contracts that is demonstrably recoverable and for which economic conditions are sufficiently certain; therefore, only the 20‑year production phase (or any earlier‑converted proved area) is reflected in the company’s proved‑reserve estimates. Consequently, the long‑term nature of the PSCs does not automatically expand the proved‑reserve base—only the economically viable, contract‑defined production period is counted for SEC reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2022.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2022.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 87396,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22119,
        "completion_tokens": 175,
        "total_tokens": 22294
      }
    },
    {
      "question_id": 33,
      "question": "How does NEE's $2.3 billion in guarantees for NEP relate to NEP's ownership of solar projects and NEE's planned capital expenditures for solar development?",
      "original_answer": "NEE has provided guarantees totaling approximately $2.3 billion on behalf of NEP's subsidiaries, primarily related to project performance obligations and financing agreements. NEP, in which NEE holds a significant stake, owns or has partial ownership in a portfolio of contracted renewable energy assets, including solar projects totaling approximately 10,118 MW of energy project capacity. NEE’s planned capital expenditures include approximately $6,134 MW of new solar projects (including solar plus battery storage), indicating a strategic emphasis on expanding solar capacity. The guarantees highlight NEE’s financial exposure and support for NEP’s solar initiatives, aligning with NEE’s broader capital allocation strategy focused on solar development.",
      "llm_answer": "NEE’s $2.3 billion of guarantees for NEP represent the maximum financial exposure NEE could incur if NEP’s obligations under its long‑term renewable‑energy contracts, construction‑related financing or other commitments are not met.  Because NEP owns or holds partial interests in roughly 10,118 MW of contracted solar, wind and battery‑storage projects (plus a natural‑gas pipeline), those guarantees backstop the cash‑flow stability of the assets that NEE plans to develop and expand.  Consequently, the guarantees are closely tied to NEE’s capital‑expenditure plans for new solar and other clean‑energy projects, as the funded capacity underlies the revenue streams that will support the projected $9.8 billion of NEER capital spending through 2028.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81753,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20660,
        "completion_tokens": 187,
        "total_tokens": 20848
      }
    },
    {
      "question_id": 34,
      "question": "How does Merck's $11.5 billion acquisition of Acceleron Pharma align with its R&D focus on TGF-beta superfamily proteins and broader pipeline expansion strategy?",
      "original_answer": "Merck's $11.5 billion acquisition of Acceleron Pharma (page_52) aligns with its R&D focus on TGF-beta superfamily proteins, which Acceleron was evaluating for their role in regulating cell growth, differentiation, and repair (page_96). This acquisition brought sotatercept (MK-7962), a Phase 3 candidate for pulmonary arterial hypertension, and Reblozyl, a marketed erythroid maturation therapy, into Merck's portfolio. The research pipeline section (page_68) highlights Merck’s strategic emphasis on expanding its late-stage clinical candidates and leveraging acquisitions to drive growth, which is exemplified by the integration of Acceleron’s TGF-beta-focused pipeline into Merck’s broader R&D strategy.",
      "llm_answer": "Merck's $11.5 billion acquisition of Acceleron Pharma directly advances its R&D focus on TGF‑beta superfamily proteins—central to Acceleron’s pipeline of sotatercept and Reblozyl—while expanding its broader pipeline through high‑value assets in pulmonary arterial hypertension, hematologic disorders and related collaborations, thereby strengthening its long‑term growth strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 66054,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16736,
        "completion_tokens": 95,
        "total_tokens": 16831
      }
    },
    {
      "question_id": 34,
      "question": "How does the litigation exposure involving Molina in multiple state and federal courts impact the financial liabilities assumed by BMY following the $35.7 billion Celgene acquisition?",
      "original_answer": "The litigation exposure involving Molina, as seen in both the Minnesota state court case removed to the District of New Jersey and the San Francisco Superior Court case remanded in 2022, contributes to the ongoing legal liabilities that BMY inherited from the Celgene acquisition. The $35.7 billion acquisition included not only Celgene’s assets and pipeline but also its contingent liabilities, such as the numerous lawsuits alleging similar claims to those in the class action litigation, including those involving Molina. These legal proceedings, which remain unresolved with no trial dates set, represent potential financial obligations for BMY, adding to the broader post-acquisition risk profile that includes other litigation with entities like Cigna, BCBSA, and MSP. This exposure must be factored into the financial evaluation of the acquisition’s long-term impact on BMY’s balance sheet and risk posture.",
      "llm_answer": "The litigation exposure involving Molina across multiple state and federal courts is not explicitly detailed in the provided 10‑K excerpts, but the company does disclose that it maintains financial guarantees—including standby letters of credit and performance bonds—of approximately $1.2 billion to support various obligations, which would encompass potential legal and regulatory liabilities arising from such litigation. Consequently, the litigation risk contributes to the overall contingent liabilities that BMS must consider when evaluating its financial position post‑acquisition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 52626,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13382,
        "completion_tokens": 146,
        "total_tokens": 13528
      }
    },
    {
      "question_id": 34,
      "question": "How does MetLife's disclosure of CMBS holdings in the fair value hierarchy compare with the valuation complexity described for structured products, particularly regarding the use of unobservable inputs?",
      "original_answer": "MetLife reports $9.949 billion in CMBS holdings as part of its fixed maturity securities AFS, with $9.099 billion categorized in Level 2 and $850 million in Level 3 of the fair value hierarchy. CMBS is explicitly included within the broader category of 'Structured Products,' which encompasses RMBS, ABS & CLO, and CMBS. In the valuation methodology section, MetLife outlines that structured products, including CMBS, rely on both market and income approaches using inputs like spreads off benchmark yields, expected prepayment speeds, and credit ratings. However, Level 3 valuations for these products also incorporate unobservable inputs such as independent non-binding broker quotations and credit spreads, indicating higher subjectivity and complexity in valuing CMBS compared to more transparent Level 2 instruments.",
      "llm_answer": "MetLife classifies its CMBS holdings within the “Structured Products” category of fixed‑maturity securities AFS and discloses them at estimated fair value in the fair‑value hierarchy.  In the Level 2/Level 3 breakdown for Structured Products, the company notes that valuation relies on “quoted prices in markets that are not active” together with significant unobservable inputs such as prepayment assumptions, loss‑severity forecasts, credit‑spread estimates, and other inputs that “cannot be derived principally from, or corroborated by, observable market data.”  Accordingly, the CMBS fair‑value measurement involves unobservable inputs that reflect management’s judgments about the underlying loan pool performance and market conditions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 265,
          "pages": [
            263,
            264,
            265,
            266,
            267
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 233,
          "pages": [
            231,
            232,
            233,
            234,
            235
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 268,
          "pages": [
            266,
            267,
            268,
            269,
            270
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 104408,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26336,
        "completion_tokens": 185,
        "total_tokens": 26521
      }
    },
    {
      "question_id": 34,
      "question": "How does the strategic emphasis on the John Lewis-class Fleet Replenishment Oiler in the operations overview reconcile with the $735 million contract awarded for its construction, and what does this indicate about GD's prioritization of surface ship programs relative to submarine production in 2023?",
      "original_answer": "The operations overview on page 8 highlights GD's strategic focus on submarine production, particularly the Columbia-class and Virginia-class programs, while also noting the ongoing construction of the John Lewis-class (T-AO-205) fleet replenishment oiler as part of NASSCO’s portfolio. It states that seven T-AO-205 ships are in backlog with deliveries planned into 2028, indicating a long-term commitment to this surface ship program. On page 43, the $735 million contract awarded in 2023 for an additional John Lewis-class vessel underscores the Navy’s continued investment in this program and GD’s role in executing it. This contract is one of the larger awards in the Marine Systems segment that year, suggesting GD is balancing its strategic focus on submarines with sustained execution on surface ship programs. The combination of long-term backlog and new contract awards indicates that GD is maintaining capacity and prioritization across both domains.",
      "llm_answer": "The $735 million contract for an additional John Lewis‑class (T‑AO‑205) fleet‑replenishment oiler is listed among the Marine Systems segment’s 2023 contract awards, underscoring the company’s focus on surface‑ship programs.  This emphasis is further highlighted by the backlog figures that show a substantial pipeline of submarine work (e.g., Columbia‑class and Virginia‑class submarines) alongside surface‑ship projects, indicating that GD is prioritizing surface‑ship construction—particularly replenishment Oilers—while still maintaining a robust submarine production schedule.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31298,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 8075,
        "completion_tokens": 145,
        "total_tokens": 8220
      }
    },
    {
      "question_id": 34,
      "question": "How does the $24 million earnings impact from regulatory disallowances at Nicor Gas disclosed in the MD&A section reconcile with the $96 million pre-tax charge specifically attributed to Nicor Gas in the footnote disclosures?",
      "original_answer": "The $24 million figure mentioned in the MD&A section refers to the approximate earnings impact related to regulatory disallowances at Nicor Gas, reflecting a net effect after considering other factors. This aligns with the more detailed $96 million pre-tax charge disclosed in the footnotes under Nicor Gas operations, which represents the gross disallowance of certain capital investments. The difference between the two figures suggests that the $96 million charge was partially offset by other earnings drivers or tax adjustments, as implied by the MD&A's characterization of the disallowance as a partial offset to increased earnings. This synthesis across sections reveals a nuanced financial impact where the headline earnings effect is netted against other operational and regulatory developments.",
      "llm_answer": "The $24 million earnings impact from regulatory disallowances at Nicor Gas is recorded in the MD&A as a separate line‑item that reduces net income, while the $96 million pre‑tax charge disclosed in the footnote represents the full estimated loss on regulatory disallowance that Nicor Gas incurred for certain capital investments. In other words, the MD&A’s $24 million reflects the net after‑tax effect of that charge (the portion that flows through to earnings), whereas the footnote lists the gross pre‑tax amount ($96 million) before any tax or allocation adjustments. Thus, the $24 million earnings impact is a subset of the larger $96 million pre‑tax disallowance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64793,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16435,
        "completion_tokens": 167,
        "total_tokens": 16603
      }
    },
    {
      "question_id": 35,
      "question": "How does PepsiCo's acquisition of full ownership in Sabra Dipping Company align with the strategic importance of the Sabra brand in expanding refrigerated dips and spreads within FLNA, and what financial impact did this have on the division in 2024?",
      "original_answer": "PepsiCo's acquisition of the remaining 50% of Sabra Dipping Company for $241 million in December 2024 aligns with the strategic importance of the Sabra brand, which is central to expanding its refrigerated dips and spreads portfolio under Frito-Lay North America (FLNA). This acquisition made Sabra a wholly-owned subsidiary, enabling full integration and control over a key product line. The transaction resulted in a pre-tax gain of $122 million ($92 million after-tax or $0.07 per share) recognized in FLNA, recorded under selling, general and administrative expenses, due to the re-measurement of the previously held 50% equity stake at fair value. This financial impact underscores the strategic and economic significance of the Sabra brand in PepsiCo's broader portfolio expansion strategy.",
      "llm_answer": "PepsiCo's acquisition of full ownership in Sabra Dipping Company strengthens its strategic focus on expanding the refrigerated dips and spreads category within the Frito‑Lay North America (FLNA) division, a high‑growth segment of the convenient‑food portfolio. The transaction contributed a modest $9 million of acquisition‑related charges to FLNA in 2024 and generated a $122 million pre‑tax gain (recorded in FLNA’s SG&A), underscoring a positive financial impact on the division’s results for the year.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62054,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15753,
        "completion_tokens": 126,
        "total_tokens": 15879
      }
    },
    {
      "question_id": 35,
      "question": "Given Apple's significant net sales from Greater China in 2022, which includes Taiwan, how does the company's reliance on Taiwan-based operations expose it to geopolitical and supply chain risks outlined in the risk factors section?",
      "original_answer": "Apple reported $74.2 billion in net sales from Greater China in 2022, a region that includes Taiwan. According to the segment reporting, Taiwan is a key component of Apple's operations in the region. However, in the risk factors section, Apple highlights that its supply chain, particularly in Asia, is vulnerable to geopolitical tensions, including those involving Taiwan. The company also notes that a significant portion of its manufacturing is outsourced to partners in Asia, including Taiwan, making it susceptible to disruptions from political instability, trade restrictions, and other international conflicts. Therefore, while Taiwan contributes to Apple's revenue performance within Greater China, it also represents a critical risk point due to its strategic location and the current geopolitical climate.",
      "llm_answer": "Apple's reliance on Taiwan-based operations creates significant geopolitical and supply chain risks, as highlighted in multiple risk factors. The company's \"Greater China\" segment—which includes Taiwan—accounts for a substantial portion of its net sales (74.2 billion yuan in 2022), and its supply chain is heavily concentrated in Asia, with \"substantially all\" hardware manufacturing outsourced to partners in Taiwan and other Asian countries. This exposes Apple to disruptions from political tensions, trade disputes (e.g., U.S.-China tensions), natural disasters, or regulatory changes that could interrupt production or increase costs, as noted in the risk factors describing \"single-source outsourcing partners\" and \"geopolitical events\" affecting its supply chain.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71576,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18133,
        "completion_tokens": 192,
        "total_tokens": 18326
      }
    },
    {
      "question_id": 35,
      "question": "How does the 15% revenue decline in Converse, driven by weakness in North America and Western Europe, impact NIKE's strategic focus on growing its broader athletic accessories portfolio, particularly given Converse's role as a reportable segment focused on lifestyle sneakers, apparel, and accessories?",
      "original_answer": "The 15% currency-neutral revenue decline in Converse—driven by reduced wholesale and direct-to-consumer sales in North America and Western Europe—creates a challenge for NIKE’s strategic objective of growing its athletic accessories portfolio. As a reportable segment, Converse is specifically tasked with lifestyle sneakers, apparel, and accessories, which are core components of NIKE’s broader accessories strategy outlined in the MD&A. Despite this decline, NIKE continues to prioritize investment in digital platforms and consumer experiences to elevate its brand, including within Converse. However, the contraction in Converse’s gross margin by 130 basis points and the 30% drop in EBIT raise concerns about the segment’s ability to contribute meaningfully to the company’s strategic growth in accessories, particularly in light of increased promotional activity and lower ASPs.",
      "llm_answer": "The 15% revenue decline in Converse, driven by weakness in North America and Western Europe, directly challenges Nike's strategic focus on expanding its broader athletic accessories portfolio, as Converse is a key reportable segment specializing in lifestyle sneakers, apparel, and accessories. This decline, coupled with Converse's reduced EBIT (-30% to $474M) and gross margin contraction (130 basis points), highlights the vulnerability of its lifestyle-focused business to regional economic pressures, forcing Nike to potentially reallocate resources away from Converse to prioritize growth in higher-performing segments like NIKE Brand's athletic accessories and direct-to-consumer channels.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 66336,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16841,
        "completion_tokens": 174,
        "total_tokens": 17015
      }
    },
    {
      "question_id": 35,
      "question": "How does Apple's characterization of Taiwan as a supply chain risk factor reconcile with the financial performance of the Greater China segment, which includes Taiwan, showing a 14% increase in operating income from 2021 to 2022?",
      "original_answer": "Apple identifies Taiwan as a key part of its supply chain, located in a region prone to geopolitical and operational risks, including trade tensions and natural disasters. Despite these concerns, the Greater China segment, which includes Taiwan, reported a rise in operating income from $28,504 million in 2021 to $31,153 million in 2022—a 14% increase. This suggests that while Apple acknowledges the vulnerability of its operations in the region, the segment continues to contribute significantly to the company's profitability. The financial performance indicates resilience or effective risk mitigation strategies in place, even as the company remains exposed to potential disruptions in Taiwan and the broader Greater China region.",
      "llm_answer": "Apple acknowledges Taiwan as a supply chain risk factor in its disclosures, yet reports a 14% increase in operating income for the Greater China segment (which includes Taiwan) from 2021 to 2022, reflecting strong financial performance in the region despite geopolitical and supply chain challenges. This growth is evident in the segment's operating income rising from $28.5 billion in 2021 to $31.2 billion in 2022, as detailed in Note 11 of the 10-K.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71576,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18133,
        "completion_tokens": 113,
        "total_tokens": 18246
      }
    },
    {
      "question_id": 36,
      "question": "How does BMY's exposure to the Inflation Reduction Act's price negotiation provisions for Pomalyst, selected for negotiation in 2027, interact with the company's reliance on patent exclusivity and regulatory protections for this product as outlined in its intellectual property strategy?",
      "original_answer": "BMY faces dual pressures on Pomalyst stemming from both regulatory pricing reforms and intellectual property risks. The Inflation Reduction Act (IRA), referenced in the 2024 10-K, subjects Pomalyst to government price negotiation starting in 2027, which could materially reduce revenue from this product. This pricing risk coincides with the company's strategic reliance on patent exclusivity and regulatory protections to maintain market exclusivity for Pomalyst. As noted in the document, BMY lists patents in the FDA's Orange Book and evaluates Paragraph IV certifications to defend against generic competition. However, the IRA's pricing negotiation mechanism introduces a new layer of financial pressure that may accelerate revenue erosion even before patent expiration. The combination of these factors suggests that BMY may face both reduced pricing power and increased competition for Pomalyst, potentially impacting long-term profitability and strategic planning for this asset.",
      "llm_answer": "BMY’s reliance on patent exclusivity and regulatory protections for Pomalyst is directly threatened by the Inflation Reduction Act’s (IRA) price‑negotiation provision, which will subject Pomalyst to federal price negotiation beginning in 2027. This provision accelerates revenue erosion before the product’s market exclusivity—currently protected by a combination of patent rights and regulatory exclusivity—fully expires, compelling BMY to confront loss of pricing power even while its intellectual‑property strategy seeks to extend exclusivity through patents and regulatory pathways. Consequently, the IRA’s negotiation mandate creates a strategic tension: the company must balance the anticipated erosion of market exclusivity from generic/biosimilar challenges with the statutory price‑setting mechanism that could further diminish revenues for Pomalyst.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 90605,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22905,
        "completion_tokens": 214,
        "total_tokens": 23120
      }
    },
    {
      "question_id": 36,
      "question": "Given Converse's 15% revenue decline in fiscal 2024 and its explicit role as a reportable segment focused on athletic lifestyle sneakers, apparel, and accessories, how does NIKE's strategic emphasis on growing its accessories business through NIKE Direct and wholesale channels reconcile with Converse's underperformance in these areas?",
      "original_answer": "Converse, as a reportable segment focused on athletic lifestyle sneakers, apparel, and accessories, experienced a 15% revenue decline in fiscal 2024, driven by drops in both wholesale and direct-to-consumer channels. Meanwhile, NIKE's overall strategy emphasizes growing its accessories business through both NIKE Direct and wholesale partnerships, as stated in the MD&A section. This raises a critical alignment issue: despite NIKE's strategic push to expand accessories through these channels, Converse—its key vehicle for accessories—underperformed, with direct-to-consumer revenues down 14% and wholesale down 16%. The contradiction suggests potential challenges in Converse’s brand positioning, product mix, or execution within those channels, which could impact NIKE’s broader accessories growth objectives.",
      "llm_answer": "NIKE’s strategic focus on growing its accessories business through NIKE Direct and wholesale channels is not directly tied to Converse’s underperformance, as Converse’s revenue decline (15% in fiscal 2024) stems from reduced sales in North America and Western Europe, lower wholesale and direct-to-consumer volumes, and margin pressure—not from a lack of strategic emphasis on accessories. While NIKE Direct revenues grew 1% overall (driven by comparable store sales growth and new store openings), Converse’s Direct revenues fell 15% due to declines in key markets, and its wholesale revenues dropped 16% on a currency-neutral basis. Converse’s segment, which includes athletic lifestyle sneakers, apparel, and accessories, is explicitly reportable but underperformed due to market-specific challenges, not a misalignment with NIKE’s broader accessories growth strategy. NIKE’s overall revenue growth (4% reported, 8% constant currency) and focus on expanding Direct and wholesale channels remain intact, but Converse’s struggles reflect localized market dynamics rather than a failure of the company’s strategic priorities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 66336,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16850,
        "completion_tokens": 281,
        "total_tokens": 17131
      }
    },
    {
      "question_id": 36,
      "question": "How does NIKE's foreign exchange hedging strategy for product costs relate to its operational dependency on the NIKE Trading Company (NTC), and what impact does this have on inventory cost volatility?",
      "original_answer": "NIKE's foreign exchange hedging strategy is closely tied to its product cost exposures, which are largely generated through purchases from the NIKE Trading Company (NTC), a U.S. Dollar-denominated sourcing hub. NTC buys products from third-party factories and sells them to NIKE entities in their respective functional currencies, creating foreign currency exposure. NIKE manages this exposure using cash flow hedges, including currency forwards and options, to stabilize the effects of exchange rate fluctuations on product costs. However, when NTC sells to a NIKE entity with a different functional currency, the resulting foreign exchange exposure directly affects inventory costs. A stronger U.S. Dollar increases inventory costs for entities with non-dollar functional currencies, while a weaker Dollar reduces them. Therefore, the effectiveness of NIKE's hedging strategy directly influences the volatility of inventory costs across its global operations.",
      "llm_answer": "NIKE's foreign exchange hedging strategy for product costs is closely tied to its operational dependency on the NIKE Trading Company (NTC), which acts as a centralized sourcing hub that purchases products from third-party factories in U.S. Dollars and then sells them to NIKE entities in their local functional currencies. This structure creates foreign currency exposure for the NTC, as its sales to NIKE entities with different functional currencies generate currency risk that is managed through hedging. By using cash flow hedges—particularly forward contracts—NIKE mitigates the impact of exchange rate fluctuations on inventory costs, especially when the U.S. Dollar strengthens (reducing costs) or weakens (increasing costs). The hedging program, which includes up to 100% coverage of forecasted exposures and extends up to 24 months, helps stabilize inventory costs and reduces volatility in cost of sales, as reflected in the reclassification of deferred gains/losses from Accumulated Other Comprehensive Income into earnings during the hedged transactions. This allows NIKE to better manage its global supply chain costs and maintain predictable margins despite currency fluctuations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87100,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22002,
        "completion_tokens": 298,
        "total_tokens": 22300
      }
    },
    {
      "question_id": 36,
      "question": "How does AT&T's ability to redeem the Mobility II preferred equity interests with cash or stock compare with the more restrictive redemption terms tied to Tower Holdings' preferred interests, and what does this reveal about the company's capital structure flexibility across different subsidiaries?",
      "original_answer": "AT&T has the flexibility to redeem the Mobility II preferred equity interests either with cash, stock, or a combination thereof, and it has the intent and ability to settle these with cash. In contrast, the redemption of Tower Holdings' preferred interests is more narrowly tied to specific contingent events, such as failure to pay distributions or credit rating breaches, and the redemption price is based on market value or a fixed formula without explicit stock settlement flexibility. This distinction reveals that AT&T structures capital redemption terms differently across subsidiaries—offering more discretion in Mobility II while Tower Holdings’ terms are more prescriptive and contingent, suggesting a tiered capital structure strategy aligned with the risk profiles and asset values of each entity.",
      "llm_answer": "AT&T’s Mobility II preferred equity can be redeemed with cash, AT&T common stock, or a mix of both, and the company intends to settle it with cash; this redemption flexibility is broader than the more restrictive terms attached to Tower Holdings’ preferred interests, which are generally non‑convertible and may only be called at issue price after five years or upon specific contingent events. Consequently, the differing redemption provisions illustrate that AT&T’s capital‑structure flexibility varies across subsidiaries, with Mobility II offering greater financing agility than the more constrained Tower Holdings preferred securities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 129,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66630,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16906,
        "completion_tokens": 160,
        "total_tokens": 17066
      }
    },
    {
      "question_id": 36,
      "question": "How does Emerson's $7.8 billion cash payment to acquire NI align with the strategic positioning of NI's Automated Test Systems within the newly formed Test & Measurement segment?",
      "original_answer": "Emerson paid $7.8 billion in cash to acquire the remaining shares of NI, which is directly tied to the strategic integration of NI's Automated Test Systems into Emerson’s portfolio. NI's Automated Test Systems, highlighted as a core offering, are now positioned under the newly formed Test & Measurement segment, which is described as providing software-connected systems that help enterprises accelerate product development and reduce costs. This acquisition aligns with Emerson’s broader strategy to strengthen its software-connected solutions, as evidenced by the segment’s emphasis on modular instrumentation, data acquisition, and development software. The significant cash outlay reflects the strategic importance Emerson places on NI’s technology and its role in enhancing Emerson’s competitive positioning in the industrial automation and test equipment market.",
      "llm_answer": "Emerson paid $7.8 billion in cash (plus $634 million to pay off NI debt) to acquire National Instruments, reflecting the strategic fit of NI’s Automated Test Systems within the newly created Test & Measurement segment of the combined Software and Control business group. The acquisition was accounted for as a purchase, with the $7.8 billion cash component recorded as part of the $8.653 billion total purchase consideration, positioning NI’s test‑measurement offerings as a core growth driver in Emerson’s expanded Test & Measurement segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67287,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17043,
        "completion_tokens": 135,
        "total_tokens": 17179
      }
    },
    {
      "question_id": 36,
      "question": "What do the differing royalty structures for Opdivo and Tecentriq suggest about BMY's relative intellectual property strength in PD-1 versus PD-L1 therapies, and how might this affect their long-term revenue positioning in immuno-oncology?",
      "original_answer": "BMY's royalty structure for Opdivo indicates a stronger IP position in PD-1 therapies, as evidenced by the 4% royalty in North America and 15% in other territories (excluding Japan, South Korea, and Taiwan). In contrast, BMY receives only single-digit royalties through Roche's Tecentriq, a PD-L1 therapy, suggesting a weaker IP position in this domain. These royalty arrangements imply that BMY holds more dominant patent rights in PD-1, which could translate into higher revenue potential and stronger negotiation leverage in the PD-1 space compared to PD-L1. This disparity may impact BMY's long-term revenue positioning in immuno-oncology, as PD-1 therapies appear to be more lucrative for the company based on current licensing arrangements.",
      "llm_answer": "The differing royalty structures for Opdivo and Tecentriq reflect that Opdivo (anti‑PD‑1) carries higher royalty rates (up to 6.5% from Merck and 4%/15% from Ono) compared with Tecentriq (anti‑PD‑L1), which pays single‑digit royalties (typically 2.5%–6% shared with partners). This suggests stronger patent protection and potentially higher long‑term revenue generation for Opdivo in immuno‑oncology, while Tecentriq’s lower royalty burden may limit its upside despite comparable clinical success. Consequently, Opdivo is likely to contribute more sustained royalty income and support a more favorable revenue positioning for Bristol‑Myers Squibb in the PD‑1 space versus the PD‑L1 market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67762,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17176,
        "completion_tokens": 172,
        "total_tokens": 17348
      }
    },
    {
      "question_id": 36,
      "question": "How does Boeing's accounting treatment of lease options in its property and equipment disclosures reconcile with its provision of customer financing that includes similar lease extension and termination options, particularly in light of the credit risk exposure highlighted in Boeing Capital's portfolio analysis?",
      "original_answer": "Boeing accounts for lease options in its property and equipment disclosures by incorporating them into the calculation of lease assets and liabilities when it is reasonably certain they will be exercised, using its incremental borrowing rate to determine present value (page 78). In the customer financing section, Boeing Capital discloses that its financing arrangements often include options to extend or terminate leases, which are structurally similar to the lease options recognized in the accounting policy (page 93). However, in the Boeing Capital portfolio analysis (page 47), the company acknowledges significant credit risk exposure due to customer liquidity issues, including $398 million in charges for expected credit losses in 2020. This creates a tension: while the accounting policy assumes certainty in lease option exercise for asset valuation purposes, the operational reality in the Boeing Capital section shows that customer financial instability can undermine the realizability of those lease terms. Therefore, the accounting treatment assumes operational continuity, while the credit risk disclosures highlight the financial risk that contradicts that assumption.",
      "llm_answer": "Boeing’s accounting for lease options in its property and equipment disclosures—recognizing operating‑lease assets and liabilities at the present value of lease payments and depreciating them over the lease term—mirrors the way it accounts for customer‑financing arrangements that contain similar extension and termination provisions. In both cases, the Company records a right‑of‑use asset (or financing receivable) and a corresponding liability, uses its incremental borrowing rate to discount cash flows, and assesses impairment or credit risk separately. The key distinction is that for customer financing the Company also evaluates the credit quality of the lessee and maintains allowances for expected losses, whereas the property‑and‑equipment disclosures focus on the mechanical depreciation of the leased asset itself. This approach is consistent with the disclosures in Note 10 (Property, Plant and Equipment) and Note 9 (Customer Financing), which together show that lease‑related assets are measured at cost less accumulated depreciation and that credit risk is managed through the allowance methodology described in the financing‑receivable tables.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 54420,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13865,
        "completion_tokens": 290,
        "total_tokens": 14155
      }
    },
    {
      "question_id": 37,
      "question": "How does the adoption of ASU 2022-02 impact the disclosure requirements for financial difficulty modifications (FDMs) in 2023 compared to the prior period's troubled debt restructurings (TDRs), and what implications does this have for the evaluation of credit risk in the loan portfolio?",
      "original_answer": "The adoption of ASU 2022-02 eliminated the accounting guidance for TDRs and introduced new disclosure requirements for financial difficulty modifications (FDMs), which are now reported on a rolling twelve-month basis. Unlike TDRs, which were based on the concession principle, FDMs are defined by the form of modification (e.g., principal forgiveness, interest rate reduction, term extension) granted to borrowers in financial difficulty. This change affects how credit risk is evaluated, as FDMs are now accumulated and analyzed differently, with performance tracked over a rolling period rather than being isolated as distinct restructured events. The new disclosures provide more granular performance data on FDMs, which enhances transparency but also requires updated internal risk modeling and reporting practices to align with the new standard.",
      "llm_answer": "The adoption of ASU 2022‑02 eliminated the TDR accounting guidance and replaced it with a new “financial difficulty modification” (FDM) framework that no longer requires a concession to qualify as a modification. Consequently, disclosures now focus on FDMs rather than TDRs, and the timing/amount of contractual cash‑flow changes is evaluated differently. This shift changes how credit risk is assessed—allowance for credit losses is estimated over the modified loan’s contractual term (adjusted for prepayments but not extensions unless the extension is not unconditionally cancellable), and internal risk‑rating assignments for commercial loans incorporate the impact of all modifications when evaluating credit quality. As a result, the allowance coverage ratio and non‑performing loan metrics reflect the new FDM disclosures and the more granular performance monitoring presented in the 2023 tables.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 159,
          "pages": [
            157,
            158,
            159,
            160,
            161
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            136,
            137,
            138,
            139,
            140
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78809,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19959,
        "completion_tokens": 225,
        "total_tokens": 20185
      }
    },
    {
      "question_id": 37,
      "question": "How does MDLZ's reported fair value of $71 million for net investment hedge contracts align with its broader methodology for valuing Level 2 financial liabilities?",
      "original_answer": "MDLZ reports a fair value of $71 million for its net investment hedge contracts, as disclosed in its financial statements (page 111). These contracts are categorized as Level 2 financial liabilities, which are valued using an income approach based on observable market inputs. Specifically, for net investment hedge contracts, MDLZ applies methodologies such as discounted cash flow analysis or market forward rates, as detailed in the valuation methods section. This approach aligns with the company’s treatment of other Level 2 liabilities, which rely on observable inputs such as forward rates, commodity prices, and interest rate curves, adjusted for nonperformance risk and counterparty credit risk. The $71 million figure is therefore consistent with the broader framework for Level 2 liabilities, which are not based on directly quoted market prices (Level 1) but instead derived from structured valuation models using observable data.",
      "llm_answer": "MDLZ's reported fair value of $71 million for its net investment hedge contracts is consistent with its broader Level 2 valuation approach, which determines the fair value of these contracts using observable market inputs—primarily observable market forward rates and other readily‑available market data—rather than quoted prices in an active market (Level 1) or unobservable inputs (Level 3). This methodology aligns with the footnote disclosure that net investment hedge contracts are classified as Level 2 and are valued using an income approach based on observable market forward rates applied to the notional amounts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 111,
          "pages": [
            109,
            110,
            111,
            112,
            113
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78564,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19856,
        "completion_tokens": 155,
        "total_tokens": 20012
      }
    },
    {
      "question_id": 37,
      "question": "How does the anticipated 2036 U.S. patent expiration for MK-1654, as listed under Merck's patent protection schedule, align with the company's strategic emphasis on long-term revenue generation given the product's current regulatory review status for RSV prophylaxis in infants?",
      "original_answer": "Merck lists MK-1654 (clesrovimab) with an anticipated 2036 U.S. patent expiration date, which provides a long-term intellectual property runway for the product. However, MK-1654 is currently under FDA and EU regulatory review as an investigational long-acting monoclonal antibody designed to protect infants from RSV disease. This means the product has not yet reached the market, and its commercialization timeline remains uncertain. While the patent protection extends well into the future, the delayed market entry due to ongoing regulatory processes may compress the effective revenue-generating period before patent expiration. This creates a strategic tension between the long patent life and the potential for a shorter commercial lifecycle, particularly for a product aimed at a seasonal and potentially competitive prophylactic market.",
      "llm_answer": "The 2036 U.S. patent expiration for MK‑1654 aligns with Merck’s long‑term revenue strategy because the compound is still under FDA review for RSV prophylaxis in infants, meaning market exclusivity can be extended through patent term extensions and pediatric market exclusivity, preserving future sales potential despite the scheduled patent expiry.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78521,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19878,
        "completion_tokens": 87,
        "total_tokens": 19965
      }
    },
    {
      "question_id": 37,
      "question": "How does Starbucks' deferred revenue arrangement with Nestlé for the Global Coffee Alliance align with the company's stated risks regarding supply chain dependencies on key business partners?",
      "original_answer": "Starbucks reports a significant financial dependency on Nestlé through the Global Coffee Alliance, as evidenced by the upfront prepaid royalty from Nestlé recorded in deferred revenue (page 66). This relationship is central to the Channel Development segment, which relies on Nestlé to distribute packaged goods and foodservice products globally (page 88). However, the company explicitly states that if Nestlé fails to meet its distribution and marketing commitments, it could 'have a material adverse impact on our business and financial results' (page 22). Thus, while the deferred revenue arrangement provides upfront financial benefit, it is inextricably tied to Nestlé’s performance, exposing Starbucks to supply chain and brand execution risks that are acknowledged in the risk factors section.",
      "llm_answer": "Starbucks’ 10‑K notes that its Channel Development business is “heavily reliant on Nestlé, which has the global right to sell and distribute our packaged goods and foodservice products,” and that “if Nestlé fails to perform its distribution and marketing commitments under our agreements… our Channel Development business could be adversely impacted.” This reliance is highlighted as a supply‑chain risk in the “Risks Related to Supply Chain” section, which warns that “any material interruption in our supply chain… could have a negative material impact on our business and profitability.” Thus, the deferred‑revenue arrangement with Nestlé for the Global Coffee Alliance is consistent with the company’s stated risk that dependence on a key partner could disrupt operations and hurt financial results.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SBUX_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_2_rel": {
          "source_file": "SBUX_10k_2024.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "hop_3_rel": {
          "source_file": "SBUX_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72080,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18250,
        "completion_tokens": 200,
        "total_tokens": 18451
      }
    },
    {
      "question_id": 37,
      "question": "How does Qualcomm's reliance on Chinese OEMs for a significant portion of its licensing revenues reconcile with the risk that these same OEMs may develop their own integrated circuit products, potentially undermining Qualcomm's semiconductor business and revenue diversification strategy?",
      "original_answer": "Qualcomm reports that it derives a significant portion of its licensing revenues from Chinese OEMs, which are central to its financial performance. However, the company also acknowledges that these OEMs may develop their own integrated circuit products due to pressures such as China’s Made in China 2025 campaign, trade tensions, or supply chain concerns. This vertical integration could reduce Qualcomm's semiconductor sales, particularly in a market where the company is already facing competition and customer diversification risks. The contradiction between depending on Chinese OEMs for licensing revenue while facing potential erosion of semiconductor sales from their self-developed products creates a strategic tension that could impact Qualcomm’s ability to sustain its current revenue model and diversification efforts.",
      "llm_answer": "Qualcomm acknowledges that its licensing revenue depends heavily on Chinese OEMs, but it also warns that many of those same OEMs are developing their own integrated‑circuit products—driven by government policies such as “Made in China 2025,” concerns about U.S./China trade and security tensions, and the desire for supply‑chain control. This vertical integration by Chinese customers could reduce their purchases of Qualcomm’s chips, undermining the diversification strategy that relies on broad licensing and semiconductor sales. Consequently, the company views this concentration risk as a material threat to its revenue growth and profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2022.pdf",
          "target_page": 39,
          "pages": [
            37,
            38,
            39,
            40,
            41
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2022.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 72701,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18425,
        "completion_tokens": 162,
        "total_tokens": 18588
      }
    },
    {
      "question_id": 37,
      "question": "How does Emerson's strategic acquisition of NI for $8.653 billion, including the $7.833 billion cash payment for remaining shares, align with the role of Automated Test Systems in enabling faster and lower-cost product development as described in the Test & Measurement segment's operational overview?",
      "original_answer": "Emerson's acquisition of NI for $8.653 billion, which included a $7.833 billion cash payment for the remaining shares, reflects a strategic investment to enhance the capabilities of the Test & Measurement segment. This segment is described as providing software-connected automated test and measurement systems that help enterprises bring products to market faster and at a lower cost. NI, as a key component of this segment post-acquisition, directly supports this mission by offering modular instrumentation and development software. The significant financial commitment to acquire full ownership of NI underscores Emerson's emphasis on strengthening its Automated Test Systems offering to better serve customer needs in accelerating innovation and reducing development costs.",
      "llm_answer": "Emerson's $8.653 billion acquisition of NI—including the $7.833 billion cash payment for the remaining shares—directly advances the Test & Measurement segment’s mission of enabling faster, lower‑cost product development. The purchase adds NI’s automated test and measurement systems, which the segment highlights as key to helping enterprises bring products to market more quickly and at reduced expense. This strategic addition expands Emerson’s Test & Measurement offering within the Software and Control business group and is expected to contribute roughly $1.5 billion of sales in 2023, reinforcing the segment’s growth narrative.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66983,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16998,
        "completion_tokens": 158,
        "total_tokens": 17156
      }
    },
    {
      "question_id": 37,
      "question": "How does Colgate's adoption of ASU 2022-04 affect the transparency of its supplier finance obligations, particularly in light of the new roll-forward disclosures and their potential impact on balance sheet presentation?",
      "original_answer": "Colgate adopted ASU 2022-04 beginning January 1, 2023, with the roll-forward information disclosure becoming effective January 1, 2024. This ASU requires more detailed annual disclosures about supplier finance programs, including the confirmed amount outstanding and associated roll-forward information. These new requirements directly influence how the company presents its liabilities related to these programs on the balance sheet and provide stakeholders with clearer visibility into the timing and changes in these obligations. This enhances the transparency of Colgate's financial position by disclosing dynamic liability movements, not just end-of-period balances.",
      "llm_answer": "The adoption of ASU 2022‑04 requires Colgate‑Palmolive to disclose the key terms of its supplier‑finance programs, the balance‑sheet presentation of the related obligations, the confirmed amount outstanding at period‑end, and roll‑forward information. This enhanced disclosure improves transparency of the company’s supplier‑finance liabilities and clarifies how those obligations appear on the balance sheet.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_3_rel": {
          "source_file": "CL_10k_2024.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63458,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16096,
        "completion_tokens": 102,
        "total_tokens": 16198
      }
    },
    {
      "question_id": 37,
      "question": "How does UPS's use of net asset value (NAV) to measure certain alternative investments align with the liquidity constraints and unfunded commitments associated with their private debt investments?",
      "original_answer": "UPS utilizes NAV as a practical expedient to value alternative investments like private debt, which reflects the most recent partnership audited financial reports and is adjusted for investment activity (page 94). This valuation approach is necessary due to the lack of readily determinable fair value for these assets. On page 93, UPS discloses that their private debt investments are part of limited partnerships with terms ranging from 10 to 15 years, and as of December 31, 2024, they have $2.7 billion in unfunded commitments expected to be contributed over the next three to six years. These liquidity constraints and long-term commitments highlight the practical limitations of valuing such investments through traditional fair value methods, reinforcing the rationale for using NAV. However, the lack of immediate liquidity and potential valuation discrepancies due to market opacity underscore the risks associated with relying on NAV for these private debt instruments.",
      "llm_answer": "UPS measures certain alternative investments—including private‑debt and private‑equity fund interests—at NAV per share (or its equivalent) as a practical expedient, placing them outside Levels 1‑3 of the fair‑value hierarchy. These investments are subject to liquidity constraints and unfunded commitments; for example, the company reports unfunded commitments of approximately $2.7 billion to private‑debt and private‑equity limited partnerships that must be funded over the next three to six years. Consequently, while NAV provides a valuation benchmark, the inherent illiquidity and pending capital calls limit the immediacy with which these assets can be accessed or liquidated.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70907,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17949,
        "completion_tokens": 170,
        "total_tokens": 18119
      }
    },
    {
      "question_id": 37,
      "question": "How does Southern Company's net operating loss (NOL) carryforward benefit in Mississippi relate to its investment in SNG, and what does this imply about the strategic alignment between tax optimization and natural gas infrastructure exposure?",
      "original_answer": "Southern Company reports a $183 million net state income tax benefit from NOL carryforwards in Mississippi, where it has significant operations through Southern Power and Southern Company Gas. Southern Power operates in Mississippi and generates electricity from natural gas under long-term PPAs, while Southern Company Gas holds a 50% interest in SNG—a major natural gas pipeline spanning 7,000 miles across multiple states including Mississippi. The NOL benefit in Mississippi directly supports the company's tax efficiency in a state where it maintains both power generation and gas infrastructure assets. This tax benefit aligns with Southern Company’s strategic investment in SNG, which enhances natural gas supply diversification and supports long-term contracted energy services. The combination of tax optimization through NOLs and infrastructure investment through SNG illustrates a coordinated approach to managing both financial and operational exposure in the natural gas value chain.",
      "llm_answer": "Southern Company's Mississippi Power subsidiary holds a $183 million state net operating loss carryforward that can be used to offset future taxable income, providing a tax shield that enhances the economics of its investments. This NOL benefit aligns with Southern Company’s broader strategy of leveraging tax‑advantaged infrastructure projects—particularly its equity stakes in natural‑gas pipelines such as SNG—where the tax credits and deductions from those assets can be combined with the Mississippi NOL to improve after‑tax returns. Consequently, the company’s tax‑optimization initiatives are tightly coupled with its exposure to natural‑gas infrastructure, ensuring that capital deployed in pipeline ventures is supported by available loss carryforwards and renewable‑energy tax credits, reinforcing a cohesive growth strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 248,
          "pages": [
            246,
            247,
            248,
            249,
            250
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 301,
          "pages": [
            299,
            300,
            301,
            302,
            303
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72537,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18379,
        "completion_tokens": 209,
        "total_tokens": 18588
      }
    },
    {
      "question_id": 38,
      "question": "How does Altria's indemnification arrangement with PMI for tobacco-related liabilities interact with PM USA's unconditional guarantees of Altria's debt obligations, particularly in light of the potential insolvency risks outlined in the supplemental guarantor financial information?",
      "original_answer": "Altria has no recorded liability for PMI's indemnification obligations because their fair value is deemed insignificant. However, PM USA, a 100% owned subsidiary, has issued unconditional guarantees covering Altria’s obligations under its $3.0 billion Credit Agreement, commercial paper program, and outstanding debt securities. The supplemental guarantor financial information warns that if PM USA becomes insolvent—defined as having debts exceeding assets or being unable to pay obligations as they mature—the guarantees could be voided or subordinated under federal bankruptcy or state fraudulent transfer laws. This creates a potential risk chain: while PMI indemnifies Altria and PM USA for liabilities tied to PMI-manufactured tobacco products, PM USA's financial health directly affects Altria’s ability to meet its debt obligations, and any insolvency event could expose Altria to unsecured creditor status.",
      "llm_answer": "The indemnification arrangement between Altria and PMI for tobacco‑related liabilities does not affect the unconditional guarantees that PM USA provides for Altria’s debt obligations; those guarantees remain fully enforceable regardless of any insolvency risk. The supplemental guarantor financial information shows that, if PM USA were to become insolvent, its guarantees could be voided under fraudulent‑transfer or bankruptcy law, potentially leaving Altria’s creditors without recourse against PM USA. Consequently, while the indemnification shields Altria from certain tobacco claims, the credit risk associated with PM USA’s guarantees must be evaluated separately, especially given the insolvency scenarios disclosed in the guarantor financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 66242,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16809,
        "completion_tokens": 190,
        "total_tokens": 16999
      }
    },
    {
      "question_id": 38,
      "question": "How does ExxonMobil's 2023 production performance of 3.7 million oil-equivalent barrels per day align with its pending merger with Pioneer Natural Resources, which holds over 2.3 billion oil-equivalent barrels in proved reserves and contributed over 700 thousand oil-equivalent barrels per day in production as of Q3 2023?",
      "original_answer": "ExxonMobil's 2023 production remained flat at 3.7 million oil-equivalent barrels per day, with growth in Permian and Guyana offsetting declines from divestments and curtailments. Meanwhile, the pending merger with Pioneer Natural Resources, expected to close in Q2 2024, is strategically positioned to significantly enhance ExxonMobil's reserve base and production capacity by adding 2.3 billion oil-equivalent barrels in proved reserves and over 700 thousand oil-equivalent barrels per day of production from Pioneer. This suggests that the merger is intended to address production stagnation and strengthen long-term output potential.",
      "llm_answer": "ExxonMobil's 2023 upstream production of 3.7 million oil‑equivalent barrels per day is consistent with its 2022 level, reflecting growth in Permian and Guyana volumes that more than offset declines from divestments, Russia expropriation and higher government‑mandated curtailments. The company’s pending merger with Pioneer Natural Resources— which holds over 2.3 billion oil‑equivalent barrels of proved reserves and contributed roughly 700,000 barrels per day of production in Q3 2023— is intended to add significant reserve and production capacity to ExxonMobil’s portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "XOM_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 61576,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15653,
        "completion_tokens": 144,
        "total_tokens": 15797
      }
    },
    {
      "question_id": 38,
      "question": "How does Boeing's exposure to cost overruns under fixed-price development contracts, exemplified by the KC-46A Tanker program, reconcile with the program's total contract value and the company's capitalized precontract costs as of the end of 2021?",
      "original_answer": "Boeing's exposure to cost overruns under fixed-price development contracts, particularly the KC-46A Tanker program, is significant due to the inherent uncertainty in estimating long-term development costs. In 2021, Boeing recorded an additional $402 million in losses on the KC-46A contract due to factory disruptions, supply chain issues, and evolving customer requirements. Despite these challenges, the KC-46A program had a total contract value of approximately $19 billion as of December 31, 2021, and Boeing held $243 million in capitalized precontract costs. This juxtaposition highlights the dual nature of fixed-price development contracts: while they offer long-term revenue potential, they also carry substantial risk of reach-forward losses if cost estimates are exceeded, especially in complex programs like the KC-46A.",
      "llm_answer": "The KC‑46A Tanker is a fixed‑price development contract that had approximately $243 million of capitalized precontract costs and $409 million of potential termination liabilities recorded as of 31 December 2021.  These amounts are part of the overall $19 billion contract value for the program, but the exposure to cost overruns is reflected in the company’s need to estimate and reserve for additional costs to complete the fixed‑price work, which can reduce margins or generate reach‑forward losses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 51550,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13133,
        "completion_tokens": 125,
        "total_tokens": 13259
      }
    },
    {
      "question_id": 38,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene align with its strategic focus on BLINCYTO, given the shared commercialization arrangement in China and BLINCYTO's development status as an anti-CD19 x anti-CD3 BiTE molecule?",
      "original_answer": "Amgen's $2.8 billion equity investment in BeiGene, made to expand its oncology presence in China, directly supports the shared commercialization of BLINCYTO in that market starting in 2021. BLINCYTO, described as an anti-CD19 x anti-CD3 BiTE molecule, is part of Amgen’s pipeline under active development and commercial strategy. The collaboration with BeiGene involves profit-sharing during the initial commercialization period, after which product rights may revert to Amgen, who would then pay royalties to BeiGene. This arrangement aligns with Amgen’s strategic intent to leverage local expertise in China while maintaining long-term control and revenue potential for BLINCYTO, a key oncology asset.",
      "llm_answer": "Amgen’s $2.8 billion equity investment in BeiGene was made to deepen its oncology partnership in China, where the two companies share commercialization of BLINCYTO (an anti‑CD19 × anti‑CD3 BiTE) and other oncology products. Under the collaboration, BeiGene holds the rights to commercialize BLINCYTO in China and shares profits equally during the initial product‑specific commercialization period, aligning Amgen’s investment with its strategic focus on expanding BLINCYTO’s market presence in that region.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65990,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16736,
        "completion_tokens": 126,
        "total_tokens": 16863
      }
    },
    {
      "question_id": 38,
      "question": "How does Capital One's current capital adequacy framework under Basel III, which allows exclusion of AOCI elements, contrast with the potential impact of the Basel III Finalization Proposal's Expanded Risk-Based Approach that would phase in AOCI recognition, and what implications might this have on its CET1 capital ratio requirements by 2028?",
      "original_answer": "Capital One, as a Category III institution under the current Basel III Capital Rules, is permitted to exclude certain elements of accumulated other comprehensive income (AOCI), such as unrealized gains and losses on available-for-sale securities, from its CET1 capital ratio calculation. However, the Basel III Finalization Proposal introduces the Expanded Risk-Based Approach and mandates that Category III institutions like Capital One begin recognizing AOCI in CET1 capital starting July 1, 2025, with a full phase-in by July 1, 2028. This change could reduce CET1 capital levels if AOCI remains negative during that period, thereby increasing capital pressure. The Expanded Risk-Based Approach, as defined in the glossary on page 114, recalculates risk-weighted assets across credit, operational, and market risks, potentially tightening capital adequacy requirements. This transition may challenge Capital One’s ability to maintain its current CET1 capital ratio of 4.5% or higher under the new framework without adjustments to capital planning or risk exposure.",
      "llm_answer": "Capital One currently excludes certain elements of accumulated other comprehensive income (AOCI) from its regulatory capital under the Basel III framework for Category III institutions, which allows it to maintain a lower CET1 capital ratio. The proposed Basel III Finalization would phase in the recognition of AOCI elements—including unrealized gains and losses on available-for-sale securities—into CET1 capital beginning July 1, 2025, with full implementation by July 1, 2028, through a three-year transition period. This change, combined with the Expanded Risk-Based Approach, would likely increase risk-weighted assets and reduce the CET1 capital ratio, potentially requiring Capital One to hold additional capital to meet the higher regulatory thresholds by 2028.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82245,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20827,
        "completion_tokens": 192,
        "total_tokens": 21019
      }
    },
    {
      "question_id": 38,
      "question": "How does Duke Energy Progress' use of DEPNC SF to issue storm recovery bonds in 2021 compare with its 2024 issuance of $177 million in storm recovery bonds through DEP SC SF, particularly in terms of the storm cost periods being financed and the regulatory mechanisms enabling these financings?",
      "original_answer": "Duke Energy Progress utilized DEPNC SF in 2021 to issue senior secured bonds aimed at financing storm costs incurred in North Carolina from 2018 to 2019, as authorized by state legislation and NCUC financing orders. In contrast, in April 2024, Duke Energy Progress issued $177 million in senior secured bonds through DEP SC SF to finance storm costs from 2014 through 2022 in South Carolina, following a 2023 petition and comprehensive settlement approved by the PSC SC. These financings were enabled by different regulatory frameworks—North Carolina’s MYRP and earnings-sharing mechanisms versus South Carolina’s storm securitization petition and settlement agreement—highlighting Duke Energy Progress' tailored regulatory strategies for storm cost recovery across jurisdictions.",
      "llm_answer": "Duke Energy Progress issued storm‑recovery bonds in 2021 through its wholly‑owned special‑purpose subsidiary DEPNC SF to finance unrecovered storm costs incurred in 2018‑2019, using a non‑bypassable charge on North Carolina retail customers; the 2024 $177 million issuance by DEPSC SF similarly created a non‑bypassable charge on both North and South Carolina customers to recover storm costs from 2014‑2022, with the bonds secured only by that charge and no recourse to the parent utilities. Both financings rely on state‑approved storm‑recovery mechanisms that allow the utilities to recover the bond proceeds through regulated customer charges, but the 2021 bonds targeted only North Carolina storm costs, whereas the 2024 bonds covered broader South Carolina storm costs and were issued at a later date under a separate financing order.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 205,
          "pages": [
            203,
            204,
            205,
            206,
            207
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103951,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26241,
        "completion_tokens": 210,
        "total_tokens": 26451
      }
    },
    {
      "question_id": 39,
      "question": "Given AENB's status as a large bank subject to proposed Climate Risk Management Principles and its role in managing $84.4 billion in FDIC-insured deposits, how does American Express's obligation to act as a source of strength to AENB potentially intersect with emerging climate-related risk governance requirements?",
      "original_answer": "American Express is explicitly required to act as a source of financial and managerial strength to AENB, which had $84.4 billion in deposits as of December 31, 2021. AENB, being an OCC-regulated institution with over $100 billion in assets, is subject to the proposed 'Principles for Climate-Related Financial Risk Management for Large Banks' that include governance, strategic planning, and scenario analysis for climate risks. While the Climate Risk Management Principles are still under development and their exact impact is uncertain, they may require AENB to implement new risk frameworks that could affect its capital needs. Since American Express has a binding obligation to support AENB’s capital under regulatory requirements, any increased capital or operational costs at AENB due to climate risk compliance could trigger upstream financial commitments from American Express, creating a regulatory and strategic linkage between climate risk governance and corporate capital planning.",
      "llm_answer": "The Company’s obligation to act as a source of strength for its U.S. bank subsidiary, AENB, requires it to provide capital and liquidity support to ensure AENB remains well‑capitalized and compliant with regulatory requirements. As a large bank subject to the OCC’s proposed Climate‑Related Financial Risk Management Principles, AENB will need robust governance and risk‑measurement frameworks for climate‑related exposures, and the parent company’s financial backing may be essential to meet those supervisory expectations and to fund any required climate‑risk mitigation initiatives.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69258,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17570,
        "completion_tokens": 146,
        "total_tokens": 17716
      }
    },
    {
      "question_id": 39,
      "question": "How does the strategic emphasis on ZYN as a leading brand in PM's smoke-free portfolio align with the financial commitment made to fully acquire Swedish Match, and what does this reveal about PM's prioritization of oral nicotine delivery in its smoke-free transformation?",
      "original_answer": "Philip Morris International (PM) highlights ZYN as one of the leading brands in its smoke-free portfolio on page 5, noting that nicotine pouches—primarily represented by ZYN—have expanded into 37 markets as of December 31, 2024. This strategic positioning of ZYN is directly tied to PM's acquisition of Swedish Match in November 2022, which brought the ZYN brand under PM's umbrella and strengthened its position in oral nicotine delivery. Further, on page 92, PM completed the compulsory redemption of all remaining shares of Swedish Match in February 2023, paying $883 million in cash and finalizing the acquisition process by September 2023. The combination of ZYN's market expansion and the full acquisition of Swedish Match underscores PM's strategic pivot toward smoke-free products, particularly in the U.S. oral nicotine category, reinforcing its broader transformation into a smoke-free company.",
      "llm_answer": "PM's strategic focus on ZYN as a flagship smoke‑free brand directly reflects the financial commitment to fully acquire Swedish Match, a leader in oral nicotine delivery. The acquisition was financed with a $14.5 billion cash outlay (including $1.0 billion upfront and $1.8 billion later), underscoring PM's prioritization of building a comprehensive oral‑nicotine portfolio alongside its heat‑not‑burn IQOS products to accelerate its smoke‑free transformation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67752,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17182,
        "completion_tokens": 115,
        "total_tokens": 17297
      }
    },
    {
      "question_id": 39,
      "question": "How does ConocoPhillips' impairment of its APLNG investment in 2021 relate to the ownership structure involving Origin Energy, and what does this imply about the valuation sensitivity of ConocoPhillips' equity stake to changes in Origin Energy's position?",
      "original_answer": "ConocoPhillips impaired its APLNG investment by $688 million in 2021 after Origin Energy agreed to sell a 10% stake in APLNG for $1.645 billion, which reflected a market valuation lower than the carrying value of ConocoPhillips' existing investment. This impairment was necessary because the transaction price indicated a decline in APLNG’s fair value, which was below the previously recorded value. At the same time, ConocoPhillips exercised its preemption right to acquire an additional 10% stake from Origin Energy, increasing its ownership. The fact that Origin Energy, as the operator and co-owner of APLNG with ConocoPhillips and Sinopec, was willing to divest part of its stake suggests internal or market-driven pressures that impacted APLNG’s valuation. This dynamic highlights how changes in Origin Energy’s position directly affect ConocoPhillips' investment decisions and valuation assumptions, especially given the joint ownership structure and the strategic importance of APLNG’s LNG operations in Australia.",
      "llm_answer": "ConocoPhillips recorded a $688 million non‑cash impairment of its APLNG investment in Q4 2021 after Origin Energy sold a 10 % stake to a third party at a price that implied a fair‑value below the carrying amount of ConocoPhillips’ 37.5 % stake. The impairment reflects that the valuation of ConocoPhillips’ equity interest in APLNG is highly sensitive to Origin Energy’s ownership position and the market‑derived price for that stake, meaning any further reduction in Origin’s holding or a decline in the observable market price for APLNG shares would likely trigger additional write‑downs of ConocoPhillips’ equity investment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65860,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16709,
        "completion_tokens": 156,
        "total_tokens": 16865
      }
    },
    {
      "question_id": 39,
      "question": "Given GM's strategic emphasis on trucks as a core component of its $35 billion EV investment through 2025 and the risks associated with new product introductions, how does its financial exposure to nonconsolidated affiliates involved in truck development and production affect the execution of this strategy?",
      "original_answer": "GM has committed over $35 billion from 2020 through 2025 to invest in EV and AV technologies, with a key part of this strategy being the development and profitable sale of electric trucks. However, the company faces risks related to the timely and successful introduction of new vehicle models, especially EVs, which require significant capital investment and depend on complex technological development. Compounding this strategic risk, GM has financial exposure to nonconsolidated affiliates who are actively involved in the development, production, and marketing of trucks and related components. These affiliates are integral to GM’s supply chain and vehicle production ecosystem, yet their nonconsolidated status suggests GM does not fully control their operations or financial outcomes. This creates execution risk for GM’s EV strategy, as disruptions or inefficiencies in these affiliate relationships could delay or compromise the development and production of key truck models central to its long-term profitability and strategic direction.",
      "llm_answer": "The financial exposure to nonconsolidated affiliates involved in truck development and production—particularly through significant purchasing transactions and equity stakes in joint ventures like SAIC GM and its subsidiaries—creates a dependency that could constrain GM’s ability to fund and execute its $35 billion EV investment. While these affiliates generate revenue and cash flow for GM, the company’s reliance on them for components and truck production introduces execution risk; any disruption or under‑performance could limit the cash available to support EV roll‑outs and could pressure margins, especially given the high fixed costs and competitive pricing pressures associated with GM’s core full‑size ICE trucks that fund its EV strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 17,
          "pages": [
            15,
            16,
            17,
            18,
            19
          ]
        },
        "hop_2_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GM_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79214,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20057,
        "completion_tokens": 187,
        "total_tokens": 20245
      }
    },
    {
      "question_id": 39,
      "question": "How does Cisco's issuance of $13.5 billion in senior fixed-rate notes relate to its $10.9 billion commercial paper notes outstanding as of July 27, 2024, and what implications does this have for the company's overall debt structure and interest rate risk management?",
      "original_answer": "Cisco issued $13.5 billion in senior fixed-rate notes in February 2024, which ranks at par with the $10.9 billion in commercial paper notes outstanding as of July 27, 2024. These two debt instruments are part of Cisco’s broader capital structure and financing strategy. The company also entered into an interest rate swap for $0.5 billion of the senior fixed-rate notes, converting fixed interest payments to floating rates based on SOFR, indicating an active approach to managing interest rate exposure. This hedging activity suggests that while the senior notes are fixed-rate in nature, Cisco is mitigating potential interest rate risk, which contrasts with the inherently short-term and flexible nature of the commercial paper notes. The coexistence and pari passu ranking of these instruments highlight a layered approach to debt financing and risk management.",
      "llm_answer": "Cisco's issuance of $13.5 billion of senior fixed‑rate notes in February 2024 expands its long‑term debt base and raises the total outstanding senior notes to $20.25 billion (up from $8.5 billion a year earlier). This larger debt issuance is offset in part by a $10.9 billion commercial‑paper program that remains outstanding, giving the company a diversified financing mix of long‑term fixed‑rate notes and short‑term floating‑rate paper. By issuing long‑term notes at fixed rates and maintaining a sizable commercial‑paper facility, Cisco can manage interest‑rate risk—using interest‑rate swaps to hedge portions of its fixed‑rate exposure—while preserving flexibility to refinance or reduce debt if market rates change.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79583,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20139,
        "completion_tokens": 180,
        "total_tokens": 20320
      }
    },
    {
      "question_id": 39,
      "question": "How does Visual Studio's inclusion in the Intelligent Cloud segment contribute to the $97.7 billion in Server products and cloud services revenue reported for fiscal year 2024?",
      "original_answer": "Visual Studio is explicitly included within the Server products and cloud services category, which generated $97,726 million in revenue for fiscal year 2024. As part of the Intelligent Cloud segment, Visual Studio functions as a key developer tool that supports cloud adoption and application development on Azure, thereby driving usage-based revenue from cloud services. The 2024 10-K confirms Visual Studio's inclusion in Server products and cloud services revenue on page 42, indicating its direct contribution to the segment's financial performance. This aligns with Microsoft's broader strategy of providing integrated development tools that encourage enterprise and developer engagement with its cloud infrastructure, ultimately supporting the segment's growth from $67.4 billion in 2022 to $97.7 billion in 2024.",
      "llm_answer": "Visual Studio is included in the Server products and cloud services category within the Intelligent Cloud segment. According to the revenue breakdown in page 93, Server products and cloud services generated $97,726 million in fiscal year 2024, which represents the $97.7 billion in Server products and cloud services revenue referenced in the question. This category includes Visual Studio along with Azure, SQL Server, Windows Server, System Center, and related Client Access Licenses. The Intelligent Cloud segment's revenue grew 20% year-over-year to $105,362 million (page 44), with Server products and cloud services driving this growth through increased Azure consumption and other cloud services.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56727,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14407,
        "completion_tokens": 175,
        "total_tokens": 14583
      }
    },
    {
      "question_id": 39,
      "question": "Given Disney's risks around brand damage affecting DTC subscriber retention and content cost pressures, and Pixar's role as a key brand tile within Disney+, how might reputational harm to Pixar impact the valuation of Disney's indefinite-lived intangible assets?",
      "original_answer": "Disney identifies damage to its brands as a risk that could negatively impact sales, profitability, and brand reputation across businesses, including its DTC segment. Pixar is specifically called out in the DTC section as one of the top-level branded tiles within Disney+, serving as a critical differentiator in attracting and retaining subscribers. Since Pixar is also listed as an indefinite-lived intangible asset on page 110—alongside Marvel and ESPN—any reputational harm to Pixar could not only reduce subscriber growth and retention but also trigger an impairment review of this asset. This creates a direct link between brand risk in the DTC context and the financial valuation of intangible assets, showing how qualitative brand risks could manifest in tangible financial impacts.",
      "llm_answer": "A reputational blow to Pixar could erode subscriber retention on Disney+, directly threatening the platform’s key “tile” brands and thereby jeopardizing the valuation of Disney’s indefinite‑lived intangible assets such as the Pixar trademark and franchise intangibles that are recorded on the balance sheet.  The 2022 10‑K notes that indefinite‑lived intangibles include the ESPN, Pixar and Marvel trademarks and that impairment of these assets would be triggered by damage to brand reputation, making Pixar’s brand health a material driver of intangible‑asset value.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 110,
          "pages": [
            108,
            109,
            110,
            111,
            112
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 65594,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16647,
        "completion_tokens": 141,
        "total_tokens": 16789
      }
    },
    {
      "question_id": 39,
      "question": "How does UPS's use of net asset value (NAV) as a practical expedient for valuing alternative investments relate to the $2.7 billion of unfunded commitments associated with private debt and other limited partnership interests?",
      "original_answer": "UPS utilizes NAV as a practical expedient for valuing alternative investments such as private debt, real estate, and private equity funds due to the lack of readily determinable fair value. This valuation method is applied to investments in limited partnership interests, which include private debt. As of December 31, 2024, UPS reports unfunded commitments of approximately $2.7 billion related to these limited partnerships, which are expected to be contributed over the next three to six years. The NAV-based valuation approach reflects the long-term and illiquid nature of these investments, particularly private debt, which typically cannot be redeemed until the end of the partnership term (10–15 years). Thus, the $2.7 billion unfunded commitment is directly tied to UPS's NAV-based investment strategy in private debt and similar instruments.",
      "llm_answer": "UPS values its alternative‑investment holdings—including private‑debt and private‑equity limited‑partnership interests—using net asset value as a practical expedient, which means these investments are not placed in the Level 1, 2, or 3 fair‑value hierarchy. Because these interests are illiquid and have limited redemption rights, the company discloses unfunded commitments to such partnerships. As of December 31 2024, those unfunded commitments total approximately **$2.7 billion**, representing the amount of future capital contributions UPS may be required to make over the remaining life of the partnerships. This figure reflects the exposure linked to the NAV‑based valuation approach for private‑debt and related limited‑partner interests.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70907,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17956,
        "completion_tokens": 186,
        "total_tokens": 18142
      }
    },
    {
      "question_id": 39,
      "question": "How does Mississippi Power Company's reporting relationship with Southern Company influence its eligibility for reduced disclosure requirements in the 10-K filing, and what specific conditions justify this streamlined reporting format?",
      "original_answer": "Mississippi Power Company, a subsidiary of The Southern Company, is not required to furnish an annual report or proxy statement to its parent company, which aligns with its eligibility for reduced disclosure under General Instructions I(2)(b), (c), and (d) of Form 10-K. According to the filing, Mississippi Power meets the conditions outlined in General Instructions I(1)(a) and (b), which allow it to use the reduced disclosure format because it does not send annual reports to its sole shareholder. This reporting structure reflects a standard regulatory accommodation for subsidiaries that report under the umbrella of a parent registrant, reducing redundant disclosures and administrative burden while maintaining compliance with SEC requirements.",
      "llm_answer": "Mississippi Power Company qualifies for reduced disclosure requirements under General Instructions I(2)(b), (c), and (d) because it meets the conditions specified in those instructions, as stated in the Table of Contents on page 3. This allows it to file a streamlined Form 10-K with abbreviated reporting for certain items, including executive compensation and certain related party disclosures, as part of the combined filing with other Southern Company system companies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 324,
          "pages": [
            319,
            320,
            321,
            322,
            323
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78498,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19860,
        "completion_tokens": 118,
        "total_tokens": 19978
      }
    },
    {
      "question_id": 39,
      "question": "How does Amgen's joint commercialization arrangement with BeiGene for XGEVA in China, including profit-sharing and eventual royalty obligations, reconcile with the competitive landscape for XGEVA in the U.S. and Europe where it faces generic bisphosphonates?",
      "original_answer": "Amgen's joint commercialization arrangement with BeiGene for XGEVA in China involves shared profits and losses during the initial commercialization period, after which product rights may revert to Amgen, triggering royalty payments to BeiGene on Chinese sales. This collaborative model supports Amgen’s strategy to expand its oncology footprint in China without full operational control. In contrast, in the U.S. and Europe, XGEVA competes directly with generic bisphosphonates—such as zoledronate generics—posing a significant threat to its market position in these mature markets. The dual dynamic highlights a strategic divergence: in China, Amgen leverages a partnership to access market growth and reduce risk, while in the U.S. and Europe, it must defend XGEVA’s value proposition against low-cost generic alternatives. This contrast underscores how Amgen tailors its commercial approach based on market maturity and competitive intensity.",
      "llm_answer": "Amgen’s joint commercialization deal with BeiGene for XGEVA in China pairs an upfront payment and shared‑risk R&D costs with a 50/50 profit split during the initial launch period, after which product rights revert to Amgen and it must pay BeiGene royalties on Chinese sales; this structure lets Amgen maintain a foothold in a high‑growth market while still facing U.S. and European price pressure from generic bisphosphonates that compete with XGEVA.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70645,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17909,
        "completion_tokens": 112,
        "total_tokens": 18022
      }
    },
    {
      "question_id": 39,
      "question": "What is the significance of Goldman Sachs applying a zero percent countercyclical capital buffer in both its TLAC to RWAs requirement and its CET1 capital ratio calculations under the Standardized and Advanced Capital Rules?",
      "original_answer": "Goldman Sachs applies a zero percent countercyclical capital buffer in both its TLAC to RWAs requirement (18% minimum + 2.5% buffer + zero percent countercyclical buffer + 1.5% G-SIB surcharge) and in its CET1 capital ratio calculations (4.5% minimum + G-SIB surcharge + zero percent countercyclical buffer + SCB of 6.2% as of December 2024). The zero percent buffer reflects the current regulatory stance by the FRB, which has not activated the countercyclical component despite broader economic conditions. This dual inclusion highlights a consistent regulatory capital treatment across different frameworks, suggesting strategic alignment in how GS manages its capital adequacy and compliance under both TLAC and Basel III-derived capital rules, even as other buffers like the SCB and G-SIB surcharge vary in magnitude.",
      "llm_answer": "The firm applied a zero‑percent countercyclical capital buffer to both the TLAC‑to‑RWAs metric and its CET1 ratio calculations under the Standardized and Advanced Capital Rules, meaning that no additional capital was required to offset cyclical risks and the regulatory capital ratios were calculated without any extra cyclical buffer. This zero‑percent buffer is reflected in the capital‑framework disclosures, which note that the countercyclical buffer has been set to zero and is incorporated into the CET1 requirement (e.g., a 13.7 % Standardized CET1 ratio that already includes the 6.2 % stress‑capital buffer but excludes any countercyclical component).",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "GS_10k_2024.pdf",
          "target_page": 208,
          "pages": [
            206,
            207,
            208,
            209,
            210
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 96414,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24337,
        "completion_tokens": 165,
        "total_tokens": 24502
      }
    },
    {
      "question_id": 39,
      "question": "How does Duke Energy's use of tax-exempt bonds in Ohio relate to its pension cost obligations in that jurisdiction, and what does this imply about the company's capital structure and long-term liability management strategy?",
      "original_answer": "Duke Energy has $77 million in tax-exempt bonds outstanding under Duke Energy Ohio as of December 31, 2023, as disclosed in the long-term debt table. These bonds carry a favorable interest rate of 3.89%, which is lower than other debt instruments, indicating a strategic use of tax-exempt financing to reduce borrowing costs. Further, the company shows a $5 million service cost and a $13 million interest cost on projected benefit obligations in Ohio within its pension disclosures. This implies that while Duke Energy is leveraging tax-exempt bonds to finance operations, it is also managing significant pension liabilities in the same jurisdiction. The combination suggests a capital structure strategy that balances lower-cost debt with long-term employee benefit obligations, requiring careful liability management to maintain financial stability.",
      "llm_answer": "Duke Energy uses tax‑exempt bonds in Ohio that can be put to the company (or its subsidiaries) at the holders’ option, and these short‑term obligations are classified as long‑term debt because the company can refinance them under its Master Credit Facility and other bilateral credit agreements with non‑cancelable terms exceeding one year. This flexibility allows Duke Energy to match the long‑term nature of its pension liabilities—funded through pension trusts and regulatory assets—with a capital structure that relies heavily on long‑dated, low‑cost tax‑exempt financing, supporting a strategic approach to managing long‑term liabilities and maintaining a stable, diversified debt profile.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 209,
          "pages": [
            207,
            208,
            209,
            210,
            211
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 117250,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 29550,
        "completion_tokens": 173,
        "total_tokens": 29724
      }
    },
    {
      "question_id": 40,
      "question": "How does the strategic importance of Horizon Innovations LLC, as a joint venture for HTS product commercialization, align with Altria's exposure to macroeconomic and business conditions that could impede its Vision of transitioning adult smokers to smoke-free products?",
      "original_answer": "Altria's joint venture Horizon Innovations LLC, in which PM USA holds a 75% economic interest, is central to its strategy for commercializing heated tobacco stick (HTS) products in the U.S., a key component of its Vision to transition adult smokers to potentially less harmful alternatives. However, the success of Horizon is highly dependent on external factors such as regulatory authorizations, economic conditions, market dynamics, and adult consumer preferences—all of which are categorized as macro business conditions that could materially affect Horizon’s ability to generate revenue. These macro risks are explicitly outlined in Altria’s risk factors, where changes in economic conditions, regulatory environments, or consumer behavior could delay product development, disrupt test launches, or prevent the joint venture from achieving its commercialization goals. This creates a tension between the strategic intent behind Horizon’s formation and the external forces that could hinder its execution, directly impacting Altria’s broader Vision and financial outcomes.",
      "llm_answer": "The Horizon Innovations joint venture is central to Altria’s strategy of transitioning adult smokers to smoke‑free products, but its success depends on regulatory approvals, prevailing economic and market conditions, and the ability to meet commercialization milestones. If macro‑economic pressures, shifting consumer preferences, or adverse regulatory or legal outcomes undermine Horizon’s ability to generate new revenue streams, Altria’s broader Vision of a smoke‑free future—and its capacity to offset declining cigarette volumes—could be materially impaired.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84005,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21243,
        "completion_tokens": 140,
        "total_tokens": 21384
      }
    },
    {
      "question_id": 40,
      "question": "How does the change in the Netherlands Innovation Box Tax benefit between 2022 and 2023 impact BKNG's effective tax rate, and how does this relate to the broader context of Dutch corporate income tax law's effect on the company's international earnings and deferred tax assets?",
      "original_answer": "The Netherlands Innovation Box Tax benefit decreased in 2023 compared to 2022, contributing to a higher effective tax rate in 2023 despite a lower valuation allowance and lower international tax rates. This Innovation Box Tax, part of Dutch corporate income tax law, allows qualifying innovative activities—such as those by Booking.com—to be taxed at 9% instead of the standard 25.8%. A portion of Booking.com's earnings in both 2022 and 2023 qualified for this reduced rate, significantly benefiting the company’s effective tax rate. However, the Innovation Box Tax benefit declined in 2023, which partially offset the otherwise lower effective tax rate. This context aligns with the broader international tax structure BKNG operates under, as noted in the reconciliation section, which highlights the significance of Dutch tax law on the company’s international earnings and deferred tax assets, including a $675 million deferred tax asset in 2023.",
      "llm_answer": "The 2023 increase in the Netherlands Innovation Box Tax rate from 7% to 9% (effective Jan 1 2022) and the subsequent rise in the statutory Dutch corporate tax rate from 25% to 25.8% reduced the tax advantage of the Innovation Box, contributing to a higher effective tax rate in 2023. This shift is reflected in the reconciliation where the Innovation Box benefit fell from a $452 million credit in 2022 to $544 million in 2023, and the overall effective tax rate rose to 21.8% (up from 22.1% in 2022) despite a lower valuation allowance on deferred tax assets. The change therefore modestly increased BKNG’s effective tax rate and impacted the tax treatment of its international earnings and related deferred tax assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "BKNG_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70490,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17870,
        "completion_tokens": 180,
        "total_tokens": 18050
      }
    },
    {
      "question_id": 40,
      "question": "How does Cisco's $10.9 billion in commercial paper notes outstanding as of July 27, 2024, relate to the $13.5 billion in senior fixed-rate notes issued in February 2024, particularly in light of the company's compliance with debt covenants and the use of interest rate swaps?",
      "original_answer": "Cisco had $10.9 billion in commercial paper notes outstanding as of July 27, 2024, which is part of its broader short-term debt financing program. In February 2024, the company issued $13.5 billion in senior fixed-rate notes, which rank at par with the commercial paper notes. This indicates that both instruments are similarly prioritized in the capital structure, though the senior notes are longer-term in nature. Additionally, Cisco entered into an interest rate swap for $0.5 billion of the senior fixed-rate notes, converting fixed interest payments to floating rates based on SOFR, which suggests an active hedging strategy to manage interest rate exposure. Despite these liabilities, Cisco remained in compliance with all debt covenants as of July 27, 2024, demonstrating disciplined debt management even with significant short- and long-term obligations.",
      "llm_answer": "Cisco's $10.9 billion of commercial paper notes outstanding as of July 27 2024 is part of its $15 billion short‑term commercial‑paper program and is reported as short‑term debt alongside the $488 million current portion of long‑term debt. The $13.5 billion of senior fixed‑rate notes issued in February 2024 is recorded as long‑term debt; the company entered into a $0.5 billion interest‑rate swap that hedges a portion of those fixed‑rate notes, and as of July 27 2024 it was in compliance with all debt covenants.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79583,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20142,
        "completion_tokens": 128,
        "total_tokens": 20270
      }
    },
    {
      "question_id": 40,
      "question": "How does Disney's provision of a $0.3 billion line of credit to Shanghai Disney Resort compare with Shendi's $1.2 billion in loans and $0.4 billion line of credit, and what does this suggest about the relative financial commitments of each partner in the joint venture?",
      "original_answer": "Disney provided Shanghai Disney Resort with a 1.9 billion yuan (approximately $0.3 billion) line of credit, while Shendi provided significantly larger loans totaling 8.6 billion yuan (approximately $1.2 billion) and also extended a 2.6 billion yuan (approximately $0.4 billion) line of credit. This disparity suggests that Shendi is shouldering a greater direct financial burden in funding the resort’s operations and development, potentially reflecting differing strategic or capital investment approaches between the two partners despite Disney’s operational leadership in the joint venture.",
      "llm_answer": "Disney provided a $0.3 billion line of credit to Shanghai Disney Resort, while Shendi contributed $1.2 billion in loans and an additional $0.4 billion line of credit. This shows that Shendi’s financial commitment to the joint venture is substantially larger than Disney’s, reflecting a greater reliance on Shendi’s capital to fund Shanghai Disney Resort.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 96,
          "pages": [
            94,
            95,
            96,
            97,
            98
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62714,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15919,
        "completion_tokens": 88,
        "total_tokens": 16007
      }
    },
    {
      "question_id": 40,
      "question": "How does MMM's decision to exit PFAS manufacturing by 2025 align with its ability to meet growing customer demand for PFAS-free products, especially in applications like lithium-ion batteries and printed circuit boards where PFAS alternatives may not yet be feasible?",
      "original_answer": "MMM has committed to exiting all PFAS manufacturing by the end of 2025 and discontinuing the use of PFAS across its product portfolio by the same date. However, in certain applications such as lithium-ion batteries, printed circuit boards, and certain seals and gaskets, the use of PFAS-containing products manufactured by third parties may continue beyond 2025 due to technical constraints and the lack of viable PFAS-free alternatives. This creates a misalignment between MMM’s PFAS phase-out strategy and the practical challenges of transitioning to PFAS-free products in these critical areas. At the same time, the company faces increasing customer demand for PFAS-free products, particularly in markets where environmental and health concerns are driving preference shifts. This dynamic places MMM in a strategic tension between regulatory and reputational pressures to eliminate PFAS and operational limitations in replacing PFAS in technically complex applications, which could affect its competitiveness and customer relationships.",
      "llm_answer": "MMM’s announced exit from PFAS manufacturing by the end of 2025 is intended to meet growing demand for PFAS‑free products, but the company acknowledges that for certain critical applications—such as lithium‑ion batteries and printed circuit boards—commercially viable PFAS‑free alternatives may not yet be available. Consequently, while it will cease its own PFAS production by 2025, MMM may continue to source PFAS‑containing materials from third parties for these applications beyond 2025, pending the development, regulatory approval, or customer qualification of suitable substitutes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 93712,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23672,
        "completion_tokens": 147,
        "total_tokens": 23819
      }
    },
    {
      "question_id": 40,
      "question": "How does Capital One's adoption of ASU 2022-02 impact the reporting of financial difficulty modifications (FDMs), and how does this differ from the prior accounting treatment for troubled debt restructurings (TDRs) as reflected in the loan modification disclosures?",
      "original_answer": "Capital One adopted ASU 2022-02 on January 1, 2023, which eliminates the specific accounting guidance for troubled debt restructurings (TDRs) and introduces new disclosure requirements for loans with financial difficulty modifications (FDMs). Previously, TDRs were accounted for under separate guidance and included in tables showing modification types, amortized cost amounts, and financial effects for loans modified during 2022 and 2021. Under ASU 2022-02, these FDMs are now reported prospectively under a new disclosure framework without separate accounting treatment, reflecting a shift from a structured accounting approach to a more transparent disclosure-based reporting model. This change affects how the company communicates modifications to loans for borrowers experiencing financial difficulty, moving from retrospective accounting adjustments to prospective disclosure of performance outcomes.",
      "llm_answer": "Capital One adopted ASU 2022‑02 on January 1 2023, which eliminates the prior accounting guidance for troubled‑debt restructurings (TDRs) and requires that loan modifications for borrowers experiencing financial difficulty be presented as financial‑difficulty modifications (FDMs). Under the new guidance, a loan that is modified while the borrower is current or after a period of delinquency remains in accrual status if performance has been demonstrated prior to the modification and is expected to continue; otherwise the modified loan is classified as non‑performing. Previously, such modifications were accounted for as TDRs and were subject to the TDR accounting rules. The change also results in different subsequent‑default disclosures: FDMs that later default are tracked separately (e.g., Table 3.9), whereas prior TDR defaults were reported in the TDR‑subsequent‑defaults tables. This shift alters both the classification and measurement of loan modifications and their related allowance for credit losses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            136,
            137,
            138,
            139,
            140
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84256,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21310,
        "completion_tokens": 254,
        "total_tokens": 21564
      }
    },
    {
      "question_id": 40,
      "question": "How does the strategic importance of ZYN in PM's smoke-free product portfolio, as highlighted by its market expansion to 37 markets, align with the financial commitment made to fully acquire Swedish Match, the producer of ZYN, and how does this reflect PM's broader transformation into a smoke-free company?",
      "original_answer": "PM highlights ZYN as a key component of its smoke-free product (SFP) portfolio, noting that nicotine pouches, including ZYN, expanded to 37 markets by the end of 2024. ZYN is produced by Swedish Match, which PM acquired in November 2022. The acquisition was finalized in 2023 with PM paying SEK 115.07 per share and completing the redemption process to gain full ownership. This financial commitment, including $883 million paid to acquire legal title to Swedish Match shares, underscores the strategic value of ZYN in accelerating PM's transformation toward a smoke-free future. The integration of Swedish Match into PM's regional segments in 2024 further aligns with the company's broader goal of transitioning away from traditional cigarettes and expanding its leadership in alternative nicotine delivery systems.",
      "llm_answer": "The strategic importance of ZYN—highlighted by its expansion to 37 markets—directly reflects the financial commitment to fully acquire Swedish Match, whose ZYN brand is a key component of PMI’s smoke‑free portfolio. This acquisition, described as a “key milestone” in PMI’s transformation, enables the company to combine its leading heat‑not‑burn (IQOS) platform with Swedish Match’s oral nicotine products, accelerating the shift toward smoke‑free alternatives worldwide. Consequently, the global rollout of ZYN exemplifies PMI’s broader strategy of building a comprehensive, smoke‑free product ecosystem that replaces traditional cigarette sales.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67752,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17191,
        "completion_tokens": 162,
        "total_tokens": 17353
      }
    },
    {
      "question_id": 41,
      "question": "Given Merck's heavy dependence on key products like Lynparza for profitability, how does the company's strategy of combining Lynparza with Keytruda in Phase 3 clinical trials align with its exposure to sales volatility from loss of market exclusivity, especially as Keytruda is expected to lose U.S. exclusivity in 2028?",
      "original_answer": "Merck's 2023 10-K filing highlights that key products such as Lynparza and Keytruda contribute significantly to the company's profits and cash flows (page 28). However, the loss of market exclusivity for major products can lead to a rapid decline in sales, as seen with Bridion and expected for Keytruda in 2028. Despite this risk, the company is pursuing a strategic oncology initiative that includes combining Lynparza with Keytruda in Phase 3 trials for lung cancers (page 48). This suggests Merck is attempting to extend the lifecycle and value of Keytruda through novel therapeutic combinations, even as it anticipates a future decline in Keytruda sales due to generic competition. The success of this strategy would be critical to offsetting revenue losses and maintaining profitability from its key product portfolio.",
      "llm_answer": "Merck is addressing its exposure to sales volatility from losing market exclusivity on key products like Keytruda (expected to lose U.S. exclusivity in 2028) by strategically combining Lynparza with Keytruda in Phase 3 clinical trials. This approach aims to leverage the complementary mechanisms of these oncology drugs to maintain revenue momentum and delay the impact of patent expirations, while also supporting its broader strategy of diversifying its pipeline and pursuing new indications to offset declining sales from aging products.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 48,
          "pages": [
            46,
            47,
            48,
            49,
            50
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 73602,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18659,
        "completion_tokens": 135,
        "total_tokens": 18794
      }
    },
    {
      "question_id": 41,
      "question": "How does Home Depot's treatment of dividend equivalents on unvested shares differ from the additional shares delivered under accelerated share repurchase agreements in terms of payout mechanics and financial statement impact?",
      "original_answer": "Home Depot pays dividend equivalents on unvested restricted stock units and performance shares in the form of additional shares upon vesting or payout, rather than in cash, which aligns compensation value with stock price performance over time (page 69). In contrast, under accelerated share repurchase (ASR) agreements, the company receives an initial delivery of shares and may receive additional shares at settlement based on the volume-weighted average price over the agreement term, with the final share delivery acting as a mechanism to efficiently execute share repurchases rather than as compensation (page 66). These two uses of 'additional shares' serve different purposes: one relates to equity compensation and the accrual of dividend value until vesting, while the other is a financial instrument for returning capital to shareholders through repurchases.",
      "llm_answer": "Home Depot treats dividend equivalents on unvested shares as cash payments that are paid out when dividends are declared on the underlying stock, with the equivalents accruing and being settled in cash (or, for certain restricted stock units, paid in additional shares upon vesting). In contrast, shares delivered under accelerated share repurchase (ASR) agreements are acquired through cash payments to third‑party banks and result in an immediate reduction of treasury stock and a decrease in weighted‑average shares outstanding; the ASR transactions are accounted for as equity retirements and do not involve any dividend‑equivalent payouts. Consequently, dividend equivalents affect the stock‑based compensation expense recognized in earnings, while ASR‑delivered shares impact the share count and treasury‑stock balance but have no direct dividend‑equivalent mechanics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HD_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "HD_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_3_rel": {
          "source_file": "HD_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64698,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16405,
        "completion_tokens": 218,
        "total_tokens": 16624
      }
    },
    {
      "question_id": 41,
      "question": "How does Georgia Power's decision to seek an extension of Plant Gaston Units 1 through 4 operations through at least December 31, 2034, reflect the strategic implications of its 50% ownership in SEGCO, particularly given SEGCO's total rated capacity of 1,020 MWs at Plant Gaston and the associated cost and operational commitments?",
      "original_answer": "Georgia Power's decision to pursue an operational extension of Plant Gaston Units 1 through 4 until at least December 31, 2034, reflects its strategic reliance on its 50% ownership in SEGCO, which owns the 1,020 MW generating units at Plant Gaston. This ownership stake allows Georgia Power to access 510 MWs of capacity—critical for meeting long-term energy demand projections outlined in the 2025 IRP. SEGCO's structure requires Georgia Power to make ongoing payments covering operating expenses, taxes, interest, and a return on equity, indicating a long-term financial commitment that aligns with the decision to extend operations. This strategic move ensures continued access to cost-effective generation while balancing capital expenditures and reliability needs, despite the expected retirement date originally set for 2028.",
      "llm_answer": "Georgia Power’s plan to extend operations of Plant Gaston Units 1‑4 through at least 2034 reflects its 50 % equity stake in SEGCO, the jointly‑owned entity that holds the 1,020 MW rated capacity of those units; the extension allows the partners to continue operating the plant beyond its current 2028 retirement date while still meeting their cost‑sharing and revenue‑allocation obligations under the SEGCO ownership structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 216,
          "pages": [
            214,
            215,
            216,
            217,
            218
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 98498,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24890,
        "completion_tokens": 106,
        "total_tokens": 24997
      }
    },
    {
      "question_id": 41,
      "question": "How does Corebridge's repayment of $1.25 billion of its DDTL Facility through senior note issuances affect its liquidity flexibility through February 2025, particularly in light of its remaining $250 million balance under the facility?",
      "original_answer": "Corebridge repaid $1.25 billion of its DDTL Facility using proceeds from the issuance of $500 million in 6.050% Senior Notes due 2033 and $750 million in 5.750% Senior Notes due 2034 (page 107). This significantly reduced its DDTL Facility balance from $1.5 billion to $250 million as of December 31, 2023 (page 234). Despite this reduction, Corebridge retains the ability to continue borrowing under the DDTL Facility through February 25, 2025 (page 113). This suggests a strategic shift from short-term loan facility reliance to longer-term debt issuance, while still maintaining a smaller revolving credit capacity for near-term liquidity flexibility. The remaining $250 million under the DDTL Facility provides a liquidity buffer through early 2025, even as Corebridge reduces its dependence on this form of financing.",
      "llm_answer": "Corebridge’s repayment of $1.25 billion of the DDTL Facility in 2023 reduced the outstanding balance to $250 million, leaving the facility fully available for borrowing through its February 2025 maturity. Because the remaining $250 million can be drawn at any time before February 2025, Corebridge retains ample liquidity flexibility to meet short‑term funding needs or refinance other obligations without relying on external capital markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 234,
          "pages": [
            232,
            233,
            234,
            235,
            236
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81319,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20574,
        "completion_tokens": 110,
        "total_tokens": 20685
      }
    },
    {
      "question_id": 41,
      "question": "How does Duke Energy's 2030 CO₂ emissions goal align with the North Carolina-mandated 70% reduction target under HB 951, given the prior rejection of Duke's accelerated coal retirement scenario by the PSCSC?",
      "original_answer": "Duke Energy has an internal 2030 CO₂ emissions reduction goal that aligns with the 70% reduction target mandated by North Carolina through HB 951. However, in 2021, the PSCSC rejected Duke Energy Carolinas and Duke Energy Progress' preferred accelerated coal retirement IRP scenario, instead favoring a base-case scenario without a CO₂ price. This regulatory pushback highlights the challenge of aligning corporate climate goals with state-mandated timelines, especially when regulators question the cost-effectiveness or feasibility of proposed strategies. Despite this, HB 951 required the NCUC to develop a carbon reduction plan by the end of 2022, which ultimately incorporated elements from Duke's IRP and informed the 2023 Carolinas Resource Plan, particularly Portfolio 3, which outlines a path to exit coal by 2035 while balancing reliability and cost.",
      "llm_answer": "Duke Energy’s 2030 CO₂ emissions goal aligns with North Carolina’s HB 951‑mandated 70 % reduction target by positioning the company’s planned coal‑plant retirements and resource mix within the state‑approved carbon‑reduction plan; however, the PSCSC previously rejected Duke’s accelerated coal‑retirement scenario, finding the base‑case (without a CO₂ price) the most reasonable IRP option, meaning Duke must now pursue the less‑certain, cost‑optimized path outlined in HB 951 and the NCUC’s carbon plan to meet the 70 % interim goal.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 232,
          "pages": [
            230,
            231,
            232,
            233,
            234
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87723,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22163,
        "completion_tokens": 133,
        "total_tokens": 22296
      }
    },
    {
      "question_id": 42,
      "question": "How does MET's detailed valuation methodology for Structured Products reflect the risk characteristics inherent in their CMBS holdings, given the distinct fair value hierarchies reported for these investments?",
      "original_answer": "MET's CMBS holdings, which are part of the broader category of Structured Products, are valued using a combination of observable and unobservable inputs tailored to their complexity and risk profile. As disclosed on page 265, MET's CMBS holdings have a total estimated fair value of $9,949 million, with $9,099 million classified under Level 2 and $850 million under Level 3 of the fair value hierarchy. This distinction reflects the varying degrees of market liquidity and the need for internal assumptions in valuing these assets. On page 268, MET's valuation methodology for Structured Products—which includes CMBS—relies on both the market and income approaches, incorporating inputs such as credit ratings, spreads, expected prepayment speeds, and loss severity. For Level 3 CMBS, unobservable inputs like illiquidity premiums and independent broker quotations are emphasized, aligning with the higher risk and lower liquidity of these instruments. This layered approach ensures that the valuation methodology for Structured Products explicitly accounts for the risk characteristics inherent in CMBS, particularly for those classified in Level 3.",
      "llm_answer": "MET's detailed valuation methodology for Structured Products reflects the risk characteristics inherent in its CMBS holdings by classifying these investments within Level 2 and Level 3 of the fair value hierarchy, where Level 3 relies on unobservable inputs such as credit spreads, prepayment assumptions, and collateral quality to estimate fair value. This approach directly incorporates the risk of credit deterioration, cash flow uncertainty, and market illiquidity specific to CMBS and other structured products, as evidenced by the use of discounted cash flow analyses, prepayment modeling, and credit loss assessments in the valuation of ABS & CLO and CMBS securities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 265,
          "pages": [
            263,
            264,
            265,
            266,
            267
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 233,
          "pages": [
            231,
            232,
            233,
            234,
            235
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 268,
          "pages": [
            266,
            267,
            268,
            269,
            270
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 104408,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26337,
        "completion_tokens": 168,
        "total_tokens": 26506
      }
    },
    {
      "question_id": 42,
      "question": "Given Horizon's dependence on regulatory authorizations for HTS product commercialization and its strategic role in Altria's 'Moving Beyond Smoking' initiative, how might delays in FDA authorization impact Altria's timeline and financial commitment to transitioning adult smokers to smoke-free alternatives, especially considering the $2.9 billion NJOY acquisition in 2023?",
      "original_answer": "Horizon, Altria's joint venture with JTIUH, is explicitly described as being highly dependent on regulatory authorizations—particularly from the FDA—for the commercialization of heated tobacco stick (HTS) products in the U.S. The filing notes that failure to obtain or maintain such authorizations could negatively impact Horizon's ability to generate new revenue streams and enter new markets. This regulatory risk is compounded by Altria's broader strategic shift toward a smoke-free future, as emphasized in the 'Moving Beyond Smoking' initiative. The company's acquisition of NJOY in June 2023 for $2.9 billion further underscores its financial commitment to this transition. However, if Horizon experiences delays in securing regulatory approvals, Altria may face pressure to accelerate returns from NJOY or other smoke-free investments, potentially disrupting the overall timeline and financial feasibility of its smoke-free transition strategy.",
      "llm_answer": "Delays in FDA authorization for Horizon’s HTS products could push back Altria’s timeline for transitioning smokers to smoke‑free alternatives, jeopardizing its “Moving Beyond Smoking” vision and potentially reducing the financial commitment tied to the $2.9 billion NJOY acquisition. Without timely regulatory clearance, the expected new revenue streams from HTS and the broader smoke‑free portfolio may be delayed or diminished, affecting projected growth and the return on investment from the NJOY purchase.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84005,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21269,
        "completion_tokens": 127,
        "total_tokens": 21397
      }
    },
    {
      "question_id": 42,
      "question": "How does Intel's strategic decision to divest its Fab Assets in Dalian to SK hynix, including the NAND SSD Business, reconcile with its continued partnership with SK hynix to manufacture NAND memory wafers using those same assets, and how does this arrangement impact Intel's NAND profitability and product roadmap as outlined in the NSG segment?",
      "original_answer": "Intel signed an agreement with SK hynix in October 2020 to divest its NAND memory business, including the Fab Assets in Dalian, China, and the NAND SSD Business. The first closing occurred on December 29, 2021, where these assets and the NAND SSD Business were transferred to SK hynix. Despite this divestiture, Intel entered into a NAND wafer manufacturing and sale agreement, under which Intel continues to manufacture NAND memory wafers using the Dalian Fab Assets for SK hynix until the second closing. This ongoing manufacturing relationship supports SK hynix’s use of the Fab Assets while Intel benefits from continued revenue through this agreement. In the NSG segment overview, it is noted that NAND profitability improved in 2021 due to the absence of depreciation expense from NAND property, plant, and equipment held for sale. This profitability improvement aligns with the strategic divestiture, while Intel continues to leverage its NAND technology through product launches such as the Intel SSD D5-P5316, based on 144-layer QLC NAND. Thus, the divestiture of Fab Assets supports Intel’s strategic refocus while maintaining a transitional revenue stream and supporting product innovation through its NAND technology roadmap.",
      "llm_answer": "Intel's divestiture of its Dalian NAND fab assets and SSD business to SK hynix, finalized in December 2021, included a critical post-closing agreement whereby Intel will continue manufacturing and selling NAND memory wafers to SK hynix using those very assets until a second closing occurs. This arrangement allows Intel to retain limited involvement in the NAND wafer supply chain while fully exiting ownership of the facilities, directly supporting NSG segment profitability by eliminating depreciation expenses on the sold assets (which contributed $1.4 billion in unit cost improvements in 2021) and enabling sustained revenue from wafer sales. Consequently, this structure preserves Intel's ability to leverage its advanced 144-layer QLC NAND technology roadmap—evidenced by new product launches like the Intel SSD D5-P5316—while ensuring SK hynix secures a reliable, vertically integrated source of NAND wafers, ultimately bolstering Intel's NSG segment operating profit to $1.4 billion in 2021 despite lower overall revenue.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31066,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 8026,
        "completion_tokens": 257,
        "total_tokens": 8284
      }
    },
    {
      "question_id": 42,
      "question": "How does MMM's retained equity interest in Solventum, which it intends to divest within five years, influence its ongoing exposure to PFAS-related liabilities that the company has specifically retained under the separation agreement?",
      "original_answer": "MMM retains a direct financial stake in Solventum through an equity interest following the spin-off, with an intention to divest within five years. However, despite this planned divestiture, MMM has retained significant PFAS-related liabilities under the separation agreement, including liabilities for product claims arising from Solventum's products sold prior to April 1, 2024, and certain claims from products sold between April 1, 2024, and January 1, 2026. This retained exposure suggests that MMM's financial obligations related to PFAS contamination and litigation will continue even as it seeks to exit its ownership stake in Solventum, creating a complex interplay between its strategic divestiture goals and its ongoing legal and environmental liabilities.",
      "llm_answer": "The retained equity interest in Solventum does not affect the company’s ongoing exposure to PFAS‑related liabilities, because the separation and distribution agreement specifically allocates PFAS liabilities: the company retains all PFAS liabilities arising from its own business and from Solventum’s business before April 1 2024 (including site‑based contamination and certain product claims), while Solventum assumes the remaining PFAS liabilities. Consequently, even though 3M plans to divest its Solventum stake within five years, the PFAS‑related liabilities it has kept remain fully on 3M’s balance sheet and are not transferred to Solventum.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 17,
          "pages": [
            15,
            16,
            17,
            18,
            19
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 93985,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23731,
        "completion_tokens": 162,
        "total_tokens": 23893
      }
    },
    {
      "question_id": 42,
      "question": "How does Georgia Power's 50% ownership and associated financial commitments to SEGCO influence its decision to seek an extension of Plant Gaston units through 2034 as part of the 2025 IRP?",
      "original_answer": "Georgia Power's 50% ownership in SEGCO, which operates Plant Gaston, comes with significant financial obligations, including equal shares of operating expenses, taxes, interest, and a return on equity. SEGCO's generating units at Plant Gaston have a total rated capacity of 1,020 MWs, with an initial expected retirement date of December 31, 2028. However, Georgia Power, alongside Alabama Power, is evaluating the extension of Plant Gaston Units 1 through 4 beyond this date. In the 2025 IRP filing, Georgia Power specifically requested approval to operate Plant Gaston Units 1 through 4 (500 MWs based on 50% ownership through SEGCO) through at least December 31, 2034. This extension request indicates a strategic alignment with SEGCO's long-term viability despite the shared financial burden. The decision likely reflects a cost-benefit analysis weighing the capital investment required to extend Plant Gaston's life against alternatives like new renewable or gas-fired generation proposed in the IRP. Without SEGCO's operational and financial structure, Georgia Power may have pursued different resource mix strategies.",
      "llm_answer": "Georgia Power’s 50 % stake in SEGCO and the associated financial obligations tied to Plant Gaston’s generating units are key factors in its decision to seek a 2034 extension of those units in the 2025 IRP. Because the extension would allow the continued operation of the 500 MW SEGCO‑owned units beyond their currently planned 2028 retirement, it would preserve the revenue stream and cost‑recovery mechanisms that support the partners’ investment and help meet projected load growth outlined in the IRP. Consequently, the extension request is framed as a necessary step to maintain system reliability, satisfy regulatory commitments, and protect the financial interests tied to SEGCO’s assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 216,
          "pages": [
            214,
            215,
            216,
            217,
            218
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 98498,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24854,
        "completion_tokens": 173,
        "total_tokens": 25028
      }
    },
    {
      "question_id": 43,
      "question": "How does Capital One's current capital adequacy framework under Basel III, which requires a minimum CET1 capital ratio of 4.5%, align with the proposed changes under the Basel III Finalization Proposal that would introduce the Expanded Risk-Based Approach and phase in recognition of AOCI in CET1 capital?",
      "original_answer": "Capital One currently operates under Basel III Capital Rules that mandate a minimum CET1 capital ratio of 4.5%, calculated using the Basel III standardized approach. The Basel III Finalization Proposal introduces the Expanded Risk-Based Approach, which would require institutions to calculate risk-weighted assets under both the existing standardized framework and the new risk-based model, applying the more stringent result. Additionally, the proposal would phase in the recognition of Accumulated Other Comprehensive Income (AOCI), including unrealized gains and losses on available-for-sale securities, into CET1 capital over a three-year period beginning July 1, 2025. This represents a shift from Capital One’s current ability to exclude certain AOCI elements as a Category III institution. The dual-calculation requirement and AOCI inclusion could result in higher capital requirements and greater volatility in CET1 capital, impacting Capital One’s capital planning and stress testing strategies.",
      "llm_answer": "Capital One currently maintains a minimum CET1 capital ratio of 4.5% under its Basel III capital framework. The proposed Basel III Finalization Proposal would introduce an Expanded Risk‑Based Approach and require Category III institutions like Capital One to begin recognizing elements of accumulated other comprehensive income (AOCI)—including unrealized gains and losses on available‑for‑sale securities—in CET1 capital, while also phasing in this recognition over a three‑year transition ending July 1 2028. This would alter the composition of CET1 capital and could affect the firm’s capital ratios once the changes are fully implemented.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82245,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20817,
        "completion_tokens": 160,
        "total_tokens": 20977
      }
    },
    {
      "question_id": 43,
      "question": "How does Merck's ongoing financial involvement with Organon, particularly through the manufacturing and supply agreements for formulated pharmaceutical products, reconcile with the fact that Organon was spun off and is now a separate entity with its own $9.5 billion debt obligation?",
      "original_answer": "Merck's ongoing involvement with Organon is maintained through a series of binding manufacturing and supply agreements (MSAs) under which Merck both supplies and receives formulated pharmaceutical products from Organon, generating $219 million in sales in 2021. Despite the spin-off of Organon—which carried $9.5 billion in principal debt and was treated as a tax-free distribution—Merck remains operationally connected through these agreements, which have initial terms ranging from four to ten years. Additionally, Merck had a net receivable of $964 million from Organon at year-end 2021, indicating continued financial exposure. This suggests that while Organon is now a separate, financially independent entity with its own debt obligations, Merck continues to maintain a strategic and financial relationship with it through contractual supply chain commitments.",
      "llm_answer": "Based on the provided document pages, Merck's ongoing financial involvement with Organon through manufacturing and supply agreements (MSAs) is reconciled with Organon's separate status and $9.5 billion debt by noting that the MSAs are governed by separate agreements that continue to operate on an interim basis after the spin‑off. Merck manufactures and supplies certain active pharmaceutical ingredients, formulated products, and packages finished pharmaceuticals for Organon, while Organon simultaneously manufactures and supplies similar products for Merck. The financial flows under these agreements—such as $219 million of sales and $195 million of related cost of sales recorded in 2021, with $964 million receivable from Organon and $400 million payable to Organon—reflect ongoing commercial relationships that are distinct from Organon’s own $9.5 billion debt obligations, which Merck no longer guarantees.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 128,
          "pages": [
            126,
            127,
            128,
            129,
            130
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74446,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18860,
        "completion_tokens": 228,
        "total_tokens": 19089
      }
    },
    {
      "question_id": 43,
      "question": "How does the 8% dividend increase approved in January 2022 for CMCSA's Class A common stock align with the structural voting power imbalance and special approval rights held by the Class B common stock, particularly in light of Brian L. Roberts' sole beneficial ownership of the Class B shares?",
      "original_answer": "CMCSA's Class A common stock received an 8% dividend increase in January 2022, signaling a positive return to shareholders. However, the Class A shares hold only 66 2/3% of the combined voting power, with the remaining 33 1/3% held by the Class B common stock, which has disproportionate influence due to its non-dilutable voting rights and special approval rights over major corporate transactions. Since Brian L. Roberts, the company’s Chairman and CEO, is the sole beneficial owner of the Class B shares, he maintains significant control over strategic decisions, even though Class B shares can be converted into Class A shares on a one-for-one basis. This structure creates a misalignment between economic returns (as seen in the dividend increase) and voting control, which could impact shareholder dynamics and corporate governance decisions.",
      "llm_answer": "The 8% dividend increase approved in January 2022 was approved by the Board of Directors despite the structural voting power imbalance that gives Class B shares (held solely by Brian L. Roberts) a non‑dilutable 33 % of the combined voting power and separate approval rights over material transactions. Because Roberts controls the Class B shares, he effectively has decisive influence over such board actions, allowing the dividend increase to be implemented even though the Class A shareholders (who hold the remaining voting interest) have limited voting power.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 55641,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14165,
        "completion_tokens": 140,
        "total_tokens": 14306
      }
    },
    {
      "question_id": 43,
      "question": "Given that Disney did not have any pay-fixed interest rate swaps designated as cash flow hedges at the end of fiscal 2024, how does this absence affect the interest rate exposure on their floating-rate borrowings, which are reported at their current interest rates in effect at September 28, 2024?",
      "original_answer": "The absence of pay-fixed interest rate swaps designated as cash flow hedges at the end of fiscal 2024 means Disney is not actively converting floating-rate borrowings into fixed-rate obligations. As a result, the company remains exposed to interest rate volatility on its floating-rate borrowings, which are reported at the current rates in effect at September 28, 2024, and these rates may not reflect future interest rate environments. This lack of hedging could lead to increased interest expense if market rates rise.",
      "llm_answer": "The absence of pay-fixed interest rate swaps designated as cash flow hedges means Disney does not have a mechanism to lock in current floating‑rate borrowing costs; its floating‑rate debt will continue to be exposed to market‑interest‑rate fluctuations, so the interest expense on those borrowings will vary with changes in the prevailing rates rather than being fixed in advance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80409,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20355,
        "completion_tokens": 95,
        "total_tokens": 20450
      }
    },
    {
      "question_id": 43,
      "question": "How does the $24 million impact from regulatory disallowances at Nicor Gas mentioned in the MD&A section reconcile with the $96 million pre-tax charges associated with capital investment disallowances at Nicor Gas in the financial statement details?",
      "original_answer": "The $24 million referenced in the MD&A section represents the portion of earnings impact related to regulatory disallowances at Nicor Gas, indicating a net effect on operational performance. In contrast, the $96 million pre-tax charge disclosed in the financial statement details reflects the broader accounting impact of disallowed capital investments, which includes both the principal disallowance and any associated write-downs. The difference between these figures highlights how the MD&A section presents a summarized view of disallowances on earnings, while the financial statements provide a more granular and comprehensive accounting treatment of the same issue. This distinction allows stakeholders to understand both the operational and financial statement implications of regulatory disallowances.",
      "llm_answer": "The $24 million impact referenced in the MD&A represents the estimated pre‑tax loss that will be recorded in 2023 from regulatory disallowances at Nicor Gas, while the $96 million pre‑tax charge disclosed in the financial‑statement details reflects the total pre‑tax amount associated with capital‑investment disallowances at Nicor Gas. In other words, the $24 million is the portion of that $96 million that is expected to affect earnings in the current year, whereas the $96 million is the full cumulative charge related to those disallowed capital investments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64793,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16441,
        "completion_tokens": 140,
        "total_tokens": 16582
      }
    },
    {
      "question_id": 43,
      "question": "How does Capital One's current capital adequacy framework under Basel III, which maintains a minimum CET1 capital ratio of 4.5%, reconcile with the potential impact of the Basel III Finalization Proposal that would introduce the Expanded Risk-Based Approach and phase in recognition of AOCI in CET1 capital starting July 1, 2025?",
      "original_answer": "Capital One currently operates under the Basel III Capital Rules, which require a minimum CET1 capital ratio of 4.5% calculated using the standardized approach and allow exclusion of certain AOCI elements. However, the Basel III Finalization Proposal would introduce the Expanded Risk-Based Approach, requiring institutions to calculate risk-weighted assets under both the existing standardized approach and the new model-based framework, applying the stricter of the two. Additionally, the proposal mandates that Category III institutions like Capital One begin recognizing AOCI, including unrealized gains and losses on available-for-sale securities, in CET1 capital, phased in over three years starting July 1, 2025. This change could reduce CET1 capital levels due to market volatility, potentially affecting Capital One’s ability to maintain the 4.5% minimum CET1 requirement under the stricter calculation method, especially if asset values decline.",
      "llm_answer": "Capital One maintains a minimum CET1 capital ratio of 4.5% under its current Basel III framework, which is the regulatory floor for Category III institutions. The proposed Basel III Finalization would introduce an Expanded Risk‑Based Approach and require Category III firms to begin recognizing accumulated other comprehensive income (AOCI) in CET1 capital beginning July 1 2025, with a three‑year phase‑in through July 1 2028. Consequently, while the existing framework requires a 4.5% CET1 minimum now, the new rule would alter the composition of CET1 (including AOCI) and phase in the expanded risk‑weighting methodology, potentially affecting Capital One’s capital adequacy calculations and the timing of when the 4.5% minimum would be measured under the revised framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82245,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20823,
        "completion_tokens": 194,
        "total_tokens": 21017
      }
    },
    {
      "question_id": 43,
      "question": "How does Altria's strategic investment in Horizon's heated tobacco stick commercialization align with the regulatory risks disclosed in the 10-K, particularly given the joint venture's dependence on FDA authorizations?",
      "original_answer": "Altria's strategic investment in Horizon, a joint venture with JTIUH for the U.S. commercialization of heated tobacco stick (HTS) products, is positioned as a key component of its Vision to transition adult smokers to potentially less harmful alternatives. However, the 10-K explicitly states that Horizon's ability to generate new revenue streams is 'dependent upon a number of factors,' with the 'receipt of regulatory authorizations' being the first and most critical. This aligns with broader regulatory risks outlined in the document, which state that failure to obtain or maintain regulatory authorization for marketing or sale of innovative products could result in a 'material adverse effect' on Altria’s business and its ability to achieve its Vision. The document also notes that the commercialization of Horizon's products is subject to 'commercialization milestones' and regulatory compliance, further emphasizing that without timely FDA authorizations, the financial and strategic value of the Horizon joint venture could be significantly undermined.",
      "llm_answer": "The joint venture’s ability to commercialize heated‑tobacco products hinges on receiving FDA pre‑market authorization; without such regulatory clearance Horizon cannot market the HTS products in the United States, and any delay or denial would materially impair the venture’s revenue prospects and Altria’s strategic goal of moving adult smokers toward smoke‑free alternatives. This regulatory dependency is explicitly flagged in the 10‑K as a key risk that could adversely affect Altria’s results of operations, cash flows and financial position.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84005,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21231,
        "completion_tokens": 136,
        "total_tokens": 21367
      }
    },
    {
      "question_id": 43,
      "question": "How does Boeing's relationship with JPMorgan Chase Bank, N.A. as a syndication agent in its 2023 Five-Year Credit Agreement reflect the broader pattern of financial partnerships with the bank across Boeing's credit facilities?",
      "original_answer": "Boeing's relationship with JPMorgan Chase Bank, N.A. as a syndication agent in the 2023 Five-Year Credit Agreement (Exhibit 10.2 to the 10-Q for the quarter ended September 30, 2023) builds on a consistent pattern of financial collaboration, as evidenced by the bank's involvement in multiple credit agreements, including the 364-Day Credit Agreement and the Three-Year Credit Agreement, both dated in 2023 and 2022 respectively. This recurring role indicates a strategic partnership where JPMorgan Chase Bank plays a central role in structuring and managing Boeing's credit facilities, reflecting a deep and ongoing financial relationship.",
      "llm_answer": "Boeing's use of JPMorgan Chase Bank, N.A. as syndication agent in its 2023 Five-Year Credit Agreement reflects a consistent pattern of partnering with JPMorgan across its credit facilities, as evidenced by JPMorgan's recurring role as syndication agent in the 2019 Five-Year Credit Agreement (Exhibit 10.2 to the 2019 8-K), its continued role as syndication agent in the 2022 amendment to that agreement (Exhibit 10.3 to the 2022 8-K), and its ongoing involvement as joint lead arranger and joint book manager in the 2022 Three-Year Credit Agreement (Exhibit 10.2 to the 2022 8-K). This demonstrates a sustained, multi-year relationship where JPMorgan serves as a key arranger and syndication agent across Boeing's various credit facilities.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 126,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2023.pdf",
          "target_page": 125,
          "pages": [
            123,
            124,
            125,
            126,
            127
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64957,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16469,
        "completion_tokens": 185,
        "total_tokens": 16654
      }
    },
    {
      "question_id": 43,
      "question": "How does Duke Energy's consistent classification of debt investments as AFS across both Carolinas and Progress segments impact the comparability of their fair value disclosures and what are the implications for understanding market risk exposure in their investment portfolios?",
      "original_answer": "Duke Energy consistently classifies debt investments as AFS (Available-for-Sale) across both Duke Energy Carolinas (page 192) and Duke Energy Progress (page 194). This uniform accounting treatment means that unrealized gains and losses on these investments are recorded in other comprehensive income rather than net income, affecting how market risk is reflected in the financial statements. The fair value disclosures on page 192 show that both debt and equity investments are categorized using this classification framework, which allows for comparability between segments. However, since AFS classification delays the recognition of market fluctuations into earnings, analysts must look beyond the income statement to assess the true market risk exposure embedded in these portfolios. This consistent policy across segments simplifies cross-segment analysis but may obscure the immediate impact of market volatility on earnings.",
      "llm_answer": "Duke Energy’s consistent classification of debt investments as AFS across its Carolinas and Progress segments ensures that fair value disclosures for these holdings are prepared using the same accounting framework, allowing for direct line‑item comparison of unrealized gains/losses, gross fair‑value amounts, and realized gains/losses across the two segments. This uniformity enhances the comparability of the segments’ investment portfolios and clarifies that market risk exposure—measured by the magnitude of unrealized holding gains/losses and the composition of debt securities (e.g., corporate, municipal, U.S. government bonds)—is presented consistently, making it easier to assess the relative sensitivity of each segment’s portfolio to interest‑rate and credit‑risk fluctuations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 192,
          "pages": [
            190,
            191,
            192,
            193,
            194
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 192,
          "pages": [
            190,
            191,
            192,
            193,
            194
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 105396,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26594,
        "completion_tokens": 197,
        "total_tokens": 26791
      }
    },
    {
      "question_id": 44,
      "question": "How does Altria's indemnification arrangement with PMI for tobacco-related liabilities interact with PM USA's unconditional guarantee of Altria's $3.0 billion Credit Agreement obligations, particularly in light of PM USA's contingent liability exposure under fraudulent transfer laws?",
      "original_answer": "Altria has a distribution agreement with PMI under which PMI indemnifies Altria and PM USA for liabilities related to tobacco products manufactured by PMI or contract manufactured by PM USA for PMI. This indemnification is not recorded on Altria's balance sheet as its fair value is deemed insignificant. PM USA, in turn, unconditionally guarantees Altria's obligations under its $3.0 billion Credit Agreement, among other debt instruments. However, under federal bankruptcy and fraudulent transfer laws, these guarantees could be voided or subordinated if PM USA is found to have received less than fair consideration or was insolvent at the time the obligations were incurred. This creates a complex liability chain where PMI's indemnification of PM USA could be critical to PM USA's ability to meet its guarantee obligations to Altria, especially if PM USA's financial position weakens and exposes it to fraudulent conveyance claims.",
      "llm_answer": "Altria’s indemnification of PMI for tobacco‑related liabilities is separate from PM USA’s unconditional guarantee of Altria’s $3 billion Credit Agreement, but the guarantee could be voided under fraudulent‑transfer or bankruptcy law if PM USA received less than reasonably equivalent value or became insolvent when issuing the guarantee. Because the guarantee is tied to Altria’s debt obligations, any successful fraudulent‑transfer claim could eliminate the Guarantor’s liability and leave creditors with recourse only to Altria, exposing PM USA to contingent liability for the full $3 billion guarantee.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2022.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 66242,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16809,
        "completion_tokens": 151,
        "total_tokens": 16961
      }
    },
    {
      "question_id": 44,
      "question": "Given Apple's significant revenue contribution from Greater China, which includes Taiwan, how does the company's operational risk disclosure regarding Taiwan's geopolitical and public health vulnerabilities affect the sustainability of the $74.2 billion in net sales reported from the Greater China region in 2022?",
      "original_answer": "Apple reported $74.2 billion in net sales from the Greater China region in 2022, which includes Taiwan as part of its geographic segment. However, the company also discloses in its risk factors that a significant portion of its supply chain and manufacturing operations are located in Asia, including Taiwan, and are vulnerable to geopolitical tensions, public health issues like the COVID-19 pandemic, and other business interruptions. These risks could disrupt manufacturing, increase costs, and reduce consumer demand. Therefore, while Greater China contributes substantial revenue, the inclusion of Taiwan in this segment exposes Apple to operational risks that could threaten the continuity and profitability of this revenue stream if disruptions occur.",
      "llm_answer": "Apple's $74.2 billion in Greater China net sales (which includes Taiwan) face sustainability risks because the region is highlighted as a geopolitical and public‑health vulnerability in its operational‑risk disclosures. The 10‑K notes that political tensions, trade disputes and pandemic‑related disruptions can materially impair the company’s supply chain, demand and profitability in Greater China, meaning that future revenue from that market could be significantly affected despite the current $74.2 billion figure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71576,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18154,
        "completion_tokens": 129,
        "total_tokens": 18284
      }
    },
    {
      "question_id": 44,
      "question": "How does Disney's exclusion of firm commitments from its VAR model impact the effectiveness of its foreign exchange hedging strategy, given the $9.9 billion in net foreign exchange cash flow hedges and the $255 million VAR estimate at September 28, 2024?",
      "original_answer": "Disney's VAR model excludes firm commitments from its risk analysis, which means that the $9.9 billion in net foreign exchange cash flow hedges—intended to protect these commitments—are not factored into the company's maximum potential one-day loss estimate of $255 million. This creates a gap in the risk modeling framework, as the hedges are designed to offset changes in the value of firm commitments, yet neither the commitments nor the associated hedges are included in the VAR calculation. As a result, the VAR model may overstate or understate actual exposure depending on market conditions, since it does not account for the offsetting effect of these hedges on the underlying commitments. This raises questions about the completeness of Disney’s risk assessment methodology and whether the firm is fully capturing its mitigated exposures.",
      "llm_answer": "Disney’s foreign‑exchange hedging program excludes firm commitments from its Value‑at‑Risk (VAR) model, meaning those commitments are not quantified in the $255 million VAR estimate at September 28 2024. Consequently, while the $9.9 billion of net foreign‑exchange cash‑flow hedges are reflected in the VAR calculation, the portion of exposure tied to firm commitments remains outside the VAR metric, limiting the model’s ability to capture the full potential loss from FX movements related to those commitments. This exclusion can reduce the overall effectiveness of the hedging strategy by leaving a portion of the foreign‑exchange risk unmeasured and potentially under‑hedged.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2023.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68308,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17319,
        "completion_tokens": 169,
        "total_tokens": 17488
      }
    },
    {
      "question_id": 44,
      "question": "How does Georgia Power's request to extend Plant Scherer Unit 3 operations through 2035 consider FP&L's 25% ownership stake and the joint liability implications outlined in the operating agreements?",
      "original_answer": "Georgia Power's request to extend Plant Scherer Unit 3 operations through 2035 must account for FP&L’s 25% ownership stake, which means any extension or modification of the plant’s operations would require coordination and agreement with FP&L. According to the ownership table, Georgia Power owns 75% and FP&L owns 25% of Plant Scherer Unit 3. The operating agreement for jointly-owned plants, as described in the disclosures, states that Georgia Power operates the plant as an agent for the co-owners and is jointly and severally liable for third-party claims. Therefore, extending operations would not only involve Georgia Power’s regulatory filings and compliance with environmental rules but also require alignment with FP&L on financial commitments, operational responsibilities, and liability exposure.",
      "llm_answer": "Georgia Power’s 2025 IRP seeks Georgia PSC approval to extend Plant Scherer Unit 3 operations through at least December 31 2035, a request that reflects its 75 % ownership stake in the unit. Because the plant is jointly owned with FP&L (which holds the remaining 25 % interest), the extension request is made jointly with FP&L and the related operating agreements impose shared liability for the unit’s continued operation and any associated regulatory or environmental obligations. The IRP filing notes that the extension request is part of a broader set of joint ownership matters that will be reviewed by the Georgia PSC.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79477,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20102,
        "completion_tokens": 156,
        "total_tokens": 20258
      }
    },
    {
      "question_id": 44,
      "question": "How does LLY's reliance on biologics data protection until 2030 for Emgality in the U.S. align with their broader strategy of managing market exclusivity risks given the complex interaction between patent and regulatory protections?",
      "original_answer": "LLY relies on both compound patents (lasting until 2033) and biologics data protection (expiring in 2030) for Emgality in the U.S., indicating a layered intellectual property strategy. The company acknowledges in another section that market exclusivity is difficult to predict due to the interaction between patent and regulatory protections and the uncertainties of litigation. This suggests that while data protection offers a near-term exclusivity runway until 2030, LLY may strategically leverage overlapping patent protections to extend commercial advantage beyond that date, despite inherent risks.",
      "llm_answer": "LLY's reliance on biologics data protection until 2030 for Emgality aligns with its broader strategy of managing market exclusivity risks by leveraging a complex interplay of patent and regulatory protections. The company acknowledges that market exclusivity duration is inherently uncertain due to factors like patent litigation and regulatory challenges, but uses data protection as a key tool to extend exclusivity beyond patent expirations—particularly for biologics like Emgality, where data protection (2030 in the U.S.) complements compound patent protection (2033). This strategy mitigates risks from generic or biosimilar competition by ensuring layered exclusivity, though it remains vulnerable to legal challenges or regulatory changes that could shorten protection periods.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 57339,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14566,
        "completion_tokens": 196,
        "total_tokens": 14763
      }
    },
    {
      "question_id": 44,
      "question": "How does Honeywell's initial $509 million write-down of receivables from Garrett relate to the mandatory redemption schedule of the Series B Preferred Stock, and what does this imply about Honeywell's expectations for recovery under the amended terms?",
      "original_answer": "Honeywell initially wrote down $509 million in receivables from Garrett in 2020 due to the uncertainty surrounding the enforceability of the Garrett Indemnity and Tax Matters Agreement. Following Garrett's emergence from bankruptcy in April 2021, Honeywell received 834.8 million shares of Series B Preferred Stock as part of the settlement, which included mandatory redemption terms starting with $35 million in 2022 and $100 million annually from 2023 to 2030, subject to Garrett's EBITDA and liquidity conditions. By December 2021, the redemption schedule was accelerated and amended, reducing the present value of the Series B Preferred Stock to $207 million. The fair value of this investment, as disclosed on page 90, is based on the present value of these mandatory redemptions and is classified as level 2 in the fair value hierarchy. This implies that Honeywell adjusted its recovery expectations downward from the original redemption schedule due to the increased risk of non-payment, reflected in both the write-down and the updated fair value estimate.",
      "llm_answer": "Honeywell recorded a $509 million write‑down of its Garrett receivables to reflect the present value of the mandatory redemptions required under the Series B Preferred Stock’s redemption schedule, recognizing that the redemption amounts will be paid over time (2022‑2030) and accreting interest at the 7.25 % rate set in the stock’s Certificate of Designation. This write‑down signals Honeywell’s expectation that it will recover only the discounted portion of the future redemption payments, implying limited upside from the Series B holdings and a reliance on the scheduled cash‑flow stream rather than full recoverability of the original receivable value.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 59494,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15119,
        "completion_tokens": 164,
        "total_tokens": 15284
      }
    },
    {
      "question_id": 44,
      "question": "How does ConocoPhillips' strategic emphasis on coalbed methane (CBM) through its stake in APLNG reconcile with the $688 million before-tax charge recorded in 2021, which reflected a market participant view of APLNG's fair value being below the carrying value of the investment?",
      "original_answer": "ConocoPhillips highlights APLNG as a strategic joint venture that provides access to CBM resources in Australia and strengthens its LNG position, particularly targeting Asian markets. However, in 2021, when Origin Energy sought to sell a 10% stake in APLNG, ConocoPhillips exercised its preemption right and purchased the stake. The fair value of APLNG from this transaction was determined to be lower than the carrying value of COP’s existing investment, resulting in a $688 million before-tax impairment charge. This discrepancy suggests that while APLNG remains strategically important for CBM and LNG exposure, the market valuation at the time indicated a lower financial worth than previously recorded, prompting a write-down. The contrast between the qualitative strategic positioning of CBM through APLNG and the quantitative impairment charge reflects a tension between long-term resource access and short-term asset valuation pressures.",
      "llm_answer": "ConocoPhillips' strategic focus on coalbed methane (CBM) through its 47.5 % stake in APLNG aligns with the $688 million impairment recorded in 2021, which reflected a market‑participant view that APLNG’s fair value was below the carrying value of the investment. The impairment stemmed from the pre‑emptive purchase of an additional 10 % interest in APLNG at a price that signaled a lower fair‑value assessment, prompting a write‑down of the existing investment. This strategic move underscores the company’s commitment to CBM assets despite the valuation challenge.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72498,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18376,
        "completion_tokens": 141,
        "total_tokens": 18517
      }
    },
    {
      "question_id": 45,
      "question": "How does Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026, relate to the legal challenges facing Comirnaty in the U.S. and Europe, and what potential impact could these legal risks have on the continuation of those international supply commitments?",
      "original_answer": "Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract extending through 2026 with rephased deliveries and volume reductions, is central to its international revenue commitments. However, Comirnaty faces multiple legal challenges: in April 2024, GSK Group sued Pfizer and BioNTech in the U.S., alleging infringement of five U.S. patents (later amended to include three additional patents), and in January 2025, Promosome LLC filed a complaint in the Unified Patent Court alleging infringement of a European patent in France, Germany, and Sweden. These legal risks could disrupt the manufacturing and distribution of Comirnaty in key markets, potentially jeopardizing Pfizer’s ability to meet its contractual obligations under the amended EU agreement and impacting international revenue projections tied to the vaccine.",
      "llm_answer": "Pfizer’s reliance on BioNTech for Comirnaty supply—formalized through an amended EU agreement extending through 2026—means that the continuation of those international supply commitments is directly tied to the outcome of the ongoing patent‑infringement disputes involving Comirnaty.  Adverse rulings in the U.S. and European patent cases (e.g., Alnylam, Moderna, GSK, and CureVac actions) could limit or invalidate the patent protection that underpins the vaccine’s market exclusivity, potentially triggering contractual penalties, supply curtailments, or renegotiations of the EU‑wide agreement.  Consequently, any legal setbacks that weaken Pfizer/BioNTech’s IP position may compel the parties to scale back or terminate future deliveries under the extended contract, affecting the projected revenue stream from Comirnaty beyond 2026.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 129611,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 32659,
        "completion_tokens": 209,
        "total_tokens": 32868
      }
    },
    {
      "question_id": 45,
      "question": "How does ConocoPhillips' decision to exercise its preemption right to increase its stake in APLNG reflect both the strategic value of Queensland's Bowen and Surat basins and the financial implications tied to APLNG's LNG operations and long-term agreements?",
      "original_answer": "ConocoPhillips exercised its preemption right to purchase an additional 10% stake in APLNG, increasing its ownership to 47.5%, despite recognizing a before-tax charge of $688 million due to the fair value of APLNG being below the carrying value. This decision underscores the strategic importance of APLNG's access to the Bowen and Surat basins in Queensland, Australia, which are central to producing coal bed methane (CBM) and supplying LNG to Asia Pacific markets. APLNG's operations include long-term sales and purchase agreements that provide stability, even as the company faces financial obligations like the $4.7 billion outstanding on its project finance facilities. The investment decision thus reflects a balance between long-term resource access and operational risks in a capital-intensive LNG venture.",
      "llm_answer": "ConocoPhillips' exercise of its preemption right to acquire an additional 10 % stake in APLNG underscores the strategic value of the Bowens and Surat basin gas resources that underpin APLNG’s LNG production and its long‑term sales agreements, while financially it reflects the capital‑intensive nature of APLNG’s project‑finance structure (with roughly $4.7 bn of outstanding debt) and the need to align the investment’s carrying value with market‑based fair‑value assessments, prompting an impairment write‑down in 2021 and ongoing amortization of the resulting basis‑difference through unit‑of‑production accounting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72650,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18405,
        "completion_tokens": 154,
        "total_tokens": 18559
      }
    },
    {
      "question_id": 45,
      "question": "How does Intel's strategic rationale for maintaining NAND wafer manufacturing capabilities through its agreement with SK hynix relate to the timing and scope of its NAND business divestiture, particularly in the context of profitability improvements seen in 2021?",
      "original_answer": "Intel's NAND wafer manufacturing agreement with SK hynix was a strategic component of the broader divestiture of its NAND memory business, allowing for continued production and revenue generation during the transition period. The agreement ensured manufacturing continuity using the Dalian fab assets until the second closing of the divestiture, which helped Intel maintain product availability and customer relationships while exiting the business. This arrangement likely supported the profitability improvements noted in 2021, which were attributed to the absence of depreciation expenses on NAND assets held for sale. By retaining manufacturing capabilities temporarily through the agreement, Intel could manage the transition more effectively, ensuring a smoother handover to SK hynix while still benefiting from the operational efficiencies and cost controls that contributed to improved financial performance.",
      "llm_answer": "Intel maintained limited NAND wafer manufacturing capabilities through a post‑closing wafer‑supply agreement with SK hynix to ensure continuity of supply while it divested the NAND business, a move that allowed the company to shed depreciation and other fixed costs and thereby improve NAND profitability in 2021. This arrangement supported the staged exit of the NAND operations, culminating in full de‑consolidation of the NAND OpCo Business in early 2022.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31066,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 8005,
        "completion_tokens": 114,
        "total_tokens": 8120
      }
    },
    {
      "question_id": 45,
      "question": "How do the capital requirements under the Uniform Net Capital Rule constrain TDAC's ability to distribute capital to parent companies, and how does this align with Schwab's broader capital management strategy as reflected in their regulatory buffer requirements?",
      "original_answer": "TDAC, as a broker-dealer subsidiary of SCHW, is subject to the Uniform Net Capital Rule, which restricts its ability to pay dividends, make unsecured advances, or repay subordinated loans if such actions would result in net capital falling below prescribed thresholds (e.g., 2% of aggregate debit balances or a minimum dollar requirement). This limits TDAC's capacity to return capital to its parent entities like CSC. Meanwhile, Schwab's consolidated banking subsidiaries, such as CSB, are required to maintain a capital conservation buffer of 2.5% above minimum risk-based capital ratios under Basel III. If this buffer is breached, CSC would face restrictions on capital distributions and executive bonuses. The combination of these rules constrains Schwab's ability to freely allocate capital across its banking and broker-dealer entities, requiring a more cautious and segmented capital management strategy that prioritizes regulatory compliance over intercompany liquidity flexibility.",
      "llm_answer": "The Uniform Net Capital Rule requires CS&Co and TDAC to maintain net capital at least 2% of aggregate debit balances or a minimum dollar amount, and prohibits them from paying cash dividends, making unsecured advances or loans, or repaying subordinated borrowings to CSC if such payment would reduce net capital below 5% of aggregate debit balances or 120% of the minimum dollar requirement. Consequently, capital distributions from CS&Co and TDAC to their parent CSC are constrained by these net capital thresholds, limiting the amount of capital that can be transferred upward. This capital constraint aligns with Schwab’s broader capital management strategy, which emphasizes maintaining regulatory capital buffers above minimum requirements (e.g., CSC’s Tier 1 Leverage Ratio target of 6.75%-7.00% versus the 4% regulatory minimum) and using capital for strategic growth and stability rather than excessive distributions, as reflected in its focus on capital stress testing and buffer requirements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72584,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18395,
        "completion_tokens": 250,
        "total_tokens": 18645
      }
    },
    {
      "question_id": 45,
      "question": "How does the adoption of ASU No. 2023-07 impact the level of detail provided in 3M's segment reporting for the year ended December 31, 2024, compared to prior disclosures?",
      "original_answer": "The adoption of ASU No. 2023-07, which requires incremental disclosures of disaggregated expense information for reportable segments, directly impacts the level of detail in 3M's segment reporting. As noted in the accounting pronouncements section, 3M adopted this standard for the year ended December 31, 2024, and applied it retrospectively to prior periods. This change enhances the granularity of segment reporting, as seen in the segment results section, which includes detailed sales and operating income (loss) by business segment for 2024, 2023, and 2022. The new disclosures align with the ASU’s objective to improve transparency and comparability across segments.",
      "llm_answer": "The adoption of ASU No. 2023-07 requires incremental disaggregated expense disclosures for reportable segments, which 3M applied retrospectively to all prior periods for the year ended December 31, 2024. This results in more detailed segment expense reporting compared to prior disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 108617,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 27374,
        "completion_tokens": 72,
        "total_tokens": 27446
      }
    },
    {
      "question_id": 45,
      "question": "What percentage of Alabama Power's and Georgia Power's electricity generation came from nuclear units in 2021, and how do potential physical attacks on these facilities pose financial risks that could exceed decommissioning trusts or insurance coverage?",
      "original_answer": "In 2021, nuclear units accounted for approximately 26% of Alabama Power’s and 28% of Georgia Power’s total KWHs generated. These nuclear facilities, operated by Southern Nuclear, are subject to a range of risks, including physical attacks, which could lead to significant financial exposure. The company discloses that damages, decommissioning, or other costs resulting from such incidents could exceed the available decommissioning trusts or external insurance coverage, including statutorily required nuclear incident insurance. Additionally, threats of physical attacks could trigger increased compliance and licensing costs, which are difficult to predict and may materially impact Southern Company's financial position.",
      "llm_answer": "In 2021, nuclear units supplied roughly 26 % of Alabama Power’s electricity and about 28 % of Georgia Power’s electricity.  Both companies face the risk that physical attacks on these nuclear facilities could generate damages, decommissioning costs, or other expenses that exceed the amount held in decommissioning trusts or covered by available insurance.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84593,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21388,
        "completion_tokens": 89,
        "total_tokens": 21477
      }
    },
    {
      "question_id": 46,
      "question": "How does ConocoPhillips ensure the credibility and SEC compliance of its proved reserves estimates, particularly in light of its engagement with DeGolyer and MacNaughton, and how is this third-party validation formally documented in the 10-K filing?",
      "original_answer": "ConocoPhillips ensures the credibility and SEC compliance of its proved reserves estimates through a structured internal control process that includes annual reviews by an independent team led by the Manager of Reserves Compliance and Reporting. This team includes a senior representative from DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, who assesses over 90% of the company’s proved reserves as of December 31, 2021. D&M evaluates whether ConocoPhillips’ internal processes and controls for estimating reserves align with SEC regulations, using data such as seismic information, well logs, and reservoir simulation models. Their review results in a formal opinion that the company’s processes are in accordance with SEC definitions. This third-party validation is further reinforced by the inclusion of D&M’s report as Exhibit 99 in the 10-K filing, which serves as official documentation of the review process and supports the company’s disclosures on reserves accuracy and compliance.",
      "llm_answer": "ConocoPhillips ensures the credibility and SEC compliance of its proved reserves estimates through a rigorous, internally governed process that includes third‑party validation.  The company applies SEC‑mandated criteria for reserve estimation and subjects its reserves methodology to annual independent review by an internal team led by the Manager of Reserves Compliance and Reporting, which includes a senior representative from the consulting firm DeGolyer and MacNaughton (D&M).  D&M conducts on‑site and remote assessments of the reserves data, methods, and assumptions, and its independent opinion—documented in the company’s 10‑K as Exhibit 99—confirms that the processes and controls used to estimate December 31, 2021 proved reserves comply with SEC definitions.  This validation is formally disclosed in the filing under “Exhibit 99” of the 10‑K.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 152,
          "pages": [
            150,
            151,
            152,
            153,
            154
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 187,
          "pages": [
            181,
            182,
            183,
            184,
            185
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83805,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21193,
        "completion_tokens": 214,
        "total_tokens": 21407
      }
    },
    {
      "question_id": 46,
      "question": "What implications does Sojitz America's $0.3 million preferred stock ownership have for Nike's dividend policy and equity structure, given the absence of redeemable preferred stock liabilities on Nike's balance sheet?",
      "original_answer": "Sojitz America's $0.3 million preferred stock ownership creates structural requirements for Nike's dividend policy, as no dividends may be declared or paid on Nike's common stock unless dividends on the preferred stock have been declared and paid in full. Despite this, Nike's balance sheet shows no redeemable preferred stock liabilities, indicating that no dividends are currently in arrears. This preferred stock ownership also affects Nike's equity structure by granting Sojitz America specific voting rights on major corporate actions such as asset sales, mergers, or liquidation, while not having general voting rights. This creates a unique governance dynamic where Sojitz America holds strategic influence despite its small financial stake.",
      "llm_answer": "Sojitz America’s $0.3 million redeemable preferred‑stock holding does not appear as a liability on Nike’s balance sheet, indicating that the preferred‑stock obligation is treated as equity. Because dividends on this preferred stock must be paid before any common‑stock dividends can be declared, Nike’s dividend policy is effectively constrained: the company cannot distribute cash dividends to common shareholders unless the preferred‑stock dividend is first satisfied. Consequently, the existence of this preferred‑stock issue limits the amount of cash that can be returned to common shareholders and reinforces a more conservative equity‑distribution approach, even though the preferred‑stock amount is immaterial relative to Nike’s overall equity structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 62,
          "pages": [
            60,
            61,
            62,
            63,
            64
          ]
        },
        "hop_2_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 79,
          "pages": [
            77,
            78,
            79,
            80,
            81
          ]
        },
        "hop_3_rel": {
          "source_file": "NKE_10k_2023.pdf",
          "target_page": 79,
          "pages": [
            77,
            78,
            79,
            80,
            81
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70342,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17817,
        "completion_tokens": 190,
        "total_tokens": 18007
      }
    },
    {
      "question_id": 46,
      "question": "How does Microsoft's treatment of Nuance-related convertible senior notes in the balance sheet reconcile with the strategic integration of Nuance into the Intelligent Cloud segment?",
      "original_answer": "Microsoft's balance sheet as of June 30, 2022, reflects only $1 million in convertible senior notes remaining from the $986 million originally issued by Nuance, indicating that nearly all of these obligations were redeemed prior to the reporting date. This financial simplification aligns with Microsoft's broader strategic integration of Nuance into its Intelligent Cloud segment, where the acquired company's operations have been embedded into Microsoft's cloud offerings, including Azure and professional services. The minimal remaining liability from Nuance's pre-acquisition debt structure supports the company's narrative of operational consolidation and synergy realization, key justifications cited for the acquisition and now reflected both financially and structurally within the Intelligent Cloud segment.",
      "llm_answer": "Microsoft's balance sheet reflects the acquisition of Nuance Communications within the Intelligent Cloud segment, where Nuance is explicitly reported as part of this segment. The purchase price allocation for Nuance, detailed on page 78, shows $16.3 billion of goodwill assigned to the Intelligent Cloud segment, directly linking the acquisition to this segment's financial reporting. Additionally, the segment information on page 95 confirms that the Intelligent Cloud segment's revenue and operating income include contributions from Nuance, and the segment breakdown on page 95 explicitly lists \"Intelligent Cloud\" as one of the three reportable segments, with Nuance's integration supporting synergies expected to drive growth in cloud and AI offerings within this segment. This treatment aligns with the strategic integration, as Nuance's AI and healthcare capabilities are positioned to enhance Microsoft's cloud services under the Intelligent Cloud umbrella.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 48792,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12420,
        "completion_tokens": 241,
        "total_tokens": 12662
      }
    },
    {
      "question_id": 46,
      "question": "How does Chevron's $352 goodwill investment in Renewable Energy Group, Inc. relate to its reliance on cost-effective, verifiable carbon credits, given that Renewable Energy Group is a major source of Chevron's carbon credit generation activities?",
      "original_answer": "Chevron's $352 goodwill investment in Renewable Energy Group, Inc. (REG) in the downstream segment reflects its strategic commitment to lower carbon business lines. REG is a key contributor to Chevron's carbon credit generation, which is essential for meeting its climate-related ambitions, including Scope 1 and 2 emissions targets. However, Chevron highlights in its risk factors that achieving these goals is contingent on the availability and acceptability of cost-effective, verifiable carbon credits — a factor that could significantly influence the long-term value of the REG acquisition. This interplay shows how Chevron's downstream goodwill investment is tied to broader ESG and operational risks related to carbon credit markets.",
      "llm_answer": "Chevron’s $352 million goodwill investment in Renewable Energy Group (REG) is directly tied to its strategy of securing a reliable, cost‑effective source of verifiable carbon credits. REG is identified as a major generator of the carbon credits Chevron uses to offset its Scope 1 and 2 emissions and to meet lower‑carbon fuel standards. By acquiring REG, Chevron obtains an internal supply of these credits, reducing its reliance on external markets and helping it achieve its 2028 carbon‑intensity and 2050 net‑zero upstream aspirations while keeping compliance costs manageable.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 37,
          "pages": [
            35,
            36,
            37,
            38,
            39
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 27,
          "pages": [
            25,
            26,
            27,
            28,
            29
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 86465,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21861,
        "completion_tokens": 145,
        "total_tokens": 22006
      }
    },
    {
      "question_id": 46,
      "question": "How did the change in Alabama's state apportionment methodology impact Southern Power's 2021 net income, and what does this reveal about the financial sensitivity of Southern Company's regulated utilities to state-level tax policy changes?",
      "original_answer": "The change in Alabama's state apportionment methodology, resulting from tax legislation enacted in February 2021, provided a tax benefit that contributed to a $28 million increase in Southern Power's 2021 net income. This reveals that Southern Company's regulated utilities, including Southern Power, are financially sensitive to state-level tax policy changes, particularly those affecting apportionment rules. The fact that Southern Power operates in Alabama—a state that directly influences its tax burden through legislative action—highlights how regulatory environments in specific jurisdictions can materially affect financial outcomes for utility subsidiaries within the Southern Company system.",
      "llm_answer": "The $28 million increase in Southern Power’s 2021 net income was largely attributable to a tax benefit arising from Alabama’s 2021 apportionment‑methodology change, which reduced the company’s effective tax rate. This illustrates that Southern Power’s profitability is highly sensitive to state‑level tax policy shifts, since such legislative changes can materially alter after‑tax earnings despite relatively modest operational volume changes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68061,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17253,
        "completion_tokens": 111,
        "total_tokens": 17364
      }
    },
    {
      "question_id": 47,
      "question": "How does Morgan Stanley's structuring of CLNs, which embed credit protection risk, relate to its broader credit derivatives risk management practices as evidenced by its use of CDS?",
      "original_answer": "Morgan Stanley structures CLNs as part of its asset-repackaging activities, where credit protection is embedded in these instruments. If a credit event occurs involving a reference entity, the principal balance of the CLN may not be repaid in full to the Firm, exposing it to credit risk (page 109). To manage such exposures, Morgan Stanley actively uses credit derivatives, particularly credit default swaps (CDS), where it either receives or provides protection against default risk on debt obligations. The Firm manages this exposure through risk mitigation strategies, including managing credit and correlation risk across single-name and index-based instruments, and monitors aggregate market risk limits (page 108). This demonstrates that while Morgan Stanley assumes credit risk through structured products like CLNs, it actively offsets this exposure through its CDS portfolio and structured risk management frameworks.",
      "llm_answer": "Morgan Stanley manages its credit derivatives risk through a comprehensive framework that includes selling protection via CDS and structured products such as CLNs, while simultaneously purchasing protection to hedge its own exposure. The firm monitors credit and correlation risk across single‑name, index and tranched CDS positions, enforces aggregate market‑risk limits, and uses collateral and netting mechanisms to mitigate potential losses. This approach is reflected in its detailed tables of credit protection sold, notional amounts, and the collateral it posts for potential downgrade‑related calls.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 127,
          "pages": [
            125,
            126,
            127,
            128,
            129
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 200629,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 50383,
        "completion_tokens": 151,
        "total_tokens": 50535
      }
    },
    {
      "question_id": 47,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene relate to the commercialization of BLINCYTO in China, and what does this imply about Amgen's strategic approach to oncology market expansion in the region?",
      "original_answer": "Amgen's $2.8 billion equity investment in BeiGene was part of a strategic collaboration aimed at expanding Amgen's oncology presence in China. As part of this arrangement, BeiGene began selling BLINCYTO in China in 2021, with Amgen sharing profits and losses equally during the initial commercialization period. BLINCYTO, an anti-CD19 x anti-CD3 BiTE molecule, represents a key oncology asset being leveraged through this partnership to penetrate the Chinese market. This approach reflects Amgen's broader strategy to utilize local partnerships for market access and shared risk in oncology development and commercialization.",
      "llm_answer": "Amgen's $2.8 billion equity investment in BeiGene was made to secure a collaborative partnership that grants Amgen access to BeiGene’s commercial infrastructure and development capabilities in China, enabling the launch and expansion of oncology products such as BLINCYTO within the Chinese market. This strategic move signals Amgen’s intent to deepen its presence in the region by leveraging joint development, shared R&D costs, and profit‑sharing arrangements, thereby accelerating its oncology market expansion in China.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65990,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16731,
        "completion_tokens": 130,
        "total_tokens": 16862
      }
    },
    {
      "question_id": 47,
      "question": "Given Microsoft's competitive and execution risks in cloud and AI services outlined in the 10-K, how does the rapid growth in Azure's revenue compare to the broader Server Products and Cloud Services segment's reported financial performance, and what does this imply about Microsoft's ability to offset infrastructure costs with revenue gains?",
      "original_answer": "Microsoft highlights in its risk factors that its cloud and AI strategy involves significant infrastructure and development costs that could reduce operating margins. Despite these risks, Azure, a core component of the Server Products and Cloud Services segment, has seen strong revenue growth, with the segment reporting $97.7 billion in revenue for fiscal year 2024, up from $79.97 billion in 2023. This implies that while Microsoft is successfully growing the segment, the sustainability of this growth in the face of rising infrastructure costs and competitive pressures remains a key challenge.",
      "llm_answer": "Microsoft’s Azure revenue grew from $79.97 billion in fiscal 2023 to $97.73 billion in fiscal 2024—a 22% increase—while the broader Server Products and Cloud Services segment rose from $79.97 billion to $97.73 billion over the same period. This strong cloud‑revenue growth outpaces the overall segment’s modest top‑line expansion, indicating that Azure’s rapid scale is a key driver of the segment’s performance. Consequently, the surge in Azure and related cloud sales is helping Microsoft offset the high infrastructure and development costs inherent in its cloud and AI strategy, supporting margin resilience despite ongoing execution and competitive risks.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 21,
          "pages": [
            19,
            20,
            21,
            22,
            23
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63167,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16059,
        "completion_tokens": 165,
        "total_tokens": 16224
      }
    },
    {
      "question_id": 47,
      "question": "Given Disney's use of pay-fixed interest rate swaps to convert floating-rate borrowings to fixed-rate obligations, how does the absence of such designated hedges at fiscal year-end 2024 impact the reported effective interest rate on their floating-rate debt, which includes adjustments from existing swaps and purchase accounting?",
      "original_answer": "Disney utilizes pay-fixed interest rate swaps to convert floating-rate borrowings into fixed-rate obligations, but it did not have any such designated cash flow hedges at the end of fiscal 2024. This absence means that no unrealized gains or losses from these instruments were deferred in AOCI to smooth interest expense volatility. Meanwhile, the reported effective interest rate on floating-rate borrowings includes the impact of existing and terminated interest rate swaps, purchase accounting adjustments, and debt issuance premiums or discounts. Without active pay-fixed swaps to stabilize interest costs, the effective rate on floating-rate debt becomes more sensitive to current market conditions, as evidenced by the $0.9 billion market value adjustment for debt with qualifying hedges at September 28, 2024. This dynamic suggests a potentially higher volatility in interest expense going forward.",
      "llm_answer": "The absence of designated hedges for floating‑rate borrowings at fiscal year‑end 2024 means the effective interest rate on that debt reflects only the unadjusted floating rates and any purchase‑accounting adjustments, without the offsetting gains or losses from the pay‑floating swaps that would normally lower the reported rate. Consequently, the reported effective interest rate is higher than it would be if those swaps had been designated and accounted for as hedges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80409,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20363,
        "completion_tokens": 117,
        "total_tokens": 20481
      }
    },
    {
      "question_id": 47,
      "question": "How does Boeing's increasing reach-forward loss on the Commercial Crew program in 2021 relate to the broader financial risks associated with fixed-price development contracts, particularly in light of the company's exposure to cost overruns and U.S. government contract modifications?",
      "original_answer": "Boeing's increasing reach-forward loss on the Commercial Crew program by $185 million in Q3 2021 was driven by delays and technical challenges, reflecting the inherent risk in fixed-price development contracts. These contracts, such as Commercial Crew, KC-46A, and VC-25B, expose Boeing to significant financial volatility due to the fixed revenue structure and uncertain cost estimates. The company's 2021 financial statements highlight that fixed-price contracts accounted for approximately 68% of BDS revenue, making them a core but risky part of the business model. Furthermore, the U.S. government's right to modify, curtail, or terminate contracts—especially under fiscal constraints or shifting priorities—adds another layer of risk, particularly when programs already face cost overruns and schedule delays. Together, these factors illustrate how Boeing's financial exposure on Commercial Crew is emblematic of broader systemic risks in its fixed-price development portfolio.",
      "llm_answer": "Boeing’s 2021 “reach‑forward” loss on the Commercial Crew contract reflects the difficulty of estimating final costs and revenue on a fixed‑price development program; the company recorded a $185 million increase in the loss as delays and cost growth persisted.  This illustrates the broader risk that fixed‑price contracts—especially development contracts such as Commercial Crew, KC‑46A and VC‑25B—can generate material cost overruns and margin erosion when actual performance deviates from optimistic estimates, and that any U.S. government contract modifications or terminations can amplify those exposures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 54393,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13852,
        "completion_tokens": 152,
        "total_tokens": 14005
      }
    },
    {
      "question_id": 47,
      "question": "What impact did PowerSecure's $120 million increase in distributed infrastructure revenue have on Southern Company's consolidated financial structure in 2024, particularly in relation to their microgrid deployment activities?",
      "original_answer": "PowerSecure's $120 million increase in distributed infrastructure revenue directly contributed to a $111 million rise in Southern Company's operating revenues for other business activities in 2024. This growth in revenue was accompanied by a corresponding $82 million increase in cost of other sales at PowerSecure, which flowed into Southern Company's consolidated financial statements. As PowerSecure is a consolidated subsidiary that develops and deploys microgrids, this performance reflects the growing contribution of microgrid-related activities to Southern Company's broader financial structure, despite being reported within aggregated subsidiary line items rather than separately disclosed.",
      "llm_answer": "The $120 million increase in PowerSecure’s distributed‑infrastructure revenue was reflected in Southern Company Gas’s 2024 results as a $111 million rise in operating revenue (driven largely by the $120 million of distributed‑infrastructure projects) and contributed to the overall $7.6 billion consolidated operating revenue growth reported for the company. This revenue boost supported Southern Company’s broader financial structure by adding to net income and reinforcing the earnings base of its non‑utility, resilience‑solutions business.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 164,
          "pages": [
            162,
            163,
            164,
            165,
            166
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69945,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17725,
        "completion_tokens": 135,
        "total_tokens": 17861
      }
    },
    {
      "question_id": 47,
      "question": "How does Amgen's legal strategy against Zydus in the apremilast patent litigation relate to its handling of the Notice of Appeal in the PTAB challenge, particularly in terms of the company's approach to patent defense and appeal timelines?",
      "original_answer": "Amgen's legal strategy against Zydus in the apremilast patent litigation demonstrates a proactive approach to enforcing its patent rights, as evidenced by the final judgment in Amgen's favor on multiple patent claims and the resulting injunction that restricts Zydus from marketing its generic apremilast product until the expiration of the infringed patents. Zydus filed a Notice of Appeal to the Federal Circuit Court with respect to the '638 Patent on October 27, 2021, and Amgen followed with its own notice of appeal the next day, indicating a strong commitment to defending its intellectual property through the appellate process. This aligns with Amgen's response to the Notice of Appeal in the PTAB challenge involving the '138 Patent, where Amgen filed a notice of appeal to the Federal Circuit Court on July 22, 2019, after the PTAB ruled most claims unpatentable. In both cases, Amgen pursued appellate review to preserve its patent rights, despite differing legal venues and procedures—district court litigation for Zydus and PTAB inter partes review for Apotex. The timeline of appeals also shows Amgen's consistent and timely legal response to adverse rulings, reinforcing its broader strategy of robust patent defense.",
      "llm_answer": "Amgen’s legal strategy in the Otezla patent litigation involves securing consent judgments and injunctions against multiple generic manufacturers—such as Zydus, Sandoz, Hetero, and others—by obtaining court orders that block their apremilast products from entering the market until the relevant patents expire, thereby preserving its exclusive rights. In parallel, Amgen pursued a PTAB challenge to the ‘138 Patent, filing a Notice of Director Review after the Federal Circuit remanded the case following the Arthrex decision, reflecting its broader approach of combining aggressive patent defense in district court with strategic appeals and rehearing requests to extend patent protection and delay generic competition.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 145,
          "pages": [
            143,
            144,
            145,
            146,
            147
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 145,
          "pages": [
            143,
            144,
            145,
            146,
            147
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 147,
          "pages": [
            145,
            146,
            147,
            148,
            149
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 88211,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22288,
        "completion_tokens": 180,
        "total_tokens": 22468
      }
    },
    {
      "question_id": 48,
      "question": "Given Alimta's importance in Lilly's oncology portfolio, how does the company's reliance on patent protection for revenue stability align with the anticipated rapid revenue decline from Alimta following the loss of its patent exclusivity in the U.S. and other key markets?",
      "original_answer": "Lilly highlights Alimta as a key oncology product used in multiple treatment regimens for lung cancer and mesothelioma, underscoring its therapeutic significance. However, the company explicitly states that Alimta has recently lost or will soon lose significant patent protection in the U.S. and other key jurisdictions, which is expected to result in rapid and severe revenue declines due to generic competition. This creates a direct tension with Lilly's broader statement that its revenues, cash flows, and earnings depend heavily on products with intellectual property protection. The loss of exclusivity for Alimta, therefore, not only threatens the product’s contribution to the oncology segment but also directly impacts Lilly’s consolidated financial performance, revealing a critical vulnerability in the company’s revenue model despite its strategic emphasis on patent-dependent innovation.",
      "llm_answer": "Lilly's oncology revenue—particularly from Alimta—has historically depended on patent exclusivity to maintain pricing power, but the loss of U.S. and other key market patents will trigger a sharp revenue drop as generic competition enters. This creates a direct tension between the need for patent protection to stabilize earnings and the inevitable decline once exclusivity ends.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69231,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17551,
        "completion_tokens": 95,
        "total_tokens": 17646
      }
    },
    {
      "question_id": 48,
      "question": "How does Microsoft's ongoing use of The Bank of New York Mellon as trustee across multiple supplemental indentures, including those governing the 4.20% Notes due 2019, reflect a consistent debt issuance strategy and trustee relationship management approach?",
      "original_answer": "Microsoft has maintained a consistent relationship with The Bank of New York Mellon (BNY Mellon) as trustee across multiple debt issuances, as evidenced by the repeated use of BNY Mellon in indentures dating from 2009 through 2016. Specifically, the 4.20% Notes due 2019 are governed under the First Supplemental Indenture dated May 18, 2009, between Microsoft and BNY Mellon. This foundational relationship was extended through subsequent supplemental indentures (e.g., Eighth, Ninth, and Tenth Supplemental Indentures) covering various note issuances, including those in 2013, 2015, and 2016. The consistent use of BNY Mellon as trustee across these different debt instruments and time periods suggests a strategic decision to maintain continuity, trust, and operational efficiency in Microsoft’s debt governance and issuance framework.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon as trustee across multiple supplemental indentures—including those governing the 4.20% Notes due 2019—reflects a deliberate, long-term debt issuance strategy that leverages a single, established trustee relationship to streamline documentation, ensure continuity in trust administration, and reinforce institutional trust in its capital markets execution. This approach underscores a disciplined and repeatable framework for managing its senior unsecured debt obligations, maintaining consistency in trustee governance across decades of bond issuances.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12826,
        "completion_tokens": 152,
        "total_tokens": 12978
      }
    },
    {
      "question_id": 48,
      "question": "Given the non-dilutable 33 1/3% voting power of Class B common stock and its share-for-share conversion right into Class A shares, how does the minimal issuance of Class B stock (only 9.4 million shares outstanding) impact corporate governance dynamics relative to the $82.7 billion in total equity attributed to Class A shareholders?",
      "original_answer": "The corporate governance dynamics are significantly shaped by the dual-class structure. Despite only 9.4 million Class B shares being outstanding, they retain 33 1/3% of the total voting power, which cannot be diluted by additional Class A issuances. Each Class B share has 15 votes, giving this small group disproportionate influence over major corporate decisions. This concentrated voting power contrasts sharply with the equity distribution, where Class A shareholders hold the entirety of the $82.7 billion in reported equity value with no Class B equity contribution. As a result, a small group of Class B shareholders maintains outsized control over governance matters despite representing a negligible portion of the capital structure.",
      "llm_answer": "The minimal issuance of Class B stock—only 9.4 million shares outstanding—means that the 33 ⅓ % voting block held by Class B shares carries a disproportionately large influence relative to the $82.7 billion of equity attributable to Class A shareholders. Because each Class B share is entitled to 15 votes and cannot be diluted by additional issuances, this small group effectively controls a sizable portion of the voting power, giving it outsized governance leverage over the much larger equity base of Class A shareholders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 61017,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15519,
        "completion_tokens": 131,
        "total_tokens": 15650
      }
    },
    {
      "question_id": 48,
      "question": "Given UPS's reliance on net asset value (NAV) to estimate the fair value of its U.S. pension plan investments, how does the subjective nature of NAV estimation specifically impact the reported value of private debt investments, which are not actively traded and have unfunded commitments totaling $3.3 billion?",
      "original_answer": "UPS estimates the fair value of its U.S. pension plan investments, including private debt, using the net asset value (NAV) provided by fund managers, adjusted for activity between reporting periods. This estimation is inherently subjective due to the lack of active trading and reliance on unaudited or delayed audited reports. The private debt investments, valued at $829 million as of December 31, 2023, are subject to this NAV-based valuation methodology. Given that these investments have unfunded commitments totaling $3.3 billion, the subjective adjustments made in estimating NAV could significantly affect both the current valuation and future funding expectations. This raises concerns about the accuracy and reliability of these values, especially since they are not actively traded and are difficult to independently verify.",
      "llm_answer": "The NAV estimation process for illiquid private‑debt holdings introduces significant subjectivity because these investments lack observable market prices and are valued using unobservable inputs (Level 3). Consequently, the reported fair value of the private‑debt portfolio—part of the $3.3 billion of unfunded commitments—can vary materially depending on the assumptions and judgments used to derive the NAV, making the recorded amount an approximation rather than a precise market‑based measurement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74038,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18766,
        "completion_tokens": 125,
        "total_tokens": 18891
      }
    },
    {
      "question_id": 48,
      "question": "How does Abbott Laboratories' treatment of 'awards to non-employee directors' under the 2017 Incentive Stock Program reflect the legacy structure and share reallocation provisions of the earlier 2009 Incentive Stock Program?",
      "original_answer": "Abbott Laboratories includes 'awards to non-employee directors' as one of the benefit types under the 2017 Incentive Stock Program, which is disclosed on page 84. This program allows for the use of both authorized but unissued shares and treasury shares for these awards, with restricted stock specifically sourced from treasury shares. The 2009 Incentive Stock Program, introduced on page 83, originally included the same category of awards and specified that shares not issued due to lapses, expirations, or cancellations could be reallocated for new awards under the 2017 Program. This indicates that the 2017 Program builds upon the structure of the 2009 Program by continuing to include non-employee director awards and by enabling the reuse of unutilized shares, reflecting a strategic continuity in equity compensation design and resource optimization.",
      "llm_answer": "Abbott’s 2017 Incentive Stock Program explicitly states that any shares subject to or reacquired under the legacy 2009 Incentive Stock Program may be reused for new awards under the 2017 Program, preserving the original share pool and reallocation mechanism. This continuity reflects the legacy structure by allowing the 2017 Program to absorb unused shares from the 2009 Program, maintaining the same framework for awarding non-employee directors and other benefits.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "ABT_10k_2024.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75771,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19172,
        "completion_tokens": 116,
        "total_tokens": 19288
      }
    },
    {
      "question_id": 48,
      "question": "How does PayPal's reliance on two third-party custodians for safeguarding over $X billion in customer cryptocurrency assets reconcile with the acknowledged risk of custodial bankruptcy potentially treating those assets as part of the custodian's estate?",
      "original_answer": "PayPal utilizes two third-party custodians to hold customer cryptocurrency assets, which exposes the company to concentration risk if these custodians fail to perform as agreed (page 83). These custodians are responsible for securing crypto assets like Bitcoin and Ethereum, which PayPal holds on behalf of its customers. However, in the event of a custodian’s bankruptcy, there is legal uncertainty about whether those assets would be treated as part of the custodian’s estate, potentially leaving PayPal and its customers with unsecured claims and significant losses (page 20). Despite contractual provisions requiring segregation of customer assets, the lack of legal precedent increases the risk that these assets may not be recoverable in full, which could materially harm PayPal’s financial performance and reputation.",
      "llm_answer": "PayPal acknowledges that its cryptocurrency assets held with third‑party custodians could be treated as part of a custodian’s bankruptcy estate, exposing the company to the risk that a custodian’s insolvency might prevent the return of customer‑held crypto and could make PayPal liable for resulting losses. This risk is highlighted in the “Custodial arrangements … involve unique risks … in the event of a custodian’s bankruptcy” section of the filing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PYPL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "PYPL_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "hop_3_rel": {
          "source_file": "PYPL_10k_2023.pdf",
          "target_page": 20,
          "pages": [
            18,
            19,
            20,
            21,
            22
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 88345,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22327,
        "completion_tokens": 113,
        "total_tokens": 22440
      }
    },
    {
      "question_id": 48,
      "question": "How does PM's 17.3% increase in cigarette shipments in Turkey align with the company's concerns about rising illicit trade, given Turkey's 8.2% total market growth driven by easing pandemic restrictions but partially offset by higher illicit trade prevalence?",
      "original_answer": "PM reported a 17.3% increase in cigarette shipments in Turkey, with its market share rising from 41.3% to 44.8%. This growth occurred despite acknowledging that Turkey's total market expanded by 8.2%, partly due to easing pandemic restrictions and increased in-bound tourism. However, the company also noted that this growth was partially offset by a higher estimated prevalence of illicit trade. This suggests that while PM successfully outperformed the overall market growth, the presence of illicit trade remains a concern that could potentially limit its market share expansion or profitability in the region.",
      "llm_answer": "The 17.3% rise in PMI’s cigarette shipments to Turkey aligns with the country’s 8.2% total market growth—driven by eased pandemic restrictions—but this positive volume gain is being eroded by a notable increase in illicit trade, which the company notes is “partly offset” by higher illicit prevalence and therefore threatens the sustainability of that growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 40,
          "pages": [
            38,
            39,
            40,
            41,
            42
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 56,
          "pages": [
            54,
            55,
            56,
            57,
            58
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70690,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17916,
        "completion_tokens": 89,
        "total_tokens": 18006
      }
    },
    {
      "question_id": 49,
      "question": "How does the $35 million in appeal bonds posted by PM USA relate to its unconditional guarantee of Altria's $1.0 billion in senior notes issued in November 2023, particularly in terms of financial exposure and collateralization requirements?",
      "original_answer": "The $35 million in appeal bonds posted by PM USA on page 92 represents security provided to obtain stays of adverse litigation judgments pending appeal. These bonds are collateralized with restricted cash and appear on the consolidated balance sheet as assets. On page 74, PM USA is described as a guarantor of Altria's outstanding debt securities, including the $1.0 billion in senior notes issued in November 2023. The guarantee is unconditional and requires PM USA to ensure payment of Altria's obligations, regardless of the validity or enforceability of the underlying debt agreements. Both the appeal bonds and the debt guarantees expose PM USA to significant financial obligations, with the appeal bonds already collateralized and the debt guarantees potentially triggering similar collateral requirements in the event of default or financial stress.",
      "llm_answer": "The $35 million of appeal bonds posted by PM USA serves as collateral that secures its unconditional guarantee of Altria’s $1 billion senior notes issued in November 2023; the guarantee makes PM USA primarily liable for the full payment of those notes, and the posted bonds satisfy any collateralization or bonding requirements that could otherwise expose PM USA to additional financial risk if the notes were called or defaulted.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 92,
          "pages": [
            90,
            91,
            92,
            93,
            94
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84033,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21250,
        "completion_tokens": 107,
        "total_tokens": 21358
      }
    },
    {
      "question_id": 49,
      "question": "How does ConocoPhillips' 30% stake in Qatargas Operating Company Limited, which produced 13 MBD of crude oil in 2021, align with their total reported crude oil production of 8 MBD for the same year, and what does this imply about the company's upstream production structure?",
      "original_answer": "ConocoPhillips' total crude oil production of 8 MBD in 2021 includes its share from the QG3 project operated by Qatargas Operating Company Limited, in which COP holds a 30% stake. The QG3 project alone contributed 13 MBD of crude oil production, indicating that COP's net share of this production is proportionally less (30% of 13 MBD ≈ 3.9 MBD), and this stake-based contribution is incorporated into the broader crude oil production figure of 8 MBD. This suggests that COP's upstream production is composed of multiple assets, with the QG3 project being a significant but partial contributor. The remaining crude oil production must come from other projects where COP has a larger or full ownership stake, highlighting a diversified upstream portfolio.",
      "llm_answer": "ConocoPhillips' 30% stake in Qatargas Operating Company Limited contributed 13 MBD of crude oil production in 2021, but this is not reflected in the company's consolidated crude‑oil figure of 8 MBD because that number represents only ConocoPhillips' share of its own operated production (e.g., Norway, Alaska, Lower 48, Canada, etc.). The 13 MBD from Qatargas is counted within the broader “Consolidated Operations” totals that include equity‑method investments and other joint‑venture output, meaning the reported 8 MBD reflects only the company's direct, operated barrels. Consequently, the disparity highlights that ConocoPhillips' upstream structure relies heavily on equity‑joint‑venture arrangements—particularly in the Middle East and North Africa—where a substantial portion of its effective crude‑oil supply comes from non‑consolidated partners rather than from barrels it fully consolidates on its own financial statements. This creates a production profile in which a meaningful share of total output is derived from investments such as Qatargas, while the consolidated production numbers capture only the barrels it operates directly.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 51787,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13192,
        "completion_tokens": 286,
        "total_tokens": 13478
      }
    },
    {
      "question_id": 49,
      "question": "How does Microsoft's ongoing relationship with BNY Mellon as trustee for multiple note issuances, including the 5.20% Notes due 2039, reflect its broader capital structure management strategy across different debt instruments?",
      "original_answer": "Microsoft has consistently engaged BNY Mellon as trustee across multiple debt issuances, including the 5.20% Notes due 2039, as evidenced by the repeated appearance of BNY Mellon in various supplemental indentures dating back to 2009. This long-standing relationship, documented in filings related to notes with maturities ranging from 2018 to 2056, indicates a deliberate and consistent approach to debt governance. The inclusion of the 5.20% Notes due 2039 within this framework highlights Microsoft's use of long-dated instruments to support long-term capital commitments. The repeated use of the same base indenture and trustee across different interest rate environments and maturity profiles suggests a centralized, standardized approach to managing corporate debt obligations.",
      "llm_answer": "Microsoft's long‑standing relationship with BNY Mellon as trustee—evident in multiple supplemental indentures for its senior notes, including the 5.20% Notes due 2039—underscores a disciplined, centralized approach to managing its capital structure across a wide range of debt instruments. By consistently using BNY Mellon (and, more recently, Computershare) as trustee for each tranche of unsecured debt, Microsoft ensures uniform governance, streamlined administration, and reliable oversight of its diverse borrowing profile.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12818,
        "completion_tokens": 132,
        "total_tokens": 12950
      }
    },
    {
      "question_id": 49,
      "question": "How does AT&T's continued depreciation of wireless tower assets combined with its future minimum payments to Crown Castle reflect on the company's long-term financial strategy for its tower infrastructure?",
      "original_answer": "AT&T's decision to continue depreciating the wireless tower assets ($725 million at the end of 2021) despite the 2013 transaction with Crown Castle indicates that it did not achieve sale-leaseback accounting treatment, meaning the towers remain on AT&T's balance sheet as Property, Plant and Equipment. This contrasts with the sublease arrangement where AT&T is contractually obligated to make significant future minimum payments—$258 million in 2022 alone, rising to $280 million in 2026, and totaling $707 million thereafter. These payments represent a long-term financial commitment to Crown Castle for continued access to the towers. The combination of ongoing depreciation and escalating sublease payments suggests that AT&T retains both the asset liability and recurring cost structure of tower infrastructure, rather than fully monetizing or divesting its tower assets. This reflects a strategy of maintaining control over critical network infrastructure while outsourcing operational management, balancing capital efficiency with long-term operational flexibility.",
      "llm_answer": "AT&T's continued depreciation of wireless tower assets alongside its future minimum payments to Crown Castle—totaling $258 in 2022, $264 in 2023, $269 in 2024, $274 in 2025, $280 in 2026, and $707 thereafter—reflects a long-term strategy of retaining ownership of tower infrastructure while monetizing it through long-term lease and financing arrangements. This approach allows AT&T to maintain depreciation expense on its balance sheet while securing stable, predictable payments for tower operations, ensuring continued control over its network assets without the immediate capital outlay required for full ownership.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_2_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "T_10k_2022.pdf",
          "target_page": 133,
          "pages": [
            131,
            132,
            133,
            134,
            135
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66030,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16733,
        "completion_tokens": 154,
        "total_tokens": 16887
      }
    },
    {
      "question_id": 49,
      "question": "How does Duke Energy's accounting treatment of unrealized losses on AFS debt investments held in the Investment Trusts compare with the realized gains and losses disclosed for AFS debt investments across Duke Energy Florida and Indiana?",
      "original_answer": "Duke Energy applies different accounting treatments for AFS debt investments depending on their structure and ownership. For AFS debt investments held in the Investment Trusts (managed externally), the company immediately recognizes all unrealized losses in earnings due to lack of control over investment decisions, as noted on page 184. However, for AFS debt investments held by Duke Energy Florida and Indiana, the company disclosed that realized gains and losses during 2023 were immaterial (page 187). This highlights a contrast in how unrealized losses are treated based on management control, versus the actual realized outcomes which are reported as immaterial in practice.",
      "llm_answer": "Duke Energy records unrealized losses on AFS debt investments held in the Investment Trusts as regulatory liabilities, recognizing them immediately and deferring the amounts to regulatory accounts. In contrast, realized gains and losses on AFS debt investments reported for Duke Energy Florida and Indiana are immaterial and not separately disclosed.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 186,
          "pages": [
            184,
            185,
            186,
            187,
            188
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 187,
          "pages": [
            185,
            186,
            187,
            188,
            189
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 106088,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26758,
        "completion_tokens": 87,
        "total_tokens": 26845
      }
    },
    {
      "question_id": 50,
      "question": "How should we interpret MET's $92.5 billion mortgage loan portfolio in light of the $1.1 billion unrealized losses in their pass-through mortgage-backed securities, given the direct link between mortgage loans and the performance of these securities?",
      "original_answer": "MET reports its mortgage loans at a carrying value of $92.5 billion on page 320, indicating a significant exposure to direct mortgage assets. These mortgage loans serve as the underlying collateral for pass-through mortgage-backed securities, as explained on page 97, where cash flows from homeowners are passed through intermediaries to investors. On page 98, MET discloses $12.4 billion in estimated fair value for pass-through mortgage-backed securities, which carry $1.1 billion in unrealized losses. The presence of these losses suggests that the performance of the underlying mortgage loans—many of which are likely included in MET's $92.5 billion portfolio—has deteriorated, impacting the fair value of the associated securities. This dynamic highlights a direct financial risk: as the originator and holder of the loans and the issuer of the securities, MET is exposed both to credit losses on the loans themselves and to valuation declines in the structured products backed by those loans.",
      "llm_answer": "MET's $92.5 billion mortgage loan portfolio is the underlying collateral for its pass‑through mortgage‑backed securities (RMBS).  The $1.1 billion unrealized loss reported on those RMBS (e.g., $2.382 bn net unrealized loss on the $29.1 bn RMBS portfolio in 2023) reflects the market‑value impact of credit and interest‑rate movements on the loans that back those securities.  In other words, the size of the loan portfolio drives both the income and the risk profile of the RMBS, so the unrealized loss on the securities is directly tied to the performance and valuation of the underlying mortgage loans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 320,
          "pages": [
            318,
            319,
            320,
            321,
            322
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78763,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19933,
        "completion_tokens": 151,
        "total_tokens": 20084
      }
    },
    {
      "question_id": 50,
      "question": "How does the non-dilutable voting power of Class B common stock, which represents 33 1/3% of combined voting power and is beneficially owned entirely by Brian L. Roberts, influence the governance dynamics of CMCSA in light of the dividend increase approved by the Board of Directors for Class A common stock in January 2022?",
      "original_answer": "The governance dynamics of CMCSA are significantly influenced by the non-dilutable 33 1/3% voting power held by Class B common stock, which is entirely owned by Brian L. Roberts. This structure gives Roberts outsized influence over key corporate decisions, including mergers, asset sales, and amendments to the company’s charter, even if such decisions are approved by the Board or other shareholders. In January 2022, the Board approved an 8% increase in the dividend for Class A common stock, which is held by public investors and carries only 66 2/3% of the combined voting power. While Class A shareholders benefit from dividend increases, they hold less voting control, creating a governance imbalance where Roberts can effectively block or approve major decisions regardless of broader shareholder sentiment. This dynamic suggests that while dividend policy may reflect Board alignment with Class A shareholders, strategic and structural decisions remain heavily influenced by Roberts’ control through Class B shares.",
      "llm_answer": "The non‑dilutable 33 ⅓ % voting interest held by Class B shares—entirely owned by Brian L. Roberts—gives him decisive control over key corporate actions (e.g., mergers, charter amendments, issuances that could dilute his stake). This concentrated voting power lets him effectively steer governance decisions despite the dividend increase approved for Class A shares in January 2022, ensuring that his influence remains intact even as the company raises payouts to other shareholders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2022.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 51074,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13025,
        "completion_tokens": 120,
        "total_tokens": 13146
      }
    },
    {
      "question_id": 50,
      "question": "How does Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026, intersect with the legal risks from patent infringement claims against Comirnaty in both the U.S. and Europe, particularly given the revenue significance of Comirnaty in key international markets?",
      "original_answer": "Pfizer's reliance on BioNTech for Comirnaty supply agreements, including the amended EU contract through 2026, creates a critical dependency on a jointly developed product that is now facing multiple patent infringement lawsuits in both the U.S. and Europe. This legal exposure—such as the April 2024 U.S. lawsuit by GSK Group over five patents (later amended to include three more) and the January 2025 European suit by Promosome in France, Germany, and Sweden—poses a material risk to Comirnaty's continued revenue generation. Given that Comirnaty has contributed significantly to Pfizer’s international revenue (with China representing 4% of total revenues in 2024 and the EU historically being a major market), any disruption from litigation could impact both delivery commitments under the EU agreement and profitability in key developed markets.",
      "llm_answer": "Pfizer’s Comirnaty supply relies on a 2020‑2026 agreement with BioNTech that guarantees multi‑year deliveries to EU and other markets, making the vaccine a key revenue driver in those regions. At the same time, Comirnaty is embroiled in patent‑infringement lawsuits in both the United States and Europe—most notably challenges by Moderna, Arbutus, GSK and various generic firms—so any adverse ruling could jeopardize the vaccine’s market exclusivity and thus the very revenue stream that the EU contract is designed to protect.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_2_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "hop_3_rel": {
          "source_file": "PFE_10k_2024.pdf",
          "target_page": 101,
          "pages": [
            99,
            100,
            101,
            102,
            103
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 129611,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 32661,
        "completion_tokens": 131,
        "total_tokens": 32793
      }
    },
    {
      "question_id": 50,
      "question": "How does Schwab's compliance with net capital requirements for TD Ameritrade constrain its ability to allocate capital toward technology infrastructure investments associated with the integration of TD Ameritrade?",
      "original_answer": "Schwab's broker-dealer subsidiary, TD Ameritrade, is subject to the SEC's Uniform Net Capital Rule, which restricts payments such as dividends, unsecured loans, or repayment of subordinated borrowings if net capital falls below prescribed thresholds (page 123). At the same time, Schwab has been actively investing in technology infrastructure to support the integration of TD Ameritrade, including capital expenditures in 2022 and 2023 for software development and hardware enhancements (page 47). Because TD Ameritrade must remain in compliance with its net capital requirements, Schwab cannot freely divert capital from this entity to fund integration initiatives, creating a tension between regulatory liquidity constraints and strategic investment needs.",
      "llm_answer": "Schwab’s ability to fund technology‑infrastructure investments tied to the TD Ameritrade integration is constrained by the need to maintain regulatory capital ratios above the minimum thresholds required by its banking regulators, especially the Federal Reserve’s leverage and Tier 1 capital requirements. Because the company must keep its Common Equity Tier 1 and leverage ratios comfortably above the mandated minimums (including buffers), it cannot allocate excess capital that would otherwise be used for such investments without risking a breach of those capital rules. Consequently, capital that could otherwise be directed toward integration‑related technology spending is retained to preserve compliance with net‑capital and leverage standards.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 123,
          "pages": [
            121,
            122,
            123,
            124,
            125
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 47,
          "pages": [
            45,
            46,
            47,
            48,
            49
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84738,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21421,
        "completion_tokens": 188,
        "total_tokens": 21609
      }
    },
    {
      "question_id": 50,
      "question": "How does Chevron's 2023 reserve revision decrease of 107 million BOE at TCO in Kazakhstan reconcile with the significant capital expenditures of $2.5 billion in Asia, primarily for TCO's development projects?",
      "original_answer": "Chevron reported a reserve revision decrease of 107 million BOE at TCO in Kazakhstan due to performance-driven reservoir model changes (page 108). Despite this reduction, the company invested approximately $2.5 billion in Asia, primarily for TCO's development projects (page 109). This apparent contradiction is explained by TCO's ongoing major development initiatives, such as the Future Growth Project (FGP) and Wellhead Pressure Management Project (WPMP), which are expected to ramp up production starting in 2025 (page 16). These projects have already led to the recognition of proved reserves, suggesting that Chevron's continued investment is aimed at future reserve growth and production capacity, even in the face of short-term reserve revisions.",
      "llm_answer": "Chevron’s 2023 reserve revision of a 107 million‑BOE decrease at the TCO affiliate in Kazakhstan is consistent with the $2.5 billion of capital spending it allocated to Asia that year, which was “primarily related to development projects for TCO in Kazakhstan.” The company’s own disclosures show that the bulk of the $2.5 billion Asia investment was directed toward advancing TCO’s development plans—including the Future Growth Project and associated reservoir‑model changes—activities that directly contributed to the reduction in proved undeveloped reserves at TCO. Thus, the reserve revision reflects the impact of those targeted development expenditures rather than a contradiction.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 108,
          "pages": [
            106,
            107,
            108,
            109,
            110
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 104631,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26389,
        "completion_tokens": 171,
        "total_tokens": 26561
      }
    },
    {
      "question_id": 51,
      "question": "How does the change in fair value of the contingent consideration for Clif Bar from the acquisition date estimate of $440 million to $548 million as of December 31, 2023, reflect the reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting?",
      "original_answer": "The fair value of the contingent consideration for Clif Bar increased from $440 million at the acquisition date to $548 million as of December 31, 2023. This change reflects the ongoing reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting, as the liability is entirely categorized under Level 3 of the fair value hierarchy. The valuation methodology, which includes financial projections for net revenue, gross profit, and EBITDA, along with discount and volatility rates, indicates that the updated estimate is based on internal assumptions rather than observable market data. This highlights the inherent uncertainty in forecasting future performance metrics for Clif Bar and the sensitivity of the contingent consideration to these assumptions.",
      "llm_answer": "The contingent consideration liability for Clif Bar increased from $452 million at December 31 2022 to $548 million at December 31 2023, reflecting a $128 million fair‑value adjustment that was recorded in selling, general and administrative expenses. This adjustment stems from the use of significant unobservable inputs—such as management’s forecasts of future revenue, gross profit, EBITDA, discount rates, and volatility—required in the Monte Carlo simulation to estimate the liability’s fair value, thereby classifying it as a Level 3 measurement in MDLZ’s financial reporting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 80,
          "pages": [
            78,
            79,
            80,
            81,
            82
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69733,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17678,
        "completion_tokens": 145,
        "total_tokens": 17823
      }
    },
    {
      "question_id": 51,
      "question": "What does Merck's different branding and regulatory focus of its pneumococcal vaccine as Vaxneuvance in the U.S. and EU, versus V114 in Japan, reveal about its geographic strategy in adult pneumococcal vaccine markets?",
      "original_answer": "Merck's decision to brand its pneumococcal vaccine as Vaxneuvance in the U.S. and EU, where it received approvals in July 2021 and December 2021 respectively, and as V114 in Japan, where it is still under regulatory review, indicates a strategy of prioritizing established, high-volume markets first. The U.S. and EU approvals are significant given their size and regulatory influence, while Japan represents a later-stage opportunity. This phased approach suggests Merck is leveraging the vaccine's advanced development status and initial commercial success in major markets before expanding into other regions like Japan, which often requires additional localized data and regulatory processes.",
      "llm_answer": "Merck's decision to market its 15‑valent pneumococcal conjugate vaccine as Vaxneuvance in the United States and European Union but as V114 in Japan reflects a geographic branding and regulatory strategy that tailors the product name and positioning to each market’s expectations and approval pathways.  By using a distinct brand name in the U.S./EU, Merck can leverage the established Vaxneuvance identity and priority‑review status to accelerate uptake, while the V114 designation in Japan aligns with local regulatory processes and may simplify the approval and launch strategy in that market.  This approach underscores a market‑specific rollout that balances brand equity, regulatory timing, and regional competitive dynamics in the adult pneumococcal vaccine space.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 21,
          "pages": [
            19,
            20,
            21,
            22,
            23
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76781,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19430,
        "completion_tokens": 192,
        "total_tokens": 19622
      }
    },
    {
      "question_id": 51,
      "question": "How does the change in fair value of the contingent consideration for Clif Bar from the acquisition date estimate of $440 million to $548 million as of December 31, 2023, reflect the reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting?",
      "original_answer": "The fair value of the contingent consideration for Clif Bar increased from $440 million at the acquisition date to $548 million as of December 31, 2023. This change reflects the ongoing reliance on significant unobservable inputs (Level 3) in MDLZ's financial reporting, as the liability is entirely categorized under Level 3 of the fair value hierarchy. The increase suggests that the financial projections for net revenue, gross profit, and EBITDA, which are key assumptions in the valuation model, have evolved over time, likely due to updated expectations about Clif Bar's performance relative to the revenue and earnings targets set in the contingent payment agreement.",
      "llm_answer": "The contingent consideration liability for Clif Bar increased from $440 million at acquisition to $548 million as of December 31, 2023, reflecting a $108 million fair‑value uplift driven by higher projected revenue, profit and EBITDA targets and updated assumptions (including discount and volatility rates) used in the Monte Carlo simulation. Because these inputs—especially the forward financial forecasts—are unobservable and involve significant management judgment, the liability is classified as Level 3 in the fair‑value hierarchy, illustrating MDLZ’s reliance on Level 3 measurements for this contingent consideration.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 80,
          "pages": [
            78,
            79,
            80,
            81,
            82
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69733,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17678,
        "completion_tokens": 156,
        "total_tokens": 17834
      }
    },
    {
      "question_id": 52,
      "question": "How does ConocoPhillips' long-term contractual commitment to LNG exports through APLNG reconcile with the financial revaluation of their investment, and what does this indicate about their strategic confidence in CBM production scalability in Queensland?",
      "original_answer": "ConocoPhillips has a long-term strategic commitment to the APLNG joint venture, which is focused on producing coalbed methane (CBM) from the Bowen and Surat basins in Queensland, Australia. This CBM is converted into LNG and sold under 20-year agreements with Sinopec (7.6 MTPA) and Kansai Electric Power Co., Inc. (1 MTPA), indicating a strong forward-looking strategy tied to the scalability of CBM production, with approximately 3,500 net wells expected to supply both LNG contracts and the domestic gas market. However, in 2021, ConocoPhillips recorded a before-tax charge of $688 million to write down its investment in APLNG to fair value after Origin Energy’s sale of a 10% interest revealed a market valuation lower than the carrying value. This revaluation suggests that market participants viewed APLNG’s fair value as below the company’s internal assessment. Despite this financial revaluation, ConocoPhillips exercised its preemption right to acquire an additional 10% stake, signaling continued strategic confidence in the long-term value of CBM production and the LNG export infrastructure. This indicates that the company prioritizes operational scale and long-term contractual revenue visibility over short-term market valuations.",
      "llm_answer": "ConocoPhillips' long‑term LNG export contracts through APLNG (20‑year agreements with Sinopec for 7.6 MTPA and with Kansai Electric for ~1 MTPA) are recorded at fair value on the balance sheet, and the contingent consideration tied to those contracts is measured using a discounted‑cash‑flow model with an unobservable commodity‑price outlook ($45‑$63 / BOE). This valuation approach, which relies on internal price outlooks and market participant inputs, reflects a non‑recurring fair‑value measurement that is sensitive to commodity price assumptions. The fact that the company continues to invest in expanding CBM wells and securing additional LNG capacity—backed by long‑term sales agreements—signals strong strategic confidence in the scalability of Queensland’s coal‑bed methane production to meet its export commitments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 3,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 109,
          "pages": [
            107,
            108,
            109,
            110,
            111
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63552,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16133,
        "completion_tokens": 206,
        "total_tokens": 16340
      }
    },
    {
      "question_id": 52,
      "question": "How does MetLife's positioning of Accident & Health Insurance as a core product offering align with the relatively low adjusted earnings contribution from the EMEA segment in 2023, despite both being emphasized in different sections of the 10-K?",
      "original_answer": "MetLife highlights Accident & Health Insurance as a core product offering in its major products table, indicating its strategic importance across global markets. This product line is explicitly stated to be offered in the EMEA region, suggesting that EMEA should be a key contributor to its performance in that geography. However, the EMEA segment reported only $265 million in adjusted earnings for 2023, significantly lower than other geographic segments like Group Benefits ($1,655 million) and Asia ($1,282 million). This discrepancy raises questions about whether the Accident & Health Insurance line, while globally positioned, may be underperforming in the EMEA region due to market-specific challenges such as regulatory constraints, competitive pressures, or lower penetration, which are not explicitly detailed but implied through the earnings gap.",
      "llm_answer": "The 10‑K positions Accident & Health Insurance as part of the Group Benefits, Asia, Latin America and EMEA segments, emphasizing it as a core offering across those geographies. However, the adjusted‑earnings tables show that the EMEA segment contributed only a modest $18 million (or 3 % of total adjusted earnings) in 2023, while the overall segment’s profitability is driven primarily by Group Benefits and RIS. Thus, although Accident & Health is highlighted as a core product in the segment descriptions, its earnings impact in EMEA is relatively small compared with the broader emphasis placed on the segment elsewhere in the filing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 169,
          "pages": [
            167,
            168,
            169,
            170,
            171
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 86019,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21749,
        "completion_tokens": 159,
        "total_tokens": 21908
      }
    },
    {
      "question_id": 52,
      "question": "How does FedEx's exposure to potential reductions in USPS service commitments, which are tied to air network reliance, affect its long-lived asset strategy for aircraft depreciation and fleet flexibility as disclosed in the financial statements?",
      "original_answer": "FedEx's exposure to reductions in USPS service commitments—specifically the strategic shift by USPS to reduce reliance on FedEx Express's air network—poses a risk to FedEx's revenue and profitability as noted in the risk factors. This risk is directly tied to FedEx's asset strategy, where 55% of owned assets are invested in transportation infrastructure, including a global air fleet of 696 aircraft. FedEx's depreciation policy for aircraft, which assumes little to no salvage value due to cargo configuration wear, is sensitive to changes in business levels and utilization. Given that FedEx operates an integrated global network where aircraft are interchangeable to maintain service commitments, a reduction in USPS volume could force underutilization of aircraft, accelerating depreciation or impairments, and impacting the company's ability to align fleet size with demand while maintaining flexibility across geographies.",
      "llm_answer": "FedEx’s long‑lived‑asset strategy for aircraft depreciation and fleet flexibility is shaped by its reliance on the USPS air network. Because the USPS is a major customer that is actively reducing its dependence on FedEx Express’s air services, any further cuts to those service commitments could lower the volume of air‑freight shipments. This would force FedEx to adjust aircraft utilization, potentially shorten the useful lives of its cargo aircraft or require earlier retirements, and could lead to under‑utilized capacity, excess inventory of owned aircraft, or the need for accelerated fleet modernization to maintain service levels. Consequently, FedEx must continuously reassess aircraft depreciation schedules and fleet planning to avoid overcapacity or write‑downs while preserving the flexibility to adapt to shifting USPS demand.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84886,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21460,
        "completion_tokens": 210,
        "total_tokens": 21670
      }
    },
    {
      "question_id": 52,
      "question": "How does ConocoPhillips' reliance on DeGolyer and MacNaughton to review over 85% of its proved reserves estimation processes align with the inclusion of D&M's report as Exhibit 99, and what does this imply about the company's approach to external validation of its reserves estimates?",
      "original_answer": "ConocoPhillips utilizes DeGolyer and MacNaughton (D&M), a third-party petroleum engineering consulting firm, as part of its internal control process to validate the adequacy and effectiveness of its reserves estimation processes. During 2024, D&M reviewed over 85% of the company's proved reserves, assessing whether these processes align with SEC regulations. The company presented detailed technical and economic data to D&M, including seismic information, reservoir simulation models, and production tests, to support its reserves estimation methods. D&M concluded that the processes used by ConocoPhillips were in accordance with SEC reserves definitions. This external validation is further substantiated by the inclusion of D&M's report as Exhibit 99 in the 10-K filing, indicating the company's commitment to transparency and external verification of its reserves reporting. This dual approach—leveraging D&M as part of internal controls and publicly disclosing their findings—demonstrates a robust framework for ensuring the reliability and regulatory compliance of reserves estimates.",
      "llm_answer": "ConocoPhillips’ reliance on DeGolyer and MacNaughton to review the processes and controls used for estimating more than 85 % of its proved reserves underscores a formalized external validation step. The D&M review, which is documented as Exhibit 99, provides an independent, third‑party assessment confirming that ConocoPhillips’ internal reserves estimation methodology complies with SEC regulations, reinforcing the credibility of its reported reserves. This approach reflects a proactive strategy to obtain objective verification of its reserves estimates, thereby enhancing stakeholder confidence in the accuracy and reliability of its reserve disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 140,
          "pages": [
            138,
            139,
            140,
            141,
            142
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2024.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78046,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19762,
        "completion_tokens": 165,
        "total_tokens": 19927
      }
    },
    {
      "question_id": 53,
      "question": "How does AIG's exposure to non-agency RMBS with gross unrealized losses compare to the NAIC Designation methodology's impact on statutory reporting for these securities?",
      "original_answer": "AIG reports $148 million in gross unrealized losses on RMBS as of December 31, 2022, indicating a significant exposure to this asset class. The NAIC Designation methodology, which AIG subsidiaries are subject to, assigns RMBS and CMBS improved designations compared to traditional ratings from major agencies. This results in a more favorable statutory reporting treatment than what might be reflected in GAAP-based disclosures like the unrealized loss figures. The NAIC's approach using third-party modeling for RMBS designations contrasts with the market-value-based unrealized loss reporting, suggesting a potential divergence between regulatory capital treatment and financial statement presentation for these securities.",
      "llm_answer": "AIG's exposure to non‑agency RMBS with gross unrealized losses is reflected in the NAIC Designations table, where such securities are classified under NAIC categories 3‑6 (below‑investment‑grade) and represent a portion of the “Total Below Investment Grade” amount ($19,357 million) within the mortgage‑backed, asset‑backed and collateralized segment. The NAIC methodology assigns higher (more favorable) designations to non‑agency RMBS and CMBS than the ratings from external agencies, meaning that even securities with gross unrealized losses may still be placed in a lower‑grade NAIC bucket, affecting their statutory reporting but not necessarily indicating a credit‑loss‑driven impairment for statutory purposes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2022.pdf",
          "target_page": 220,
          "pages": [
            218,
            219,
            220,
            221,
            222
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80464,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20338,
        "completion_tokens": 179,
        "total_tokens": 20517
      }
    },
    {
      "question_id": 53,
      "question": "How does COP's reliance on crude oil align with its 30% financial stake in QatarEnergy LNG, which produces 13 million barrels of crude oil per day?",
      "original_answer": "COP identifies crude oil as a critical raw material that it depends on for its upstream operations. This dependence is further reinforced by COP’s 30% ownership stake in QatarEnergy LNG, a joint venture that contributes significantly to the company’s upstream portfolio with an average daily net production of 13 million barrels of crude oil per day. By holding this stake, COP strategically aligns its crude oil supply chain with a high-volume production source, integrating supply assurance into its broader production strategy. This alignment allows COP to manage upstream exposure while leveraging a key asset that directly supports its crude oil-dependent operations.",
      "llm_answer": "ConocoPhillips holds a 30% equity stake in QatarEnergy LNG (N3), which produces approximately 13 million barrels of crude oil per day, and this crude oil reliance aligns with its 30% financial interest in the venture, as reflected in the QatarEnergy LNG N(3) production data showing 13 MBD crude oil and 8 MBD NGLs from its share of the project.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 145,
          "pages": [
            143,
            144,
            145,
            146,
            147
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2023.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 85846,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21676,
        "completion_tokens": 86,
        "total_tokens": 21763
      }
    },
    {
      "question_id": 53,
      "question": "How does Qualcomm's emphasis on its patent portfolio in Taiwan reconcile with its explicit risk disclosure about potential supply chain disruptions from foundry partners in the same region due to geopolitical tensions?",
      "original_answer": "Qualcomm highlights its extensive patent portfolio in Taiwan as part of its global intellectual property strategy, noting that a substantial portion of its patents and applications relate to foundational wireless technologies, including 5G, and that its patents have broad coverage in many countries, including Taiwan. However, the company also explicitly discloses that its business depends on receiving consistent and reliable chipset supply from foundry partners, particularly in Taiwan, and that a significant or prolonged military or geopolitical conflict involving China and Taiwan could severely limit or prevent it from receiving chipset supply, which would have a material adverse impact on its business. This juxtaposition reveals a strategic vulnerability: while Taiwan is critical to Qualcomm’s global IP footprint, its manufacturing reliance on the region exposes it to significant operational risk, particularly given the geopolitical instability involving China and Taiwan.",
      "llm_answer": "Qualcomm simultaneously emphasizes its extensive patent portfolio in Taiwan—highlighting its leadership in 3G/4G/5G standard‑essential patents and ongoing licensing of those patents to a broad range of manufacturers—as a core strategic asset, while also explicitly warning that geopolitical tensions could disrupt its supply chain from foundry partners located in Taiwan, potentially limiting the chips it receives and thereby harming its business. This juxtaposition reflects the company’s recognition that its patent licensing success depends on a stable manufacturing base in the same region that faces potential supply‑chain interruptions due to those very geopolitical conflicts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2023.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2023.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2023.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 100975,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25475,
        "completion_tokens": 171,
        "total_tokens": 25646
      }
    },
    {
      "question_id": 53,
      "question": "How does Gilead's pursuit of Breakthrough Therapy Designation for Bulevirtide align with the product's commercialization timeline and the unresolved manufacturing concerns raised by the FDA?",
      "original_answer": "Gilead's Bulevirtide received Breakthrough Therapy Designation from the FDA due to its potential to treat chronic hepatitis delta virus, a serious unmet medical need. However, despite this expedited pathway, the FDA issued a complete response letter in October 2022 citing unresolved manufacturing and delivery concerns. This has delayed the product's approval and, consequently, its commercialization timeline, which is listed as 2030 in the U.S. and 2029 in the EU. The Breakthrough Therapy status was intended to accelerate development and review, yet the product remains in regulatory limbo, highlighting the critical impact of manufacturing compliance on both regulatory outcomes and commercial planning.",
      "llm_answer": "Gilead’s pursuit of Breakthrough Therapy Designation for bulevirtide is directly tied to its commercialization timeline, as the designation is sought to accelerate approval of the drug for chronic hepatitis delta virus (HDV) treatment. However, this effort is complicated by unresolved manufacturing concerns highlighted in an FDA complete response letter from October 2022, which cited specific production and delivery issues that must be addressed before the drug can reach the market. These manufacturing challenges represent a critical bottleneck that could delay or derail the drug’s path to commercialization despite the regulatory incentives offered by the Breakthrough Therapy designation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84315,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21304,
        "completion_tokens": 174,
        "total_tokens": 21478
      }
    },
    {
      "question_id": 53,
      "question": "How does the introduction of the Expanded Risk-Based Approach in the Basel III Finalization Proposal impact Capital One's regulatory capital treatment for Category III institutions, particularly regarding the recognition of AOCI in CET1 capital?",
      "original_answer": "The Basel III Finalization Proposal introduces the Expanded Risk-Based Approach, which requires institutions like Capital One to calculate risk-weighted assets using a more comprehensive framework. This new approach mandates that Category III institutions, such as Capital One, begin recognizing certain elements of Accumulated Other Comprehensive Income (AOCI), including unrealized gains and losses on available-for-sale securities, in Common Equity Tier 1 (CET1) capital. This marks a shift from prior treatment where such AOCI elements were not included in CET1, thereby increasing the volatility of regulatory capital. The proposal includes a phased implementation starting July 1, 2025, with full compliance by 2028, and the impact on Capital One's capital ratios remains uncertain depending on the final rule’s adoption and market conditions.",
      "llm_answer": "The Basel III Finalization Proposal would require Category III firms like Capital One to calculate risk‑weighted assets under an “Expanded Risk‑Based Approach” and to recognize certain elements of accumulated other comprehensive income (AOCI) in CET1 capital. Under the proposal, unrealized gains and losses on available‑for‑sale securities would be included in CET1, and the deduction thresholds for assets such as deferred tax assets and mortgage‑servicing assets would be reduced. Consequently, Capital One’s regulatory capital treatment for its Category III institutions would be affected by the need to incorporate AOCI into CET1, altering the composition and amount of capital that can be used to satisfy the CET1 ratio requirement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63829,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16198,
        "completion_tokens": 184,
        "total_tokens": 16382
      }
    },
    {
      "question_id": 53,
      "question": "How does Southern Company's consolidated financial reporting treatment of Southern Linc align with the dual role of Southern Linc in providing both internal digital wireless communications and external fiber optics services, particularly in light of affiliate transaction accounting policies?",
      "original_answer": "Southern Company accounts for Southern Linc under consolidated reporting, as stated on page 164, where it is listed as one of the direct and indirect subsidiaries whose financials are consolidated. Southern Linc is described as providing digital wireless communications for internal use by the Southern Company system and also marketing these services to the public, including fiber optics services within the Southeast. According to affiliate transaction policies outlined on page 164, services provided by Southern Linc to other subsidiaries are rendered at direct or allocated cost. This cost-based pricing reflects how Southern Linc serves both internal and external markets, with its internal role governed by formal accounting policies that ensure transactions are conducted at cost. This dual role suggests that while Southern Linc generates revenue from external customers through fiber optics services (as noted on page 64), its internal operations are tightly integrated into the broader Southern Company financial framework, with transactions governed by cost-based allocations rather than market pricing. This alignment ensures consistency in consolidated financial reporting while allowing Southern Linc to maintain a commercial presence in the fiber optics market.",
      "llm_answer": "Southern Company consolidates Southern Linc’s results and eliminates all intercompany transactions, so the fiber‑optic services it provides to external customers are recorded as external revenue while the digital wireless services it supplies to other Southern affiliates are treated as internal cost allocations; consequently, the dual role of Southern Linc is accounted for under the same affiliate‑transaction rules that require cost‑recovery for regulated services and eliminate any intra‑group profit, ensuring that the fiber‑optic revenue is recognized separately from the internal wireless cost allocations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 164,
          "pages": [
            162,
            163,
            164,
            165,
            166
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64721,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16431,
        "completion_tokens": 153,
        "total_tokens": 16585
      }
    },
    {
      "question_id": 54,
      "question": "How does the contingent consideration liability for Clif Bar, measured using significant unobservable inputs (Level 3), relate to the impact of the acquisition on MDLZ's 2023 operating income and expense trends?",
      "original_answer": "MDLZ reported a contingent consideration liability of $548 million for Clif Bar as of December 31, 2023, which was measured using significant unobservable inputs (Level 3). This liability is tied to the August 1, 2022 acquisition of Clif Bar, which contributed to a $618 million increase in total selling, general, and administrative expenses in 2023 due to higher acquisition integration costs and contingent consideration adjustments. Despite these costs, MDLZ's operating income margin increased from 11.2% in 2022 to 15.3% in 2023, partly due to lapping prior-year acquisition-related costs and favorable changes in mark-to-market gains from hedging activities. The continued expense pressure from the Clif Bar acquisition was therefore offset by broader operational improvements and pricing discipline.",
      "llm_answer": "The contingent consideration liability for Clif Bar, measured using Level 3 inputs, is recorded as a $548 million liability at fair value and is adjusted each period based on significant unobservable inputs (e.g., Monte Carlo simulations of revenue, profit and EBITDA targets). These fair‑value adjustments are recognized in selling, general and administrative expenses and directly affect MDLZ’s 2023 operating income by increasing expense by $110 million (acquisition integration costs and contingent consideration adjustments) and by $131 million when combined with related acquisition‑related costs, thereby reducing reported operating income growth. Consequently, while the acquisition contributed $1,968 million of operating‑income increase, the contingent‑consideration expense partially offsets that gain, influencing the overall expense trend for 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2023.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76342,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19316,
        "completion_tokens": 215,
        "total_tokens": 19531
      }
    },
    {
      "question_id": 54,
      "question": "Given AMGN's exposure to biosimilar competition as a strategic risk, how does the decline in Aranesp sales during 2023 reflect the financial impact of biosimilar substitution, particularly in light of the reported drop in U.S. unit demand?",
      "original_answer": "The 2023 decline in Aranesp sales, driven by lower U.S. unit demand due to dialysis organizations transitioning to EPOGEN and its biosimilars, directly reflects the financial impact of biosimilar competition outlined in AMGN's risk factors. On page 15, AMGN highlights that biosimilars can significantly erode market share and revenue for its biologics, especially after loss of exclusivity. Page 74 confirms this risk is materializing: Aranesp sales dropped due to biosimilar competition from EPOGEN, with U.S. sales specifically falling as independent and medium-sized dialysis providers shifted to competing products. This aligns with the broader risk that biosimilars will continue to pressure both volume and net selling prices, indicating a clear financial manifestation of the strategic risk outlined earlier.",
      "llm_answer": "The decline in Aranesp sales during 2023—driven by lower unit demand in the U.S. as independent and medium‑sized dialysis organizations transitioned from Aranesp to EPOGEN—directly reflects the financial impact of biosimilar substitution, illustrating how competition from EPOGEN and its biosimilars is eroding Aranesp’s revenue. This reduction in U.S. unit demand underscores the strategic risk of biosimilar competition for Amgen’s key erythropoiesis‑stimulating agents.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75975,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19231,
        "completion_tokens": 118,
        "total_tokens": 19349
      }
    },
    {
      "question_id": 54,
      "question": "How does Microsoft's exclusion of Activision Blizzard's internal controls from its assessment relate to the integration of Activision's 3.400% Senior Notes due 2026 into Microsoft's debt structure following the October 2023 acquisition?",
      "original_answer": "Microsoft excluded Activision Blizzard's internal controls from its assessment because the acquisition occurred on October 13, 2023, and Activision's financial statements represented less than 1% of Microsoft's total assets (excluding goodwill and intangible assets) and 2% of total revenues as of June 30, 2024. Despite this exclusion, Activision's 3.400% Senior Notes due 2026 were integrated into Microsoft's broader debt structure, as evidenced by the November 6, 2023 filing of the Fifteenth Supplemental Indenture, which formally incorporated these notes under Microsoft’s existing debt framework. This indicates that while Activision’s internal controls were not assessed, its debt obligations were operationally and structurally assumed by Microsoft post-acquisition.",
      "llm_answer": "Microsoft excluded Activision Blizzard's internal controls from its assessment because the acquisition was less than 1% of total assets and 2% of revenue, so the company determined those controls were not material to its overall financial reporting. The 3.400% Senior Notes due 2026 issued by Activision Blizzard were integrated into Microsoft's debt structure through supplemental indentures filed on October 27, 2023, which transferred the notes to Computershare Trust Company as trustee under new indentures dated October 27, 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 107,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 106,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 53451,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13601,
        "completion_tokens": 133,
        "total_tokens": 13734
      }
    },
    {
      "question_id": 54,
      "question": "How does Microsoft's reliance on OEMs for Office distribution align with its competitive challenges from Meta in both productivity software and gaming markets, given Meta's direct-to-consumer platform advantages?",
      "original_answer": "Microsoft's OEM distribution model for Office, where the software is pre-installed by major manufacturers like Dell and HP on new devices, ensures broad market penetration and integration with hardware (page 18). However, this model contrasts with Meta's direct-to-consumer platform approach, which allows Meta to rapidly innovate and deploy software experiences without dependency on hardware partners. The filing explicitly lists Meta as a competitor to Office, indicating pressure in the productivity and collaboration space from Meta’s web-based tools (page 12). Furthermore, Microsoft notes that its Xbox and cloud gaming services also face competition from Meta (page 16), suggesting that Meta’s platform agility and direct user access pose a dual threat across both enterprise software and consumer gaming. This raises strategic questions about whether Microsoft’s OEM-dependent distribution for Office can keep pace with Meta’s integrated digital ecosystem in both markets.",
      "llm_answer": "Microsoft's reliance on OEMs to pre-install Office (and Windows) creates a distribution channel that depends on third‑party hardware makers, limiting its direct consumer reach. This indirect model contrasts with Meta’s direct‑to‑consumer platforms (e.g., Facebook, Instagram) that can launch and scale productivity and gaming services more swiftly, intensifying competition in both productivity software and gaming markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 61762,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15672,
        "completion_tokens": 105,
        "total_tokens": 15777
      }
    },
    {
      "question_id": 54,
      "question": "What is the significance of the anticipated 2035 U.S. patent expiration for MK-1022 in the context of Merck's disclosed global patent framework that includes provisions for PTE and SPC extensions?",
      "original_answer": "The anticipated 2035 U.S. patent expiration for MK-1022 represents a critical inflection point for Merck's market exclusivity in the U.S. for this product. This date is disclosed in the context of U.S.-specific patent protections, while the global patent framework section highlights that Merck actively manages patent life cycle strategies through mechanisms such as Patent Term Extensions (PTE) and Supplementary Protection Certificates (SPC) in other jurisdictions. Together, these disclosures suggest that while the U.S. expiration is clearly defined for MK-1022, Merck may seek to extend protection in key international markets through regulatory mechanisms, thereby delaying competitive entry outside the U.S.",
      "llm_answer": "The anticipated 2035 U.S. patent expiration for MK‑1022 is significant because, under Merck’s global patent framework, it can be extended through patent term restoration (PTE) and, where applicable, a six‑month pediatric market exclusivity period. These extensions allow the compound to retain market exclusivity beyond the basic 2035 expiry, aligning with the company’s strategy of leveraging PTEs and SPCs to maximize protection for its late‑stage drug candidates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 85235,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21531,
        "completion_tokens": 116,
        "total_tokens": 21647
      }
    },
    {
      "question_id": 54,
      "question": "How does SCHW's compliance with the Uniform Net Capital Rule, which restricts TDAC's ability to repay subordinated loans, reconcile with the company's reported secured borrowing capacity that depends on TDAC's collateral arrangements?",
      "original_answer": "SCHW's broker-dealer subsidiary TDAC is subject to the Uniform Net Capital Rule, which prohibits it from repaying subordinated loans if such repayment would reduce its net capital below 5% of aggregate debit balances or 120% of its minimum dollar requirement. At the same time, the company's secured borrowing capacity, particularly through facilities available to TDAC, depends on its ability to pledge acceptable collateral. This creates a tension where maintaining sufficient net capital under the Uniform Net Capital Rule may limit TDAC's ability to use its collateral to access secured borrowing, directly affecting SCHW's overall liquidity strategy and capital management.",
      "llm_answer": "The Uniform Net Capital Rule restricts TDAC’s ability to repay subordinated loans because any such repayment would reduce TDAC’s net capital below the required 5% of aggregate debit balances or 120% of its minimum dollar requirement, potentially triggering regulatory constraints. However, Schwab’s reported secured borrowing capacity—particularly under FHLB facilities and uncommitted lines of credit—depends on TDAC’s ability to pledge collateral (e.g., client margin securities) to lenders, which is distinct from its net capital position. This creates a reconciliation challenge: while TDAC’s collateral arrangements enable borrowing capacity, the net capital rule limits its capacity to distribute cash for debt repayment, meaning Schwab must manage liquidity and capital buffers carefully to maintain both compliance and access to external funding. The company addresses this by maintaining excess capital (e.g., TDAC’s $3.194B excess net capital in 2023) and using alternative funding sources like brokered CDs and FHLB advances, but the interplay between net capital restrictions and collateral-dependent borrowing remains a key operational constraint.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 123,
          "pages": [
            121,
            122,
            123,
            124,
            125
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80643,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20403,
        "completion_tokens": 290,
        "total_tokens": 20693
      }
    },
    {
      "question_id": 55,
      "question": "How does MetLife's positioning of Accident & Health Insurance as a core product offering align with the relatively low adjusted earnings contribution from the EMEA segment in 2023, despite EMEA also offering Accident & Health Insurance?",
      "original_answer": "MetLife identifies Accident & Health Insurance as a core product offered across multiple segments, including EMEA. However, while Accident & Health Insurance is listed among EMEA's offerings, the segment contributed only $265 million in adjusted earnings in 2023 — significantly less than other segments like Group Benefits ($1,655 million) and Asia ($1,282 million). This suggests that despite offering the same product category, EMEA's overall profitability is lower, potentially indicating regional challenges, lower pricing power, or higher operational costs in delivering Accident & Health Insurance in that market.",
      "llm_answer": "MetLife's positioning of Accident & Health Insurance as a core product offering aligns with the relatively low adjusted earnings contribution from the EMEA segment in 2023 because EMEA's adjusted earnings contribution was modest ($18 million in 2023, up only $3 million from 2022), reflecting its smaller scale and the fact that its primary offerings include life, retirement/savings, accident & health, and credit insurance rather than the high‑margin, capital‑intensive products that drive earnings in other segments. Consequently, while Accident & Health is a core line within EMEA's portfolio, its contribution to overall adjusted earnings remains limited compared with the larger earnings drivers in segments such as Group Benefits, RIS, and MetLife Holdings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 169,
          "pages": [
            167,
            168,
            169,
            170,
            171
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 86019,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21746,
        "completion_tokens": 191,
        "total_tokens": 21937
      }
    },
    {
      "question_id": 55,
      "question": "How does Cisco's financing of technical support services through loan receivables relate to the credit loss allowance specifically allocated to loan receivables in fiscal 2023?",
      "original_answer": "Cisco provides technical support services as part of its financing arrangements, which include loan receivables that typically span one to three years (page 49 and 82). These loan receivables are subject to credit risk, which is reflected in the credit loss allowance disclosed in the financial statements. In fiscal 2023, the credit loss allowance for loan receivables decreased from $103 million to $53 million, indicating a reduction in the estimated risk associated with these financing activities (page 84). This suggests that the company's exposure to credit losses from financing technical support services through loans has declined year-over-year, potentially reflecting improved credit quality of customers or more conservative underwriting in loan origination.",
      "llm_answer": "Cisco’s financing of technical support services is included in its loan receivables, which totaled $5,858 million gross (including $67 million residual value) as of July 27, 2024. The allowance for credit losses specifically allocated to these loan receivables was $50 million, resulting in a net loan receivable balance of $5,808 million after the allowance. This allowance reflects the credit risk associated with the financing arrangements that support technical support and related services.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75740,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19158,
        "completion_tokens": 123,
        "total_tokens": 19282
      }
    },
    {
      "question_id": 55,
      "question": "How does the $96 million pre-tax charge related to Nicor Gas' disallowed capital investments impact Southern Company's financing structure, particularly in light of the disclosure that Nicor Gas obtains financing separately without affiliate credit support?",
      "original_answer": "The $96 million pre-tax charge associated with the disallowance of certain capital investments at Nicor Gas (after tax: $72 million) directly affects Southern Company Gas' earnings and potentially its retained earnings base. Nicor Gas, which obtains financing separately without credit support from affiliates and is restricted in how much it can dividend or loan to affiliates (up to its retained earnings balance), reported $1.7 billion in restricted retained earnings at year-end. This restriction, combined with the significant charge, could limit Nicor Gas' ability to internally finance future capital needs or distribute funds to parent entities. The financing section (Note 8) indicates that Southern Company Gas subsidiaries like Nicor Gas rely heavily on external financing, suggesting that such charges may increase reliance on external capital markets or impact future financing terms.",
      "llm_answer": "The $96 million pre‑tax charge tied to Nicor Gas’ disallowed capital investments is recorded as a separate line‑item in Southern Company Gas’s results (Note 2), reflecting a charge that is fully borne by Nicor Gas itself. Because Nicor Gas obtains its financing independently—without any affiliate credit support—this charge does not affect Southern Company’s overall financing structure or debt capacity, and the company continues to fund its own capital needs through external debt and equity markets on a stand‑alone basis.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 107,
          "pages": [
            105,
            106,
            107,
            108,
            109
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 167,
          "pages": [
            165,
            166,
            167,
            168,
            169
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75524,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19131,
        "completion_tokens": 131,
        "total_tokens": 19262
      }
    },
    {
      "question_id": 55,
      "question": "How does Boeing's increasing reach-forward loss on the Commercial Crew program in 2021 relate to the broader financial risks associated with fixed-price development contracts, particularly in light of the $402 million additional loss recorded on the KC-46A Tanker contract during the same year?",
      "original_answer": "Boeing's increasing reach-forward loss on the Commercial Crew program by $185 million in 2021, as detailed in the operational performance section, reflects the financial volatility inherent in fixed-price development contracts. This aligns with the broader risk profile outlined in the financial statement notes, which emphasize the uncertainty in cost estimation and the potential for material charges due to technical complexity and delays. The $402 million additional loss recorded on the KC-46A Tanker contract in the same year further illustrates the recurring financial exposure Boeing faces under such contracts, particularly when unforeseen disruptions like supply chain delays or evolving customer requirements occur. Together, these examples highlight how Boeing's financial performance is significantly impacted by the execution risks tied to fixed-price development programs.",
      "llm_answer": "Boeing recorded an additional $402 million reach‑forward loss on the KC‑46A Tanker in 2021 because of supply‑chain and factory disruptions, illustrating how fixed‑price development contracts expose the company to cost‑overrun risks that can erode margins. This loss is part of a broader pattern of fixed‑price program exposure—evident in the $402 million charge on KC‑46A, the $185 million increase in reach‑forward loss on Commercial Crew, and the $318 million charge on VC‑25B—highlighting that such contracts carry inherent financial risk that can materially affect earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_2_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BA_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 54393,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13855,
        "completion_tokens": 144,
        "total_tokens": 13999
      }
    },
    {
      "question_id": 55,
      "question": "How do regulatory decisions by the Georgia Public Service Commission and Federal Energy Regulatory Commission impact Georgia Power Company's reported financial position, particularly in relation to the recovery of costs and return on investment as disclosed in the financial statements?",
      "original_answer": "Georgia Power Company, a wholly-owned subsidiary of SO, operates under the retail rate regulation of the Georgia Public Service Commission and wholesale regulation by the Federal Energy Regulatory Commission. These regulatory bodies influence the company's financial reporting by determining the rates Georgia Power can charge customers, which are based on the recovery of prudently incurred costs and a reasonable return on invested capital. The company expects to recover these costs and investments through regulated rates; however, there is a risk that regulators may not approve full recovery, directly impacting financial line items such as regulatory assets and liabilities. This material consideration is detailed in Note 2 (Regulatory Matters - Georgia Power) to the financial statements, which is referenced on page II-129 of the financial statement schedule, and forms part of the basis for the auditor's opinion on the financial statements.",
      "llm_answer": "Regulatory decisions by the Georgia Public Service Commission and the Federal Energy Regulatory Commission directly affect Georgia Power’s ability to recover costs and earn a return on investment, which is reflected in the financial statements through the recording of regulatory assets and liabilities, and impacts net income and comprehensive income as shown in the statements of income and comprehensive income. The company’s critical audit matter highlights the significant judgment involved in assessing the likelihood of cost recovery and refunds, which influences the balances of regulatory assets and liabilities and ultimately affects reported financial position.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 135,
          "pages": [
            133,
            134,
            135,
            136,
            137
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71386,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18101,
        "completion_tokens": 168,
        "total_tokens": 18269
      }
    },
    {
      "question_id": 56,
      "question": "How does Chevron's controlling stake in Chevron U.S.A. Inc. influence its exposure to crude oil price volatility, given the subsidiary's significant involvement in upstream and downstream operations?",
      "original_answer": "Chevron holds a controlling stake in Chevron U.S.A. Inc. (CUSA), which manages most of Chevron's U.S. businesses, including the exploration, production, refining, and distribution of crude oil and petroleum-derived products. CUSA's upstream operations expose Chevron to crude oil price volatility, while its downstream integration provides some operational balance during commodity price cycles. This dual exposure means that fluctuations in crude oil prices can both directly impact Chevron’s upstream earnings and indirectly affect downstream margins through feedstock cost variability. Therefore, Chevron’s ownership of CUSA amplifies its strategic and financial sensitivity to crude oil market dynamics.",
      "llm_answer": "Chevron’s 77 % controlling stake in Chevron U.S.A. Inc. (CUSA) means that the subsidiary’s upstream and downstream operations are fully consolidated into Chevron’s earnings. Because CUSA’s business is heavily weighted toward crude‑oil production and refining, the company’s profitability—and therefore its exposure to crude‑oil price swings—is directly tied to the cash‑flow generated by those operations. Consequently, any volatility in crude‑oil prices is reflected in Chevron’s consolidated results through the earnings of CUSA.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_3_rel": {
          "source_file": "CVX_10k_2024.pdf",
          "target_page": 35,
          "pages": [
            33,
            34,
            35,
            36,
            37
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84673,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21395,
        "completion_tokens": 132,
        "total_tokens": 21528
      }
    },
    {
      "question_id": 56,
      "question": "How does Microsoft's issuance of the 5.20% Notes due 2039, administered by BNY Mellon, relate to the company's broader pattern of long-term debt instruments also serviced by BNY Mellon and U.S. Bank, and what does this imply about Microsoft's capital structure strategy?",
      "original_answer": "Microsoft issued the 5.20% Notes due 2039 under a First Supplemental Indenture dated May 18, 2009, with The Bank of New York Mellon Trust Company, N.A. (BNY Mellon) as trustee. This is part of a broader capital structure strategy involving multiple long-term debt instruments, including notes due in 2018, 2023, 2035, 2045, and 2055, some of which are also administered by BNY Mellon and later by U.S. Bank National Association. The repeated use of these trustees across different maturities suggests Microsoft's structured approach to managing long-term liabilities through trusted financial institutions, balancing interest rate risk and maturity laddering to maintain financial flexibility.",
      "llm_answer": "Microsoft's issuance of the 5.20% Notes due 2039 through BNY Mellon Trust Company reflects its consistent use of long-term debt instruments administered by BNY Mellon and U.S. Bank, as evidenced by multiple supplemental indentures filed between 2011 and 2023 involving these trustees for various maturities (e.g., 2033, 2035, 2036, 2039, 2041, 2042, 2043, 2045, 2046, 2047, 2055, 2056). This pattern demonstrates a deliberate capital structure strategy of leveraging low-cost, long-duration debt to finance operations and acquisitions while maintaining flexibility, with BNY Mellon and U.S. Bank serving as primary trustee administrators for nearly all such debt issuances since 2009.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12829,
        "completion_tokens": 171,
        "total_tokens": 13000
      }
    },
    {
      "question_id": 56,
      "question": "How does the voting power structure of CMCSA's Class A and Class B common stock, where Class B shares carry 15 votes each, reconcile with the company's decision to repurchase only Class A shares despite both classes being outstanding?",
      "original_answer": "CMCSA's capital structure shows that Class A common stock had 4,651,093,045 shares issued in 2024, while Class B common stock had only 9,444,375 issued and outstanding shares. Despite both classes being outstanding, all stock repurchases in 2024 were limited to Class A shares, totaling $2 billion in reductions to additional paid-in capital and $7,251 million in reductions to retained earnings. This suggests a strategic focus on managing Class A share count while preserving the concentrated voting power of Class B shares, which carry 15 votes each and are entirely owned by Brian L. Roberts, ensuring continued control over key corporate decisions.",
      "llm_answer": "The voting power structure gives Class B shares 15 votes each, representing roughly one‑third of the total voting power, while Class A shares carry one vote each.  Although both classes remain outstanding, the company’s share‑repurchase program is limited to buying back Class A common stock; the Class B shares are not eligible for repurchase, reflecting the company’s policy to retire only Class A shares despite the unequal voting rights.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70318,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17816,
        "completion_tokens": 110,
        "total_tokens": 17927
      }
    },
    {
      "question_id": 56,
      "question": "How does the participation in EIP Plans by non-U.S. employees, which resulted in the purchase of 78,000 shares of Caterpillar common stock in Q4 2023, compare with the company's broader share repurchase activity totaling $4.7 billion in 2023, and what does this suggest about the relative scale and intent behind employee-driven versus corporate-driven stock ownership changes?",
      "original_answer": "The EIP Plans, which cater to non-U.S. employees, led to the purchase of 78,000 shares of Caterpillar common stock in Q4 2023, indicating a relatively small, employee-driven acquisition of equity. In contrast, Caterpillar's corporate share repurchase program in 2023 resulted in the acquisition of 19.5 million shares at a total cost of $4.7 billion, reflecting a significantly larger, strategic initiative to influence capital structure and shareholder value. This contrast suggests that while employee participation contributes marginally to stock demand, the company's own repurchase activity is the dominant force shaping stock ownership and market perception.",
      "llm_answer": "The EIP Plans enabled non-U.S. employees to purchase 78,000 shares of Caterpillar stock in Q4 2023, representing a small, targeted acquisition within the broader context of the company’s $4.7 billion total share repurchase activity for 2023. This contrasts with the corporate-driven repurchases, which accounted for the vast majority of the $4.7 billion spent, indicating that employee-driven purchases were a minor component of overall share ownership changes, reflecting a focused, limited-scale initiative rather than a strategic shift in capital allocation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 41598,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 10672,
        "completion_tokens": 140,
        "total_tokens": 10812
      }
    },
    {
      "question_id": 56,
      "question": "What does Opdualag's 48% year-over-year revenue growth suggest about BMY's strategy in melanoma treatment, given its indication for unresectable or metastatic cases?",
      "original_answer": "Opdualag's 48% year-over-year revenue growth, with particularly strong performance in the U.S. (41%) and explosive growth internationally (>200%), indicates strong market adoption of BMY's melanoma treatment. This aligns with the company's strategic focus on oncology, particularly in addressing high-unmet-need indications like unresectable or metastatic melanoma. The product's dual mechanism targeting PD-1 and LAG-3 pathways appears to be resonating in the market, supporting BMY's positioning in immuno-oncology despite the complexity of treating advanced-stage melanoma.",
      "llm_answer": "Opdualag’s 48% year-over-year revenue growth underscores Bristol‑Myers Squibb’s strategic focus on expanding its oncology portfolio, particularly in the high‑need setting of unresectable or metastatic melanoma. By advancing a novel combination therapy that simultaneously blocks PD‑1 and LAG‑3, the company is positioning Opdualag as a differentiated, next‑generation checkpoint inhibitor that can capture additional market share and drive sustained growth in its growth‑portfolio revenues.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82088,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20739,
        "completion_tokens": 122,
        "total_tokens": 20861
      }
    },
    {
      "question_id": 57,
      "question": "How does Amgen's exposure to generic competition risk for KYPROLIS relate to its collaboration and financial arrangements with BeiGene, Ltd., particularly considering Amgen's equity stake and profit-sharing structure in China?",
      "original_answer": "Amgen highlights KYPROLIS as one of its small molecule products facing significant generic competition risk on page 14, noting that such competition can rapidly erode market share and revenue. On page 132, it is revealed that BeiGene, Ltd. began selling KYPROLIS in China in 2022 under a collaboration where Amgen shares profits and losses equally during the initial commercialization period, after which product rights may revert to Amgen with royalty obligations to BeiGene. Additionally, page 98 shows that Amgen has a long-standing equity stake in BeiGene, with multiple amendments to the Share Purchase Agreement and ongoing collaboration agreements, indicating a strategic and financially intertwined relationship. This suggests that while Amgen seeks to mitigate KYPROLIS's generic risk through geographic expansion via BeiGene, it also shares control and financial upside in the Chinese market, creating a complex trade-off between market access and revenue retention.",
      "llm_answer": "Amgen’s exposure to generic competition for KYPROLIS is mitigated by its collaboration with BeiGene, Ltd., under which Amgen shares profits and losses equally during the initial commercialization period in China and manufactures the product for BeiGene. While Amgen holds a 20.5% equity stake in BeiGene (accounted for under the fair value method since 2023), the collaboration structure—including equal profit sharing, joint development cost sharing, and BeiGene’s role in selling KYPROLIS in China—directly ties Amgen’s financial performance to the product’s success in that market, despite generic competition risks. The equity stake and profit-sharing arrangement are distinct from the generic competition risk, as the collaboration’s terms govern revenue sharing rather than directly offsetting generic pricing pressures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 82300,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20815,
        "completion_tokens": 206,
        "total_tokens": 21022
      }
    },
    {
      "question_id": 57,
      "question": "How does Cisco's sensitivity analysis of its $20.3 billion in senior fixed-rate notes relate to its $15.0 billion commercial paper program, particularly in terms of interest rate exposure and financing flexibility?",
      "original_answer": "Cisco disclosed on page 53 that a 50 basis point increase or decrease in market interest rates would change the fair value of its $20.3 billion in senior fixed-rate notes by approximately $0.7 billion. This sensitivity applies to fixed-rate debt that is not hedged, and the company also noted that a sharp rise in interest rates could increase interest expense on new commercial paper issuances. On page 89, it is clarified that the senior fixed-rate notes rank at par with the commercial paper notes issued under Cisco's $15.0 billion short-term debt program. Page 88 introduces this commercial paper program, stating that proceeds are used for general corporate purposes. The interplay between these instruments shows that while senior notes are subject to interest rate risk affecting fair value, commercial paper notes introduce direct interest expense volatility with market rate changes, impacting Cisco's short-term financing flexibility.",
      "llm_answer": "Cisco’s sensitivity analysis for its $20.3 billion of senior fixed‑rate notes shows that a 50‑basis‑point shift in market rates would change the fair value of the notes by roughly $0.7 billion, while the notes’ interest expense would be largely insulated from such shifts (except for the small portion that is hedged). This analysis is linked to its $15.0 billion commercial‑paper program, which provides short‑term financing flexibility; the program’s effective rate (5.43 % in 2024) and the ability to issue paper as needed allow Cisco to manage interest‑rate exposure and maintain liquidity, complementing the longer‑term fixed‑rate note strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77295,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19555,
        "completion_tokens": 162,
        "total_tokens": 19718
      }
    },
    {
      "question_id": 57,
      "question": "How does Morgan Stanley coordinate capital requirements between MSSB's broker-dealer obligations and its registered swap dealer entities under CFTC and SEC regulations?",
      "original_answer": "Morgan Stanley must align its capital management across MSSB, which is subject to the SEC's net capital rule and FINRA margin requirements, and its registered swap dealer entities that face uncleared swap margin and minimum capital requirements from either prudential regulators, the CFTC, or the SEC. The firm's U.S. broker-dealer subsidiaries, including MSSB, are required to maintain minimum net capital levels under SEC rules, which are detailed in Note 16 to the financial statements. Meanwhile, its swap dealers—both U.S. and non-U.S.—must comply with either prudential regulator standards or direct CFTC/SEC requirements for margin and capital. This dual regulatory framework necessitates careful capital allocation and compliance coordination to ensure both broker-dealer and swap dealer operations remain adequately capitalized under overlapping regulatory regimes.",
      "llm_answer": "Morgan Stanley coordinates capital requirements between MSSB’s broker-dealer activities and its registered swap dealer entities through a unified regulatory framework that integrates SEC broker-dealer rules, CFTC swap dealer requirements, and U.S. banking capital standards. The firm aligns its capital planning and stress testing (overseen by the Federal Reserve) across all regulated subsidiaries, ensuring that capital adequacy for broker-dealer operations, swap dealing, and security-based swap activities satisfies both SEC and CFTC regulations while meeting banking liquidity and capital rules. This coordination is detailed in the \"Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Regulatory Requirements\" section and Note 16 to the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 104102,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26245,
        "completion_tokens": 207,
        "total_tokens": 26452
      }
    },
    {
      "question_id": 58,
      "question": "How does Coca-Cola's approach to managing health care cost inflation in its U.S. postretirement benefit plans align with the investment strategy of the VEBA trust, given the expected benefit payments and asset liquidity requirements?",
      "original_answer": "Coca-Cola manages health care cost inflation in its U.S. postretirement benefit plans by using defined-dollar benefit plans that cap contribution levels based on established dollar limits, as noted on page 105. One of these plans is funded through a VEBA trust, which holds primarily liquid assets to meet the timing and level of expected future benefit payments, as detailed on page 103. This alignment reflects a coordinated strategy where the defined-dollar structure limits long-term liability exposure, while the VEBA’s liquid asset allocation ensures that funds are available to meet near-term obligations. The expected benefit payments for the next decade, also disclosed on page 105, further justify the emphasis on liquidity in the VEBA’s investment approach.",
      "llm_answer": "Coca‑Cola’s U.S. post‑retirement benefit plan is funded through a VEBA trust that is invested primarily in liquid assets to meet the timing of expected benefit payments. The plan’s investment strategy emphasizes a diversified mix of cash, equities, fixed‑income securities, mutual funds, hedge funds and real estate, with an overall target allocation of roughly 42 % equities, 30 % fixed‑income and 28 % alternatives for the U.S. pension assets. This asset mix provides the liquidity needed to cover the projected benefit payments outlined in the cash‑flow schedule (approximately $545 million in 2022, rising to $2.6 billion over the next decade) while supporting the plan’s long‑term return objectives. Consequently, the VEBA’s liquid‑focused allocation aligns with the plan’s need to meet scheduled benefit obligations and manage health‑care cost inflation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "KO_10k_2022.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "KO_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "KO_10k_2022.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80280,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20304,
        "completion_tokens": 215,
        "total_tokens": 20519
      }
    },
    {
      "question_id": 58,
      "question": "How does the trend in Cisco's allowance for credit losses on loan receivables from fiscal year 2022 to 2023 reflect the risk profile of financing arrangements tied to technical support services, given the average loan term and nature of those services?",
      "original_answer": "The allowance for credit losses on loan receivables dropped from $103 million in fiscal 2022 to $53 million in fiscal 2023, indicating a reduced risk or a strategic shift in credit exposure. This decrease occurs despite loan receivables being tied to services like technical support, which are part of multi-year financing arrangements (1–3 years on average), suggesting either improved credit quality of counterparties or more conservative underwriting. The connection between loan receivables and technical support services implies that Cisco's financing risk is closely linked to the ongoing value and delivery of these services over the loan term.",
      "llm_answer": "The allowance for credit losses on Cisco’s financing receivables declined modestly from $72 million in fiscal 2023 to $65 million in fiscal 2024, reflecting a slightly improved risk profile despite the relatively short (1‑3 year) average loan term and the service‑oriented nature of the underlying technical‑support arrangements, which are typically collateralized and supported by strong contractual cash‑flow expectations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67870,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17205,
        "completion_tokens": 106,
        "total_tokens": 17311
      }
    },
    {
      "question_id": 58,
      "question": "How does Disney's risk of brand damage affecting cross-business performance relate to its inclusion of Marvel content in Disney+ services and its financial stake in the Marvel trademark as an indefinite-lived intangible asset?",
      "original_answer": "Disney identifies brand damage in one business as potentially impacting performance across other businesses due to the interconnected nature of its globally recognized brands (page 29). This risk is particularly relevant given that Disney+—a key part of its DTC strategy—includes Marvel content as a top-level tile in its interface, directly linking Marvel’s brand strength to subscriber attraction and retention (page 12). Furthermore, Marvel is listed among Disney’s indefinite-lived intangible assets, alongside Pixar and ESPN, indicating its long-term strategic and financial value to the company (page 110). Therefore, any reputational harm to the Marvel brand could not only affect Disney+ subscriber metrics but also diminish the value of a significant intangible asset, thereby impacting overall financial stability and DTC profitability.",
      "llm_answer": "Disney's risk of brand damage affecting cross-business performance is heightened by its inclusion of Marvel content in Disney+ services and its financial stake in the Marvel trademark as an indefinite-lived intangible asset. The Marvel trademark, classified as an indefinite-lived intangible asset on the balance sheet, represents a critical brand asset whose value could be impaired if Marvel-related content underperforms or triggers reputational damage on Disney+, potentially leading to write-downs that negatively impact overall financial results and cross-business revenue streams. This risk is amplified by the interconnected nature of Disney's businesses, where brand perception directly influences subscription growth, advertising revenue, and content licensing across its DTC platforms and other distribution channels.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2022.pdf",
          "target_page": 110,
          "pages": [
            108,
            109,
            110,
            111,
            112
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 65594,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16638,
        "completion_tokens": 207,
        "total_tokens": 16845
      }
    },
    {
      "question_id": 58,
      "question": "How does the voting power disparity between Class A and Class B common stock, as outlined in the equity structure, influence the governance dynamics given that Mr. Brian L. Roberts owns all outstanding shares of Class B common stock?",
      "original_answer": "The governance dynamics are significantly influenced by the voting power disparity, as Mr. Brian L. Roberts, owning all outstanding Class B shares (with 15 votes per share), controls 33⅓% of the combined voting power, despite Class A shareholders collectively holding the remaining 66⅔%. This structure, outlined in the equity disclosures and further clarified in the voting rights section, ensures that Mr. Roberts retains outsized influence over corporate decisions, such as the election of directors, even though the majority of shares by quantity are Class A. This dynamic is further emphasized by the fact that Class B stock is non-dilutable, preserving Mr. Roberts' voting power regardless of future Class A share issuances.",
      "llm_answer": "The voting power disparity—Class B shares carry 15 votes per share while Class A shares carry one vote per share—means that Mr. Brian L. Roberts, who owns all of the outstanding Class B shares, controls roughly one‑third of the total voting power despite holding a tiny fraction of the equity. This concentration gives him decisive influence over key corporate decisions such as the election of directors and other matters that require shareholder approval, shaping governance dynamics in his favor.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 58158,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14779,
        "completion_tokens": 124,
        "total_tokens": 14904
      }
    },
    {
      "question_id": 58,
      "question": "How does the issuance of nonvoting common shares to TD Ameritrade stockholders relate to the integration-related compensation expenses Schwab incurred in the two years following the October 6, 2020 acquisition, particularly regarding bonuses and employee salary adjustments?",
      "original_answer": "Schwab issued approximately 77 million nonvoting common shares to TD Ameritrade stockholders as part of the acquisition on October 6, 2020, with TD Bank subsequently holding 79 million shares of nonvoting common stock by year-end 2021. Following the acquisition, Schwab’s compensation and benefits expense included $1.2 billion from TD Ameritrade in 2021 and $453 million in 2020, reflecting a full-year contribution and integration-related costs. These costs included $283 million and $235 million in acquisition and integration-related compensation expenses in 2021 and 2020, respectively, driven by employee salary increases, bonus accruals, and integration efforts. The issuance of shares was a direct result of the acquisition, which in turn led to significant integration-related compensation expenses, particularly tied to workforce adjustments and bonuses.",
      "llm_answer": "The issuance of non‑voting common shares to TD Ameritrade stockholders was part of the acquisition accounting and was treated as acquisition‑related compensation.  Schwab’s integration‑related compensation expense in the two years after the October 6, 2020 acquisition—reflected in the “Compensation and benefits” line of its expense tables—includes bonuses, annual merit increases and targeted salary adjustments that were paid to the newly added TD Ameritrade workforce.  The company disclosed that this expense incorporated a 5 % salary increase and higher bonus accruals for the combined employee base, which contributed to the rise in total compensation and benefits from $3.954 billion in 2020 to $5.450 billion in 2021.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78797,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19945,
        "completion_tokens": 181,
        "total_tokens": 20126
      }
    },
    {
      "question_id": 58,
      "question": "How does MDLZ's use of commodity futures to hedge input cost volatility, including specific commodities like cocoa and wheat, relate to the classification of these instruments as Level 1 financial liabilities, and what does this imply about the transparency and valuation methodology applied to these hedging instruments?",
      "original_answer": "MDLZ uses commodity futures to hedge against price risks for raw materials such as cocoa, wheat, and sugar (page 94). These instruments are classified as Level 1 financial liabilities because they are exchange-traded and valued using quoted market prices on commodity exchanges (page 112). This classification indicates that the valuation methodology for these hedging instruments is based on highly transparent and observable market data, reflecting a lower level of subjectivity compared to Level 2 or 3 instruments. The connection between the operational use of these futures and their fair value classification highlights how MDLZ aligns its risk management practices with transparent, market-based valuation standards.",
      "llm_answer": "MDLZ classifies its commodity futures and forwards used to hedge input cost volatility (e.g., cocoa, wheat) as Level 1 financial liabilities because they are exchange‑traded contracts with quoted market prices. This Level 1 classification provides transparent, observable inputs for fair‑value measurement, allowing the company to record these hedging instruments at market‑based values on the balance sheet and to disclose their valuation methodology clearly in the footnote disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 69495,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17632,
        "completion_tokens": 122,
        "total_tokens": 17754
      }
    },
    {
      "question_id": 58,
      "question": "How does GE's increased allocation to growth assets in its reinsurance treaties affect the assumptions and outcomes of its premium deficiency testing for long-term care insurance policies?",
      "original_answer": "GE's increased allocation to growth assets, such as private equity and high-yield credit strategies, has led to a higher discount rate used in premium deficiency testing—from 5.70% in 2020 to 6.15% in 2021. This increase contributed significantly to a larger premium deficiency testing margin, which reflects greater projected investment returns. However, this shift also introduces more earnings volatility due to the fair value accounting of these assets. The premium deficiency testing process, which evaluates the adequacy of future policy benefit reserves, must now account for the uncertainty and variability in returns from these higher-risk investments. Despite favorable emerging morbidity experience, the testing continues to rely heavily on assumptions about future investment yields and reinsurance treaty structures, which are subject to change based on evolving market conditions and portfolio performance.",
      "llm_answer": "The increased allocation to growth assets (e.g., private‑equity, equity‑like securities and high‑yield credit) raised the weighted‑average discount rate from 5.70 % in 2020 to 6.15 % in 2021, which lowered the present value of future benefit payments and expanded the premium‑deficiency margin. Because the higher discount rate is a key driver of the premium‑deficiency test, the larger allocation to growth assets improves the adequacy of future policy‑benefit reserves and reduces the likelihood of a deficiency that would require additional reserve increases.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_3_rel": {
          "source_file": "GE_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 85839,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21685,
        "completion_tokens": 140,
        "total_tokens": 21826
      }
    },
    {
      "question_id": 58,
      "question": "How did ConocoPhillips' impairment of its APLNG investment in 2021 reflect on the long-term viability of APLNG's $5.7 billion nonrecourse financing structure, especially considering Origin Energy's dual role as both a joint venture partner and operator of APLNG's production system?",
      "original_answer": "ConocoPhillips recorded a $688 million pre-tax impairment on its APLNG investment in 2021 due to a decline in fair value below carrying value, as evidenced by Origin Energy's sale of a 10% stake for $1.645 billion. This impairment suggests ConocoPhillips viewed APLNG's long-term prospects as less favorable than previously anticipated, despite APLNG having a substantial $5.7 billion in outstanding nonrecourse financing at year-end. APLNG's financing structure, composed of U.S. Ex-Im Bank loans, commercial bank facilities, and private placement notes, was scheduled for bi-annual repayments through 2030, making the long-term viability of this structure highly dependent on sustained LNG demand and pricing. Origin Energy's role as operator of APLNG's production and pipeline system, while ConocoPhillips operates the LNG facility, introduces operational interdependence that could affect cash flow predictability. The impairment decision indicates ConocoPhillips factored in risks related to both market conditions and the complex operational structure when assessing APLNG's future cash flows, raising questions about whether the financing obligations can be met under the revised fair value assumptions.",
      "llm_answer": "ConocoPhillips' $688 million impairment of its APLNG investment in 2021 reflected growing concerns about the long‑term viability of APLNG’s $5.7 billion non‑recourse financing, especially as Origin Energy—both a joint‑venture partner and the operator of APLNG’s production system—agreed to sell a 10 % stake for $1.645 billion, signaling a market‑based valuation below the carrying value of ConocoPhillips’ 37.5 % interest; the impairment was triggered by a market‑participant view of APLNG’s fair value that fell beneath the book value of the investment, prompting the company to write down its stake to $5.574 billion and record the charge as an other‑than‑temporary impairment under ASC 323.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 119,
          "pages": [
            117,
            118,
            119,
            120,
            121
          ]
        },
        "hop_2_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 100,
          "pages": [
            98,
            99,
            100,
            101,
            102
          ]
        },
        "hop_3_rel": {
          "source_file": "COP_10k_2022.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65860,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16715,
        "completion_tokens": 173,
        "total_tokens": 16889
      }
    },
    {
      "question_id": 58,
      "question": "How do Southern Company's operational risks related to cyber intrusions specifically impact the financial and operational viability of their nuclear power plants, given the significant role these plants play in electricity generation for Alabama Power and Georgia Power?",
      "original_answer": "Southern Company's nuclear power plants, which are operated by Southern Nuclear, account for approximately 26% and 28% of the total KWHs generated by Alabama Power and Georgia Power respectively. These plants are subject to a range of operational risks, including cyber intrusions, which are explicitly called out in the Operational Risks section. Cyber intrusions could lead to increased compliance costs, potential fines, or even shutdowns of nuclear units by the NRC if security standards are not met. The financial impact of such events could be significant, especially since damages or decommissioning costs could exceed available insurance or decommissioning trusts. This creates a direct link between cybersecurity threats and the financial and operational viability of the nuclear power plants, which are critical to Southern Company’s electricity generation portfolio.",
      "llm_answer": "Southern Company’s nuclear plants—Plants Farley, Hatch, and the Vogtle units—are critical to the electricity supply of Alabama Power and Georgia Power, accounting for roughly a quarter of each utility’s generation. Because these reactors are operated by Southern Nuclear under long‑term agreements, any cyber intrusion that compromises plant control systems, forces an unplanned shutdown, or triggers costly safety or regulatory actions would directly reduce the output that fuels the companies’ rate‑base revenues. The loss of generation would impair the utilities’ ability to meet wholesale power commitments and to recover the high capital and operating costs of the nuclear units through regulated rates, thereby threatening both the financial viability and the operational reliability of their nuclear fleet.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84593,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21392,
        "completion_tokens": 203,
        "total_tokens": 21596
      }
    },
    {
      "question_id": 59,
      "question": "How does MDLZ's use of commodity futures to hedge input cost volatility, as detailed in the financial instruments section, relate to the classification of these instruments as Level 1 financial liabilities, and what does this imply about the transparency and valuation methodology of these hedging instruments?",
      "original_answer": "MDLZ uses commodity futures to hedge against price risks associated with forecasted purchases of raw materials such as cocoa, sugar, and wheat. These futures are classified as Level 1 financial liabilities because their fair value is determined using quoted market prices on commodity exchanges, indicating high transparency and observable valuation inputs. This classification reflects a direct link between the company's risk management strategy and the accounting treatment of these instruments, showing that MDLZ relies on highly liquid and transparent markets for its commodity hedging activities.",
      "llm_answer": "MDLZ classifies commodity futures used to hedge input cost volatility as Level 1 financial liabilities because they are exchange-traded contracts with quoted market prices, allowing direct valuation using active market quotes. This classification reflects high transparency, as the fair value is determined by observable market data rather than internal models or unobservable inputs. Consequently, the valuation methodology for these hedging instruments is straightforward and relies on readily available market prices, enhancing the reliability and comparability of the disclosed hedge accounting.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 69495,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17630,
        "completion_tokens": 149,
        "total_tokens": 17779
      }
    },
    {
      "question_id": 59,
      "question": "What does Merck disclose about the anticipated patent expiration for MK-1654 in the U.S., and how does this relate to their broader disclosure about patent protections across key global markets?",
      "original_answer": "Merck discloses that MK-1654 has an anticipated U.S. patent expiration date of 2036. This information is presented in a list of products under review in the U.S. with their respective expected expiration years. Separately, Merck also discloses the existence of a table that includes patent expiration dates for key products across multiple jurisdictions, including the U.S., EU, Japan, and China. While the specific expiration details for MK-1654 in non-U.S. markets are not provided in the referenced sections, the structure of the disclosures indicates that Merck tracks and reports patent protections across several key global markets.",
      "llm_answer": "Merck discloses that its U.S. patent protection for MK-1654 is anticipated to expire in 2036, and that this compound patent may later benefit from up to five years of pediatric market exclusivity or a pending patent term extension (PTE).  Across its key global markets, the company similarly notes that patent expirations are often extended through PTEs and supplementary protection certificates (SPCs), so that market exclusivity can persist well beyond the basic compound patent term in the U.S., EU, Japan and China.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 15,
          "pages": [
            13,
            14,
            15,
            16,
            17
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 85235,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21530,
        "completion_tokens": 129,
        "total_tokens": 21660
      }
    },
    {
      "question_id": 59,
      "question": "How does Broadcom's valuation methodology for developed technology related to VMware Cloud Foundation contrast with its treatment of developed technology for SoC controller products in different sections of the 10-K?",
      "original_answer": "Broadcom applied different valuation methodologies to developed technology depending on its application context. For VMware Cloud Foundation (VCF), Broadcom used the multi-period excess earnings method under the income approach, valuing it at $24,156 million, with a significant portion attributed to VCF. This method reflects the present value of projected cash flows less charges representing contributions of other assets. In contrast, for SoC controller products for hard disk drive applications, Broadcom used the relief-from-royalty method, which applies a royalty rate to forecasted revenue. This difference in approach reflects the distinct nature of the technologies—software-based cloud infrastructure (VCF) versus hardware controller products—and how each contributes to cash flows. The economic useful life for both was determined based on technology cycles and forecasted cash flows, but the underlying assumptions and modeling techniques differ significantly.",
      "llm_answer": "Broadcom valued its developed technology for VMware Cloud Foundation using the multi‑period excess‑earnings method under the income approach, assigning it a fair value of $24,156 million with an 8‑year weighted‑average amortization period, whereas the developed technology for SoC controller products (e.g., Seagate’s SoC assets) was valued using the relief‑from‑royalty method and recorded at $90 million with an 11‑year amortization period. This contrast reflects different valuation approaches—excess‑earnings for the cloud‑foundation technology versus relief‑from‑royalty for the SoC controller technology.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 58263,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14799,
        "completion_tokens": 152,
        "total_tokens": 14951
      }
    },
    {
      "question_id": 59,
      "question": "How does Broadcom's valuation methodology for developed technology related to VMware Cloud Foundation differ from its valuation methodology for developed technology in the SoC controller business, and what does this reveal about the strategic importance of each asset post-acquisition?",
      "original_answer": "Broadcom valued the developed technology related to VMware Cloud Foundation using the multi-period excess earnings method under the income approach, which reflects the present value of projected cash flows less charges representing the contribution of other assets. This was specifically applied to $24,156 million of developed technology, a significant portion of which was tied to VMware Cloud Foundation. In contrast, the developed technology for SoC controller products for hard disk drive applications was valued using the relief-from-royalty method, which applies a royalty rate to forecasted revenue. The difference in methodologies reveals that Broadcom views VMware-related developed technology as more closely tied to direct cash flows and core operations, while SoC controller technology is seen through the lens of licensing potential. This distinction underscores the strategic integration of VMware's cloud infrastructure as a core growth engine versus the more traditional, royalty-based monetization of storage controller IP.",
      "llm_answer": "Broadcom valued its developed technology for the SoC controller business using the relief‑from‑royalty method (a royalty rate applied to forecasted revenue) and assigned it a weighted‑average amortization period of 11 years, whereas the developed technology acquired in the VMware Cloud Foundation acquisition was valued using the multi‑period excess‑earnings method and carries a shorter weighted‑average amortization of 8 years. This contrast shows that the SoC controller assets are treated as mature, revenue‑generating intangibles with longer useful lives, while the VMware Cloud Foundation technology is viewed as a strategic, growth‑oriented asset that will be amortized more quickly as its product lifecycle progresses. Consequently, the differing methodologies and amortization periods reflect the strategic priority of accelerating value capture from the Cloud Foundation platform to support Broadcom’s broader cloud‑infrastructure strategy, whereas the SoC controller intangibles are positioned as a stable, cash‑generating foundation for its semiconductor business.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 58263,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14816,
        "completion_tokens": 269,
        "total_tokens": 15085
      }
    },
    {
      "question_id": 59,
      "question": "What is the relationship between CVS's $266 million investment in Common Collective Trusts and the guaranteed obligations of $1.3 billion in Separate Accounts assets, and how does the role of Common Collective Trusts within Separate Accounts inform the risk profile of this pension-related guarantee?",
      "original_answer": "CVS reports a $266 million investment in Common Collective Trusts as part of its pension investments on page 166. These Common Collective Trusts are further described on page 151 as components of Separate Accounts assets, which are used to fund large case pension products where contract holders bear the investment risk. On page 177, CVS discloses that it guarantees certain Separate Accounts assets totaling $1.3 billion, which are contractually required to fund specific pension annuities. Since Common Collective Trusts are part of these Separate Accounts, the performance and valuation of these trusts directly influence the ability of contract holders to maintain required funding levels. If the value of investments like the Common Collective Trusts declines, the Company may be obligated to cover shortfalls, thereby increasing its financial exposure under these guarantees.",
      "llm_answer": "The $266 million investment by CVS in Common Collective Trusts is part of the Separate Accounts structure that holds roughly $1.3 billion of guaranteed pension obligations; these trusts are classified as Level 2 fair‑value assets within the Separate Accounts, meaning their valuations rely on observable inputs from underlying funds. Because the trusts’ underlying investments are primarily equity securities and the guarantees are tied to the performance of those assets, the risk profile of the pension guarantee is directly linked to market fluctuations in the trust holdings, exposing the Company to investment‑return risk that could affect its ability to meet the $1.3 billion contractual obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 177,
          "pages": [
            175,
            176,
            177,
            178,
            179
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70304,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17837,
        "completion_tokens": 176,
        "total_tokens": 18013
      }
    },
    {
      "question_id": 59,
      "question": "How does Capital One's exposure to the Expanded Risk-Based Approach, introduced by the Basel III Finalization Proposal, affect its CET1 capital requirements under the proposed phase-in timeline?",
      "original_answer": "Capital One is subject to the Basel III Finalization Proposal, which introduces the Expanded Risk-Based Approach for calculating risk-weighted assets. This approach would require Capital One to calculate its risk-based capital ratios under both the Expanded Risk-Based Approach and the existing Basel III standardized approach, being bound by the lower of the two ratios. The proposal also mandates that Category III and IV institutions like Capital One recognize certain elements of AOCI, including unrealized gains and losses on available-for-sale securities, in CET1 capital starting July 1, 2025, with a three-year phase-in period. This change could lead to greater volatility in CET1 capital and may constrain capital flexibility during the phase-in period, especially if AOCI values decline. The final impact remains uncertain due to the proposal's pending status and potential modifications before adoption.",
      "llm_answer": "Based on the Basel III Finalization Proposal discussed on pages 118‑123, the Expanded Risk‑Based Approach would require Capital One to calculate risk‑weighted assets under both the new framework and the existing standardized approach, and to use the lower resulting ratio for all capital‑buffer requirements. The proposal also phases in the recognition of AOCI in CET1 capital and other changes to CET1 deductions, with a proposed effective date of July 1 2025 and a three‑year transition through July 1 2028. Consequently, under the proposed phase‑in timeline, Capital One’s CET1 capital requirements would be adjusted downward initially (due to the transition rules and AOCI treatment) but would eventually reflect the more stringent risk‑weighting of the Expanded Risk‑Based Approach, potentially raising the effective CET1 ratio needed to meet regulatory minimums.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "COF_10k_2024.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 63829,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16185,
        "completion_tokens": 217,
        "total_tokens": 16402
      }
    },
    {
      "question_id": 59,
      "question": "What explains the 131.7% increase in wholesale revenues from sales to affiliated companies in 2024, and how does this revenue shift align with the cost-sharing mechanisms outlined under the IIC framework administered by SCS?",
      "original_answer": "The 131.7% increase in wholesale revenues from sales to affiliated companies in 2024 was primarily due to a 165.5% increase in the volume of KWH sales, driven by higher energy demand from affiliated companies. This revenue shift aligns with the IIC framework, which governs how power pool transactions are managed across Southern Company’s integrated system. Under the IIC, SCS administers the coordinated operation of electric facilities, including centralized economic dispatch and the proportionate sharing of costs and revenues from power pool transactions. This structured coordination facilitates the internal reallocation of energy resources, directly influencing the volume and value of intercompany sales, and ensures that costs and revenues are shared according to predefined mechanisms. Therefore, the significant increase in affiliate revenues reflects both operational dynamics and the structured cost and revenue allocation under the IIC, as executed by SCS.",
      "llm_answer": "The 131.7% surge in wholesale revenues from sales to affiliated companies in 2024 stems from a 165.5% jump in volume of kilowatt-hour sales to affiliates, driven by heightened energy demand within the Southern Company power pool under the IIC framework. This revenue shift aligns with the IIC’s cost-sharing mechanism, where affiliated entities recover specified costs and share revenues from power pool transactions administered by SCS, ensuring that surplus energy sold to partners like Georgia Power and Mississippi Power is compensated through the centralized economic dispatch system while maintaining each company’s lowest-cost resource retention.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 66125,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16770,
        "completion_tokens": 163,
        "total_tokens": 16933
      }
    },
    {
      "question_id": 60,
      "question": "How does the voting structure of Class A Common Stock relate to the book value of Series B Preferred Stock, and what implications does this have for shareholder influence in key corporate decisions?",
      "original_answer": "The Class A Common Stockholders have full voting rights on all matters on which stockholders generally are entitled to vote, whereas Series B Preferred Stockholders have no voting rights except in limited circumstances, such as specific merger or consolidation scenarios. As of September 30, 2024, there were 1,733 shares of Class A Common Stock issued and outstanding, giving these shareholders significant influence over corporate governance. Meanwhile, the Series B Preferred Stock had a book value of $540 million as of the same date, but holders of this stock do not participate in general voting, which limits their influence on strategic decisions. This structure implies that holders of Class A Common Stock maintain control over major corporate actions, even though Series B Preferred Stock has economic value but no corresponding voting power.",
      "llm_answer": "The voting structure of class A common stock is tied to the book value of the series B preferred stock: class A holders receive one vote per share, while series B (and series C) preferred shareholders have limited voting rights that apply only to specific matters such as certain mergers or amendments affecting their preferences. Because the conversion rate of the preferred stock can adjust the number of as‑converted class A shares, changes in the book value of the series B preferred stock affect the effective voting power of class A holders in key corporate decisions. Consequently, any shift in the preferred‑stock book value can alter the influence that class A shareholders wield over matters that require a vote.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103511,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26107,
        "completion_tokens": 180,
        "total_tokens": 26287
      }
    },
    {
      "question_id": 60,
      "question": "How does MO's reliance on regulatory authorizations for future revenue growth from innovative tobacco products, particularly in relation to Horizon's commercialization efforts, reconcile with the uncertainty surrounding the FDA's PMTA review timelines and Horizon's strategic importance as a joint venture with JTIUH?",
      "original_answer": "MO identifies regulatory authorizations as a critical factor for the success of Horizon, which is a joint venture with JTIUH aimed at commercializing heat-not-burn tobacco products (HTS) in the U.S. The company acknowledges that Horizon's ability to generate new revenue streams is heavily dependent on receiving these authorizations. However, MO also highlights the unpredictability of the FDA's PMTA review process, which could delay product launches and allow competitors to capture market share. This uncertainty contrasts with Horizon's strategic importance as MO's primary vehicle for entering the HTS market, as emphasized in the MD&A section where Horizon is described as a majority-owned joint venture central to the company's 'Moving Beyond Smoking' initiative. The sensitivity of Horizon's revenue potential to regulatory timelines raises concerns about MO's ability to meet its long-term financial forecasts, especially given that a 1% increase in the discount rate used in the 2024 impairment test could have triggered a $125 million impairment charge for the e-vapor reporting unit, indicating high sensitivity to forecast assumptions.",
      "llm_answer": "MO's reliance on regulatory authorizations for future revenue growth from innovative tobacco products, particularly Horizon's commercialization, is directly tied to the uncertainty of FDA PMTA review timelines, which could delay or prevent market entry for products like NJOY ACE. This uncertainty poses a material risk to Horizon's strategic importance as a joint venture with JTIUH, as regulatory delays could undermine its ability to generate anticipated revenue streams and impact the company's ability to achieve its 2028 goals for smoke-free product growth.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2024.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84757,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21450,
        "completion_tokens": 140,
        "total_tokens": 21590
      }
    },
    {
      "question_id": 60,
      "question": "How does Microsoft's OEM distribution strategy for Office relate to its competitive positioning against Meta in the productivity and collaboration software market, given Meta's presence in adjacent digital platforms that could encroach on enterprise productivity tools?",
      "original_answer": "Microsoft leverages its broad OEM distribution network, which includes major partners like Dell, HP, and Lenovo, to pre-install Office on new devices, ensuring widespread adoption and integration into enterprise workflows. This distribution model strengthens Office's entrenched position in the productivity software market, which directly competes with offerings from Meta and other tech companies. Meta is mentioned as a competitor to Office due to its growing presence in digital collaboration and communication platforms, particularly through social and messaging tools that could serve as informal productivity hubs. Meanwhile, Microsoft's broader product and service development strategy, led by the 'Experiences and Devices' engineering group, includes Office as a central component in its end-user experiences, reinforcing its differentiation against Meta. Thus, the OEM-driven reach of Office, combined with Microsoft's integrated product development approach, forms a key part of its competitive defense against Meta's expansion into adjacent productivity domains.",
      "llm_answer": "Microsoft's OEM distribution strategy for Office – primarily through pre‑installing Microsoft 365 (formerly Office 365) on devices sold by OEMs and bundling it with Windows licensing – reinforces its competitive positioning against Meta by embedding the Office suite directly into the hardware and software ecosystems that enterprises and consumers use. This deep integration, coupled with Microsoft’s broader productivity and collaboration platform (Teams, Viva, LinkedIn, Dynamics 365) and its cloud‑based services, creates a sticky, end‑to‑end solution that makes it harder for Meta’s adjacent social‑media and messaging tools to displace Microsoft’s entrenched productivity offering.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 61762,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15686,
        "completion_tokens": 171,
        "total_tokens": 15858
      }
    },
    {
      "question_id": 60,
      "question": "How does Cisco's financing of technical support services relate to the $53 million credit loss allowance for loan receivables as of July 29, 2023, and what risk exposure does this represent given the $27.9 billion in channel partner financing from fiscal 2022?",
      "original_answer": "Cisco provides technical support services as part of its financing arrangements, which include loan receivables tied to the sale of hardware, software, and services (including technical support). These loan receivables are subject to credit risk, as evidenced by the $53 million allowance for credit losses on loan receivables as of July 29, 2023. This allowance reflects the company's estimate of potential defaults on these financing arrangements. Given that technical support services are embedded in loan packages, any credit risk associated with loan defaults indirectly affects the risk profile of services like technical support. Furthermore, in fiscal 2022, the volume of channel partner financing was $27.9 billion, with $1.7 billion of that amount subject to guarantees by Cisco as of July 29, 2023. This indicates that Cisco retains contingent liability exposure on financing arrangements that include technical support services, which could impact the credit loss allowance if defaults occur.",
      "llm_answer": "Cisco’s financing of technical support services is recorded as part of its loan receivables, which totaled $5.8 billion (gross) as of July 27 2024 and carried an allowance for credit losses of $50 million. This allowance represents the company’s estimate of uncollectible amounts from customers who receive technical‑support financing, and it is included in the overall $53 million credit‑loss provision disclosed for loan receivables in fiscal 2023.  \n\nThe exposure related to channel‑partner financing is substantial: Cisco reported $27.9 billion of channel‑partner financing arrangements in fiscal 2022, and the related guarantees and deferred revenue represent a potential liability if customers or partners default. Combined with the $53 million allowance for loan‑receivable credit losses, this creates a risk that a significant portion of the $27.9 billion in channel financing could become uncollectible, especially if economic conditions deteriorate or payment terms become delinquent.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75740,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19179,
        "completion_tokens": 248,
        "total_tokens": 19428
      }
    },
    {
      "question_id": 60,
      "question": "How does the allocation of $21.7 billion in 2023 stock-based compensation expenses tied to Class C stock awards reconcile with the company's repurchase strategy for Class A shares, given the identical dividend and liquidation rights between these classes?",
      "original_answer": "The $21.7 billion in 2023 stock-based compensation expenses under the Alphabet 2021 Stock Plan primarily involves Class C stock awards, which contributes to dilution pressure from RSUs vesting over time. To offset this dilution and optimize shareholder value, Alphabet repurchases both Class A and Class C shares based on market conditions and relative trading prices. Despite differing voting rights, both share classes have identical dividend and liquidation rights, ensuring equitable treatment in earnings allocation. The repurchase strategy for Class A shares, therefore, complements the company's broader capital allocation approach by balancing the dilutive impact of Class C stock awards while maintaining proportionate value distribution across share classes.",
      "llm_answer": "The $21.7 billion of 2023 stock‑based compensation expense tied to Class C stock awards is recorded as a charge against earnings that is allocated to Class A, B and C stock on a pro‑rata basis because the three classes have identical dividend and liquidation rights; consequently, the expense is reflected in the undistributed earnings allocation for each class and ultimately reduces the per‑share earnings of Class C stock in the same proportion as the other classes. This allocation is consistent with the company’s share‑repurchase program, which authorizes purchases of both Class A and Class C shares and treats them identically in terms of economic cost and market conditions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 83,
          "pages": [
            81,
            82,
            83,
            84,
            85
          ]
        },
        "hop_2_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "hop_3_rel": {
          "source_file": "GOOGL_10k_2023.pdf",
          "target_page": 81,
          "pages": [
            79,
            80,
            81,
            82,
            83
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 90436,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22847,
        "completion_tokens": 170,
        "total_tokens": 23018
      }
    },
    {
      "question_id": 60,
      "question": "How does UPS's increase in contributions to the New England Teamsters & Trucking Industry Pension Fund from $145 million in 2021 to $234 million in 2023 align with the financial improvement plan's requirements, given the fund's continued red zone status in both years?",
      "original_answer": "UPS's contributions to the New England Teamsters & Trucking Industry Pension Fund increased significantly from $145 million in 2021 to $234 million in 2023. According to page 95, this pension fund has remained in the red zone status in both 2022 and 2023, indicating severe underfunding. Page 94 clarifies that UPS's collectively-bargained contributions satisfy the requirements of all implemented financial improvement plans (FIPs) and that no surcharges are currently required. The increase in contributions aligns with the FIP's requirements for red zone plans, which typically mandate higher employer contributions to address funding deficiencies. Despite the fund remaining in the red zone, UPS's increased contributions reflect compliance with the FIP's mandated funding levels without triggering additional surcharges, suggesting a structured approach to addressing the pension fund's financial distress.",
      "llm_answer": "UPS’s contributions to the New England Teamsters & Trucking Industry Pension Fund rose from $145 million in 2021 to $234 million in 2023, reflecting the fund’s continued red‑zone status and the implementation of its financial improvement plan; the company’s agreed‑upon contributions satisfy the plan’s FIP/RP requirements and are not subject to additional surcharges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22194,
        "completion_tokens": 92,
        "total_tokens": 22286
      }
    },
    {
      "question_id": 60,
      "question": "Given Gilead's decision in January 2024 to discontinue enrollment in the Phase 3 NSCLC trial for the zimberelimab/domvanalimab combination, how does this clinical development strategy align with the long-term commercial potential of domvanalimab, which retains U.S. and EU patent protection until 2037?",
      "original_answer": "Gilead’s decision to halt enrollment in the Phase 3 NSCLC trial for the zimberelimab/domvanalimab combination suggests a strategic reassessment of the clinical viability or competitive positioning of this regimen in a key oncology indication. Despite this setback, domvanalimab remains protected by patents in both the U.S. and EU through 2037, preserving a long runway for potential development in alternative indications or combination strategies. This creates a tension between the near-term discontinuation decision—likely based on interim data, competitive landscape, or cost-benefit analysis—and the long-term asset value implied by the patent timeline. The continuation of patent protection opens the door for Gilead to pivot the development strategy for domvanalimab, potentially in other tumor types or in combination with other therapies, even if the NSCLC indication is deprioritized.",
      "llm_answer": "Gilead’s January 2024 decision to halt enrollment in the Phase 3 NSCLC trial for the zimberelimab/domvanalimab combination does not diminish the long‑term commercial outlook for domvanalimab, which remains protected by U.S. and EU patents extending to 2037; the company continues to advance the antibody as part of its oncology pipeline and retains strong patent‑based exclusivity for the foreseeable future.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2023.pdf",
          "target_page": 8,
          "pages": [
            6,
            7,
            8,
            9,
            10
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 88006,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22249,
        "completion_tokens": 102,
        "total_tokens": 22351
      }
    },
    {
      "question_id": 60,
      "question": "Given UPS's reliance on net asset value (NAV) to estimate the fair value of its U.S. pension plan investments, how does the company's exposure to private debt—valued at $829 million as of December 31, 2022—factor into the overall subjectivity and risk associated with NAV-based valuations for illiquid assets?",
      "original_answer": "UPS's U.S. pension plans held $9.9 billion in hedge fund, private debt, private equity, and real estate investments as of December 31, 2023, which were valued primarily using net asset value (NAV) from fund managers. Private debt, specifically, represented $829 million of the U.S. plan assets in 2022. These NAV-based valuations are inherently subjective due to the lack of readily determinable fair values and require management adjustments based on unaudited or audited reports received with a lag. Since private debt investments are illiquid and often lack active markets, their fair value estimates are particularly sensitive to assumptions and inputs used by fund managers. This subjectivity increases audit complexity and introduces valuation risk, especially given that unfunded commitments to such funds are expected to be contributed over the next 3–6 years, tying UPS to future capital obligations based on potentially uncertain valuations.",
      "llm_answer": "UPS’s pension assets include $948 million of private‑debt investments that are classified as Level 3 because they lack a readily determinable fair value and are valued using NAV‑based estimates. Because these illiquid assets rely on subjective, unobservable inputs to derive their NAV, they increase the overall estimation risk and subjectivity of the pension portfolio’s fair‑value measurement, amplifying potential volatility and audit complexity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74038,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18766,
        "completion_tokens": 112,
        "total_tokens": 18878
      }
    },
    {
      "question_id": 61,
      "question": "Why are forecasted foreign currency transactions included in Disney's foreign exchange hedging program but excluded from the Value at Risk (VAR) model, and how does this exclusion affect the company's overall assessment of financial risk exposure?",
      "original_answer": "Disney actively hedges forecasted foreign currency transactions as part of its foreign exchange risk management strategy, with $9.9 billion in notional amounts of net foreign exchange cash flow hedges as of September 28, 2024. These forecasted transactions are intended to be protected against exchange rate fluctuations through forward and option contracts. However, the company explicitly excludes forecasted transactions, firm commitments, and foreign currency receivables/payables from its Value at Risk (VAR) model, which focuses only on financial instruments like derivatives and market-sensitive equity investments. The VAR model estimates a maximum one-day loss of $255 million at fiscal year-end 2024. By excluding forecasted transactions from the VAR model, Disney does not incorporate the potential volatility or risk associated with these future transactions into its quantitative risk metric, even though they are actively hedged. This creates a divergence between the company's proactive hedging strategy and its formal risk measurement framework, suggesting that the VAR model may understate the full scope of foreign exchange risk the company manages.",
      "llm_answer": "The Company’s foreign‑exchange hedging program includes forecasted foreign‑currency transactions because those contracts are used to lock in rates for expected cash flows and therefore are part of the firm’s risk‑management strategy. However, the Value at Risk (VAR) model deliberately excludes those forecasted transactions—along with firm commitments and foreign‑currency receivables/payables—so that the VAR calculation reflects only existing, marked‑to‑market positions and not anticipated hedged exposures. Consequently, the VAR figure understates the full market‑risk exposure that the hedging program is designed to mitigate, and the company’s overall risk assessment must consider the excluded forecasted transactions separately from the VAR‑derived loss estimates.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67110,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17017,
        "completion_tokens": 193,
        "total_tokens": 17211
      }
    },
    {
      "question_id": 61,
      "question": "How does Southern Power's stated useful life for wind assets compare with the contract period duration for the Reading wind project, and what might this imply about the company's long-term revenue visibility from wind energy projects?",
      "original_answer": "Southern Power indicates that wind assets have a useful life of up to 30 years, yet the Reading wind project, located in Kansas, operates under a PPA contract period of only 12 years. This discrepancy suggests that while the company can utilize wind assets for an extended period, the revenue visibility from projects like Reading is significantly shorter, potentially requiring Southern Power to renegotiate or secure new contracts to fully capitalize on the asset's operational lifespan.",
      "llm_answer": "Southern Power's wind assets have a stated useful life of up to 30 years, while the Reading wind project's PPA contract period is 12 years. This shorter contract duration relative to the asset's useful life suggests limited long-term revenue visibility from wind energy projects, as the contractual revenue stream may expire before the asset's full economic life is realized.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71748,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18175,
        "completion_tokens": 93,
        "total_tokens": 18268
      }
    },
    {
      "question_id": 61,
      "question": "How does BlackRock's tax reconciliation disclosure for foreign jurisdictions like the UK relate to its non-GAAP presentation of separate account assets managed through BlackRock Life Limited, particularly in light of the economic separation of these assets from stockholders' equity?",
      "original_answer": "BlackRock reports in its tax reconciliation on page 105 that it earns income in foreign jurisdictions such as the UK, which have different statutory tax rates than the 21% U.S. federal rate. This international tax exposure includes operations through entities like BlackRock Life Limited, a UK-based life insurance subsidiary. On page 55, the company explains that BlackRock Life Limited holds separate account assets for pension contracts, which are legally segregated and not available to creditors or economically attributable to BlackRock, despite being consolidated under GAAP. The non-GAAP 'as adjusted' statement excludes these assets and liabilities, aligning with management’s view that they do not impact stockholders' equity or cash flows. Therefore, while the UK operations contribute to foreign taxable income, the economic and financial reporting treatment of BlackRock Life Limited’s separate accounts reflects a structural separation that limits direct financial exposure to these assets in BlackRock’s core equity position.",
      "llm_answer": "BlackRock’s tax reconciliation for foreign jurisdictions such as the UK is reflected in its “as‑adjusted” financial statements, which exclude the impact of separate‑account assets and liabilities (including those held by BlackRock Life Limited) that are economically isolated from stockholders’ equity. This separation means the foreign‑jurisdiction tax effects—e.g., the UK’s different statutory rate—are captured only in the adjusted tax expense and deferred tax balances, not in the equity‑level results, allowing the company to present a clearer view of the economic impact of its UK‑based separate‑account operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BLK_10k_2023.pdf",
          "target_page": 105,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        },
        "hop_2_rel": {
          "source_file": "BLK_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "BLK_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 99701,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25174,
        "completion_tokens": 155,
        "total_tokens": 25330
      }
    },
    {
      "question_id": 61,
      "question": "How does the $2,316 million impairment charge recorded by PMI on its investment in Rothmans, Benson & Hedges Inc. relate to the unresolved allocation issue under the CCAA Proposed Plan involving CAD 32.5 billion in aggregate settlement obligations?",
      "original_answer": "PMI recorded a $2,316 million non-cash impairment charge on its investment in Rothmans, Benson & Hedges Inc. (RBH) due to uncertainty and potential liability stemming from the unresolved allocation of the CAD 32.5 billion aggregate settlement amount under the CCAA Proposed Plan. This impairment reflects PMI’s assessment that the fair value of its investment had declined below its carrying value, primarily driven by the risk that RBH could be allocated a significant portion of the global settlement. The CCAA process, which RBH entered in 2019, resulted in deconsolidation and a shift to equity method accounting, and the Proposed Plan filed in October 2024 introduced new impairment indicators due to the unresolved allocation issue among RBH, ITL, and JTIM. The impairment decision was based on a discounted cash flow analysis that incorporated estimates of future sales, margins, and the likely share of the CAD 32.5 billion settlement allocated to RBH.",
      "llm_answer": "The $2,316 million impairment charge reflects PMI’s assessment that the fair value of its remaining stake in Rothmans, Benson & Hedges (RBH) is lower than its carrying amount, driven largely by the unresolved allocation of the CAD 32.5 billion settlement amount among RBH, Imperial Tobacco Canada and JTI‑Macdonald under the CCAA‑Proposed Plan. Because the settlement‑allocation issue remains unsettled, PMI concluded that the investment was impaired and recorded the charge as a subsequent‑event adjustment in 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81181,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20536,
        "completion_tokens": 129,
        "total_tokens": 20665
      }
    },
    {
      "question_id": 62,
      "question": "How does Altria's reliance on PM USA's unconditional guarantees for $1.0 billion in new senior notes issued in November 2023 align with the financial obligations and liquidity commitments PM USA itself faces, including $3.4 billion in annual State Settlement Agreement payments?",
      "original_answer": "Altria issued $1.0 billion in new senior notes in November 2023, which are unconditionally guaranteed by PM USA. These guarantees expose PM USA to significant financial obligations, as it is a 100% owned subsidiary responsible for Altria's debt payments. At the same time, PM USA itself faces substantial liquidity commitments, including an average of $3.4 billion in annual payments under State Settlement Agreements through 2024. This creates a dual financial strain, where PM USA must both guarantee Altria's new debt and meet its own large-scale obligations, raising concerns about its capacity to manage both without impacting cash flow or creditworthiness.",
      "llm_answer": "Altria’s reliance on PM USA’s unconditional guarantees for the $1 billion of senior notes issued in November 2023 is consistent with PM USA’s broader financial obligations, as the guarantees cover all of PM USA’s debt‑related commitments, including its $3.4 billion annual State Settlement Agreement payments and other contractual liabilities. The guarantees remain in force regardless of PM USA’s own liquidity position, ensuring that Altria can meet the note obligations even if PM USA’s cash flows are strained by those settlement payments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82136,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20780,
        "completion_tokens": 135,
        "total_tokens": 20916
      }
    },
    {
      "question_id": 62,
      "question": "How does the $24 million earnings impact from regulatory disallowances at Nicor Gas, disclosed in the MD&A section, reconcile with the $96 million pre-tax charges associated with disallowed capital investments at Nicor Gas in the financial statement footnotes?",
      "original_answer": "The $24 million earnings impact mentioned in the MD&A section on page 86 reflects the net effect of various items, including regulatory disallowances at Nicor Gas. This figure is partially offset by other earnings drivers. In contrast, the $96 million pre-tax charges disclosed in the footnotes on page 302 represent the gross financial impact of disallowed capital investments at Nicor Gas. The difference in magnitude and presentation—net versus gross—highlights how the same regulatory disallowance issue is quantitatively framed differently depending on the document section, with MD&A providing a consolidated earnings view and the footnotes offering detailed cost breakdowns.",
      "llm_answer": "The $24 million earnings impact disclosed in the MD&A reflects the estimated loss recorded for the regulatory disallowance of certain capital investments at Nicor Gas, while the footnote footnote 2 notes that the full pre‑tax charge related to those disallowed investments totals $96 million. Thus, the $24 million figure represents the portion of that $96 million charge that was recognized in earnings during the period, with the remainder accounted for in other balance‑sheet or tax adjustments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 302,
          "pages": [
            300,
            301,
            302,
            303,
            304
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69904,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17719,
        "completion_tokens": 124,
        "total_tokens": 17843
      }
    },
    {
      "question_id": 62,
      "question": "How does PM's impairment charge of $2,316 million for its investment in Rothmans, Benson & Hedges Inc. relate to the unresolved allocation of the CAD 32.5 billion CCAA settlement among RBH, ITL, and JTIM, and what does this indicate about the financial exposure and strategic implications for PM despite the deconsolidation of RBH from its financial statements?",
      "original_answer": "PM recorded a $2,316 million non-cash impairment charge for its investment in Rothmans, Benson & Hedges Inc. (RBH) due to the uncertainty and potential financial liability stemming from the unresolved allocation of the CAD 32.5 billion CCAA settlement among RBH, ITL, and JTIM. Despite RBH being deconsolidated from PM's financial statements since 2019, the company still faces significant financial exposure through its continuing investment in RBH, which is tied to the outcome of the Proposed Plan under the CCAA proceedings. The unresolved Allocation Issue creates uncertainty in estimating PM's ultimate liability or financial impact, which affects the fair value of PM's investment in RBH and results in a material impairment. This illustrates that even though RBH is no longer consolidated, PM remains strategically and financially exposed to its Canadian subsidiary's litigation and restructuring outcomes.",
      "llm_answer": "The $2,316 million impairment charge reflects that, after de‑consolidating RBH, PMI concluded that the fair value of its remaining equity stake was lower than its carrying amount, largely because the unresolved allocation of the CAD 32.5 billion settlement among RBH, ITL and JTIM creates a material contingent liability that could diminish the investment’s value. This exposure shows that, despite no longer consolidating RBH, PMI remains financially tied to the settlement outcome and may still be required to fund a portion of the global settlement, limiting its strategic flexibility and increasing the risk that any adverse ruling or payment obligation could affect its overall earnings and capital allocation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81181,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20564,
        "completion_tokens": 178,
        "total_tokens": 20743
      }
    },
    {
      "question_id": 63,
      "question": "How does the $2,316 million non-cash impairment charge recorded by PMI for its investment in Rothmans, Benson & Hedges Inc. relate to the unresolved allocation issue under the CCAA Proposed Plan involving a CAD 32.5 billion global settlement amount?",
      "original_answer": "PMI recorded a $2,316 million non-cash impairment charge for its investment in Rothmans, Benson & Hedges Inc. (RBH) due to uncertainty and developments regarding the unresolved allocation of the CAD 32.5 billion global settlement amount under the CCAA Proposed Plan. The CCAA proceedings, initiated by RBH in 2019, resulted in PMI deconsolidating RBH and accounting for its investment as an equity security. As of December 31, 2024, PMI determined that the fair value of its investment was significantly lower than its carrying value, primarily due to the unresolved allocation issue among RBH, ITL, and JTIM under the Proposed Plan. Despite the lack of an agreed allocation or court ruling, PMI used estimates and assumptions—such as the allocation share of RBH, sales volumes, and operating margins—to calculate the impairment. Thus, the impairment charge directly reflects PMI’s assessment of the financial impact of the unresolved CCAA settlement allocation.",
      "llm_answer": "The $2,316 million non‑cash impairment charge reflects the write‑down of PMI’s investment in Rothmans, Benson & Hedges (RBH) after PMI concluded that the fair value of its RBH stake was lower than its carrying amount, largely because the unresolved allocation of the CAD 32.5 billion global settlement—under the CCAA‑Proposed Plan—creates a significant uncertainty that depresses the investment’s recoverable value. This impairment underscores how the pending settlement negotiations directly affect the valuation of PMI’s continuing interest in RBH.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 130,
          "pages": [
            128,
            129,
            130,
            131,
            132
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 99,
          "pages": [
            97,
            98,
            99,
            100,
            101
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 81181,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20536,
        "completion_tokens": 137,
        "total_tokens": 20673
      }
    },
    {
      "question_id": 63,
      "question": "How does NEE's disclosure of its Special Use Funds' fair value treatment on the balance sheet reconcile with the regulatory exposure of Nuclear Decommissioning Reserve Funds to potential future funding mandates by the NRC and NDFC?",
      "original_answer": "NEE reports that its Special Use Funds, which include Nuclear Decommissioning Reserve Funds, are primarily composed of marketable securities carried at fair value (with market adjustments for debt securities generally flowing through other comprehensive income). These funds support future decommissioning expenditures for Seabrook, Duane Arnold, and Point Beach. However, despite no current ongoing funding requirements, the NRC and NDFC retain the authority to mandate additional contributions in the future. This regulatory risk is not quantified in the fair value disclosures, creating a potential misalignment between the reported value of the funds and the future obligations that may be imposed by regulators, which could significantly impact NEE's liquidity and capital planning.",
      "llm_answer": "NEE’s Special Use Funds—including the Nuclear Decommissioning Reserve Fund—are recorded on the balance sheet at fair value, with market‑valued securities and fund earnings reflected as regulatory assets or liabilities. Because these funds are subject to potential future NRC and NDFC mandates that could require additional decommissioning financing, any shortfall between the fair‑value balance and the amount needed to meet those mandates would create a regulatory liability (or asset) that must be recognized and could affect future funding requirements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 112210,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 28287,
        "completion_tokens": 139,
        "total_tokens": 28426
      }
    },
    {
      "question_id": 63,
      "question": "How does the $122 million pre-tax gain from acquiring Sabra align with PepsiCo's strategic emphasis on branded dips within Frito-Lay North America?",
      "original_answer": "PepsiCo acquired the remaining 50% ownership in Sabra Dipping Company for $241 million, resulting in a $122 million pre-tax gain. This acquisition made Sabra a wholly-owned subsidiary, which aligns with PepsiCo's strategic focus on branded dips under Frito-Lay North America (FLNA), as Sabra is known for its refrigerated dips and spreads. FLNA’s portfolio includes branded dips, and the integration of Sabra strengthens this segment. The pre-tax gain may provide additional financial flexibility to invest in or expand FLNA’s branded dip offerings, reinforcing the company’s strategic emphasis on this category.",
      "llm_answer": "The $122 million pre‑tax gain from acquiring Sabra is recorded in the Frito‑Lay North America (FLNA) division and is reflected in selling, general and administrative expenses. This gain aligns with PepsiCo’s strategic focus on expanding branded dips within FLNA, reinforcing its branded‑dip portfolio and growth objectives in that segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "PEP_10k_2024.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62054,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15727,
        "completion_tokens": 84,
        "total_tokens": 15812
      }
    },
    {
      "question_id": 64,
      "question": "How does Morgan Stanley's governance structure, including both the Board-level Risk Committee (BRC) and the Climate Risk Committee, specifically address the operational risks to facilities and people posed by physical climate risks as outlined in its 2024 10-K?",
      "original_answer": "Morgan Stanley identifies physical climate risks—such as floods, hurricanes, and rising sea levels—as potential threats that could lead to increased operational risk by endangering its facilities and personnel. These risks are managed under an overarching Enterprise Risk Management (ERM) framework that integrates climate risk considerations into existing processes. The Board-level Risk Committee (BRC) oversees firmwide risks, including climate risk, and receives updates on scenario analysis and climate risk integration efforts. Additionally, the Climate Risk Committee, co-chaired by the Chief Risk Officer and Chief Sustainability Officer, shapes the firm’s approach to managing these risks in alignment with the overall risk framework. This dual governance structure ensures that physical climate risks are systematically translated into operational risk mitigation strategies at both strategic and tactical levels.",
      "llm_answer": "Morgan Stanley’s governance structure addresses physical climate‑risk threats to facilities and people through a dedicated Climate Risk Committee that is co‑chaired by the Chief Risk Officer and the Chief Sustainability Officer and reports to the Board‑level Risk Committee (BRC). The BRC oversees firm‑wide risks, including climate risk, and receives regular updates on scenario analysis and integration of climate considerations into the Firm’s risk‑management processes. Additionally, the Board’s Operations and Technology Committee (BOTC) monitors operational‑risk exposures—such as cyber‑attacks, natural disasters, and other disruptions—that could affect facilities and personnel, ensuring that resilience programs and business‑continuity plans are in place to mitigate physical climate impacts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "MS_10k_2024.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 73784,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18688,
        "completion_tokens": 200,
        "total_tokens": 18888
      }
    },
    {
      "question_id": 64,
      "question": "How does Amgen's equity stake in BeiGene, Ltd., acquired for $2.8 billion in 2020, influence the commercialization and competitive risk profile of KYPROLIS, especially given that KYPROLIS is a small molecule product vulnerable to generic competition and is already being sold by BeiGene in China under a profit-sharing arrangement?",
      "original_answer": "Amgen acquired a $2.8 billion equity stake in BeiGene, Ltd. in 2020 to expand its oncology presence in China. As part of the collaboration, BeiGene began selling KYPROLIS in China in 2022, with Amgen and BeiGene sharing profits and losses equally during the initial commercialization period. KYPROLIS, being a small molecule product, is particularly vulnerable to generic competition following patent expiration, as seen with Sensipar, where Amgen lost significant market share and revenue quickly after generic entry. This dual exposure—through both equity investment and joint commercialization—heightens Amgen's risk, as a loss of exclusivity for KYPROLIS could not only erode its own sales but also impact the financial returns from its strategic stake in BeiGene.",
      "llm_answer": "Amgen’s $2.8 billion equity stake in BeiGene gives it a commercial partnership in which BeiGene markets KYPROLIS in China under a profit‑sharing arrangement, but KYPROLIS remains a small‑molecule drug that is vulnerable to generic competition; consequently, the partnership does not eliminate the competitive risk that generic entrants could erode sales, especially since the product is already being sold by BeiGene in China and the equity investment does not confer control over BeiGene’s commercial decisions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 132,
          "pages": [
            130,
            131,
            132,
            133,
            134
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2024.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 82300,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20841,
        "completion_tokens": 128,
        "total_tokens": 20969
      }
    },
    {
      "question_id": 64,
      "question": "How does Gulfstream's anticipation of FAA certification for the G700 in early 2024, as described in the product development section, align with the financial implications of increased inventory and customer deposits reported in the financial section?",
      "original_answer": "Gulfstream's expectation that the G700 will enter service following FAA certification in early 2024 (from the product development section) directly informs the company's production ramp-up activities described in the financial section. This forward-looking certification timeline has led to a significant increase in total inventories during 2023, specifically tied to G700 production, in anticipation of certification. Simultaneously, customer deposits associated with firm orders for these new aircraft have increased, reflecting strong market interest and aligning with the strategic introduction of a next-generation model that features advanced technologies and performance capabilities.",
      "llm_answer": "Gulfstream's anticipation of FAA certification for the G700 in early 2024 is driving a ramp‑up of production and a build‑up of inventory, which is reflected in the higher carrying amounts of inventories and work‑in‑process reported in the financial statements.  At the same time, customer deposits tied to firm orders for the new aircraft have risen, increasing the balances of customer advances and deposits shown on the balance sheet.  Thus, the expected certification supports higher inventory levels and larger customer‑deposit liabilities, aligning the product‑development outlook with the financial impact of increased inventory and deposit amounts.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 46872,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 11956,
        "completion_tokens": 163,
        "total_tokens": 12120
      }
    },
    {
      "question_id": 64,
      "question": "What is the significance of consistently classifying debt investments as AFS across multiple Duke Energy subsidiaries, and how does this uniform accounting treatment impact the comparability of their respective investment portfolios?",
      "original_answer": "The consistent classification of debt investments as AFS across Duke Energy Carolinas (page 192), Duke Energy Florida, and Duke Energy Progress (page 194) indicates a standardized accounting policy for fixed-income securities within the regulated utility framework. This uniform treatment ensures that unrealized gains and losses on debt investments are recorded in other comprehensive income rather than net income, directly affecting how each subsidiary's financial performance is measured and compared. The identical disclosure language across subsidiaries suggests a coordinated approach to financial reporting, despite their separate regulatory environments.",
      "llm_answer": "The consistent classification of debt investments as Available-for-Sale (AFS) across Duke Energy’s subsidiaries ensures that unrealized gains and losses on these securities are recorded in other comprehensive income (OCI) until realized, maintaining uniformity in accounting treatment. This standardized approach enhances the comparability of investment portfolio performance across subsidiaries, as all entities use the same valuation methodology and reporting framework for AFS securities. Consequently, investors can reliably compare portfolio returns and risk profiles across Duke Energy’s subsidiaries, knowing that differences in reported gains or losses reflect actual market movements rather than accounting variations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 192,
          "pages": [
            190,
            191,
            192,
            193,
            194
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2022.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103391,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26082,
        "completion_tokens": 181,
        "total_tokens": 26263
      }
    },
    {
      "question_id": 64,
      "question": "What financial or operational responsibilities does Kyowa Kirin have under the AMG 451 collaboration, and how does this reflect Amgen's global development and commercialization strategy for the product outside of Japan?",
      "original_answer": "Under the collaboration agreement, Kyowa Kirin Co., Ltd. (KKC) co-promotes AMG 451 with Amgen in the United States and has opt-in rights to co-promote the product in various markets outside the U.S., including Europe and Asia. Amgen leads global development, manufacturing, and commercialization of AMG 451, except in Japan. This reflects Amgen's strategy to maintain control over the product's development and manufacturing while leveraging regional partners like KKC to expand commercial reach and share promotional responsibilities in key markets. The structure suggests Amgen aims to optimize resource allocation by engaging local partners for market access and commercial execution, while retaining central oversight of the product lifecycle.",
      "llm_answer": "Under the AMG 451 collaboration, Amgen leads global development, manufacturing and commercialization of the antibody (except in Japan), while Kyowa Kirin co‑promotes the product in the United States and has opt‑in rights to co‑promote it in other markets. Amgen pays KKC an upfront $400 million fee, shares global development costs equally (excluding Japan), reimburses KKC for commercialization costs incurred outside the U.S. and Japan, may owe up to $850 million in milestones, and pays double‑digit royalties on global sales (excluding Japan). This structure reflects Amgen’s broader global development and commercialization model—bearing primary R&D and commercialization expenses while leveraging partner co‑promotion and cost‑sharing arrangements to bring products to market worldwide.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 122,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 122,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76477,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19352,
        "completion_tokens": 198,
        "total_tokens": 19550
      }
    },
    {
      "question_id": 64,
      "question": "How does AIG's borrowing relationship with the FHLB of Dallas, including the $3,357 million in obligations due by 2027-2028, relate to the role of The Variable Annuity Life Insurance Company, which is a member of that FHLB and holds an A.M. Best rating of A?",
      "original_answer": "AIG's Life and Retirement segment has significant borrowing obligations tied to the FHLB of Dallas, including $3,357 million due between 2027 and 2028. These borrowings are secured through funding agreements issued by AIG's life insurance subsidiaries, including The Variable Annuity Life Insurance Company, which is a member of the FHLB of Dallas. Membership allows AIG to pledge assets—such as the $8.7 billion in collateral reported—as security for these obligations. The A.M. Best rating of A for The Variable Annuity Life Insurance Company suggests a strong credit profile, which likely supports AIG's ability to access favorable borrowing terms through the FHLB system. This interplay shows how AIG leverages the credit strength and FHLB membership of its insurance subsidiaries to manage liquidity and borrowing costs.",
      "llm_answer": "AIG’s borrowing relationship with the FHLB of Dallas includes $3,357 million of obligations due by 2027‑2028, which are backed by collateral pledged by The Variable Annuity Life Insurance Company (VA Life), a member of that FHLB that holds an A.M. Best rating of A. This collateral supports the FHLB borrowing capacity used by AIG’s Life and Retirement segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 109602,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 27644,
        "completion_tokens": 90,
        "total_tokens": 27735
      }
    },
    {
      "question_id": 65,
      "question": "How does MDLZ's use of exchange-traded commodity futures as Level 1 financial liabilities impact earnings volatility, given their stated hedging strategy for raw material price risk?",
      "original_answer": "MDLZ's exchange-traded commodity futures, classified as Level 1 financial liabilities and valued at $X (hypothetical placeholder for actual value from page 112), directly impact earnings volatility because these instruments are marked-to-market through earnings without the deferral benefits of hedge accounting. This creates tension with MDLZ's stated hedging strategy (page 94), where they use commodity futures to mitigate price risk on forecasted purchases of raw materials like cocoa, sugar, and wheat. Despite these hedging activities, the fair value changes in Level 1 commodity futures are immediately recognized in earnings, exposing MDLZ to short-term volatility even as they attempt to manage long-term input cost risks. This accounting treatment contrasts with their Level 2 instruments, which may be designated as hedges and have their fair value changes deferred through accumulated other comprehensive earnings.",
      "llm_answer": "MDLZ’s Level 1 exchange‑traded commodity futures are recorded at quoted market prices, so they are not marked‑to‑market through earnings; instead, the company uses them as part of its broader hedging program to offset raw‑material price volatility. Because these futures are classified as Level 1 assets, their fair‑value changes are relatively transparent and can add to earnings volatility only when gains or losses are realized or when hedge accounting fails, but the overall impact on earnings is limited by the company’s designated hedging strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 112,
          "pages": [
            110,
            111,
            112,
            113,
            114
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 69495,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17598,
        "completion_tokens": 138,
        "total_tokens": 17736
      }
    },
    {
      "question_id": 65,
      "question": "How does Disney's strategy of bundling ESPN+ with Disney+ and Hulu relate to the financial interdependencies between ESPN's programming costs and ABC Network's affiliate fee structure?",
      "original_answer": "Disney's strategy of bundling ESPN+ with Disney+ and Hulu aims to drive subscriber growth for ESPN+ by leveraging the broader Disney ecosystem. ESPN+ offers live sports and on-demand content, and as of September 2024, had approximately 26 million paid subscribers. This bundling strategy likely enhances ESPN+'s distribution and monetization potential through combined subscription models. Meanwhile, ABC Network pays ESPN for programming rights, as noted in the Sports segment section, where fees paid by ABC Network to ESPN are recognized in segment revenues and later eliminated in consolidation. ESPN's operating expenses include significant programming and production costs, particularly for licensed sports rights. The financial interdependency arises because ESPN's ability to secure and retain valuable sports rights depends on revenue generated through these internal arrangements with ABC Network and other Disney segments. Therefore, ESPN+'s subscriber growth strategy must be evaluated in the context of how ESPN's broader programming costs are subsidized by internal payments from ABC Network, which itself relies on affiliate fees charged to MVPDs for the right to deliver its programming, including content from ESPN.",
      "llm_answer": "Disney's bundling of ESPN+ with Disney+ and Hulu reflects the financial interdependencies between ESPN's programming costs and ABC Network's affiliate fee structure. Specifically, ESPN's high programming costs (e.g., $3.463B in domestic programming expenses in 2024) are offset by affiliate fee revenues from MVPDs for ESPN's linear networks, while bundling drives subscriber growth for Disney+ and Hulu, enhancing overall segment profitability and offsetting costs through cross-platform revenue synergies. This strategy leverages Disney's control over both content (ESPN) and distribution (ABC Network), ensuring stable affiliate fee income to support ESPN's expensive sports rights while expanding DTC revenue streams.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_2_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_3_rel": {
          "source_file": "DIS_10k_2024.pdf",
          "target_page": 78,
          "pages": [
            76,
            77,
            78,
            79,
            80
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62307,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15804,
        "completion_tokens": 180,
        "total_tokens": 15984
      }
    },
    {
      "question_id": 65,
      "question": "How does the increase in stock compensation expense for AspenTech stock-based plans in fiscal 2023 compared to 2022 relate to the overall growth in Emerson's total stock compensation expense from continuing operations during the same period?",
      "original_answer": "The increase in AspenTech stock-based compensation expense from $32 million in fiscal 2022 to $82 million in fiscal 2023 significantly contributed to the overall growth in Emerson's total stock compensation expense from continuing operations, which rose from $125 million in 2022 to $250 million in 2023. This indicates that AspenTech's compensation plans played a key role in driving the doubling of Emerson’s continuing stock-based compensation costs, reflecting the integration and expanded use of AspenTech’s plans post-acquisition.",
      "llm_answer": "The increase in AspenTech stock‑based compensation expense for fiscal 2023 versus 2022 was $165 million, and the overall growth in Emerson’s total stock‑compensation expense from continuing operations rose from $125 million in 2022 to $250 million in 2023 – a $125 million increase that reflects the additional AspenTech‑related compensation costs. Consequently, the $165 million rise in AspenTech expense contributed a substantial portion of the $125 million net increase in Emerson’s continuing‑operations stock‑compensation expense between the two years.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62114,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15766,
        "completion_tokens": 139,
        "total_tokens": 15905
      }
    },
    {
      "question_id": 65,
      "question": "How does Cyprus Mines Corporation's involvement in the Imerys bankruptcy mediation affect JNJ's $9 billion reserve for talc-related liabilities following the termination of the multi-state investigation mediation?",
      "original_answer": "Cyprus Mines Corporation, as a former owner of Imerys talc mines, is actively involved in the Imerys bankruptcy mediation, which seeks to resolve talc-related claims by channeling them into a trust along with Imerys’s indemnification rights against JNJ. This chain of liability could expose JNJ to future claims from the trust after initial payments are made by Imerys and Cyprus. Meanwhile, the multi-state investigation mediation involving 42 states was terminated in March 2023, with New Mexico and Mississippi proceeding in state court. This termination removes a centralized mechanism for resolving regulatory inquiries, potentially increasing JNJ’s exposure and complicating liability estimation. Since JNJ has already recorded a $9 billion reserve—of which approximately one-third is a current liability—this evolving legal landscape introduces uncertainty about whether the reserve remains sufficient, especially if additional claims or settlements emerge from either the Imerys/Cyprus mediation process or the ongoing state-level investigations.",
      "llm_answer": "The termination of the multi-state investigation mediation and Cyprus Mines’ involvement in the Imerys bankruptcy have no direct impact on JNJ’s $9 billion talc reserve; the reserve remains tied to the ongoing talc litigation and the company’s settlement strategy, not to the status of the mediation or the Cyprus‑Imerys bankruptcy proceedings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91651,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23139,
        "completion_tokens": 86,
        "total_tokens": 23225
      }
    },
    {
      "question_id": 65,
      "question": "How does Schwab's reliance on unsecured credit facilities provided by various external banks relate to TDAC's regulatory capital requirements, and what implications does this have for Schwab's risk exposure in maintaining liquidity under stress scenarios?",
      "original_answer": "Schwab depends on unsecured credit facilities totaling $600 million from various external banks, specifically for TDAC. This funding is critical for TDAC’s operations as a broker-dealer, which must comply with SEC net capital rules requiring it to maintain minimum net capital of the greater of 2% of aggregate debit balances or a minimum dollar requirement. At the same time, Schwab’s broader banking subsidiaries are considered 'well capitalized' under Basel III rules, which include buffers like the 2.5% capital conservation buffer. However, TDAC is not subject to Basel III but rather the SEC’s Uniform Net Capital Rule, making its capital adequacy dependent on brokerage-related liquidity and client transaction balances. Schwab’s reliance on external banks for TDAC’s credit facilities introduces counterparty risk and potential liquidity constraints during market stress, especially if TDAC fails to meet its regulatory capital thresholds or if external banks reduce available credit lines.",
      "llm_answer": "Schwab’s reliance on unsecured credit facilities from external banks—particularly the $600 million senior unsecured revolving line held by TDAC and the uncommitted unsecured lines accessed by CSC and CS&Co—creates a direct link to TDAC’s regulatory capital requirements because any draw on these facilities increases short‑term borrowings, which count toward the Tier 1 and Total Risk‑Based Capital ratios disclosed in the capital‑adequacy tables.  Consequently, under stressed scenarios where client cash outflows spike and the Liquidity Coverage Ratio falls, Schwab may need to tap these facilities, raising its leverage and potentially pushing capital ratios closer to the minimum thresholds (e.g., 4.5 % CET1, 6 % Tier 1, 8 % Total Capital), thereby heightening the risk that insufficient capital could impair its ability to meet regulatory requirements and maintain liquidity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_3_rel": {
          "source_file": "SCHW_10k_2022.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69093,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17515,
        "completion_tokens": 220,
        "total_tokens": 17736
      }
    },
    {
      "question_id": 65,
      "question": "How does Altria's commercial paper program relate to its November 2023 issuance of $1.0 billion in senior unsecured notes, particularly in light of PM USA's unconditional guarantee of the company's commercial paper obligations?",
      "original_answer": "Altria's commercial paper program, which is guaranteed by PM USA as noted on page 49, provides short-term liquidity to support the company's operations. This program is part of the broader capital structure that includes longer-term debt instruments like the $1.0 billion in senior unsecured notes issued in November 2023 (page 74). These notes, with maturities in 2028 and 2033 at interest rates of 6.200% and 6.875% respectively, are also guaranteed by PM USA. The unconditional guarantee from PM USA across both short-term (commercial paper) and long-term debt instruments enhances Altria's borrowing capacity and creditworthiness, allowing the company to access capital markets at favorable terms despite being a holding company that relies on subsidiary cash flows.",
      "llm_answer": "Altria's November 2023 $1 billion issuance of senior unsecured notes was funded in part through its commercial‑paper program, which is unconditionally guaranteed by PM USA. The guarantee ensures that any commercial‑paper obligations of Altria are backed by PM USA, providing additional security for the notes and reinforcing the company’s overall financing structure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82136,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20767,
        "completion_tokens": 91,
        "total_tokens": 20859
      }
    },
    {
      "question_id": 66,
      "question": "How does the limited voting rights structure of Series B Preferred Stock influence corporate governance dynamics in relation to the Class A Common Stock composition, given the $1,031 million book value of preferred stock and 1,733 million Class A shares outstanding?",
      "original_answer": "The Series B Preferred Stock has no voting rights except for specific defined matters such as mergers or changes in equity structure, where they vote as a separate class with limited scope (e.g., ensuring parity with Class A Common Stock in certain transactions). This restricted influence contrasts sharply with the broad voting rights of Class A Common Stockholders, who have the right to vote on all matters generally subject to shareholder approval. Given that the total book value of preferred stock is $1,031 million and there are 1,733 million Class A shares outstanding, the governance structure heavily favors Class A Common Stockholders, as they not only hold a larger number of shares but also wield comprehensive voting power, while preferred stockholders remain largely passive in decision-making outside narrowly defined scenarios.",
      "llm_answer": "The Series B Preferred Stock’s limited voting rights mean that, unlike the Class A common shares (1,733 million shares with full voting rights), holders of the Series B Preferred can only vote on a narrow set of matters—primarily certain consolidation, merger or charter‑amendment decisions—using the number of shares they hold as their voting power. This constrained voting structure limits the influence of Series B Preferred holders on broader corporate governance issues, even though the $1,031 million book value of the preferred stock and the 1,733 million Class A shares outstanding reflect significant equity stakes that could affect governance dynamics.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103511,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26124,
        "completion_tokens": 165,
        "total_tokens": 26289
      }
    },
    {
      "question_id": 66,
      "question": "How does the difference in voting rights between Class A and Class B common stock impact the concentration of corporate control, especially in light of Mr. Brian L. Roberts’ ownership of all outstanding Class B shares?",
      "original_answer": "The disparity in voting rights between Class A and Class B common stock significantly concentrates corporate control in the hands of Mr. Brian L. Roberts. Class A common stock, of which 4,842,108,959 shares were issued in 2023, grants voting rights that are dependent on the outstanding share count relative to Class B stock. In contrast, each share of Class B common stock carries 15 votes and represents approximately 33 1/3% of the combined voting power, a percentage that is non-dilutable under the company's articles of incorporation. Since Mr. Roberts owns all 9,444,375 outstanding shares of Class B common stock, he maintains outsized influence over key corporate decisions, including director elections, despite holding a minority of total shares. This structure ensures that his voting power remains structurally protected, regardless of share repurchases or changes in Class A ownership.",
      "llm_answer": "The Class B shares carry 15 votes per share and represent roughly one‑third of the combined voting power of all common stock, while Class A shares have one vote per share and make up the remaining two‑thirds. Because Mr. Brian L. Roberts owns all of the outstanding Class B shares, he controls about 33 % of the total voting power, giving him a decisive influence over major corporate decisions despite the smaller economic ownership stake. This structure concentrates corporate control in the hands of a single shareholder.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 58158,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14775,
        "completion_tokens": 131,
        "total_tokens": 14906
      }
    },
    {
      "question_id": 66,
      "question": "How does Southern Company's joint ownership structure of Plant Scherer Unit 3, in which Florida Power & Light holds a 25% stake, influence Georgia Power's 2025 Integrated Resource Plan request to extend the unit's operation through at least December 31, 2035?",
      "original_answer": "Southern Company's subsidiaries, including Georgia Power and Mississippi Power, operate under a complex joint ownership structure where multiple entities hold stakes in shared generation assets. Plant Scherer Unit 3 is owned 75% by Georgia Power and 25% by FP&L (as shown in the ownership table). This joint ownership arrangement means Georgia Power does not have unilateral control over the asset. Despite this, Georgia Power included a request in its 2025 IRP to extend Plant Scherer Unit 3's operation through at least December 31, 2035. The inclusion of this request in the IRP filing with the Georgia PSC suggests that Georgia Power is seeking regulatory support and alignment with FP&L to maintain the unit’s operational life, which is critical for meeting long-term generation reliability and capacity needs. The request also aligns with broader strategic goals to maintain dispatchable generation capacity while navigating environmental compliance requirements.",
      "llm_answer": "Southern Company’s 2025 IRP (filed Jan. 31 2025) asks the Georgia PSC to approve extending Plant Scherer Unit 3—of which Georgia Power holds a 75 % stake and Florida Power & Light owns 25 %—through at least Dec 31 2035.  The plan ties this extension to the unit’s continued economic viability and to the need for additional capacity in Georgia Power’s resource mix, and it will be reviewed by the Georgia PSC (decision expected July 2025).  Thus, the joint ownership arrangement gives Georgia Power a strong incentive to keep the unit operating beyond 2035, but the final approval rests with the regulator.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 45,
          "pages": [
            43,
            44,
            45,
            46,
            47
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 79477,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20117,
        "completion_tokens": 151,
        "total_tokens": 20268
      }
    },
    {
      "question_id": 67,
      "question": "How does Altria's reliance on its Commercial Paper Program, which is guaranteed by PM USA, affect its financial risk profile given PM USA's unconditional guarantee obligations and its role as a 100% owned subsidiary?",
      "original_answer": "Altria's reliance on its Commercial Paper Program introduces financial risk due to its dependence on PM USA's unconditional guarantees to support short-term liquidity needs. PM USA, as a 100% owned subsidiary, fully and unconditionally guarantees Altria's obligations under the commercial paper program, making it directly liable for any defaults. However, PM USA also faces significant fixed obligations, including $3.4 billion in annual payments related to State Settlement Agreements and FDA user fees, which could constrain its ability to fulfill guarantee obligations if cash flows are strained. This interdependency increases Altria's financial risk, as the parent company's access to operating cash flows is contingent on PM USA's financial health and its capacity to meet both its guaranteed obligations and its own fixed commitments.",
      "llm_answer": "Altria’s reliance on its Commercial Paper Program, which is fully guaranteed by its 100% owned subsidiary PM USA, creates a direct contingent liability for the parent company. Because PM USA’s guarantee is unconditional and absolute—covering all of Altria’s debt obligations under the program regardless of circumstances—any default by Altria on its commercial paper borrowings would immediately trigger PM USA’s payment obligation. This structure amplifies Altria’s financial risk, as the parent could be required to fund short‑term liquidity needs of the operating subsidiaries through its guaranteed program, potentially straining cash flows if market access tightens or if the subsidiary’s creditworthiness is questioned. Nonetheless, the guarantee also provides investors with comfort that Altria’s short‑term borrowing costs remain low, since the program’s debt is backed by the full faith and credit of a financially strong, consolidated subsidiary.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 74,
          "pages": [
            72,
            73,
            74,
            75,
            76
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82136,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20765,
        "completion_tokens": 239,
        "total_tokens": 21004
      }
    },
    {
      "question_id": 67,
      "question": "Given that BMY completed its acquisition of Celgene in November 2019, how might the ongoing litigation with Molina—initiated in May 2021 over claims related to Thalomid and Revlimid—affect BMY's financial exposure, particularly since these liabilities arose after the acquisition was finalized and are not included in the initial valuation?",
      "original_answer": "The litigation with Molina, which began in May 2021, centers on claims related to Celgene’s products Thalomid and Revlimid. Since the acquisition of Celgene by BMY was finalized in November 2019, these liabilities arose post-acquisition and would not have been included in the initial fair value assessment of assets and liabilities assumed at the time of the $35.7 billion transaction. As a result, any potential damages or settlements from this litigation would directly impact BMY’s current financial position rather than being absorbed as part of the acquisition accounting. The complaint also references off-label marketing allegations, which could carry significant financial or reputational risks, further exposing BMY to unforeseen costs not accounted for in the original acquisition valuation.",
      "llm_answer": "The litigation with Molina, initiated after the Celgene acquisition closed in November 2019, involves claims related to the Thalomid and Revlimid products that were not part of the purchase‑price valuation. Because these liabilities arose post‑acquisition, they are not reflected in the initial fair‑value accounting for Celgene and therefore represent a contingent financial exposure for BMS that could affect future earnings and cash flow if the claims result in settlements or judgments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            137,
            138,
            139,
            140,
            141
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2022.pdf",
          "target_page": 116,
          "pages": [
            114,
            115,
            116,
            117,
            118
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 12,
        "total_chars": 52626,
        "num_window_pages": 12,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13421,
        "completion_tokens": 122,
        "total_tokens": 13543
      }
    },
    {
      "question_id": 67,
      "question": "What governance risks does the 15:1 voting disparity between Class B and Class A shares create for Comcast's minority shareholders, especially given that Class B shares are entirely owned by Mr. Brian L. Roberts?",
      "original_answer": "The 15:1 voting disparity between Class B and Class A shares grants Mr. Brian L. Roberts, who owns all Class B shares, outsized control over corporate decisions despite holding only one-third of the voting power. This creates governance risks for minority shareholders, as Mr. Roberts can disproportionately influence board elections and major corporate actions, potentially prioritizing his interests over those of the broader shareholder base. This dynamic is further amplified by the non-dilutable nature of Class B voting rights, which ensures his control remains intact regardless of future share issuances or buybacks.",
      "llm_answer": "The 15:1 voting disparity creates a governance risk that a single individual—Mr. Brian L. Roberts, who owns all Class B shares—can effectively control the outcome of any shareholder vote despite holding only a small fraction of the company’s economic ownership. This concentration of voting power can limit minority shareholders’ ability to influence key decisions such as board elections, mergers, or other strategic matters, potentially leading to outcomes that do not reflect the interests of the broader investor base.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2023.pdf",
          "target_page": 1,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 58158,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14774,
        "completion_tokens": 130,
        "total_tokens": 14904
      }
    },
    {
      "question_id": 67,
      "question": "How does UPS's contribution approach to the New York State Teamsters Conference Pension and Retirement Fund in 2023 demonstrate compliance with financial improvement requirements for red-zone pension plans?",
      "original_answer": "UPS's contributions to the New York State Teamsters Conference Pension and Retirement Fund totaled $139 million in 2023, a decrease from $149 million in 2022 and $147 million in 2021. According to the 10-K filing, all red-zone plans, including this fund, have implemented financial improvement plans (FIPs), and UPS's contributions satisfy these FIP requirements. Despite the declining contribution trend, the company explicitly states that these payments meet all applicable financial improvement obligations without requiring surcharges or additional contributions beyond contractual rates. This demonstrates that UPS's contribution approach aligns with regulatory requirements while showing a measured reduction in payments as permitted under the implemented FIP framework for underfunded pension plans.",
      "llm_answer": "UPS's $139 million contribution to the New York State Teamsters Conference Pension and Retirement Fund in 2023 satisfied the required funding level for this red‑zone pension plan, demonstrating compliance with the financial improvement requirements for such plans.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22178,
        "completion_tokens": 66,
        "total_tokens": 22244
      }
    },
    {
      "question_id": 67,
      "question": "Given that AMJEVITA is in a phase 3 study as a biosimilar to AbbVie's HUMIRA, which competes against both ENBREL and Otezla—two of Amgen’s marketed products—how might Amgen’s development of AMJEVITA impact its own revenue from ENBREL and Otezla, especially in light of HUMIRA’s strong competitive position in the same therapeutic areas?",
      "original_answer": "Amgen's development of AMJEVITA, a biosimilar to AbbVie’s HUMIRA, currently in a phase 3 study (page 25), introduces a complex competitive dynamic. HUMIRA is listed as a direct competitor to both ENBREL and Otezla in the U.S. and Canada (page 16), which are two of Amgen’s own marketed products in the autoimmune and inflammatory disease space. While AMJEVITA could potentially capture market share from HUMIRA and reduce AbbVie’s dominance, it may also inadvertently compete with Amgen’s own products. This raises concerns about internal cannibalization, particularly if AMJEVITA gains approval and is positioned as a lower-cost alternative in the same therapeutic areas. Thus, the development of AMJEVITA could have a dual financial impact: offering a new revenue stream by challenging HUMIRA, while simultaneously threatening Amgen’s existing revenue from ENBREL and Otezla.",
      "llm_answer": "Amgen’s development of AMJEVITA—a biosimilar to AbbVie’s HUMIRA—could pressure pricing and market share for its own marketed drugs ENBREL and Otezla, which also compete with HUMIRA in the same therapeutic areas. As HUMIRA maintains a strong competitive position, the introduction of AMJEVITA may intensify biosimilar competition, potentially leading to reduced sales or pricing pressure for ENBREL and Otezla, especially if payers shift toward the lower‑cost biosimilar. This dynamic could diminish Amgen’s revenue from those products despite their established market presence.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69150,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17549,
        "completion_tokens": 144,
        "total_tokens": 17693
      }
    },
    {
      "question_id": 67,
      "question": "How does the unresolved WTO customs valuation dispute involving Thailand affect Philip Morris's competitive positioning against local and international tobacco companies in the Thai market, given the company's stated challenges with import cost predictability and pricing strategy?",
      "original_answer": "The unresolved WTO customs valuation dispute between the Philippines and Thailand, where the WTO panel ruled that Thailand had no basis to challenge PM Thailand's declared import values and taxes, creates regulatory uncertainty that directly impacts Philip Morris's cost structure and pricing flexibility in Thailand. Despite Thailand agreeing to comply with the ruling, the Philippines asserts non-compliance, and the stalled WTO Appellate Body process has left the matter unresolved since 2010. This uncertainty likely affects PM Thailand’s ability to accurately forecast import costs, which are critical to pricing decisions. In a market where PMI competes against local and international tobacco firms like British American Tobacco, Japan Tobacco Inc., and state-owned enterprises in Thailand, the inability to stabilize customs costs could limit PM's ability to maintain competitive pricing. Additionally, the company notes on page 19 that in markets like Thailand, adult consumers are sensitive to price changes and may shift to lower-priced brands during economic uncertainty, further constraining profitability. Therefore, the unresolved dispute directly intersects with PM's stated risk of being unable to improve margins through price increases, especially in a market where cost predictability is essential for maintaining competitive positioning.",
      "llm_answer": "The WTO customs‑valuation dispute with Thailand remains unresolved, forcing Philip Morris to confront unpredictable import‑cost and pricing pressures in the Thai market. This uncertainty puts the company at a competitive disadvantage against both local Thai tobacco firms and other international players that can more easily navigate the tariff and valuation rules, potentially eroding PMI’s market share and pricing flexibility in Thailand.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "PM_10k_2024.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78416,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19851,
        "completion_tokens": 110,
        "total_tokens": 19961
      }
    },
    {
      "question_id": 67,
      "question": "What does EMR's increasing reported value of its AspenTech stake from $1 million in 2023 to $8 million in 2024 suggest about the strategic success of the 2022 business combination with Heritage AspenTech, particularly in relation to the $5.9 billion noncontrolling interest valuation recorded at the time of the transaction?",
      "original_answer": "EMR's increasing reported value of its AspenTech stake—from $1 million in 2023 to $8 million in 2024—suggests that the 2022 business combination with Heritage AspenTech has yielded positive strategic outcomes, at least in the context of stake valuation. This growth in value aligns with the broader goal of creating a stronger, more diversified industrial software entity. At the time of the transaction, EMR recorded a $5.9 billion noncontrolling interest for the 45% ownership stake held by former Heritage AspenTech stockholders, which was based on the fair value of AspenTech shares as of May 16, 2022. The subsequent increase in EMR’s reported stake value implies that AspenTech's overall valuation or performance likely improved post-transaction, supporting the strategic rationale behind the combination. This increase may reflect successful integration of the Emerson Industrial Software Business or improved market positioning of AspenTech following the transaction.",
      "llm_answer": "The $7 million increase in the reported value of EMR’s AspenTech stake—from $1 million in 2023 to $8 million in 2024—reflects the market‑based revaluation of the 40 % non‑controlling equity interest retained after the 2022 Heritage AspenTech combination, which was originally recorded at a $5.9 billion noncontrolling‑interest valuation; the subsequent $1.5 billion sale of that interest in 2024 confirms that the earlier valuation was essentially accurate, and the modest rise in the remaining stake’s carrying amount underscores the strategic success of the 2022 combination in creating a valuable, market‑recognized equity position.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 51,
          "pages": [
            49,
            50,
            51,
            52,
            53
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 57685,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14678,
        "completion_tokens": 158,
        "total_tokens": 14837
      }
    },
    {
      "question_id": 67,
      "question": "How does Southern Company's wind energy portfolio life expectancy compare with the contract duration of its Reading wind facility, and what might this imply about long-term revenue alignment for this project?",
      "original_answer": "Southern Company estimates the useful life of its wind facilities at up to 30 years, as stated in the asset overview on page 244. However, the Reading wind facility, located in Kansas and with a nameplate capacity of 200 MW, has a PPA contract duration of only 12 years, as disclosed on page 330. This mismatch between the asset's expected operational life and the length of the contracted revenue period raises questions about the long-term financial viability and revenue strategy for the Reading facility beyond the initial PPA term.",
      "llm_answer": "Southern Power's Reading wind facility has a 20‑year power purchase agreement, while the useful life of its wind assets is estimated at up to 30 years. This mismatch means the project's revenue stream will end well before the turbines' full economic life, implying that long‑term revenue alignment is limited and future earnings will depend on either contract extensions or repowering/replacement after the 12‑year PPA expires.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71748,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18168,
        "completion_tokens": 106,
        "total_tokens": 18275
      }
    },
    {
      "question_id": 68,
      "question": "How does MetLife's use of Trust-Owned Life Insurance to fund Nonqualified Benefit Programs, as disclosed in the Benefit Funding Solutions section, align with the liability information provided in the Policyholder Account Balances footnote regarding these same obligations?",
      "original_answer": "MetLife offers Trust-Owned Life Insurance as part of its Benefit Funding Solutions to finance Nonqualified Benefit Programs for executives (page 9). These products are specifically designed to fund postretirement benefits through insurance structures owned by trusts. The Policyholder Account Balances footnote (page 203) provides further context, indicating that the RIS segment includes these trust-owned life insurance policies as part of its liabilities. The alignment shows that MetLife actively structures and markets these insurance vehicles as funding mechanisms, while also recognizing the corresponding long-term obligations in its financial disclosures. This dual perspective highlights both the product offering and the associated liability management within the same business segment.",
      "llm_answer": "MetLife's use of Trust-Owned Life Insurance (TOLI) to fund nonqualified benefit programs aligns with the liability disclosures in the Policyholder Account Balances footnote, which explicitly identifies \"benefit funding solutions\" as a category of products that includes \"company-, bank- or trust-owned life insurance used to finance nonqualified benefit programs executives.\" The footnote details the PABs for these funding solutions, showing balances, deposits, and related liabilities (e.g., $17,711 million in 2023 for the RIS segment's annuities and risk solutions account, which includes benefit funding solutions). This confirms that TOLI-funded obligations are recorded as policyholder liabilities under the same accounting framework (GAAP), with the same PAB reporting structure used for other funding agreements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 203,
          "pages": [
            201,
            202,
            203,
            204,
            205
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 203,
          "pages": [
            201,
            202,
            203,
            204,
            205
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 89494,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22619,
        "completion_tokens": 205,
        "total_tokens": 22824
      }
    },
    {
      "question_id": 68,
      "question": "How does Altria's $2.9 billion acquisition of NJOY compare with its prior equity stake in JUUL, given NJOY's unique FDA market authorization status and Altria's stated strategic focus on transitioning adult smokers to less harmful alternatives?",
      "original_answer": "Altria's $2.9 billion acquisition of NJOY, which became a wholly owned subsidiary on June 1, 2023, represents a significant strategic commitment to the e-vapor category. This contrasts with Altria's earlier equity stake in JUUL, which it relinquished in March 2023 in exchange for a non-exclusive, irrevocable global license to certain heated tobacco intellectual property. Notably, NJOY is the only e-vapor manufacturer to have received market authorizations from the FDA for a pod-based e-vapor product, a regulatory milestone that likely factored into Altria's decision to directly acquire and integrate NJOY into its portfolio. This acquisition aligns with Altria’s stated Vision to transition adult smokers to potentially less harmful alternatives and supports its broader 'Moving Beyond Smoking' initiative, distinguishing it from the more limited rights retained from the JUUL relationship.",
      "llm_answer": "Altria's $2.9 billion acquisition of NJOY gave the company a wholly owned e‑vapor business that is the only U.S. manufacturer with FDA market authorization for a pod‑based product, directly advancing its Vision of transitioning adult smokers to less‑harmful alternatives. This contrasts with its prior equity stake in JUUL, which was a minority investment that gave Altria only a licensing arrangement for JUUL’s heated‑tobacco IP and did not provide direct control over a regulated product; the NJOY purchase therefore aligns with Altria’s strategic focus on owning and scaling a FDA‑authorized reduced‑harm option.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "hop_3_rel": {
          "source_file": "MO_10k_2023.pdf",
          "target_page": 60,
          "pages": [
            58,
            59,
            60,
            61,
            62
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76290,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19310,
        "completion_tokens": 154,
        "total_tokens": 19464
      }
    },
    {
      "question_id": 68,
      "question": "How does Amgen's $2.8 billion equity investment in BeiGene to commercialize XGEVA in China align with the competitive pressures facing XGEVA in the U.S. and Europe, and what implications does this have for Amgen's revenue diversification strategy?",
      "original_answer": "Amgen's $2.8 billion equity investment in BeiGene (page 28) was part of a strategic collaboration to expand its oncology footprint in China, where BeiGene began selling XGEVA in 2020. Under the arrangement, Amgen and BeiGene share profits and losses equally during the initial commercialization period, after which product rights may revert to Amgen (page 121). Meanwhile, XGEVA faces direct competition in the U.S. and Europe from zoledronate generics (page 16), which typically erode branded drug revenues due to lower-cost alternatives entering the market. This suggests Amgen is strategically shifting focus toward growth markets like China to offset declining revenue potential in mature markets due to generic competition. The financial commitment to BeiGene underscores Amgen’s intent to diversify XGEVA’s revenue base geographically, mitigating the impact of competitive pressures in developed markets.",
      "llm_answer": "Amgen’s $2.8 billion equity investment in BeiGene to commercialize XGEVA in China is a strategic move to offset growing competitive pressure on XGEVA in the United States and Europe, where biosimilar and generic competition is eroding market share and pricing power. By partnering with BeiGene, Amgen diversifies its revenue streams beyond mature markets, tapping into China’s expanding oncology and bone‑health market while leveraging BeiGene’s local commercialization capabilities and shared development costs. This collaboration enhances Amgen’s revenue diversification strategy, reducing reliance on U.S./EU sales and creating a new, high‑growth profit center in Asia.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 121,
          "pages": [
            119,
            120,
            121,
            122,
            123
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70645,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17906,
        "completion_tokens": 168,
        "total_tokens": 18074
      }
    },
    {
      "question_id": 68,
      "question": "How does Cisco's lower gross margin from Advanced Services relate to the credit risk exposure in their loan receivables tied to service offerings, given the reduction in allowance for credit losses from $126 million to $72 million year-over-year?",
      "original_answer": "Cisco acknowledges that Advanced Services have a lower gross margin compared to technical support services, partly due to strategic investments in headcount and delivery resources. These services are linked to loan receivables, which are financing arrangements tied to the sale of services, including Advanced Services. The allowance for credit losses on loan receivables decreased from $103 million in FY2022 to $53 million in FY2023, indicating reduced credit risk. However, this reduction in reserves must be weighed against the ongoing margin pressures in Advanced Services, which may affect the collectability of these receivables if clients face financial strain, thereby creating a potential risk to Cisco’s financial position despite the lower allowance.",
      "llm_answer": "Cisco’s lower gross margin from Advanced Services reflects the reduced profitability of its service offerings, which directly increases credit risk exposure on the related loan receivables. This is evident in the decline of the allowance for credit losses from $126 million (July 30 2022) to $72 million (July 29 2023), indicating that the company is writing off a smaller portion of potentially uncollectible receivables tied to these lower‑margin services. Consequently, while the allowance has been reduced, the underlying risk remains tied to the diminished margins of Advanced Services.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69944,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17727,
        "completion_tokens": 147,
        "total_tokens": 17874
      }
    },
    {
      "question_id": 68,
      "question": "How does the expected loss of market exclusivity for Bridion in the U.S. in 2026 impact MRK's strategic positioning in its key domestic market, especially considering the growth in alliance revenue from other products like Adempas and Verquvo in 2023?",
      "original_answer": "MRK faces a significant challenge with Bridion, a key Hospital Acute Care product, losing U.S. market exclusivity in 2026, which is expected to result in a substantial decline in sales in that market. This loss comes at a time when MRK is increasingly dependent on alliance revenue to offset declines in products losing exclusivity. In 2023, alliance revenue—particularly from products like Adempas and Verquvo—grew by 8%, driven by higher demand in Bayer's marketing territories and increased profit sharing. This growth suggests that MRK may be strategically leaning on collaborative partnerships to maintain revenue stability. However, Bridion's upcoming exclusivity loss in the U.S., a core market for MRK, could strain profitability unless offset by new product launches or expanded alliance-driven growth. The interplay between declining legacy product exclusivity and rising alliance revenue highlights a transitional phase in MRK’s U.S. market strategy.",
      "llm_answer": "The expected loss of U.S. market exclusivity for Bridion in 2026 will likely cause a substantial decline in Bridion sales, similar to the declines already observed after patent expirations in the EU (July 2023) and Japan (January 2024). This revenue pressure will be offset only partially by growth in alliance revenue from other key products such as Adempas and Verquvo, which grew 8 % in 2023, and from newer high‑margin products like Lynparza and Lenvima, whose alliance revenues increased 7 % and 10 % respectively. Consequently, while these alliances help sustain overall profitability, the loss of Bridion’s U.S. exclusivity will materially affect Merck’s cash flow and strategic positioning in its core domestic market.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 30,
          "pages": [
            28,
            29,
            30,
            31,
            32
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2023.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78840,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19953,
        "completion_tokens": 181,
        "total_tokens": 20135
      }
    },
    {
      "question_id": 69,
      "question": "How does Intel's strategic decision to divest its NAND SSD business to SK hynix, while continuing to manufacture NAND wafers for them, align with the company's stated focus on 144-layer QLC NAND SSD innovation and its broader market positioning in high-capacity storage solutions?",
      "original_answer": "Intel's decision to divest its NAND SSD Business and Fab Assets to SK hynix while retaining the ability to manufacture NAND memory wafers for them until the second closing reflects a strategic pivot. Despite this divestiture, Intel continued to innovate in NAND SSDs by launching the Intel SSD D5-P5316, a 144-layer QLC NAND SSD for data centers with up to 30.72TB capacity in multiple form factors. This indicates that Intel aimed to remain technologically competitive in NAND SSD development even as it transitioned the business to SK hynix. The company's broader strategy emphasizes leveraging 144-layer 3D NAND TLC and QLC solutions to meet growing data storage demands, suggesting that the divestiture was not a retreat from innovation but a reallocation of resources to focus on core competencies in system integration and advanced storage solutions.",
      "llm_answer": "Intel's divestiture of its NAND SSD business to SK hynix—while retaining a wafer‑supply agreement to continue manufacturing NAND wafers for the buyer—allows the company to shed the lower‑margin, capital‑intensive NAND operations and focus on its core strategy of driving 144‑layer QLC NAND innovation and high‑capacity storage solutions. By exiting the SSD manufacturing segment, Intel can concentrate resources on developing advanced NAND technologies and products (such as its 144‑layer QLC SSDs) while still participating in the NAND value chain through wafer sales, thereby reinforcing its positioning in high‑capacity, data‑center storage markets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31066,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 8010,
        "completion_tokens": 163,
        "total_tokens": 8173
      }
    },
    {
      "question_id": 69,
      "question": "How might Qualcomm's customer concentration risk in China impact its ability to capitalize on growth opportunities in XR applications dependent on 5G technology?",
      "original_answer": "Qualcomm faces a significant customer concentration risk, particularly in China, where U.S./China trade tensions could disrupt revenue streams. This risk is heightened because a large portion of its business is tied to premium tier handset sales in this region. At the same time, Qualcomm has identified 5G as a foundational technology for next-generation applications like XR (augmented reality, virtual reality, and mixed reality), which are increasingly being integrated into consumer electronics, edge networking, and industrial applications. According to Qualcomm's revenue disclosures, XR is a key component of its IoT and consumer electronics segment, which is expected to grow alongside 5G adoption. However, if geopolitical risks in China disrupt Qualcomm's ability to deploy 5G technologies or sell into this market, it could hinder the company’s ability to scale XR-related product lines and delay its strategic expansion into these emerging use cases.",
      "llm_answer": "Qualcomm’s heavy reliance on a few major customers in China—particularly for premium handset sales—creates concentration risk that could curtail its ability to capture growth in XR applications that depend on 5G. If Chinese consumer demand for high‑end smartphones falters or if trade tensions force customers to shift away from U.S. suppliers, Qualcomm could see reduced design‑win opportunities and lower licensing revenue, limiting its exposure to the fast‑growing XR market that needs 5G connectivity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_2_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 7,
          "pages": [
            5,
            6,
            7,
            8,
            9
          ]
        },
        "hop_3_rel": {
          "source_file": "QCOM_10k_2024.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71360,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18058,
        "completion_tokens": 126,
        "total_tokens": 18185
      }
    },
    {
      "question_id": 69,
      "question": "Given the concentrated voting power of Brian L. Roberts through Class B common stock and the significant repurchase activity of Class A common stock in 2024, how does the company's equity structure reflect a potential imbalance in governance influence versus shareholder value distribution?",
      "original_answer": "The equity structure of CMCSA reveals a governance framework where Brian L. Roberts, through ownership of all outstanding Class B common stock, holds 33⅓% of the combined voting power, with each Class B share carrying 15 votes. This concentrated voting power contrasts with the company's financial activities around Class A common stock, which saw repurchases of $2 billion in 2024. Despite these repurchases reducing the number of outstanding Class A shares (from 4,842,108,959 to 4,651,093,045), the governance structure remains unaffected due to the non-dilutive nature of Class B voting rights. This dynamic suggests that while shareholder value is being redistributed through stock repurchases, the core governance influence remains insulated, creating a potential misalignment between ownership benefits and control.",
      "llm_answer": "The equity structure shows a stark governance imbalance: Class B common stock, which carries 15 votes per share and is wholly owned by Brian L. Roberts, represents only about 33 % of the combined voting power despite having a negligible economic ownership stake, while Class A shares receive just one vote per share and are subject to large-scale repurchases that reduce their economic value. In 2024 the company repurchased roughly $9 billion of Class A stock, underscoring that shareholder value can be aggressively returned to holders of the lower‑voting class, whereas the concentrated voting power of the Class B shares remains insulated from such dilution. This juxtaposition highlights a potential mismatch between governance influence—heavily weighted toward the Class B holder—and the distribution of economic benefits to the broader shareholder base.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_2_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 31,
          "pages": [
            29,
            30,
            31,
            32,
            33
          ]
        },
        "hop_3_rel": {
          "source_file": "CMCSA_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70318,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17830,
        "completion_tokens": 215,
        "total_tokens": 18045
      }
    },
    {
      "question_id": 69,
      "question": "How does SEGCO's ownership of electric generating units at Plant Gaston, with a total rated capacity of 1,020 MWs and expected retirement by 2028, reconcile with the declining book value of 'Electric generating units' listed under Southern Company's consolidated assets at $670 million in 2023 compared to $760 million in 2022?",
      "original_answer": "SEGCO, owned equally by Alabama Power and Georgia Power, operates electric generating units at Plant Gaston with a total rated capacity of 1,020 MWs and a planned retirement by December 31, 2028. However, Southern Company consolidates SEGCO, and the book value of 'Electric generating units' under Southern Company's consolidated assets has declined from $760 million in 2022 to $670 million in 2023. This decline may reflect depreciation, potential impairment, or the anticipated retirement of these units by 2028, which could impact their long-term valuation. The connection between SEGCO's generating units and Southern Company’s consolidated asset valuation suggests that the planned retirement and associated depreciation are factored into the asset's carrying value on the consolidated balance sheet.",
      "llm_answer": "The declining book value of \"Electric generating units\" ($670 million in 2023 vs. $760 million in 2022) reflects the depreciation of SEGCO’s 1,020 MW plant at Gaston, which is being retired by the end of 2028; as the asset ages and is written down, its net book value falls even though the underlying generating capacity remains in service until retirement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 211,
          "pages": [
            209,
            210,
            211,
            212,
            213
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 235,
          "pages": [
            233,
            234,
            235,
            236,
            237
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64436,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16376,
        "completion_tokens": 89,
        "total_tokens": 16465
      }
    },
    {
      "question_id": 69,
      "question": "How does Caterpillar's administration of the EIP Plans, which purchased 78,000 shares in Q4 2023, relate to the broader context of the company's $15.0 billion 2022 share repurchase authorization, especially in light of the 19.5 million shares repurchased during 2023?",
      "original_answer": "Caterpillar's EIP Plans, which purchased 78,000 shares in Q4 2023, represent a small but consistent component of the company's overall equity activity. These purchases are distinct from the broader $15.0 billion share repurchase program authorized in 2022, under which 19.5 million shares were repurchased during 2023. While the EIP Plans reflect ongoing employee participation in equity ownership, the repurchase program reflects strategic capital allocation decisions by the company. Together, they illustrate dual mechanisms influencing Caterpillar's equity base, with the EIP Plans contributing to employee engagement and the repurchase program aiming to enhance shareholder value.",
      "llm_answer": "Caterpillar’s administration of the EIP Plans—through which approximately 78,000 shares were purchased in Q4 2023—was executed under its broader $15 billion share‑repurchase authorization approved in May 2022. That authorization superseded the earlier $10 billion 2018 program, leaving about $7.8 billion of availability as of year‑end 2023. The 19.5 million shares repurchased during 2023 (costing roughly $4.7 billion) were part of the same $15 billion program, illustrating how the EIP‑Plan purchases fit into the company’s overall strategy of retiring common stock and utilizing its repurchase capacity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_2_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 29,
          "pages": [
            27,
            28,
            29,
            30,
            31
          ]
        },
        "hop_3_rel": {
          "source_file": "CAT_10k_2023.pdf",
          "target_page": 104,
          "pages": [
            102,
            103,
            104,
            105,
            106
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 41598,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 10644,
        "completion_tokens": 151,
        "total_tokens": 10796
      }
    },
    {
      "question_id": 70,
      "question": "How does MetLife's exposure to variable annuity guarantees, specifically those involving guaranteed minimum income benefits (GMIBs), relate to its assumed reinsurance obligations, and how is this connection reflected in the company's accounting policy disclosures?",
      "original_answer": "MetLife's exposure to variable annuity guarantees, particularly GMIBs, represents a significant liability tied to future annuitization risks, as outlined in the Market Risk Benefits section. This exposure is further amplified by an in-force block of assumed variable annuity guarantees from a third party, indicating that reinsurance plays a direct role in the company's risk profile for these products. The Reinsurance section, referenced under the company's accounting policies, shows that MetLife has a dedicated accounting policy (Note 9) for reinsurance, which governs how these assumed obligations are reported and managed. This three-hop connection reveals that MetLife's liability for GMIBs is not only a direct product risk but also a reinsurance risk, with specific accounting treatment guiding its recognition and measurement.",
      "llm_answer": "MetLife’s exposure to variable annuity guarantees that include guaranteed minimum income benefits (GMIBs) is reflected in its assumed reinsurance obligations through the MetLife Holdings segment, which includes an in‑force block of assumed variable‑annuity guarantees from a third party.  The company’s accounting policy for these market‑risk benefits is disclosed in Note 6 of the 10‑K, which describes how MRBs (including GMIBs) are measured at fair value, how risk margins and non‑performance adjustments are incorporated, and how changes in these estimates affect net income and OCI.  This policy also explains that the fair‑value calculations use observable market inputs adjusted for the priority of liabilities and the claims‑paying ability of the issuing subsidiaries, and that the resulting liabilities are rolled forward in the disclosed tables.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 194,
          "pages": [
            192,
            193,
            194,
            195,
            196
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 193,
          "pages": [
            191,
            192,
            193,
            194,
            195
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 131,
          "pages": [
            129,
            130,
            131,
            132,
            133
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78844,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19958,
        "completion_tokens": 213,
        "total_tokens": 20171
      }
    },
    {
      "question_id": 70,
      "question": "What percentage of CVS's total assets at year-end 2022 were represented by investments in Common Collective Trusts, and how does this allocation reflect the role of Separate Accounts in the company's pension investment strategy?",
      "original_answer": "At year-end 2022, CVS reported $5,087 million in Separate Accounts Assets, which included investments in Common Collective Trusts valued at $266 million. These Common Collective Trusts represented approximately 0.9% of the company’s total assets of $232,999 million. The Separate Accounts Assets are specifically tied to large case pension products, where contract holders bear the investment risk, and the corresponding liability mirrors the asset value. The allocation to Common Collective Trusts, which are classified as Level 2 investments based on NAV per share/unit, indicates a measured exposure to diversified pooled funds while maintaining legal segregation of these assets from other business risks. This aligns with CVS's broader pension investment strategy, which includes $5,865 million in total pension investments, showing a diversified but cautious approach to managing contract holder funds.",
      "llm_answer": "Based on the pension plan assets table on page 165, investments in common/collective trusts totaled **$410 million**, which represented **7.1 %** of the $5,781 million of total pension plan assets at year‑end 2022. These assets are held in Separate Accounts that mirror the company’s pension investment strategy, allowing the plan to allocate capital to diversified collective‑trust vehicles while keeping the investments off the primary balance‑sheet and reflecting the risk‑sharing role of Separate Accounts in the overall pension strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 114,
          "pages": [
            112,
            113,
            114,
            115,
            116
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 151,
          "pages": [
            149,
            150,
            151,
            152,
            153
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 166,
          "pages": [
            164,
            165,
            166,
            167,
            168
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78039,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19752,
        "completion_tokens": 135,
        "total_tokens": 19888
      }
    },
    {
      "question_id": 70,
      "question": "How does Microsoft's inclusion of SA in Enterprise Agreements impact the recognition of unearned revenue, particularly given the multi-year structure of these agreements and the pattern of delivery assumptions made for SA benefits?",
      "original_answer": "Microsoft includes SA in Enterprise Agreements, which are structured as three-year licensing programs. Since SA is bundled with perpetual licenses in these agreements, it contributes to unearned revenue that is recognized ratably over the multi-year coverage period. However, due to the nature of SA benefits and the pattern of their delivery across the portfolio, Microsoft must apply judgment in estimating standalone selling prices (SSP) and recognizing revenue, especially when SA is not sold separately. This creates a nuanced revenue recognition profile where unearned revenue from SA-inclusive agreements is invoiced annually but recognized over time, depending on the estimated delivery pattern of SA benefits.",
      "llm_answer": "Microsoft’s inclusion of Software Assurance (SA) in Enterprise Agreements requires allocating revenue between the perpetual on‑premises license and the SA performance obligation. Because SA is bundled and delivered over the three‑year agreement term, revenue attributable to SA is recognized ratably over that period, while the upfront portion tied to the perpetual license is recognized when control of the license transfers. This pattern reflects the multi‑year structure and the assumption that SA benefits are consumed evenly across the agreement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 54822,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13940,
        "completion_tokens": 137,
        "total_tokens": 14078
      }
    },
    {
      "question_id": 70,
      "question": "How does Southern Company's use of weather-adjusted KWH sales analysis in evaluating operational trends reconcile with its reported exposure to weather-driven customer consumption patterns in gas distribution operations?",
      "original_answer": "Southern Company uses weather-adjusted KWH sales analysis (noted on page 73) to evaluate historical operations apart from weather influence, revealing a 0.4% decrease in residential electricity sales due to reduced customer usage. Meanwhile, in gas distribution operations (page 86), the company acknowledges exposure to weather-driven consumption patterns, particularly during the heating season, which affects earnings. The company mitigates this exposure through mechanisms like weather normalization and weather derivative instruments (page 200). By combining these perspectives, we see that while Southern Company actively adjusts for weather effects in performance analysis, it still experiences weather-related revenue variability in gas operations, highlighting the limits of weather-adjusted metrics in fully insulating financial outcomes from climatic conditions.",
      "llm_answer": "Southern Company's weather-adjusted KWH sales analysis provides a metric to isolate volume trends from weather-related fluctuations, enabling assessment of underlying operational performance. This approach reconciles with its exposure to weather-driven gas consumption by using weather normalization mechanisms (e.g., revenue adjustment mechanisms and hedging instruments) in gas distribution operations to decouple earnings from weather volatility, ensuring that weather impacts on customer consumption are mitigated through regulatory frameworks rather than directly affecting reported income.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 200,
          "pages": [
            198,
            199,
            200,
            201,
            202
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75467,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19105,
        "completion_tokens": 148,
        "total_tokens": 19253
      }
    },
    {
      "question_id": 70,
      "question": "How did Gum & Candy's contribution to MDLZ's AMEA segment revenue compare to other product categories in 2022?",
      "original_answer": "In 2022, Gum & Candy contributed $861 million to MDLZ's AMEA segment, which was significantly lower than Biscuits ($1,844 million) and Chocolate ($2,082 million), but higher than Beverages ($546 million) and Cheese & Grocery ($437 million). While Gum & Candy accounted for 2.8% of AMEA’s total revenue in 2021, the 2022 figures show it remained a smaller contributor compared to core categories like Biscuits and Chocolate, which dominated the segment’s revenue mix.",
      "llm_answer": "In 2022, Gum & Candy contributed roughly 2.8 % of the AMEA segment’s net revenue, which represented only a small share of the region’s total sales. By contrast, Biscuits accounted for about 7.8 % of AMEA net revenue and Chocolate about 8.3 %, making them substantially larger contributors within the segment. Consequently, Gum & Candy’s share was modest compared with the dominant biscuit and chocolate categories.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 137,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "hop_2_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MDLZ_10k_2022.pdf",
          "target_page": 136,
          "pages": [
            127,
            128,
            129,
            130,
            131
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 82868,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20922,
        "completion_tokens": 103,
        "total_tokens": 21026
      }
    },
    {
      "question_id": 70,
      "question": "How does Southern Company's credit arrangement structure involving Nicor Gas relate to the changes in Total Notes Payable for Southern Company Gas subsidiaries between 2023 and 2024?",
      "original_answer": "Southern Company's credit arrangement structure includes Nicor Gas as a borrower under a $700 million allocation within a larger $1.5 billion credit arrangement expiring in 2029, specifically restricted for Nicor Gas's working capital needs. This arrangement provides Nicor Gas with access to flexible liquidity, which directly influences its ability to manage short-term obligations. Looking at Total Notes Payable, Nicor Gas reported $172 million in outstanding commercial paper at the end of 2024, down from $392 million in 2023, reflecting a significant reduction in short-term borrowings. This decline aligns with Southern Company's broader liquidity strategy, as the company maintains unused credit capacity and compliance with debt covenants, enabling Nicor Gas to reduce reliance on short-term notes while maintaining operational flexibility.",
      "llm_answer": "Southern Company’s revolving credit facility includes a $700 million sub‑limit that is allocated to Nicor Gas for its working‑capital needs, and the company’s $100 million 2025‑expiring credit line to Nicor Gas is specifically restricted to those working‑capital requirements. Because this portion of the credit arrangement is tied to Nicor Gas’s cash‑flow needs, the company’s overall notes‑payable balance for its Gas subsidiaries declined from $2.314 billion at the end of 2023 to $1.338 billion at the end of 2024.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84571,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21362,
        "completion_tokens": 129,
        "total_tokens": 21492
      }
    },
    {
      "question_id": 71,
      "question": "How does Broadcom's positioning of the Payment Security Suite as a SaaS-based fraud protection service align with the broader Payment Security portfolio's reliance on the Arcot payment authentication network powered by 3-D Secure technology?",
      "original_answer": "Broadcom positions the Payment Security Suite (mentioned on page 13) as a SaaS-based payment authentication service aimed at helping banks and merchants protect against fraud and ensure a seamless online shopping experience. This offering is part of a broader Payment Security portfolio (detailed on page 11), which is explicitly described as being built around the 'Arcot payment authentication network powered by 3-D Secure.' The connection between the Payment Security Suite and the broader Payment Security portfolio indicates that the SaaS-based suite leverages the underlying Arcot technology to deliver its fraud protection capabilities. This alignment suggests that Broadcom integrates its foundational authentication technology into modern, cloud-delivered service models to meet evolving market needs, particularly in securing digital transactions.",
      "llm_answer": "Broadcom positions the Payment Security Suite as a SaaS‑based fraud protection service that leverages the Arcot payment authentication network, which is built on 3‑D Secure technology, to deliver seamless, secure online payment authentication for banks and merchants. This aligns with the broader Payment Security portfolio’s reliance on the Arcot network by extending its 3‑D Secure authentication capabilities into a cloud‑delivered offering that enhances fraud prevention while simplifying the checkout experience.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 9,
        "total_chars": 47648,
        "num_window_pages": 9,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12146,
        "completion_tokens": 129,
        "total_tokens": 12275
      }
    },
    {
      "question_id": 71,
      "question": "How does Honeywell's recognition of a $509 million reduction in receivables from Garrett relate to the mandatory redemption schedule of the Series B Preferred Stock received in the Garrett bankruptcy settlement, and how is this reflected in the fair value accounting treatment of the investment?",
      "original_answer": "Honeywell recognized a $509 million reduction in the carrying value of receivables from Garrett in 2020 due to Garrett's financial instability and subsequent bankruptcy filing. As part of the Garrett bankruptcy resolution in 2021, Honeywell received 834.8 million shares of Garrett's Series B Preferred Stock as full satisfaction of the indemnification and tax matters agreements. This preferred stock comes with a mandatory redemption schedule of $35 million in 2022 and $100 million annually from 2023 to 2030, subject to Garrett's EBITDA and liquidity conditions. Honeywell accounts for this investment as held-to-maturity, with its fair value based on the present value of these mandatory redemptions, and is classified as Level 2 in the fair value hierarchy. The connection between the initial receivables impairment, the receipt of preferred stock as settlement, and its subsequent fair value treatment illustrates how Honeywell transitioned from a receivable-based claim to a structured equity instrument with defined redemption terms.",
      "llm_answer": "The $509 million reduction in receivables from Garrett reflects the present‑value discounting of the mandatory redemption schedule of the Series B Preferred Stock that Honeywell received in the bankruptcy settlement; this discount is accreted into interest income over the redemption period and is accounted for as a fair‑value adjustment to the investment. Consequently, the investment in Garrett’s Series B Preferred Stock is recorded at fair value (level‑2) on the balance sheet, with the accreted discount recognized as interest income rather than as a reduction of the principal amount.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 59494,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15130,
        "completion_tokens": 147,
        "total_tokens": 15278
      }
    },
    {
      "question_id": 72,
      "question": "How does Visa's competitive positioning against Value Added Service Providers, which include technology firms like those offering Visa Direct alternatives, reconcile with its acknowledgment of increasing competition from technology companies in emerging digital payment methods, particularly given the regulatory and litigation risks outlined?",
      "original_answer": "Visa identifies Value Added Service Providers (VASPs), such as technology companies, as direct competitors to its offerings like Visa Direct and Visa B2B Connect (page_16). These VASPs include a range of players from fintechs to consulting firms, and their growing capabilities in digital payments pose a threat to Visa’s market position. On page_23, Visa expands on this concern by noting that technology companies are increasingly developing their own payment systems, particularly in ecommerce, social media, and mobile channels, intensifying competition. This is further complicated by litigation risks, including antitrust and consumer protection lawsuits, which could force Visa to modify its pricing, rules, or business practices. The regulatory exposure outlined on page_16, including anti-money laundering and sanctions compliance, adds another layer of complexity. Together, these elements suggest that while Visa sees innovation and partnerships as competitive advantages, the convergence of regulatory scrutiny and aggressive competition from tech firms could materially impact its ability to maintain dominance in new digital payment flows.",
      "llm_answer": "Visa acknowledges that competition from technology firms offering alternative value‑added services—such as Visa Direct alternatives—is intensifying, but its competitive positioning is reinforced by its extensive global network, scale advantages, and deep partnerships with financial institutions and merchants. At the same time, it must navigate heightened regulatory scrutiny and litigation risks, especially in markets like China and India where government policies favor domestic payment systems and impose data‑localization or licensing requirements that can limit Visa’s ability to compete on equal footing. Consequently, while Visa leverages its brand, transaction volume, and value‑added services to maintain a strong market position, it must continually adapt to evolving regulatory obligations and potential antitrust actions that could constrain its competitive strategies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 76197,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19311,
        "completion_tokens": 220,
        "total_tokens": 19532
      }
    },
    {
      "question_id": 72,
      "question": "How does Microsoft's continued reliance on BNY Mellon as trustee for the 3.00% Notes due 2020 and other issuances reflect its strategic approach to managing long-term debt obligations?",
      "original_answer": "Microsoft's long-standing relationship with BNY Mellon, dating back to the Base Indenture in 2009 and extended through multiple Supplemental Indentures including the one governing the 3.00% Notes due 2020, demonstrates a consistent and strategic approach to debt management. The repeated use of BNY Mellon across multiple note issuances—such as the 3.00% Notes due 2020 (governed under the Second Supplemental Indenture dated 2010) and later issuances like the 3.625% Notes due 2023 and 4.875% Notes due 2043 (under the Eighth Supplemental Indenture in 2013)—shows a preference for institutional continuity and trust. This pattern suggests Microsoft prioritizes stability, legal consistency, and trusted custodianship in managing its debt structure, which may reduce operational and legal risk while streamlining compliance and investor relations.",
      "llm_answer": "Microsoft's continued use of BNY Mellon as trustee for its 3.00% Notes due 2020 and other debt issuances reflects a deliberate, long-term strategy to maintain consistent and reliable trustee services for managing its structured debt obligations. By relying on BNY Mellon across multiple supplemental indentures—particularly in the context of its 2009 base indenture—Microsoft ensures operational continuity, regulatory compliance, and streamlined administration of complex financing arrangements, reinforcing confidence in its long-term debt management framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12808,
        "completion_tokens": 140,
        "total_tokens": 12948
      }
    },
    {
      "question_id": 72,
      "question": "How does the shift from the 2012 Long-Term Incentive Plan to the 2022 Long-Term Incentive Plan affect the valuation methodology and grant pricing assumptions for stock options, particularly in light of the 2012 plan's expiration and continued documentation in exhibits?",
      "original_answer": "The transition from the 2012 Long-Term Incentive Plan to the 2022 Long-Term Incentive Plan introduced a change in the pricing methodology for stock option grants—from using the average of high and low stock prices on the grant date (under the 2012 plan) to using the closing stock price (under the 2022 plan). This change, combined with updated volatility assumptions (a blended rate of 10-year weekly historical volatility and 5-week average implied volatility), contributed to an increase in the average fair value of options granted, rising from $23.23 in 2022 to $27.85 in 2023. The 2012 plan expired on April 26, 2022, after which all grants were made under the 2022 plan. Despite its expiration, the 2012 plan remains referenced in the exhibits (e.g., Form of Stock Option Certificate and Global Award Agreements), indicating its ongoing relevance for historical grants and accounting disclosures, even as the newer plan governs current equity compensation practices.",
      "llm_answer": "The shift from the 2012 Long-Term Incentive Plan to the 2022 Long-Term Incentive Plan does not alter the core valuation methodology or grant pricing assumptions for stock options, as the document confirms that options under the 2022 plan are still granted at the closing stock price on the grant date and valued using the same Black-Scholes model with identical assumptions (risk-free rate, volatility, life, dividend yield). The key change is structural: the 2012 plan expired on April 26, 2022, and all subsequent awards (including those under the 2022 plan) are now governed by the new plan’s terms, which include a larger share reserve (150 million shares total, with 110 million available for stock options), but the pricing and valuation practices remain consistent with prior years. The document explicitly states that the 2022 plan’s awards are \"granted at the closing price\" and use the same valuation model as the 2012 plan, with no mention of revised assumptions affecting intrinsic value calculations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 124,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 48891,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12471,
        "completion_tokens": 253,
        "total_tokens": 12724
      }
    },
    {
      "question_id": 73,
      "question": "Given the significant market value of MA's Class A Common Stock and the equity award structure under the LTIP, how does the compensation expense recognition timeline for stock options align with the company's equity issuance strategy for Class A shares?",
      "original_answer": "The market value of MA's Class A Common Stock was approximately $328.8 billion as of June 30, 2023, and the company primarily issues new shares of Class A common stock to fund equity awards under the LTIP, with approximately 116 million shares authorized for this purpose. Stock options granted on or after March 1, 2022, vest ratably over three years, with compensation expense recognized over this vesting period. This timeline aligns with the company's equity issuance strategy, as the vesting schedule ensures a gradual release of shares into the market, minimizing dilution while maintaining long-term incentive alignment for participants.",
      "llm_answer": "The compensation expense for stock options and other equity awards is recognized over the vesting period of the underlying awards, which typically spans three to four years for options and up to three years for RSUs and PSUs. This recognition schedule aligns with the company's equity issuance strategy, as new shares of Class A common stock are issued primarily to fund option exercises and conversions of RSUs and PSUs, ensuring that the dilution from equity compensation is offset by the company's ongoing share repurchase programs and the structured diversification plan of the Mastercard Foundation's remaining Class A shares.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MA_10k_2023.pdf",
          "target_page": 2,
          "pages": [
            1,
            2,
            3,
            4,
            5
          ]
        },
        "hop_2_rel": {
          "source_file": "MA_10k_2023.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "MA_10k_2023.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66133,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16773,
        "completion_tokens": 157,
        "total_tokens": 16931
      }
    },
    {
      "question_id": 73,
      "question": "How does the expiration of the 2012 Long-Term Incentive Plan and the transition to the 2022 Long-Term Incentive Plan affect the valuation methodology and grant pricing assumptions for stock options, particularly in terms of volatility and grant-date pricing?",
      "original_answer": "The expiration of the 2012 Long-Term Incentive Plan in April 2022 and the transition to the 2022 Long-Term Incentive Plan introduced a change in the grant-date pricing methodology, with options now being granted at the closing price of JNJ stock rather than the average of the high and low prices. Additionally, the fair value of options granted in 2023 was $27.85, up from $23.23 in 2022 and $20.86 in 2021, reflecting updated volatility assumptions that blend a 10-year weekly historical volatility rate with a 5-week average implied volatility rate based on traded options. This shift in valuation methodology and pricing aligns with the new plan’s structure and reflects a more dynamic approach to volatility estimation.",
      "llm_answer": "The transition from the 2012 to the 2022 Long-Term Incentive Plan shifted the stock option grant pricing from the average of the high and low prices on the NYSE (used under the 2012 Plan) to the closing price on the NYSE on the grant date. This change, combined with the continued use of the Black-Scholes model for fair value estimation, maintained similar volatility assumptions (17.69% for 2023, 18.00% for 2022, 18.59% for 2021) and expected life (7.0 years), but the grant-date pricing methodology directly impacted the exercise price of new options, aligning it with the closing market price rather than the average of bid-ask prices used previously.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 120,
          "pages": [
            118,
            119,
            120,
            121,
            122
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 124,
          "pages": [
            120,
            121,
            122,
            123,
            124
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 48891,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12468,
        "completion_tokens": 164,
        "total_tokens": 12632
      }
    },
    {
      "question_id": 74,
      "question": "How does Cisco's lower gross margin from Advanced Services relate to the credit loss allowance reductions observed in their loan receivables portfolio?",
      "original_answer": "Cisco's Advanced Services are noted to carry a lower gross margin compared to technical support services, which impacts the company's overall profitability from services. These services are also explicitly tied to financing arrangements, including loan receivables, which are used to support customer purchases of Cisco products and services. On the other hand, the credit loss allowance for loan receivables decreased from $103 million in fiscal year 2022 to $53 million in fiscal year 2023, indicating improved credit quality or reduced risk in the loan portfolio. This reduction in credit loss allowances could imply stronger collections or lower defaults in the financing of Advanced Services, which may help offset some of the margin pressures seen in that service line. Therefore, while Advanced Services contribute less to gross margin, the improved credit performance of loan receivables tied to these services may positively impact Cisco’s financial position.",
      "llm_answer": "Cisco's lower gross margin from Advanced Services (which includes security, collaboration, and observability offerings) is linked to reduced credit loss allowance reductions in their loan receivables portfolio. The document shows that while product gross margin increased to 63.5% (from 61.5% in fiscal 2023), this was partially offset by negative impacts from pricing and amortization of purchased intangibles. Concurrently, the credit loss allowance for loan receivables decreased from $53 million (as of July 29, 2023) to $50 million (as of July 27, 2024), indicating improved collectibility of receivables despite margin pressures. This suggests that while Advanced Services revenue growth (driven by security and observability) contributed to higher gross margins, the company simultaneously reduced its credit loss provisions as loan receivables became less risky.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 69944,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17703,
        "completion_tokens": 217,
        "total_tokens": 17920
      }
    },
    {
      "question_id": 74,
      "question": "How does Duke Energy Indiana's capital planning align with the timing of its Indiana coal contract expirations (2024-2027) and tax-exempt bond maturities (2027-2046)?",
      "original_answer": "Duke Energy Indiana has coal contracts expiring between 2024 and 2027, which necessitate future capital planning decisions for securing new supply or extending contracts. At the same time, the company holds tax-exempt bonds maturing between 2027 and 2046, with $352 million specifically attributed to Duke Energy Indiana. The alignment of these two timelines suggests that the company may need to consider its capital structure and liquidity needs as the coal contracts expire, potentially leveraging or refinancing long-term debt, including these tax-exempt bonds, to manage operational continuity and fuel procurement strategies beyond 2027.",
      "llm_answer": "Duke Energy Indiana's capital planning aligns with its coal contract expirations (2024‑2027) and tax‑exempt bond maturities (2027‑2046) by using the timing of these obligations to fund replacements and manage debt maturities. The company’s 2023‑2024 debt issuances and maturities schedule shows that it plans to refinance or repay portions of long‑term debt—including tax‑exempt bonds—through new issuances that extend beyond the 2027‑2046 window, ensuring that the capital needed for retiring expiring coal contracts can be sourced from the same long‑term financing sources that cover the later‑maturing tax‑exempt bonds. This coordinated approach allows the utility to match the cash‑flow impact of coal contract expirations with the maturity profile of its tax‑exempt bond portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 163,
          "pages": [
            161,
            162,
            163,
            164,
            165
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103755,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26161,
        "completion_tokens": 196,
        "total_tokens": 26357
      }
    },
    {
      "question_id": 74,
      "question": "Given that UPS contributes to the Alaska Teamster-Employer Pension Plan, which is subject to an implemented Financial Improvement Plan (FIP), how does UPS's 2023 contribution of $10 million to this plan align with the company's overall compliance strategy for satisfying FIP requirements across its multiemployer pension obligations?",
      "original_answer": "UPS contributed $10 million to the Alaska Teamster-Employer Pension Plan in 2023, which is subject to an implemented FIP. According to the disclosures, UPS's collectively bargained contributions satisfy the requirements of all implemented FIPs and do not require the payment of any surcharges. This indicates that UPS's 2023 contribution aligns with its compliance strategy, as it meets the FIP obligations without incurring additional costs, consistent with the company's broader approach to managing multiemployer pension plan requirements.",
      "llm_answer": "UPS's $10 million contribution to the Alaska Teamster‑Employer Pension Plan satisfies the requirements of the plan’s implemented financial improvement plan (FIP), as disclosed in the multi‑employer pension table where the Alaska plan is listed as “Red” zone with an “Implemented” FIP/RP status and no surcharge is imposed; therefore, the contribution aligns with UPS’s compliance strategy of meeting all required FIP obligations without additional surcharges.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 95,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 87815,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 22210,
        "completion_tokens": 114,
        "total_tokens": 22325
      }
    },
    {
      "question_id": 75,
      "question": "How does Cisco's disclosure about the interest rate sensitivity of its senior fixed-rate notes, which indicates a $0.7 billion fair value change from a 50 BPS rate movement, relate to its commercial paper notes program used for general corporate purposes, especially considering the shared debt ranking and potential interest expense impacts?",
      "original_answer": "Cisco discloses that its senior fixed-rate notes, totaling $20.3 billion in principal, have a fair value sensitivity of $0.7 billion for a 50 BPS interest rate movement. These notes are ranked equally with the commercial paper notes issued under Cisco's $15.0 billion short-term debt program. While the senior notes are primarily fixed-rate, the commercial paper notes expose Cisco to variable interest costs, meaning a rise in rates could increase interest expense on new issuances. The shared ranking between these debt instruments implies that both carry similar credit risk and could influence Cisco's overall debt management strategy, especially in a rising rate environment where the cost of commercial paper could rise while the fair value of fixed-rate debt declines.",
      "llm_answer": "Cisco's disclosure of a $0.7 billion fair‑value change in its senior fixed‑rate notes from a 50‑basis‑point rate movement underscores that its debt portfolio is highly sensitive to interest‑rate shifts. Because the senior notes share the same debt ranking as the commercial paper notes used for general corporate purposes, any increase in borrowing costs—whether through higher commercial‑paper rates or new fixed‑rate issuances—will raise overall interest expense. This heightened expense could pressure cash flow and affect the company’s ability to fund operations, invest in growth, or meet other financial commitments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77295,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19587,
        "completion_tokens": 155,
        "total_tokens": 19743
      }
    },
    {
      "question_id": 75,
      "question": "How does AMD's risk disclosure around wafer purchase targets under the Wafer Supply Agreement with GLOBALFOUNDRIES U.S. Inc. for 2022–2025 reconcile with the binding contractual amendments filed as Exhibit 10.63 on page 97?",
      "original_answer": "AMD's risk disclosure on page 23 outlines that under the Wafer Supply Agreement (WSA) with GLOBALFOUNDRIES (GF), AMD has annual wafer purchase targets through 2025 and may be required to pay GF a portion of the difference if those targets are not met. This creates a financial exposure risk tied to demand forecasting. The contractual amendment referenced on page 97 (Exhibit 10.63) confirms the binding nature of these commitments, including GF's obligation to provide minimum annual capacity and AMD's corresponding purchase obligations. This alignment shows that the qualitative risk described in the narrative section is underpinned by enforceable contractual terms, reinforcing the materiality of potential shortfalls or overcommitments in wafer procurement.",
      "llm_answer": "The 2022‑2025 wafer purchase targets under the GLOBALFOUNDRIES U.S. Inc. Wafer Supply Agreement are set out in the amendment to the agreement (Exhibit 10.63), which amends the previously incorporated Wafer Supply Agreement (Exhibit 10.50) and its subsequent amendments.  The amendment establishes minimum annual capacity allocations and corresponding purchase targets for AMD, with penalties for missing those targets, and replaces any prior exclusivity provisions, thereby reconciling the contractual obligations with the filing of the amendment as Exhibit 10.63 on page 97.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83904,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21209,
        "completion_tokens": 143,
        "total_tokens": 21352
      }
    },
    {
      "question_id": 75,
      "question": "How does MMM's retained equity interest in Solventum, which it intends to divest within five years, influence its ongoing exposure to PFAS-related liabilities that are specifically allocated to Solventum post-April 2024, particularly in light of MMM's retained obligations for certain product claims sold by Solventum through 2025?",
      "original_answer": "MMM retains an equity interest in Solventum and intends to divest it within five years, but during the holding period, Solventum assumes PFAS liabilities arising from its operations post-April 1, 2024, except for certain product claims sold between April 2024 and January 1, 2026, which MMM still retains liability for. This creates a hybrid exposure for MMM, where despite the spin-off and Solventum’s responsibility for future liabilities, MMM remains financially and legally exposed to legacy PFAS product claims from Solventum’s business during a transitional period. This exposure complicates MMM’s risk management and financial planning during the divestiture timeline.",
      "llm_answer": "MMM retains a 20% equity stake in Solventum and has contractually agreed to indemnify and defend Solventum for any PFAS‑related product claims that are sold by Solventum from April 1 2024 through December 31 2025. Consequently, even though the liability for those claims is allocated to Solventum, MMM’s ongoing exposure remains because it must still cover legal costs and any settlements or judgments arising from those product claims during the five‑year divestiture window. This retained indemnification obligation means MMM cannot fully walk away from PFAS liabilities tied to Solventum’s post‑spin‑off product sales.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 17,
          "pages": [
            15,
            16,
            17,
            18,
            19
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 93985,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23756,
        "completion_tokens": 155,
        "total_tokens": 23911
      }
    },
    {
      "question_id": 75,
      "question": "How does the Southern Company's 131.7% increase in wholesale affiliate revenues, driven by a 165.5% rise in KWH sales volume under the FERC-approved intercompany coordination framework, reflect its operational dependency on Southern Company Services for power pool management?",
      "original_answer": "The Southern Company's 131.7% increase in wholesale revenues from sales to affiliates in 2024, primarily due to a 165.5% increase in the volume of KWH sales, is directly tied to the intercompany coordination framework (IIC) approved by the FERC. The IIC governs the operation of the Southern Company power pool, under which the traditional electric operating companies and Southern Power Company coordinate their generation resources to achieve economic efficiency and reliability. This coordination is administered by Southern Company Services (SCS), which manages the centralized economic dispatch and operational control of the integrated electric system. The significant increase in affiliate sales volume underscores the importance of SCS in facilitating these transactions, as reflected in the dependency on SCS for managing power pool operations and the associated costs, which are included in other operations and maintenance expenses or capitalized to property, plant, and equipment. Therefore, the revenue growth from affiliate sales is not only a result of increased demand from affiliated companies but also a reflection of the critical role SCS plays in enabling these transactions through the IIC framework.",
      "llm_answer": "The Southern Company's 131.7% surge in wholesale affiliate revenues—driven by a 165.5% jump in KWH sales volume—directly reflects its operational reliance on Southern Company Services (SCS) to manage the Southern Company power pool, as evidenced by the IIC framework enabling coordinated generation dispatch, excess energy sharing, and cost recovery among affiliated entities like Alabama Power and Southern Power. This structure allows affiliate sales to be settled monthly through SCS, making the power pool's performance central to Southern Company's wholesale revenue strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 12,
          "pages": [
            10,
            11,
            12,
            13,
            14
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 165,
          "pages": [
            163,
            164,
            165,
            166,
            167
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 66125,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16783,
        "completion_tokens": 145,
        "total_tokens": 16928
      }
    },
    {
      "question_id": 75,
      "question": "Given BMY's ongoing legal liability for Onglyza despite divesting the product to AstraZeneca in 2014 and the continued financial interest indicated by Farxiga's trademark status, how does BMY's historical exposure to AstraZeneca's diabetes portfolio affect its current risk profile?",
      "original_answer": "BMY's ongoing legal liability for Onglyza, despite divesting the product to AstraZeneca in 2014, shows that divestiture did not fully remove BMY from financial risk associated with the product. This is evident from the litigation still pending in the Sixth Circuit as of December 2022. Meanwhile, Farxiga, another AstraZeneca diabetes drug, is listed in BMY’s 2023 10-K with trademark attribution, indicating a continued financial linkage to AstraZeneca’s diabetes portfolio. Together, these facts suggest that BMY remains exposed to legacy risks from its former diabetes business, despite no longer owning the products directly. This ongoing entanglement affects BMY’s current risk profile by maintaining legal and financial exposure to a therapeutic area it has ostensibly exited.",
      "llm_answer": "BMY's historical co-development and co-promotion of diabetes products with AstraZeneca (e.g., Onglyza) and its ongoing legal exposure to AstraZeneca's diabetes portfolio, including the divestiture of Onglyza to AstraZeneca in 2014 and continued financial interest indicated by Farxiga's trademark status, directly informs its current risk profile by creating shared liability exposure for diabetes-related litigation and regulatory matters, particularly as it relates to ongoing product liability and securities litigation involving AstraZeneca's diabetes portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 118,
          "pages": [
            116,
            117,
            118,
            119,
            120
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2023.pdf",
          "target_page": 138,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 106683,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26921,
        "completion_tokens": 141,
        "total_tokens": 27062
      }
    },
    {
      "question_id": 76,
      "question": "Given the 23% year-over-year growth in Server products and cloud services revenue to $97.7 billion in fiscal 2024, how does Microsoft's strategic positioning of SQL Server as a core component of this growth align with its disclosure that SQL Server revenue is reported alongside Client Access Licenses (CALs) rather than as a standalone product?",
      "original_answer": "Microsoft's Server products and cloud services segment grew from $79.97 billion in fiscal 2023 to $97.73 billion in fiscal 2024, a 23% increase, underscoring its strategic importance. Within this segment, SQL Server is highlighted as a core product, yet its revenue is not reported separately but rather bundled with Client Access Licenses (CALs) and other server products like Windows Server. This reporting methodology, disclosed in the Intelligent Cloud section, contrasts with the prominence given to SQL Server as a key enabler of enterprise data management and cloud infrastructure. The bundling suggests that SQL Server's financial performance is interwoven with broader licensing strategies, potentially masking its individual contribution to growth. Thus, while SQL Server is positioned as a foundational element of Microsoft's enterprise offerings, its financial impact must be inferred indirectly through aggregated reporting rather than direct revenue attribution.",
      "llm_answer": "Microsoft reports SQL Server revenue alongside Client Access Licenses (CALs) rather than as a standalone product, as noted in the \"Server products and cloud services\" description on page 10, where CAL revenue is \"reported along with the associated server product.\" This reporting approach aligns with its segment structure, where SQL Server falls under the Intelligent Cloud segment's server products and cloud services, which grew 22% to $97.7 billion in fiscal 2024 (page 93). The company discloses Microsoft Cloud revenue—which includes Azure, Office 365 Commercial, LinkedIn, and Dynamics 365—as a key metric (page 41), but SQL Server's revenue is not isolated; instead, it is bundled with CALs and other server offerings within the broader server products and cloud services category that drove 20% Intelligent Cloud segment growth (page 44). This integration reflects Microsoft's strategy of positioning SQL Server as part of its cloud and enterprise solutions ecosystem rather than a discrete revenue stream.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56727,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14450,
        "completion_tokens": 253,
        "total_tokens": 14703
      }
    },
    {
      "question_id": 76,
      "question": "How does Microsoft's inclusion of SA in Open Value agreements affect the recognition pattern and unearned revenue treatment of multi-year licenses compared to other volume licensing programs?",
      "original_answer": "Microsoft's Open Value agreements, designed for small and medium organizations, include Software Assurance (SA) and allow customers to license cloud services and on-premises software over a three-year period with the option to purchase perpetual licenses or subscribe. Since SA is included, it introduces complexity in determining the standalone selling price (SSP) and the pattern of delivery, requiring judgment in revenue recognition. On page 64, it is noted that SA and cloud services are part of unearned revenue, which is generally invoiced annually and recognized ratably over the coverage period. This creates a different revenue recognition and unearned revenue dynamic compared to other programs like the Microsoft Products and Services Agreement, where SA is optional, potentially altering the timing and structure of revenue recognition and unearned liabilities.",
      "llm_answer": "Microsoft's inclusion of Software Assurance (SA) in Open Value agreements results in ratable revenue recognition for the associated perpetual licenses over the agreement period, as SA is treated as a distinct performance obligation that is satisfied over time. This contrasts with other volume licensing programs like Enterprise Agreements, where SA is also included but the recognition pattern may differ based on contract structure, though Open Value specifically ties SA inclusion to ratable revenue recognition for multi-year perpetual license purchases.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 54822,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13930,
        "completion_tokens": 139,
        "total_tokens": 14070
      }
    },
    {
      "question_id": 76,
      "question": "How does AIG's ownership stake in United States Life Insurance Company in the City of New York, which is a member of FHLB of New York, relate to the specific borrowing obligations AIG has disclosed under the FHLB of New York facility, particularly in terms of liquidity strategy and credit support commitments?",
      "original_answer": "AIG holds a stake in United States Life Insurance Company in the City of New York, which is a member of the FHLB of New York. This membership enables AIG’s Life and Retirement companies to access collateralized borrowing through the FHLB system, with $241 million of borrowing obligations specifically attributed to the FHLB of New York facility as of December 31, 2023. These borrowings are supported by $8.7 billion in pledged assets, including those backing funding agreements, and are part of a broader liquidity strategy that also includes a $3.357 billion borrowing facility with the FHLB of Dallas. The stake in the life insurer thus directly supports AIG’s access to secured financing and contributes to its overall funding and liquidity positioning.",
      "llm_answer": "AIG’s ownership stake in the United States Life Insurance Company in the City of New York—an FHLB of New York member—provides it with additional collateralized borrowing capacity, allowing the company to tap the FHLB facility for liquidity and to obtain favorable funding spreads. This borrowing is reflected in the disclosed FHLB‑related debt maturities and is integrated into AIG’s overall liquidity strategy, which seeks to maintain ample cash‑flow flexibility and credit support commitments while leveraging its FHLB membership to meet short‑term funding needs.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 109602,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 27657,
        "completion_tokens": 141,
        "total_tokens": 27799
      }
    },
    {
      "question_id": 76,
      "question": "How does Honeywell's recognition of a $509 million reduction in receivables from Garrett relate to the mandatory redemption schedule of the Series B Preferred Stock received in the Garrett bankruptcy settlement, and how is this reflected in the fair value accounting treatment of the investment?",
      "original_answer": "Honeywell recognized a $509 million reduction in the carrying value of receivables from Garrett in 2020 due to the uncertainty surrounding the enforceability of the Garrett Indemnity and Tax Matters Agreement during Garrett’s bankruptcy proceedings. As part of the Garrett bankruptcy settlement confirmed in April 2021, Honeywell received $375 million in cash and 834.8 million shares of Garrett’s Series B Preferred Stock, which replaced the previous receivables. The Series B Preferred Stock has a mandatory redemption schedule of $35 million in 2022 and $100 million annually from 2023 to 2030, subject to Garrett’s EBITDA and liquidity conditions. Honeywell accounts for this investment as held-to-maturity, with its fair value based on the present value of these mandatory redemptions, and classified as Level 2 in the fair value hierarchy. This reflects a shift from a direct receivable to a structured equity instrument with defined redemption rights, which is now valued based on observable market data and contractual redemption terms.",
      "llm_answer": "The $509 million reduction in the receivable from Garrett reflects the present‑value adjustment of the amounts owed under the Garrett Indemnity and Tax Matters Agreement, which was recorded at the time Garrett filed for Chapter 11.  This adjustment is incorporated into the fair‑value accounting for Honeywell’s investment in Garrett’s Series B Preferred Stock: the investment is carried at the fair value of the mandatory redemption schedule (discounted at 7.25 %), and the present‑value of the redemption amounts is recognized as a gain that will accrete into interest income over the redemption period.  Consequently, the $509 million reduction is reflected in the fair‑value measurement of the investment and is amortized as interest income over the mandatory redemption schedule of the Series B Preferred Stock.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 24,
          "pages": [
            22,
            23,
            24,
            25,
            26
          ]
        },
        "hop_2_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 102,
          "pages": [
            100,
            101,
            102,
            103,
            104
          ]
        },
        "hop_3_rel": {
          "source_file": "HON_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 59494,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15130,
        "completion_tokens": 204,
        "total_tokens": 15334
      }
    },
    {
      "question_id": 77,
      "question": "How does MetLife's exposure to interest rate risk in its Retirement and Income Solutions segment relate to the scale of its life insurance business as reported in the consolidated financial statements?",
      "original_answer": "MetLife's Retirement and Income Solutions (RIS) segment contains both short- and long-duration products, including pension risk transfers and structured settlements, which are exposed to interest rate risk under hypothetical rate scenarios. This exposure affects gross margins and is mitigated through ALM strategies. RIS is part of the U.S. segment, which also includes Group Benefits, and together they offer a range of life and annuity-based products. According to the consolidated financial statements, life insurance revenue totaled $22.87 billion in 2021, indicating a significant portion of MetLife's business is tied to life insurance products that may be affected by interest rate fluctuations. Therefore, the interest rate sensitivity described in the RIS segment likely has a material impact on the broader life insurance business as a whole.",
      "llm_answer": "MetLife’s exposure to interest‑rate risk in its Retirement and Income Solutions (RIS) segment is closely tied to the scale of its overall life‑insurance business.  The RIS segment, which includes capital‑market products, pension‑risk transfers, structured settlements and benefit‑funding solutions, is reported alongside the rest of the U.S. segment (which also includes Group Benefits) and together accounts for roughly $35 billion of premiums, $5.3 billion of universal‑life and investment‑type policy fees, and $17.8 billion of net investment income in the consolidated statements (see page 184).  Because RIS’s earnings are sensitive to reinvestment risk and to changes in interest‑rate driven cash‑flow timing, the impact of a rising or falling rate environment is reflected in the segment’s adjusted earnings volatility—something that is measured against the broader size and profitability of the Company’s life‑insurance operations reported in the consolidated financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 190,
          "pages": [
            188,
            189,
            190,
            191,
            192
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 80666,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20401,
        "completion_tokens": 247,
        "total_tokens": 20648
      }
    },
    {
      "question_id": 77,
      "question": "How does CVS account for its Red Oak Sourcing joint venture with Cardinal Health in its consolidated financial statements, given the quarterly payments received from Cardinal and the 50% ownership structure?",
      "original_answer": "CVS consolidates Red Oak Sourcing, LLC in its financial statements despite the 50% ownership because it has determined that it is the primary beneficiary of the VIE, with the ability to direct Red Oak's activities. Although Red Oak is jointly owned with Cardinal Health and neither company holds inventory on behalf of the other, CVS receives quarterly payments from Cardinal that began in October 2014 and are tied to milestones, with payments increasing as those milestones are met. These payments, which totaled $183 million annually from 2019 to 2021, reduce CVS’s carrying value of inventory and are recognized in cost of products sold when the related inventory is sold. This accounting treatment reflects CVS’s control over the entity’s operations despite equal ownership, and the financial impact of the payments is directly tied to inventory cost recognition rather than revenue or equity method accounting.",
      "llm_answer": "CVS consolidates Red Oak Sourcing, LLC in its Retail/LTC segment because it is the primary beneficiary of the variable interest entity, despite the 50% ownership structure with Cardinal Health. The Company receives quarterly payments from Cardinal that are recognized in cost of products sold as inventory is sold, and these payments are unrelated to the equity ownership stake.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_2_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 18,
          "pages": [
            16,
            17,
            18,
            19,
            20
          ]
        },
        "hop_3_rel": {
          "source_file": "CVS_10k_2022.pdf",
          "target_page": 138,
          "pages": [
            136,
            137,
            138,
            139,
            140
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 58227,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14787,
        "completion_tokens": 94,
        "total_tokens": 14881
      }
    },
    {
      "question_id": 77,
      "question": "How does Intel reconcile its strategic decision to divest its NAND business to SK hynix with its ongoing commitment to manufacture NAND memory wafers at the Dalian facility until the second closing?",
      "original_answer": "Intel decided to divest its NAND memory business, including the Dalian fabrication facility, to SK hynix in October 2020, with the first closing completed on December 29, 2021. Despite this divestiture, Intel remains contractually obligated to manufacture NAND memory wafers at that facility for SK hynix until the second closing, which ensures a transitional supply arrangement. This ongoing manufacturing commitment reflects a strategic balance between exiting the NAND business and maintaining short-term operational continuity to support customer needs and fulfill contractual obligations. This transitional phase allows Intel to manage the financial and operational implications of the divestiture while still leveraging its existing manufacturing capabilities in the near term.",
      "llm_answer": "Intel reconciles its divestiture of the NAND business to SK hynix with its continued wafer production at the Dalian fab by noting that, after the first closing on December 29 2021 (which sold the Fab Assets and the NAND SSD Business), the company entered into a wafer‑manufacturing and sale agreement with SK hynix. Under this agreement, Intel will continue to manufacture and sell NAND memory wafers using the Dalian facility until the second closing, even though it is de‑consolidating its remaining interests in the NAND OpCo Business in Q1 2022【page_34】. This arrangement allows Intel to honor its supply commitments while gradually exiting the NAND business.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "hop_3_rel": {
          "source_file": "INTC_10k_2022.pdf",
          "target_page": 34,
          "pages": [
            32,
            33,
            34,
            35,
            36
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 31066,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 7989,
        "completion_tokens": 165,
        "total_tokens": 8155
      }
    },
    {
      "question_id": 77,
      "question": "How does Cisco's disclosure about the $1.5 billion in interest rate swaps hedging fixed-rate senior notes affect the interpretation of their $10 billion commercial paper program, particularly in light of the $9.0 billion in senior fixed-rate notes outstanding?",
      "original_answer": "Cisco disclosed a $10 billion commercial paper program on page 53, with $0.6 billion outstanding as of July 30, 2022. These commercial paper notes rank at par with the senior fixed-rate notes, which totaled $9.0 billion in principal as of the same date. Cisco also disclosed that it had entered into $1.5 billion in interest rate swaps to hedge certain fixed-rate senior notes, converting their fixed interest rates to floating rates based on LIBOR. This hedging activity, detailed on page 90, suggests an active interest rate risk management strategy. Given that a 50 BPS change in interest rates would impact the fair value of the unhedged fixed-rate debt by $0.3 billion (as noted on page 57), the hedging through swaps likely mitigates some of this exposure, which in turn may influence the relative attractiveness of issuing floating-rate commercial paper versus fixed-rate debt. This interplay reveals a strategic balance between managing interest rate exposure and maintaining flexibility in short-term financing.",
      "llm_answer": "Cisco’s disclosure that it entered into $1.5 billion of interest‑rate swaps to hedge the fixed‑rate senior notes does not alter the fact that the company still has $9 billion of senior fixed‑rate notes outstanding; the swaps merely convert the fixed interest on that debt to floating rates, leaving the principal amount of the notes unchanged. Consequently, the $10 billion commercial‑paper program remains a separate source of short‑term financing that is not directly tied to the hedged senior notes, even though the interest‑rate swap exposure is linked to the same underlying debt.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 77633,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19654,
        "completion_tokens": 146,
        "total_tokens": 19801
      }
    },
    {
      "question_id": 77,
      "question": "How does FedEx plan to maintain its service commitments to customers given the USPS's strategic changes to reduce reliance on FedEx Express's air network, which the company reported negatively impacted 2022 results?",
      "original_answer": "FedEx faces challenges due to the USPS's strategic changes to reduce reliance on FedEx Express's air network, which had a direct negative impact on FedEx's 2022 results. The company acknowledges this risk and highlights its integrated global air network as a key mitigation strategy. With a fleet of 696 aircraft (including approximately 300 supplemental aircraft), FedEx Express maintains an interchangeable and flexible global network that allows for route optimization and cost-effective delivery adjustments. This flexibility is critical to adapting to changes in volume and maintaining service commitments despite the reduction in USPS air transportation contracts.",
      "llm_answer": "FedEx plans to maintain its service commitments by continuing to invest in its integrated global network and by leveraging its capital‑intensive infrastructure—including aircraft, facilities, technology, and automation—to meet projected volume levels and service standards despite the USPS’s shift away from relying on FedEx Express’s air network, which contributed to a decline in 2022 results. The company emphasizes that its long‑term growth strategy, fleet planning, and ongoing investments in automation, data analytics, and network modernization are designed to preserve reliability and on‑time delivery for customers even as external competitors and strategic changes evolve.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_3_rel": {
          "source_file": "FDX_10k_2022.pdf",
          "target_page": 69,
          "pages": [
            67,
            68,
            69,
            70,
            71
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84886,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21452,
        "completion_tokens": 170,
        "total_tokens": 21623
      }
    },
    {
      "question_id": 77,
      "question": "What is the financial and strategic rationale behind Merck granting royalty-free licenses to generic manufacturers for molnupiravir in low- and middle-income countries, given their collaborative development and supply agreement with Ridgeback that includes commitments to produce millions of therapy courses at risk?",
      "original_answer": "Merck granted royalty-free licenses to generic manufacturers for molnupiravir in over 100 low- and middle-income countries through the Medicines Patent Pool, as long as the WHO maintains the Public Health Emergency of International Concern classification for COVID-19. This decision aligns with their strategic partnership with Ridgeback, under which both companies are investing at risk to produce millions of therapy courses globally. Despite forgoing potential royalty revenue from these regions, Merck’s approach supports broader public health goals and enhances global access, which could help build goodwill and strengthen their reputation as a leader in pandemic response. The financial rationale is reinforced by Merck’s advance purchase agreements in more than 30 markets and tiered pricing strategies that likely preserve profitability in higher-income regions.",
      "llm_answer": "Merck’s royalty‑free licensing strategy for molnupiravir in low‑ and middle‑income countries is part of its broader access plan that includes a risk‑based manufacturing commitment with Ridgeback (the partner that co‑developed the drug).  Under the collaboration, Merck agreed to invest at risk to produce millions of treatment courses and to grant voluntary licenses to generic manufacturers and the Medicines Patent Pool, enabling generic production in more than 100 LMICs once local regulatory approvals are obtained.  This approach, together with tiered pricing and supply agreements with governments, ensures that affordable molnupiravir can reach patients in those markets while Merck retains commercial rights in higher‑income regions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 67176,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17051,
        "completion_tokens": 185,
        "total_tokens": 17236
      }
    },
    {
      "question_id": 78,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related liabilities relate to the Cyprus Mines Corporation's involvement in the Imerys bankruptcy mediation, and what does this imply about the company's exposure to the multi-state investigation into talcum powder marketing?",
      "original_answer": "Johnson & Johnson has established a $9 billion reserve, payable over 25 years, to resolve current and future talc-related claims, which encompasses actual and contemplated settlements, including those tied to the Imerys bankruptcy proceedings. Cyprus Mines Corporation, which previously owned certain Imerys talc mines, filed for bankruptcy and proposed a plan that would allow it to contribute to a trust under the Imerys Plan in exchange for legal protection from talc claims. Cyprus, along with Imerys and claimants’ representatives, has been engaged in ongoing mediation since late 2021, with the Bankruptcy Court extending the mediation through December 2023. This indicates that J&J's liability exposure is being managed through structured legal frameworks involving third-party entities like Cyprus and Imerys, which seek to consolidate and channel talc claims through trusts. However, despite these mediation efforts, forty-two states and the District of Columbia have pursued a separate multi-state investigation into J&J’s marketing of talcum powder products. Although the states agreed to mediation in the LTL Bankruptcy Case in March 2022, New Mexico and Mississippi later opted out and resumed their cases in state court, with the broader mediation ultimately being terminated in March 2023. This suggests that while J&J has attempted to consolidate and manage talc-related liabilities through structured bankruptcy and mediation processes involving entities like Cyprus, it still faces parallel regulatory scrutiny that is not fully addressed through those mechanisms.",
      "llm_answer": "Johnson & Johnson has set aside roughly $9 billion in reserves to cover current and future talc‑related liabilities, reflecting the exposure from the multi‑state investigation into its talc marketing practices and the ongoing litigation stemming from that inquiry. This reserve underscores the company’s significant potential financial impact from the investigation and related lawsuits.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91651,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23156,
        "completion_tokens": 96,
        "total_tokens": 23253
      }
    },
    {
      "question_id": 78,
      "question": "How does Gulfstream's increased R&D investment tied to G700 certification align with the anticipated FAA certification timeline and its expected impact on 2024 revenue and operating margin guidance?",
      "original_answer": "Gulfstream's 2023 R&D expenses increased due to ongoing product development efforts, particularly those related to the G700 certification (page 37). This aligns with the production ramp-up of the G700 in anticipation of its FAA certification (page 71). The company expects the G700 to enter service following FAA certification in early 2024 (page 5), which supports the anticipated increase in Aerospace segment revenue to approximately $12 billion in 2024 and an expected operating margin of approximately 15%. The alignment of R&D investment, certification timing, and revenue guidance shows a coordinated strategy to bring the G700 to market and drive margin expansion.",
      "llm_answer": "Gulfstream's increased R&D investment tied to G700 certification aligns with the anticipated FAA certification timeline of early 2024, positioning the G700 to enter service shortly after certification. This timing is expected to drive a modest rise in 2024 revenue—reflected in the company's outlook of about $12 billion for the Aerospace segment—and to boost operating margin to roughly 15%, up from the 13.7% recorded in 2023.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 37,
          "pages": [
            35,
            36,
            37,
            38,
            39
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 42958,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 10969,
        "completion_tokens": 107,
        "total_tokens": 11076
      }
    },
    {
      "question_id": 78,
      "question": "Given the time-sensitive structure of the contingent value right tied to regulatory approval, how does the Fast Track designation for PR006 affect LLY's financial exposure related to the Prevail acquisition?",
      "original_answer": "The Fast Track designation for PR006, as noted in the regulatory context, increases the likelihood and potentially accelerates the timeline for FDA approval, which directly impacts LLY’s financial exposure tied to the Prevail acquisition. The CVR structure entitles Prevail shareholders to an additional $4.00 per share (approximately $160 million total) if regulatory approval of a Prevail product occurs by December 31, 2024. If approval occurs after that date, the CVR payout decreases by approximately 8.3 cents per month until December 1, 2028, after which it expires with no value. Since Fast Track designation is intended to expedite development and review for therapies addressing serious conditions and unmet medical needs, it improves the probability of earlier approval for PR006, which in turn increases the likelihood that LLY will pay the full contingent amount. This creates a strategic trade-off: while the Fast Track status enhances the value of the acquisition by improving the timeline and probability of success, it also increases LLY’s near-term financial exposure due to the full CVR payout being more likely.",
      "llm_answer": "The Fast Track designation for PR006 (and PR001) does not alter the accounting treatment of the contingent consideration tied to regulatory approval. Because the CVR payment is contingent on achieving regulatory approval by a specific date and is subject to a declining value after that date, LLY does not recognize any contingent payments until the approval occurs. Consequently, the Fast Track status does not increase LLY’s financial exposure to the Prevail acquisition; the exposure remains limited to the $747.4 million cash portion of the purchase price and the potential, but unrecognized, CVR liability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 39,
          "pages": [
            37,
            38,
            39,
            40,
            41
          ]
        },
        "hop_2_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "hop_3_rel": {
          "source_file": "LLY_10k_2022.pdf",
          "target_page": 66,
          "pages": [
            64,
            65,
            66,
            67,
            68
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70694,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17902,
        "completion_tokens": 152,
        "total_tokens": 18055
      }
    },
    {
      "question_id": 78,
      "question": "How does MetLife's offering of Retirement and Savings products in the EMEA segment compare to the financial metrics disclosed for EMEA in terms of policyholder account balances and deferred acquisition costs in 2021?",
      "original_answer": "MetLife offers Retirement and Savings products as part of its EMEA segment, which are reflected in the segment’s financial metrics. In 2021, the EMEA segment reported policyholder account balances of $9,392 million and deferred acquisition costs (DAC) and value of business acquired (VOBA) of $1,623 million. These figures indicate the segment's investment in acquiring and maintaining retirement and savings-related policies, while also reflecting the liabilities tied to these products. The relatively high policyholder account balances compared to DAC and VOBA suggest a mature book of business with significant accumulated value in policyholder accounts.",
      "llm_answer": "MetLife's EMEA segment reported policyholder account balances of $9,392 million and deferred acquisition costs of $1,623 million for 2021, which are disclosed in the consolidated supplementary insurance information (page 327). These figures are part of the segment’s financial metrics and are consistent with the overall segment totals shown for 2021.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 327,
          "pages": [
            325,
            326,
            327,
            328,
            329
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83124,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21019,
        "completion_tokens": 87,
        "total_tokens": 21107
      }
    },
    {
      "question_id": 78,
      "question": "How does NEE's disclosure of collateral posting requirements tied to credit ratings downgrades reconcile with the treatment of nuclear decommissioning reserve funds as part of special use funds, particularly in terms of financial flexibility and risk exposure?",
      "original_answer": "NEE discloses that if its subsidiaries' credit ratings were downgraded to below investment grade, they could be required to post up to $2.4 billion in additional collateral (as of December 31, 2023), which could significantly constrain financial flexibility. These collateral requirements apply to derivative contracts and are tied to credit ratings, with certain protections already in place via credit facilities. Meanwhile, the nuclear decommissioning reserve funds, which are a component of special use funds, hold restricted assets for future decommissioning liabilities at Seabrook, Duane Arnold, and Point Bech. These funds are primarily invested in marketable securities and are marked to fair value, directly impacting other comprehensive income. The connection lies in the fact that both collateral obligations and decommissioning reserves are held within the broader category of 'special use funds' on NEE’s consolidated balance sheets. However, while decommissioning funds are restricted for a specific long-term liability, collateral postings are contingent and variable based on credit conditions. This distinction reveals a dual-layered risk profile: one operational and market-linked (collateral), the other regulatory and long-term (decommissioning), both of which affect NEE’s liquidity and financial flexibility in different ways.",
      "llm_answer": "NEE’s disclosure of collateral posting requirements tied to credit‑rating downgrades is framed by its broader regulatory‑accounting framework for asset‑retirement obligations and special‑use funds.  Under the rate‑regulation rules that govern FPL and NEER, any increase in AROs or related nuclear‑decommissioning reserves is recorded as a regulatory liability (or asset) and is amortized over the asset’s useful life, ensuring that the financial impact of downgrade‑triggered collateral calls is offset by corresponding regulatory assets that preserve cash‑flow flexibility.  At the same time, the nuclear‑decommissioning reserve funds—held in special‑use funds and marked‑to‑market—provide a dedicated, ring‑fenced source of capital that can absorb collateral outflows without jeopardizing the utility’s ability to meet other regulatory‑required expenditures, thereby limiting direct risk exposure while maintaining the required collateral posture.  This dual treatment allows NEE to satisfy rating‑agency collateral triggers while preserving the regulatory‑driven funding mechanisms that underpin its long‑term financial flexibility.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 86,
          "pages": [
            84,
            85,
            86,
            87,
            88
          ]
        },
        "hop_2_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "hop_3_rel": {
          "source_file": "NEE_10k_2023.pdf",
          "target_page": 73,
          "pages": [
            71,
            72,
            73,
            74,
            75
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 112210,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 28294,
        "completion_tokens": 283,
        "total_tokens": 28578
      }
    },
    {
      "question_id": 79,
      "question": "How does Johnson & Johnson's $9 billion reserve for talc-related claims reflect its exposure through both direct litigation and potential indemnification obligations arising from the Imerys bankruptcy mediation?",
      "original_answer": "Johnson & Johnson has established a $9 billion reserve to address current and future talc-related claims, which includes both direct litigation exposure and potential indemnification obligations. This reserve reflects the company's estimate of probable loss following the dismissal of the LTL 2 bankruptcy case. Separately, Imerys, JNJ's former talc supplier, filed for bankruptcy and proposed a plan that would channel all talc-related claims against it into a trust, along with its alleged indemnification rights against JNJ. Mediation involving Imerys, Cyprus, and claimants has been ongoing since late 2021, with amended plans filed in 2023 and revised trust distribution procedures in early 2024. The continuation of this mediation, combined with unresolved direct litigation in federal and state courts—including the multi-district litigation expected to go to trial in early 2025—suggests that JNJ’s $9 billion reserve may not fully capture the long-term financial impact of these interconnected legal challenges.",
      "llm_answer": "Johnson & Johnson’s $9 billion reserve reflects the company’s exposure to talc‑related liability both through direct litigation—including the large number of personal‑injury claims and the $2.5 billion Ingham verdict—and through its indemnification obligations stemming from the Imerys bankruptcy mediation, where Imerys sought to channel talc claims to a trust and obtain indemnification from J&J. The reserve therefore covers anticipated settlements, judgments and the potential reimbursement of Imerys‑related claims.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2023.pdf",
          "target_page": 97,
          "pages": [
            95,
            96,
            97,
            98,
            99
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91651,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23139,
        "completion_tokens": 130,
        "total_tokens": 23269
      }
    },
    {
      "question_id": 79,
      "question": "How does Microsoft's inclusion of Software Assurance (SA) in Enterprise Agreements relate to the revenue recognition challenges described in the contract balances section, particularly regarding unearned revenue from volume licensing programs?",
      "original_answer": "Microsoft's Enterprise Agreements include Software Assurance (SA), which is a key component of their volume licensing programs aimed at medium and large organizations over a three-year period. SA is bundled with perpetual licenses or subscriptions under these agreements, contributing to unearned revenue that is invoiced annually and recognized ratably over the coverage period. However, the company notes that due to the nature and benefits of the SA program, judgment is required to assess the pattern of delivery, including the exercise pattern of benefits across the customer portfolio. This complicates revenue recognition, as SA is not sold separately, and its standalone selling price (SSP) must be estimated using available market and customer data. The unearned revenue from SA and cloud services under volume licensing programs is therefore subject to variability based on customer behavior and contract terms, making it a significant consideration in Microsoft's financial reporting.",
      "llm_answer": "Microsoft's inclusion of Software Assurance (SA) in Enterprise Agreements creates unearned revenue from volume licensing programs because SA is bundled with perpetual on-premises licenses and recognized ratably over the contract period as a distinct performance obligation. This results in revenue being deferred and recognized incrementally rather than upfront, directly contributing to the unearned revenue balances reported in Note 13 of the financial statements.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 54822,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13943,
        "completion_tokens": 116,
        "total_tokens": 14060
      }
    },
    {
      "question_id": 79,
      "question": "How does UPS's reliance on net asset value (NAV) as a practical expedient for valuing private equity fund investments reflect both the illiquidity characteristics of these funds and the audit challenges associated with estimating their fair value?",
      "original_answer": "UPS reports that private equity funds are valued at NAV per the most recent partnership audited financial reports, adjusted for investment activity between reporting periods, due to the lack of readily determinable fair value. These funds typically have 10- to 15-year terms with limited redemption provisions, making them highly illiquid. At the same time, the audit process highlights that NAV estimates for these funds require significant auditor judgment due to the subjective assumptions involved, especially since audited financial reports from fund managers are often received in arrears. This dual perspective underscores the tension between the practical need for NAV-based valuation and the inherent complexity and subjectivity in verifying those values during the audit.",
      "llm_answer": "UPS uses NAV as a practical expedient to value illiquid private‑equity, hedge‑fund, real‑estate and private‑debt investments, acknowledging that these assets lack readily observable market prices and must be estimated using unobservable inputs. This reliance creates audit challenges because auditors must evaluate the completeness, reliability and subjectivity of management’s NAV estimates, testing controls and corroborating inputs to ensure the valuations are fairly presented.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 77282,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19559,
        "completion_tokens": 120,
        "total_tokens": 19679
      }
    },
    {
      "question_id": 79,
      "question": "How does American Express's reliance on AENB for $84.4 billion in deposits relate to the regulatory constraints on AENB's dividend payments, and how does this interplay affect the company's broader compliance with federal banking regulations?",
      "original_answer": "American Express relies heavily on AENB for deposit funding, with $84.4 billion in deposits as of December 31, 2021, which is a core component of its funding strategy. However, AENB is subject to strict regulatory constraints on dividend payments, limited to available retained earnings and subject to capital adequacy requirements. As of the same date, AENB had only $3.6 billion in retained earnings available for dividends, which could constrain the amount of capital it can return to the parent company. This dynamic is further complicated by the broader regulatory environment, where American Express must comply with federal banking laws that require it to be a 'source of strength' to AENB and maintain capital plans that ensure regulatory compliance. If AENB's capital levels fall below required thresholds, both its ability to pay dividends and American Express’s broader financial flexibility could be restricted, highlighting the interplay between operational funding needs, regulatory capital constraints, and compliance obligations.",
      "llm_answer": "American Express's reliance on AENB for $84.4 billion of deposits subjects the bank to federal capital‑adequacy rules that impose dividend restrictions: AENB can only pay dividends from retained earnings and must retain enough capital to satisfy the CET1, Tier 1 and Total‑capital ratios (including the stress‑capital buffer and capital‑conservation buffer), as well as the leverage ratio. Consequently, any shortfall in AENB’s capital ratios—driven by the large deposit base and associated regulatory buffers—triggers constraints on discretionary capital distributions, limiting the parent company’s ability to pay dividends or repurchase shares and requiring ongoing compliance with federal banking regulations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64541,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16379,
        "completion_tokens": 178,
        "total_tokens": 16557
      }
    },
    {
      "question_id": 79,
      "question": "How does the expected revenue increase from the G700 aircraft entry into service reconcile with the increased inventory costs tied to FAA certification delays mentioned in different sections of the 10-K?",
      "original_answer": "The Aerospace segment's operating margin increased by 50 basis points in 2023 to 13.7%, with expectations of reaching approximately 15% in 2024, driven by the anticipated entry into service of the G700 aircraft and an increase in new aircraft deliveries to approximately 160 (page 37). However, the ramp-up in production of new Gulfstream models, including the G700, led to an increase in total inventories in anticipation of FAA certification (page 71). This inventory buildup reflects the operational costs and financial risk associated with certification delays. Meanwhile, the company explicitly notes on page 5 that the G700 is expected to enter service following FAA certification in early 2024, indicating that the timing of certification directly impacts revenue realization. Therefore, the expected revenue growth hinges on timely FAA certification, while the increased inventory costs suggest that delays or uncertainties in certification could strain short-term financial performance.",
      "llm_answer": "The 10‑K shows that inventory rose to $8.58 billion in 2023 because the company was building up stock of parts and raw materials in anticipation of the G700’s FAA certification and the accompanying increase in production of new Gulfstream models.  At the same time, the “Accounts Receivable” and “Unbilled Receivables” sections note that large customer advances and progress‑billing amounts tied to long‑term defense contracts (including the G700 program) are being recorded as cash inflows, offsetting the higher inventory outlay.  Thus, the expected revenue boost from the G700’s entry‑into‑service is being funded by those advances and progress billings, while the inventory cost increase reflects the pre‑certification ramp‑up needed to support that future revenue.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 37,
          "pages": [
            35,
            36,
            37,
            38,
            39
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2023.pdf",
          "target_page": 5,
          "pages": [
            3,
            4,
            5,
            6,
            7
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 42958,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 10971,
        "completion_tokens": 192,
        "total_tokens": 11163
      }
    },
    {
      "question_id": 80,
      "question": "How does American Express's reliance on AENB for $84.4 billion in deposits relate to the constraints imposed by banking regulations on AENB's dividend capacity, and how does this interplay affect American Express's broader compliance strategy with federal banking oversight?",
      "original_answer": "American Express relies on AENB as its primary U.S. bank subsidiary to source $84.4 billion in deposits, which are insured by the FDIC and serve as a key component of its funding strategy. However, AENB is subject to strict banking regulations that limit its ability to pay dividends to its parent company, particularly if doing so would cause AENB to fall below required capital adequacy standards or be deemed an unsafe banking practice. In 2021, AENB paid $8.1 billion in dividends to American Express, but retained earnings available for future dividends were only $3.6 billion as of year-end, indicating a potential constraint on future capital distributions. Given that American Express is under comprehensive federal oversight and must comply with regulations that include being a 'source of strength' to AENB, the company must carefully balance its capital planning and dividend strategy to remain compliant with regulators like the Federal Reserve and OCC. This interplay highlights how American Express must align its funding and capital distribution decisions with regulatory expectations to avoid enforcement actions and maintain operational flexibility.",
      "llm_answer": "American Express relies on AENB to fund roughly $84.4 billion of deposits, which constrains the bank’s ability to pay dividends because federal banking rules limit dividend distributions to amounts that preserve capital adequacy and safety‑and‑soundness. Consequently, AENB’s dividend capacity is restricted to retained earnings that meet the Federal Reserve’s and OCC’s capital‑ratio and stress‑buffer requirements, shaping American Express’s broader compliance strategy of maintaining capital above the effective minimum (e.g., 7 % CET1) and carefully planning dividend payouts within its capital‑plan submissions to avoid regulatory penalties.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_2_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 153,
          "pages": [
            151,
            152,
            153,
            154,
            155
          ]
        },
        "hop_3_rel": {
          "source_file": "AXP_10k_2022.pdf",
          "target_page": 14,
          "pages": [
            12,
            13,
            14,
            15,
            16
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64541,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16387,
        "completion_tokens": 161,
        "total_tokens": 16548
      }
    },
    {
      "question_id": 80,
      "question": "How does Apple's characterization of China Mainland as a supply chain risk factor relate to the financial performance of the Greater China segment, given that the segment includes China Mainland and reported $74.2 billion in net sales in 2022?",
      "original_answer": "Apple identifies China Mainland as a key part of its supply chain and notes that trade tensions, tariffs, and other disruptions in the region could materially impact its business, particularly by increasing costs and reducing gross margins. Despite these risks, the Greater China segment—which includes China Mainland, Hong Kong, and Taiwan—reported $74.2 billion in net sales in 2022, showing strong demand in the region. This suggests that while Apple faces operational and geopolitical risks in China Mainland, the broader Greater China market remains a significant revenue driver. The contrast between the risk-focused discussion of China Mainland and the positive financial performance of the Greater China segment highlights the dual nature of the region as both a strategic asset and a potential vulnerability for Apple.",
      "llm_answer": "Apple's 2022 10‑K identifies China Mainland as a supply‑chain risk factor, noting that most hardware is manufactured by outsourcing partners in China and that disruptions there could affect product availability, quality and costs. This risk contributed to the Greater China segment’s $74.2 billion net sales in 2022, but the filing does not link the risk factor to any specific financial performance impact on that segment. Consequently, while the risk is highlighted, the document provides no quantitative evidence that it materially altered the segment’s sales or profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_2_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 25,
          "pages": [
            23,
            24,
            25,
            26,
            27
          ]
        },
        "hop_3_rel": {
          "source_file": "AAPL_10k_2022.pdf",
          "target_page": 52,
          "pages": [
            50,
            51,
            52,
            53,
            54
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62270,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15810,
        "completion_tokens": 145,
        "total_tokens": 15955
      }
    },
    {
      "question_id": 80,
      "question": "How does UPS's disclosure regarding the $2.7 billion in unfunded commitments to private debt and private equity funds relate to their use of NAV as a valuation methodology for alternative investments?",
      "original_answer": "UPS reports a $2.7 billion unfunded commitment related to private debt and private equity funds on page 93, which are valued using NAV as a practical expedient due to the lack of readily determinable fair value. This NAV-based valuation approach is further referenced on page 94, where UPS clarifies that certain investments are measured at NAV per share or its equivalent. The use of NAV allows UPS to value these illiquid investments consistently with ASC measurement principles, despite the potential for differences between reported NAV and actual fair value. The $2.7 billion unfunded commitment underscores the ongoing capital exposure tied to these NAV-measured investments, highlighting the importance of NAV disclosures in understanding the company's long-term investment commitments.",
      "llm_answer": "UPS uses NAV as a practical expedient to value its alternative investments—including private‑equity, private‑debt, real‑estate and hedge‑fund interests—because these assets lack readily determinable market prices. The $2.7 billion of unfunded commitments disclosed represents the portion of those alternative‑investment assets for which the partnership agreements require future capital contributions, and the NAV‑based valuation methodology is applied to estimate their fair value.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2024.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 70907,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17950,
        "completion_tokens": 120,
        "total_tokens": 18070
      }
    },
    {
      "question_id": 80,
      "question": "Given the increase in Series B Preferred Stock book value from $456 million to $540 million year-over-year and the limited voting rights of preferred stockholders, how does this shift in capital structure affect the likelihood or dynamics of potential corporate combinations or strategic transactions involving Class A Common Stockholders?",
      "original_answer": "The increase in Series B Preferred Stock book value from $456 million to $540 million indicates a growing capital commitment from preferred stockholders, who hold no voting rights except in specific corporate events such as mergers or combinations. This dynamic could influence the strategic calculus of such transactions by concentrating voting power among Class A Common Stockholders, who retain full voting rights on general matters. However, any merger or consolidation where preferred stockholders would receive non-identical securities would require their separate approval, creating a dual-class dependency in key decisions. Thus, while the capital base tied to preferred stock has grown, the structural voting limitations may still preserve Class A Common Stockholders' control in shaping major corporate actions.",
      "llm_answer": "The rise in Series B Preferred Stock book value—from $456 million to $540 million year‑over‑year—reflects a larger liability that carries limited voting rights. Because preferred shareholders can only vote on a narrow set of matters (e.g., certain consolidation, merger or similar transactions that would alter their rights), their increased equity stake does not translate into broader governance influence. Consequently, any strategic transaction that requires preferred‑stockholder approval—such as a merger or combination that would affect their preferences—must secure affirmative votes from the series B (and series C) holders, but the limited voting power means such approvals are typically easier to obtain than with common shareholders. This dynamic can make corporate combinations that involve restructuring of the preferred‑stock hierarchy more feasible, yet it also means that any transaction must be structured to satisfy the preferences of the higher‑value, low‑voting preferred class, potentially constraining the range of viable deals for Class A common stockholders.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 58,
          "pages": [
            56,
            57,
            58,
            59,
            60
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2024.pdf",
          "target_page": 61,
          "pages": [
            59,
            60,
            61,
            62,
            63
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 103511,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 26142,
        "completion_tokens": 270,
        "total_tokens": 26413
      }
    },
    {
      "question_id": 81,
      "question": "How does MetLife's focus on Retirement and Savings products in the EMEA region align with the segment's financial obligations and liabilities, particularly in terms of policyholder account balances and future policy benefits?",
      "original_answer": "MetLife offers Retirement and Savings products, such as fixed annuities and pension products, as part of its global portfolio. These products are specifically offered in the EMEA region, indicating a strategic emphasis on retirement solutions in that market. In 2022, the EMEA segment reported $9,392 million in policyholder account balances and $3,639 million in future policy benefits, other policy-related balances, and policyholder dividend obligations. This significant level of liabilities tied to policyholder obligations reflects the long-term nature of retirement and savings products, which require sustained financial commitments. The alignment between the EMEA segment's product offerings and its reported liabilities underscores MetLife's exposure to long-duration contracts in this region and highlights the financial responsibility tied to fulfilling future retirement and savings obligations.",
      "llm_answer": "MetLife's focus on Retirement and Savings products in EMEA aligns with the segment's financial obligations by supporting the segment's policyholder account balances and future policy benefits through the pricing of these products, which is based on expected investment returns, mortality, longevity and expense assumptions. This pricing strategy ensures that the segment's liabilities, including future policy benefits and policyholder account balances, are appropriately reflected and managed within the overall segment capital and risk framework.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 184,
          "pages": [
            182,
            183,
            184,
            185,
            186
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2022.pdf",
          "target_page": 327,
          "pages": [
            325,
            326,
            327,
            328,
            329
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83124,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21022,
        "completion_tokens": 137,
        "total_tokens": 21159
      }
    },
    {
      "question_id": 81,
      "question": "How does Cisco's issuance of $0.6 billion in commercial paper notes relate to its $9.0 billion in senior fixed-rate notes, particularly in light of the interest rate sensitivity of the fixed-rate debt and the company's broader debt management strategy?",
      "original_answer": "Cisco's short-term commercial paper program, with $0.6 billion outstanding as of July 30, 2022, serves as a flexible source of liquidity for general corporate purposes. This short-term debt sits alongside $9.0 billion in senior fixed-rate notes, which carry a carrying value of $8.9 billion and a fair value of $9.7 billion as of the same date. The company has also entered into interest rate swaps on $1.5 billion of these fixed-rate notes to convert them to floating rates, mitigating interest rate exposure. A 50 BPS change in interest rates would decrease or increase the fair value of the unhedged fixed-rate debt by approximately $0.3 billion. This suggests Cisco is managing a mix of short-term liquidity via commercial paper and longer-term fixed-rate debt, with active hedging to manage interest rate risk across its capital structure.",
      "llm_answer": "Cisco’s $0.6 billion commercial‑paper issuance is a short‑term financing tool that complements its larger $9 billion senior fixed‑rate note program. The fixed‑rate notes carry interest‑rate sensitivity, so the company hedges portions of that exposure (e.g., interest‑rate swaps) and monitors market‑rate shifts that would affect the fair value of the debt. By issuing commercial paper at lower, floating rates, Cisco can manage overall debt‑service costs and preserve liquidity while maintaining a diversified funding mix that supports its broader debt‑management strategy.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 53,
          "pages": [
            51,
            52,
            53,
            54,
            55
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 77633,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19652,
        "completion_tokens": 143,
        "total_tokens": 19796
      }
    },
    {
      "question_id": 81,
      "question": "How does Cisco's disclosure of interest rate sensitivity for its senior fixed-rate notes reconcile with the company's reliance on commercial paper notes for general corporate purposes, particularly considering the floating rate exposure of the latter?",
      "original_answer": "Cisco disclosed on page 57 that a 50 BPS increase or decrease in market interest rates would change the fair value of its fixed-rate debt (excluding $1.5 billion of hedged debt) by approximately $0.3 billion. This indicates sensitivity to interest rate movements despite the fixed nature of these senior notes. On page 90, it is noted that the senior fixed-rate notes rank at par with future commercial paper notes issued under the company's short-term debt program. Finally, on page 89, Cisco states that it uses proceeds from commercial paper notes, which typically carry floating interest rates, for general corporate purposes. The floating rate exposure of commercial paper means that rising interest rates would increase Cisco’s short-term borrowing costs, contrasting with the largely fixed exposure profile of the senior notes. Therefore, while the senior notes provide rate stability (except for the unhedged portion), the commercial paper introduces variable rate risk, suggesting a diversified but potentially volatile debt structure.",
      "llm_answer": "Cisco discloses interest rate sensitivity for its senior fixed-rate notes by quantifying the hypothetical impact of a 50 basis‑point change in market rates on the fair value of the un‑hedged portion of that debt (approximately a $0.3 billion swing), while noting that such a change would not affect the interest expense on the fixed‑rate notes themselves. At the same time, the company relies on commercial paper for general corporate purposes, which is a floating‑rate instrument; thus, the floating‑rate exposure of the commercial paper is inherently aligned with current market rates and does not generate the same fixed‑rate sensitivity that the senior notes exhibit. Consequently, the note disclosures and the commercial paper usage are consistent: the fixed‑rate notes are assessed for market‑rate risk in isolation, whereas the commercial paper’s cost fluctuates with rates, eliminating any conflict between the two financing sources.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 57,
          "pages": [
            55,
            56,
            57,
            58,
            59
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2022.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 80371,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 20334,
        "completion_tokens": 235,
        "total_tokens": 20569
      }
    },
    {
      "question_id": 81,
      "question": "How does GD's reliance on commercial paper issuances for liquidity needs align with the $4 billion credit facility's role in supporting those same obligations, given the company's emphasis on maintaining a strong balance sheet?",
      "original_answer": "GD states on page 46 that it believes cash from operations, supplemented by commercial paper issuances, is sufficient to meet both short- and long-term liquidity needs. However, on page 75, the company discloses a $4 billion committed bank credit facility that exists specifically to support commercial paper issuances. This implies that while GD is not currently issuing commercial paper (as none was outstanding on December 31, 2024), the credit facility acts as a liquidity backstop to maintain flexibility and preserve a strong balance sheet, aligning with the company's stated capital deployment priorities and financial discipline.",
      "llm_answer": "GD’s $4 billion revolving credit facility provides a committed source of liquidity that backs the company’s ability to meet short‑term commercial‑paper obligations and other working‑capital needs, while its strong balance sheet and cash‑flow generation allow it to rely on commercial‑paper issuances as an additional, flexible financing source for liquidity.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 44379,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 11328,
        "completion_tokens": 89,
        "total_tokens": 11418
      }
    },
    {
      "question_id": 81,
      "question": "How does Amgen's patent protection timeline for polypeptide-based molecules like Tarlatamab align with the clinical development stage of Tarlatamab in small cell lung cancer?",
      "original_answer": "Amgen has polypeptide-related patent protection for Tarlatamab in both the U.S. and Europe extending through 2036, as shown in the intellectual property table. Meanwhile, Tarlatamab is in phase 3 clinical trials for small cell lung cancer, indicating it is in a later but still investigational stage of development. This suggests Amgen is aligning long-term patent protection with ongoing clinical development to maximize commercial exclusivity if Tarlatamab reaches market approval.",
      "llm_answer": "Amgen's patent protection for Tarlatamab, a half‑life‑extended anti‑DLL3 × anti‑CD3 BiTE, is projected to last until 2036 in both the United States and Europe, as shown in the patent‑expiration table for Phase 3 candidates. This timeline aligns with Tarlatamab’s current clinical development stage—it has completed a Phase 2 trial in advanced SCLC and received FDA Breakthrough Therapy and Priority Review designations, with a BLA submission targeting approval (PDUFA date June 12, 2024). Consequently, the patent exclusivity is expected to cover the product through the anticipated regulatory approval and commercial launch.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65061,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16486,
        "completion_tokens": 156,
        "total_tokens": 16642
      }
    },
    {
      "question_id": 81,
      "question": "How does the $829 million allocation to private debt in UPS's U.S. pension plans relate to the company's reliance on NAV estimates for auditing these illiquid investments?",
      "original_answer": "UPS allocated $829 million to private debt within its U.S. pension plans, which are valued using net asset value (NAV) as a practical expedient due to the lack of readily determinable fair values. These private debt investments are subject to subjective NAV estimations based on audited or unaudited financial reports from fund managers, with adjustments for investment activity between reporting periods. The audit process for these NAV-based valuations required significant auditor judgment and procedures to evaluate the reliability and completeness of inputs, including direct confirmation with fund managers and comparison of prior estimates to audited results. This creates a three-hop chain where the disclosed private debt amount (from the pension asset allocation table) is tied to NAV valuation practices and further to the audit scrutiny around those estimates, revealing both the strategic investment decision and the operational risk in reporting its value.",
      "llm_answer": "The $829 million allocated to private‑debt investments is classified as a Level 3, unobservable‑input valuation that relies on NAV estimates. Because these assets are not traded on active markets, auditors must subjectively evaluate the completeness, reliability and relevance of the inputs used to estimate their NAV, making the valuation a critical audit matter. This dependence on NAV estimates underpins the audit focus on the accuracy of the private‑debt fair‑value measurement.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_2_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "hop_3_rel": {
          "source_file": "UPS_10k_2023.pdf",
          "target_page": 63,
          "pages": [
            61,
            62,
            63,
            64,
            65
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74038,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18731,
        "completion_tokens": 120,
        "total_tokens": 18852
      }
    },
    {
      "question_id": 81,
      "question": "Given Southern Power's stated useful life of wind assets as up to 30 years, how does the 12-year PPA contract period for the Glass Sands wind project completed in 2021 align with the company's long-term asset utilization strategy?",
      "original_answer": "Southern Power reports a useful life of wind assets as up to 30 years, suggesting a long-term operational outlook for such facilities. However, the Glass Sands wind project, completed in November 2021, operates under a PPA with a contract period of only 12 years. This shorter-term agreement appears inconsistent with the asset's expected longevity, potentially signaling a strategic decision to prioritize near-to-mid-term revenue stability over long-term contractual commitments in certain markets.",
      "llm_answer": "Southern Power's 12-year PPA for the Glass Sands wind project aligns with its long-term asset utilization strategy by leveraging the asset's 30-year useful life estimate. The shorter PPA term allows for periodic renegotiation and potential repowering opportunities, while the underlying asset remains on the books for up to 30 years, supporting sustained depreciation and potential future revenue streams beyond the contract term.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 330,
          "pages": [
            328,
            329,
            330,
            331,
            332
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 71748,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18174,
        "completion_tokens": 107,
        "total_tokens": 18281
      }
    },
    {
      "question_id": 82,
      "question": "How does Amgen's revised collaboration with Novartis on Aimovig, effective January 1, 2022, impact Amgen's competitive positioning in the U.S. market, especially given Novartis's direct competition with Otezla and Nplate in key therapeutic areas?",
      "original_answer": "Amgen's revised collaboration with Novartis on Aimovig, effective January 1, 2022, removed U.S. cost-sharing and royalty obligations, giving Amgen full control over Aimovig’s U.S. commercialization. This change likely strengthens Amgen’s ability to directly compete in the U.S. market. However, Novartis remains a competitor to Amgen in several therapeutic areas, including with Otezla and Nplate, where Novartis markets Cosentyx and PROMACTA/REVOLADE, respectively. This dual relationship—where Novartis both collaborates globally on Aimovig and competes directly in other product lines—creates a complex competitive dynamic that could influence Amgen’s market strategy and performance in neurology and hematology.",
      "llm_answer": "Amgen's revised collaboration with Novartis on Aimovig, effective January 1 2022, removes Novartis’s role in U.S. commercialization and royalty payments, allowing Amgen to retain full control of the U.S. market for the migraine drug. This shift is significant because Novartis directly competes with Amgen in key therapeutic areas through its own products such as Otezla and Nplate, so ending the partnership eliminates a major source of competitive pressure and aligns Amgen’s commercial strategy with its own pipeline and pricing strategies.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 28,
          "pages": [
            26,
            27,
            28,
            29,
            30
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2022.pdf",
          "target_page": 16,
          "pages": [
            14,
            15,
            16,
            17,
            18
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 66370,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16831,
        "completion_tokens": 135,
        "total_tokens": 16967
      }
    },
    {
      "question_id": 82,
      "question": "How does the allocation of Fixed Income Securities and Cash Equivalents within TXN's U.S. Retiree Health Care Plan reflect the plan's approach to managing liability risk, given the $251 million in plan assets allocated to this category in 2021?",
      "original_answer": "The U.S. Retiree Health Care Plan allocated $251 million, or 64% of its total assets, to Fixed Income Securities and Cash Equivalents in 2021. This reflects a conservative risk management strategy, prioritizing capital preservation and stable returns to better match the plan’s long-term liability profile. The high allocation to fixed income suggests an emphasis on reducing volatility in plan returns, which is consistent with the plan’s need to meet predictable healthcare obligations to retirees.",
      "llm_answer": "The $251 million allocation to Fixed Income Securities and Cash Equivalents in the U.S. Retiree Health Care Plan reflects a deliberate strategy to manage liability risk by holding a substantial, relatively stable portion of plan assets in low‑volatility, interest‑rate‑sensitive instruments. This allocation aligns with the plan’s target range of 65%‑80% for fixed‑income and cash equivalents, ensuring that a significant share of assets can meet upcoming benefit payments and reducing exposure to market fluctuations, while the remaining assets are invested in equities to provide growth that helps offset long‑term liability increases.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "TXN_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_2_rel": {
          "source_file": "TXN_10k_2022.pdf",
          "target_page": 50,
          "pages": [
            48,
            49,
            50,
            51,
            52
          ]
        },
        "hop_3_rel": {
          "source_file": "TXN_10k_2022.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72783,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18430,
        "completion_tokens": 159,
        "total_tokens": 18589
      }
    },
    {
      "question_id": 83,
      "question": "How does Amgen's patent protection timeline for polypeptide-based molecules, including Tarlatamab, align with the company's strategic investment in advancing Tarlatamab into phase 3 trials for small cell lung cancer?",
      "original_answer": "Amgen has disclosed that Tarlatamab, an investigational polypeptide-based molecule for small cell lung cancer, is protected by patents expiring in 2036 in both the U.S. and Europe. This long-duration patent protection aligns with Amgen's decision to invest in initiating phase 3 trials for Tarlatamab, indicating a strategic commitment to its development and commercialization. The extended IP protection provides Amgen with a competitive window to recoup R&D investments and establish market positioning in a high-need therapeutic area.",
      "llm_answer": "Amgen's patent protection for Tarlatamab—its half-life-extended anti-DLL3 × anti‑CD3 BiTE—is projected to last until 2036 in both the United States and Europe (see the Phase 3 Patent Information table). This long‑term exclusivity aligns with the company’s strategy of investing heavily in advancing Tarlatamab through clinical development, including its recent Phase 2 DeLLphi‑301 results, FDA Breakthrough Therapy designation, and a priority‑review BLA with a June 12 2024 PDUFA date, all of which support moving the candidate into Phase 3 trials for small‑cell lung cancer.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "hop_3_rel": {
          "source_file": "AMGN_10k_2023.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 65061,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16496,
        "completion_tokens": 143,
        "total_tokens": 16640
      }
    },
    {
      "question_id": 83,
      "question": "How does Broadcom's positioning of the Payment Security Suite as a SaaS-based fraud prevention service align with the strategic emphasis on 3-D Secure technology within their broader Payment Security portfolio, and what does this suggest about their approach to securing online transactions?",
      "original_answer": "Broadcom positions the Payment Security Suite as a SaaS-based payment authentication service aimed at helping banks and merchants protect against fraud and ensure a seamless online shopping experience (page 13). This offering is explicitly tied to the company's broader Payment Security portfolio, which is described as being powered by 3-D Secure technology (page 11). The inclusion of 'Arcot payment authentication network powered by 3-D Secure' under the Payment Security category indicates that the Payment Security Suite is built on this foundational authentication framework. This alignment suggests that Broadcom is leveraging its established 3-D Secure infrastructure to deliver modern, cloud-delivered payment authentication solutions that address evolving fraud risks in digital commerce. The strategic emphasis on this technology within the portfolio table, alongside the SaaS delivery model described in the narrative, reflects an integrated approach to payment security that combines proven authentication methods with scalable cloud services.",
      "llm_answer": "Broadcom positions its Payment Security Suite as a SaaS-based fraud prevention service that leverages 3-D Secure technology within its broader Payment Security portfolio, emphasizing a cloud-native approach to securing online transactions. This alignment reflects a strategic focus on modern, scalable authentication solutions that enhance transaction security while improving user experience, underscoring Broadcom’s commitment to integrating advanced payment protection into its infrastructure software offerings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "hop_3_rel": {
          "source_file": "AVGO_10k_2022.pdf",
          "target_page": 11,
          "pages": [
            9,
            10,
            11,
            12,
            13
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 9,
        "total_chars": 47648,
        "num_window_pages": 9,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12159,
        "completion_tokens": 128,
        "total_tokens": 12287
      }
    },
    {
      "question_id": 83,
      "question": "How does Southern Power's investment in battery energy storage, including the Garland Solar Storage facility, align with its strategy to utilize tax credits and manage operational risk in its long-term power purchase agreements?",
      "original_answer": "Southern Power's investment in battery energy storage, including the Garland Solar Storage facility in Kern County, CA, with 88 MW nameplate capacity and a 20-year PPA, is part of a broader strategy to leverage federal tax credits such as ITCs and PTCs. These investments are structured to maximize tax equity partnerships, where partners take the majority of federal tax benefits, allowing Southern Power to monetize these incentives while reducing its own capital exposure. This aligns with the company's approach to managing operational risk under long-term PPAs, where fixed and variable costs are often passed through to customers via energy charges, and where the integration of storage enhances dispatchability and reliability of renewable energy output. Garland Solar Storage, as a co-located battery facility, supports this model by enabling better utilization of solar generation and optimizing revenue under long-term contracts.",
      "llm_answer": "Southern Power's investments in battery energy storage, such as the Garland Solar Storage facility, are designed to leverage federal Investment Tax Credits (ITCs) and Production Tax Credits (PTCs) that materially improve project economics and cash flow. These tax credits, which are partially utilized through tax equity partnerships, are expected to be fully realized by 2028, supporting Southern Power's strategy to manage long-term power purchase agreement (PPA) risk while generating stable revenue from contracted PPAs. The Garland facility, operational since 2021–2022, exemplifies this approach, enabling Southern Power to monetize clean energy incentives and enhance the financial viability of its renewable energy portfolio.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 290,
          "pages": [
            288,
            289,
            290,
            291,
            292
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 92921,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23465,
        "completion_tokens": 183,
        "total_tokens": 23648
      }
    },
    {
      "question_id": 84,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for formulated pharmaceutical products factor into the financial impact of the spin-off as reflected in Merck's discontinued operations reporting?",
      "original_answer": "Merck's spin-off of Organon involved a complex transition framework including multi-year manufacturing and supply agreements (MSAs), under which Merck agreed to toll manufacture and supply certain formulated pharmaceutical products for Organon. These agreements generated $219 million in sales and $195 million in cost of sales in 2021, indicating continued economic interaction post-spin-off. However, the spin-off also resulted in the classification of Organon's businesses (including women's health, biosimilars, and established brands) as discontinued operations, with Merck incurring $556 million in separation costs in 2021 and $743 million in 2020. The continuation of manufacturing relationships under the MSAs suggests that while Organon was spun off as a separate entity, Merck retained a strategic role in its supply chain, which complicates the clean separation of financial results and raises questions about the long-term implications of these interdependencies on Merck's reported discontinued operations.",
      "llm_answer": "The ongoing manufacturing relationship between Merck and Organon—specifically the manufacturing and supply agreements (MSAs) that require Merck to produce and toll‑manufacture certain formulated pharmaceutical products for Organon—is treated as part of the discontinued operations.  Because these activities generated $219 million of sales and $195 million of related cost of sales in 2021, the associated income and expenses are reported within “Income from Discontinued Operations, Net of Taxes” in Merck’s consolidated statement of income, reflecting the financial impact of the spin‑off.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 146,
          "pages": [
            144,
            145,
            146,
            147,
            148
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68538,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17365,
        "completion_tokens": 147,
        "total_tokens": 17513
      }
    },
    {
      "question_id": 84,
      "question": "How does Microsoft's inclusion of Software Assurance (SA) in Open Value agreements affect the recognition pattern of unearned revenue for multi-year on-premises licenses compared to other volume licensing programs?",
      "original_answer": "Microsoft includes Software Assurance (SA) in Open Value agreements, which are designed for small and medium organizations licensing over a three-year period. Since SA is included by default, this affects the revenue recognition pattern because SA benefits are delivered over time, requiring judgment in estimating standalone selling prices (SSP) and recognizing revenue ratably over the coverage period. This contrasts with other licensing models where SA may be optional or not bundled, allowing for more upfront revenue recognition. The unearned revenue related to such programs, including SA and cloud services, is generally invoiced annually and recognized over the contract term, as noted in the financial reporting section on unearned revenue.",
      "llm_answer": "Microsoft’s inclusion of Software Assurance (SA) in Open Value agreements requires ratable recognition of revenue for the perpetual on‑premises licenses that are bundled with SA, because SA is treated as a distinct performance obligation that is delivered over the contract term. In contrast, other volume‑licensing programs that do not include SA generally recognize the on‑premises license revenue upfront at the point of sale, with SA (when purchased separately) recognized over time; thus, Open Value’s bundled SA results in a different, more deferred revenue pattern for multi‑year on‑premises licenses.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 19,
          "pages": [
            17,
            18,
            19,
            20,
            21
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2022.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 54822,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13936,
        "completion_tokens": 152,
        "total_tokens": 14088
      }
    },
    {
      "question_id": 84,
      "question": "How does the inclusion of AspenTech in Emerson's 2023 segment revenue data relate to the performance stock units granted by AspenTech, and what does this imply about Emerson's strategic alignment with AspenTech's post-acquisition incentive structure?",
      "original_answer": "Emerson includes AspenTech in its 2023 segment revenue data with a reported revenue of $1 million for 2023 and an expected increase to $8 million in 2024, indicating AspenTech's growing contribution to Emerson’s overall performance. AspenTech, now operating as a separate publicly traded company post-acquisition, grants performance stock units (PSUs) that vest based on predefined goals tied to annual contract value and free cash flows. At the same time, Emerson’s disclosures on page 72 indicate that up to 175% of these PSUs could vest upon achievement of performance goals, showing a strong emphasis on performance-based incentives. This alignment suggests that Emerson is structuring AspenTech’s compensation strategy to incentivize outcomes that directly support revenue growth and financial performance, consistent with the increasing revenue expectations seen in the segment data.",
      "llm_answer": "The inclusion of AspenTech’s performance stock units in Emerson’s 2023 segment revenue reflects the integration of AspenTech’s incentive structure into Emerson’s post‑acquisition compensation framework, where performance units tied to contract‑value growth and free‑cash‑flow targets can vest up to 150 % (or, as noted on page 72, up to 175 %) of the award if predefined goals are met. This alignment ensures that Emerson’s stock‑based compensation expense for AspenTech is contingent on achieving the same performance metrics that drive segment earnings, thereby tying a portion of the reported segment revenue to the achievement of those incentive‑based targets. Consequently, Emerson’s strategic alignment with AspenTech’s post‑acquisition incentive structure is demonstrated by the contingent nature of the performance units—only the portion that vests contributes to compensation expense, reinforcing the linkage between financial results and the achievement of AspenTech’s performance goals.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 55,
          "pages": [
            53,
            54,
            55,
            56,
            57
          ]
        },
        "hop_2_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 70,
          "pages": [
            68,
            69,
            70,
            71,
            72
          ]
        },
        "hop_3_rel": {
          "source_file": "EMR_10k_2023.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 67398,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17091,
        "completion_tokens": 249,
        "total_tokens": 17340
      }
    },
    {
      "question_id": 84,
      "question": "How does Bank of America's exposure to Nonbank VIEs as disclosed in the long-term debt maturity table relate to the valuation risks associated with Structured Liabilities in the fair value measurement section?",
      "original_answer": "Bank of America's exposure to Nonbank VIEs is detailed in the long-term debt maturity table on page 137, where the company reports $564 million in debt associated with these entities, maturing in varying amounts from 2024 through thereafter. These Nonbank VIEs issue Structured Liabilities, a category of debt whose repayment terms are tied to the performance of other financial instruments, as noted on page 136. The fair value measurement section on page 154 reveals that Structured Liabilities are valued using complex quantitative models that incorporate both observable and unobservable market inputs, including interest rate curves, equity or commodity prices, and volatility factors. This introduces significant estimation risk, particularly when market inputs are not readily available or must be extrapolated. Therefore, while the maturity table provides a quantitative view of BAC's exposure to Nonbank VIEs, the fair value section highlights the qualitative risks embedded in Structured Liabilities, which are sensitive to market conditions and model assumptions, suggesting that the actual economic exposure may differ materially from the face value reported in the maturity schedule.",
      "llm_answer": "Bank of America’s exposure to non‑bank VIEs disclosed in the long‑term debt maturity table reflects the amount of structured‑liability debt that is backed by assets held in those consolidated VIEs, which are themselves subject to valuation risk under the fair‑value measurement framework. This risk is highlighted in the fair‑value section, where the Corporation notes that the fair value of structured liabilities (including those issued by non‑bank VIEs) is highly sensitive to observable market inputs and may require significant adjustments for credit risk, liquidity, and other unobservable assumptions. Consequently, the VIE‑related debt maturities represent a direct exposure to the valuation uncertainties described in the fair‑value measurement disclosures.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 137,
          "pages": [
            135,
            136,
            137,
            138,
            139
          ]
        },
        "hop_2_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 136,
          "pages": [
            134,
            135,
            136,
            137,
            138
          ]
        },
        "hop_3_rel": {
          "source_file": "BAC_10k_2023.pdf",
          "target_page": 154,
          "pages": [
            152,
            153,
            154,
            155,
            156
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 14,
        "total_chars": 114646,
        "num_window_pages": 14,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 28894,
        "completion_tokens": 191,
        "total_tokens": 29086
      }
    },
    {
      "question_id": 84,
      "question": "Why does Mississippi Power qualify for the reduced disclosure format in its 10-K filing, and how does its status as a non-reporting subsidiary impact its governance and reporting obligations to Southern Company?",
      "original_answer": "Mississippi Power qualifies for the reduced disclosure format under General Instructions I(1)(a) and (b) of Form 10-K because it meets the conditions specified in those instructions. This reduced format is available to subsidiaries that are not required to file annual reports with the SEC or provide annual reports to their sole shareholder. As noted in its signature section, Mississippi Power does not send an annual report or proxy statement to its parent company, Southern Company, and does not prepare such reports after filing its Form 10-K. This aligns with the governance structure where Mississippi Power operates as a wholly-owned subsidiary with limited standalone reporting obligations, reflecting a streamlined regulatory compliance model that supports its integrated role within the Southern Company system.",
      "llm_answer": "Mississippi Power qualifies for the reduced disclosure format in its 10-K filing because, as a non-reporting subsidiary of The Southern Company, it meets the conditions in General Instructions I(1)(a) and (b) of Form 10-K and is therefore permitted to use the reduced disclosure format specified in General Instructions I(2)(b), (c), and (d). Its status as a non-reporting subsidiary means it does not file separate Forms 10-K, 10-Q, or other periodic reports with the SEC and instead relies on The Southern Company’s consolidated filings for its reporting obligations, resulting in less extensive standalone governance and financial disclosures compared to reporting subsidiaries.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 372,
          "pages": [
            344,
            345,
            346,
            347,
            348
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2022.pdf",
          "target_page": 4,
          "pages": [
            2,
            3,
            4,
            5,
            6
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 13,
        "total_chars": 67121,
        "num_window_pages": 13,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17010,
        "completion_tokens": 170,
        "total_tokens": 17180
      }
    },
    {
      "question_id": 85,
      "question": "How does BMY's strategic partnership with 2seventy bio, which includes profit-sharing on U.S. sales of anti-BCMA products like Abecma, reflect in both the collaborative agreement terms and the financial performance metrics reported for 2024?",
      "original_answer": "BMY's strategic partnership with 2seventy bio involves joint development and commercialization of anti-BCMA products, including Abecma, which received FDA approval in 2021 for treating relapsed or refractory multiple myeloma. Under the agreement, 2seventy bio has the right to participate in the U.S. development and commercialization of licensed products, including a 50/50 profit share in exchange for reduced milestone payments. This arrangement is directly reflected in BMY's financial performance for 2024, where U.S. net product sales of Abecma were $242 million, and the related profit-sharing costs amounted to $43 million. This demonstrates how the collaborative structure with 2seventy bio directly impacts BMY's financials through shared profitability and cost obligations.",
      "llm_answer": "BMY's strategic partnership with 2seventy bio, which grants the company profit‑sharing rights on U.S. sales of anti‑BCMA products such as Abecma, is reflected both in the terms of the collaboration agreement and in the 2024 financial metrics.  The agreement provides 2seventy bio a 50/50 co‑development and profit‑share in the United States in exchange for reduced milestone payments, and the partnership’s financial impact is evident in the alliance‑related expense line items reported in the 2024 Form 10‑K.  Specifically, the company recorded $43 million of profit‑sharing costs for Abecma in 2024 (up from $109 million in 2023 and $49 million in 2022), and the related “Payments to/(from) alliance partners” section shows research‑and‑development outlays of $237 million and acquired IPRD expense of $880 million attributable to the 2seventy bio collaboration, underscoring how the partnership’s profit‑sharing arrangement is captured in BMS’s 2024 earnings.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 134,
          "pages": [
            132,
            133,
            134,
            135,
            136
          ]
        },
        "hop_2_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "hop_3_rel": {
          "source_file": "BMY_10k_2024.pdf",
          "target_page": 91,
          "pages": [
            89,
            90,
            91,
            92,
            93
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 73501,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18614,
        "completion_tokens": 240,
        "total_tokens": 18854
      }
    },
    {
      "question_id": 85,
      "question": "How does ACN manage the financial risk associated with short-term, easily terminable client contracts while pursuing a strategy of deepening client relationships through long-term AI and managed services investments?",
      "original_answer": "ACN acknowledges in its accounting policies (page 43) that the majority of its contracts are terminable by clients on short notice with little or no penalties, and only the non-cancelable portion is included in performance obligations. This creates a risk of revenue volatility if clients delay, reduce, or eliminate spending. Despite this, ACN is pursuing a strategy of deepening client relationships through long-term AI and managed services investments, as noted on page 6, where it states that managed services are strategic for clients seeking to leverage AI and automation. To manage this risk, ACN emphasizes innovation and strategic investments, including $6.6 billion across 46 acquisitions in fiscal 2024, to build capabilities that align with client needs and drive long-term value. This suggests a dual approach of mitigating contract risk through continuous innovation and expansion of high-value offerings that encourage client retention and deeper partnerships.",
      "llm_answer": "ACN mitigates the financial risk of short‑term, easily terminable contracts by pairing them with long‑term AI and managed‑services investments that generate recurring revenue and higher‑margin bookings; it offsets the volatility of consulting engagements through the growth of managed‑services revenue (up 4% USD, 5% local in fiscal 2024) and by maintaining a diversified client base across geographic markets and industry groups, while using early‑termination fees and variable consideration estimates to protect profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ACN_10k_2023.pdf",
          "target_page": 43,
          "pages": [
            41,
            42,
            43,
            44,
            45
          ]
        },
        "hop_2_rel": {
          "source_file": "ACN_10k_2023.pdf",
          "target_page": 22,
          "pages": [
            20,
            21,
            22,
            23,
            24
          ]
        },
        "hop_3_rel": {
          "source_file": "ACN_10k_2023.pdf",
          "target_page": 6,
          "pages": [
            4,
            5,
            6,
            7,
            8
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75816,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19189,
        "completion_tokens": 132,
        "total_tokens": 19321
      }
    },
    {
      "question_id": 85,
      "question": "How does the allocation of PFAS-related liabilities between MMM and Solventum, effective April 1, 2024, impact MMM's financial exposure to product claims involving Solventum's products sold between April 1, 2024, and January 1, 2026, especially in light of MMM's historical litigation costs and the spin-off's indemnification framework?",
      "original_answer": "MMM retains liability for PFAS-related product claims arising from Solventum's products sold between April 1, 2024, and January 1, 2026, unless the products fall under specific exceptions such as new PFAS-containing products introduced by Solventum post-spin-off or modified products. Given MMM's historical litigation experience—where the average cost per claim has increased due to a higher proportion of serious injury cases like mesothelioma—the company may face elevated costs for these retained claims. However, the spin-off agreement includes indemnification provisions where Solventum assumes certain liabilities, potentially mitigating MMM's exposure. This creates a nuanced financial risk profile where MMM remains exposed to legacy liabilities and near-term product claims, despite the separation, and must balance this with insurance recoverables and indemnification rights under the distribution agreement.",
      "llm_answer": "The separation and distribution agreement assigns Solventum responsibility for product‑claim liabilities involving PFAS that arise from Solventum’s products sold between April 1 2024 and January 1 2026, while the Company retains all other PFAS‑related liabilities. Consequently, MMM’s exposure to claims tied to Solventum’s products in that period is limited to the indemnification and defense obligations set out in the agreement, and it will not record accruals for those future claims unless they become probable and reasonably estimable.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 95587,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24154,
        "completion_tokens": 135,
        "total_tokens": 24289
      }
    },
    {
      "question_id": 85,
      "question": "How does Southern Company's credit arrangement structure for Nicor Gas align with the reported decrease in Nicor Gas' short-term notes payable from $392 million in 2023 to $172 million in 2024?",
      "original_answer": "Southern Company's credit arrangements include a $700 million allocation for Nicor Gas under a multi-year credit facility expiring in 2029, which provides working capital flexibility. This arrangement allows Nicor Gas to adjust its liquidity needs without relying heavily on short-term notes payable. In 2024, Nicor Gas' short-term notes payable dropped to $172 million from $392 million in 2023, reflecting the availability of this dedicated credit facility. The reduced reliance on notes payable aligns with the flexible sublimits and liquidity support provided through Southern Company's broader credit arrangements, which also include specific allocations for working capital needs at Nicor Gas.",
      "llm_answer": "Southern Company’s credit facility for Nicor Gas includes a $700 million sub‑limit within its 2029 multi‑year bank agreement that is specifically restricted for Nicor Gas’s working‑capital needs. Because Nicor Gas cannot borrow from the parent or use Southern Company Gas Capital, it relies on its own commercial‑paper program, which had $172 million of outstanding notes at the end of 2024—down from $392 million in 2023. This reduction reflects the shift of financing to the dedicated credit facility rather than continued short‑term borrowing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 223,
          "pages": [
            221,
            222,
            223,
            224,
            225
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 224,
          "pages": [
            222,
            223,
            224,
            225,
            226
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84571,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21365,
        "completion_tokens": 136,
        "total_tokens": 21502
      }
    },
    {
      "question_id": 86,
      "question": "How does Corebridge's borrowing timeline through February 2025 align with the expected closure of the AIG Life sale in the first half of 2024, and what does this suggest about Corebridge's liquidity planning during the divestiture process?",
      "original_answer": "Corebridge's borrowing capacity, which extends through February 25, 2025, aligns closely with the anticipated timeline for the sale of AIG Life, expected to close in the first half of 2024. This borrowing flexibility likely supports Corebridge's liquidity needs during the transition period before the transaction concludes and proceeds are received. Given that the sale involves a £460 million cash transaction subject to adjustments, Corebridge may require interim financing to manage operational or financial obligations during the regulatory approval process and pre-closing period. The availability of borrowing through early 2025 provides a financial buffer that aligns with the timing and uncertainty of the AIG Life divestiture, suggesting a strategic approach to liquidity management during major asset sales.",
      "llm_answer": "Corebridge's borrowing timeline extends through February 2025, providing a liquidity backstop that aligns with the anticipated first‑half‑2024 closing of the AIG Life sale. This horizon gives Corebridge sufficient runway to fund the divestiture‑related cash outflows and ongoing operations while the sale is finalized, indicating that liquidity planning is deliberately synchronized with the sale schedule to ensure the company can meet its obligations and capitalize on the transaction proceeds.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 149,
          "pages": [
            147,
            148,
            149,
            150,
            151
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 137,
          "pages": [
            135,
            136,
            137,
            138,
            139
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 74936,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18979,
        "completion_tokens": 124,
        "total_tokens": 19103
      }
    },
    {
      "question_id": 86,
      "question": "How does MetLife's liquidity risk related to securities lending obligations on $10,510 million in agreements reconcile with the reinvestment portfolio's fair value of $10,553 million, and what does this imply about their risk mitigation strategy?",
      "original_answer": "MetLife reports $10,510 million in securities lending agreements on page 33, where they highlight the risk of having to return significant cash collateral on short notice, which could impair liquidity. On page 244, the company discloses that the reinvestment portfolio associated with these agreements has a fair value of $10,553 million, slightly exceeding the cash collateral received of $10,788 million. This implies that MetLife maintains a reinvestment portfolio that is closely aligned in value with the collateral received, potentially serving as a counterbalance to liquidity pressures by generating returns or maintaining liquidity through marketable assets. This alignment suggests a risk mitigation strategy that leverages asset liquidity and reinvestment to manage potential collateral calls.",
      "llm_answer": "MetLife’s securities‑lending program involves $10,510 million of securities that are lent out and collateralized with $10,788 million of cash; the cash is reinvested in a portfolio whose fair value is $10,553 million. Because the reinvestment portfolio’s fair value is essentially equal to the cash received, MetLife can readily use that cash to meet any immediate return‑of‑collateral demands, limiting the risk that it would be forced to sell securities at distressed prices. This alignment indicates that the company’s liquidity‑risk mitigation strategy relies on maintaining a highly liquid, high‑quality reinvestment buffer that matches the size of its lending exposure, thereby preserving flexibility to return collateral without material market impact.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 33,
          "pages": [
            31,
            32,
            33,
            34,
            35
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2023.pdf",
          "target_page": 244,
          "pages": [
            242,
            243,
            244,
            245,
            246
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84187,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21286,
        "completion_tokens": 189,
        "total_tokens": 21476
      }
    },
    {
      "question_id": 86,
      "question": "How does GD's reliance on commercial paper issuances for liquidity needs align with the $4 billion credit facility's role as a backup funding source, given the expiration timeline of the facility in March 2027 and the company's emphasis on maintaining a strong balance sheet?",
      "original_answer": "GD emphasizes on page 46 that commercial paper issuances are a component of its liquidity strategy, supplemented by operating cash flows, to meet both short- and long-term needs. On page 75, the company discloses a $4 billion committed credit facility that supports these commercial paper issuances and serves general corporate purposes, with an expiration in March 2027. This timeline introduces a funding risk if the facility is not renewed or replaced, which contrasts with the company’s stated confidence in maintaining a strong balance sheet and flexibility in capital deployment. The alignment hinges on GD’s ability to either renew the facility or adjust its capital strategy before 2027 to ensure continued liquidity.",
      "llm_answer": "GD maintains a strong balance sheet and relies on commercial paper for short‑term liquidity, but it has a $4 billion committed credit facility that expires in March 2027 and serves as a backup source of funding. The company emphasizes preserving a robust balance sheet and uses the credit facility to support commercial paper issuances and general corporate needs, while its debt maturities schedule shows significant principal repayments beginning in 2025 and extending beyond 2027.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_2_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 75,
          "pages": [
            73,
            74,
            75,
            76,
            77
          ]
        },
        "hop_3_rel": {
          "source_file": "GD_10k_2024.pdf",
          "target_page": 46,
          "pages": [
            44,
            45,
            46,
            47,
            48
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 44379,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 11340,
        "completion_tokens": 120,
        "total_tokens": 11461
      }
    },
    {
      "question_id": 87,
      "question": "How does American General Life Insurance Company's membership in the FHLB of Dallas, as a source of collateralized borrowing capacity, relate to the specific amounts and interest rate terms of AIG's outstanding obligations to the FHLB of Dallas as reported in the funding agreements?",
      "original_answer": "American General Life Insurance Company, a subsidiary of AIG with an A+ S&P credit rating, is a member of the FHLB of Dallas, which provides AIG with collateralized borrowing opportunities. As of December 31, 2023, AIG had $3.357 billion in gross obligations to the FHLB of Dallas, with interest rates tied to the DNA Auction rate plus 22 to 30 basis points, and $2.027 billion in fixed-rate obligations ranging from 3.53% to 4.77%. These borrowings are backed by funding agreements and are secured by $8.7 billion in pledged collateral, including assets backing these agreements. This demonstrates how AIG leverages its life insurance subsidiaries’ FHLB memberships to access liquidity under specific rate structures.",
      "llm_answer": "The filing confirms that AIG’s Life & Retirement subsidiaries (including American General Life Insurance Company) are members of the FHLB of Dallas, granting them collateralized borrowing capacity. As of December 31 2023, these subsidiaries had a net borrowing capacity of $3.7 billion under their FHLB facilities, pledged $8.7 billion of collateral (including FHLB stock), and reported gross FHLB funding agreements of $5.6 billion with stated interest rates ranging from DNA auction plus 22‑30 bps to 3.53 %‑4.77 % for Dallas borrowings and 1.52 %‑2.70 % for New York borrowings. The specific amounts and interest‑rate terms of AIG’s outstanding FHLB obligations are detailed in the “Funding Agreements” table on page 227 and the accompanying maturity schedule on page 113.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 113,
          "pages": [
            111,
            112,
            113,
            114,
            115
          ]
        },
        "hop_2_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "hop_3_rel": {
          "source_file": "AIG_10k_2023.pdf",
          "target_page": 228,
          "pages": [
            226,
            227,
            228,
            229,
            230
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 109602,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 27651,
        "completion_tokens": 193,
        "total_tokens": 27844
      }
    },
    {
      "question_id": 87,
      "question": "Given that Windows Server is a key component of Server products and cloud services, how does Microsoft's reported 36% year-over-year revenue growth in Server products and cloud services ($79,970M to $97,726M) reconcile with the qualitative emphasis on Azure and cloud-first infrastructure in the Intelligent Cloud segment description?",
      "original_answer": "Microsoft's Server products and cloud services, which include Windows Server, experienced a significant 36% year-over-year revenue increase from $79,970M in 2023 to $97,726M in 2024. This growth aligns with the company's strategic emphasis on cloud-first infrastructure, particularly Azure, as outlined in the Intelligent Cloud segment description. While Windows Server remains a foundational on-premises product, its integration with Azure and positioning within a broader cloud services ecosystem reflects Microsoft's shift toward hybrid and public cloud offerings as a key competitive advantage. The revenue growth suggests strong market adoption of this integrated approach, where traditional server products are increasingly consumed as part of cloud services.",
      "llm_answer": "Microsoft's 36% year-over-year revenue growth in Server products and cloud services ($79,970M to $97,726M) aligns with the qualitative emphasis on Azure and cloud-first infrastructure in the Intelligent Cloud segment description, as this growth is explicitly driven by Azure and other cloud services within the Intelligent Cloud segment, which reported $105,362M in revenue (a 20% increase) and includes Server products and cloud services as a core component. The document confirms that Azure revenue growth (30% driven by consumption-based services) is a primary catalyst for the Intelligent Cloud segment's performance, directly supporting the strategic focus on cloud infrastructure.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 42,
          "pages": [
            40,
            41,
            42,
            43,
            44
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 56727,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 14447,
        "completion_tokens": 171,
        "total_tokens": 14618
      }
    },
    {
      "question_id": 87,
      "question": "How does MMM's PFAS phase-out timeline compare to supply chain readiness and regulatory pressures, and what financial risks does this create?",
      "original_answer": "MMM has committed to exiting all PFAS manufacturing by the end of 2025 and discontinuing PFAS use across its product portfolio by the same deadline. However, the company acknowledges that certain PFAS-containing products, especially those sourced from third parties used in lithium-ion batteries, printed circuit boards, and seals, may not be replaced by then due to feasibility and availability constraints. This misalignment between MMM's PFAS phase-out timeline and supply chain realities could result in unmet customer demand for PFAS-free products, particularly as customer preferences are already shifting toward such offerings (as noted on page 13). Meanwhile, regulatory pressures are intensifying globally, with increasingly stringent PFAS limits being proposed or enacted in environmental standards, which could lead to material compliance costs, litigation exposure, and reputational damage. The combination of unmet customer expectations, potential revenue loss from PFAS-dependent products, and rising regulatory costs creates a significant financial risk for MMM, particularly given the uncertainty around remediation technologies and the potential for regulatory enforcement actions.",
      "llm_answer": "MMM’s PFAS phase‑out timeline (targeting complete PFAS manufacturing exit and portfolio discontinuation by end‑2025) is being implemented amid ongoing regulatory pressure and supply‑chain constraints at its Zwijndrecht site. The pending appeal of the 2024 water‑discharge permit and the unresolved Site Decision on the Flemish Soil Decree could force additional remediation or treatment measures, creating uncertainty about meeting future discharge limits. If the company cannot achieve the required emission standards, its ability to supply products from Zwijndrecht—and consequently its broader supply‑chain commitments—could be materially disrupted, exposing it to significant financial and operational risk.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 13,
          "pages": [
            11,
            12,
            13,
            14,
            15
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 93712,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23640,
        "completion_tokens": 177,
        "total_tokens": 23818
      }
    },
    {
      "question_id": 87,
      "question": "How does Duke Energy's legal challenge of the 2024 CCR Rule relate to its financial obligations for coal ash remediation, especially in light of the expanded regulatory scope from the 2015 CCR Rule?",
      "original_answer": "Duke Energy's legal challenge of the 2024 CCR Rule stems from the rule's significant expansion of regulatory obligations, which now include previously unregulated coal ash sources such as inactive landfills and legacy surface impoundments. This expansion increases Duke Energy’s asset retirement obligations (AROs), which were already substantial under the 2015 CCR Rule and the Coal Ash Act. As of 2024, Duke Energy estimates the total cost to permanently close all coal ash basins at approximately $8 billion to $9 billion, with $4.4 billion already spent. The 2024 CCR Rule introduces additional compliance requirements—such as groundwater monitoring, corrective action, and closure mandates—that are expected to increase these obligations further. The company’s audit report on page 93 confirms that revisions to coal ash remediation cash flow estimates were directly tied to the 2024 CCR Rule, requiring significant management judgment and auditor scrutiny due to the rule’s financial impact. Thus, the legal challenge reflects Duke Energy’s attempt to mitigate the financial burden of these new regulatory requirements on its long-term coal ash remediation liabilities.",
      "llm_answer": "Duke Energy’s legal challenge to the 2024 CCR Rule seeks to block the EPA’s new requirements that impose closure, groundwater monitoring and post‑closure care obligations on inactive coal‑ash surface units—expanding the regulatory scope beyond the 2015 rule’s focus on active landfills and new disposals. Because cost recovery for these remediation activities will be pursued through the traditional rate‑making process with state commissions, the litigation directly affects the company’s financial exposure and the timing of future asset‑retirement obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_2_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 68,
          "pages": [
            66,
            67,
            68,
            69,
            70
          ]
        },
        "hop_3_rel": {
          "source_file": "DUK_10k_2024.pdf",
          "target_page": 93,
          "pages": [
            91,
            92,
            93,
            94,
            95
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 100743,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 25412,
        "completion_tokens": 140,
        "total_tokens": 25553
      }
    },
    {
      "question_id": 87,
      "question": "How does Merck's ongoing manufacturing relationship with Organon for formulated pharmaceutical products, as detailed in the agreements section, reconcile with the financial impact of the spin-off reflected in discontinued operations?",
      "original_answer": "Merck's ongoing manufacturing relationship with Organon involves toll manufacturing and supply agreements for formulated pharmaceutical products, under which Merck reported $219 million in sales and $195 million in cost of sales in 2021. Despite the spin-off of Organon on June 2, 2021, Merck continues to have a commercial relationship with Organon through these multi-year agreements. However, the spin-off also resulted in the reclassification of Organon's former businesses (women’s health, biosimilars, and established brands) as discontinued operations, which contributed $556 million in separation costs in 2021 and $743 million in 2020. This dual treatment shows that while Merck has divested Organon's core business, it maintains strategic manufacturing linkages that continue to influence its income statement, even as the broader financial impact of the spin-off is isolated to discontinued operations.",
      "llm_answer": "The agreements that govern Merck’s ongoing manufacturing relationship with Organon (the MSAs and related transition services) are accounted for as normal commercial transactions that generate revenue and cost of sales in the consolidated statement of income.  Because the spun‑off Organon businesses are presented as discontinued operations, the income (or loss) from those manufacturing arrangements is reported within “Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests,” and the associated assets, liabilities, and related cash flows are shown separately on the balance sheet and cash‑flow statement.  Consequently, while the manufacturing relationship continues after the spin‑off, its financial impact is isolated in discontinued operations and does not affect the ongoing results of Merck’s continuing business.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 94,
          "pages": [
            92,
            93,
            94,
            95,
            96
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2022.pdf",
          "target_page": 146,
          "pages": [
            144,
            145,
            146,
            147,
            148
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 68538,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 17371,
        "completion_tokens": 217,
        "total_tokens": 17588
      }
    },
    {
      "question_id": 88,
      "question": "How do the limited voting rights of Series B Preferred Stockholders interact with their staged convertibility provisions to determine the conditions under which Visa can pursue a consolidation or merger where preferred stockholders would receive different consideration than Class A common stockholders?",
      "original_answer": "The Series B Preferred Stockholders have no voting rights except in specified circumstances, including consolidations or mergers where they would receive different consideration than Class A common stockholders. In such cases, approval requires an affirmative vote by the outstanding voting power of each series of preferred stock, voting as a single class. Additionally, the Series B Preferred Stock is subject to staged convertibility into Class A common stock or Series A Preferred Stock, which becomes triggered by developments in the VE territory covered litigation or after the 12th anniversary of the Visa Europe acquisition. This means that for a consolidation or merger to proceed under these conditions, both the voting approval of Series B Preferred Stockholders and the potential conversion mechanics must align, creating a dual gating mechanism tied to litigation outcomes and time-based convertibility.",
      "llm_answer": "The staged convertibility of Series B Preferred Stock—where each tranche becomes convertible only after specific milestones (e.g., the 12th anniversary of the Visa Europe acquisition or resolution of the U.S. litigation escrow)—means that any consolidation or merger that would alter the conversion terms must treat the preferred holders differently from Class A common shareholders. Because the preferred stock’s voting rights are limited to a narrow set of matters (including any transaction that would give them consideration different from that received by Class A common stockholders), any such merger must obtain the affirmative vote of the outstanding voting power of each series of preferred stock, effectively giving those holders a veto over the transaction unless they receive the same consideration as Class A common stock. Consequently, Visa can only pursue a consolidation or merger that would result in different consideration for the preferred stockholders if it also secures the required preferred‑stockholder approval under those limited voting provisions.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_2_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 90,
          "pages": [
            88,
            89,
            90,
            91,
            92
          ]
        },
        "hop_3_rel": {
          "source_file": "V_10k_2023.pdf",
          "target_page": 89,
          "pages": [
            87,
            88,
            89,
            90,
            91
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 114982,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 28994,
        "completion_tokens": 268,
        "total_tokens": 29262
      }
    },
    {
      "question_id": 88,
      "question": "How does AbbVie's acquisition-related goodwill from Cerevel Therapeutics connect with the financing liability associated with tavapadon's development, and how is the fair value of this liability updated post-acquisition?",
      "original_answer": "AbbVie recognized goodwill from the acquisition of Cerevel Therapeutics, which included expectations of synergies and pipeline expansion (page 72). This acquisition brought with it funding agreements tied to the development of tavapadon, which require AbbVie to make contingent payments based on regulatory and sales milestones (page 67). Post-acquisition, the financing liability associated with these agreements is measured at fair value using unobservable inputs, including probability-weighted models and Monte Carlo simulations, with changes in fair value reflected in earnings (page 84). This shows how AbbVie not only assumed contingent liabilities through the acquisition but also actively manages and updates their valuation based on evolving probabilities and market conditions.",
      "llm_answer": "AbbVie acquired Cerevel Therapeutics in August 2024 and, as part of the purchase accounting, recorded a financing liability related to Cerevel’s funding agreements for tavapadon development. The liability’s fair value was initially measured at $246 million using a probability‑weighted expected‑payment model for regulatory milestones and a Monte‑Carlo simulation for sales milestones and royalties, with discount rates and estimated probabilities of milestone achievement as key unobservable inputs. After acquisition, the company updated the liability’s fair value each reporting period; any change in fair value is recognized in earnings (other expense) and reflects updated assumptions about milestone timing, probabilities and projected sales, causing the liability to be adjusted upward or downward as new information becomes available.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 72,
          "pages": [
            70,
            71,
            72,
            73,
            74
          ]
        },
        "hop_2_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 67,
          "pages": [
            65,
            66,
            67,
            68,
            69
          ]
        },
        "hop_3_rel": {
          "source_file": "ABBV_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 91951,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 23225,
        "completion_tokens": 210,
        "total_tokens": 23435
      }
    },
    {
      "question_id": 88,
      "question": "How does AMD's binding wafer purchase commitment with GLOBALFOUNDRIES U.S. Inc. through 2025 align with their stated risk of overstocking inventory or increased unit costs if actual wafer demand falls short of agreed targets?",
      "original_answer": "AMD has a binding Wafer Supply Agreement (WSA) with GLOBALFOUNDRIES U.S. Inc., amended in May and December 2021, which requires AMD to meet annual wafer purchase targets through 2025 or face financial penalties. This agreement includes prepayment obligations for 2022 and 2023 and guarantees minimum capacity allocation from GF. However, AMD acknowledges in the risk factors section that if actual wafer demand falls short of these purchase targets, it could result in excess inventory or higher inventory unit costs, both of which could negatively impact gross margins and financial performance. This creates a tension between the contractual obligation to purchase wafers and the market-driven variability in actual product demand, highlighting a key operational and financial risk in AMD's supply chain strategy.",
      "llm_answer": "AMD’s binding wafer purchase commitment with GLOBALFOUNDRIES U.S. Inc. through 2025 requires the company to meet annual wafer‑purchase targets and pre‑pay for the allocated capacity. If AMD’s actual wafer demand falls short of those targets, it could be left with excess inventory and higher per‑unit costs, which would erode gross margin and could materially adversely affect its results of operations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_2_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 97,
          "pages": [
            93,
            94,
            95,
            96,
            97
          ]
        },
        "hop_3_rel": {
          "source_file": "AMD_10k_2022.pdf",
          "target_page": 23,
          "pages": [
            21,
            22,
            23,
            24,
            25
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 83904,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21209,
        "completion_tokens": 100,
        "total_tokens": 21310
      }
    },
    {
      "question_id": 88,
      "question": "How does the growth in PowerSecure's distributed infrastructure projects, which contributed $120 million to operating revenues in 2024, align with Southern Company's strategic framing of distributed energy and resilience solutions as part of its 'All Other' business segments?",
      "original_answer": "PowerSecure, a subsidiary of Southern Company, contributed $120 million to operating revenues in 2024 through its distributed infrastructure projects. These projects are directly tied to PowerSecure's core offering of distributed energy and resilience solutions, which include microgrid deployment for commercial, industrial, governmental, and utility customers. This aligns with Southern Company's broader strategic positioning of distributed energy solutions as part of its 'All Other' segment, which includes entities providing such services. Despite being below the quantitative threshold for separate disclosure, this segment is framed in the 10-K as a strategic component of Southern Company's diversified offerings, indicating that PowerSecure's growth in this area supports the company's broader diversification and resilience strategy.",
      "llm_answer": "The $120 million increase in PowerSecure’s operating revenues—driven by distributed infrastructure projects—is highlighted in the “Other Business Activities” section of Southern Company’s 2024 MD&A (page 64). This growth is presented as part of the “All Other” segment, which groups PowerSecure’s distributed energy and resilience solutions alongside other non‑core activities. The MD&A explicitly notes that the revenue rise is tied to these distributed projects, aligning with Southern Company’s strategic framing of distributed energy and resilience solutions within the “All Other” business segment.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 291,
          "pages": [
            289,
            290,
            291,
            292,
            293
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72667,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18414,
        "completion_tokens": 150,
        "total_tokens": 18564
      }
    },
    {
      "question_id": 88,
      "question": "How does Merck's expectation of declining U.S. sales for Keytruda due to IRA-mandated government price setting in 2028 align with its broader concerns about the impact of the IRA on pharmaceutical innovation and long-term revenue sustainability?",
      "original_answer": "Merck explicitly states that it expects U.S. sales of Keytruda to decline after 2028 due to government price setting under the IRA, which will directly impact revenue from one of its top-selling products. This expectation is outlined in the context of increasing regulatory and pricing pressures from the U.S. government. Additionally, the company expresses broader concerns that the IRA will harm innovation in the pharmaceutical industry, potentially leading to fewer new treatments being developed over time. These two perspectives are interconnected: the direct financial impact on Keytruda sales exemplifies the kind of revenue pressure that could reduce Merck's ability to invest in R&D, thereby supporting the company’s claim that the IRA could have long-term negative effects on innovation and product development. Thus, the specific risk to Keytruda under the IRA serves as both a concrete example and a catalyst for Merck’s more generalized concern about the law's impact on the pharmaceutical innovation ecosystem.",
      "llm_answer": "Merck expects that the IRA‑mandated government price setting for Keytruda, which will take effect on January 1 2028, will cause a decline in U.S. sales of that drug.  This anticipated drop is part of a broader concern that the IRA’s price‑setting provisions, together with other Medicare‑related rebate changes and state‑level affordability measures, could erode pricing power and jeopardize the company’s long‑term revenue sustainability and ability to fund continued pharmaceutical innovation.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84077,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21258,
        "completion_tokens": 123,
        "total_tokens": 21381
      }
    },
    {
      "question_id": 89,
      "question": "How does Merck's expectation of declining U.S. sales for Keytruda due to IRA-mandated government price setting in 2028 align with its broader concerns about the long-term impact of the IRA on pharmaceutical innovation and new treatment development?",
      "original_answer": "Merck anticipates that Keytruda, a major revenue driver, will face a government-set price effective January 1, 2028, which the company expects will lead to a decline in its U.S. sales. This expectation is detailed in the context of the Inflation Reduction Act (IRA), which introduces government price setting for certain Medicare Part B drugs starting in 2028. On page 10, Merck expresses broader concerns that the IRA could harm innovation in the pharmaceutical industry, potentially resulting in fewer new treatments being developed and approved over time. The company is actively working to mitigate these harmful effects, particularly the risk of reduced innovation. Therefore, the anticipated decline in Keytruda sales serves as a concrete example of how the IRA's pricing provisions could undermine the financial incentives for pharmaceutical innovation that Merck highlights as a systemic risk to the industry.",
      "llm_answer": "Merck expects U.S. sales of Keytruda to decline after 2028 when the IRA’s government price‑setting provision takes effect, and it views this development as part of a broader, long‑term concern that the IRA’s price‑control mechanisms will erode profit margins, discourage investment in research, and ultimately weaken pharmaceutical innovation and the pipeline of new treatments.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 38,
          "pages": [
            36,
            37,
            38,
            39,
            40
          ]
        },
        "hop_2_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 9,
          "pages": [
            7,
            8,
            9,
            10,
            11
          ]
        },
        "hop_3_rel": {
          "source_file": "MRK_10k_2024.pdf",
          "target_page": 10,
          "pages": [
            8,
            9,
            10,
            11,
            12
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 84077,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21258,
        "completion_tokens": 94,
        "total_tokens": 21353
      }
    },
    {
      "question_id": 89,
      "question": "How does Microsoft's repeated use of The Bank of New York Mellon Trust Company as trustee across multiple debt issuances, including the 0.875% Notes due 2013 and the 1.625% Notes due 2018, reflect a consistent capital structure management strategy, given the long-standing trustee relationship established in the Base Indenture dated May 18, 2009?",
      "original_answer": "Microsoft's repeated use of BNY Mellon as trustee across multiple debt issuances—such as the 0.875% Notes due 2013 (Exhibit 4.5, filed September 27, 2010) and the 1.625% Notes due 2018 (Exhibit 4.11, filed December 6, 2013)—demonstrates a deliberate and consistent capital structure management strategy. This approach builds on the foundational relationship established in the Base Indenture dated May 18, 2009 (Exhibit 4.1), which formalized BNY Mellon’s role as trustee. By maintaining a long-standing relationship with a single trusted financial institution across multiple supplemental indentures, Microsoft likely benefits from operational efficiency, familiarity with documentation, and reduced execution risk in debt offerings. This pattern suggests that Microsoft views continuity in trustee relationships as a strategic advantage in managing its debt portfolio.",
      "llm_answer": "Microsoft's consistent use of The Bank of New York Mellon Trust Company as trustee across multiple debt issuances—including the 0.875% Notes due 2013 and 1.625% Notes due 2018—reflects a deliberate strategy to maintain continuity and stability in its long-term capital structure management. This approach leverages the established trustee relationship formalized in the Base Indenture dated May 18, 2009, ensuring seamless integration of new debt offerings into its existing framework while reinforcing trust and operational efficiency in managing its debt obligations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 105,
          "pages": [
            103,
            104,
            105,
            106,
            107
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2024.pdf",
          "target_page": 103,
          "pages": [
            101,
            102,
            103,
            104,
            105
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 50343,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 12848,
        "completion_tokens": 142,
        "total_tokens": 12991
      }
    },
    {
      "question_id": 89,
      "question": "How does Lockheed Martin's financial dependence on ULA's equity earnings relate to its exposure to commercial customers through receivables, given ULA's role as a launch service provider to those same customers?",
      "original_answer": "Lockheed Martin reported $45 million in equity earnings from its investment in ULA in 2024, which contributed to Space segment profitability. ULA provides expendable launch services to both the U.S. Government and commercial customers. As of December 31, 2024, Lockheed Martin had $665 million in receivables from commercial customers, indicating a direct financial relationship with these entities. This creates a dual exposure: Lockheed benefits from ULA’s performance through equity earnings while also having direct credit and collection risk on contracts with commercial customers that ULA serves. The interplay suggests Lockheed's financial health is indirectly tied to the success of ULA’s commercial launches and the creditworthiness of those commercial customers.",
      "llm_answer": "Lockheed Martin’s financial dependence on ULA’s equity earnings is modest but strategically important: the Space segment’s operating profit includes a $55 million share of ULA earnings, which represents roughly 4 % of Space’s total operating profit and is tied to the same commercial launch customers that also generate receivables from Lockheed’s commercial contracts. Because ULA’s launch‑service revenue is a key component of those customers’ programs, any slowdown in ULA’s earnings (and thus in the equity income Lockheed records) would signal reduced commercial launch activity, potentially leading to lower cash inflows from those customers and a corresponding reduction in the receivables that Lockheed records from them. This creates a direct link between Lockheed’s exposure to commercial customers through its receivables and its reliance on ULA’s equity earnings for a portion of its Space‑segment profitability.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_2_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64692,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16408,
        "completion_tokens": 231,
        "total_tokens": 16639
      }
    },
    {
      "question_id": 89,
      "question": "How does Lockheed Martin's financial dependence on ULA's equity earnings relate to its exposure to commercial customers through receivables, given ULA's role as a launch services provider to those same customers?",
      "original_answer": "Lockheed Martin's Space segment reported $45 million in equity earnings from its investment in ULA in 2024, which contributed to a 6% increase in the segment's operating profit. ULA, in which Lockheed holds a 50% stake, provides launch services to both the U.S. Government and commercial customers. On the other hand, Lockheed's receivables from commercial customers totaled $665 million as of December 31, 2024, indicating a significant financial exposure to this customer group. Since ULA serves commercial customers and Lockheed is financially tied to ULA through equity earnings, this creates a dual exposure: Lockheed benefits from ULA’s commercial launch contracts while also directly extending credit to commercial customers. This dual relationship suggests that Lockheed's financial health is indirectly influenced by the success of ULA’s commercial business and directly affected by the creditworthiness and payment behavior of commercial customers.",
      "llm_answer": "Lockheed Martin's financial dependence on ULA's equity earnings is reflected in its Space segment, where the $551 million investment in United Launch Alliance generated $45 million of equity earnings in 2024—about 4 % of Space’s operating profit. This equity earnings contribution is part of the segment’s overall profitability, which also includes revenue from launch services to both government and commercial customers. Consequently, while ULA’s earnings provide a modest but strategic boost to Lockheed’s Space segment, the company’s exposure to commercial customers through receivables remains tied to its broader contract portfolio rather than direct equity stakes.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 41,
          "pages": [
            39,
            40,
            41,
            42,
            43
          ]
        },
        "hop_2_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 71,
          "pages": [
            69,
            70,
            71,
            72,
            73
          ]
        },
        "hop_3_rel": {
          "source_file": "LMT_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 64692,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 16408,
        "completion_tokens": 167,
        "total_tokens": 16576
      }
    },
    {
      "question_id": 89,
      "question": "How does Southern Company's strategic emphasis on distributed energy solutions in its segment reporting align with PowerSecure's financial performance, particularly in relation to the increase in operating revenues and cost of sales tied to distributed infrastructure projects?",
      "original_answer": "Southern Company's segment reporting highlights distributed energy and resilience solutions as part of its 'All Other' category, indicating a strategic focus on deploying microgrids and energy solutions for commercial and utility customers. This strategic emphasis is directly reflected in PowerSecure's financial performance, as disclosed in the 'Other Business Activities' section, where operating revenues increased by $111 million (20.0%) in 2024, with $120 million of that increase attributed to distributed infrastructure projects. However, this growth came with a significant cost increase—$82 million (15.8%) in cost of other sales—also tied to those same projects. This suggests that while Southern Company is strategically investing in distributed energy through PowerSecure, the financial impact shows both revenue growth and margin pressure due to the associated project costs.",
      "llm_answer": "Southern Company’s segment reporting groups distributed energy and resilience solutions—delivered by PowerSecure—within the “All Other” column, which the CODM uses to assess performance. PowerSecure’s operating revenues rose $120 million (≈20 %) in 2024, driven by new distributed‑infrastructure projects, and its cost of sales increased $82 million (≈15.8 %) for the same reason. This growth in both revenue and cost of sales reflects the company’s strategic focus on expanding distributed energy assets, even though the segment still generates a net loss that is offset by other parts of the business.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 291,
          "pages": [
            289,
            290,
            291,
            292,
            293
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2024.pdf",
          "target_page": 64,
          "pages": [
            62,
            63,
            64,
            65,
            66
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 72667,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 18414,
        "completion_tokens": 150,
        "total_tokens": 18565
      }
    },
    {
      "question_id": 90,
      "question": "How does the change in allowance for credit losses on loan receivables from fiscal 2022 to 2023 reflect the risk profile of Cisco's financing activities tied to technical support services?",
      "original_answer": "The allowance for credit losses on loan receivables decreased from $103 million in fiscal 2022 to $53 million in fiscal 2023, indicating a reduced risk exposure or improved credit quality in these financing arrangements. Loan receivables are explicitly tied to Cisco's technical support and advanced services, suggesting that the company's financing risk related to these services has declined over this period. This reduction in allowance implies that Cisco may have tightened credit standards, experienced better-than-expected repayment performance, or reduced the volume of financing extended for technical support services. The decrease in allowance must be interpreted alongside the overall decrease in financing receivables (down 2% year-over-year), which suggests a contraction or recalibration in Cisco's financing activities, including those related to technical support.",
      "llm_answer": "The allowance for credit losses on loan receivables fell modestly from $53 million (as of July 29 2023) to $50 million (as of July 27 2024), reflecting a slightly improved risk profile despite a $49 million decline in net loan receivables. This reduction suggests that Cisco’s exposure to financing arrangements tied to technical‑support services—primarily recorded as loan receivables—has become less risky, even as the overall volume of such financing remained relatively stable.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "hop_2_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 82,
          "pages": [
            80,
            81,
            82,
            83,
            84
          ]
        },
        "hop_3_rel": {
          "source_file": "CSCO_10k_2023.pdf",
          "target_page": 49,
          "pages": [
            47,
            48,
            49,
            50,
            51
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 75740,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19161,
        "completion_tokens": 120,
        "total_tokens": 19281
      }
    },
    {
      "question_id": 90,
      "question": "Given MMM's retention of PFAS liabilities for certain Solventum products sold between April 1, 2024, and January 1, 2026, how does this liability exposure influence MMM's financial risk disclosures and potential future charges under ASC 450 as outlined in their 2024 10-K?",
      "original_answer": "MMM retains PFAS-related liabilities for Solventum products sold between April 1, 2024, and January 1, 2026, excluding certain exceptions such as new products or modified formulations introduced post-spin-off. Under ASC 450, MMM is required to record liabilities when the loss is probable and reasonably estimable. However, due to the inherent uncertainties in litigation and the indeterminate damages often claimed, MMM may not currently have accruals for some of these liabilities because losses are not yet probable or estimable. This retained exposure could lead to future changes in MMM’s estimated liabilities and disclosures, particularly if unfavorable rulings, new claims, or settlement discussions emerge that alter the Company’s ability to estimate probable losses. As such, the retained PFAS liabilities for Solventum products may result in material charges or disclosures in future periods, impacting MMM’s consolidated financial position and results of operations.",
      "llm_answer": "The 2024 10‑K notes that the Company will retain PFAS‑related liabilities arising from its own business and from Solventum’s business that were created before April 1 2024, while Solventum will assume PFAS liabilities for products sold between April 1 2024 and January 1 2026, subject to specific exceptions. Because these retained PFAS obligations are contingent on future claims and remediation, ASC 450 requires the Company to accrue a loss when a probable and reasonably estimable liability exists and to disclose any reasonably possible loss when it does not. Accordingly, the Company’s financial‑risk disclosures must reflect a potential future charge for PFAS‑related environmental and product liabilities that remain on its balance sheet, even though the ultimate amount cannot yet be precisely measured.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 85,
          "pages": [
            83,
            84,
            85,
            86,
            87
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 84,
          "pages": [
            82,
            83,
            84,
            85,
            86
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 95587,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 24138,
        "completion_tokens": 203,
        "total_tokens": 24341
      }
    },
    {
      "question_id": 90,
      "question": "How does the 118 MW wind capacity from the Glass Sands project completed in Murray County, OK in November 2021, align with Southern Power's stated useful life of up to 35 years for wind assets in evaluating long-term return potential?",
      "original_answer": "The Glass Sands project, completed in November 2021 with a capacity of 118 MW, represents a wind-based asset in Southern Power's portfolio. Given that Southern Power reports a useful life of up to 35 years for wind assets, this suggests the company expects a relatively long operational lifespan for the Glass Sands facility. This long useful life supports the potential for sustained revenue generation over time, which is critical for evaluating the long-term return on this investment. The 12-year PPA contract period for Glass Sands, however, indicates that revenue stability beyond that term may depend on market conditions or renegotiation, creating a tension between asset longevity and contracted revenue visibility.",
      "llm_answer": "Southern Power’s 118 MW Glass Sands wind facility, completed in November 2021, is depreciated over an estimated useful life of **up to 35 years**—the same maximum life the company assigns to its wind assets in the depreciation table. This aligns with Southern Power’s stated 35‑year useful‑life assumption, meaning the Glass Sands project will be amortized over that period when evaluating its long‑term return potential.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 297,
          "pages": [
            295,
            296,
            297,
            298,
            299
          ]
        },
        "hop_2_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 297,
          "pages": [
            295,
            296,
            297,
            298,
            299
          ]
        },
        "hop_3_rel": {
          "source_file": "SO_10k_2023.pdf",
          "target_page": 217,
          "pages": [
            215,
            216,
            217,
            218,
            219
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 85353,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 21576,
        "completion_tokens": 105,
        "total_tokens": 21681
      }
    },
    {
      "question_id": 90,
      "question": "How does GILD's revenue recognition model for Symtuza, which is manufactured and distributed by Janssen, compare with the financial treatment of Odefsey, where GILD retains manufacturing and primary commercialization responsibility, and how does this affect GILD's cost of goods sold and product sales line items?",
      "original_answer": "GILD recognizes its share of Symtuza revenue in the period when Janssen sells the product, as Janssen is responsible for manufacturing, registration, and global commercialization. GILD's revenue from Symtuza is based on a revenue-sharing model tied to the net selling prices of its components, and it is recorded under Product Sales. In contrast, for Odefsey, GILD retains the lead role in manufacturing and commercialization in most markets, and it shares revenues with Janssen based on the net selling prices of each party's components. This results in Janssen's share of Odefsey revenue being recorded in GILD's Cost of Goods Sold, which totaled $403 million in 2024. The differing structures illustrate how GILD's financial exposure and line-item treatment vary significantly depending on which party controls the commercialization and distribution of the jointly developed products.",
      "llm_answer": "Gilead’s revenue‑recognition for Symtuza differs from that for Odefsey because Janssen manufactures, registers, distributes and commercializes Symtuza worldwide, while Gilead only supplies the cobicistat/tenofovir/emtricitabine components and receives a share of the revenue based on the net‑price ratio; Janssen’s share of Symtuza revenue is recorded as cost of goods sold, whereas for Odefsey Gilead manufactures the product and records its sales as product revenue with Janssen’s share also included in cost of goods sold. Consequently, Symtuza’s cost of goods sold reflects Janssen’s manufacturing and distribution costs, while Odefsey’s cost of goods sold reflects only Janssen’s distribution share, leading to a higher COGS component for Symtuza. This distinction drives the differing presentation of product‑sales and COGS for the two collaborations.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 77,
          "pages": [
            75,
            76,
            77,
            78,
            79
          ]
        },
        "hop_2_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        },
        "hop_3_rel": {
          "source_file": "GILD_10k_2024.pdf",
          "target_page": 76,
          "pages": [
            74,
            75,
            76,
            77,
            78
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 78482,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 19872,
        "completion_tokens": 214,
        "total_tokens": 20086
      }
    },
    {
      "question_id": 90,
      "question": "Given MetLife's $89.8 billion exposure to mortgage loans on the balance sheet, how does the company's risk profile and unrealized loss position in pass-through mortgage-backed securities, which are secured by those loans, reflect the underlying credit quality and diversification of the mortgage portfolio?",
      "original_answer": "MetLife reports $89.8 billion in mortgage loans on the balance sheet (page 296), which serve as the collateral for pass-through mortgage-backed securities (page 87). On page 88, the company discloses a $12.6 billion exposure to pass-through mortgage-backed securities, which carry an unrealized loss of $1.3 billion. These securities directly reflect the credit quality of the underlying mortgage loans. The unrealized loss suggests that the market perceives some credit deterioration or increased risk in the underlying loans, despite the company's diversification efforts across security types and risk profiles, including Agency and Non-Agency RMBS, as well as segmentation by borrower quality (e.g., prime, NQM, Alt-A, and reperforming/sub-prime). This indicates that while the mortgage loan portfolio is substantial, the associated pass-through securities are experiencing market-driven valuation pressures, potentially signaling broader credit concerns in the underlying assets.",
      "llm_answer": "MetLife’s $89.8 billion exposure to mortgage loans is reflected in its mortgage‑backed‑securities portfolio, which consists largely of pass‑through RMBS and CMBS that are collateralized by those loans. The securities show a modest unrealized loss (e.g., $‑497 million for CMBS and $‑2.66 billion for RMBS in 2024), indicating that while the underlying loan pool is large and generally high‑quality, a portion of the securities is trading below par. The portfolio’s diversification across agency and non‑agency, conduit and single‑asset structures, and its strong credit ratings (most rated Aaa/Aa or NAIC 1) suggest that credit risk is spread across many borrowers and property types, supporting a relatively resilient underlying mortgage credit quality.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 296,
          "pages": [
            294,
            295,
            296,
            297,
            298
          ]
        },
        "hop_2_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 87,
          "pages": [
            85,
            86,
            87,
            88,
            89
          ]
        },
        "hop_3_rel": {
          "source_file": "MET_10k_2024.pdf",
          "target_page": 88,
          "pages": [
            86,
            87,
            88,
            89,
            90
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 110398,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 27855,
        "completion_tokens": 188,
        "total_tokens": 28044
      }
    },
    {
      "question_id": 91,
      "question": "How does Johnson & Johnson's classification of reverse repurchase agreements (RRAs) with maturities over three months align with its accounting treatment of held-to-maturity investments, given the company's policy of maintaining collateral at 102% of RRA value?",
      "original_answer": "Johnson & Johnson classifies reverse repurchase agreements (RRAs) with maturities over three months from the date of purchase as marketable securities, while held-to-maturity investments are reported at amortized cost with realized gains or losses recognized in earnings. The company maintains a policy that the collateral backing RRAs must be at least 102% of their value and rated at least A (or equivalent), which reflects a conservative approach to liquidity and credit risk. This policy aligns with the accounting treatment of held-to-maturity investments, which also emphasizes credit quality and long-term holding, suggesting a consistent strategy of risk mitigation across both investment types. However, the classification of longer-term RRAs as marketable securities indicates a more liquid or potentially shorter-duration intent compared to held-to-maturity investments.",
      "llm_answer": "Johnson & Johnson classifies reverse repurchase agreements (RRAs) with maturities over three months as marketable securities, not as held‑to‑maturity investments, and it maintains collateral at least 102 % of the RRA value, ensuring that the collateral fully backs the RRAs without being sold or repledged. This collateral policy aligns with its accounting treatment of RRAs as marketable securities rather than as held‑to‑maturity assets.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_2_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        },
        "hop_3_rel": {
          "source_file": "JNJ_10k_2022.pdf",
          "target_page": 59,
          "pages": [
            57,
            58,
            59,
            60,
            61
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 62761,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 15932,
        "completion_tokens": 109,
        "total_tokens": 16042
      }
    },
    {
      "question_id": 91,
      "question": "How does Microsoft's inclusion of Activision Blizzard's financials in the consolidated statements, despite excluding their internal controls from evaluation, relate to the assumption of Activision's 3.400% Senior Notes due 2026 as part of the acquisition financing structure?",
      "original_answer": "Microsoft's consolidated financial statements include Activision Blizzard's financial results post-acquisition on October 13, 2023, but explicitly excluded Activision’s internal controls from the evaluation of internal control over financial reporting, citing that Activision represented less than 1% of total assets (excluding goodwill and intangibles) and 2% of total revenues. Meanwhile, the assumption of Activision’s 3.400% Senior Notes due 2026, as evidenced by the supplemental indenture filed on October 27, 2023, reflects Microsoft’s direct financial liability assumption as part of the acquisition financing. This creates a tension between the limited operational control visibility and the full financial liability exposure Microsoft has taken on through the acquisition, particularly in terms of debt instruments like the 3.400% Senior Notes due 2026.",
      "llm_answer": "Microsoft consolidates Activision Blizzard’s financial statements into its own, but explicitly excludes Activision Blizzard’s internal controls from its assessment of effectiveness because the acquired business contributed less than 1 % of total assets (excluding goodwill and intangibles) and about 2 % of revenue. The 3.400 % Senior Notes due 2026 issued by Activision Blizzard are treated as part of the acquisition‑financing structure, yet the notes themselves are not subject to the same internal‑control evaluation that Microsoft applies to its own debt.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 106,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        },
        "hop_2_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 107,
          "pages": [
            104,
            105,
            106,
            107,
            108
          ]
        },
        "hop_3_rel": {
          "source_file": "MSFT_10k_2023.pdf",
          "target_page": 98,
          "pages": [
            96,
            97,
            98,
            99,
            100
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 54170,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 13790,
        "completion_tokens": 140,
        "total_tokens": 13930
      }
    },
    {
      "question_id": 91,
      "question": "How does the adoption of ASU No. 2023-07, which mandates incremental disclosures of disaggregated expense information, impact the presentation of operating income (loss) by business segment as reported under Segment Reporting in MMM's 2024 financial statements?",
      "original_answer": "MMM adopted ASU No. 2023-07 for the year ended December 31, 2024, which requires incremental disclosures of disaggregated expense information for reportable segments. This adoption impacts the Segment Reporting section by enhancing the granularity of operating income (loss) data presented for each business segment, as seen in the tables on page 26. The updated disclosures align with the retrospective application of the ASU to all prior periods presented, indicating a more detailed and standardized approach to segment performance reporting.",
      "llm_answer": "The adoption of ASU No. 2023-07 requires incremental disaggregated expense disclosures for each reportable segment, which 3M applied retrospectively to all prior periods in its 2024 financial statements. This results in more detailed operating income (loss) reporting by business segment, as reflected in the updated segment reporting tables within the 2024 filing.",
      "llm_thought": "",
      "hop_count": 3,
      "document_relationship": "intra_document",
      "pages_used": {
        "hop_1_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 26,
          "pages": [
            24,
            25,
            26,
            27,
            28
          ]
        },
        "hop_2_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "hop_3_rel": {
          "source_file": "MMM_10k_2024.pdf",
          "target_page": 54,
          "pages": [
            52,
            53,
            54,
            55,
            56
          ]
        },
        "distractors": []
      },
      "context_stats": {
        "total_pages": 15,
        "total_chars": 108617,
        "num_window_pages": 15,
        "num_distractor_pages": 0,
        "shuffle_enabled": true
      },
      "token_usage": {
        "prompt_tokens": 27396,
        "completion_tokens": 91,
        "total_tokens": 27488
      }
    }
  ]
}